<SEC-DOCUMENT>0001171843-15-006102.txt : 20151110
<SEC-HEADER>0001171843-15-006102.hdr.sgml : 20151110
<ACCEPTANCE-DATETIME>20151106161257
ACCESSION NUMBER:		0001171843-15-006102
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20151106
DATE AS OF CHANGE:		20151106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		151210865

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gff10q_110615p.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
     <TITLE></TITLE>
</HEAD><BODY STYLE="font: 10pt Times New Roman, Times, Serif">





<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: black 1.1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>UNITED STATES</b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Washington, D.C. 20549</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">_____________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>FORM 10-Q</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>_____________</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Quarterly Report Pursuant to Section 13 or 15(d)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>For the quarterly period ended September&nbsp;30, 2015</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Commission File Number 000-23186</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>_____________</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 24pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>_____________</b></p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center; width: 50%">DELAWARE</td>
    <td style="font-weight: bold; text-align: center; width: 50%">62-1413174</td></tr>
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center">(State of other jurisdiction of <br>
incorporation or organization)</td>
    <td style="font-weight: bold; text-align: center">(I.R.S. Employer <br>
Identification No.)</td></tr>
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center">4505 Emperor Blvd., Suite&nbsp;200 <br>
Durham, North Carolina</td>
    <td style="font-weight: bold; text-align: center; vertical-align: bottom">27703</td></tr>
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center">(Address of principal executive offices)</td>
    <td style="font-weight: bold; text-align: center">(Zip Code)</td></tr>
</table>


<p style="font-size: 10pt; text-align: left; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(919) 859-1302</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Registrant&#8217;s telephone number, including area code)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">_____________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required
to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such
shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements
for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <font style="font-family: Wingdings">x</font> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<font style="font-family: Wingdings">&#168;</font></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of
Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit
and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <font style="font-family: Wingdings">x</font> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<font style="font-family: Wingdings">&#168;</font></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, or a non- accelerated filer or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221;
&#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 20%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 44%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 22%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 10%; padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Wingdings">x</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Accelerated&nbsp;filer</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Wingdings">&#168;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Non-accelerated filer</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <TD NOWRAP STYLE="padding-right: 0.8pt"><font style="font: 10pt Wingdings">&#168;</font><font style="font-size: 10pt"> &nbsp;&nbsp;(Do not check if a smaller reporting company)</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Smaller reporting company</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Wingdings">&#168;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2
of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <font style="font-family: Wingdings">&#168;</font> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<font style="font-family: Wingdings">x</font></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The number of shares of Common Stock, par value $0.01, of the Registrant outstanding
as of October 31, 2015 was 73,336,871.&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>INDEX</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>


<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b></b></p>

<table border="0" cellpadding="2" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 3%">&nbsp;</td>
    <td style="vertical-align: middle; width: 89%">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 8%">Page No.</td></tr>
<tr style="vertical-align: middle">
    <td colspan="3" style="text-align: center">Part I. Financial Information</td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left"><a href="#a_001">Item&nbsp;1. Financial Statements:</a></td>
    <td style="text-align: right"><a href="#a_001">3</a></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle"><a href="#a_002">Consolidated Balance Sheets &#8212; September&nbsp;30, 2015 and December&nbsp;31, 2014</a></td>
    <td style="text-align: right"><a href="#a_002">3</a></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle"><a href="#a_003">Consolidated Statements of Comprehensive Loss &#8212; Three and Nine Months Ended September&nbsp;30, 2015 and 2014</a></td>
    <td style="text-align: right"><a href="#a_003">4</a></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle"><a href="#a_004">Consolidated Statements of Cash Flows &#8212; Nine Months Ended September&nbsp;30, 2015 and 2014</a></td>
    <td style="text-align: right"><a href="#a_004">5</a></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle"><a href="#a_005">Notes to Consolidated Financial Statements</a></td>
    <td style="text-align: right"><a href="#a_005">6</a></td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left"><a href="#a_006">Item&nbsp;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
    <td style="text-align: right"><a href="#a_006">19</a></td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left"><a href="#a_007">Item&nbsp;3. Quantitative and Qualitative Disclosures About Market Risk</a></td>
    <td style="text-align: right"><a href="#a_007">31</a></td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left"><a href="#a_008">Item&nbsp;4. Controls and Procedures</a></td>
    <td style="text-align: right"><a href="#a_008">31</a></td></tr>
<tr style="vertical-align: middle">
    <td colspan="3" style="text-align: center">Part II. Other Information</td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left"><a href="#a_009">Item&nbsp;1A. Risk Factors</a></td>
    <td style="text-align: right"><a href="#a_009">32</a></td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left"><a href="#a_010">Item&nbsp;6. Exhibits</a></td>
    <td style="text-align: right"><a href="#a_010">47</a></td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left"><a href="#a_011">Signatures</a></td>
    <td style="text-align: right"><a href="#a_011">48</a></td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left">EX-10.1</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left">EX-10.2</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left">EX-10.3</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left">EX-31.1</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left">EX-31.2</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left">EX-32.1</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: left">EX-32.2</td>
    <td>&nbsp;</td></tr>
</table>


<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b></b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>PART I. FINANCIAL INFORMATION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_001"></a>Item 1. Financial Statements</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_002"></a>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>September&nbsp;30, 2015 and December&nbsp;31, 2014</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share data)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015<br> (Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014<br> (Note 1)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">46,627</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">54,540</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,622</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">150</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">23,700</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">18,232</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receivables from collaborations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,495</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,849</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Receivables from product sales</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,641</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">683</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,970</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,172</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred collaboration expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">88</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">76</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Total current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">84,502</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">89,343</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">47,787</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">41,116</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Furniture and equipment, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,146</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">207</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">282</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">177</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">5,239</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6,031</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">138,956</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">136,874</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Equity</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3,782</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,849</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">23,027</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,329</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,517</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,029</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,102</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,481</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred product sales revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,605</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-recourse notes payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">30,000</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">30,000</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Total current liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">64,444</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">57,293</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,122</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,552</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred rent</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">345</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">394</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stockholders&#8217; equity:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,337 in 2015 and 71,955 in 2014</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">733</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">720</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Additional paid-in capital</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">556,095</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">542,943</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accumulated other comprehensive loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(130</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(492,782</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(467,898</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">64,045</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">75,635</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total liabilities and stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">138,956</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">136,874</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_003"></a>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Periods Ended September 30, 2015 and 2014</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share data-Unaudited)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Nine Months</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; text-align: left">Product sales, net</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">5,699</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">6,236</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">126</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,776</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,951</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Collaborative and other research and development</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">5,162</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">3,233</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">35,643</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6,211</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Total revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,987</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,238</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">43,655</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,162</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cost of products sold</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,346</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,361</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Research and development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,067</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,036</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">53,711</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">33,286</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Selling, general and administrative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,731</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,812</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,326</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,413</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Royalty</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">5</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">507</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">78</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Total operating expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">24,149</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,848</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">65,905</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">38,777</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Loss from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(13,162</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(11,610</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(22,250</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(30,615</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest and other income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">134</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">367</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">50</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,241</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,217</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3,862</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3,684</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">(Loss) gain on foreign currency derivative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(352</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">4,082</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">861</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">732</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(14,621</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(8,731</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(24,884</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(33,517</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Basic and diluted net loss per common share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.20</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.12</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.34</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.52</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Weighted average shares outstanding</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">73,262</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">71,801</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">72,752</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">65,057</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized gain (loss) on available for sale investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">91</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">129</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Comprehensive loss</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(14,530</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(8,732</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(24,755</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(33,519</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in"><b></b></p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_004"></a><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Nine Months Ended September&nbsp;30, 2015 and 2014</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands-Unaudited)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Operating activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; text-align: left">Net loss</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(24,884</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(33,517</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Depreciation and amortization</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">137</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">137</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,773</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,550</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Amortization of debt issuance costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">329</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">329</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Change in fair value of foreign currency derivative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">793</td><td style="font-size: 10pt; text-align: left"></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(732</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 20pt">Receivables</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,995</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,123</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 20pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">683</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Prepaid expenses and other assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,331</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(29</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(117</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">45</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Accounts payable and accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,582</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,602</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(512</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">957</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Deferred revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,602</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(880</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Net cash provided by (used in) operating activities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,712</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(24,661</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investing activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Acquisitions of furniture and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,076</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(41</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Change in restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,472</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Purchases of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(48,343</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(15,852</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Sales and maturities of investments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">35,874</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">29,000</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Net cash (used in) provided by investing activities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(15,017</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">13,108</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Financing activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Sale of common stock, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,175</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">106,600</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Exercise of stock options</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,861</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,636</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Employee stock purchase plan sales</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">356</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">310</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 20pt">Net cash provided by financing activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,392</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">111,546</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">(Decrease) Increase in cash and cash equivalents</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(7,913</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">99,993</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">54,540</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">21,164</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt">Cash and cash equivalents at end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">46,627</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">121,157</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_005"></a><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 1 &#8212; Significant Accounting Policies</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>The Company</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology
company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of
diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its
capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina.
The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop
small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative
cash flows from operations since inception.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient
liquidity, with its existing cash and investments of $119,736, to continue its planned operations into 2017. The Company&#8217;s
liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key
development and regulatory events in the future. In order to continue its operations substantially beyond 2017 it will need to:
(1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&nbsp;out-license
rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raise
additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory
approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research and development programs;
and/or (6)&nbsp;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities,
including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from its effective shelf
S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&nbsp;&nbsp;Additionally,
the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock,
depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed
with the Securities and Exchange Commission on November&nbsp;6, 2013. The Company will continue to incur operating losses and negative
cash flows until revenues reach a level sufficient to support ongoing operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Basis of Presentation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;). Royalty Sub was formed in connection
with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a
further description of this transaction. All intercompany transactions and balances have been eliminated.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial
reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete
financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present
fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There
were no adjustments other than normal recurring adjustments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the
financial statements for the year ended December&nbsp;31, 2014 and the notes thereto included in the Company&#8217;s 2014 Annual
Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance
sheet as of December&nbsp;31, 2014 has been derived from the audited consolidated financial statements included in the Company&#8217;s
most recent Annual Report on Form 10-K.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Reclassifications</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Certain balance sheet amounts as of December 31, 2014 have been reclassified
to conform to the 2015 presentation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held
in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities
of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to
the short-term nature of these items.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Restricted Cash</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of September 30, 2015 reflects $150 the Company
is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program,
$70 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes
(defined in Note 4) and $1,402 the Company is required to maintain as collateral for a letter of credit associated with the lease
execution and build-out of its new Birmingham research facilities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Investments</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance
with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment
policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow
requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government
agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable
debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments,
municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s
investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years
and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market
risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize
this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the
need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to
interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company
has not realized any significant losses from its investments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale.
Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be
other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments
for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary
declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in
the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions
recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature
at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from
the balance sheet date are classified as long-term. At September 30, 2015, the Company believes that the costs of its investments
are recoverable in all material respects.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#8217;s
investments by type. The estimated fair value of the Company&#8217;s fixed income investments are classified as Level 2 in the
fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted
prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets
that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30,
    2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br> Fair&nbsp;Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">23,119</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">42</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">28</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(2</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">23,187</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,249</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">141</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(14</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,402</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,909</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">28</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">10</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(49</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,898</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,277</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">211</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(65</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br> Fair&nbsp;Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">20,307</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">22</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(23</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">20,306</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,152</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">151</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(47</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,261</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,838</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(63</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,781</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,297</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(133</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#8217;s
investments at September&nbsp;30, 2015 and December&nbsp;31, 2014.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; font-size: 10pt; text-align: left">Maturing in one year or less</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">23,700</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">18,232</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,183</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">25,459</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,604</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">15,657</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Receivables from Collaborations</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Receivables from collaborations are recorded for amounts due to the Company
related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables
from Shionogi, and product sales to Green Cross Corporation (&ldquo;Green Cross&rdquo;) and Seqirus UK Limited (&ldquo;SUL&rdquo;).
These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September
30, 2015 and December&nbsp;31, 2014, the Company had the following receivables.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><font style="font-size: 10pt">Billed</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><font style="font-size: 10pt">Unbilled</font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="border-bottom: black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">Total</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">5,444</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">5,444</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">129</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">129</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><P STYLE="margin: 0">Seqirus UK Limited</P>


</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,051</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,444</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,495</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,778</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,778</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi &amp; Co. Ltd.</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,071</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,778</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,849</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and
Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of
indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates
are subject to audit by the U.S. Government.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Receivables from Product Sales</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the
Company related to sales of RAPIVAB<sup>&#174;</sup>. These receivables are evaluated to determine if any reserve or allowance should
be established at each reporting date.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">At December 31, 2014, the Company&rsquo;s inventory consisted of RAPIVAB
finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out
(&ldquo;FIFO&rdquo;) method, or market. The Company expenses costs related to the production of inventories as research and development
expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which
generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs
related to the production of inventories. In connection with the June 2015 SUL collaboration, the Company sold all of its available
RAPIVAB finished goods inventory to SUL in accordance with terms stipulated in the licensing agreement.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the Food and Drug Administration (&#8220;FDA&#8221;)
approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB commercial inventories.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s inventory consisted of the following at September&nbsp;30,
2015 and December&nbsp;31, 2014:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; font-size: 10pt; text-align: left">Work in process</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">267</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished Goods</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">416</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">683</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Patents and Licenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed
processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred
as recoverability of such expenditures is uncertain.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party
vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these
contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records
liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of
the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel
to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost
incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service
providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of
each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the
accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses
include:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">fees paid to investigative sites in connection with clinical trials;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">professional fees.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates
of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary
from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such
as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company
estimates the time period over which services will be performed and the level of effort expended in each period. If the actual
timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
As of September 30, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their
short-term settlement.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Income Taxes</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#8217;s accounting for
income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting
and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect
when the differences are expected to reverse.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Accumulated Other Comprehensive Loss</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains
and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified
from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive
Loss. During the nine months ended September 30, 2015, realized gains of $13 were reclassified out of accumulated other comprehensive
loss. No reclassifications out of accumulated other comprehensive loss were recorded during the nine months ended September 30,
2014.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research
and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable
and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery
has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability
is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research
and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing
performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received
under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined
by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result
of changes in the estimated revenue period are recognized prospectively.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under certain of the Company&#8217;s license agreements, the Company
receives royalty payments based upon its licensees&#8217; net sales of covered products. The Company recognizes royalty revenues
when it can reliably estimate such amounts and collectability is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each
deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered,
limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables
requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset,
or another performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">In June 2015, the Company entered into a License Agreement (the &ldquo;SUL
Agreement&rdquo;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture
and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone
payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory
and (iii) regulatory support to obtain Canadian and European Union (&ldquo;EU&rdquo;) marketing approvals. The Company received
an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be
deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue
in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized
during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement
will be recognized over the expected period of involvement in these regulatory support activities.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these
revenue recognition criteria are recorded as deferred revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Under the terms of the SUL Agreement, the Company may receive up to $12,000
in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the
FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch
of Health Canada (&ldquo;Health Canada&rdquo;) for an adult indication in Canada. The Company evaluated each event based payment
under the provisions of ASU 2010-17, <I>Milestone Method of Revenue Recognition</I>, and determined that each event based payment
met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based
payments were achieved during the periods presented.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a
reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within
the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious
Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><i>Product Sales</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially
all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our
specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is
persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably
assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United
States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state
and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be primarily
responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales, and the Company&rsquo;s commercial sales will be
minimal.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate
gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes,
but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through
to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with
authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following
significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting
estimates, and require it to use information from external sources.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Rebates and Chargebacks</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under
these programs relating to RAPIVAB sales.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials
between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers
covered under federally qualified programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on
multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience,
changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory
or negotiated prices), changes in prescription demand patterns and utilization of the Company&#8217;s product through public benefit
plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from
third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions
each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within
nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#8217;s estimates, additional
reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with the Company&#8217;s specialty distributors, the
Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual
contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of
these fees by applying the contractual rates to such product sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Returns</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does
not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Advertising</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response
advertising when promoting RAPIVAB.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three and nine
months ended September&nbsp;30, 2015 and 2014:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Three Months</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Nine Months</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,699</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">6,236</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">126</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,776</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,951</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -20pt; padding-left: 20pt">Collaborative and other research and development revenues:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt">U.S. Department of Health and Human Services</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,582</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,937</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,788</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,323</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Green Cross Corporation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">132</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">132</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Shionogi (Japan)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">888</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">888</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><P STYLE="margin: 0">Seqirus UK Limited</P>


</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">152</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">21,835</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total collaborative and other research and development revenues</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">5,162</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">3,233</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">35,643</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6,211</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,987</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,238</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">43,655</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,162</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s research and development costs are charged to
expense when incurred. Research and development expenses include all direct and indirect development costs related to the development
of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for
future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related
goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel
costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials
and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s
manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued
by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s
on-going review of the level of services actually performed.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties,
such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;),
and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance
fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which
case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments
as incurred.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid
to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration
paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred
without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion
to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with
the associated revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on
their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value
of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is
recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding
performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Interest Expense and Deferred Financing Costs</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended September&nbsp;30, 2015
and 2014 was $1,241 and $1,217, respectively, and for the nine months ended September 30, 2015 and 2014 was $3,862 and $3,684,
respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance
of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs
are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization
of deferred financing costs included in interest expense was $110 for each of the three months ended September&nbsp;30, 2015 and
2014, and $329 for each of the nine months ended September&nbsp;30, 2015 and 2014.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Currency Hedge Agreement</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">In connection with the issuance by Royalty Sub of
the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with
changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting
treatment; therefore, mark-to-market adjustments are recognized in the Company&rsquo;s Consolidated Statements of Comprehensive
Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 and 2014 resulted in a loss of $793 and
a gain of $732, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices
in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level
2 in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized a currency exchange gain of $1,654 during
the first nine months of 2015 associated with the exercise of a U.S. Dollar/Japanese yen currency option.</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company is also required to post collateral in connection with
the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of September 30, 2015 and December
31, 2014, no hedge collateral was posted under the agreement.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Net Loss Per Share</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Net loss per share is based upon the weighted average number of common
shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented
herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&rsquo;s
employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended September&nbsp;30,
2015 and 2014 does not include 3,821 and 4,240, respectively, of such potential common shares, as their impact would be anti-dilutive.
The calculation of diluted earnings per share for the nine months ended September&nbsp;30, 2015 and 2014 does not include 3,673
and 3,986, respectively, of such potential common shares, as their impact would be anti-dilutive.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Use of Estimates</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP
requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results
could differ from those estimates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><b><i>Significant Customers and Other Risks</i></b></p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">The Company relies primarily on three specialty distributors to purchase
and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB
product sales to date and accounted for predominantly all of the Company&rsquo;s outstanding receivables from product sales. The
loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However,
the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other
peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with
the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&rsquo;s partners
and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">The Company&rsquo;s primary source of revenue that has an underlying cash
flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS
and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs
for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&rsquo;s
collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development
contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&rsquo;s future Consolidated
Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of
RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then
the principal, on the Company&rsquo;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal
of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&rsquo;s
drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform
their services, this could significantly impact the Company&rsquo;s ability to complete its drug development activities.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 27pt"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 27pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">The Company relies on single source manufacturers
for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates
in development.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Credit Risk</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially
subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess
cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits.
The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities
that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio
of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables
discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which
there is no assumed credit risk.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in"><b><i></i></b></p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In April 2015, the FASB issued ASU No.2015-03, <i>Simplifying the
Presentation of Debt Issuance Costs</i>. This standard amends existing guidance to require the presentation of debt issuance costs
in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is
effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect
this ASU will have a material impact on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued ASU 2014-09 &#8211; <i>Revenue from Contracts
with Customers</i>, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core
principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an
amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This
ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from
customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain
or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now
be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017.
Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company
is currently evaluating the impact this ASU will have on its consolidated financial statements.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 2 &#8212; Stock-Based Compensation</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of September 30, 2015, the Company had two stock-based employee
compensation plans, the Stock Incentive Plan (&#8220;Incentive Plan&#8221;) and the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
both which were amended and restated in March 2014 and approved by the Company&#8217;s stockholders in May 2014. Stock-based compensation
expense of $7,773 ($7,553 of expense related to the Incentive Plan and $220 of expense related to the ESPP) was recognized during
the first nine months of 2015, while $6,550 ($6,388 of expense related to the Incentive Plan and $162 of expense related to the
ESPP) was recognized during the first nine months of 2014.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There was approximately $14,839 of total unrecognized compensation
cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of September 30, 2015.
That cost is expected to be recognized as follows: $1,782 during the remainder of 2015, $5,632 in 2016, $4,627 in 2017, $2,508
in 2018 and $290 in 2019. In addition, the Company has approximately $11,982 of unrecognized compensation cost related to outstanding
performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred and
the award vests. At the time of vesting, compensation expense will be recognized.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Stock Incentive Plan</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards
to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted
with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Since March&nbsp;1, 2011, stock
option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company
made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after
two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively.
These awards vest upon successful completion of specific development milestones. As of September 30, 2015, 75% of the August 2013
grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which
vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of
2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered
BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of September 30, 2015, 25% of
the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation
expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to
non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5
to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in
the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive
Plan.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Awards<br> Available</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Options<br> Outstanding</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Weighted<br> Average<br> Exercise<br> Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt">Balance December 31, 2014</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">2,362</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">9,605</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">6.21</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(155</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,319</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,319</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11.99</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,102</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.36</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">28</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(28</td><td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">9.05</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance September 30, 2015</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">917</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,794</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">7.19</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during the
first nine months of 2015 and 2014, the fair value was estimated on the date of grant using a Black-Scholes option pricing model
and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during
the first nine months of 2015 and 2014 was $8.15 and $8.19, respectively. The fair value of the stock option awards is amortized
to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions
used by the Company to value the stock option awards granted during the first nine months of 2015 and 2014. The expected life is
based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption
that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting
(if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s
publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or
option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield
currently available on zero-coupon government issues with a remaining term equal to the expected term.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Weighted Average Assumptions for Stock Option Awards Granted
to</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Employees and Directors under the Incentive Plan</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Expected Life in Years</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected Volatility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">83</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">87</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.5</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.6</td><td style="font-size: 10pt; text-align: left">%</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Employee Stock Purchase Plan</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of 1,475 shares of common stock to
be purchased under the ESPP, of which 497 shares remain available for purchase at September 30, 2015. Eligible employees may authorize
up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month
purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee
may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued
41 shares during the first nine months of 2015 under the ESPP. Compensation expense for shares purchased under the ESPP related
to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 3 &#8212; Collaborative and Other Research and Development Contracts</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;).</i>
In January 2007, BARDA/HHS awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the
treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment
of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir
program and to increase funding by $77,191. On February&nbsp;24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000
contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized
with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to
support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an
NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30,
2014 according to its terms.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 31, 2015, the Company announced that the Biomedical Research
and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for
Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases
caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430
drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the
potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options
within this contract.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;).</i>
In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease.
NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this
contract as of September 30, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year
period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430
for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase
1 human clinical trial. As of September 30, 2015, a total of $29,875 has been awarded under exercised options within this contract.
BCX4430 is the lead compound in the Company&#8217;s BSAV research program.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic
assessments of progress and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality
of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These
contracts are terminable by the government at any time for breach or without cause.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><I>Seqirus UK Limited (&ldquo;SUL&rdquo;).</I> On June 16, 2015, the
Company and Seqirus UK Limited (&quot;SUL&quot;), a limited company organized under the laws of the United Kingdom and a subsidiary
of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &quot;SUL Agreement&quot;)
granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
together constituting the &quot;Territory&quot;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is
currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment
in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated
influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and
associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue
government stockpiling outside the U.S.</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's
subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets.
SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. The Company will exercise
sole decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and is
responsible for all associated costs.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">In December 2013, the Company submitted a New Drug Application (&quot;NDA&quot;)
for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval
commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility
for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory
filings and interactions with the Health Canada and the European Medicines Agency (&quot;EMA&quot;) until marketing approval for
RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee,
composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the
commercialization of RAPIVAB in the Territory and any additional development.</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received
an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement
of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult
indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement
to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales,
as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically,
the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract
Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the
Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events
impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire,
on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from
the date of the SUL Agreement (the &quot;Royalty Term&quot;). The Company developed RAPIVAB under a license from UAB and will owe
sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The term of the SUL Agreement shall continue on a country-by-country
basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate
the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement,
subject to applicable cure periods, or if the other party suffers an insolvency event. The Company may also terminate the SUL Agreement
if SUL or any of its affiliates seek to challenge the validity of the Company's patents. Termination does not affect a party's
rights which have accrued prior thereto, but there are no stated payments in connection with termination other than payments of
obligations previously accrued. For all terminations exercised by the Company, the SUL Agreement provides for the termination of
any sublicenses granted by SUL to third parties, and in the case of termination by the Company for cause, the ceasing of SUL's
activities with respect to RAPIVAB, the discontinued use of all Company intellectual property and the termination of licenses and
rights previously granted to SUL. If requested by the Company, SUL shall also promptly sell to the Company all licensed product
it then holds in stock, otherwise, SUL may continue to sell such licensed product for designated periods.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;).</i> In
February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in
Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi
obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and
will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In
October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include
Taiwan and to provide rights for Shionogi to perform a Phase&nbsp;3 clinical trial in Hong Kong. Shionogi has commercially launched
peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Green Cross Corporation (&#8220;Green Cross&#8221;).</i> In June
2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of
the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company
received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale
of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross
will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products
in Korea.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;).</i>
In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development
and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology. Under
the terms of the license agreement, as amended, Mundipharma obtained worldwide rights to forodesine. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial
Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively).</i> In June 2000, the Company licensed a series of potent
inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration
are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or
any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement
to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially
reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed
product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors,
single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future
payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which
can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement
may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by
the Licensors.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which
the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from
research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed
to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed
PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company
may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received
from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect.
The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In consideration for these modifications in 2010, the Company issued
to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally,
at the Company&#8217;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid
by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination
of cash and shares.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, the Company further amended its agreements
with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined)
received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June&nbsp;19, 2012, the Company further amended its agreements
with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to
exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions,
any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash,
in shares of the Company&#8217;s common stock, or in a combination of cash and shares.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On January 6, 2014, the Carbohydrate Chemistry Research Team from
Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#8220;VUW&#8221;)
to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts
relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst
is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties,
the terms and conditions of the contracts are substantially the same.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"><I>The University of Alabama at Birmingham (&ldquo;UAB&rdquo;).</I> The
Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain
rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company
has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other
third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year
terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company
upon three months&rsquo; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other
parties&rsquo; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall
resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements,
but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes
products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</P>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 4 &#8212; Royalty Monetization</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Overview</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing
transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi
licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received
net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest
reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account
has been fully utilized with the September 2012 interest payment.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and
sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things,
(i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the
right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency
Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi
in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted
as a result of this transaction.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Non-Recourse Notes Payable</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to
institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA
Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;),
by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are
payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the
Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest
at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive
any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s obligations to pay principal and interest on the
PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company
may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion
pay any interest shortfall on, the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On September&nbsp;1, 2014, Royalty Sub was unable to pay the full
amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified
as current liabilities on the Consolidated Balance Sheet. As a result of the event of default under the PhaRMA Notes, the holders
of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and
the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes.
In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment
of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event
of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from
Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating
the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease
to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default
of the PhaRMA Notes is not expected to have a significant impact on the Company&#8217;s future results of operations or cash flows.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture
includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of
Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters
typical for indentures used in structured financings of this type.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any
time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid
interest through the redemption date on the PhaRMA Notes being redeemed.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Foreign Currency Hedge</i></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the
Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen
relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at
a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided
the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year,
the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">The Currency Hedge Agreement does not qualify for hedge accounting treatment;
therefore, mark-to-market adjustments are recognized in the Company&rsquo;s Consolidated Statement of Comprehensive Loss. Cumulative
mark-to-market adjustments resulted in a loss of $460 and a gain of $4,082 for the three months ended September&nbsp;30, 2015 and
2014, respectively and a loss of $793 and a gain of $732 for the nine months ended September&nbsp;30, 2015 and 2014, respectively.
During the nine months ended September&nbsp;30, 2015, the Company realized a currency exchange gain of $1,654 associated with the
exercise of a U.S. Dollar/Japanese yen currency option. The Company is also required to post collateral in connection with the
mark-to-market adjustments based on defined thresholds. As of September 30, 2015 and December&nbsp;31, 2014, no collateral was
posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum
premium payments remaining payable under the Currency Hedge Agreement. As of September 30, 2015, the maximum amount of hedge collateral
the Company may be required to post is $9,750.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 5 &#8212; Stockholders&#8217; Equity</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration
statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell
securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time
to time at prices and on terms to be determined at the time of sale.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;6, 2013, the Company filed a $125,000 shelf registration
statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company
to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from
time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration
statement.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_006"></a>Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>This Quarterly Report on Form 10-Q contains statements of a forward-looking
nature relating to future events or the future financial performance of BioCryst. Such statements are only predictions and the
actual events or results may differ materially from the results discussed in the forward-looking statements. Factors that could
cause or contribute to such differences include those discussed below and elsewhere in this report, as well as those discussed
in other filings made by the Company with the Securities and Exchange Commission, including the Company&#8217;s Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See &#8220;Information Regarding Forward-Looking Statements.&#8221;</i></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>Cautionary Statement</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The discussion herein contains forward-looking statements within the
meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221;
created in Section&nbsp;21E. Forward looking statements regarding our financial condition and our results of operations that are
based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted
within the United States (&#8220;U.S. GAAP&#8221;), as well as projections for the future. The preparation of these financial statements
requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based
on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results
of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We operate in a highly competitive environment that involves a number
of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies,
including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of
regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the
need for future capital, competition associated with products, potential competition associated with our products and product candidates
and retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or
our collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction
of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain
market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate
significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will
have sufficient funding to meet our future capital requirements. Statements contained in Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute,
forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ
materially from expected results. The most significant known risks are discussed in the section entitled &#8220;Risk Factors.&#8221;
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.&nbsp;We caution you not to place undue reliance on any forward-looking statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our revenues are difficult to predict and depend on numerous factors,
including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality
of influenza, ongoing discussions with government agencies regarding future RAPIVAB and/or BCX4430 development and stockpiling
procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related
to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones
by us or our collaborative partners.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Our operating expenses are also difficult to predict and depend on several
factors, including research and development expenses (and whether these expenses are reimbursable under government contracts),
drug manufacturing, clinical research activities, the ongoing requirements of our development programs, the anticipated regulatory
approval of our drug candidates, expenses related to building a commercial organization, and the availability of capital and direction
from regulatory agencies, which are difficult to predict. Management may be able to control the timing and level of research and
development and selling, general and administrative expenses, but many of these expenditures will occur irrespective of our actions
due to contractually committed activities and/or payments.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a result of these factors, we believe that period to period comparisons
are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of the foregoing
factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event,
the prevailing market price of our common stock could be materially adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Overview</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are a biotechnology company that designs, optimizes and develops
novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases
in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology,
crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process
known as structure-guided drug design. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Critical Accounting Policies and Estimates</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The accompanying discussion and analysis of our financial condition
and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared
in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities.
We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and
regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public
accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and
manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Corporate Highlights</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><b><i>RAPIVAB (peramivir injection)</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">RAPIVAB was approved by the FDA on December 19, 2014 for the treatment
of acute uncomplicated influenza in adult patients who have been symptomatic for no more than two days. We have elected the &ldquo;Sell-Through&rdquo;
revenue recognition methodology and recognized approximately $0.6 million of RAPIVAB product sales in the first nine months of
2015. With the approval, commercial availability and out-licensing collaboration of RAPIVAB, we have moved our focus to obtaining
a stockpiling procurement contract with the U.S. Government.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 20 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">On June 16, 2015, we and Seqirus UK Limited, a limited company organized
under the laws of the UK (&quot;SUL&quot;) and a subsidiary of CSL, entered into a License Agreement (the &quot;SUL Agreement&quot;)
granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
together constituting the &quot;Territory&quot;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is
currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment
in the world. We retain all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. government,
while SUL has the right to pursue government stockpiling outside the U.S.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's
subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets.
SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. We will exercise sole
decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and are responsible
for all associated costs.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 11.25pt 0 0">Under the terms of the SUL Agreement, we are responsible for
fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment we will
transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and
the European Union (&ldquo;EU&rdquo;), we are also responsible for regulatory filings and interactions with the Health Products
and Food Branch of Health Canada (&quot;Health Canada&quot;) and the European Medicines Agency (&quot;EMA&quot;) until marketing
approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, we and SUL formed a joint steering
committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress
of the commercialization of RAPIVAB in the Territory and any additional development.</P>



<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Under the terms of the SUL Agreement, we received an upfront payment of
$33.7 million, and we may receive up to $12.0 million in additional milestone payments related to the successful achievement of
regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication
in the EU and (iii) by Health Canada for an adult indication in Canada. We are also entitled under the SUL Agreement to receive
tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well
as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, we receive
tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined
as July 1 &ndash; June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory,
other than in the U.S., during a Contract Year, each subject to certain downward adjustments for circumstance or events impacting
the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country
basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement
(the &quot;Royalty Term&quot;).</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">The term of the SUL Agreement shall continue on a country-by-country basis
until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate the SUL
Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement, subject
to applicable cure periods, or if the other party suffers an insolvency event. We may also terminate the SUL Agreement if SUL or
any of its affiliates seek to challenge the validity of our patents. Termination does not affect a party's rights which have accrued
prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued.
For all terminations exercised by us, the SUL Agreement provides for the termination of any sublicenses granted by SUL to third
parties, and in the case of termination by us for cause, the ceasing of SUL's activities with respect to RAPIVAB, the discontinued
use of all of our intellectual property and the termination of licenses and rights previously granted to SUL. If requested by us,
SUL shall also promptly sell to us all licensed product it then holds in stock, otherwise, SUL may continue to sell such licensed
product for designated periods.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b><i>HAE Program</i></b></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Avoralstat, formerly known as BCX4161</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On December 18, 2014, we announced the dosing of the first patient
in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered avoralstat in patients
with HAE. OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of avoralstat,
300 mg and 500 mg, administered three-times daily compared with placebo. This trial is being conducted in the U.S., Canada and
Europe and approximately 100 HAE patients have been enrolled. The primary efficacy endpoint for the trial is the mean angioedema
attack rate for each avoralstat dose group compared to placebo. Avoralstat has Orphan Drug designation in the U.S. and Europe and
has Fast Track designation for the treatment of HAE in the U.S.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">On October 8, 2015, we announced that the OPuS-2 trial completed enrollment,
and we anticipate the final OPuS-2 patient visits will occur in January 2016. Accordingly, we expect to report results in early
2016. The results of this trial will then be provided for regulatory discussions intended to determine the scope of any additional
information that may be required for completion of avoralstat registration. We have been corresponding with regulatory agencies
regarding a deferral of a two-year rat carcinogenicity study for avoralstat. The results from this type of study are normally required
to be available at the time of submission for approval. Currently, we have reached agreement with the EMA to defer submission of
these results as a post-filing commitment. Agreement has not been reached with the FDA regarding a deferral at this time and the
most recent (September 2015) communication from the FDA indicated that we would be required to complete the two year rat carcinogenicity
at the time of filing for avoralstat. At the end-of-Phase 2 meeting following the completion of OPuS-2, we plan to engage in further
dialogue with the FDA to discuss deferral, in the context of all available toxicology and clinical data. We plan to initiate a
two-year rat carcinogenicity study in early 2016. Without a deferral, we expect our NDA filing to occur in 2018.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 21 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>BCX7353 and other 2nd generation HAE compounds</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2015, we selected BCX7353 to advance into Phase 1 development
as a once-daily, oral prophylactic HAE treatment. BXC7353 is structurally different from avoralstat, but has a similar mechanism
of action targeting plasma kallikrein. On May 13, 2015, we announced the initiation of a Phase 1 clinical trial to evaluate the
safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><font style="font-size: 10pt">On October 8, 2015, we announced</font>
<font style="font-size: 10pt">that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX7353 in
healthy volunteers successfully met all of its objectives. Oral BCX7353 was generally safe and well tolerated at all doses up to
500 mg once-daily for 7 days and 350 mg once-daily for 14 days in healthy volunteers, and no dose-limiting toxicity was identified.
</font></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BCX7353 plasma levels increased in approximate proportion to dose,
and drug exposure was not affected by dosing with food. The half-life of BCX7353 was estimated at 50-60 hours. After daily dosing,
blood levels met or exceeded a predicted target therapeutic range throughout the 24 hour dosing interval. Inhibition of the target
enzyme, plasma kallikrein, was measured in a sensitive and specific bioassay. Daily dosing with BCX7353 strongly inhibited plasma
kallikrein at all four dose levels; the degree of inhibition was dose-related (p &lt; 0.0001) and inhibition was sustained throughout
the 24 hour dosing interval. This pharmacodynamic effect correlated strongly to the achieved drug concentration (r = 0.91, p &lt;
0.0001).</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"><FONT STYLE="font-size: 10pt">There were no serious adverse events (&ldquo;AEs&rdquo;)
and most AEs observed were mild. Two subjects discontinued the study due to moderate gastrointestinal AEs. One subject developed
a delayed-type hypersensitivity rash after completing seven days of study drug; the rash resolved quickly with oral and topical
steroids. No clinically significant laboratory abnormalities were seen at any dose or duration tested. The safety, tolerability,
drug exposure and on-target plasma kallikrein inhibition results strongly support advancing the development program into a Phase
2 study in HAE patients.</FONT> <FONT STYLE="font-size: 10pt">A Phase 2, four week dose ranging trial to evaluate the safety, tolerability,
pharmacokinetics, pharmacodynamics and efficacy of BCX7353 as a preventative treatment to reduce the frequency of attacks in HAE
patients is expected to begin in early 2016.</FONT></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On October 27, 2015 the Japanese Ministry of Health Labor &amp; Welfare
(&#8220;MHLW&#8221;) announced that BioCryst&#8217;s BCX7353 was one of six products designated under MHLW&#8217;s new &#8220;Sakigake&#8221;
fast track review system. The Sakigake Designation System promotes R&amp;D in Japan, aiming at early practical application for
innovative pharmaceutical products. This designation provides for additional interactions with the regulatory agency in Japan from
early development through filing, and prioritized development and review, with the aim of introduction of the product as soon as
possible to address a serious unmet medical need.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">In addition to BCX7353, we have succeeded in inventing several uniquely
different plasma kallikrein inhibitor molecules from distinct structural classes. Accordingly, we have selected additional drug
candidates that have suitable pharmacologic properties to advance into preclinical development. The development of these candidates
is approximately two years behind BCX7353.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>BCX4430</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">On December 15, 2014, we announced the dosing of the first subject in
a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of BCX4430 in healthy volunteers. The main
goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430
administered via i.m. injection in healthy subjects. This Phase 1 study is expected to continue in 2016.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Results of Operations (three months ended September 30, 2015 compared to the three
months ended September 30, 2014)</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">For the three months ended September 30, 2015, total revenues were $11.0
million as compared to $3.2 million for the three months ended September 30, 2014. The increase in revenue in the third quarter
of 2015, as compared to 2014, resulted from higher levels of product and collaboration revenue associated with the sale of RAPIVAB
and the SUL out-licensing transaction, as well as increased collaboration revenue associated with the development of BCX4430 under
the NIAID/HHS and BARDA/HHS contracts. Revenues in the third quarter of 2015 included $5.7 million of RAPIVAB product revenue and
$0.2 million of collaborative revenue related to the SUL out-licensing transaction, $0.1 million of royalty revenue from Shionogi
and Green Cross associated with sales of peramivir in Japan and Korea, $4.6 million of reimbursement of collaborative expenses
from NIAID/HHS and BARDA/HHS related to the development of BCX4430 and $0.3 million associated with collaborative revenue amortization
from other corporate partnerships. Revenues in the third quarter of 2014 included $2.9 million of reimbursement of collaborative
expenses from NIAID/HHS related to the development of BCX4430 and $0.3 million associated with collaborative revenue amortization
from other corporate partnerships.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 22 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Research and development (&ldquo;R&amp;D&rdquo;) expenses increased to
$20.1 million for the third quarter of 2015 from $13.0 million in 2014. The increase in 2015 R&amp;D expenses, as compared to 2014,
reflect increased spending on our HAE program, and to a lesser extent, higher expenses associated with two discovery-stage rare
disease projects. The increase in spending on our HAE program was associated with the clinical advancement of avoralstat and BCX7353.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Selling, general and administrative (&ldquo;SG&amp;A&rdquo;) expenses
increased to $2.7 million for the third quarter of 2015 as compared to $1.8&nbsp;million in 2014. The increase of $0.9 million
is primarily associated with initiation of activities in preparation for commercialization of our HAE product candidates and to
a lesser extent commercial expenses associated with RAPIVAB. With the completion of the SUL transaction, we do not anticipate incurring
substantial commercial expenses to promote RAPIVAB in the future. We do expect our SG&amp;A expenses to be higher than in previous
quarters due to administrative expenses associated with corporate growth in preparation for future NDA and other regulatory filings
and for HAE product commercialization.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense related to the non-recourse notes issued in conjunction
with the non-dilutive peramivir royalty monetization transaction in March 2011 was $1.2&nbsp;million in the third quarter of 2015
and 2014. In addition, a mark-to-market loss of $0.5 million was recognized in the third quarter of 2015 related to our foreign
currency hedge, compared to a mark-to-market gain of $4.1 million in the same quarter of 2014, both resulting from changes in the
U.S. dollar/Japanese yen exchange rate in the related time periods. In addition, we realized a currency exchange gain of $0.1 million
in the third quarter of 2015 related to the exercise of a U.S. Dollar/Japanese yen currency option under our foreign currency hedge.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Results of Operations (nine months ended September 30, 2015 compared to the nine months
ended September 30, 2014)</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">For the nine months ended September 30, 2015, total revenues were $43.7
million as compared to $8.2 million for the nine months ended September 30, 2014. The increase in 2015 was primarily due to recognizing
revenue associated with the SUL out-licensing transaction, RAPIVAB product revenue and increased collaboration revenue associated
with BCX4430 development. Revenues in the first nine months of 2015 included $5.7 million of RAPIVAB product revenue and $21.8
million of collaborative revenue related to the SUL Agreement, $1.8 million of royalty revenue from Shionogi and Green Cross associated
with sales of peramivir in Japan and Korea, $12.8 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS
related to the development of BCX4430 and $0.9 million associated with collaborative revenue amortization from other corporate
partnerships. In addition, we recorded approximately $0.6 million of RAPIVAB revenue under the &ldquo;Sell-Through&rdquo; revenue
recognition methodology. Revenues in the first nine months of 2014 included $2.0 million of royalty revenue from Shionogi and Green
Cross associated with sales of peramivir in Japan and Korea, $5.3 million of reimbursement of collaborative expenses from NIAID/HHS
and BARDA/HHS related to the development of BCX4430 and i.v. peramivir and $0.9 million associated with collaborative revenue amortization
from other corporate partnerships.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">R&amp;D expenses increased to $53.7 million for the first nine months
of 2015 from $33.3 million in 2014. The increase in 2015 R&amp;D expenses, as compared to 2014, reflect increased spending on our
HAE program, and to a lesser extent, our BCX4430 program and two rare disease projects. &nbsp;</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes our R&amp;D expenses for the periods
indicated (amounts are in thousands).</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended<br> September 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended<br> September&nbsp;30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">R&amp;D expenses by program:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; font-size: 10pt; padding-left: 10pt">Avoralstat</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">7,296</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">4,822</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">19,390</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">13,634</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">BCX4430</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,394</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,204</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,746</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,877</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">2nd generation HAE compounds</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,308</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,530</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,415</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,450</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Peramivir</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">647</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">608</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,685</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,970</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Other research, preclinical and development costs</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">2,422</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">872</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,475</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">3,355</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total R&amp;D expenses</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">20,067</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">13,036</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">53,711</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">33,286</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">SG&amp;A expenses increased to $10.3 million for the first nine months
of 2015 as compared to $5.4&nbsp;million in 2014. The increase of $4.9 million is primarily associated with initiation of commercial
organization in preparation for commercialization of our HAE drug candidates, unrestricted grants awarded to the U.S. and international
HAE patient advocacy groups, as well as deal-related expenses associated with the SUL out-license transaction.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense related to the non-recourse notes issued in conjunction
with the non-dilutive peramivir royalty monetization transaction in March 2011 was $3.9&nbsp;million in the first nine months of
2015, compared to $3.7 million in the first nine months of 2014. In addition, a mark-to-market loss of $0.8 million was recognized
in the first nine months of 2015 related to our foreign currency hedge, compared to a mark-to-market gain of $0.7 million in the
same period in the prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods.
In addition, a realized currency exchange gain of $1.6 million was recognized in the first nine months of 2015 related to the exercise
of a U.S. Dollar/Japanese yen currency option under our foreign currency hedge.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 23 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Cash expenditures have exceeded revenues since our inception and we expect
our 2015 operating expenses to exceed our 2015 revenues. Our operations have principally been funded through public offerings and
private placements of equity securities; cash from collaborative and other research and development agreements, including U.S.
Government contracts for peramivir and BCX4430; and to a lesser extent, the PhaRMA Notes financing. To date, we have been awarded
a BARDA/HHS peramivir development contract totaling $234.8 million, which expired on June 30, 2014, a NIAID/HHS BCX4430 development
contract totaling $34.0 million, which is ongoing, and a BARDA/HHS BCX4430 development contract totaling $36.2 million, which is
also ongoing. The total amount of NIAID/HHS and BARDA/HHS funding obligated under awarded options in the active contracts is $29.9&nbsp;million
and $16.3 million, respectively. Most recently, we completed a successful public offering in June 2014 of 11.5 million shares of
common stock at a price of $10.00 per share following the release of our OPuS-1 clinical trial results, which provided net proceeds
to us of approximately $107.8 million. This financing and the recently completed SUL out-licensing transaction provides us liquidity
into 2017. We retain the ability to offer for sale approximately $160.0 million of securities, including common stock, preferred
stock, depositary shares, stock purchase contracts, warrants, and units from effective shelf registration statements, which we
filed with the Securities and Exchange Commission. In addition to the above, we have received funding from other sources, including
other collaborative and other research and development agreements; government grants; equipment lease financing; facility leases;
research grants; and interest income on our investments.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of September 30, 2015, we had net working capital of $20.1 million,
a decrease of approximately $12.0 million from $32.1 million at December&nbsp;31, 2014. The decrease in working capital was principally
due to our normal operating expenses associated with the development of our product candidates. Our principal sources of liquidity
at September 30, 2015 were approximately $46.6 million in cash and cash equivalents; approximately $71.5 million in investments
considered available-for-sale; and approximately $7.5 million in receivables from collaborations. We anticipate our cash and investments
will fund our operations into 2017.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We intend to contain costs and cash flow requirements by closely managing
our third party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain
research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant
losses, as we continue to pursue our research and development activities and begin to build a commercial infrastructure. We may
incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual
property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective
of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient
to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies,
and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our
investments.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We extended or executed additional lease obligations in 2015 for our
Birmingham, Alabama operations, which increases the obligation by $5.6 million and extends these new obligations through 2026.
These operating lease obligations encompass future rental obligations of our Birmingham operating facilities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We plan to finance our needs principally from the following:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">lease or loan financing and future public or private equity financing;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">our existing capital resources and interest earned on that capital;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">payments under existing and executing new contracts with the U.S. Government; and</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">payments under collaborative and licensing agreements with corporate partners.</td></tr>
</table>


<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs continue to advance, our costs will increase. Our
current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and
additional personnel resources and testing required for the continuing development of our product candidates will consume significant
capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending
on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for
our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for BCX4430, the amount
of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for
the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical
trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates and the
progression of our other programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 24 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at September 30, 2015, we believe these resources
will be sufficient to fund our operations into 2017. Our future liquidity needs, and ability to address those needs, will largely
be determined by the success of our product candidates and key development and regulatory events in the future. In order to continue
our operations substantially beyond 2017, we will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of
our programs, including procurement contracts; (2)&nbsp;out-license rights to certain of our products or product candidates, pursuant
to which we would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources;
(4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce
spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. We retain the ability to offer
for sale approximately $160.0 million of securities, including common stock, preferred stock, depositary shares stock purchase
contracts, warrants, and units from our effective shelf S-3 registration statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our long-term capital requirements and the adequacy of our available
funds will depend upon many factors, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="text-align: left; width: 3%; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the magnitude of work under our government contracts;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the progress and magnitude of our research, drug discovery and development programs;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the timing, progress and magnitude of building out our commercial capabilities;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">changes in existing collaborative relationships or government contracts;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">our ability to negotiate favorable development and marketing strategic alliances for certain product candidates;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">successful commercialization of marketed products by either us or our partners;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">our ability to engage sites and enroll subjects in our clinical trials;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">increases in personnel and related costs to support the development and commercialization of our product candidates;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the scope of manufacturing of our drug substance and product candidates required for future NDA filings;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">competitive and technological advances;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the time and costs involved in obtaining regulatory approvals as well as the success or failure of obtaining regulatory approvals both in the United States and in other major markets;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">post-approval commitments for RAPIVAB and other products that receive regulatory approval; and</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We expect that we will be required to raise additional capital
to complete the development and commercialization of our current product candidates and we may seek to raise capital in the near
future. Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements
with corporate partners or from other sources, including governmental agencies in general and existing government contracts specifically,
may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities,
with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect
of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements
may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale
back or eliminate certain of our research and development programs. Our future working capital requirements, including the need
for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as
rate of reimbursement by U.S. Government agencies of our BCX4430 expenses and any future decisions regarding the future of the
RAPIVAB and BCX4430 programs, including those relating to stockpiling procurement. More specifically, our working capital requirements
will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates;
obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and
changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of
business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing
processes developed on our behalf by third parties; and the level of required administrative support for our daily operations.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Financial Outlook for 2015</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Based upon our development plans, expected operations and our awarded
government contracts, we expect 2015 operating cash usage to be in the range of $8 to $18 million upon adjusting our previously
predicted range for the first nine months of operations including the SUL transaction, and expect our total 2015 operating expenses
to continue to be in the range of $75 to $95 million. Our operating expense range excludes equity-based compensation expense due
to the difficulty in accurately projecting this expense as it is significantly impacted by the volatility and price of our stock,
as well as vesting of our outstanding performance-based stock options. Our operating cash forecast excludes any impact of our royalty
monetization, and hedge collateral posted or returned, but includes the impact of the $33.7 million payment received associated
with the SUL transaction. Our ability to remain within our operating expense and operating cash target ranges is subject to multiple
factors, including unanticipated or additional general development and administrative costs and other factors described under the
Risk Factors located elsewhere in this report.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of September 30, 2015, we do not have any unconsolidated entities
or off-balance sheet arrangements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Critical Accounting Policies</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have established various accounting policies that govern the application
of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve
significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities.
Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management
are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the
nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which
could have a material impact on the carrying values of assets and liabilities and the results of operations. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements included in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2014, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating
our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial
statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Our inventories consist of RAPIVAB finished goods and work in process,
which are valued at the lower of cost or market using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor,
overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value
of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition,
we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in
addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval
of RAPIVAB in December 2014, we began capitalizing costs associated with the production of RAPIVAB commercial inventories. In connection
with the June 2015 SUL collaboration, we sold all of our available RAPIVAB finished goods inventory to SUL in accordance with terms
stipulated in the licensing agreement.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We enter into contractual agreements with third-party vendors who
provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts
are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under
these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and
purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level
of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority
of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of
each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates
with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 26 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">fees paid to investigative sites in connection with clinical trials;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates;&nbsp;and</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">professional fees.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We base our expenses related to clinical trials on our estimates of
the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful
enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over
which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services
or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have
begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We recognize revenues from collaborative and other research and development
arrangements and product sales. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive
evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s
price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research
and development fees are recognized as revenue when the earnings process is complete and we have no further continuing performance
obligations or we have completed the performance obligations under the terms of the agreement. Fees received under licensing agreements
that are related to future performance are deferred and recognized over an estimated period determined by management based on the
terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables, we evaluate
whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as a result of
changes in the estimated revenue period are recognized prospectively.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under certain of our license agreements, we receive royalty payments
based upon our licensees&#8217; net sales of covered products. We recognize royalty revenues when we can reliably estimate such
amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product sales is subject to returns.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by us on a stand-alone basis. In most cases we expect to use TPE or BESP for allocating consideration to each deliverable. The
consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the
consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the
use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another
performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0">In June 2015, we entered into a License Agreement
(the &quot;SUL Agreement&quot;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to
develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable
upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license
rights, (ii) inventory and (iii) regulatory support to obtain Canadian and EU marketing approvals. We received an upfront payment
of $33.7 million from SUL of which $7.0 million was determined to be contingent upon EU marketing approval and will be deferred
until that time. Approximately $21.8 million of the upfront payment was allocated to the license rights and recognized as revenue
in the second quarter. Approximately $3.7 million of the upfront payment was allocated to the sale of inventory and was recognized
in the third quarter when the inventory transfer was completed. Approximately $1.2 million of the revenue from the SUL Agreement
will be recognized ratably over the expected period of involvement in these regulatory support activities.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the SUL Agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying
these revenue recognition criteria are recorded as deferred revenue.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Under the terms of the SUL Agreement, we may receive up to $12.0 million
in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the
FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication
in Canada. We evaluated each event based payment under the provisions of ASU 2010-17, <I>Milestone Method of Revenue Recognition</I>,
and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the
milestone method of accounting. No event based payments were achieved during the periods presented.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0"></P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 27 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. Under
our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Product Sales</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We recognize revenue for sales of RAPIVAB when title and substantially
all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our
specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is
persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably
assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United
States, we sell RAPIVAB to specialty distributors, who, in turn, sell to physician offices, hospitals and federal, state and commercial
health care organizations.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions to revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We utilize data from external sources to help estimate gross-to-net
sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External sourced data includes, but is not limited
to, information obtained from specialty distributors with respect to their inventory levels and sell-through to customers, and
information from third-party suppliers of market research data to the pharmaceutical industry.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have categorized and described more fully the following significant
sales deductions, all of which involve estimates and judgments, which we consider to be critical accounting estimates, and requires
us to use information from external sources.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Rebates and Chargebacks</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, we maintain reserves for amounts payable under these programs
relating to RAPIVAB sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials
between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers
covered under federally qualified programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on
multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience,
changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory
or negotiated prices), changes in prescription demand patterns and utilization of our product through public benefit plans, and
the levels of RAPIVAB inventory in the distribution channel. We acquire prescription utilization data from third-party suppliers
of market research data to the pharmaceutical industry. We update our estimates and assumptions each period and record any necessary
adjustments to reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent
actual rebates and chargebacks differ from our estimates, additional reserves may be required or reserves may need to be reversed,
either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with our specialty distributors, we provide an IMA fee
based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in our individual contracts. We track sales
to our specialty distributors each period and accrue a liability relating to the unpaid portion of these fees by applying contractual
rates to such sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><i>Product Returns</i></p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not record a product return allowance as we do not offer the
ability to return goods once a bona fide shipment has been accepted by a specialty distributor.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development costs are charged to expense when incurred.
Advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.
Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs,
clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of
various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed
by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts
and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, we have license agreements with third parties, such
as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments
as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized
over the related revenue recognition period. We expense maintenance payments as incurred.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments paid
to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic
partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt
of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being
recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We group our R&amp;D expenses into two major categories: direct external
expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct
laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials,
as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by program. Indirect
expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our
research and development efforts. These costs apply to work on our clinical and preclinical candidates as well as our discovery
research efforts.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Stock-Based Compensation</i></b> &nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values.
Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense
on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related
assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected
term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line
basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to
the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative
adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation
expense is recognized until &#8220;performance&#8221; has occurred. Significant management judgment is also required in determining
estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future
changes in estimates, may differ substantially from our current estimates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Foreign Currency Hedge</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with our issuance of the PhaRMA Notes, we entered into
a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to
the U.S.&nbsp;dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen
per dollar for which we may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement
remains in effect. A payment of $2.0&nbsp;million will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is
worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with establishing the Currency
Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience additional quarterly
volatility in our financial results. We will not be required at any time to post collateral exceeding the maximum premium payments
remaining payable under the Currency Hedge Agreement. In establishing the hedge, we provided initial funds of approximately $2.0&nbsp;million
to support our potential hedge obligations. As of September 30, 2015, the maximum amount of hedge collateral we may be required
to post is $9.8 million.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment and therefore mark-to-market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Cumulative
mark-to-market adjustments for the nine months ended September 30, 2015 resulted in a $0.8 million loss. Mark-to-market adjustments
are determined by quoted prices in markets that are not actively traded and for which significant inputs are observable directly
or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting principles. We
are also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of September
30, 2015, no collateral was posted under the agreement.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Tax</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We account for uncertain tax positions in accordance with accounting
principles generally accepted in the U.S. Significant management judgment is required in determining our provision for income taxes,
deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation
allowance against all potential tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting
of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of taxable income
in each of the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 29 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Information Regarding Forward-Looking Statements</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">This filing contains forward-looking statements within the meaning
of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
in Section&nbsp;21E. All statements other than statements of historical facts contained in this filing are forward-looking statements.
These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our
future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions
containing these forward-looking statements are principally contained in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as any amendments
we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements
about:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">the initiation, timing, progress and results of our preclinical testing, clinical trials, and to the extent applicable, post-marketing commitments, for our HAE product candidates, RAPIVAB, BCX4430, and our&nbsp;&nbsp;other research and development efforts;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the further preclinical development, clinical development, commercialization, or post marketing studies by either us or partners of our product candidates and products, including our HAE program, RAPIVAB, BCX4430, and early stage discovery programs;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of BCX4430;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the potential for government stockpiling orders of RAPIVAB, additional regulatory approvals of RAPIVAB or milestones royalties or profit from commercial sales of RAPIVAB by us or our partners;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the potential use of RAPIVAB as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">our ability to establish and maintain collaborations or out-license rights to our drug candidates;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">plans, programs, progress and potential success of our collaborations, including Seqirus UK Limited (&#8220;SUL&#8221;) for RAPIVAB, Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">Royalty Sub&#8217;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product candidates and technology;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">our ability to operate our business without infringing the intellectual property rights of others;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">estimates of our expenses, revenues, capital requirements, annual cash utilization and our needs for additional financing;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">our ability to raise additional capital to fund our operations;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">our financial performance;&nbsp;and</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: middle">competitive companies, technologies and our industry.</td></tr>
</table>


<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These statements relate to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking
statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those
listed under &#8220;Risk Factors.&#8221; Any forward-looking statement reflects our current views with respect to future events
and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry
and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for
any reason, even if new information becomes available in the future.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_007"></a>Item 3. Quantitative and Qualitative Disclosures about Market Risk</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><i>Interest Rate Risk</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are subject to interest rate risk on our investment portfolio and
borrowings under our PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We invest in marketable securities in accordance with our investment
policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs
and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit
exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions,
commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest
in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment
to fluctuate.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our investment exposure to market risk for changes in interest rates
relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value
due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses.
Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure
portfolio liquidity. A hypothetical 100 basis point drop in interest rates along the entire interest rate yield curve would not
significantly affect the fair value of our interest sensitive financial instruments. We generally have the ability to hold our
fixed-income investments to maturity and therefore do not expect that our operating results, financial position or cash flows will
be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations
due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market
value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#8217; issuers.
To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding
the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest
rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant
losses from our investments.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not use interest rate derivative instruments to manage exposure
to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk
and reinvestment risk. We reduce default risk by investing in investment grade securities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Foreign Currency Risk</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The majority of our transactions occur in U.S. dollars and we do not
have operating subsidiaries or investments in foreign countries. Therefore, we are not subject to significant foreign currency
exchange risk in our normal operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative
to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on our potential obligations under
the Currency Hedge Agreement as determined by periodic mark-to-market adjustments. Provided the Currency Hedge Agreement remains
in effect, we may be required to pay an annual premium in the amount of $2.0&nbsp;million from May&nbsp;2016 through May&nbsp;2020.
Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined
in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_008"></a>Item 4. Controls and Procedures</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We maintain a set of disclosure controls and procedures that are designed
to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the
Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation,
under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer,
of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that, as of September 30, 2015, the Company&#8217;s disclosure controls
and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted
by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s
rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company
in such reports is accumulated and communicated to the Company&#8217;s management, including the Chief Executive Officer and Chief
Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There have been no changes in our internal control over financial
reporting that occurred during the quarter ended September 30, 2015 that have materially affected, or are reasonably likely to
materially affect, the Company&#8217;s internal control over financial reporting.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 31 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART II. OTHER INFORMATION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_009"></a>ITEM&nbsp;1A.</b> <b><i>RISK FACTORS</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>An investment in our common stock involves risks. You should consider
carefully all of the information that is included or incorporated by reference in this report before investing in our common stock.
In particular, you should evaluate the</i><i> uncertainties and risks referred to or described below</i><i>, which may adversely
affect our business, financial condition, liquidity or results of operations.</i></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks Relating to Our Business</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have incurred losses since our inception, expect to continue to incur
such losses, and may never be profitable.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Since our inception, we have not achieved sustained profitability. We
expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development efforts
progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.&nbsp;</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To become profitable, we, or our collaborative partners, must successfully
manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable
agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future
license agreements or revenues directly from product sales.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Because of the numerous risks and uncertainties associated with developing
our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are
unable to achieve and sustain profitability, the market value of our common stock will likely decline.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our success depends upon our ability to advance our products through
the various stages of development, especially through the clinical trial process.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To receive the regulatory approvals necessary for the sale of our
product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate
is safe and effective. The development process and related regulatory process are complex and uncertain. Because of the cost and
duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results
in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable
commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. BCX4430, avoralstat,
BCX7353 and our other rare disease product candidates), even after earlier clinical trials show promising results. The development
of our product candidates, including our clinical trials, may not be adequately designed or executed, which could affect the potential
outcome and analysis of study results. Any of our product candidates may produce undesirable side effects in humans. The pre-clinical
and clinical data from our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials
of a product candidate. Undesirable data or side effects in humans could also result in the FDA or foreign regulatory authorities
refusing to approve the product candidate for any targeted indications. In addition, the FDA or other regulatory agencies may determine
that study data from our product candidates necessitates additional studies or study designs which differ from our planned development
strategy, and regulatory agencies may also require patient monitoring and testing or may implement restrictions or other conditions
on our development activities, any of which could materially impact the cost and timing of our planned development strategy. We,
our partners, the FDA or foreign regulatory authorities may suspend or terminate clinical trials at any time if we or they believe
the trial participants face unacceptable health risks. Clinical trials may fail to demonstrate that our product candidates are
safe or effective and have acceptable commercial viability. Regulatory authorities may interrupt, delay or halt clinical trials
for a product candidate for any number of reasons.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to successfully complete clinical trials is dependent
upon many factors, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&#8226;</td>
    <td style="vertical-align: bottom; width: 95%">our ability to find suitable clinical sites and investigators to enroll patients;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">the ability to maintain contact with patients to provide complete data after treatment;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">our product candidates may not prove to be either safe or effective;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</td></tr>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&#8226;</TD>
    <TD STYLE="vertical-align: bottom">formulation improvements may not work as expected, which could negatively impact commercial demand for our
product candidates;</TD></TR>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">manufacturing or quality control problems could affect the supply of product candidates for our trials; and</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">delays or changes in our planned development strategy, the regulations or guidelines, or other unexpected conditions or requirements by governmental agencies.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Clinical trials are lengthy and expensive. We or our partners incur
substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that
the tests and trials will ever result in the commercial sale of a product. For example, clinical trials require adequate supplies
of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment, including in our planned
clinical trials for HAE, can result in increased costs and longer development times. Even if we or our partners successfully complete
clinical trials for our product candidates, we or our partners might not file the required regulatory submissions in a timely manner
and may not receive regulatory approval for the product candidates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 0.25in"><B><I>We focus on rare diseases, which may create additional risks and challenges.</I></B></P>



<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><B><I></i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Because the focus of our Company is developing drugs for rare diseases,
we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the
equivalent designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not
to grant such designations. We cannot guarantee that we will be able to receive orphan drug status from the FDA or equivalent regulatory
designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy or fast track designation, which may
provide certain potential benefits such as more frequent meetings with the FDA to discuss the development plan and intensive guidance
on an efficient drug development program as well as potential eligibility for rolling review or priority review. Even if we are
successful in obtaining any such designation by the FDA or other regulatory agency for our product candidates, such designations
may not lead to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates
will receive marketing approval. Additionally, we may not be able to maintain such designations for our product candidates, and
our competitors may obtain these designations for their product candidates, which could impact our ability to develop and commercialize
our product candidates and may adversely impact our business, financial condition or results of operations.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">We have received orphan and fast track designations for avoralstat in
the United States. Despite this designation; we may not experience a faster development, review or approval process compared to
the conventional FDA procedures. The FDA may withdraw fast track designation if it believes the designation is no longer supported
by data from our clinical development program. Although we have also received Sakigake designation for BCX7353 in Japan; we may
not experience a faster development, review or approval process compared to the conventional process.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our clinical trials may not adequately show that our product candidates
are safe or effective.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Progression of our product candidates through the clinical development
process is dependent upon our trials indicating our product candidates have adequate safety and efficacy in the patients being
treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve
either of these in any of our programs, including avoralstat, BCX7353 and our other rare disease product candidates, could result
in delays in our trials or require the performance of additional unplanned trials. This could result in delays in the development
of our product candidates and could result in significant unexpected costs or the termination of programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to reach milestones or to make annual minimum payments or
otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional
remedies.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable or fail to meet payment obligations, performance
milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments for RAPIVAB, or
development and commercial diligence obligations, are unable or fail to make milestone payments or material data use payments in
accordance with applicable provisions, or fail to pay the minimum annual payments under our respective licenses, our licensors
may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate
or commercialization of the product would cease.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to obtain additional financing or acceptable partnership
arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">As our programs advance, our costs are likely to increase. Our current
and planned discovery, pre-clinical and clinical trials plus the related development, manufacturing, regulatory approval process
requirements, and additional personnel resources and testing required for supporting the development of our product candidates
will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly depending
on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements for
our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for BCX4430 or from other new partnerships
with third parties for the development of our product candidates, including avoralstat, BCX7353 and our other rare disease product
candidates; the commercial success of peramivir by our partners; the amount or profitability of any orders for RAPIVAB or BCX4430
by any government agency or other party; the progress and results of our current and proposed clinical trials for our most advanced
product candidates, including avoralstat, BCX7353 and our other rare disease product candidates; the progress made in the manufacture
of our lead products and the progression of our other programs.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital at any time.
Additional funding, whether through additional sales of securities or collaborative or other arrangements with corporate partners
or from other sources, including governmental agencies in general and from any BARDA/HHS or NIAID/HHS contract specifically, may
not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities,
with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect
of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements
may require us to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable partnership
may require us to delay, scale-back or eliminate certain of our research and development programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 33 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In order to continue future operations and continue our drug development
programs, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government
funding, we may decide to access the equity or debt markets or seek other sources to meet liquidity needs. Our ability to raise
additional capital may be limited and may greatly depend upon the success of ongoing development related to our current drug development
programs, including post approval studies for RAPIVAB,&nbsp;the progress, timeline and ultimate outcome of&nbsp;the avoralstat
development program (including, but not limited to, the OPuS-2 clinical trial, long-term human safety studies, and the timing of
carcinogenicity studies), progress of BCX7353 and our other rare disease product candidates, funding for and continued successful
development of BCX4430, and progress of our early discovery programs. In addition, constriction and volatility in the equity and
debt markets may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure to many
different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include
investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable in the current economic and
political environment. Any such instability may impact these parties&#8217; ability to fulfill contractual obligations to us or
they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers may be negatively
impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place severe downward
pressure on the stock and credit markets, which could reduce the return available on invested corporate cash, which if severe and
sustained could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue
development of our product candidates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If BARDA/HHS or NIAID/HHS were to eliminate, reduce or delay funding
from our contracts, this would have a significant negative impact on our revenues and cash flows.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our projections of revenues and incoming cash flows are substantially
dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our BCX4430 program. If BARDA/HHS or NIAID/HHS were
to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain additional
funding for continued development or regulatory registration for these product candidates or significantly reduce or stop the
development effort.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In contracting with BARDA/HHS and NIAID/HHS, we are subject to various
U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which
may limit our reimbursement or if we are found to be in violation could result in contract termination. U.S. Government contracts
typically contain extraordinary provisions that would not typically be found in commercial contracts. For instance, government
contracts permit unilateral modification by the government, interpretation of relevant regulations (i.e., federal acquisition regulation
clauses), and the ability to terminate without cause. In addition, U.S. Government contracts are subject to an in-process review,
where the U.S. Government will review the project and its options under the contract. As such, we may be at a disadvantage as compared
to other commercial contracts. U.S. Government contracts are subject to audit and modification by the government at its sole discretion.
If the U.S. Government terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance
with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have special contracting
requirements, which create additional risks of reduction or loss of funding.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have recently completed work under a contract with BARDA/HHS for
the development of our neuraminidase inhibitor, peramivir. We also have entered into contracts with BARDA/HHS and NIAID/HHS for
the development of BCX4430 as a treatment for diseases caused by RNA pathogens, including Marburg virus disease and Ebola virus
disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including
general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found
to be in violation, could result in contract termination. U.S. Government contracts typically contain extraordinary provisions
that would not typically be found in commercial contracts. For instance, government contracts permit unilateral modification by
the government, interpretation of relevant regulations (i.e., federal acquisition regulation clauses), and the ability to terminate
without cause. In addition, U.S. Government contracts are subject to the in-process review described above. As such, we may be
at a disadvantage as compared to competitors that do not rely on U.S. Government contracts.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">U.S. Government contracts typically contain unfavorable termination
provisions and are subject to audit and modification by the government at its sole discretion, each of which subjects us to additional
risks. These risks include the ability of the U.S. Government to unilaterally:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="font-size: 10pt; vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="font-size: 10pt; vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="font-size: 10pt; vertical-align: middle; width: 95%">terminate or reduce the scope of our contract; and</td></tr>
<tr>
    <td style="font-size: 10pt; vertical-align: bottom">&nbsp;</td>
    <td style="font-size: 10pt; vertical-align: top; text-align: left">&#8226;</td>
    <td style="font-size: 10pt; vertical-align: middle">audit and object to our contract-related costs and fees, including allocated indirect costs.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 34 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The U.S. Government may terminate its contracts with us either for
its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience
provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work
completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination
or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses
under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments
under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further,
if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance
with the contract schedule and terms, significant negative impact on our cash flows and operations could result. As a U.S. Government
contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting practices and
are subject to periodic audits and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of,
and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating,
compensation and management information systems. Audits conducted by the U.S. Government for the completed BARDA/HHS contract have
been performed and concluded through fiscal 2009; all subsequent fiscal years are still open and auditable. Audits under the active
BARDA/HHS and NIAID/HHS contracts may occur at the election of the U.S. Government. Based on the results of its audits, the U.S.
Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the
amount of revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition,
in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect
cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from
us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal
penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments,
fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation
if allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs
may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased
risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared
to private sector commercial companies.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to successfully commercialize or establish collaborative
relationships to commercialize certain of our product candidates or if any partner terminates or fails to perform its obligations
under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our business strategy is to increase the asset value of our product
candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with
third parties as appropriate. As needed, potential third-party alliances could include preclinical development, clinical development,
regulatory approval, marketing, sales and distribution of our product candidates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Currently, we have established collaborative relationships with Mundipharma
for the development and commercialization of forodesine and with each of Shionogi and Green Cross for the development and commercialization
of peramivir, in Japan, Taiwan and South Korea. Most recently we have established a collaborative relationship with Seqirus UK
Limited for RAPIVAB in the United States and countries other than Israel, Japan, Korea and Taiwan. The process of establishing
and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">our contracts for collaborative arrangements may expire;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">our partners may choose to pursue alternative technologies, including those of our competitors;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">we may have disputes with a partner that could lead to litigation or arbitration;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">we do not have day to day control over the activities of our partners and have limited control over their decisions;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">we or our partners may not devote sufficient capital or resources towards our product
    candidates; and</td></tr>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&#8226;</TD>
    <TD STYLE="vertical-align: middle">we or our partners may not comply with applicable government regulatory requirements.</TD></TR>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 35 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 12pt 0 0">If we or our partners fail to fulfill our responsibilities in a
timely manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated,
or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our
partner. In the case of our collaboration with SUL, we continue to have certain promotional regulatory and government pricing risks
because we hold the RAPIVAB NDA and our partner is conducting the marketing and commercialization efforts.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 12pt 0 0">If we are unable to establish and maintain collaborative relationships
on acceptable terms, we may have to delay or discontinue further development of one or more of our product candidates, undertake
commercialization activities at our own expense or find alternative sources of funding. Any delay in the development or commercialization
of our product candidates would severely affect our business, because if our product candidates do not progress through the development
process or reach the market in a timely manner, or at all, we may not receive additional future event payments and may never receive
milestone, product sales or royalty payments.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We do not have a great deal of experience in commercializing our products
or technologies, and our future revenue generation is uncertain.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not have a great deal of experience in commercializing our products
or technologies. We currently have limited marketing capability, no direct or third-party sales force and limited distribution
capabilities. We may be unable to establish or sufficiently increase these capabilities for products we currently, or plan to,
commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status of our preclinical and clinical
programs. If we fail to advance these programs to the point of being able to enter into successful collaborations, we will not
receive any potential future event or other collaborative payments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to receive revenue from products we commercialize presents
several risks, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">we or our collaborators may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep FDA marketing approval;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">reimbursement is constantly changing, which could greatly affect usage of our products; and</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.</td></tr>
</table>


<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If our development collaborations with third parties, such as our development
partners and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We rely heavily upon other parties for many important stages of our
product candidate development, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">licensing or designing of enzyme inhibitors for development as product candidates;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">execution of some preclinical studies and late-stage development for our compounds and product candidates;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">management of our clinical trials, including medical monitoring and data management;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">execution of additional toxicology studies that may be required to obtain approval for our product candidates; and</td></tr>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&#8226;</TD>
    <TD STYLE="vertical-align: middle">formulation improvement strategies and methods, including those for avoralstat; and</TD></TR>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 36 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to engage in successful collaborations at any one of these
stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from
other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research
organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting
materials, drug substance and product candidates or manage our regulatory function breached their obligations to us or perform
their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent
both the development of our product candidates and the availability of any potential commercial product.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we lose our relationship with any one or more of these parties,
we could experience a significant delay in both identifying another comparable provider and then contracting for its services.
We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it
is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service
as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices
(&#8220;cGLP&#8221;), current Good Manufacturing Practices (&#8220;cGMP&#8221;) and current Good Clinical Practices (&#8220;cGCP&#8221;),
and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently,
if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates
could be delayed, and our business, financial condition and results of operations could be materially adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Commercialization of RAPIVAB by our partners is subject to the potential
commercialization risks described herein and numerous additional risks. Any potential revenue benefits to us in the form of milestones,
royalties or other consideration are highly speculative.</i></b> &nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Commercialization success of RAPIVAB is uncertain and is subject to
all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition,
commercialization of RAPIVAB is subject to further risks and commercialization may be negatively impacted by a number of factors,
including, but not limited to, the following:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">RAPIVAB may not prove to be adequately safe and effective for market approval in markets other than the United States;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">necessary funding for post marketing commitments and further development of RAPIVAB may not be available timely, at all, or in sufficient amounts;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for RAPIVAB;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">a limited number of governmental entities are expected to be the primary potential stockpiling customers for RAPIVAB and if we are not successful at marketing RAPIVAB to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for RAPIVAB;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">the commercial demand and acceptance for RAPIVAB by healthcare providers and by patients may not be sufficient to result in substantial revenues of RAPIVAB to our partners and may result in little to no milestones or royalties to us;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">effectiveness of marketing efforts for RAPIVAB by our partners;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">market satisfaction with existing alternative therapies;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">perceived efficacy relative to other available therapies;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">disease prevalence;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">cost of treatment;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">pricing and availability of alternative products;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">marketing and sales activities of competitors;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">shifts in the medical community to new treatment paradigms or standards of care; and</td></tr>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&#8226;</TD>
    <TD STYLE="vertical-align: middle">relative convenience and ease of administration.</TD></TR>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 37 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If any or all of these and other risk factors occur, we will not attain
significant revenues or gross margins from RAPIVAB and our stock price and or cash flows may be adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We are subject to various federal and state laws regulating the marketing
of RAPIVAB and, if we do not comply with these regulations, we could face substantial penalties.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our sales, promotion and other activities related to RAPIVAB, or any
of our other products under development following their regulatory approval, are subject to regulatory and law enforcement authorities
in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. We
are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including both federal and
state anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our distributors,
might be challenged under anti-kickback or similar laws. Violations of fraud and abuse laws may be punishable by civil or criminal
sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Because we continue to hold the NDA for RAPIVAB in the United States,
we may be held responsible for any and all sales, promotion and other activities related to RAPIVAB, as well as any of our other
products under development following their regulatory approval. We are subject to regulatory and law enforcement authorities in
addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. We are
subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including both federal and state
anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our partners,
might be challenged under anti-kickback or similar laws. Violations of fraud and abuse laws may be punishable by civil or criminal
sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.
&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have a number of outstanding post-marketing commitments to the
FDA that we retain despite our partnership, which we may not complete successfully or on time for any number of reasons, including
but not limited to lack of funds to complete the studies or insufficient interest by appropriate sites, investigators or study
subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a pediatric patient study of RAPIVAB
and to submit the final results of this clinical trial to the FDA. Depending on the outcome of this clinical trial, we may be unable
to expand the indication for RAPIVAB or we may be required to include specific warnings or limitations on dosing this product,
which could negatively impact sales of RAPIVAB and negatively impact our relationship with our partner. We may be subject to penalties
if we fail to comply with post-approval legal and regulatory requirements and our products could be subject to continual recordkeeping
and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies. Regulatory approval of a product
may be subject to limitations on the indicated uses for which the product may be marketed or to the other restrictive conditions
of approval that limit our ability to promote, sell or distribute a product. Furthermore, RAPIVAB, and any other future product
candidates&#8217; approval, may contain requirements for costly post-marketing testing and surveillance to monitor its safety or
efficacy.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Advertising and promotion are subject to stringent FDA rules and oversight
and as the holder of the NDA we may be held responsible for any advertising and promotion conducted by our partner that is not
in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent
with the FDA approvals for approved products, and must be appropriately substantiated and fairly balanced with information on the
safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed as well and
as the NDA holder of RAPIVAB we are required to make expedited and periodic adverse event reports to the FDA and other regulatory
authorities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, the research, manufacturing, distribution, sale and promotion
of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department
of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. Until we can
successfully transfer the pricing responsibilities to our partner, we remain responsible for pricing and rebate programs. Pricing
and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended,
and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply
Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially
subject to federal and state consumer protection and unfair competition laws.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If our operations with respect to RAPIVAB or our other products which
are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described
above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties,
damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring
of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs
can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal
expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance
with all applicable federal and state fraud and abuse laws may be costly.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 38 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We and our partners may be subject to new legislation, regulatory proposals
and healthcare payor initiatives that may increase our costs of compliance and adversely affect our ability to market our products,
including RAPIVAB, obtain collaborators and raise capital.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2010, the President signed the Patient Protection and Affordable
Care Act, or PPACA, which makes extensive changes to the delivery of health care in the U.S. The PPACA includes numerous provisions
that affect pharmaceutical companies, some of which became effective immediately and others of which will be taking effect over
the next several years. For example, the PPACA seeks to expand health care coverage to the uninsured through private health insurance
reforms and an expansion of Medicaid. The PPACA will also impose substantial costs on pharmaceutical manufacturers, such as an
increase in liability for rebates paid to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare
prescription drug benefit, an annual fee imposed on all manufacturers of brand prescription drugs in the U.S., and an expansion
of an existing program requiring pharmaceutical discounts to certain types of hospitals and federally subsidized clinics. The PPACA
also contains cost containment measures that could reduce reimbursement levels for health care items and services generally, including
pharmaceuticals. It also will require reporting and public disclosure of payments and other transfers of value provided by pharmaceutical
companies to physicians and teaching hospitals. We cannot predict what effect the PPACA or other healthcare reform initiatives
that may be adopted in the future will have on our business. Further, it remains unclear whether there will be any changes made
to provisions of the PPACA or other health care laws through acts of Congress in the future. The continuing efforts of the government,
insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care
could result in decreased net revenues from our pharmaceutical products and decrease potential returns from our development efforts.
In addition, pharmaceutical and device manufacturers will also be required to report and disclose investment interests held by
physicians and their immediate family members during the preceding calendar year. &nbsp;Failure to submit required information
may result in civil monetary penalties for payments, transfers of value or ownership or investment interests not reported in an
annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time consuming, and companies
that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe
harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such
a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, there have been a number of other legislative and regulatory
proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and proposed
at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable
unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational
expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could fact
a material adverse effect on our business, financial condition, results of operations and growth prospects.&nbsp; As a result of
these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change
our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of
operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Managed care organizations are increasingly challenging the prices
charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many managed
care organizations negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement
levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the managed care organization&#8217;s
patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months
before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party
payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product
we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement
on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial
condition and results of operations. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>There are risks related to the potential government use or sale of RAPIVAB.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Government use or sale of RAPIVAB in emergency situations, or otherwise,
may result in the use of RAPIVAB which is outside of its approved use. To the extent that RAPIVAB is used as a treatment for influenza
by any government entity, there can be no assurance that it will prove to be generally safe, well-tolerated and effective. Such
government use of RAPIVAB may create certain liabilities for us. There is no assurance that we or our manufacturers will be able
to fully meet the demand for RAPIVAB in the event of additional orders. Further, we may not achieve a favorable price for additional
orders of RAPIVAB in the United States or in any other country. Our competitors may develop products that could compete with or replace peramivir. We may face competition
in markets where we have no existing intellectual property protection or are unable to successfully enforce our intellectual property
rights.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">There is no assurance that the non-U.S. partnerships
that we have entered into for peramivir will result in any order for peramivir in those countries. There is no assurance that RAPIVAB
will be approved for any use or will achieve market approval in additional countries. In the event that any emergency use or market
approval is granted, there is no assurance that any order by any non-U.S. partnership or commercialization of RAPIVAB in other
countries will be substantial or will be profitable to us. The sale of peramivir, emergency use or other use of peramivir in any
country may create certain liabilities for us.</P>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 39 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Because we have limited manufacturing experience, we depend on third-party
manufacturers to manufacture our product, product candidates and the materials for our product candidates. Often, especially early
in the development and commercialization process, we have only one source for manufacturing. If we cannot rely on existing third-party
manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have limited manufacturing experience and only a small scale manufacturing
facility. We currently rely upon third-party manufacturers to manufacture the materials required for our product, product candidates
and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party manufacturers to
perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party manufacturers,
which may be the only manufacturer we have engaged, may encounter difficulties with meeting our requirements including but not
limited to problems involving:</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">&nbsp;</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">inconsistent production yields;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">product liability claims or recalls of commercial product;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">difficulties in scaling production to commercial and validation sizes;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">interruption of the delivery of materials required for the manufacturing process;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">scheduling of plant time with other vendors or unexpected equipment failure;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">potential catastrophes that could strike their facilities or have an effect on infrastructure;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">poor quality control and assurance or inadequate process controls; and</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies, particularly associated with RAPIVAB and planned studies for avoralstat, BCX7353 and BCX4430.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These contract manufacturers may not be able to
manufacture the materials required for our product candidates at a cost or in quantities necessary to make them commercially viable.
We also have no control over whether third-party manufacturers breach their agreements with us or whether they may terminate or
decline to renew agreements with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may
not continue to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the location where
the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the
FDA&rsquo;s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the
launch of a product. The FDA or similar foreign regulatory agencies at any time may also implement new standards, or change their
interpretation and enforcement of existing standards for manufacture, packaging or testing of products. If we or our contract manufacturers
are unable to comply, we or they may be subject to regulatory action, civil actions or penalties.&nbsp;</P>



<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable to maintain current manufacturing or other contract
relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor
manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers,
we may not be able to complete development of, seek timely approval of, or market, our product candidates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our raw materials, drug substances, and product candidates are manufactured
by a limited group of suppliers and some at a single facility. If any of these suppliers were unable to produce these items, this
could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Royalties and milestone payments from Shionogi under our license agreement
with Shionogi (the &#8220;Shionogi Agreement&#8221;) will be required to be used by Royalty Sub to service its obligations under
its PhaRMA Notes, and generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations
under the PhaRMA Notes.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0
million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone
payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and,
if approved for commercial sale, Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar foreign currency hedge
arrangement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest
in Royalty Sub. Payments from Shionogi to us under the Shionogi Agreement will generally not be available to us for other purposes
until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated
to Royalty Sub&#8217;s debt service and not available to us for product development or other purposes. As of September 1, 2014,
the payments from Shionogi were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an
event of default with respect to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be
able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest
in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture or other documents related to&nbsp;the
PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following
repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 40 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><b><i>Because an event of default has occurred under the PhaRMA Notes,
the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing
the PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments
that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Royalty Sub&rsquo;s ability to service its payment obligations in respect
of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks. Royalty
Sub&rsquo;s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination
of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns,
product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable
to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the
PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and
our equity interest in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture&nbsp;or other documents
related to&nbsp;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise
accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We may be required to pay significant premiums under the foreign currency
hedge arrangement entered into by us in connection with the issuance of the PhaRMA Notes. In addition, because our potential obligations
under the foreign currency hedge are marked to market, we may experience additional quarterly volatility in our operating results
and cash flows attributable to the foreign currency hedge arrangement.&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a foreign currency hedge arrangement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the
amount of $2.0 million in each May, provided the foreign currency hedge arrangement remains in effect, continuing through May 2020.
Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined
in accordance with the foreign currency hedge arrangement) is such that the U.S. dollar is worth 100 yen or less. We will be required
to mark-to-market our potential obligations under the currency hedge and post cash collateral, which may cause us to experience
additional quarterly volatility in our operating results and cash flows as a result. Additionally, we may be required to pay significant
premiums or a termination fee under the foreign currency hedge agreement entered into by us in connection with the issuance of
the PhaRMA Notes. We are required to maintain a foreign currency hedge at 100 yen per dollar under the agreements governing the
PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 41 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we or our partners do not obtain and maintain governmental approvals
for our product candidates under development, we or our partners will not be able to sell these potential products, which would
significantly harm our business because we will receive no revenue.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We or our partners must obtain regulatory approval before marketing
or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or
sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our
partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining
FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign
government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development,
our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval.
If the FDA delays regulatory approval of our product candidates, our management&#8217;s credibility, our value and our operating
results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated
uses for a product candidate and/or may require post-approval studies.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The FDA regulates, among other things, the record keeping and storage
of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical
data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a
significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs
damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products,
whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements
are wide ranging and govern, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">adverse drug experience reporting regulations;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">product promotion;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">product manufacturing, including good manufacturing practice requirements;&nbsp;and</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">product changes or modifications.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to comply with existing or future regulatory requirements,
or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will
not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We face intense competition, and if we are unable to compete effectively,
the demand for our products, if any, may be reduced.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The biotechnology and pharmaceutical industries are highly competitive
and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications
that we are working on. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational
pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than
we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing
organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining
FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of
product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and
commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA
exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing
of desirable disease targets, licensing of desirable product candidates, and development and marketing of our product candidates
from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition
may also arise from, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">other drug development technologies;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">methods of preventing or reducing the incidence of disease, including vaccines;&nbsp;and</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">new small molecule or other classes of therapeutic agents.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Developments by others may render our product candidates or technologies
obsolete or noncompetitive.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We and our partners are performing research on or developing products
for the treatment of several disorders including HAE, recurrent/refractory peripheral T-cell lymphoma and broad spectrum antivirals
which may be developed as medical countermeasures. We expect to encounter significant competition for any of the pharmaceutical
products we plan to develop. Companies that complete clinical trials, obtain required funding or government support, obtain required
regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve
a significant competitive advantage. Such is the case with Eisai Co. Ltd.&#8217;s TARGRETIN&#174; for cutaneous T-cell lymphoma
and the current neuraminidase inhibitors marketed by GSK and Roche for influenza and CINRYZE&#174; and FIRAZYR&#174; for HAE, marketed
by Shire Pharmaceuticals, Inc., and KALBITOR&#174; for HAE, marketed by Dyax Corporation. Therapeutic products with potentially
promising data to treat Ebola include Mapp Biopharmaceutical, Inc.&#8217;s ZMapp (antibody-based) and Gilead Sciences, Inc.&#8217;s
(small molecule), both of which have been used in Ebola infected patients. Further, several pharmaceutical and biotechnology firms,
including major pharmaceutical companies and specialized structure-based drug design companies, have announced efforts in the field
of structure-based drug design and molecules in development in the fields of HAE and in other therapeutic areas where we have discovery
and development efforts ongoing. If one or more of our competitors&#8217; products or programs are successful, the market for our
products may be reduced or eliminated.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 42 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Compared to us, many of our competitors and potential competitors
have substantially greater:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">capital resources;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">research and development resources, including personnel and technology;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">regulatory experience;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">preclinical study and clinical testing experience;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">manufacturing and marketing experience;&nbsp;and</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">production facilities.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Any of these competitive factors could impede our funding efforts,
render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to adequately protect or enforce our intellectual property
rights or secure rights to patents of others, the value of those rights would diminish.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success will depend in part on our ability and the abilities of
our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark
and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to
preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad.
The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual
questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;),
the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor
predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical
patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights
may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates
in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely
on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity
in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability
to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction
to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions.
The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We also rely on trade secrets to protect technology in cases when
we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain
the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our
ability to receive patent protection or protect our proprietary information may be imperiled.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We may be involved in lawsuits to protect or enforce our patents, the
patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful</i></b>.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Competitors may infringe or otherwise violate our patents, the patents
of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to
file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any litigation or defense proceeding
could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#8217;
patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and
products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications
are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently
infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors
that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally
cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors,
we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country
or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be
available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with
the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive,
which would give our competitors access to the same intellectual property.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 43 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners are unable or fail to adequately initiate, protect,
defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish
to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to
produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use
of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy
infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions
have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions.
We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding
foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed
certain trademark and trade name applications worldwide. We cannot assure you as to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">the degree and range of protection any patents will afford against competitors with similar products;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">if and when patents will issue;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents;&nbsp;or</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If the USPTO or other foreign patent office upholds patents issued
to others or if the USPTO grants patent applications filed by others, we may have to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">obtain licenses or redesign our products or processes to avoid infringement;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">stop using the subject matter claimed in those patents;&nbsp;or</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">pay damages.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We may initiate, or others may bring against us, litigation or administrative
proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent office. Any
judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application could materially
and adversely affect our business, financial condition and results of operations. In addition, the costs of any such proceeding
may be substantial whether or not we are successful.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success is also dependent upon the skills, knowledge and experience,
none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants,
advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone
outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These
agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of
any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information
is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates
and any such events would significantly impair the value of such product candidates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We face an inherent risk of liability in the event that the use or misuse
of our products results in personal injury or death and our product liability insurance coverage may be insufficient.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">If the use or misuse of peramivir or any other regulatory body-approved
products we or a partner may sell in the future harms people, we may be subject to costly and damaging product liability claims
brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product
candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We
cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product
candidates and, therefore, the amount of insurance coverage we currently may not be adequate to cover all liabilities or defense
costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability
that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity
could be harmful to our business.</P>



<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<!-- Field: Page; Sequence: 44 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We face an inherent risk of product liability exposure related to
the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us
of our product candidates. We have product liability insurance covering our commercial sale of RAPIVAB and our clinical trials.
Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient
insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse
effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates
causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought
against us, with or without merit, could result in:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">withdrawal of clinical trial volunteers or patients;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">damage to our reputation and the reputation of our products, resulting in lower sales;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">regulatory investigations that could require costly recalls or product modifications;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">litigation costs;&nbsp;and</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">the diversion of management&#8217;s attention from managing our business.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Insurance coverage is increasingly more costly and difficult to obtain
or maintain.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While we currently have insurance for our business, property, directors
and officers, and our products insurance is increasingly more costly and narrower in scope, and we may be required to assume more
risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required
to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our
insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on
our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain
or maintain insurance coverage at reasonable costs or at all.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If our facility incurs damage or power is lost for a significant length
of time, or if we incur significant cost overruns or delays in the construction of our new discovery facilities in Birmingham,
Alabama, </i></b><b><i>our business will suffer.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We store clinical and stability samples at our facility that could
be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in
addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant
delays in our drug development process.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, we store most of our preclinical and clinical data at
our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer
systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug
development process and any system failure could harm our business and operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">We also face the risk that the costs and time
required in connection with the construction of our new discovery facilities in Birmingham, Alabama could exceed our current expectations.
If there is a significant cost overrun or significant delay in the completion of the construction, our business, financial condition,
and results of operations could be adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>A significant disruption in our information technology systems or a
cyber-security breach could adversely affect our business.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are increasingly dependent on information technology systems to
operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks
or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee
error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information
technology systems could negatively impact operations.&nbsp;If our systems are damaged, fail to function properly or otherwise
become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions
or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results
of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant
legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data
security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information
technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and
any such events could adversely affect our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to retain our existing key personnel or fail to attract and
retain additional key personnel, the development of our product candidates and commercialization of our products and the related
expansion of our business will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are highly dependent upon our senior management and scientific
team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition
for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract
and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm
our business because we rely upon these personnel for many critical functions of our business.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 45 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If because of our use of hazardous materials, we violate any environmental
controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development involves the controlled use of hazardous
materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing
the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these
materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed
our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could
require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks relating to investing in our common stock</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our existing principal stockholders hold a substantial amount of our
common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Several of our stockholders own greater than 5% of our outstanding common
stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations based
upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters requiring
approval of the stockholders, including the election of our directors and other corporate actions.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our stock price has been, and is likely to continue to be, highly volatile,
which could result in the value of an investment in our common stock to decline significantly.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">The market prices for securities of biotechnology companies
in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated
frequently, and these fluctuations are often not related to our financial results. For the twelve months ended September 30, 2015,
the 52-week range of the market price of our stock was from $7.85 to $16.83 per share. The following factors, in addition to other
risk factors described in this section, may have a significant impact on the market price of our common stock:</p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 9pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 9pt"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<table border="0" cellpadding="0" cellspacing="5" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 3%">&#8226;</td>
    <td style="vertical-align: middle; width: 95%">announcements of technological innovations or new products by us or our competitors;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">developments or disputes concerning patents or proprietary rights;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">additional dilution through sales of our common stock or other derivative securities;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">status of new or existing licensing or collaborative agreements and government contracts;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">announcements relating to the status of our programs;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">developments and announcements regarding new and virulent strains of influenza;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">we or our partners achieving or failing to achieve development milestones;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">publicity regarding certain public health concerns for which we are or may be developing treatments;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">regulatory developments in both the United States and foreign countries;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">public concern as to the safety of pharmaceutical products;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">actual or anticipated fluctuations in our operating results;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">changes in financial estimates or recommendations by securities analysts;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">changes in the structure of healthcare payment systems, including developments in price control legislation;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">additions or departures of key personnel or members of our board of directors;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">economic and other external factors or other disasters or crises; and</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">&#8226;</td>
    <td style="vertical-align: middle">period-to-period fluctuations in our financial results.</td></tr>
</table>


<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<!-- Field: Page; Sequence: 46 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Future sales and issuances of securities may dilute the ownership interests
of our current stockholders and cause our stock price to decline.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">Future sales of our common stock by current stockholders into the public
market could cause the market price of our stock to fall. As of October&nbsp;31, 2015, there were 73,336,871 shares of our common
stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition.
We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms
to be determined at the time of sale.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0">As of October 31, 2015, there were 9,820,203 stock options and restricted
stock units outstanding, 890,262 shares available for issuance under our Amended and Restated Stock Incentive Plan, and 497,204
shares available for issuance under our Employee Stock Purchase Plan. In addition, we could also make equity compensation grants
outside of our Stock Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock
options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If some or all of such shares are sold or otherwise issued into the
public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of
all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices.
Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities
in the future at a time and price that our management deems acceptable, or at all.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have anti-takeover provisions in our corporate charter documents
that may result in outcomes with which you do not agree.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our board of directors has the authority to issue up to 4,800,000
shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without
further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may
adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third
parties to acquire a majority of our outstanding voting stock.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, our certificate of incorporation provides for staggered
terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors
and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment
of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make
more difficult a merger, tender offer or proxy contest involving us.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have never paid dividends on our common stock and do not anticipate
doing so in the foreseeable future.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have never paid cash dividends on our stock. We currently intend
to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash
dividends on our common stock in the foreseeable future.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_010"></a>Item&nbsp;6. Exhibits</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">See the Exhibit&nbsp;Index attached to this quarterly report and incorporated herein
by reference.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_011"></a><b>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 6th day of November, 2015.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td colspan="2" style="vertical-align: middle">BIOCRYST PHARMACEUTICALS, INC.</td></tr>
<tr>
    <td style="vertical-align: middle; width: 50%">&nbsp;</td>
    <td style="vertical-align: middle; width: 30%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 20%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: middle; border-bottom: black 1.1pt solid">/s/ Jon P. Stonehouse</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: middle">Jon P. Stonehouse</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td rowspan="2" style="vertical-align: middle">&nbsp;</td>
    <td colspan="2" style="font-style: italic; vertical-align: middle">President and Chief Executive Officer</td></tr>
<tr>
    <td style="font-style: italic; vertical-align: middle">(Principal Executive Officer)</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: middle; border-bottom: black 1.1pt solid">/s/ Thomas R. Staab, II</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: middle">Thomas R. Staab, II</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td rowspan="2" style="vertical-align: middle">&nbsp;</td>
    <td colspan="2" style="font-style: italic; vertical-align: middle">Senior Vice President, Chief Financial Officer</td></tr>
<tr>
    <td style="font-style: italic; vertical-align: middle">and Treasurer</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td colspan="2" style="font-style: italic; vertical-align: middle">(Principal Financial and Principal Accounting Officer)</td></tr>
</table>


<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>INDEX TO EXHIBITS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<table border="0" cellpadding="2" cellspacing="3" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td colspan="2" style="font-weight: bold; vertical-align: top; text-align: center">Number</td>
    <td style="font-weight: bold; vertical-align: middle">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">Description</td></tr>
<tr>
    <td style="text-align: left; width: 2%; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left; width: 5%">3.1</td>
    <td style="vertical-align: middle; width: 1%">&nbsp;</td>
    <td style="width: 92%">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed December&nbsp;22, 2006.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">3.2</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed July&nbsp;24, 2007.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">3.3</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Certificate of Increase of Authorized Number of Shares of Series&nbsp;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed November&nbsp;4, 2008.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">3.4</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed May&nbsp;7, 2014.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">3.5</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Certificate of Increase of Authorized Number of Shares of Series&nbsp;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&nbsp;3.2 to the Company&#8217;s Form&nbsp;8-K filed May&nbsp;7, 2014.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">3.6</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Amended and Restated Bylaws of Registrant effective October&nbsp;29, 2008. Incorporated by reference to Exhibit&nbsp;3.2 to the Company&#8217;s Form&nbsp;8-K filed November&nbsp;4, 2008.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">(10.1)&#8224;</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated July 8, 2015. (Portions omitted pursuant to request for confidential treatment.)</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">(10.2)&#8224;</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated August 25, 2015. (Portions omitted pursuant to request for confidential treatment).&nbsp;</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <TD NOWRAP STYLE="vertical-align: top; text-align: left">(10.3)&#8224;</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Amendment #14 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 16, 2015. (Portions omitted pursuant to request for confidential treatment.)</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">(31.1)</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Certification of the Chief Executive Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">(31.2)</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Certification of the Chief Financial Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">(32.1)</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">(32.2)</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</td></tr>
<tr>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">(101)</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td>Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three months ended September 30, 2015, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements.</td></tr>
</table>


<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">______________</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; width: 3%"><font style="font-size: 10pt">(&nbsp;&nbsp;)</font></td>
    <td style="padding-right: 3.8pt; width: 97%"><font style="font-size: 10pt">Filed or furnished herewith.</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">&#8224;</font></td>
    <td style="padding-right: 3.8pt"><font style="font-size: 10pt">Confidential treatment requested.</font></td></tr>
</table>


<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">49</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right">EXHIBIT 10.1</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh2_1.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh2_2.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>




<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%; text-align: center">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exh_102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">EXHIBIT 10.2</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh3_1.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh3_2.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh3_3.jpg" ALT="">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted
in places marked &quot;***&quot; and has been filed separately with the</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">Securities and Exchange Commission pursuant to a Confidential Treatment
Application with the Commission.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>



<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font-size: 10pt; margin: 0"><B>ATTACHMENT 1</B></P>

<P STYLE="font-size: 10pt; margin: 0">Statement of Work</P>

<P STYLE="font-size: 10pt; margin: 0">HHSO100201500007C</P>

<P STYLE="font-size: 10pt; margin: 0">BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies</P>

<P STYLE="font-size: 10pt; margin: 0">August 19, 2015</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 6pt 0"><FONT STYLE="font-size: 12pt"><B>PREAMBLE</B></FONT><B> </B></P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Independently and not as an agent of the Government, the Contractor shall furnish all
the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed
to perform the Statement of Work submitted in response to the BARDA Broad Agency Announcement (BAA) CBRN-BAA-10-100-SOL-00013.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The Government reserves the right to modify the milestones, progress, schedule, budget,
or deliverables to add or delete deliverables, process, or schedules if the need arises. Because of the nature of this research
and development (R&amp;D) contract and the complexities inherent in this and prior programs, at designated milestones the Government
will evaluate whether work should be redirected, removed, or whether schedule or budget adjustments should be made.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin: 24pt 0 6pt"><FONT STYLE="font-size: 12pt">Overall
Objectives and Scop</FONT>e</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The overall objective of this contract is to advance the development of BCX4430, a novel
small molecule nucleoside with broad spectrum antiviral activity being developed for diseases caused by RNA pathogens. BCX4430,
an inhibitor of viral RNA &ndash; dependent RNA polymerase (RdRp), is the lead compound in our broad-spectrum antiviral program
to meet the need for a parenteral, direct-acting antiviral medical countermeasure (MCM) having efficacy across multiple viruses.
The scope of work for this contract includes preclinical and manufacturing development activities that fall into the following
areas: manufacturing of clinical trial material, manufacturing process improvements and development, non-clinical toxicology studies;
and all associated regulatory, quality assurance, management, and administrative activities. The proposed activities take into
account the Ebola virus disease (EVD) outbreak in West Africa. The R&amp;D effort will contribute toward an NDA filing for BCX4430.
Overall, this Statement of Work (SOW) focuses on:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Drug substance (DS) and drug product (DP) manufacturing process development activities that will
be conducted at US based facilities, which will result in the ability to consistently produce high quality, cGMP compliant material
and deliver drug supply that could be available for deployment as a medical countermeasure during the Ebola crisis and support
future clinical and non-clinical studies</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Nonclinical development activities to advance the intramuscular (IM) and intravenous (IV) formulation
through NDA-enabling toxicology including *** and *** studies in the ***</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-indent: 0in; margin: 24pt 0 6pt 0.25in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 24pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 12pt">1</FONT></TD><TD><FONT STYLE="font-size: 12pt">BASE:
                                         Manufacture of Clinical Trial Material</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">Duration: 18 months</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Drug Substance and Drug Product cGMP manufacturing by US suppliers to support non-clinical
and clinical activities. Drug Substance will be produced following an *** starting with ***, which will be used as the GMP starting
material to produce BCX4430.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The primary objectives will be to</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Produce *** batches of BCX4430 drug substance following ***.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Conduct drug product process improvements that will be focused on validation of analytical methods, stress testing, stability
studies, and process design space optimization</TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Procurement of Starting Materials</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall procure the starting materials to produce *** of the current manufacturing
process of BCX4430. The key starting materials to be procured are *** and ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.1.1.&nbsp;&nbsp; Procurement of Starting Materials
to produce two 35 kg batches of BCX1777</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall procure *** and *** for the manufacture of *** of *** to support
a *** campaign (WBS 1.4.1 and 1.4.2) and a *** batch of BCX4430 (Clinical Trial Material Batch *** WBS1.7.1)</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Further Process Improvements of ***</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct further process improvements that may be identified focused
on improving the existing plant-scale processes following generally the same ***.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0"><B>1.2.1 Conduct Process Improvements</B></P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct the process improvements with existing plant-scale processes.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0"><B>1.2.2 Determination that Process is Sufficient to move to Commercial Scale up</B></P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall evaluate the processes developed and provide sufficient information
through a deliverable that will enable BARDA to determine that the processes are sufficient to move to commercial scale &ndash;up
activities.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Manufacture of *** at ***</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce *** of *** will be utilized as the starting material for
the manufacture of BCX4430 in accordance with cGMP guidance.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.3.1.&nbsp;&nbsp; Manufacture of *** of ***
(Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce *** of *** using the existing process at ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.3.2.&nbsp;&nbsp; Manufacture of *** of ***
(Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce *** of *** using the existing process at ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Manufacturing Campaign of BCX4430</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce *** batches of BCX4430 at *** in compliance with cGMP.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.4.1.&nbsp;&nbsp; Manufacturing of *** of cGMP
BCX4430 (DS Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce and release *** of cGMP BCX4430 ***.</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 6pt 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.4.2.&nbsp;&nbsp; Manufacturing of *** of cGMP
BCX4430 (DS Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce and release *** of cGMP BCX4430 ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.4.3.&nbsp;&nbsp; Prepare a Campaign Summary
Report</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall prepare a campaign summary report of the manufacture and release
of DS Batches ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.4.4.&nbsp;&nbsp; Drug Substance Stability Studies</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall place samples from DS Batch *** of BCX4430 on a *** stability program
at *** and a *** accelerated stability study at ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">Table 1. BCX4430 Drug Substance Stability
Study Sampling Points</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: navy">
    <TD ROWSPAN="2" STYLE="border: navy 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0; color: white"><B>Test</B></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0; color: white"><B>ID</B></P></TD>
    <TD COLSPAN="10" STYLE="border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Months</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>0</B></FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>1</B></FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>3</B></FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>6</B></FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>9</B></FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>12</B></FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>18</B></FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey"><B>24</B></FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey"><B>48</B></FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey"><B>60</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 11%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: navy 1pt solid; border-right: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">C</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">D</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">E</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">F</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">G</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 6pt 0">NOTE: BARDA will only cover stability activities
for <FONT STYLE="font-size: 10pt">***</FONT>.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">Table 2. BCX4430 Drug Substance Stability
Tests</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 60%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: navy">
    <TD STYLE="width: 17%; border: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Test ID</B></FONT></TD>
    <TD STYLE="width: 83%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Test</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">C</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">D</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">E</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">F</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">G</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Drug Product Development</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct drug product process improvements that will be focused on
validation of analytical methods, stress testing, stability studies, and process design space optimization.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct formulation development activities and produce a sterile,
parenteral formulation containing *** of the active compound per unit in compliance with cGMP guidance. Initial development efforts
will be focused on delivering *** that tolerates terminal sterilization and provides an acceptable stability profile to support
a *** shelf life. Additionally, studies to include: *** will be conducted to evaluate the feasibility of ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.5.1.&nbsp;&nbsp; Stress Conditions Studies</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct a series of experiments under conditions outlined in ICH
guidance to evaluate the stability of the drug product made from available drug substance.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.5.2.&nbsp;&nbsp; Design Space Studies</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct studies to evaluate and define the design space of the formulation
process.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.5.3.&nbsp;&nbsp; Analytical Method Validation</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct analytical methods validation or qualification as listed
in the table below.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">Table 3. BCX4430 Drug Product Methods
that will be Validated or Qualified</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: navy">
    <TD STYLE="width: 42%; border: navy 1pt solid; font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal; color: white">Test</FONT></TD>
    <TD STYLE="width: 58%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal; color: white">Method and Objective</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.5.4.&nbsp;&nbsp; Prepare Process Development
Report for DP</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall prepare a process development report summarizing the experiments
and results of the studies conducted to define the process and evaluate the formulation.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.5.5.&nbsp;&nbsp; Pre-formulation and Physicochemical
Properties Studies</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct studies to determine the physicochemical properties of the
drug substance and identify potential formulations and primary packaging for an IM injection based on stability and ability to
be produced on manufacturing lines.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.5.6.&nbsp;&nbsp; Feasibility Runs</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct small-scale, nonGMP manufacturing runs of potential formulations
and formats.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.5.7.&nbsp;&nbsp; Extractable/Leachable Study</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct studies to determine drug product stability in primary packaging
and of syringe types that will be used for delivery.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.5.8.&nbsp;&nbsp; Excipient Compatibility Studies
for IV Formulation from IM</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct studies to evaluate the compatibility of the IM formulation
added to various standard IV fluids.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.9pt"></TD><TD STYLE="width: 21.6pt">1.6.</TD><TD>Manufacturing of Drug Product to Support Clinical Trials</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce *** batches of approximately *** of drug product suitable
for clinical trial use. The drug product will produced from the *** cGMP DS Batches *** (WBS 1.4.1 and 1.4.2)</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.6.1.&nbsp;&nbsp; Manufacture of Clinical Trial
Material (CTM Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce approximately *** per cGMP for use in clinical trials which
will include active drug and placebo batches to support the future clinical safety study.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.6.2.&nbsp;&nbsp; Manufacture of Clinical Trial
Material (CTM Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce approximately *** per cGMP for use in clinical trials which
will include active drug and placebo batches to support the future clinical safety study.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.6.3.&nbsp;&nbsp; Prepare a Campaign Summary
Reports</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall prepare a campaign summary report of the manufacture and release
of CTM Batches ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.6.4.&nbsp;&nbsp; Drug Product Stability Studies
- Active</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall place drug product on stability based on the following conditions:</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">Table 4. BCX4430 Drug Product Stability
Testing Conditions and Sampling</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: navy">
    <TD STYLE="width: 29%; border: navy 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Stability Conditions</FONT></TD>
    <TD STYLE="width: 27%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Configuration</FONT></TD>
    <TD STYLE="width: 44%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Test Points</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">NOTE: BARDA will only cover stability
activities for <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; margin: 6pt 0 6pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">Testing at each interval,
unless otherwise specified below, will include:</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 6pt 0 6pt 0.5in">***</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.6.5.&nbsp;&nbsp; Drug Product Stability Studies
- Placebo</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall place drug product on stability based on the following conditions:</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">Table 5. BCX4430 Drug Product Stability
Testing Conditions and Sampling</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: navy">
    <TD STYLE="width: 29%; border: navy 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Stability Conditions</FONT></TD>
    <TD STYLE="width: 27%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Configuration</FONT></TD>
    <TD STYLE="width: 44%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Test Points</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 6pt 0 6pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">Testing at each interval,
unless otherwise specified below, will include:</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 6pt 0 6pt 0.5in">***</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">NOTE: BARDA will only cover stability
activities for <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.6.6.&nbsp;&nbsp; Comparability Study</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct comparability studies evaluating drug substance produced
by *** and ***, and the subsequently produced drug product, will be conduct per FDA Guidance. These studies will evaluate: in-process
checks, impurity profiles, release testing results, and stability profiles at standard and accelerated conditions to ensure the
material produced by both manufacturers is substantially comparable.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Manufacture of Additional Supply</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">That contractor shall produce *** of BCX4430 based on *** facility and subsequently produce
*** of drug product at *** suitable for clinical trial use.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.7.1.&nbsp;&nbsp; Manufacturing of *** cGMP
BCX4430 (DS Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce *** of cGMP BCX4430 from ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.7.2.&nbsp;&nbsp; Prepare a Campaign Summary
Report</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall prepare a campaign summary report of the manufacture and release
of ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.7.3.&nbsp;&nbsp; Manufacturing of approximately
*** (CTM Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce approximately *** of cGMP BCX4430 drug product using drug
substance from the *** cGMP BCX4430 (DS Batch ***, WBS 1.7.1).</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.7.4.&nbsp;&nbsp; Prepare a Campaign Summary
Report</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall prepare a campaign summary report of the manufacture and release
of CTM Batches ***</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.7.5.&nbsp;&nbsp; Stability Studies for DS and
DP</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct drug substance and drug product stabilities for the DS and
DP manufactured in from the *** of cGMP BCX4430 drug substance based on *** (WBS 1.6).</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">NOTE: BARDA will only cover stability
activities for <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">1.7.6.&nbsp;&nbsp; Comparability Studies</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct comparability studies evaluating drug substance produced
by *** and both process at ***, and the subsequently produced drug product, will be conduct per FDA Guidance. These studies will
evaluate: in-process checks, impurity profiles, release testing results, and stability profiles at standard and accelerated conditions
to ensure the material produced by both manufacturers and both *** process are substantially comparable.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt">2
Option 1: Commercial Scale up and NDA Registration Batches</FONT></P>



<P STYLE="font-size: 10pt; margin: 6pt 0">Duration: ***</P>

<P STYLE="font-size: 10pt; margin: 0">Go/No Go Criteria to Initiate: WBS 1.2.2 BARDA approval of process developed</P>

<P STYLE="font-size: 10pt; margin: 0">Through optimization of manufacturing processes, BARDA will evaluate and determine what process
should be sufficient to initiate commercial scale up activities in this Option. This Option will add value to the project through
conducting manufacturing regulatory activities that will be needed for future product approval with the FDA.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Decision Criteria:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>***</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>***</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The objective is to produce DS registration batches from the qualified process, ***.
This will be determined upon the conclusion of the DS development effort being undertaken by BioCryst and funded by NIAID that
is scheduled to conclude in December 2015. Additionally during this stage, the DP manufacturing process would be finalized for
the commercial presentation and registration batches produced.</P>





<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Procurement</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall procure the *** starting materials needed to produce BCX4430.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.1.1.&nbsp;&nbsp; Procurement of ***</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall qualify a vendor(s) to produce the *** and procure enough material
to support the manufacture of *** batches of BCX4430 drug substance.</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.1.2.&nbsp;&nbsp; Procurement of ***</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall qualify a vendor(s) to produce the *** and procure enough material
to support the manufacture of *** batches of BCX4430 drug substance.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Drug Substance Process Scale-up</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct process development work targeting a *** that can be scaled
to plant equipment. This work will include: development of a *** through lab scale studies, process hazard evaluation including
RC-1 and digital scanning calorimetry, lab scale qualification runs, pilot plant scale-up technical batches, necessary modifications
to analytical methods based on the ***, and plant-scale registration runs.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2.1</TD><TD>Further Process Improvements of Final Route</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct further process improvements that may be identified focused
on improving the *** to be scaled up. The *** will be based either ***.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2.2</TD><TD>Process Hazard Evaluation</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct process hazard evaluation studies needed for the scale-up
of the optimized process into the plant.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -1in; margin: 12pt 0 0 1in">2.2.3 Scale-up Technical Run</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct a nonGMP manufacturing run at plant-scale to ensure the
safety and output of the optimized process.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.2.4 Analytical Method Development and Qualification</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall modify, add to, revalidate, or requalify the analytical methods.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2.5</TD><TD>Prepare Process Development Report</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall prepare a process development report describing the experiments
and results leading to the selection of the optimized manufacturing process</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Manufacture of cGMP Drug Substance Registration Batches</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce *** cGMP batches of BCX4430 following the *** at a scale
comparable to the estimated commercial scale.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.3.1</TD><TD>Manufacture of DS Batch (DS Batch ***)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall manufacture a batch of cGMP BCX4430 at plant scale.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.3.2&nbsp;&nbsp;&nbsp;&nbsp; Manufacture of
DS Batch (DS Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall manufacture a batch of cGMP BCX4430 at plant scale.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.3.3&nbsp;&nbsp;&nbsp;&nbsp; Manufacture of
DS Batch (DS Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall manufacture a batch of cGMP BCX4430 at plant scale.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.3.4&nbsp;&nbsp;&nbsp;&nbsp; Prepare Campaign
Summary Report</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall prepare a report summarizing the conduct, observations, and results
of the manufacturing of DS Batches ***.</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Drug Product Registration Batches</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall produce *** drug product lots at *** that will be used as the NDA
registration batches.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.4.1&nbsp;&nbsp;&nbsp;&nbsp; Manufacture of
DP Registration (DPR Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall manufacture a NDA registration batch of cGMP BCX4430 drug product
at a scale at least *** the estimated commercial scale.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.4.2&nbsp;&nbsp;&nbsp;&nbsp; Manufacture of
DP Registration (DPR Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall manufacture a NDA registration batch of cGMP BCX4430 drug product
at a scale at least *** the estimated commercial scale.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.4.3&nbsp;&nbsp;&nbsp;&nbsp; Manufacture of
DP Registration (DPR Batch ***)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall manufacture a NDA registration batch of cGMP BCX4430 drug product
at a scale at least *** the estimated commercial scale.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.4.4&nbsp;&nbsp;&nbsp;&nbsp; Prepare campaign
summary report</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall prepare a report summarizing the conduct, observations, and results
of the manufacturing of DPR Batches ***.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stability studies for DS and DP</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct drug substance and drug product stabilities as described
in Table 2 and Table 3 .</P>

<P STYLE="font-size: 10pt; margin: 6pt 0"><B>NOTE: BARDA will only cover stability activities for </B>***</P>

<P STYLE="font-size: 10pt; margin: 6pt 0"><B></B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Comparability study</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall conduct comparability studies evaluating drug substance produced
for clinical trials in the base period versus the NDA registration batches manufactured via *** in Option 1, and the subsequently
produced drug product, will be conduct per FDA Guidance. These studies will evaluate: in-process checks, impurity profiles, release
testing results, and stability profiles at standard and accelerated conditions to ensure the material produced by both processes
is substantially comparable.<BR>
<BR></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt">3
Option 2: Nonclinical NDA-enabling Toxicology</FONT></P>



<P STYLE="font-size: 10pt; margin: 6pt 0">Duration: ***</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Go/No Go Criteria to Initiate: Availability of cGMP BCX4430 *** DS batch manufactured
under NIAID contract HHSO100201500007C</P>

<P STYLE="font-size: 10pt; margin: 0">Through completion of manufacturing of Drug substance there will be material to conduct further
regulatory activities such as the IM non-clinical NDA-enabling toxicology studies in this option. This Option will add value to
the project through conducting additional non-clinical activities that will support a potential future NDA.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Decision Criterion:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">***</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">***</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall perform nonclinical GLP studies of BCX4430 to characterize ***.</P>



<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>GLP <FONT STYLE="font-size: 10pt">***</FONT> Toxicology</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall for each toxicology study develop the protocol, select and qualify
the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Studies include:</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.1.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct GLP <FONT STYLE="font-size: 10pt">***</FONT> toxicology study - <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.1.2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct GLP <FONT STYLE="font-size: 10pt">***</FONT> general toxicology study - <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
***</FONT> toxicology</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall for each *** study segment develop the protocol, select and qualify
the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Studies include:</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.2.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct <FONT STYLE="font-size: 10pt">***</FONT> assessment in <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"> 3.2.2.&nbsp;&nbsp;&nbsp;Conduct <FONT STYLE="font-size: 10pt">***</FONT> Dose Range Finding Studies in the <FONT STYLE="font-size: 10pt">***</FONT></P>



<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.2.3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct Definitive <FONT STYLE="font-size: 10pt">***</FONT> toxicology in the <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.2.4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct <FONT STYLE="font-size: 10pt">***</FONT> toxicology <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Nonclinical ADME</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall procure radiolabeled BCX4430. In addition for each ADME study, the
contractor shall develop the protocol, select and qualify the vendor, conduct the study and analyze study data resulting in a final
study report. Studies include:</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.3.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct Radiolabeled ADME study - <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">3.3.2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct Radiolabeled ADME &ndash; <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; margin: 6pt 0">A listing of the proposed studies for the nonclinical NDA-enabling toxicology studies
is provided.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">Table 6 Nonclinical NDA-enabling
Toxicology Studies</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: navy">
    <TD STYLE="width: 9%; border: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Study #</FONT></TD>
    <TD STYLE="width: 25%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Description</FONT></TD>
    <TD STYLE="width: 55%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Objective(s)</FONT></TD>
    <TD STYLE="width: 11%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Species (N)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">GLP </FONT>***<FONT STYLE="font-size: 10pt"> general toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">GLP </FONT>***<FONT STYLE="font-size: 10pt"> general toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">*** assessment</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">*** Dose Range Finding</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0">***</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><FONT STYLE="background-color: yellow"></FONT></P></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">*** Dose Range Finding</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0 0 0 1.5pt">***</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><FONT STYLE="background-color: yellow"></FONT></P></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">Definitive *** toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">Definitive *** toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">*** toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">Radiolabeled ADME</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">Determine the absorption, distribution, metabolism and excretion of the test article following IM dosing</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">Radiolabeled ADME</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">Determine the absorption, metabolism and excretion of the test article following IM dosing</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; text-indent: 0in; margin: 24pt 0 6pt 0.25in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt">4
Option 3: <I>In vitro</I> Experiments &ndash; IV</FONT></P>



<P STYLE="font-size: 10pt; margin: 6pt 0">Duration: ***</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Go/No Go to Initiate: Selection of a preliminary IV formulation (LRI) based on initial
studies</P>

<P STYLE="font-size: 10pt; margin: 0">Through completion of earlier studies, it will be determined what is an appropriate IV formulation
to continue with toxicology studies of the IV formulation under this Option. This Option will add value to determine if there is
any identified toxicology in <I>in vitro</I> assays before moving to animal studies in Option 4.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Decision Criterion:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">***</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.9pt"></TD><TD STYLE="width: 21.6pt">4.1.</TD><TD><FONT STYLE="font-size: 10pt">***</FONT> &ndash; IV</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall develop the protocol, select and qualify the vendor, conduct the
experiments and analyze the data resulting in a study report.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.9pt"></TD><TD STYLE="width: 21.6pt">4.2.</TD><TD>Conduct <FONT STYLE="font-size: 10pt">***</FONT> Test &ndash; IV</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall develop the protocol, select and qualify the vendor, conduct the
experiment and analyze the data resulting in a study report.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">A listing of the proposed experiments for the <I>in vitro</I> experiments to be conducted
in advance of the nonclinical NDA-enabling toxicology studies for the IV formulation is provided in <FONT STYLE="color: blue">Table
7</FONT> .</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">Table 7 In vitro Experiments - IV</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: navy">
    <TD STYLE="width: 9%; border: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Study #</FONT></TD>
    <TD STYLE="width: 25%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Description</FONT></TD>
    <TD STYLE="width: 55%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Objective(s)</FONT></TD>
    <TD STYLE="width: 11%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Species (N)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 6pt 0"><B>4.3 Study Report on all in vitro assays</B></P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall submit a summarized study report with data and conclusions from
all in vitro experiments conducted in table 7 to determine whether there is any toxicology before advancing into non-clinical NDA
enabling toxicology studies (Option 5).</P>

<P STYLE="font-size: 10pt; margin: 6pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt">5
Option 4: Nonclinical NDA-enabling Toxicology - IV</FONT></P>



<P STYLE="font-size: 10pt; margin: 6pt 0">Duration: ***</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Go/No Go Criteria to Initiate: WBS 4.3 Study Report on all <I>in vitro</I> assays</P>

<P STYLE="font-size: 10pt; margin: 0">Through completion of the IV <I>in vitro</I> toxicology studies with the IV formulation conducted
in Option 3 and summarized in WBS 4.3, it will be determined if the IV formulation is safe to move into non-clinical toxicology
animal studies in this Option. This Option will add value to the project through conducting additional non-clinical activities
that will support a potential future NDA.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">Decision Criterion:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">***</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">***</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">5.1.</TD><TD>GLP <FONT STYLE="font-size: 10pt">***</FONT> Toxicology &ndash; IV</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall for each toxicology study develop the protocol, select and qualify
the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report. Studies include:</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">5.1.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct GLP <FONT STYLE="font-size: 10pt">***</FONT> IV general toxicology study - <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">5.1.2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct GLP <FONT STYLE="font-size: 10pt">***</FONT> IV toxicology study - <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">5.2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
***</FONT> toxicology - IV</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall for each *** study segment develop the protocol, select and qualify
the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report. Studies include:</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">5.2.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct <FONT STYLE="font-size: 10pt">***</FONT> assessment in <FONT STYLE="font-size: 10pt">***</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.2.2.</TD><TD>Conduct <FONT STYLE="font-size: 10pt">***</FONT> Dose Range Finding Studies in the <FONT STYLE="font-size: 10pt">***</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">5.2.3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct Definitive <FONT STYLE="font-size: 10pt">***</FONT> toxicology in the <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">5.2.4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT>Conduct <FONT STYLE="font-size: 10pt">***</FONT> toxicology <FONT STYLE="font-size: 10pt">***</FONT></P>

<P STYLE="font-size: 10pt; margin: 6pt 0">A listing of the proposed studies for the nonclinical NDA-enabling toxicology studies
for the IV formulation is provided in Table 8.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 6pt 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.75in; margin: 6pt 0 6pt 0.75in">Table 8. Nonclinical NDA-enabling
Toxicology Studies for an IV Formulation</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: navy">
    <TD STYLE="width: 9%; border: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Study #</FONT></TD>
    <TD STYLE="width: 25%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Description</FONT></TD>
    <TD STYLE="width: 55%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Objective(s)</FONT></TD>
    <TD STYLE="width: 11%; border-top: navy 1pt solid; border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Species (N)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">GLP </FONT>***<FONT STYLE="font-size: 10pt"> IV general toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid"><FONT STYLE="font-size: 10pt">GLP </FONT>***<FONT STYLE="font-size: 10pt"> IV general toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">*** assessment</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">*** Dose Range Finding</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0 0 0 1.5pt">***</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><FONT STYLE="background-color: yellow"></FONT></P></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">*** Dose Range Finding</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0 0 0 1.5pt">***</P>
        <P STYLE="font-size: 10pt; text-indent: 0in; margin: 0"><FONT STYLE="background-color: yellow"></FONT></P></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">Definitive *** toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">Definitive *** toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; border-left: navy 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">*** toxicology</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: navy 1pt solid; border-bottom: navy 1pt solid; text-indent: 0in"><FONT STYLE="font-size: 10pt">***</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 6pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt">6
Program Management</FONT></P>



<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall provide all expertise needed for the implementation of the activities
to be performed under this contract, including: research, manufacturing, regulatory, clinical, statistical analyses, management
and administrative activities.</P>



<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">6.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Technical and Project Management Support</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall appoint a Principal Investigator (PI) who will be responsible for
all aspects of project performance and communication with the BARDA.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall provide project management that will ensure day-to-day monitoring
and tracking of progress and timelines, the coordination of project activities and costs incurred.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall provide all managerial and administrative functions necessary for
overall planning, monitoring, and implementing activities for the completion of the strategic product development plan.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall provide for all necessary legal affairs required to ensure the timely
acquisition of all proprietary rights, including intellectual property rights and all materials needed to perform the project,
as well as reporting to the Government all inventions made in the performance of the project.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">6.2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subcontractor Management</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 6pt 0">The contractor shall provide for tracking, coordination and oversight
of subcontractor efforts and manage communications with subcontractors.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">6.3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Risk Management</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall identify project risks, develop risk management strategies and implement
mitigation actions.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">6.4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Earned Value Management (EVM)</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall provide EVM information.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">6.5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Project Communications</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 6pt 0">The contractor shall provide for project communications including communications
with BARDA and external experts.</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 6pt 0">The contractor shall provide planning and steps required for the conduct
of contract review meetings.</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 6pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt">7
Regulatory</FONT></P>



<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall ensure adherence to FDA regulations and guidance, including requirements
for the conduct of animal studies and assays under GLP, the manufacturing of the therapeutic product under cGMP, and the conduct
of clinical trials under GCP standards.</P>



<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">7.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Regulatory Authority Interactions</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall prepare and submit documentation and correspondence to regulatory
authorities as required. The contractor shall request and conduct meetings with regulatory authorities to ensure the development
program is conducted in accordance with regulatory guidelines and expectations.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">7.2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Quality Assurance</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 6pt 0">The contractor shall maintain quality assurance documentation. The
contractor shall arrange for audits of subcontractor facilities to ensure all planned procedures comply with the FDA regulations
and guidance that are required to meet GLP, cGMP and GCP standards. In addition, the contractor shall ensure that all contractor
and/or subcontractor records and staff are available for site visits or audits.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 12pt 0 0">7.3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Expert Collaborations</P>

<P STYLE="font-size: 10pt; margin: 6pt 0">The contractor shall collaborate with experts in the field in the design of experiments
and studies that support the advancement of the development program.</P>

<P STYLE="font-size: 10pt; margin: 6pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font-size: 10pt; margin: 6pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0"><B>ATTACHMENT 2</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>MILESTONE AND DELIVERABLES CHART</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>August 20, 2015</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>HHSO100201500007C</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: #3366FF">
    <TD STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="color: white">WBS</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="color: white">Milestone</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="color: white">Deliverable</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="color: white">Success Criteria</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="color: white">Timing</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Go/No-Go</FONT><BR>
<FONT STYLE="font-size: 10pt; color: white">for initiation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="7" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>CLIN 0001 - MANUFACTURE OF CLINICAL TRIAL MATERIAL</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.2.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Process Improvements Report</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Report on Process Development</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Process Developed</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.2.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Determination of Sufficient Process for Commercial Scale up</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Evaluation report </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">BARDA approval of developed process</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.3.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture </FONT>***<FONT STYLE="font-size: 10pt"> (Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.3.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture </FONT>***<FONT STYLE="font-size: 10pt"> (Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.4.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture cGMP BCX4430 (</FONT>***<FONT STYLE="font-size: 10pt"> campaign DS Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.4.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture cGMP BCX4430 (</FONT>***<FONT STYLE="font-size: 10pt"> campaign DS Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.4.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Reports</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Reports (DS Batches </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS Campaigns</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.4.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug substance stability study </FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Initial Report on stability activities </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Product Development</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">DP Process Development Report (WBS 1.5.4)</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">Pre-formulation and Physicochemical Report (WBS1.5.5)</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">Extractable/Leachable Report (WBS 1.5.7)</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of Studies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.5.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Excipient Compatibility Report for IV Formulation</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Compatibility Report </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">IV formulation completed</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture cGMP DP (CTM Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"></TD></TR></TABLE>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">Manufacture cGMP DP (CTM Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-top: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Reports</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Reports (CTM Batches </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DP Campaigns</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Product stability study - Active</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Initial Report on stability activities </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability Data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Product stability study - Placebo</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Initial Report on stability activities </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability Data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.6 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Study</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Protocol and Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS and DP Campaigns</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.1 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture cGMP BCX4340 (</FONT>***<FONT STYLE="font-size: 10pt"> campaign DS Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable DS process </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Report</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Reports (DS Batch</FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS Campaign</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture cGMP DP (CTM Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Report</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Report (CTM Batches </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS Campaigns</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance and Drug Product stability study</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Initial report on stability activities </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability Data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture of 1.7.1 drug substance and 1.7.2 drug product</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Study</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Protocol and Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparable DS and DP profiles</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="7" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>CLIN 0002 &ndash; COMMERCIAL SCALE UP AND NDA REGISTRATION BATCHES</B></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Go/No Go Criteria to Initiate: WBS 1.2.2 BARDA approval of process
        developed </B></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.2</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance Process Scale-up </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Process Development Report (WBS 2.2.4)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Selection of the optimized manufacturing process</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">*** <FONT STYLE="font-size: 10pt">process</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">2.3.1</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4340 DS (DS Registration Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 Registration</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***<FONT STYLE="font-size: 10pt"> process </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">2.3.2</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4340 DS (DS Registration Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 Registration DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***<FONT STYLE="font-size: 10pt"> process </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">2.3.3</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4340 DS (DS Registration Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 Registration DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">*** <FONT STYLE="font-size: 10pt">process </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"></TD></TR></TABLE>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.3.4</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">Campaign Reports (DS Batches </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">Completion of DS Campaign</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">2.4.1</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4430 DP (DP Registration Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">2.4.2</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4430 DP (DP Registration Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">2.4.3</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4430 DP (DP Registration Batch </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.4.4</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Report (CTM Registration Batches </FONT>***<FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS Campaigns</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.5</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug substance and Drug Product stability study</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Report on stability activities </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability Data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.6</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Study</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Protocol and Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparable DS and DP profiles</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="7" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>CLIN 0003 &ndash; NONCLINICAL NDA-ENABLING TOXICOLOGY </B></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><FONT STYLE="font-size: 10pt"><B>Go/No Go Criteria to Initiate: /availability
        of </B></FONT>***<FONT STYLE="font-size: 10pt"><B> cGMP batch of DS manufactured under NIAID contract HHSO100201500007C</B></FONT></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.1.1</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Complete GLP </FONT>***<FONT STYLE="font-size: 10pt">Tox Study - </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Established NOAEL</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance confirming to release criteria</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.1.2</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Complete GLP </FONT>*** <FONT STYLE="font-size: 10pt">Tox Study - </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Established NOAEL</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance confirming to release criteria</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.2.1</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct </FONT>***<FONT STYLE="font-size: 10pt"> assessment in </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.2.2</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct </FONT>*** <FONT STYLE="font-size: 10pt">Dose Range Finding Studies in the </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.2.3</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct Definitive </FONT>***<FONT STYLE="font-size: 10pt"> toxicology in the </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.2.4</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct </FONT>*** <FONT STYLE="font-size: 10pt">toxicology </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.3.1</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct Radiolabeled ADME study - </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Characterize drug disposition</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable Radiolabel Material</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.3.2</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><FONT STYLE="font-size: 10pt">Conduct Radiolabeled ADME &ndash; </FONT>***</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Characterize drug disposition</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable Radiolabel Material </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="7" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"></TD></TR></TABLE>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="7" STYLE="border: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>CLIN 0004 &ndash; IN VITRO EXPERIMENTS &ndash; IV</B></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Go/No Go to Initiate: selection of an appropriate preliminary IV formulation</B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">4.1.</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct </FONT>***<FONT STYLE="font-size: 10pt"> Test &ndash; IV</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No effect on </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">IV formulation WBS 1.5.8</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">4.2.</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct </FONT>***<FONT STYLE="font-size: 10pt"> &ndash; IV</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No effect on mitotic apparatus</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">In Vitro IV experiments</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study report on all In Vitro assays with recommendation to proceed CLIN0005</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No toxicology <I>in vitro</I></FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="7" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>CLIN 0005 &ndash; NONCLINICAL NDA-ENABLING TOXICOLOGY &ndash; IV</B></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Go/No Go to Initiate: WBS 4.3 Completion of <I>***</I> IV toxicology
        studies</B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.1.1</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Complete GLP </FONT>*** <FONT STYLE="font-size: 10pt">IV Tox Study - </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Established NOAEL</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance confirming to release criteria</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.1.2</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Complete GLP </FONT>*** <FONT STYLE="font-size: 10pt">IV Tox Study - </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Established NOAEL</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance confirming to release criteria</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.2.1</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct </FONT>***<FONT STYLE="font-size: 10pt"> assessment in </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.2.2</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct </FONT>***<FONT STYLE="font-size: 10pt"> Dose Range Finding Studies in the </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.2.3</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct Definitive </FONT>*** <FONT STYLE="font-size: 10pt">toxicology in the </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.2.4</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct </FONT>*** <FONT STYLE="font-size: 10pt">toxicology </FONT>***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>ATTACHMENT 3</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>BCX4430 MANUFACTURING SUMMARY</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>August 20, 2015</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; border: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Starting Material</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>DS Campaign</B></FONT></TD>
    <TD STYLE="width: 6%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>CMO</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>DS Process Desc</B></FONT></TD>
    <TD STYLE="width: 7%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>DS Timing</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>DP Campaign</B></FONT></TD>
    <TD STYLE="width: 8%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>DP Timing</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Use</B></FONT></TD>
    <TD STYLE="width: 6%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Funding</B></FONT></TD></TR>
<TR>
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD ROWSPAN="6" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR>
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR>
    <TD ROWSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD ROWSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">***</TD></TR>
<TR>
    <TD COLSPAN="9" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">***</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>Attachment 4</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>HHSO100201500007C</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>August 20, 2015</B></P>

<P STYLE="font-size: 10pt; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">***</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">All activities covered under this BioCryst contract will provide merit
and value to the Government by ensuring that funding supported under the Base period results in progress towards several activities
to ensure moving the BioCryst BCX4430 compound through the development pipeline for future FDA approval. This activities include
manufacturing clinical trial material to be used in clinical trials as an urgent need to the Ebola epidemic in west Africa (Base),
commercial scale up and manufacturing of registration batches, a regulatory approval requirement (Option 1), non-clinical toxicology
studies to support NDA regulatory requirements (Option 2) and non-clinical toxicology studies of the IV formulation first in vitro
(Option 3) and then in animals (Option 4) to support NDA regulatory requirements. BioCryst&rsquo;s ability to complete three critical
GO/NO GO contract milestones in the Base period will determine, whether to exercise any follow-on option phases to continue supporting
development of the compound.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">There are 4 decision points which will trigger advancement to Options.&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Trigger 1 (for start of Option 1):&nbsp; Further optimization processes
for manufacturing will be developed under the WBS 1.2&nbsp; Once these activities are sufficient to warrant a scale up manufacturing
process, as will be evaluated in a delivered report, process development (milestone WBS1.2, July 2015), Option 1 can begin.&nbsp;
In Option 1, the process developed in WBS 1.2 and other processes being developed to manufacture the BCX4430 compound will be evaluated,
such that BioCryst can select a process of most value to the Government to generate </FONT>***<FONT STYLE="font-size: 10pt"> drug
substance registration batches that will then be used to make </FONT>***<FONT STYLE="font-size: 10pt"> drug product registration
batches at a scale at least </FONT>***<FONT STYLE="font-size: 10pt"> the estimated commercial scale which is a regulatory requirement
for qualifying a GMP process for manufacturing.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0">Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</P><P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Trigger 2 (for start of Option 3): In order to conduct toxicology experiments in animals, the IV
formulation of BCX4430 will first need to be assessed <I>in vitro</I> through *** as well as *** (Option 3)&nbsp;before moving
into animals. Initially a go/no go milestone was established to evaluate excipient compatibility of the IV formulation before initiating
these studies. However, since BioCryst has determined that the BCX4430 drug substance to be used in these studies will be available
and released *** as well as having identified a preliminary IV solution (LRI) based on initial results, it was determined that
there was sufficient data to support the initiation of these <I>in vitro </I>toxicology studies of this formulation - Option 3
(in Vitro experiments- IV) before moving in to animal toxicology studies (Option 4).</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Trigger 3 (for start of Option 2):&nbsp; In order to conduct further regulatory activities&nbsp;to
support NDA activities, toxicology experiments will need to be conducted in animals as well as radiolabeled absorption, metabolism
and excretion studies.&nbsp; The original go/no go criteria was to generate enough drug substance material WBS 1.4.1 that conformed
to release criteria to use in these studies. However additional batches of BCX4430 have been manufactured that will start to be
available *** and therefore should provide enough material to conduct these non-clinical animal toxicology studies in Option 2,
a NDA regulatory requirement.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Trigger 4 (for start of Option 4):&nbsp; In order to proceed with conducting further regulatory
activities to support NDA activities for the IV formulation, toxicology experiments will need to be conducted in animals.&nbsp;
However, this can only proceed if the preliminary toxicology studies performed <I>in vitro,</I> as evaluated in the <I>in vitro</I>
study report (WBS 4.3, ***)&nbsp;demonstrate that the IV formulation is safe.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0 0 10pt"><B>&nbsp;</B></P>



<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exh_103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">EXHIBIT 10.3</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh1_1.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh1_2.jpg" ALT=""></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh1_3.jpg" ALT=""></P>
<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Jon P. Stonehouse, certify that:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="vertical-align: top; text-align: center">1.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center; width: 4%">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left; width: 4%">&nbsp;</td>
    <TD STYLE="width: 92%">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">2.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">3.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">4.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">a.</td>
    <TD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">b.</td>
    <TD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">c.</td>
    <TD>evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">d.</td>
    <TD>disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">5.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">a.</td>
    <TD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">b.</td>
    <TD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</td></tr>
</table>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt; width: 50%"><FONT STYLE="font-size: 10pt">Date: November 6, 2015</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; padding-right: 0.8pt; width: 30%"><FONT STYLE="font-size: 10pt">/s/ Jon P. Stonehouse</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Jon P. Stonehouse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Thomas R. Staab, II, certify that:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="text-align: center; vertical-align: top">1.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; width: 4%; vertical-align: top">&nbsp;</td>
    <TD STYLE="width: 4%; text-align: left; vertical-align: top">&nbsp;</td>
    <TD STYLE="width: 92%">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">2.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">3.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">4.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">a.</td>
    <TD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">b.</td>
    <TD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">c.</td>
    <TD>evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">d.</td>
    <TD>disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">5.</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">a.</td>
    <TD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="text-align: left; vertical-align: top">b.</td>
    <TD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</td></tr>
</table>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt; width: 50%"><FONT STYLE="font-size: 10pt">Date: November 6, 2015</FONT></TD>
    <TD STYLE="border-bottom: Black 1.1pt solid; padding-right: 0.8pt; width: 30%"><FONT STYLE="font-size: 10pt">/s/ Thomas R. Staab, II</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Thomas R. Staab, II</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</FONT></TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 32.1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
on Form 10-Q for the period ending September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the
&ldquo;Report&rdquo;), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350,
as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="vertical-align: middle; width: 4%">&nbsp;</td>
    <TD STYLE="text-align: center; width: 4%; vertical-align: top">(1)</td>
    <TD STYLE="width: 92%">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</td></tr>
<tr>
    <TD STYLE="vertical-align: middle">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: middle">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: top">(2)</td>
    <TD>The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</td></tr>
</table>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.1pt solid; padding-right: 0.8pt; font-size: 10pt; width: 25%"><FONT STYLE="font-size: 10pt">/s/ Jon P. Stonehouse</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt; width: 75%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Jon P. Stonehouse</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 4.4pt 0pt 0.25in">President and Chief Executive Officer</P>
        <P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 4.4pt 0pt 0.25in">Date: November 6, 2015</P></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>exh_322.htm
<DESCRIPTION>EXHIBIT 32,2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 32.2</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
on Form 10-Q for the period ending September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the
&ldquo;Report&rdquo;), I, Thomas R. Staab, II, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350,
as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="vertical-align: middle; width: 4%">&nbsp;</td>
    <TD STYLE="text-align: center; width: 4%; vertical-align: top">(1)</td>
    <TD STYLE="width: 92%">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</td></tr>
<tr>
    <TD STYLE="vertical-align: middle">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: middle">&nbsp;</td>
    <TD STYLE="text-align: center; vertical-align: top">(2)</td>
    <TD>The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</td></tr>
</table>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.1pt solid; padding-right: 0.8pt; font-size: 10pt; width: 25%"><FONT STYLE="font-size: 10pt">/s/ Thomas R. Staab, II</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt; width: 75%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Thomas R. Staab, II</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font-size: 10pt; margin: 0pt 4.4pt 0pt 0">Senior Vice President, Chief Financial Officer and Treasurer</P>
        <P STYLE="font-size: 10pt; margin: 0pt 4.4pt 0pt 0">Date: November 6, 2015</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>bcrx-20150930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:12PM UTC 2015-11-06--><xbrli:xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:bcrx="http://www.biocryst.com/20150930" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="bcrx-20150930.xsd" xlink:type="simple"/>
  <bcrx:AccruedExpensesPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2180515">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;professional fees.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September 30, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:AccruedExpensesPolicyTextBlock>
  <bcrx:AdvanceNoticePeriodForTerminationOfAgreement contextRef="d_2015-01-01_2015-09-30_TypeOfArrangementAxis-AECOMAndIRLMember" id="c2177318">P60D</bcrx:AdvanceNoticePeriodForTerminationOfAgreement>
  <bcrx:AnnualLicenseFeeMaximum contextRef="i_2015-09-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c2177317" unitRef="iso4217-usd">500000</bcrx:AnnualLicenseFeeMaximum>
  <bcrx:AnnualLicenseFeeMinimum contextRef="i_2015-09-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c2177316" unitRef="iso4217-usd">150000</bcrx:AnnualLicenseFeeMinimum>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c2176929" unitRef="iso4217-usd">42000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176934" unitRef="iso4217-usd">141000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c2176939" unitRef="iso4217-usd">28000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-09-30" decimals="-3" id="c2176944" unitRef="iso4217-usd">211000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c2176949" unitRef="iso4217-usd">22000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176954" unitRef="iso4217-usd">151000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2014-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c2176959" unitRef="iso4217-usd">6000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2014-12-31" decimals="-3" id="c2176964" unitRef="iso4217-usd">179000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2015-09-30" decimals="-3" id="c2176970" unitRef="iso4217-usd">27183000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2014-12-31" decimals="-3" id="c2176971" unitRef="iso4217-usd">25459000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock contextRef="d_2015-01-01_2015-09-30" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 65%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;23,700&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;18,232&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;27,183&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;25,459&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;20,604&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;15,657&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;71,487&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2015-09-30" decimals="-3" id="c2176972" unitRef="iso4217-usd">20604000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2014-12-31" decimals="-3" id="c2176973" unitRef="iso4217-usd">15657000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AveragematurityForPortfolioInvestments contextRef="d_2015-01-01_2015-09-30_RangeAxis-MaximumMember" id="c2177181">P1Y180D</bcrx:AveragematurityForPortfolioInvestments>
  <bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities contextRef="d_2015-01-01_2015-09-30_RangeAxis-MaximumMember" id="c2177098">P18Y</bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities>
  <bcrx:CollaborativeAgreementAdditionalContractValue contextRef="d_2009-09-01_2009-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="INF" id="c2177278" unitRef="iso4217-usd">77191000</bcrx:CollaborativeAgreementAdditionalContractValue>
  <bcrx:CollaborativeAgreementAdditionalContractValue contextRef="d_2011-02-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="INF" id="c2177279" unitRef="iso4217-usd">55000000</bcrx:CollaborativeAgreementAdditionalContractValue>
  <bcrx:CollaborativeAgreementAdjustedContractValue contextRef="d_2007-01-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="INF" id="c2177281" unitRef="iso4217-usd">234852000</bcrx:CollaborativeAgreementAdjustedContractValue>
  <bcrx:CollaborativeAgreementContractValue contextRef="d_2007-01-01_2007-01-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="INF" id="c2177274" unitRef="iso4217-usd">102661000</bcrx:CollaborativeAgreementContractValue>
  <bcrx:CollaborativeAgreementPeriodOfcontract contextRef="d_2015-01-01_2015-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" id="c2177293">P5Y</bcrx:CollaborativeAgreementPeriodOfcontract>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176808" unitRef="iso4217-usd">5162000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176809" unitRef="iso4217-usd">3233000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176810" unitRef="iso4217-usd">35643000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176811" unitRef="iso4217-usd">6211000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-07-01_2015-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c2177012" unitRef="iso4217-usd">4582000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-07-01_2014-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c2177013" unitRef="iso4217-usd">2937000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c2177014" unitRef="iso4217-usd">12788000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c2177015" unitRef="iso4217-usd">5323000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-07-01_2015-09-30_CounterpartyNameAxis-GreenCrossCorporationMember" decimals="-3" id="c2177016" unitRef="iso4217-usd">132000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-07-01_2014-09-30_CounterpartyNameAxis-GreenCrossCorporationMember" id="c2177017" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-09-30_CounterpartyNameAxis-GreenCrossCorporationMember" decimals="-3" id="c2177018" unitRef="iso4217-usd">132000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-09-30_CounterpartyNameAxis-GreenCrossCorporationMember" id="c2177019" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-07-01_2015-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c2177020" unitRef="iso4217-usd">296000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-07-01_2014-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c2177021" unitRef="iso4217-usd">296000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c2177022" unitRef="iso4217-usd">888000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c2177023" unitRef="iso4217-usd">888000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-07-01_2015-09-30_CounterpartyNameAxis-CSLMember" decimals="-3" id="c2177024" unitRef="iso4217-usd">152000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-07-01_2014-09-30_CounterpartyNameAxis-CSLMember" id="c2177025" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-09-30_CounterpartyNameAxis-CSLMember" decimals="-3" id="c2177026" unitRef="iso4217-usd">21835000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-09-30_CounterpartyNameAxis-CSLMember" id="c2177027" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2177028" unitRef="iso4217-usd">5162000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2177029" unitRef="iso4217-usd">3233000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177030" unitRef="iso4217-usd">35643000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2177031" unitRef="iso4217-usd">6211000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2181970">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the CSL transaction as CSL will be responsible for commercial sales on a worldwide basis with the exception of Israel, Japan, Korea and Taiwan.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB (i.e., peramivir) and BCX4430 development expenses, which was earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of the NIAID/HHS and BARDA/HHS BCX4430 programs/collaboration could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company&amp;#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
  <bcrx:ContractTerm contextRef="d_2007-01-01_2007-01-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c2177420">P4Y</bcrx:ContractTerm>
  <bcrx:CurrencyHedgeAgreementPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2181966">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 and 2014 resulted in a loss of $792 and a gain of $732, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized a currency exchange gain of $1,653 during the first nine months of 2015 associated with the exercise of a U.S. Dollar/Japanese yen currency option.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of September 30, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:CurrencyHedgeAgreementPolicyTextBlock>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2015-09-30" decimals="0" id="c2176759" unitRef="iso4217-usd">282000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2014-12-31" decimals="0" id="c2176760" unitRef="iso4217-usd">177000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176892" unitRef="iso4217-usd">117000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176893" unitRef="iso4217-usd">-45000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2179795">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $119,736, to continue its planned operations into 2017. The Company&amp;#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond 2017 it will need to: (1)&amp;nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;nbsp;raise additional capital through equity or debt financings or from other sources; (4)&amp;nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&amp;nbsp;reduce spending on one or more research and development programs; and/or (6)&amp;nbsp;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&amp;nbsp;&amp;nbsp;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November&amp;nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember" decimals="0" id="c2177203" unitRef="iso4217-usd">1782000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember" decimals="0" id="c2177211" unitRef="iso4217-usd">290000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember" decimals="0" id="c2177209" unitRef="iso4217-usd">2508000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember" decimals="0" id="c2177207" unitRef="iso4217-usd">4627000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember" decimals="0" id="c2177205" unitRef="iso4217-usd">5632000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
  <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts contextRef="d_2015-01-01_2015-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="c2177292" unitRef="iso4217-usd">34002000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2181963">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Interest expense for the three months ended September&amp;nbsp;30, 2015 and 2014 was $1,214 and $1,217, respectively, and for the nine months ended September 30, 2015 and 2014 was $3,862 and $3,684, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended September&amp;nbsp;30, 2015 and 2014, and $329 for each of the nine months ended September&amp;nbsp;30, 2015 and 2014.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
  <bcrx:Interestreserve contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c2177336" unitRef="iso4217-usd">3000000</bcrx:Interestreserve>
  <bcrx:LongtermInvestmentMaturityMinimum contextRef="d_2015-01-01_2015-09-30_RangeAxis-MinimumMember" id="c2177101">P12Y</bcrx:LongtermInvestmentMaturityMinimum>
  <bcrx:MaturityPeriodOfHighQualityMarketablesecurities contextRef="d_2015-01-01_2015-09-30_RangeAxis-MaximumMember" id="c2177097">P3Y</bcrx:MaturityPeriodOfHighQualityMarketablesecurities>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2015-01-01_2015-09-30_RangeAxis-MinimumMember" id="c2177099">P3Y</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2015-01-01_2015-09-30_RangeAxis-MaximumMember" id="c2177100">P12Y</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2015-03-03" decimals="-6" id="c2177366" unitRef="iso4217-usd">150000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2013-11-06" decimals="-6" id="c2177368" unitRef="iso4217-usd">125000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAmountOfCollateralRequiredToPost contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2177364" unitRef="iso4217-usd">9750000</bcrx:MaximumAmountOfCollateralRequiredToPost>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c2177123" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="INF" id="c2177305" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-01-01_2015-09-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c2177313" unitRef="iso4217-usd">4000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMinimum contextRef="d_2015-01-01_2015-09-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c2177312" unitRef="iso4217-usd">1400000</bcrx:MilestonePaymentMinimum>
  <bcrx:NumberOfMilestonesaAchieved contextRef="d_2015-01-01_2015-09-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c2177223" unitRef="xbrli-pure">3</bcrx:NumberOfMilestonesaAchieved>
  <bcrx:NumberOfStockbasedCompensationPlans contextRef="d_2015-01-01_2015-09-30" decimals="INF" id="c2177188" unitRef="xbrli-pure">2</bcrx:NumberOfStockbasedCompensationPlans>
  <bcrx:PaymentsForModificationOfLicenseAgreement contextRef="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c2177324" unitRef="iso4217-usd">90000</bcrx:PaymentsForModificationOfLicenseAgreement>
  <bcrx:PercentageOfCarryingAmountInExcessOfFairValue1 contextRef="i_2015-09-30_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="INF" id="c2177423" unitRef="xbrli-pure">0.5</bcrx:PercentageOfCarryingAmountInExcessOfFairValue1>
  <bcrx:PercentageOfCommonStockSharesBeginning contextRef="d_2015-01-01_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c2177261" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
  <bcrx:PercentageOfCommonStockSharesEnding contextRef="d_2015-01-01_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c2177262" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesEnding>
  <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum contextRef="d_2015-01-01_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c2177260" unitRef="xbrli-pure">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
  <bcrx:PeriodOfAgreement contextRef="d_2015-01-01_2015-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c2177329">P25Y</bcrx:PeriodOfAgreement>
  <bcrx:PrivatePlacementOfSeniorSecuredNotes contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="0" id="c2177339" unitRef="iso4217-usd">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2015-01-01_2015-09-30_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="INF" id="c2177288" unitRef="iso4217-usd">16300000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="c2177290" unitRef="iso4217-usd">5000000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2015-01-01_2015-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="c2177297" unitRef="iso4217-usd">29875</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:RemainingAggregateOfferingPrice contextRef="i_2013-11-06" decimals="-6" id="c2177371" unitRef="iso4217-usd">10000000</bcrx:RemainingAggregateOfferingPrice>
  <bcrx:RenewablePeriodOfAgreement contextRef="d_2015-01-01_2015-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c2177330">P5Y</bcrx:RenewablePeriodOfAgreement>
  <bcrx:RequiredForeignCurrencyHedgePerDollar contextRef="i_2014-12-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c2177353" unitRef="iso4217-jpy">100</bcrx:RequiredForeignCurrencyHedgePerDollar>
  <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c2177334" unitRef="iso4217-usd">22691000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="0" id="c2177081" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c2177333" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RoyaltyMonetizationTextBlock contextRef="d_2015-01-01_2015-09-30" id="s80474">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 4 &amp;#x2014; Royalty Monetization&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Overview&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March&amp;nbsp;9, 2011, the Company completed a $30,000&amp;nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&amp;nbsp;from the transaction after transaction costs of $4,309&amp;nbsp;and the establishment of a $3,000&amp;nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&amp;nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&amp;nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&amp;nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &amp;#x201c;Currency Hedge Agreement&amp;#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&amp;#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Non-Recourse Notes Payable&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March&amp;nbsp;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &amp;#x201c;PhaRMA Notes&amp;#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&amp;nbsp;9, 2011 (the &amp;#x201c;Indenture&amp;#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&amp;nbsp;per annum, payable annually in arrears on September&amp;nbsp;1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Royalty Sub&amp;#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&amp;#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On September&amp;nbsp;1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the Consolidated Balance Sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&amp;#x2019;s future results of operations or cash flows.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 18; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Foreign Currency Hedge&lt;/div&gt;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&amp;nbsp;will be required if, on May&amp;nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments resulted in a loss of $460 and a gain of $4,082 for the three months ended September&amp;nbsp;30, 2015 and 2014, respectively and a loss of $793 and a gain of $732 for the nine months ended September&amp;nbsp;30, 2015 and 2014, respectively. During the nine months ended September&amp;nbsp;30, 2015, the Company realized a currency exchange gain of $1,654 associated with the exercise of a U.S. Dollar/Japanese yen currency option. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of September 30, 2015 and December&amp;nbsp;31, 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of September 30, 2015, the maximum amount of hedge collateral the Company may be required to post is $9,750.&lt;/div&gt;&lt;/div&gt;</bcrx:RoyaltyMonetizationTextBlock>
  <bcrx:RoyaltyTerm contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" id="c2177306">P10Y</bcrx:RoyaltyTerm>
  <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock contextRef="d_2015-01-01_2015-09-30" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;September 30, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Billed&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Unbilled&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Total&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5,444&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5,444&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;129&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;129&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;div style=" margin: 0"&gt;Seqirus UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,922&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,922&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,051&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,444&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;7,495&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;3,849&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
  <bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock contextRef="d_2015-01-01_2015-09-30" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Three Months&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Nine Months&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,699&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;6,236&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;126&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,776&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,951&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: -20pt; padding-left: 20pt"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,582&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,937&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;12,788&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,323&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Shionogi (Japan)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;888&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;888&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;&lt;div style=" margin: 0"&gt;Seqirus UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;152&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,835&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;5,162&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;3,233&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;35,643&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;6,211&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;10,987&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;3,238&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;43,655&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;8,162&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock>
  <bcrx:SecuritiesOffered contextRef="d_2015-03-03_2015-03-03" decimals="0" id="c2177077" unitRef="iso4217-usd">150000000</bcrx:SecuritiesOffered>
  <bcrx:SecuritiesOffered contextRef="d_2013-11-06_2013-11-06" decimals="0" id="c2177079" unitRef="iso4217-usd">10000000</bcrx:SecuritiesOffered>
  <bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount contextRef="i_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="0" id="c2177267" unitRef="iso4217-usd">25000</bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember" id="c2177240">P1Y</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177045" unitRef="xbrli-shares">1319000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2015-01-01_2015-09-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c2177236" unitRef="xbrli-pure">0.25</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2015-01-01_2015-09-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c2177238" unitRef="xbrli-pure">1</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177051" unitRef="xbrli-shares">28000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement contextRef="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c2177323" unitRef="iso4217-usd">5911000</bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement>
  <bcrx:TransactionCosts contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c2177335" unitRef="iso4217-usd">4309000</bcrx:TransactionCosts>
  <dei:AmendmentFlag contextRef="d_2015-01-01_2015-09-30" id="c-14">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2015-01-01_2015-09-30" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2015-01-01_2015-09-30" id="c-13">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2015-01-01_2015-09-30" id="c-12">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2015-01-01_2015-09-30" id="c-11">2015-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2015-01-01_2015-09-30" id="c-10">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2015-01-01_2015-09-30" id="c-2">0000882796</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2015-10-31" decimals="INF" id="c-9" unitRef="xbrli-shares">73336871</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2015-01-01_2015-09-30" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2015-01-01_2015-09-30" id="c-5">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2015-01-01_2015-09-30" id="c-1">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2015-01-01_2015-09-30" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2015-01-01_2015-09-30" id="c-8">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2015-01-01_2015-09-30" id="c-3">bcrx</dei:TradingSymbol>
  <us-gaap:AccountsPayableCurrent contextRef="i_2015-09-30" decimals="0" id="c2176766" unitRef="iso4217-usd">3782000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2014-12-31" decimals="0" id="c2176767" unitRef="iso4217-usd">2849000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember" decimals="0" id="c2176743" unitRef="iso4217-usd">7495000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember" decimals="0" id="c2176744" unitRef="iso4217-usd">3849000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember" id="c2176745" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember" decimals="0" id="c2176746" unitRef="iso4217-usd">5641000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2015-09-30" decimals="0" id="c2176768" unitRef="iso4217-usd">23027000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="0" id="c2176769" unitRef="iso4217-usd">11329000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2015-09-30" decimals="0" id="c2176791" unitRef="iso4217-usd">-1000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2014-12-31" decimals="0" id="c2176792" unitRef="iso4217-usd">-130000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2015-09-30" decimals="0" id="c2176789" unitRef="iso4217-usd">556095000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2014-12-31" decimals="0" id="c2176790" unitRef="iso4217-usd">542943000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-UnvestedPerformanceSharesMember_PlanNameAxis-IncentivePlanMember" decimals="0" id="c2177419" unitRef="iso4217-usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-09-30" decimals="0" id="c2177190" unitRef="iso4217-usd">7773000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-09-30_PlanNameAxis-IncentivePlanMember" decimals="0" id="c2177191" unitRef="iso4217-usd">7553000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="0" id="c2177192" unitRef="iso4217-usd">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-09-30" decimals="0" id="c2177196" unitRef="iso4217-usd">6550000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-09-30_PlanNameAxis-IncentivePlanMember" decimals="0" id="c2177197" unitRef="iso4217-usd">6388000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="0" id="c2177198" unitRef="iso4217-usd">162000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2015-07-01_2015-09-30" decimals="0" id="c2179792" unitRef="iso4217-usd">110000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2015-01-01_2015-09-30" decimals="0" id="c2179793" unitRef="iso4217-usd">329000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2014-07-01_2014-09-30" decimals="0" id="c2177144" unitRef="iso4217-usd">110000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2014-01-01_2014-09-30" decimals="0" id="c2177147" unitRef="iso4217-usd">329000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2177164" unitRef="xbrli-shares">3821000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2177165" unitRef="xbrli-shares">4240000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177168" unitRef="xbrli-shares">3673000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2177169" unitRef="xbrli-shares">3986000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2015-09-30" decimals="0" id="c2176763" unitRef="iso4217-usd">138956000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2014-12-31" decimals="0" id="c2176764" unitRef="iso4217-usd">136874000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2015-09-30" decimals="0" id="c2176753" unitRef="iso4217-usd">84502000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2014-12-31" decimals="0" id="c2176754" unitRef="iso4217-usd">89343000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-09-30" decimals="-3" id="c2176974" unitRef="iso4217-usd">71487000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2014-12-31" decimals="-3" id="c2176975" unitRef="iso4217-usd">59348000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c2176932" unitRef="iso4217-usd">23187000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176937" unitRef="iso4217-usd">27402000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c2176942" unitRef="iso4217-usd">20898000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c2176952" unitRef="iso4217-usd">20306000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176957" unitRef="iso4217-usd">27261000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2014-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c2176962" unitRef="iso4217-usd">11781000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c2176930" unitRef="iso4217-usd">28000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176935" unitRef="iso4217-usd">26000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c2176940" unitRef="iso4217-usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-09-30" decimals="-3" id="c2176945" unitRef="iso4217-usd">64000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" id="c2176950" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176955" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" id="c2176960" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2014-12-31" decimals="-3" id="c2176965" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c2176931" unitRef="iso4217-usd">-2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176936" unitRef="iso4217-usd">-14000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c2176941" unitRef="iso4217-usd">-49000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-09-30" decimals="-3" id="c2176946" unitRef="iso4217-usd">-65000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c2176951" unitRef="iso4217-usd">-23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176956" unitRef="iso4217-usd">-47000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c2176961" unitRef="iso4217-usd">-63000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2014-12-31" decimals="-3" id="c2176966" unitRef="iso4217-usd">-133000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c2176928" unitRef="iso4217-usd">23119000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176933" unitRef="iso4217-usd">27249000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c2176938" unitRef="iso4217-usd">20909000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-09-30" decimals="-3" id="c2176943" unitRef="iso4217-usd">71277000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c2176948" unitRef="iso4217-usd">20307000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c2176953" unitRef="iso4217-usd">27152000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2014-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c2176958" unitRef="iso4217-usd">11838000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2014-12-31" decimals="-3" id="c2176963" unitRef="iso4217-usd">59297000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2015-09-30" decimals="-3" id="c2176968" unitRef="iso4217-usd">23700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2014-12-31" decimals="-3" id="c2176969" unitRef="iso4217-usd">18232000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2015-09-30" decimals="0" id="c2176741" unitRef="iso4217-usd">23700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2014-12-31" decimals="0" id="c2176742" unitRef="iso4217-usd">18232000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2015-09-30" decimals="0" id="c2176755" unitRef="iso4217-usd">47787000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2014-12-31" decimals="0" id="c2176756" unitRef="iso4217-usd">41116000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="d_2015-01-01_2015-09-30" id="c-16">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;September 30, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;23,119&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;42&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(2&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;23,187&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;27,249&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;141&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;26&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(14&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;27,402&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;20,909&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;10&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(49&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;20,898&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;71,277&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;211&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(65&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;71,487&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,307&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;22&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(23&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,306&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;27,152&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;151&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(47&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;27,261&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;11,838&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;6&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(63&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;11,781&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,297&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;179&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(133&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-09-30" decimals="0" id="c2176737" unitRef="iso4217-usd">46627000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="0" id="c2176738" unitRef="iso4217-usd">54540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2013-12-31" decimals="-3" id="c2176925" unitRef="iso4217-usd">21164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-09-30" decimals="-3" id="c2176927" unitRef="iso4217-usd">121157000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176922" unitRef="iso4217-usd">-7913000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176923" unitRef="iso4217-usd">99993000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2179798">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="d_2015-01-01_2015-09-30" id="c2180483">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Restricted cash as of September 30, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $70 in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,402 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2015-01-01_2015-09-30" id="s80473">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 3 &amp;#x2014; Collaborative and Other Research and Development Contracts&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;U.S.&amp;nbsp;Department of Health and Human Services (&amp;#x201c;BARDA/HHS&amp;#x201d;).&lt;/div&gt; In January 2007, BARDA/HHS awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&amp;nbsp;24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014 according to its terms.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 15; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March 31, 2015, the Company announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services&amp;#x2019; Office of the Assistant Secretary for Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&amp;nbsp;This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options within this contract.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;).&lt;/div&gt; In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of September 30, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. As of September 30, 2015, a total of $29,875 has been awarded under exercised options within this contract. BCX4430 is the lead compound in the Company&amp;#x2019;s BSAV research program.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&amp;#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;).&lt;/div&gt; On June 16, 2015, the Company and Seqirus UK Limited (&amp;quot;SUL&amp;quot;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &amp;quot;SUL Agreement&amp;quot;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &amp;quot;Territory&amp;quot;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. The Company will exercise sole decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and is responsible for all associated costs.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;      &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0"&gt;In December 2013, the Company submitted a New Drug Application (&amp;quot;NDA&amp;quot;) for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&amp;quot;EMA&amp;quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement (the &amp;quot;Royalty Term&amp;quot;). The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.&lt;/div&gt;        &lt;!-- Field: Page; Sequence: 16; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The term of the SUL Agreement shall continue on a country-by-country basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement, subject to applicable cure periods, or if the other party suffers an insolvency event. The Company may also terminate the SUL Agreement if SUL or any of its affiliates seek to challenge the validity of the Company's patents. Termination does not affect a party's rights which have accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations exercised by the Company, the SUL Agreement provides for the termination of any sublicenses granted by SUL to third parties, and in the case of termination by the Company for cause, the ceasing of SUL's activities with respect to RAPIVAB, the discontinued use of all Company intellectual property and the termination of licenses and rights previously granted to SUL. If requested by the Company, SUL shall also promptly sell to the Company all licensed product it then holds in stock, otherwise, SUL may continue to sell such licensed product for designated periods.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;).&lt;/div&gt; In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan and to provide rights for Shionogi to perform a Phase&amp;nbsp;3 clinical trial in Hong Kong. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;).&lt;/div&gt; In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Mundipharma International Holdings Limited (&amp;#x201c;Mundipharma&amp;#x201d;).&lt;/div&gt; In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&amp;#x201c;PNP&amp;#x201d;) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained worldwide rights to forodesine. &amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&amp;#x201c;AECOM&amp;#x201d; and &amp;#x201c;IRL&amp;#x201d; respectively).&lt;/div&gt; In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &amp;#x201c;Licensors&amp;#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&amp;nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&amp;nbsp;days advance notice or in the event of material uncured breach by the Licensors.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&amp;nbsp;any milestone payments the Company may receive in the future under its license agreement dated February&amp;nbsp;1, 2006 with Mundipharma and (ii)&amp;nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company&amp;#x2019;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On November&amp;nbsp;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On June&amp;nbsp;19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&amp;#x2019;s common stock, or in a combination of cash and shares.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 17; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&amp;#x201c;VUW&amp;#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;).&lt;/div&gt; The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&amp;#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&amp;#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2015-09-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2179764" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2014-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2179765" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2177421" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2177422" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2015-09-30" decimals="INF" id="c2177380" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2014-12-31" decimals="INF" id="c2177381" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-09-30" decimals="0" id="c2177382" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2014-12-31" decimals="0" id="c2177383" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2015-09-30" decimals="0" id="c2177384" unitRef="xbrli-shares">73337000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2014-12-31" decimals="0" id="c2177385" unitRef="xbrli-shares">71955000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2015-09-30" decimals="0" id="c2177386" unitRef="xbrli-shares">73337000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2014-12-31" decimals="0" id="c2177387" unitRef="xbrli-shares">71955000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2015-09-30" decimals="0" id="c2176787" unitRef="iso4217-usd">733000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2014-12-31" decimals="0" id="c2176788" unitRef="iso4217-usd">720000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176869" unitRef="iso4217-usd">-14530000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176870" unitRef="iso4217-usd">-8732000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176871" unitRef="iso4217-usd">-24755000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176872" unitRef="iso4217-usd">-33519000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2181230">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on investments available-for-sale and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the nine months ended September 30, 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during the nine months ended September 30, 2014.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2015-01-01_2015-09-30" id="c2181971">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2015-01-01_2015-09-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember" decimals="1" id="c2177172" unitRef="xbrli-pure">0.9</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2179796">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;). Royalty Sub was formed in connection with a $30,000&amp;nbsp;financing transaction the Company completed on March&amp;nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&amp;nbsp;31, 2014 and the notes thereto included in the Company&amp;#x2019;s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&amp;nbsp;31, 2014 has been derived from the audited consolidated financial statements included in the Company&amp;#x2019;s most recent Annual Report on Form 10-K.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:CostOfGoodsSold contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176817" unitRef="iso4217-usd">1346000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2014-07-01_2014-09-30" id="c2176818" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CostOfGoodsSold contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176819" unitRef="iso4217-usd">1361000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2014-01-01_2014-09-30" id="c2176820" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CostsAndExpenses contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176833" unitRef="iso4217-usd">24149000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176834" unitRef="iso4217-usd">14848000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176835" unitRef="iso4217-usd">65905000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176836" unitRef="iso4217-usd">38777000</us-gaap:CostsAndExpenses>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c2177340" unitRef="xbrli-pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DeferredCostsCurrent contextRef="i_2015-09-30" decimals="0" id="c2176751" unitRef="iso4217-usd">88000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent contextRef="i_2014-12-31" decimals="0" id="c2176752" unitRef="iso4217-usd">76000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2015-09-30" decimals="0" id="c2176782" unitRef="iso4217-usd">345000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2014-12-31" decimals="0" id="c2176783" unitRef="iso4217-usd">394000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c2177120" unitRef="iso4217-usd">3740000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c2177122" unitRef="iso4217-usd">1223000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-09-30_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember" decimals="0" id="c2176772" unitRef="iso4217-usd">2102000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2014-12-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember" decimals="0" id="c2176773" unitRef="iso4217-usd">1481000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-09-30_DeferredRevenueArrangementTypeAxis-DeferredProductSalesMember" decimals="0" id="c2176774" unitRef="iso4217-usd">16000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2014-12-31_DeferredRevenueArrangementTypeAxis-DeferredProductSalesMember" decimals="0" id="c2176775" unitRef="iso4217-usd">5605000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2015-09-30" decimals="0" id="c2176780" unitRef="iso4217-usd">10122000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2014-12-31" decimals="0" id="c2176781" unitRef="iso4217-usd">3552000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176877" unitRef="iso4217-usd">137000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176878" unitRef="iso4217-usd">137000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DerivativeForwardExchangeRate1 contextRef="i_2015-09-30_CurrencyAxis-JapanYenMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c2177349" unitRef="xbrli-pure">100</us-gaap:DerivativeForwardExchangeRate1>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2014-01-01_2014-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="0" id="c2177154" unitRef="iso4217-usd">732000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2015-01-01_2015-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="0" id="c2177157" unitRef="iso4217-usd">1654000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeLossOnDerivative contextRef="d_2015-01-01_2015-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="0" id="c2177153" unitRef="iso4217-usd">793000</us-gaap:DerivativeLossOnDerivative>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2015-01-01_2015-09-30" id="s80470">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 2 &amp;#x2014; Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of September 30, 2015, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&amp;#x201c;Incentive Plan&amp;#x201d;) and the Employee Stock Purchase Plan (&amp;#x201c;ESPP&amp;#x201d;), both which were amended and restated in March 2014 and approved by the Company&amp;#x2019;s stockholders in May 2014. Stock-based compensation expense of $7,773 ($7,553 of expense related to the Incentive Plan and $220 of expense related to the ESPP) was recognized during the first nine months of 2015, while $6,550 ($6,388 of expense related to the Incentive Plan and $162 of expense related to the ESPP) was recognized during the first nine months of 2014.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;There was approximately $14,839 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of September 30, 2015. That cost is expected to be recognized as follows: $1,782 during the remainder of 2015, $5,632 in 2016, $4,627 in 2017, $2,508 in 2018 and $290 in 2019. In addition, the Company has approximately $11,982 of unrecognized compensation cost related to outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&amp;#x2019;s stock at the date of grant. Since March&amp;nbsp;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of September 30, 2015, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of September 30, 2015, 25% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&amp;nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 14; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;Related activity under the Incentive Plan is as follows:&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 55%; font-size: 10pt"&gt;Balance December 31, 2014&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,362&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;9,605&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;6.21&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock unit awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(155&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock unit awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(1,319&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,319&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;11.99&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(1,102&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4.36&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(28&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;9.05&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance September 30, 2015&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;917&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;9,794&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;7.19&lt;/td&gt;      &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For stock option awards granted under the Incentive Plan during the first nine months of 2015 and 2014, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the first nine months of 2015 and 2014 was $8.15 and $8.19, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the first nine months of 2015 and 2014. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&amp;#x2019;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted Average Assumptions for Stock Option Awards Granted to&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Employees and Directors under the Incentive Plan&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 70%; font-size: 10pt; text-align: left"&gt;Expected Life in Years&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;83&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;87&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1.5&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1.6&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Employee Stock Purchase Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 497 shares remain available for purchase at September 30, 2015. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 41 shares during the first nine months of 2015 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &amp;#x201c;look-back&amp;#x201d; option were determined using a Black-Scholes option pricing model.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2015-07-01_2015-09-30" decimals="INF" id="c2176857" unitRef="iso4217-usd-per-xbrli-shares">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-07-01_2014-09-30" decimals="INF" id="c2176858" unitRef="iso4217-usd-per-xbrli-shares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2015-01-01_2015-09-30" decimals="INF" id="c2176859" unitRef="iso4217-usd-per-xbrli-shares">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-01-01_2014-09-30" decimals="INF" id="c2176860" unitRef="iso4217-usd-per-xbrli-shares">-0.52</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2181968">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended September&amp;nbsp;30, 2015 and 2014 does not include 0,000 and 0,000, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the nine months ended September&amp;nbsp;30, 2015 and 2014 does not include 0,000 and 0,000, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember" decimals="0" id="c2177202" unitRef="iso4217-usd">14839000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2015-09-30_AwardTypeAxis-PerformanceSharesMember" decimals="0" id="c2177213" unitRef="iso4217-usd">11982000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="d_2015-01-01_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2177362" unitRef="iso4217-usd">1654000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2015-07-01_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2177354" unitRef="iso4217-usd">-460000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2014-07-01_2014-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2177355" unitRef="iso4217-usd">4082000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2015-01-01_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2177358" unitRef="iso4217-usd">-793000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2014-01-01_2014-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2177359" unitRef="iso4217-usd">732000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176849" unitRef="iso4217-usd">-352000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176850" unitRef="iso4217-usd">4082000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176851" unitRef="iso4217-usd">861000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176852" unitRef="iso4217-usd">732000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176825" unitRef="iso4217-usd">2731000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176826" unitRef="iso4217-usd">1812000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176827" unitRef="iso4217-usd">10326000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176828" unitRef="iso4217-usd">5413000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember" decimals="INF" id="c2177284" unitRef="iso4217-usd">13314000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember" decimals="INF" id="c2177286" unitRef="iso4217-usd">22855000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="INF" id="c2177287" unitRef="iso4217-usd">36169000</us-gaap:GovernmentContractReceivable>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2180516">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176894" unitRef="iso4217-usd">12582000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176895" unitRef="iso4217-usd">3602000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176898" unitRef="iso4217-usd">1602000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176899" unitRef="iso4217-usd">-880000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176883" unitRef="iso4217-usd">-793000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176884" unitRef="iso4217-usd">732000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176896" unitRef="iso4217-usd">-512000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176897" unitRef="iso4217-usd">957000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176888" unitRef="iso4217-usd">-683000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2014-01-01_2014-09-30" id="c2176889" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176890" unitRef="iso4217-usd">-1331000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176891" unitRef="iso4217-usd">29000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176886" unitRef="iso4217-usd">-1995000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176887" unitRef="iso4217-usd">1123000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176905" unitRef="iso4217-usd">1472000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176906" unitRef="iso4217-usd">-1000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2015-01-01_2015-09-30" id="c2180514">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:InterestAndOtherIncome contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176841" unitRef="iso4217-usd">134000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176842" unitRef="iso4217-usd">14000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176843" unitRef="iso4217-usd">367000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176844" unitRef="iso4217-usd">50000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense contextRef="d_2015-07-01_2015-09-30" decimals="0" id="c2177137" unitRef="iso4217-usd">1241000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2014-07-01_2014-09-30" decimals="0" id="c2177138" unitRef="iso4217-usd">1217000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-09-30" decimals="0" id="c2177141" unitRef="iso4217-usd">3862000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2014-01-01_2014-09-30" decimals="0" id="c2177142" unitRef="iso4217-usd">3684000</us-gaap:InterestExpense>
  <us-gaap:InterestPayableCurrent contextRef="i_2015-09-30" decimals="0" id="c2176770" unitRef="iso4217-usd">5517000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent contextRef="i_2014-12-31" decimals="0" id="c2176771" unitRef="iso4217-usd">6029000</us-gaap:InterestPayableCurrent>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2015-09-30" id="c2176999" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2014-12-31" decimals="-3" id="c2177000" unitRef="iso4217-usd">416000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet contextRef="i_2015-09-30" id="c2176747" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InventoryNet contextRef="i_2014-12-31" decimals="0" id="c2176748" unitRef="iso4217-usd">683000</us-gaap:InventoryNet>
  <us-gaap:InventoryPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2180513">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;At September 30, 2015 and December 31, 2014, the Company&amp;#x2019;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;During 2014, in connection with the Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB commercial inventories.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company&amp;#x2019;s inventory consisted of the following at September&amp;nbsp;30, 2015 and December&amp;nbsp;31, 2014:&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%; text-align: left"&gt;Work in process&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;267&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished Goods&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;416&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.25pt"&gt;Net inventories&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;683&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2015-09-30" id="c2176997" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2014-12-31" decimals="-3" id="c2176998" unitRef="iso4217-usd">267000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InvestmentPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2180511">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September 30, 2015, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair value of the Company&amp;#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;September&amp;nbsp;30, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Amortized&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Accrued&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Fair&amp;nbsp;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 45%; text-align: left"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;23,119&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;42&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;28&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;(2&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;23,187&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;27,249&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;141&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;26&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;(14&lt;/td&gt; &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;27,402&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,909&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(49&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,898&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;71,277&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;211&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;64&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(65&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;71,487&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Amortized&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Accrued&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Fair&amp;nbsp;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 45%; text-align: left"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;20,307&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;22&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;(23&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;20,306&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;27,152&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;151&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;5&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;(47&lt;/td&gt; &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;27,261&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,838&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(63&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,781&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;59,297&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;179&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(133&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;59,348&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at September&amp;nbsp;30, 2015 and December&amp;nbsp;31, 2014.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;23,700&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;18,232&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;27,183&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;25,459&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,604&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,657&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;71,487&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;59,348&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:InvestmentsAndCash contextRef="i_2015-09-30" decimals="0" id="c2177067" unitRef="iso4217-usd">119736000</us-gaap:InvestmentsAndCash>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2015-09-30" decimals="0" id="c2176797" unitRef="iso4217-usd">138956000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2014-12-31" decimals="0" id="c2176798" unitRef="iso4217-usd">136874000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2015-09-30" decimals="0" id="c2176778" unitRef="iso4217-usd">64444000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2014-12-31" decimals="0" id="c2176779" unitRef="iso4217-usd">57293000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermNotesPayable contextRef="i_2015-09-30" decimals="0" id="c2176776" unitRef="iso4217-usd">30000000</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable contextRef="i_2014-12-31" decimals="0" id="c2176777" unitRef="iso4217-usd">30000000</us-gaap:LongTermNotesPayable>
  <us-gaap:LossOnSaleOfInvestments contextRef="d_2015-01-01_2015-09-30" decimals="0" id="c2179767" unitRef="iso4217-usd">0</us-gaap:LossOnSaleOfInvestments>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176920" unitRef="iso4217-usd">5392000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176921" unitRef="iso4217-usd">111546000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176911" unitRef="iso4217-usd">-15017000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176912" unitRef="iso4217-usd">13108000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176900" unitRef="iso4217-usd">1712000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176901" unitRef="iso4217-usd">-24661000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176874" unitRef="iso4217-usd">-24884000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176875" unitRef="iso4217-usd">-33517000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176853" unitRef="iso4217-usd">-14621000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176854" unitRef="iso4217-usd">-8731000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2181972">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;In April 2015, the FASB issued ASU No. 2015-03, &lt;div style="display: inline; font-style: italic;"&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt;. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect this ASU will have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;In May 2014, the FASB issued ASU 2014-09 &amp;#x2013; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/div&gt;, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018, however early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176837" unitRef="iso4217-usd">-13162000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176838" unitRef="iso4217-usd">-11610000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176839" unitRef="iso4217-usd">-22250000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176840" unitRef="iso4217-usd">-30615000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2015-09-30" decimals="0" id="c2176761" unitRef="iso4217-usd">5239000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2014-12-31" decimals="0" id="c2176762" unitRef="iso4217-usd">6031000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176865" unitRef="iso4217-usd">91000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176866" unitRef="iso4217-usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176867" unitRef="iso4217-usd">129000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176868" unitRef="iso4217-usd">-2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities contextRef="d_2015-01-01_2015-09-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c2177352" unitRef="iso4217-usd">1950000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176907" unitRef="iso4217-usd">48343000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176908" unitRef="iso4217-usd">15852000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176903" unitRef="iso4217-usd">1076000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176904" unitRef="iso4217-usd">41000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2015-09-30" decimals="INF" id="c2177372" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2014-12-31" decimals="INF" id="c2177373" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2015-09-30" decimals="0" id="c2177374" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2014-12-31" decimals="0" id="c2177375" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2015-09-30" decimals="0" id="c2177378" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2014-12-31" decimals="0" id="c2177379" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2015-09-30" decimals="0" id="c2177376" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2014-12-31" decimals="0" id="c2177377" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2015-09-30" decimals="0" id="c2176785" unitRef="iso4217-usd">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="i_2014-12-31" decimals="0" id="c2176786" unitRef="iso4217-usd">0</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2015-09-30" decimals="0" id="c2176749" unitRef="iso4217-usd">4970000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2014-12-31" decimals="0" id="c2176750" unitRef="iso4217-usd">6172000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2015-01-01_2015-09-30" id="c2179797">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176914" unitRef="iso4217-usd">1175000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176915" unitRef="iso4217-usd">106600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c2177117" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c2177118" unitRef="iso4217-usd">7000000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="INF" id="c2177304" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember" decimals="INF" id="c2177311" unitRef="iso4217-usd">250000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176909" unitRef="iso4217-usd">35874000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176910" unitRef="iso4217-usd">29000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176916" unitRef="iso4217-usd">3861000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176917" unitRef="iso4217-usd">4636000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockPlans contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176918" unitRef="iso4217-usd">356000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176919" unitRef="iso4217-usd">310000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2015-09-30" decimals="0" id="c2176757" unitRef="iso4217-usd">1146000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2014-12-31" decimals="0" id="c2176758" unitRef="iso4217-usd">207000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c2176976" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c2176977" unitRef="iso4217-usd">5444000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c2176978" unitRef="iso4217-usd">5444000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" decimals="-3" id="c2176979" unitRef="iso4217-usd">129000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" id="c2176980" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" decimals="-3" id="c2176981" unitRef="iso4217-usd">129000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember" decimals="-3" id="c2176982" unitRef="iso4217-usd">1922000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember" id="c2176983" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember" decimals="-3" id="c2176984" unitRef="iso4217-usd">1922000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c2176985" unitRef="iso4217-usd">2051000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c2176986" unitRef="iso4217-usd">5444000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-09-30" decimals="-3" id="c2176987" unitRef="iso4217-usd">7495000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c2176988" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c2176989" unitRef="iso4217-usd">2778000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c2176990" unitRef="iso4217-usd">2778000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c2176991" unitRef="iso4217-usd">1071000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c2176992" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c2176993" unitRef="iso4217-usd">1071000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c2176994" unitRef="iso4217-usd">1071000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c2176995" unitRef="iso4217-usd">2778000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31" decimals="-3" id="c2176996" unitRef="iso4217-usd">3849000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2180512">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi&amp;nbsp;&amp;amp; Co. Ltd., product sales to Green Cross Corporation and CSL Limited. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September 30, 2015 and December&amp;nbsp;31, 2014, the Company had the following receivables.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;September 30, 2015&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;5,444&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;5,444&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;129&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;129&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;CSL Limited&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,922&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,922&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;2,051&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;5,444&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;7,495&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;3,849&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&amp;reg;&lt;/div&gt;. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2014-01-01_2014-09-30" decimals="0" id="c2179788" unitRef="iso4217-usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2015-01-01_2015-09-30" decimals="0" id="c2177113" unitRef="iso4217-usd">13000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176821" unitRef="iso4217-usd">20067000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176822" unitRef="iso4217-usd">13036000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176823" unitRef="iso4217-usd">53711000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176824" unitRef="iso4217-usd">33286000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2015-01-01_2015-09-30" id="c2181961">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="i_2015-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" decimals="0" id="c2177096" unitRef="iso4217-usd">1402000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2015-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CertificatesOfDepositMember" decimals="0" id="c2177093" unitRef="iso4217-usd">150000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2015-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" decimals="0" id="c2177094" unitRef="iso4217-usd">70000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2015-09-30" decimals="0" id="c2176739" unitRef="iso4217-usd">1622000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="0" id="c2176740" unitRef="iso4217-usd">150000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2015-09-30" decimals="0" id="c2176793" unitRef="iso4217-usd">-492782000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2014-12-31" decimals="0" id="c2176794" unitRef="iso4217-usd">-467898000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2015-01-01_2015-09-30" id="c2181960">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;In June 2015, the Company entered into a License Agreement (the &amp;#x201c;Agreement&amp;#x201d;) granting CSL Limited (&amp;#x201c;CSL&amp;#x201d;) and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from CSL of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the current quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter when the inventory transfer was completed. Approximately $1,223 of this revenue will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Under the terms of the Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the European Union and (iii) by Health Canada for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the CSL worldwide license of RAPIVAB, CSL will be primarily responsible for sales of RAPIVAB other than U.S. Government stockpiling sales and the Company&amp;#x2019;s commercial sales will be minimal.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) Fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The Company recorded the following revenues for the three and nine months ended September&amp;nbsp;30, 2015 and 2014:&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Nine Months&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 56%; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;5,699&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;6,236&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;126&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;5&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,776&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,951&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,581&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;2,937&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;12,788&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;5,323&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;132&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;132&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Shionogi (Japan)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;296&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;296&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;888&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;888&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;CSL Limited&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;153&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,835&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,162&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,233&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;35,643&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,211&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;10,987&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;3,238&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;43,655&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;8,162&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c2177119" unitRef="iso4217-usd">21777000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2177032" unitRef="iso4217-usd">10987000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2177033" unitRef="iso4217-usd">3238000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177034" unitRef="iso4217-usd">43655000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2177035" unitRef="iso4217-usd">8162000</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176829" unitRef="iso4217-usd">5000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2014-07-01_2014-09-30" id="c2176830" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:RoyaltyExpense contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176831" unitRef="iso4217-usd">507000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176832" unitRef="iso4217-usd">78000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176804" unitRef="iso4217-usd">126000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176805" unitRef="iso4217-usd">5000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176806" unitRef="iso4217-usd">1776000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176807" unitRef="iso4217-usd">1951000</us-gaap:RoyaltyRevenue>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176800" unitRef="iso4217-usd">5699000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2014-07-01_2014-09-30" id="c2176801" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176802" unitRef="iso4217-usd">6236000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2014-01-01_2014-09-30" id="c2176803" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueNet contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176812" unitRef="iso4217-usd">10987000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176813" unitRef="iso4217-usd">3238000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176814" unitRef="iso4217-usd">43655000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176815" unitRef="iso4217-usd">8162000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2015-01-01_2015-09-30" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 65%; font-size: 10pt; text-align: left"&gt;Work in process&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;267&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Finished Goods&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;416&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;683&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2015-01-01_2015-09-30" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt"&gt;Balance December 31, 2014&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,362&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;9,605&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;6.21&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock unit awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(155&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock unit awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,319&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,319&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;11.99&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,102&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4.36&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(28&lt;/td&gt; &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;9.05&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance September 30, 2015&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;917&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;9,794&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;7.19&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2015-01-01_2015-09-30" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-size: 10pt; text-align: left"&gt;Expected Life in Years&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;83&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;87&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.6&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176879" unitRef="iso4217-usd">7773000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176880" unitRef="iso4217-usd">6550000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" id="c2177215">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" id="c2177217">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177042" unitRef="xbrli-shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177039" unitRef="xbrli-shares">155000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2015-01-01_2015-09-30" decimals="3" id="c2177061" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2014-01-01_2014-09-30" decimals="3" id="c2177062" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-01-01_2015-09-30" decimals="3" id="c2177059" unitRef="xbrli-pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2014-01-01_2014-09-30" decimals="3" id="c2177060" unitRef="xbrli-pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-09-30" decimals="3" id="c2177063" unitRef="xbrli-pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2014-01-01_2014-09-30" decimals="3" id="c2177064" unitRef="xbrli-pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="d_2015-01-01_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c2177264" unitRef="xbrli-shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c2177258" unitRef="xbrli-shares">1475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c2177259" unitRef="xbrli-shares">497000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2014-12-31" decimals="-3" id="c2177036" unitRef="xbrli-shares">2362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2015-09-30" decimals="-3" id="c2177054" unitRef="xbrli-shares">917000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-09-30" decimals="INF" id="c2177056" unitRef="iso4217-usd-per-xbrli-shares">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177052" unitRef="xbrli-shares">28000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-09-30" decimals="INF" id="c2177053" unitRef="iso4217-usd-per-xbrli-shares">9.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177046" unitRef="xbrli-shares">1319000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c2177219" unitRef="xbrli-shares">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2014-01-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c2177220" unitRef="xbrli-shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2015-01-01_2015-09-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c2177251" unitRef="iso4217-usd-per-xbrli-shares">8.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2014-01-01_2014-09-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c2177252" unitRef="iso4217-usd-per-xbrli-shares">8.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2014-12-31" decimals="-3" id="c2177037" unitRef="xbrli-shares">9605000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-09-30" decimals="-3" id="c2177055" unitRef="xbrli-shares">9794000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2014-12-31" decimals="INF" id="c2177038" unitRef="iso4217-usd-per-xbrli-shares">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-09-30" decimals="INF" id="c2177050" unitRef="iso4217-usd-per-xbrli-shares">4.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-09-30" decimals="INF" id="c2177047" unitRef="iso4217-usd-per-xbrli-shares">11.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2015-01-01_2015-09-30" id="c2181962">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; has occurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" decimals="INF" id="c2177214" unitRef="xbrli-pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" decimals="INF" id="c2177216" unitRef="xbrli-pure">0.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2015-01-01_2015-09-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c2177221" unitRef="xbrli-pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2015-01-01_2015-09-30" id="c2177057">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2014-01-01_2014-09-30" id="c2177058">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember" id="c2177241">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2015-01-01_2015-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember" id="c2177242">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2015-01-01_2015-09-30" id="s80462">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 1 &amp;#x2014; Significant Accounting Policies&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $119,736, to continue its planned operations into 2017. The Company&amp;#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond 2017 it will need to: (1)&amp;nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;nbsp;raise additional capital through equity or debt financings or from other sources; (4)&amp;nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&amp;nbsp;reduce spending on one or more research and development programs; and/or (6)&amp;nbsp;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&amp;nbsp;&amp;nbsp;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November&amp;nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;). Royalty Sub was formed in connection with a $30,000&amp;nbsp;financing transaction the Company completed on March&amp;nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&amp;nbsp;31, 2014 and the notes thereto included in the Company&amp;#x2019;s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&amp;nbsp;31, 2014 has been derived from the audited consolidated financial statements included in the Company&amp;#x2019;s most recent Annual Report on Form 10-K.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 6; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Restricted cash as of September 30, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $70 in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,402 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September 30, 2015, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair value of the Company&amp;#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;September 30, 2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;23,119&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;42&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(2&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;23,187&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;27,249&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;141&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;26&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(14&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;27,402&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;20,909&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;10&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(49&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;20,898&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;71,277&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;211&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(65&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;71,487&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;December 31, 2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,307&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;22&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(23&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,306&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;27,152&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;151&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(47&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;27,261&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;11,838&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;6&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(63&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;11,781&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,297&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;179&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(133&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;      &lt;!-- Field: Page; Sequence: 7; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at September&amp;nbsp;30, 2015 and December&amp;nbsp;31, 2014.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 65%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;23,700&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;18,232&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;27,183&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;25,459&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;20,604&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;15,657&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;71,487&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, and product sales to Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;) and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;). These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September 30, 2015 and December&amp;nbsp;31, 2014, the Company had the following receivables.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;September 30, 2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Billed&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Unbilled&lt;/div&gt;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td colspan="3" style="border-bottom: black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Total&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5,444&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5,444&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;129&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;129&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;div style=" margin: 0"&gt;Seqirus UK Limited&lt;/div&gt; &lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,922&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,922&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,051&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,444&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;7,495&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" margin-top: 0; margin-bottom: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;December 31, 2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Billed&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Unbilled&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Total&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;3,849&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&amp;reg;&lt;/div&gt;. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;At December 31, 2014, the Company&amp;#x2019;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories. In connection with the June 2015 SUL collaboration, the Company sold all of its available RAPIVAB finished goods inventory to SUL in accordance with terms stipulated in the licensing agreement.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During 2014, in connection with the Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB commercial inventories.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 8; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted of the following at September&amp;nbsp;30, 2015 and December&amp;nbsp;31, 2014:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 65%; font-size: 10pt; text-align: left"&gt;Work in process&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;267&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Finished Goods&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;416&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net inventories&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;683&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;      &lt;table border="0" cellpadding="0" cellspacing="5" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;       &lt;tr&gt;     &lt;td style="vertical-align: middle; width: 2%"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; text-align: left; width: 3%"&gt;&amp;#x2022;&lt;/td&gt;     &lt;td style="vertical-align: middle; width: 95%"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td style="vertical-align: middle"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; text-align: left"&gt;&amp;#x2022;&lt;/td&gt;     &lt;td style="vertical-align: middle"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td style="vertical-align: middle"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; text-align: left"&gt;&amp;#x2022;&lt;/td&gt;     &lt;td style="vertical-align: middle"&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;nbsp;and&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td style="vertical-align: middle"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; text-align: left"&gt;&amp;#x2022;&lt;/td&gt;     &lt;td style="vertical-align: middle"&gt;professional fees.&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September 30, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the nine months ended September 30, 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during the nine months ended September 30, 2014.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 9; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;In June 2015, the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&amp;#x201c;Health Canada&amp;#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 20pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 20pt"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales, and the Company&amp;#x2019;s commercial sales will be minimal.&lt;/div&gt;        &lt;!-- Field: Page; Sequence: 10; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) Fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 11; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the three and nine months ended September&amp;nbsp;30, 2015 and 2014:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Three Months&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;Nine Months&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,699&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;6,236&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;126&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,776&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,951&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; text-indent: -20pt; padding-left: 20pt"&gt;Collaborative and other research and development revenues:&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4,582&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,937&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;12,788&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,323&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Green Cross Corporation&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Shionogi (Japan)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;888&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;888&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;&lt;div style=" margin: 0"&gt;Seqirus UK Limited&lt;/div&gt; &lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;152&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,835&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;5,162&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;3,233&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;35,643&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right"&gt;6,211&lt;/td&gt;      &lt;td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;10,987&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;3,238&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;43,655&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;8,162&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; has occurred.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Interest expense for the three months ended September&amp;nbsp;30, 2015 and 2014 was $1,241 and $1,217, respectively, and for the nine months ended September 30, 2015 and 2014 was $3,862 and $3,684, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended September&amp;nbsp;30, 2015 and 2014, and $329 for each of the nine months ended September&amp;nbsp;30, 2015 and 2014.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 12; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 and 2014 resulted in a loss of $793 and a gain of $732, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized a currency exchange gain of $1,654 during the first nine months of 2015 associated with the exercise of a U.S. Dollar/Japanese yen currency option.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of September 30, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended September&amp;nbsp;30, 2015 and 2014 does not include 3,821 and 4,240, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the nine months ended September&amp;nbsp;30, 2015 and 2014 does not include 3,673 and 3,986, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;      &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0"&gt;The Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 27pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 27pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 13; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In April 2015, the FASB issued ASU No.2015-03, &lt;div style="display: inline; font-style: italic;"&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt;. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect this ASU will have a material impact on its consolidated financial statements.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In May 2014, the FASB issued ASU 2014-09 &amp;#x2013; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/div&gt;, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2015-01-01_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c2177269" unitRef="xbrli-shares">41000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2177049" unitRef="xbrli-shares">1102000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="i_2015-09-30" decimals="0" id="c2176795" unitRef="iso4217-usd">64045000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31" decimals="0" id="c2176796" unitRef="iso4217-usd">75635000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2015-01-01_2015-09-30" id="s80475">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 5 &amp;#x2014; Stockholders&amp;#x2019; Equity&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On November&amp;nbsp;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration statement.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:UseOfEstimates contextRef="d_2015-01-01_2015-09-30" id="c2181969">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c2176861" unitRef="xbrli-shares">73262000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c2176862" unitRef="xbrli-shares">71801000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2015-01-01_2015-09-30" decimals="-3" id="c2176863" unitRef="xbrli-shares">72752000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2014-01-01_2014-09-30" decimals="-3" id="c2176864" unitRef="xbrli-shares">65057000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="iso4217-jpy">
    <xbrli:measure>iso4217:JPY</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-06-01</xbrli:startDate>
      <xbrli:endDate>2006-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2007-01-01_2007-01-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2007-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2007-01-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2011-02-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2009-09-01_2009-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-09-01</xbrli:startDate>
      <xbrli:endDate>2009-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-05-01</xbrli:startDate>
      <xbrli:endDate>2010-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-02-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>
      <xbrli:endDate>2011-02-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-11-06_2013-11-06">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-11-06</xbrli:startDate>
      <xbrli:endDate>2013-11-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-09-30_CounterpartyNameAxis-CSLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-09-30_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-09-30_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-07-01_2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-07-01_2014-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-07-01_2014-09-30_CounterpartyNameAxis-CSLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-07-01_2014-09-30_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-07-01_2014-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-07-01_2014-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:StockOptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:StockOptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest50PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_AwardTypeAxis-UnvestedPerformanceSharesMember_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:UnvestedPerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_CounterpartyNameAxis-CSLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-03-03_2015-03-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-03</xbrli:startDate>
      <xbrli:endDate>2015-03-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">bcrx:ContingentUponEuMarketingApprovalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-16</xbrli:startDate>
      <xbrli:endDate>2015-06-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-07-01_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-07-01_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-07-01_2015-09-30_CounterpartyNameAxis-CSLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-07-01_2015-09-30_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-07-01_2015-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-07-01_2015-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-11-06">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-11-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredCollaborativeRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_DeferredRevenueArrangementTypeAxis-DeferredProductSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredProductSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AwardTypeAxis-PerformanceSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_AwardTypeAxis-StockOptionsAndRestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:StockOptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_CurrencyAxis-JapanYenMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">bcrx:JapanYenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredCollaborativeRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_DeferredRevenueArrangementTypeAxis-DeferredProductSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredProductSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-10-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>bcrx-20150930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:12PM UTC 2015-11-06--><xsd:schema xmlns:bcrx="http://www.biocryst.com/20150930" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20150930">
  <xsd:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-roles/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-roles-2015-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.biocryst.com/20150930/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-income-loss-unaudited" roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies" roleURI="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Disclosure - Note 1 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation" roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 2 - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts" roleURI="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization" roleURI="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 4 - Royalty Monetization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity" roleURI="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 5 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.biocryst.com/20150930/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-tables" roleURI="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-tables" roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 2 - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-details-textual" roleURI="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-fair-value-of-the-companys-investments-by-type-details" roleURI="http://www.biocryst.com/20150930/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Statement - Note 1 - Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-scheduled-maturity-for-the-companys-investments-details" roleURI="http://www.biocryst.com/20150930/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Statement - Note 1 - Scheduled Maturity for the Company's Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-summary-of-receivables-details" roleURI="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Statement - Note 1 - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-inventory-details" roleURI="http://www.biocryst.com/20150930/role/statement-note-1-inventory-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Statement - Note 1 - Inventory (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-summary-of-revenues-details" roleURI="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-revenues-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Statement - Note 1 - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-details-textual" roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 2 - Stock-Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stock-incentive-plan-activities-details" roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stock-incentive-plan-activities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Statement - Note 2 - Stock Incentive Plan Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" roleURI="http://www.biocryst.com/20150930/role/statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Statement - Note 2 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" roleURI="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization-details-textual" roleURI="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity-details-textual" roleURI="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bcrx_AECOMAndIRLMember" name="AECOMAndIRLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ASPRBARDAContractMember" name="ASPRBARDAContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AdditionalDevelopmentOptionsMember" name="AdditionalDevelopmentOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" name="AdvanceNoticePeriodForTerminationOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AgreementMember" name="AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMaximum" name="AnnualLicenseFeeMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMinimum" name="AnnualLicenseFeeMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_August2013Member" name="August2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesAccruedInterest" name="AvailableForSaleSecuritiesAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" name="AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" name="AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AveragematurityForPortfolioInvestments" name="AveragematurityForPortfolioInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" name="AveragematurityPeriodOfHighQualityMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BaseContractMember" name="BaseContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLLimitedMember" name="CSLLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollaborationReceivablesMember" name="CollaborationReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementAdditionalContractValue" name="CollaborativeAgreementAdditionalContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementAdjustedContractValue" name="CollaborativeAgreementAdjustedContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementContractValue" name="CollaborativeAgreementContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementPeriodOfcontract" name="CollaborativeAgreementPeriodOfcontract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopment" name="CollaborativeAndOtherResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" name="CollaborativeAndOtherResearchAndDevelopmentRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollateralForCreditMember" name="CollateralForCreditMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ContingentUponEuMarketingApprovalMember" name="ContingentUponEuMarketingApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ContractTerm" name="ContractTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyDomain" name="CurrencyDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyHedgeAgreementMember" name="CurrencyHedgeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CurrencyHedgeAgreementPolicyTextBlock" name="CurrencyHedgeAgreementPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2014Member" name="December2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseAssets" name="DeferredCollaborationExpenseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" name="DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DeferredCollaborativeRevenueMember" name="DeferredCollaborativeRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DeferredProductSalesMember" name="DeferredProductSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanMember" name="IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_Interestreserve" name="Interestreserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JPRRoyaltySubLLCMember" name="JPRRoyaltySubLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JapanYenMember" name="JapanYenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LongtermInvestmentMaturityMinimum" name="LongtermInvestmentMaturityMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" name="MaturityPeriodOfHighQualityMarketablesecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityperiodOfShortTermInvestment" name="MaturityperiodOfShortTermInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumAmountOfCollateralRequiredToPost" name="MaximumAmountOfCollateralRequiredToPost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MilestonePaymentMaximum" name="MilestonePaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMinimum" name="MilestonePaymentMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfMilestonesaAchieved" name="NumberOfMilestonesaAchieved" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfStockbasedCompensationPlans" name="NumberOfStockbasedCompensationPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PaymentsForModificationOfLicenseAgreement" name="PaymentsForModificationOfLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" name="PercentageOfCarryingAmountInExcessOfFairValue1" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesBeginning" name="PercentageOfCommonStockSharesBeginning" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesEnding" name="PercentageOfCommonStockSharesEnding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PeriodOfAgreement" name="PeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PhaRMANotesMember" name="PhaRMANotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RAPIVABMember" name="RAPIVABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" name="RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RemainingAggregateOfferingPrice" name="RemainingAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_RenewablePeriodOfAgreement" name="RenewablePeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RequiredForeignCurrencyHedgePerDollar" name="RequiredForeignCurrencyHedgePerDollar" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" name="RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" name="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" name="RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyMonetizationMember" name="RoyaltyMonetizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyMonetizationTextBlock" name="RoyaltyMonetizationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivableMember" name="RoyaltyReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyTerm" name="RoyaltyTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" name="ScheduleOfRevenuesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SecuritiesOffered" name="SecuritiesOffered" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" name="ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" name="SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ShionogiAndCoLtdMember" name="ShionogiAndCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" name="StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_StockOptionsAndRestrictedStockMember" name="StockOptionsAndRestrictedStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UABMember" name="UABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_USDepartmentOfHealthAndHumanServicesMember" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UnvestedPerformanceSharesMember" name="UnvestedPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest50PercentEachYearUntilFullyVestedMember" name="Vest50PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" name="statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-inventory-details" name="statement-statement-note-1-inventory-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" name="statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-tables" name="statement-statement-note-1-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-summary-of-receivables-details" name="statement-statement-note-1-summary-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-summary-of-revenues-details" name="statement-statement-note-1-summary-of-revenues-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" name="statement-statement-note-2-stock-incentive-plan-activities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stockbased-compensation-tables" name="statement-statement-note-2-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" name="statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>bcrx-20150930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:13PM UTC 2015-11-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20150930.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20150930.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20150930.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-inventory-details" xlink:href="bcrx-20150930.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:href="bcrx-20150930.xsd#statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>bcrx-20150930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:13PM UTC 2015-11-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-document-and-entity-information" xlink:href="bcrx-20150930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20150930.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies" xlink:href="bcrx-20150930.xsd#statement-note-1-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20150930.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UnvestedPerformanceSharesMember" xlink:label="bcrx_UnvestedPerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_UnvestedPerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20150930.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20150930.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity" xlink:href="bcrx-20150930.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20150930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-tables" xlink:href="bcrx-20150930.xsd#statement-note-1-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20150930.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-1-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_SecuritiesOffered" xlink:label="bcrx_SecuritiesOffered" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossOnSaleOfInvestments" xlink:label="us-gaap_LossOnSaleOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnSaleOfInvestments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SecuritiesOffered" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NumberOfMilestonesaAchieved" xlink:label="bcrx_NumberOfMilestonesaAchieved" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UnvestedPerformanceSharesMember" xlink:label="bcrx_UnvestedPerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_UnvestedPerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMilestonesaAchieved" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementAdditionalContractValue" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementAdjustedContractValue" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementPeriodOfcontract" xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ContractTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RemainingAggregateOfferingPrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20150930.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborativeRevenueMember" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredProductSalesMember" xlink:label="bcrx_DeferredProductSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_DeferredCollaborativeRevenueMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_DeferredProductSalesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20150930.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20150930.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-inventory-details" xlink:href="bcrx-20150930.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stock-incentive-plan-activities-details" xlink:href="bcrx-20150930.xsd#statement-note-2-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:href="bcrx-20150930.xsd#statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:href="bcrx-20150930.xsd#statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20150930.xsd#statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-receivables-details" xlink:href="bcrx-20150930.xsd#statement-note-1-summary-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-revenues-details" xlink:href="bcrx-20150930.xsd#statement-note-1-summary-of-revenues-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>bcrx-20150930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:12PM UTC 2015-11-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a License Agreement (the "Agreement") granting rights to develop, manufacture and commercialize RAPIVAB&#174;.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AgreementMember" xlink:to="bcrx_AgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="bcrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementsignificantaccountingpoliciespolicies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2stockbasedcompensationtables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueProductLineMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1fairvalueofthecompanysinvestmentsbytypedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:to="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1scheduledmaturityforthecompanysinvestmentsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:to="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityperiodOfShortTermInvestment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of Short Term Investment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityperiodOfShortTermInvestment" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1summaryofreceivablesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:to="bcrx_statement-statement-note-1-summary-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-inventory-details" xlink:label="bcrx_statement-statement-note-1-inventory-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-inventory-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1inventorydetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-inventory-details" xlink:to="bcrx_statement-statement-note-1-inventory-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LongtermInvestmentMaturityMinimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investment Maturity, Minimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongtermInvestmentMaturityMinimum" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1summaryofrevenuesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:to="bcrx_statement-statement-note-1-summary-of-revenues-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2stockincentiveplanactivitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:to="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:label="bcrx_statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2weightedaverageassumptionsforstockoptionawardsgrantedtoemployeesanddirectorsundertheincentiveplandetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:to="bcrx_statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</link:label>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from upfront payment allocated to the regulatory support for the Canadian and EU marketing approvals, portion to be recognized ratably over the expected period of involvement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NotesToFinancialStatements" xlink:label="bcrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatements" xlink:to="bcrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="bcrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</link:label>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from the sale of inventory to be recognized when the inventory transfer is complete.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [Member]</link:label>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited (&#8220;CSL&#8221;) and its affiliates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLMember" xlink:to="bcrx_CSLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_SecuritiesOffered" xlink:label="bcrx_SecuritiesOffered" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SecuritiesOffered-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SecuritiesOffered</link:label>
    <link:label xlink:label="bcrx_SecuritiesOffered-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Offered</link:label>
    <link:label xlink:label="bcrx_SecuritiesOffered-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents securities offered for sale.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuritiesOffered" xlink:to="bcrx_SecuritiesOffered-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInterestPayableNet</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty and Milestone Revenue Recognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognition royalty and milestone revenue recognized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UAB [Member]</link:label>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UAB</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AECOM and IRL</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementAdditionalContractValue" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementAdditionalContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Additional Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative agreement additional contract value during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementAdjustedContractValue" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementAdjustedContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Adjusted Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement adjusted contract value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Financing Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityForPortfolioInvestments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity for Portfolio Investments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity for portfolio investments during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityForPortfolioInvestments" xlink:to="bcrx_AveragematurityForPortfolioInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RAPIVABMember</link:label>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repesents RAPIVAB product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivableTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseAssets</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseAssets" xlink:to="bcrx_DeferredCollaborationExpenseAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Decrease) Increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance September 30, 2015 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards Available (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance September 30, 2015 (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueAdditions</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance September 30, 2015 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_CurrencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PaymentsForModificationOfLicenseAgreement</link:label>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Modification of License Agreement</link:label>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents payments for modifications of license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ContractTerm</link:label>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Term</link:label>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between the contract date and its expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContractTerm" xlink:to="bcrx_ContractTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, for Modification of License Agreement</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock issued during period value for modification of license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Life in Years</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyTerm</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Term</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between the date of the Agreement and its expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyTerm" xlink:to="bcrx_RoyaltyTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance Notice Period for Termination of Agreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents advance notice period for termination of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Revenues</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on available for sale investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL Limited [Member</link:label>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited which is a company organized under the laws of Australia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLLimitedMember" xlink:to="bcrx_CSLLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted stock unit awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted stock unit awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award first vesting period after grant date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReceivablesNetCurrent</link:label>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of Agreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RenewablePeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewable Period of Agreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents renewable period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of furniture and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMaximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalesRevenueNet</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMinimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Receivable From Awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMaximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestrictedCashAndCashEquivalents</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMinimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shionogi and Co. Ltd [Member]</link:label>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Department of Health and Human Services</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative and other research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-recourse notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of schedule of revenues from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyTransactionGainLossRealized</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Realized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLossOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeGainOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities accrued interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueServicesNetAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development revenues:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_SalesRevenueServicesNetAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of available for sale securities debt maturities fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities debt maturities after one through two years fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromLicenseFeesReceived</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementPeriodOfcontract" xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementPeriodOfcontract</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Period of Contract</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement period of contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:to="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeForwardExchangeRate1</link:label>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Forward Exchange Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborationReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Receivables [Member]</link:label>
    <link:label xlink:label="bcrx_CollaborationReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents receivables from collaborations for reimbursable research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationReceivablesMember" xlink:to="bcrx_CollaborationReceivablesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PrivatePlacementOfSeniorSecuredNotes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement of Senior Secured Notes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborativeRevenueMember" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborativeRevenueMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Collaborative Revenue [Member]</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborativeRevenueMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue deferred under collaborative arrangements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborativeRevenueMember" xlink:to="bcrx_DeferredCollaborativeRevenueMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredProductSalesMember" xlink:label="bcrx_DeferredProductSalesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredProductSalesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Product Sales [Member]</link:label>
    <link:label xlink:label="bcrx_DeferredProductSalesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred revenue related to product sales.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredProductSalesMember" xlink:to="bcrx_DeferredProductSalesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue recognition royalty and milestone revenue recognized, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInRestrictedCash</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement contract value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractValue" xlink:to="bcrx_CollaborativeAgreementContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAmountOfCollateralRequiredToPost</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Amount of Collateral Required to Post</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum amount of collateral required to post.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CollateralAlreadyPostedAggregateFairValue</link:label>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestAndOtherIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,337 in 2015 and 71,955 in 2014</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentsAndCash</link:label>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Loss) gain on foreign currency derivative</link:label>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_HedgingDesignationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RemainingAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RemainingAggregateOfferingPrice" xlink:to="bcrx_RemainingAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NondesignatedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NondesignatedMember" xlink:to="us-gaap_NondesignatedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished Goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossOnSaleOfInvestments" xlink:label="us-gaap_LossOnSaleOfInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossOnSaleOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossOnSaleOfInvestments</link:label>
    <link:label xlink:label="us-gaap_LossOnSaleOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on Sale of Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossOnSaleOfInvestments" xlink:to="us-gaap_LossOnSaleOfInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDerivativeAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RequiredForeignCurrencyHedgePerDollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required Foreign Currency Hedge Per Dollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignExchangeContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeContractMember" xlink:to="us-gaap_ForeignExchangeContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_Interestreserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Reserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Interestreserve" xlink:to="bcrx_Interestreserve-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent upon EU Marketing Approval [Member]</link:label>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about the contingent proceed which is upon EU marketing approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContingentUponEuMarketingApprovalMember" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_TransactionCosts</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JapanYenMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen [Member]</link:label>
    <link:label xlink:label="bcrx_JapanYenMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Japanese Yen.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JapanYenMember" xlink:to="bcrx_JapanYenMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentContractReceivable</link:label>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UnvestedPerformanceSharesMember" xlink:label="bcrx_UnvestedPerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UnvestedPerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested Performance Shares [Member]</link:label>
    <link:label xlink:label="bcrx_UnvestedPerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents unvested performance shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UnvestedPerformanceSharesMember" xlink:to="bcrx_UnvestedPerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options and Restricted Stock [Member]</link:label>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock options and restricted stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockOptionsAndRestrictedStockMember" xlink:to="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2014 [Member]</link:label>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2014.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2014Member" xlink:to="bcrx_December2014Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of August 2013.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_August2013Member" xlink:to="bcrx_August2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 50% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 50% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents currency hedge agreement policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents debt maturities after two years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-employee directors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NonEmployeeDirectorsMember" xlink:to="bcrx_NonEmployeeDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NumberOfMilestonesaAchieved" xlink:label="bcrx_NumberOfMilestonesaAchieved" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfMilestonesaAchieved-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfMilestonesaAchieved</link:label>
    <link:label xlink:label="bcrx_NumberOfMilestonesaAchieved-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Milestones Achieved</link:label>
    <link:label xlink:label="bcrx_NumberOfMilestonesaAchieved-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of milestones achieved.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfMilestonesaAchieved" xlink:to="bcrx_NumberOfMilestonesaAchieved-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of performance awards that remain unvested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueNoncurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrencyAxis" xlink:to="us-gaap_CurrencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Salary to Purchase Common Stock, Maximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfStockbasedCompensationPlans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock-based Compensation Plans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of stock based compensation plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfStockbasedCompensationPlans" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Carrying Amount in Excess of Fair Value</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of carrying amount in excess of fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesEnding</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Ending</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares ending.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesEnding" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesBeginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Beginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRentCreditNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>bcrx-20150930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 08:12PM UTC 2015-11-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-document-and-entity-information" xlink:href="bcrx-20150930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20150930.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies" xlink:href="bcrx-20150930.xsd#statement-note-1-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20150930.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UnvestedPerformanceSharesMember" xlink:label="bcrx_UnvestedPerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_UnvestedPerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20150930.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20150930.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity" xlink:href="bcrx-20150930.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20150930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-tables" xlink:href="bcrx-20150930.xsd#statement-note-1-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20150930.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-1-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_SecuritiesOffered" xlink:label="bcrx_SecuritiesOffered-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossOnSaleOfInvestments" xlink:label="us-gaap_LossOnSaleOfInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnSaleOfInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SecuritiesOffered-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NumberOfMilestonesaAchieved" xlink:label="bcrx_NumberOfMilestonesaAchieved-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UnvestedPerformanceSharesMember" xlink:label="bcrx_UnvestedPerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_UnvestedPerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMilestonesaAchieved-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementAdditionalContractValue" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementAdjustedContractValue" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAgreementPeriodOfcontract" xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ContractTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementPeriodOfcontract-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-n2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity-details-textual" xlink:href="bcrx-20150930.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RemainingAggregateOfferingPrice-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20150930.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets-1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborativeRevenueMember" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredProductSalesMember" xlink:label="bcrx_DeferredProductSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_DeferredCollaborativeRevenueMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_DeferredProductSalesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets-1" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20150930.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20150930.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-inventory-details" xlink:href="bcrx-20150930.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-inventory-details" xlink:label="bcrx_statement-statement-note-1-inventory-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-inventory-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-stock-incentive-plan-activities-details" xlink:href="bcrx-20150930.xsd#statement-note-2-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n7" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n7" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n7" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n7" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n7" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:href="bcrx-20150930.xsd#statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:label="bcrx_statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:href="bcrx-20150930.xsd#statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n7" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20150930.xsd#statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-receivables-details" xlink:href="bcrx-20150930.xsd#statement-note-1-summary-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-revenues-details" xlink:href="bcrx-20150930.xsd#statement-note-1-summary-of-revenues-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20150930/role/statement-note-1-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20150930.xsd#bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exh2_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh2_1.jpg
M_]C_X  02D9)1@ ! @$ 8P!C  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**6DH ****
M "EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!**6DH 1._UIU-3O]:=0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\^*W"*J $OB23+EBN ?E+8V@ Z"DK 'BIOMQMOLKLK231QLA8EY(D=RNYD6
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M=577;FWO+M)(M\$=_;0!]RJR^?%;A%5 "7Q))ERQ7 /REL;0 =!17*0>.C-
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M3>W[>2;4BUPT\KJ?.-OT((8'S>2<>U '06^GV]JY>*,(3#%%\O"A(BQC4*.
M%WMC [^PJ%["SF-Q"0"TK1RRJ'._.T)'(,'*$>4-K+C!7(Y&:PG^V^5)C[7M
M_=>3G?O^R^=']HW;?G\_9NV[OWFS;M_>^;5)K*=GU.ZM#?@1Z="UJ)/-#/*A
MN6 ^<>=(%8_ZN4D'=RI3R\ '6ZEI<&K1"*X#E1(CC9+)$=R'*G=&RG@\CGJ
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ML,E<A<( =:NC:=$PB" ,RQ-@R-O86\WG*YRV6*RR;F8Y+%OF)S4MO86=O/\
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M^=H+$\DH#@E:NZU#=37;*5NF(U'3VC"!C;_9EDMV<M_RSR)0Y)'[T8!/[K-
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M10 M%)10 M%)10 M,>%)"C,H)1MRD@$J=I7(]#AB,CL2*=10 M%%)0 4444
M%+24M !1110 4444 %%%)0 U.A^I_G3A34Z?B?YTX4 +1110 4444 %%%% "
M4M%% !3$A2,NRJ 7;<Q  +':%R?4X4#)[ "GT4 1);I$B1Q@(B!0JH J@*,!
M0 . /0?RJ6BB@ HHHH **** "BBB@ HHHH *2EI* "EI*6@ HHI* %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** $I*6DH =1110 4444 %%%% !1110 4444 %%%% !1244 +1244 +
M124M !1110 4444 %%)10 M%)10 M%%)0 M)2T4 )12T4 )112T %%%)0 M%
M)2T %%%% !124M !1110 4444 %)2TE ")2BFIT_$THH =1110 4444 %%%%
M !1110 4444 %%%% !1110 44E+0 4444 %%%% !2444 %%%% !111B@ HS1
MBC% !1110 4M)1F@!:*2EH 2BBC- !11FC- !11NHH **-V*,YH **** %HI
M*6@ HHHH **** "BBB@ I*6DH *2EI* '4444 %%%% !1110 4444 %%%)0
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M%N9I)RHCC$D:@DH9#F3)7 52<C.>,=<U'9>'3;F.6:X::47/GNY54#-]G:W
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MOF !]HW!22N<<X) )&>G%/Q0**8#4''XTH&*$Z4H-( Q28IU)3 !2-2TC<T
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MEAAG#8!S\O.1G! 3=N@)7.IS1FN=M1=W#RJ=1E A?:Y\B% ?E+$[F1AW'3'
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M)/M3N X75@D<@:XN&:(2[E-Q(LA\IG0_==5R=A/;(Y-:9T2 ]7G_ / JX_\
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M9HO+&TEAN9R19+:[<%<8R"<]<=,$4\^&+D,\KNA*O'MPI7]W%(&1%* LF$)
MV\Y['&3U]!4&AZ@<Q'X9E\R.X)C60/;Y W.NQ&RRY.#G.&!.>1[FI3X>-P C
M3*T8DF)4H7R7NEF.23@X"[>G<_2NBVBB@#E+;PQ<V$AN+:Z22=1L+21DA@26
M(?#[BV"N&ZX4#H:?#X2DC"Q_: 8P\4F#&2S.D7E@$ES\F1NV_@"*ZC%% &!#
MX8$5LT+2%B\D3,<$?ZMD.T?,<*=O0'OUJ)?"\DXB2YGWQ1HJ; FPLJJZ@$JP
MQD. P'!VCITKI** .?3PN5B=#/DM8&USY:X"C(0COQDY&[D^F *A'A RL%DN
M&$2N7BB0 "-F?>Q#<!ARRKE> :Z>B@+F;INBPZ3')'#PLDK2$=@6 ! SGCCO
MG\JHQ^$H;<$P2O%)Y=LJR#!8- C1J^&!4Y1MI&,8]#S6_BEIW S[+3#9*56>
M1LA\EO+SN=V<OP@&<L?;VJ_1BEI/4!*,TM% "4M)2T )6?KZ^9IUXGK:S#/U
M1JT:IZPI:RN0,<P2]2%'W3W. /J:$!7.C65W(+HH2SJ"2'D56S&8]Q3<%SL8
MC)&<5-=:1;W<GFOO#;0N5EDC! )(!", <$GK5(:V88K1(E$KS6YD0,XB9P@0
ML%!!^8AL@<#CD@<U;EUFVBD2-F.Y]G'ER';O.$#D+\FX\#=C-%P)8].BC6%%
M&%A^X.N,*4')R> <=:A?0K61YG*MF92L@WN%8%2I!7..A["I4U."2<P*QW@X
M^XX0G&XJ'(VE@.< D\'T-/OKL6-O-<$9$<3N1TSM4G'Z4MP(8M&MHMIVLQ61
M9 S.[-O6/RPY))R=O!I(]"L8RI6!/EB>,<9^1SN=3GJ&/7/OZFH)-<!LI[N$
MQ2^2K-^[E$B':NXC<HX..V/2KMSJ$5J5#EB6SA51I&..IVH"<#(R<8Y [BG<
M+$:Z+:+%Y/E*8]JJ4;+*0NT+D,3G&T8ST[4J:1:(K*((P&5U;Y!RKG+*>.03
MU%17.N6MJ SLQ7RQ(62.250AR0Y,:L #@X)]#2PZNCW,MLWWTE"!1DD@Q)(6
M/H!NP3TZ#J0"7 E_LFU\HPF%"A"!E*A@VP +G/7&!C/I4MK:Q648BA0(H)PH
MX R23@?4U-FL;^VWMK*YN;@)F&61%P2D;$$*HW-T^8[2Q& 03TH V:6L>VU.
M:9(P&0R2R.HS%+'Y>(R^&1R&8C Z[,@@@#OI6LDLJ9EC"-N<8#;Q@,0IR /O
M  X[9Q0!-24M)0 B=!2TB=!2T 9VJ,$GLF[_ &A@.,GF"7I4T6HV\T;2QR*Z
MJ,DJP?CG!^4GKVK/\40O=1V\*9S)-)'G (&^VF7<0>H&<D5!>65S=KG[.8]D
M*)MC:-9&^=6RC9(7R]I*YZY(^7K0,TY-7M8X?/,BE/5<N,@$G&T$G&#GC@ D
M]#4MQJ,%I+%#(6W2DA J._0J"254A0"PY.!6-+9W5YIMRFR7?+@KN:)93F-.
M&*A1P?E8$DX'7H*N:M9/?HCK'('V,JE)S"\9?;RVT[6"X!/WN1PIH$6)-7M8
MYQ;N7#%P@S%)L+%=P7?MVY(]ZE@U""YE:*/>2N[+>7((\JVT@2%0I(/& 3WJ
M.>UDGGM2V"L1>0L./GV&, #)X(=CWQ@53M].E2_:5;=(5#,3(LI<RAMYV[-H
MV_,VXGL>!D$FD!?34[>2W>YW$1QARQ9'4C9G=E6 ;C![4^SNX[Z,.@9>@96!
M5U. =K*>0<$'Z8(X(-9UG9WNR]\R&!&>421 -O0L(UP6Q&A.'7.>OY FWI=O
M-$UQ+,H4S3B0*&W%0(HXP"< ;ODR<9 [$]:8%ZD"XI<T$T &**!2T )11FEH
M 0T8HHS0 4E*:*  4M)10 M%)29H 6L[4_\ 761QG%T>X&,P2C//7K6C6;K"
M$B!\ [+J$GYBA )V9!!&?O=#U&1UQ0!HJ.*=3%;BEW9H =129%&:  T#WI-U
M+D&@ Q1BDW8I<T &*,49HS0 8HI"^.U&^@!<4M,WT;Z 'TE)OHW"@!:6F[A1
MN'K0 ZBDS2T %%%% !1110 4444 %%%% !1110 4E+10 AHI#UI10 M%)2T
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M4UPS+<S*<1,@;:KQ(VX<%1\JGU]+.H0VUK?^1]D1A(+7S&9YV4[IC'&"JHR
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MQEB3G(.>:W\8HH PR+"!85\NX(BE:1"J73?.V69BP!W9WGJ2#DCU%7!K4/\
M<G_\!;C_ .-UH8HQ0!0DUB*,X*3'@'BWG;J,]D/_ -;I2?VU$K%3%<?+U_T>
M8C'J"%(/T'/J.#C0Q10!0EUF*)MOESMC'W;>9AS[A,4T:[ 1S%<CC_GTN/\
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MIBW&?Q6$'\C6C13^2^Y 9HTJ;))OKCGMB#'Z0\4LFE2RQ^6;VXYW98>2K$$
M8R(AC'8C!YZ],:5)BC^M@,Q=%=$V+>W/3&2T;-CTRT9Y]^OJ:=_9!XS=7!([
M[U&>V"%4#],UHTM'R_ +?U<K6EI]E!'F229(YD;<1@8P, "K I:*0!1113 *
M*** "BBB@ HHHH **** "BBB@!I^]^%+2'[WX4M !2TE+0 4444 %%%% !24
MM% %'6!*]K+'#&SLZE/E* C<,%OG90<=<9YZ>]9%Q;W=I'*##*^RX$B/;>4K
M*#"0Q2.5W!YR&4]=Q89-=#.[QQNR+O8*2JY"[B!P,GIGUK/CU&X,<@:)3*DR
MQ[5=BAW!&W;MF0 &YX[&@"N8;Y4M5"N"7E\PKY7RA\[79=P4OR"VT,N=V >*
M@ETJXCF58%E\J"*U54)A\N7R6+ 9^^&&1C[H)&#QS5PZO,R)MC4-BX9P6)4+
M ^Q]IVC))(QD#CKZ5IQ2>:JL.A (SUY&: *L%C/%,\CW4CJV=L96,(N23@%4
M#'';)^N:YNSTB]L[62-8KAC+:K"XDFADVDC ,8\S 1 6."03\H&.2.EAO)GN
MI8'C0*D:.&$A8D.S*ORE!C[ASR>W7M"FOVSPM,VY%6-'^9<$J[,J$#KR5./6
MC8&4%TR\>9E/[M4NEE61"@SNMVCD"QMO"_.<G/7<3UY-F"PN+58 $5S%:O",
MMA3\R!&/!(#!<GKCISUJ>WU,LS"52@,B(@8$/N*;F0\D' &=RG;@^Q-(=?MC
MM\L22$J[%5C;<JHY1V*L ?E88*@%CV!I-W H)I%Y"$96.ZW:U2(?N]LD<:A7
M<EE8J2))!P>.V>_0YJBVL0AEQED8Q#S%PR R$! <'/.1VQR#TIBZY;GS&;<J
MHTP+LI"DP_? /?&#TZX..AP :5%9-OK339D,+I&8490VQ6)=L( 0Y4[\X )!
M4CGAA4@UM&"@0R[VF,13Y-RL$,F"=^W!09!!/Y\47'8T:6LW^VD94:.&63=
MDI"JNY4?.W(9ADG!X7)X^F6R>(K6&[%HQ(;>BY+1C#. 5&PN'.=PY"D>IX.
M+&I24R8D(VTA3M."1E0<<$C(R/Q'UK#TOQ,MU:-,Y25H_*,GD,I4!U!R=SX7
M:<ALM_"6.!P&(Z"DK(NO$L%D6\Y&0"4HI:2!58CJ0S2@8''!P>>G7&E:W*7D
M23)]UT5ATZ$9[9%%F@):6D%!H 6BL;1KNZFE:.YW*ZQ(71U488]2A3ADZCJ2
M".<5-K-[)8FW93PTS(5R@W?NG95!;H690HY[_3 .QI=:6LW0;\ZE:BX)R&DE
MVG&/E5V5?QP.:T:!!12T4 %%%% !1110 4444 %%%% !1110 4AZ?A2TAZ4
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MEI* "BBEH 2BEHH 2BEHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$95;EMR@@8##RNIY(Z<?G4(UN]VDR6T,95B'#7:_(,9!;"' .1[\CM3_ *W
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M*M<F5Y+DNTB1 EXHR,HZ.<@ 94[!A<X&6/)-=!11<# M/"HM+A)!*64-">0
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M S6@!@4M% !1110 4E+10 44E% "T444 %%%% !1110 4444 %%%% !1110
MF**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;_%3J:>M.H ****
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M-_"KM%:I+AEVCS]C$'J3N3 (XXR>,\YX*; TJ*QVO=5'2QB/S*/^/KUQEO\
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M10 4444 %%%% !1110 4444 %%%% !1110 WO3J;WIU !1110 4444 %%%%
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MP:U8,VT74.<9QYB9QZXS2N.S+M+51=1MG3S%FC*XSN# KC&<YSCI4'_"1Z8
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M-@GHK <XX.!;&F3"Q2URIS(-_)"K&9-[1K\O("_(OW>.>.E:^*,4 (*6EHH
M*2EHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FOTIU-?I0
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MFGTM #=H]*-M.HH ;M% 4#I2TM #=HH5 G  ')/'N<FG44 )BEHHH *2EHH
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MHW4 +249Q10 M%)10 M%%% !1110 4444 %%%% !1110 4444 -[TZF]Z=0
M4444 %%%% !1110 4444 %%%% !1124 +1110 44E&: %HI*6@ HHHH **2E
MH **** "BBB@ HI** %HI** %HHHH **** "BDS10 M%)FB@!:*3-% "T4E%
M "T4E&: %IK]/QIU-;I0 II:0CBCI0 C5E^'E*P39!'^FWIY.0<W$AR!G@=L
M<<\]ZU#6;H:LJW (Q_IEP<;MPP7)!QD[<]<>ISP#B@"_/G8<9/!X!QGCIGM7
M,^'=0OHM-M52T\S%JFTB6- 3C@8//3&3Z]JZF3[I^E<9IVG&]LK:6$;R;":-
MESY9<!U*QC)^7NN[MG/7%(9K3ZYJ414+IP;=P,W42Y;!.!USP,_GQQFGQ:MJ
M<F=VFA<*3S<H<GTX4]:R9=%N?-1TM%!#V[)CR42-4NI9&4XR1E&7)0')'4]#
MKZO;2--#*MI]I"07*[<QC#/Y>.9", @,"1G@].:8;$DFI:CYI2.R0IM8AVN
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M7)<E?FEPJ]L_+\Q^FWUYS@6"M^N[8(>3D EAMYYZ+\V1D]L'CGK6CBDVC.[
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M[A@8&3GTXJG_ ,(]IG_/G;_]^8_\*7^P=-_Y\X/^_*?X4 7&G1%+E@% )))
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M'];D@O(3R'7A]GWA][^[]?:G&YB )++@'!Y'!]#57^Q=/#;OLL&=NW/E)G&
M,9QTP.E/32K*,AEMX@0, B-00/0<=* _K<L+,CDJ&!(QD \C/3-/J!+2",J5
MC0% 0I"@%0>H'' J>@!:*2EH **** "BBB@ HHHH **** "BBB@!HZTZFCK3
MJ "BBB@ HHHH **** "DI:* &,2.E49-0N$8K]CF;!/*M#@^_,@/YBK[<5B;
MUCTX7A=]ZP-*6W,W.%=A@G&TE1\HP,=,9H&BR;^\="R6C@@9"LT0W<'"@AS@
MYQDD>N,T@U.]#X-A)LVYR)(=V[/3;O QCON_"J.HW-W:W,@@E 4&S;85&TF>
M9H2,]0/EW<<YR>G%/TWQ%+=W9M98E4A>JONR0H+$ X;;G(R1C(ZYXHL!=_M*
MZ).+&4?+P2\/7G@XD.!TY&>O2D;4+\%0+$G*Y)\V, 'TZ\_6N='C&]F='C6(
M(%+.K$8.[!2(%78^;\K!0<9SDH,5I3>*9(Y9(DB60B7RP5+D1LS/&@D^7C<X
M7TX;@$+E@1>75+[ +6+ ;23B6-B,=L#K^%/^W7Q2)A:#<TH5U,RY1,D;\@$'
M@ X'KUJC:^)I+J.9U@SLFBC4,1'S),8MC8\PJR\$Y&>>@X)9-XI>']WY2>:!
M)\N\_,4$X8@;<XS".?1O7J 7OMM^)"3;-CS60*)$*&,$?OL[<ACG&S/3Z4^2
M_OE#[;,MC;MQ,@W9//7&"*RKOQ)/ WS&*,+,ZY).UP%N54'*_*2\(Z$GM]7V
M7B:?4+D0);&+Y\%G8,0,.P#(I!5B$Z'W]LK7S O'4-0RW^@\! 1B9,L<X*C.
M,$#GGC^KO[0O0/\ CSQE5QF4'YB5&#M5L 9.3@]"<=,XJ>*;BXBB?=!'YD\(
M W;F*N\64 R1N4,P?H1@' R*L7?BF2UO)K<HJQQ%0TK;MJ;HPZEB <!F^7MU
M!&<$4_D,U$OKQR_^B<+'P?, WR<Y10R@[01]]L9Z@$<TZ.ZOG0,UNBG825$N
MXANR_= (]3GZ9K%7Q-+ERQ6/(@.)3A%W([E<J@;)V[<G//OA2W_A*KBW)C>-
M2[%VC#,4<HH.%VE5)=F&P #.3G!VD$LQ?,V(;W4752UFJ_>R//!(_N_PX.>_
M/';/=HU+4@RAK#@YW%9HR1CI@'&0?PQ6=!K][L<A!(4WD_(Q)*!!Y "=')8\
MG.,'*_W99=9NY;61U4!Q;6LXV#! E9MRX8.#@+UQ^76BS[!]Q?GO-1B7*6B.
MP&2HGP.3C"ED&<#DY"^V:&O-24G_ $.,@;3\MQR<G! #1KR.O.![UGP^)9I-
M/FNC$JO'.D1&=P!8Q@L<E?N[^5)4\8.TYPEMXFG:.1KB#RC&DI8,IR3$D4AX
MR2NY7.!\V,=3T)\@-'[9J. 3:1CY <?:.<_W>(\9_''OZP&^U;[RV49!4$ W
M)'J>AA!R??\ QJD?%<Q:YQ;[1#!)-A\HP$9PT949^9@ P.1@.IP>\>H>(KVS
MDF"1K*1Y(5 I^4EK@$'<5+%O+51TY8%0QP&/D!KQWNHG[]H@X4_+/NX[@91?
MF'8< _WA3$OM4DB$@LXLE P1KAU?)&=I!@P#VZU%:ZA<SWS(Q7RUCFRBQMN5
MED54+.>I=0S* !P?XA@U1T_Q!J<C0?:+;Y7G:-]D39P8XBK@B1UVAG8,=QX'
M08;!\@-0WFK@9^Q0'Y2<"[;.<?=Y@ S^GO4BW6IE03:0@^GVEN/Q$%9&K^(M
M1M)Y(;:U:0;T"L8)=@! W$N#AN<CC&,@Y;D5-%JE]=63RE'63[;"%0H8W$;2
M1$J=PP?E8@L!C'N#1\@NC0^TZIVMH/\ P)?_ .,4P7VJX!-E%RA;'VDD@C&$
M/[K&3GL<<=>F<^XU>_EMPL 19FM9I2/+9V5D2+]V%)'S[I.O/3[O8:%K>S&*
M;S2"P^T%0!M;"2R*.I ^Z%]/<G-'R A>.]F61C8P RI^\7SSO?Y" K$0D'T^
M]4HBO8T:-;6 JV209VP2P&[/[CG)R23DGO[5EU>ZN;:9V3RV-E)*BA3YD;#<
MNT[C\QR/1?3%5U\17ENX1XFDS-M.(F#<[28P 3\RHQD!(^91CCK1\@L7S9W$
MV\26=N-P<Y$A<EF3:2=T&.1P2<\<8/2HUM;R-VFBLK:-V?+,)F5FP2"6VP#.
M03C).."1D8J;3;V^EG:*X5<*"-R(ZKN"Q/U9FX/F$#_=)[X%2^N=5@6.-4:?
M%ZGF2(@B(C\R-PJJ9.5(8J6SP =W=J LB7[-=;D!TZV(\LQDB;A8\8V<P [?
M:I4M+F*-(TL[5 IR%60E0<Y./W  R"V3CO[U?N(OML#(LCH'3AT.UQGN"1P?
MPKFH=0U+2H=P5[@I9V3O$X=IFDE9T?#9)7&T$@J>_3FC<-C7%K=,8O,M+8^5
M]T^:69.  5S ,=.V*C2TN)U*RV-N 96W R;P02"7 \H9).3@XZ#/M136=6N[
M6&2.(*[7T<9/D2[/*:,$R%&(8!6;'4<CGO2VOB#4)51V@ 'EVQ<>7(,!Q"TD
MFXG&T!W&.3E>XW87WBT+L%K?VP/EVUL"$(4"5E0$\L57R<@,<$C=C@=\FGQ6
MMRX8-96JAG=C^]+99@59B/) )8$Y.<D'!JO9:U=WD5[.(F40LZQQF!_.)"*X
M;#,A.=W"X4]LU"NK:N5W>4C;1%D>3+&7,D\D7&]LKM558Y!Z]0,&F,T)(KQ0
M@\B"3!4G+D'=NSO_ -7@8))/?TYZP_8KB-VD6QL_G!W_ +PY8D]2WD<]3G.?
M\8+'4;OR+F9V+?Z4 &:"9%5?*C!80L2^ V<C([MD"J]EK=_<-!"1@^3:,V8G
M#MN>#S'#8V;<.X(P"""?H :/V:Y\J-1:VIVNIV[F5!MSMVGRC@KA,''KTXIM
MN=18!_)MW8/*-[2.C;2Y)4#R3@<#N<@#KUJ"/5=5^PRS-$GFKY&W]W-CY]N]
M3&-SDIDY*Y!^H(J+_A(;NYAF,"$LL:$?N),KO2!LG!8;E\QV* DX _$L*_F7
M+2UN[92BVEJJDMD+(5!!)PN%@ P <4^2VO&)<6EKOY*LTC$AL 9_U.?X5[]A
MZ5ER:UJ<L,G[L[E,941V\ZLR%X_G!8X!Y;*')XYR,Y;<Z[J=E+;P6MJTO"!]
MX?>3L1G&[)"D!A\S'&21R0:0[FNEM>Y ,-JH"@+C>VS *[<;%W#!X(VXR1@]
MU>RNY26:"U)))^;<Y7@ \[!NR%']W&!UQ5>UO;^YCD<$\7T*C-O)"3$5BWX2
M0[@,ELL<]\=L&CZE?W\L?F+M01EG/D219? 4Q#S&/W2<EAD'H,8-&H$ZI? G
M9#;\,W5I%P6^8X/E\Y)Y(QSGOQ2""\3A;2UQZ><P_A"_\\/[H ^G%4I]1UF&
M90L:LIA:3!BD!R0Y$1*AEW*0O)9<YP 34=UK.H(WEH-^;661<VUQ$SD>9\H7
MDJ5(0<D$[N.2*?R_,7S-=H[QT4>1;_,P5U,C,OEX(P/W0R<GH1CJ,U"\5]*B
MQFWM0@:,;"[NN%8'@>4H& /E&.N#VP:.DZQ=ZN]M(/FB\Q2S)%+$N3#.'0ER
M=P5@G/3=[U))<:E<WL,; K$MU(7V1R1X55D\H&3>5<. "<# . >3BE\OS#^N
MA?1;] Q$4&XL2<.Z[^ H)^3@@ >O3&143Q:BZR*T5J0Y (+OA@1M(;,9SD<?
MX]\N]DU$--]G-Q]HWW>058P>4(Y#!LR/+SGR^AW9)SQD4'4=8LW=$C\S"W4F
M6BG8LPEFV*N,J!M5, L,@\;B>*N^UPMYFTBWX,A,<"Y0%"'<G?@ [OD''H1S
MQT]&S#5"#Y8MQ^Y&"3(<2=^,?=]._P!:98WM\=1EMIDS"D*,L@C90SX7<-Q.
M.I/ S]01@[ I?(#'G_M5VS'%:C 7;NED8AL'=TB''.!T.,^O$A_M,1N<6Y?.
M%7,@4<=2V"3SVP/K6K12LOZ8S&=]:_@BM!\A',DI^;UXC''M^M.5M5)8F.V'
M[D[</(W[WL3\@PGMR?>M:BG9=OS#7^DC)8ZI 8PGV8H%(;B1#GHA51OP/4?K
M2H=7 &_[,Q&<X$B[N1@9^;;@=\-GI@=1JT8HT[?F!0A;4-H,OD[AU"[\'CH&
M/3!]CGVZU'*VJJ1L^S, PSGS$++CG@;MI!Z?>R/3'.G5/6$:2QN54$DV\H
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M=%&** %HHHH **** "BBB@ HHHH **** "BBB@!HZTZFCK3J "BBB@ HHHH
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MPNX.RR#>3O)9XV1G;/+$Y#=>HR,9.=(:%;+)*X4_OE=906+!]V.N<G@9"@'
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MUKX<@M(E225W(C$99FP2#Y8V^P^0 #/<]2<U;M]'MK242QJ0P4J/G8@+G(4
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M*Y?S3&"68.<,0KD8P6 .&Q@$9!P>1S1'H=G%L(0G8VY=SNW/RX^\QR!L7 /
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M **** "BBB@ HHHH **** "BBB@ HHHH :M.IJTZ@ HHHH *2EI* "EI*6@
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MG<I)R<GC!5V!IVEC:Z<=D0PS*3\SL\C .6))<ECAI#DD]Z21+*X661V1E>W
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MZ7IUO!^]=EC SN>YE  ("8#M)PIR!@''2JLFA7D3)(DJRNCQD,S"$[5AECV
M)$RC:TA93MYR0>@S)J&EWM\967RT8K:;,2$\Q2^:^28R!Z+\I]2.U&O<"PUM
MIDTL/SKE@C1HLQ5'"<JPC5@K8"C!P> /05#;VFD7J>3'*DJ_=""X:0#,;IM
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M. =_SJ2I<@!DC8 )DESY@48]3]"70AG]N7,UI-<Q6K-MVF-022Z,J/O (7)
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MKP&;C*Q@A<$_-U]8Y=3U2V$NZ-9" P0I;R@9#Q*&(#N2,.3@<X4]>W09%'%
M')Q:_J[12/\ 96#$(4+02E,_N%D&U0' &YV'#%N<'Y<&_H^JW]Y=>7<P[$^S
MH_\ J9%^8K&2-[';U9AMP2-IR>.=W-'%%D F:6CBC- "TF:,BC-( HHHW"F
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MT!0!<@2R!#N;)XP=R\#MU&<O4"J?"<H8N)8RWF.RL4G#J'8MM5DN%V@;B,#
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M:KP%%+0 4444 %%%% !1110 4444 %%%% !1110 U:=3>AIU !1110 4444
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MFGB7,:X5 FZ-DQEFR0"YSCU"C:3:2SN59)?L%J'C78A$S95=V !^XX &<8_
M<XHBM+R!I7CL[57D9B76X<ME@H)YM^^T$]B1R*$AD4DM_;1W!64D*L*F1U&0
M_P OG2(F,%=K9 SC<" I'%*]W=I:7ZB8A[9F*OM#,R^6)1G( R<X.% '058%
MK($6);.W0! "%8[5!;/RYAVD@J&QQSC/8F(:?.(O(6QM#'DML+E5W?WO]2>3
MD]OQ.:/S"X_Q%+/':R3V[$[+>5@@"@DX^^WF=D&?EQSGUQ6JEPC!!O!+)N'8
MD#&2 ><<CZ9K&;3;F?R_.LK8JB$A3)O^8D'_ )XC'<\#!Z=#5Q$NWVS2P1"1
M8\*/,;'S;2X)"<<@=FSCM2%N58)9&NW\NX+H&G20\E _WHT&T_)Y:Y#-P"<?
MQ'B+2I[R>,VMS(PF,"2B19$EZC81A5  XR,YSDD-D9$YL9@Y=+&TS(#YA+D,
MX9?F4D0_WO7.1U )X;;VKK&RQ6MNBOG<FUT#C^Z<QCIG&2#D9P!TIV'<BL[N
M>>STXM*VZ4IO8X1B1&T@7[OW6*XSP2._-%QJ%Y!9_:=_S1P%I$782</_ *PA
MARI56) 8>BG/(E%C<-#Y+6EL0"#M)(0X.[;M\HC')P?QQG-,N--N+@)NLK3*
MA0/WK J@_P"68S <*0,$#CD\=Z07N="AW#-+BLV.XU"-$WP0LVWYMDS<-G'
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M 7]HI-HJ@TNI9XMX#Q_S\R#GT_U'3W_2D\[4O^>$&?\ KX<C_P!$4K/^F@-
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M) R0,^@R?SHVU1,NI<8A@/3/[Z0#ODY\H^W'ZTB/J0'SQ6Y^7M-(,G(]8C@
M9]<^U C0VBFB(#\S[]:H))JFWYHK<-SP)I"#SP,^4,<=^?ISPU9=7 7=%:GK
MNQ-*,^F/W1Q^M(+&EL%+L'I5!9-2 YB@S@=)7P3W'^JXQ^.?:@3:GCF"W_\
M B3_ .,4?(#1HK/:74N,10'US,XQ[?ZHY^O'ICO07U$$?)!CDGYW'8X7[G/;
MYO\ QWCE@7\T9JBKZB<YC@Z$C$CGGLOW.G^U_P".TJR:@?O10]#TF<\\X'^J
M&0>,GMZ''(!=S15)9=0[P0_]_P!S_P"T:7S+[!_<PYR,?OFQCG//E?3M0!<S
M15'S-0X_<0]>?W[]/^_-#2:@ <0P]1C]^XX^ODG'Y4 7Z*HK+?8YAA_[_,1V
M_P"F0]_\]'&6\&3Y,9XXQ*>3QZQC'>@"W156.:[9F!A0 '@^:3GD]@GIBK5
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M.1N&\DF->0 =N<')N-3U&T>56GE\](V+1E%$7E):LPF)6-E#>:>0K8W?)D@
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M#2 H#E5&\[5^9@,D\< 9)^E&X#%U*=L_Z#.,>K0<].G[WWI7U&= "+*=LCD
MP9'.,<R_CQFLD>([E%V^6CN&@#.C?N?GN'A/4[A]WC ;!Z^Y:Z_=30+(SVX8
M,?,R3SA5^1!&\NXEF SG(X&PGBE8#474[@L ;&X&3U+6^![\3$_I3SJ$ZKN^
MR3'KQF'/'_;7^59=GXBEN+:69@@9(H6*@/E=Z*P8X)!4Y+8!R%&#R2!'%XEF
M!<3H/W17<\>73#,$! #9;.2N #AAR?1M>0(OW>M74$$LOV&9-L;MN9H"HP"<
MD";.!W'6ELM4N)8U<V5P2Z(Q.Z$+DJ.BM-E1QT_/FH-(UAM3MGFFP,#=M4#*
M@KG'RR.2?P4_[(K1TLDVD!)8DQ(?F #<J#@@ =.G2D#(WU&Y\IW2RF+*/E0O
M I8_7S" /7/X9J*'5;UC^\TV=/D!SYML_P V#N48ESCI@X&?05<T_4(]2A$T
M6=I)'S#:W!X.#R-PPPSV(-4_^$AAC;9<(]N-Y3=*T:KNV[\;@YZCI_\ KIAY
M$HU.=AD6,W?JT Z''_/6HGU:]5@%TZ4KM//F6X.>PQYG3WS^%(?$-NB(RJ[;
MMN -I;#1B08);#'!Z DGL#5JXU,03+ (I)"0I8H 0@9MJLV2."<],G )QBDF
M%BM%JEZZJ9-.E4\[@)8& X/0[QGMUQ_C*]]=! R6<A.[D&2($#&<\.0>>,?Y
M->+Q58W*!XGWDP&4HI1G'* 1D!CB1BX 7N>*E_X2&TW*H8DM';.N,#<L\GE*
MP!(. <;N.,CN<4[KL%F.CO[TL UDP&XY/FQD =CUSD^GZTO]H7@8@V3X#D B
M2+!7UY8')]/UJ*;Q)## ;CRI3&41E;"*K!G" AF<!?O _.5X.>QQ/+JZ1V\,
MPC=S,4$<:[&=BRE@,AMG"@DG=C ZT778".;4;U!\EA(QXQ^]A P0#R2_!&2.
MA''6ECU*\;.;"1<$]9(3E?P<_-[=/]JHT\01.ZKY4H4E59R%V*[2M#Y9^;)8
M.NT[00,@YP<TG_"36ZP1SO'(BR11R(&V9*NZH#D.0,%U)R1@,/?!=#WZ$WV^
M[89^Q2<] 9(>.<<X<_7C-(-0O-[*;&3&!M;S(<$XS@C?D<\< TU?$$#RQQA6
M/F;,,&B(RPR!M#[CUY(4CWP#AUUKD-K(8RKLPD*$+MSQ&LA(!8%N'' RQYP#
MBC<5A!?7Q0$V1W'''G1X'.#N.>PY&T-GVJ5;J\;.+<#(!7=(HQTR&V[L'GC&
MX''44V^UF&P\W>"?*CB=OFC08D=D4;I'1<Y4]2/;)XJO/XEBMU+-!/A;5)WP
MJ;D5@Y"LN_=NRA!P" >I R: +"WEZS ?9, @G)E3Y?0-C/)]LCWJ87,Y S 0
M22.73C'0G!/!]LU6U/78M+(#HS$E>C1H/F61L[I71>!&<\^E/BUA9)C#Y4@
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MVZU/;:W!*J&3]T9&P@)#*P^7#*ZDJ5.Y<'/4@=>*=!K=G<B,I*#YC84$,I/
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M.!@1@'KW!/I2-H1)&VZF4*3L4"$A>".-T1/ .!SG%:N:,T 9R:4T0 6>5<
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MDC2,YE4()"3,)\$E2" RC&0< 8]:D&A!"K)<S*X\S=(!"6?>5)W;HRO&T 8
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MXMEQY$D9(+H779)NSA1(2<C &?>G^(VNH5C:V>1<"0D1Q>8W !!'R.,]0%(
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M3%%Q6.=T*:YNY)C)%Y/^CP^2C0A?*),D;KD8+ F)6QD<8Z<5'"-1!L(;R(2
MQ.+B4QQ$?/&[-$<'Y5!5 2%(<XY'0]/BBD,Y^\AO$O(HK542)8%(&0%RL@#)
MMVM@!#Q@#KU(&*SIKV2_,8B&&CE990$0^6[74:J-S*P#!2QW*#TSDUV.*,4
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MTJ[O6M]\T7F.MO#(NX*AD>5"S %0%7YL*,@D<D]<BNNHW7F61DW%FNYD,9A
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M\T@# ZY/\LQ_\)898C*ELP7?L5FFMXP7'5#N?CH?4TR32+J:.V@F4.L0=?\
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MR#UR318-#1N?%L=F"TUO+&-I.7>W7D+NVA3,&+8[ 9Y'K2?\):FY5^S2;FV
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M7%!-)NH 7:*0K03BES0 @%+BD)I<XH ,48HS29H 7%%)NHR* '4E)NHW8HN
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M]AW0^TU.XB>=;PQXBC@),2N0'<MN0YR3@;3T'!R>M3C43>Q;[$I(0X#>87C
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M11QS$&*UFA5BH8Y<H=^#QP4Z=Z=@--(DY( Y';CU/4?4TXH!V%('" 9/H,G
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M8?/&$QT>-V.<.N0R2QXX<]N.H.<8 )(M718PUP C$R@JI,G^KD\LX(4$Y)
MQG)  IUWKEE8B-I90!(CNA 9P54 DY4$=QCU) &344NBBZ11-)A@TI)B41*=
M_4%3O)&<$@DACRP(XHE\/6=Q!'!*"Z1VS0 ''*MY9R< '<#&"",8/X80$DFN
MV,8!:8#*,_1L@*&+9&/E(V-P<'Y2,9!HDURS@D>-Y -CJA)Z;F!;;[8 R2>
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MO>GKW LVVM65V&:.9"%0.<D*0NT-NP<$#!&3VZ'FI?MMJ\:R>9&4;.&W*5.
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MDD[<CDD<],\T7?<+(H,MM"T2N+L/(LA"&\D+'81N  G(9@.<*2<9[\4.]I#
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MA*EO"T2>:P!D8R!4\O=M;<0HP5SSUZ8Z*HC;Q&3S-B[\ ;L#=@9P,]<<G\Z
M.;%PCRQHT[[A>7QF7SW!6+;, 64-\JC";3P!P1@GED5_*B7)FG*!(;0>8[XB
M?=(ZB167(02KM!91\IR>2*ZD1+G=@9( SWP.@_6D2)8U"J     !@ #H,4G8
M#.T"\2[A<I)O"RE<B7ST'RJV%DP"PYZGD'(Z"JNN7$L$QV2E5:VD\Q0Q+X'
MD0+RI0G)(ZKG@D"MP#%--O&[K(54LH(#8&X XR >HS@9IV QO[;>V"),T88W
M%K&JL</(DJH"P&X<ARYS@C"D8[C+N?$MS)8R-NC;S+-W#1;D*EH)W !WMRI@
M8'ODCIMYZUK:-W#LBEAT8@$COP:<D21_=4#@#@8X'0?09H Y^ZUV>SBN&\V"
M8QBT(,:D!5FDVY;=+M/RX8'>/4X&"3_A(+@69F8Q(Z7L4+!]N"&9 W"2OL90
M^2"Q^Z<@9XWH[:*'=L15WL6;"@98]2<=2>YIJV4"1B)8T"#HH4!?RQBBX$/V
MF11;8>)O,DPS#Y0P\MV&P;FYR!W/&:N4SR4^7Y1\ARO XX*\>G!(^E/H ANY
M)(X9&B7<X1BJGH6 .!^)KF[&^-Q82^=<E'%M!*TR39'SLYQB0%4(92I '3 X
MX ZK%0FTA*NIC7$A)<;1ALC!R.^0,<TK 8%[?.;2P:-]X:,ER9S K8A.<S*<
MYST'KR<8S5OSV/\ 93O(V]V ?DQ[MUM(QW1@@?>4$ C@\"M*:R@GC\J2)'3/
MW&567KGH1CK4C*DGRL <%3@X/0Y4X^HX^E"L!SVH7MS;:HB*CR%I8-FR8E4A
M;Y)#) #G@Y(?;CD9;C:="QU'S;Z:%W<,R,Z1L@4(D;F(MD#)WL"PR3\N.!WT
M?+4,7P-Q !.!D@9(&?;)Q]33MBYSCG&,]Z=@.6LM5E>R:1VVLT=C*\GG,ZA)
MI-LAP0!'M"MG' ZD\5>ECF:'RXGDECCNG#[92LK1[6^42%E.4D(R=X.%())X
M.LEE#&KJL: 2,S. H 8M]XD8Y)[YZTAT^W*1QF%"L94QKL7:A484J,8!';'2
MC0+D.B3O<V-M)(26:",DG&22HYXXYZU?IN*7- "T4F:,T +129HS0 M%)FC-
M "T4F:* %HI,T9YQ0 M%)10 M%)FB@!:8/OGZ"G&FCEOPH ?2444 +1244 +
M1110 4444 %%)FB@!:*2B@!:*2B@!:*2C- "T4F:,T +1244 +1244 +124M
M !1244 +1110 44E% "T4E+0 44E+0 444F: %HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** &CK3J:.M.H **** "BBB@ HH
MHH ***2@ KF]9OS;W9GC,I%J(A(%F58L2'Y@\3LN2$.49<Y8X/W<5TM,(H C
M6X3S3#N^<(&*]]I) /Y@U#JL/GPX,QB4,K.P8H=BG<PW*RE00.3GBK8P:4C-
M ')V#R+:Z<UO<EGN)49O,=I@&^RN)!RP)&X E<\-3Y/$UP(K5FV1F1+G>P,9
M&^&14 !DDC7:Q))&XG' /\0ZC;1@4 ]2.UF:>".1T*,T:L4/)4D E>@Z=.E8
M&G^()KNX,/FP.XN+F)HT5E>,1F3;(V7;Y3M4'Y0,MUKI#S5:TLH;!62($!I'
M<Y9G^9V+,?F)QDDG XI 8J>)FEM[B99(5\NR@F!()"NV_?&WSCD%0.HP3SFG
M2ZS.(K69;JTV3SNIDVEXD'ENX&X3*&(9"I.1G/08P=_:#5>YT^*Z>*1]V8GW
M)AW0 XQDA2 >,CG/!([FF!BR>(9E"%Y;>%?+=M\@8B8AV4>4N]>"J[NK$!EZ
MYR0>(YGO88/W:!EAWQX#S*SJ&92#*CC (Y$; <DD8('0[ :=MHT[ <WHOB"[
MOKXP2HH4B4E/W:R1;2  0LKL0>Y9$YQCKBMG5KJ2SMVDCV@AHP2P)55+JK.0
M".%4ECR.!R:M8Q2XS0_)6 YJ^U.6:R=FN8E!O((UF0,B.C&,L5(ESP2P8A^B
ML.#R-S3T\NWC D$@VY#@LP8'D$%W<XYX^8U8*YIP % &*;Y[?57BFN8D1HH#
M'&P*LQ9I5VJ3)@MD#.%Y! P.IBTG4)1*D;RH\<DU^J!B?.S%.P !9SO4+Z+Q
M@<UO%:-M '.P^(@NG7,R20O)#)(N?,_=DM(0C?ZQRJL3P&8#CJJX(T="U"34
M;;S9"I.]A\JA5X]UDE4_57([<$$#1P#38X5A4(BA54   8  X  '0"@#&U/4
MFL[SRTN(HV>VW_OV/E@1L<X4,N"V_ELGA>AZA\>JB2YLY"RJEQ;MM4L58,VQ
MQU.&R, < CG&<D#4DMHIB"Z*Q'JH/\ZDVT:!J11RLV08V&&(R2O('?@G@_G6
M7:WXMXM099-Z6\SA26,N-L$;LI);)PY;@GCIP!6SBHUM8D(*HH(7;D* =O\
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M8(\TL*N2O+Q[RWR@\+\A .<YZ@#!*:?J=Q>V\DI@PRM,%7<H#%'=0N<G!^4
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M*K,<=< 9-0/IJ--'/OD!1=H D;:1UY'?G&3U.!GBK#H)%*L 00001D$'J,4
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MQ1:_4"W2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 0<\@G>,<>M2[:4+B@!<44M% !1110 E%+24 %+110 4444 %%%)0 M%)2T
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MPRD@X(Q4U !24M% !1244 +1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %%%% !1110 4444 %%%% !1110 E+35IU !1110 4E+24 +124M
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M))P !U))H ?125%)=1Q2)$Q(9\[?E."0"2-V,9P"<9S0!-1244 %+29 I-U
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M>U3&50P0D;B"0,\D# )QZ#(S]:+@/HI <TM !1124 +1244 +1244 +1124
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M2V^+DR,[LAQ99<;2 1.!(I387.,?7G-:;7\\$[PM> F-03_H[,%.TNP=E 7
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MS2QR'$BJC8+SD_=11[ 8'%=)2&@5SE[YH[]$M)["ZER\L@#2I&<;RC_,LP.
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M)W(9,2%#(RG>P(^56Z?=()J.QLM*M -][&Q$BN!@+M9?*+ !F;:Q,7W1@C.
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M#UJB-#T\?\ND/_?I/\*/[!T\_P#+K#_W[7_"@"]D4N:H_P!BV2XQ;QC!R,(
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MX4&"4(P.%8_,-Q7'ICO0!T!&:-HK)36FG:1($60BX,:D/A"!$LI8L V/O;>
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M?CZ46_JZ U\T5F))JN3OAMP.<8GD8]. <PCJ>_;T-3"6^./W,7W3G]\_WN<
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M ,9)/8<@?C5D4 +2!0.E+10 E%+24 %&**6@!*6BB@ HHHH 2BBEH 2BEHH
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M9<?([*A 55*=4PJ_="@[<?[.>]7:0'-8.MZW+#>06MHK22!MTJH WR$8"G)
M&21\Q/RCGH>9A!U'9=F_+0;=C>=EC4LQ  !)).  .IS7.:IXKF1X4T^W\_S)
MM@8L%5\?>"<Y('(+XVK[U->QGR_/U5LKE0EK'DH6W953T,K' XP%Z\8YJSI>
MG2><U[= "9DV*B_=BCSD)D?>;/+'UX''6XQA#WI+FWTZ7_4EMO1:?Y&H*=16
M3JGB*#3%;<DK/G:BB*0!W/10Y7:<_6LXQE-VBKOR*;2W-&XN8K1#),ZHHQEF
M8*HSP.33+&_@U*(36[AT)8 C(Z$@]<=Q7GC75QXF?=Y$ES-AEQMVVUN"<$ ,
M0&DP.K$#..N*Z33I=3TN!+:WTK]W&"%W7488Y))) ! ))R1G'I6\\-R1^)<]
M]4Y1BK?-W(52[VT]&SIJ6N=L]7U.34_LDJ6Y10S2&(R.T:D'RPS-M&XG'&,D
M9. *Z$&L)P<&D[:J^CON6G<*"<4M(:D9EK'YM]=(2<&VMQP2IP6FZ$'.>O(Q
M6(NDW]NMNJ*V\6L4>X; J!('!C+!M^3)W''(YR!6[;*1J5SDDYMK4X../GF&
M!@>V><]:L7NI6NFKNN9DC!!QN8 G'7 /)/L*:3;LE=@9^C(D.]8[::%2X4*^
M-J[5Y(4,P"G^\.I/-8]M;72>6D$$JO)"D=QO!B3?E2S;U&2=J2?O!N.YUY/
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M$BNBTU9?LL'G_P"L\F/S,XSNVC=TXZ^E6J*AE **6B@!**6B@ HHHH ****
M"BBB@ HHHH **** "BBB@!*6D'>EH **** "BBB@ HHHH ***2@!:2EIK'%
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M##;QM<1:DME-82(,MG:PFDP1E&VQY'3E@"?;ISKV'BK3-1WB*X7**68-F,@
M$D_.!D #DCI4US<WD<<C16P=E90BF8('!VY.[:<8R>H[>],,MW< I)9IM8X.
MZ4$;#U! 4_-ZJ,K_ +51*=.27N<KM;277O9I_F.TEUO\CG$^)]G)J MPF( 6
M!F.XDX7@A I.">/7!R<=*Z"P\3V.I3^1$Y#E=P#*R;A[;@,^OT^AI]LALU(@
MLTC#'. 409QSNV@\^F,_A3@[O()6L_GV$!RT>1C)VDC) )Z8SUY JISHOX8.
M.EK\U]>[5@2EU:^X9J6J312BUM(O,F*;OF.V)%)VAV;OSGY5Y(!Z5CQR0SW,
M/EN=0G$L>Z0@&"%20690OR*<+Q@ELCJ>AU+O3+?59DDN;,,4*[2S*2.IY ."
MN<<$GKTQFI(Y_L<2K':>6@4G&Z)%3DDEL' 7OE=QZ\9ZJ-2$8V2=[>FOKV\M
M :;?D37MRGF1VGF-&\RR%&7;GY-I8#<&&2#Z=,]#BI+6QMM-5O*0+N)9FY+,
M<DDLS9+'D\DFHFO7* K Y;LNZ/)'][(<C'3ID\]*@O#_ &C \5Q92,A*Y0M'
MDX8$'Y9.@QGK^%9\VEM4NMAVZF=K7B8_9WDLPYAC.);A5S@%MF(PQ =L\EON
M@>N:;;^*=$TFR#6UPLA9CP7'G.Y."S[\$9(R68 ?A@5IV]XWEK%'9RP_*H *
MQ[%!XS\KXP.Z@[O053T/28M%A&R*2239@,1ABF[?@!VP@R_*D@D@G!K95*7+
M9IJSV3W]78BTK_UIZ&!_PG%E XNYV^T7)0[(T!6*$''&YQRS?Q, ?3IUZ+P[
MXMM=;B4,Z)-ABT?(P 3T+ 9X&3CI5;3/"NG6+M=>1)/(YSF8*[ [\[\,!@GK
MD_-]#D5)JNA6&LW GN;65R$ '.U"N<Y^\",9S@X/L:NI/#2T2GI]K3[N7L**
MFM=/3];EBZ\66JMY5IF[E*Y"0?. .@+./E49P#R2,CBL/6;6\O[F"35;=V@"
ML5CM09"K$@[9#P>G!*\?W<<UT5K+#I\216EJ0I&55%5<C RW) ].2<GWJTNH
M*P3:CG><+A& X."26 "XZ\X)[9/%9PK1I.\(OKJW[VO:VQ3@Y+WG\EL9^DZY
MI_\ 9[W$"&&"$LN&54Z '@ G.2>.Y/O3)_[7UE,1[;.)^,DEKG:3UP/E0E>W
M4'O6)=WMO_;4'E02^2LBR3?(^WSI 4B8Q$?(V1U(!;.<'@GK!J2APGERY)&/
MW4F#GWQ@8[[B*<I*#YHQNY:^]K;_ #8DG+1O;MH/TW38=*B\J$'&2S,3EV8]
M79N['U_I5JJK:@BE1M<[B0/W;YR#@YXX'N<#WIT=\DCA L@)9EYBD"Y4 GDK
MC'/!Z'MGFL6W)MO5LT2MH6****0&=;\:E<G_ *=K7_T.>LOQ5I;$&_@M[:1X
MXG+FX\QAM0;@%13M)Z]:T+7_ )"=UP<_9[7.3VW38(_'BM-XDF7:ZAAD'! (
MR#D'!]",BJIS<))KY^@I*ZL<UX1TR^T6*9KP6Z1R%ICLW*R,0ORD$;0J@'OQ
M]*O62MKDBWDR$1(<P(W<_P#/8CU/\.>G4=<TZ[0ZQ=&V(_<PE6EX;YW(RL?8
M8 PS=>H'K6OBM)SWDU[\ETZ+_@DQ73HOQ9S>MZM<7-T^DPPH#)#S),Y5"K A
M@JKAF.,]".0>PS3?".FPV=M]MDF:1MDD?F.^56..1@-N3A5PH/4UN:CI5KJJ
M!+F)9 #D9Z@^Q'(Z<^M4[F%=0F2R50(8@#*!PO3]W%QV_B(] /6J4XN'+&\?
MYGZ?Y@TT[O7L06:+>3-J]SA42)O(!S\L?),C?[3#GCH/6FS>()HM+N+]8A\L
MA$.X$!XRX5'*]1D'IQG&> :O:QI1U@10NV(0^Z502&?;]U,C^'/)[\#'J*.L
M>'+C4?-CBNO+AF*%XS&& *A0"IR".$''^-$94Y./.TM5H[V44]M.K$U))V_I
MOJ36L&M@@33VQ!.21&[,.^  4!].>WO6S12UC*7,]DO16+2M_P $**2BI&+1
M110 4444 %%%% !1110 4444 %%%% !1110 @XI:0'-+0 4444 %%%% !111
M0 4E+24 +5/4&NU0&U6-F')$C,H/(X! .,C//./0YR+E5-4:58#Y!PY:-0<
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M^ %! 0X.Y2 C;6)Q@'C/2[11M%,##?QEIT6=TC## '*,N,G'.0-N,'AL$X)
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M]_=^OMUJIJLT=U!Y:LK!KB%&&X8(\U?,0YZY7(*]QQ3SX=TP];*W_P"_,?\
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MI96N=P*Q6Z,IQM$N&ED"A<C:!(J@]3MY)QDI+X7MY)?.\ZY!^?@7,H7YR2>
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MHH **** "DI:* $HHHH #TI$^Z/I2GI2)T% #J*04M !1110 4444 )12TE
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"4M%% !1124 %%%% !1110 4M)10 M%%% !1110 A4$@XY&<?C2T44 %%%%
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MF*/-3^\/SH ?13=Z^H_.C<OJ* '44FX49% "T4E% "T4F:* "EI** %HI**
M%HI** %HI*,T +129HS0 4444 %%%+0 E%%% !2TE% "T4F:* %HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exh2_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh2_2.jpg
M_]C_X  02D9)1@ ! @$ 8P!C  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
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MS;\&4' QP4Q5?PC]LCFNHYFF>'R[=HGECN(\LQE63 NI9I1C:H(8KZA<-N8
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M+MD5@X.W*DALD$@Y!-7J* ,R'PY80.KI$1M8,1YDFQG!R)'3=MDDR =[@MD
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M#/RON')_O'.G110 4444 %%%% !1110 4444 %%%% !24M)0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W5I#?
M1M#<1I+&V,HZAT."",JP(.",U+10!%:VD-C&L-O&D2+G"(H1!DY.%4 #).:F
MI** %HHHH **2B@!:2BB@ IKPI(49E!*-N4D E3M*Y'H<,1D=B13J* "EI**
M %HI** "EHHH **** "DI:2@!:2EHH 2EI** %HHHH **** "BBDH 6BDHH
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MEI* "EHHH **** "BBB@ HHHH **** "BBB@!#10:* %HHHH **** $I:**
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M2F"61ASM8Q%%**21C<7X8]!U!IR:''''M$TID,YF\XE3)O*[,X*[,;/E VX
MZ#/-+-HL<L,40EE0QQ&,.K#>R, &!)4CYMH)( .1P11IW @N-:EWQ-"BF,_9
M"^[(?%PYC7&. 4."<YR"<8QRL.IW$LJY">7)<SP( &W@Q!_F9LXP3&W '<<U
M9ETF*299-S* (LQC:(SY3%H_X=PVDYX(' SD<4D&DQ03&19'*^8\BQDJ45WS
MN=25W#.YN-V/F.!18"N-1N;7SQ-LD,:P!2BM&#)(S+M.6<X&4.?<_2K$5S<6
MJS/>; D<>_S4W ,!N+9C)8J5 '<YSQZ"673K>9)T8<3G<_)!SL5 0>Q 48(Z
M$9ZU%_90>-XY9Y9 [1EBQ7E58'9M557:V"&^7+ D$],%@*AOM0<01PB-9)4N
M)OWRM\J*R[(RJ[<-B103GC!X:G1:S/>O'Y*H%\BSE<-DL1<,RX!! !0+GD'/
M3CK5S4-.2^"_O'B*[AOC*JVUAAER0>#P>.<@$'(ILFCPO*DBED"K$I1=H5A$
MQ>('@D!&)(VD9S@Y'%(/D5UO[C[4%.SRVNFA VG>-L#2[MV<<E<8QTI]C/=?
M;)8I9$D7:6(1"!"?EV1[B?F+*2QX!'7 #+5C^S(OM/VG<Q.=VW=\@?9Y>_'K
MM^7KCVR2:ATW1QIC9%Q/(,/\LC*1EV#,WRJI)SW)..<4[ :5+29HS0 BTZF@
MBE)H ,T4<44 %%)FES0 449HS0 449%)N'K0 M%)N'K2Y% !11N%&11< I:3
M-&:0!2TFX"C-, HI"V*7(/2D M)29HW47 6BDW#UHW"F M+3=V:,B@!U-*98
M')XSQQ@YH#@]Z7- !BBC.*3>I[CKCK0 M%)D4A<"E>P#J*:9%')('('Y]*03
M(W 8'GUHNNX$E)2;A2[A0!C3,/[;ME&,BQNB>.0#)!CGZYXJ77&GB17@F=&^
M95C1$9I'.-@^<'@8);&.,DD 4EQM_M:V.1Q9WGZR6_\ A5F^TZ"_9&D+@H&
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MT_Y^?_L:Z.BB_P#5A?UN<Y%X-5""VH:@X!SM-TP!]CM"G\B*?'X02'&+Z_.
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M-)@C@G)]N.,YY/X<4 .S12%P*:\NT9"D\@8&.YQGDCIU/Z9- #Z*;Y@H#@T
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M <TM !1110 4444 %%%% !1110 4444 ,?J*?3'ZBGT %%%% !1110 4444
M%)2T4 1S1^8I7)&01D'!&1C(/K6(/"D*H4CN;M!\NT+<R80+_"H)(Q]<GT(K
M?IN*5@.>_P"$/@RQ%S=KD_+MN9!LZ_=Y[Y/7-3/X5MB5_>W0VR%A_I4_?.1R
M_'!(R.?>I'L7N[AS*K%4O5*DEU^001M\I4C(\U02#QD'N*QI$U +)Y$EP'%Z
M6;='.<(IE95R[E&5B%!,8 QUS5*X?,U3X5M-P(DN0 6.T7EQC+=6_P!9UZ\Y
M[G-1CP=9%"K/<L202QNKC<6'\1_>8S[XJ&.&^E@?>TZR-?1.A R$#1QL002
M8T)(('7'UJNEO>R,?.AD,S+-Y#@EDAD^T2DG><$*59,9&&5=N#]TK\0OYFA'
MX2M(E*E[ILMD_P"E7&2<YYQ(,_C69K/AN*Q-N]HUPGF7MNDNVXFYC9FW DR9
MY)Z^O3&3770N9%#%2I(!VG&1['!(R/8UC>)UW-I_!/\ Q,K<D#_@77V'4T):
M@++X:MMA&;IP>"IN[@Y!X/WI<8 ZTQ/"-D@0#SQL8E<7$PQGKC#\?A6_10.[
M[F"/"5NOEXEN2$<G!NI^A!X&)!CGG-(/"%MQNENFQ)OYNIL>R\,. >0>N1UK
M?HH$<ZW@S3Y'>1Q,S,1\S7$S$< 8SOSCC/.3^&!0/!]DH,:^>J\'BYG XR N
M-W0"NAHH20[ON_O.?7PC8KE5-RI"X!6ZN1M'H#OQCCI]*D;PI:G&'N1@83%W
M<?)P1E<OP<5N44"WWU,(>$K($8-P-K%E_P!+N?E8@@L/WG!.XY/N?6AO!UB[
M(Q,Y*8V?Z3.=G0';E^,@5NT4 <^O@ZQC?<KW(/4?Z3,,$_>(.[.6[\U*OA"Q
M"J/WQVN7!-S/G>>KYW\,>Y%;=% &(GA*RC! ,VUG#E?M$^-X.0^=^<_CV'I3
M9/!UA(,?OOO[\_:9R=^,!^7/S#L:WJ3%*R[ 81\':=@@I*<N'/\ I-Q@O_>_
MUG7WZT-X0L&))\[EPS W-Q@L.C']YU'K6[13 Q9/"=A,K)()F5FW$&ZN2"?4
M@R<GCK2?\(K8<_Z_EPY_TNYY88(8_O>HP,'KP*N:['-+92K K,Y  "D!N6&2
M Q .!D[21NZ9&:YS['?RVLL1@D+7=H85_A$>))RK.&D8J-DJD+N8C!7'&"!<
MU3X.TX@\3#=)YC8N[KE_[W^MZ^_6G?\ "(6//S7'+ASB[N>2.Y_><UFMX9N)
MH;DOM9IY@K(?,P56Y!#L3-SM097:4XXQG #IK:YL?.L0L\S2Z:(TF"D('7[0
M<,Y;Y3\RA>2>F3WI6\@T-!_"=DR.NZXP^<_Z7<'KQWDP?QS2MX8M9-P9[DJR
M[2IN[@J1SGK)SG.#GBL6XT.=6U%UMY"92_S*(][!GBW .)0S+A"VPJN<E=V<
M&E^Q3MIX$EJ5C!1A&L;$8:Y>4YMA(<K@1Y3(*@L >,4[!\_Q-B7PI93;MSW!
MW!0<W4[<*<@?,YS@D]:1O"EJ^[][<_-C/^E3YP.@^_S^-86E:%=),TT]JV[[
M'''$0RX0K;A"/]:, G(QL/)SFKGV34]/!F1&EDCECP-[!95>%8B""[G*N S%
MN,#(/)HV"YH-X4MV+$7-XN4  %W-\O\ M#+$Y^N1[4^3PI82IL<SE<8 -U<$
M <' !D]0#^%8\FDW=E<.3%/<QX"QJD@C;S5AMU68OO5EW;64L/N\]F.6W%A?
M7PU"W*7(+-( X)52KSAEVL\Q1@(^JA%XRI89Y!KO?\37'A&R'(>Y_P!64_X^
M[CIZ??[>G3VI1X1LQ_'<YV@9^UW&>.,_ZSK^GM5KP_:R65G'#(H4JTHPHV@C
MS&*MMRVW<,';GC.,#&!ITA/U9BQ^%K2+.U[G+8+$7ET"3@#)Q*.< 5$W@W3Y
M%8/]H?<5+[KNY.\J  S#S,$C _(5O44_D!@IX+TP(5*2G(PV;FX.1Z']Y[TK
M>$+!R3^_&1AL75S\R\_(<R<CD\5N**7%%@\S'/A>S;=DSG<FTYNK@_+_ '?]
M9T]J9'X2L8R6_?D^68P3=3DA#C* [^!P*V\44K+L@,,^$+'*%?/4H JD7,^0
MH_A!+G (X(':HU\%V$10H9U\MB8\7$PV XW*OS<!L'/?D\],=!13 PQX2L55
M50SIL8E2MS-E<D$XRYQG'./YU&G@NQ1D*O<@(VY5%S* "<Y88;()[D5T%% &
M"_@VR.P+)<H%??A;J;#-_>.7//N,&D;P5IY8,#< !R^T75QMWDC]Y@N?F&.O
MO],;]% 7,-_"5F^_,ES\Q!/^EW!]/5^>@ZYIS>%K1@W[RY^8 ?\ 'W<=/^_F
M#^.:VL4'BC3LON"YQEMX;M=4O=3BEEFR&MXP5N)?,$?DHQ!W.=RDDXW ]_PU
M%\(680+YMS]P(W^E3?,H4J 1NQ@9S@8&?;BETPAM6U(@KD"T3  ##$9;)QU!
MW8!Z\8Z $Y<6DW:;-MF8VB2V,K*\7^DR1S1N[Y# EAL)4N!NWG.WG(!J+X5L
MQ@"2X!\O8/\ 2IP<#L/GZ>W3VIMYX5TV8#SFE*[-BAKF8J.<\;G]AQTX'%4[
M71]0\RWN60*8KF9UC)!EQ<74IDRRN4P(G5L#<21@$8Y@B\+W1L&M98T8?V64
MC#;6*3LOS*22> W*D=,D= * V-(>%-,EV,CR@*@"!;F7:%R&X.\X!]CC\>:K
M:SX:LK&QN+B SI)%:3&,BZG^4A"PQ\_KVZ<U8O/#L5P' MHR!=VK*"$($:^0
MLFT$?*-B$%>^/<"JNH>'HK"VU.<*0JVDX@0ME(]T1:5D4'"[V.",<8.#@XHM
M_5AW]2U8>%K6-(V,L[$1@!EN[A5(*C+ "3Y03D@ GKU]+$?A>T4 >9=<=_ME
MSD_7$F/RQ69;VLU_IYMO(D WL=V_&0]PDJ.LA.XX0Y)X.00<&EO=+O+^*YCN
M+=93AS'\R89E6)58*?N%\-TY R,]"06@M[H%K)?06;_:&AD@G9@UW<,I96C"
M\&0] 3Z#GO5MO!.G2* ?/]_]*N.1TP<OTQQ398XK'5+""- J?99TC&YL?*\3
M$8Y (4$Y[]#VKH@*/D"T,)O!VGR @B;!&&_TFX.]<$;6)DY'/^>:=-X2LICE
MFN.1M;_2[CYEP?E.9#QR3C_Z];E)BE8+LP'\%Z;(<NDC?NECP9YB-B@;5QOQ
M@8S]>>M(G@W3(]V4D.X$',\WW>R_?Z"I=<MYG\^.*)G-U:^0'4C$; 2X9\D$
M+\_4 GC&,D Y4VBZC&[.J>:IENY!&74<M>PRJH8G&UD0MTX.<]0*>R TQX0T
MT _++RFP_P"DW'*?W#^\^[[=*:W@[3F.<3_ZKRO^/JX_U?\ SS_UGW?]GI2?
MV+]GTZ^BAB DF6[ ^Z"V2XB7.<!0I 49  [#FL^[\)ODA%B<&*[(7RECB#.+
M=54+N)4D1D[E/#<]/E(!I'P?IORY27B/R_\ CXGQL_N?ZS@>PI8_!^F +B-Q
MM0JN+BX&%/4?ZSI53^S[AYI)I[1I"TNZ "1%,1X.YVW_ "DG'*;N%Z= ;7A[
M3GL+F[9HG'F32,':.!01YCD -&QD;ANK_IG%%AF?K?A[3=+AB=-\922%5/VJ
M9=D;3QI+C,GRKAN2/6M&+P9IT'EF-95\H,(\7-P-F[[VW]Y\N>^.M3>*1&;,
M"0*5-Q:[@V-I'VB/(.>V.M:XH$<]!X"TB$HZP,&7HPFE5OKD..>:D/@S3E55
M194VEBA6XFRC'JRY<@'\*WJ3%%P.?'@?20RL(6!5BP(FE!R>IR'SGWZTL?@C
M28E15A<!'WKB:8;6X^88?@\#D5OXHH Y[_A M&**GV<[59F \V7 +  G&_OM
M'Y4LG@31I7:1H&+,223/-DD]23OKH*6@# ;P5I3,6,+DL<DFXN"2>F23)R>:
MCG\!:-.2TD#.3U+3SD_F9*W;EGCB=HTWLJ,53(7<0,A<G@9/&:X^71=6L3;>
M2/,> 22!PX"%I0OG1MO.]MQ#-G')8?= Q2MY M/(THO >C1!E6W8 C! GG (
MSG!_>>H!_"@> -%!R+=@?433?_%U2MM"GLP8VA:1EW"WE)4F/_2'8,QWY+'<
M')4<CY2..;-Q:7K!8HTEB5'=/,1TR1)=Q$,NTD\(&)W+@<CD9IZCN^Y8_P"$
M'T@KM,#$<YS/-@YQG(W^P_(4C>!-&(Q]FX_ZZR__ !=0II,UQ/;27,1WIJ$I
M8AB$*!9'C?:K$!=^T@-R"2.YSTU"5@NS!'@C2=H7R#@$D#S9< G&<#?QG J6
M/PAID2LJPD!@,_O)">.>"6R/PQ6U13NQ&;IFA6FDR226Z,#)C<2[OTS@?,2
M!GM6C2TE(!:*2EH **** "BBB@ HHHH **** &MU%.IK=12T +1110 4444
M%%%% !1110 4444 )5:>]M[5)7DD55C +DG[N1D ^Y!&!UY'K5DUS]R)%M[Z
M&.)W>2Y9"5(8XF1,28<KPBL!@'''4#) !L)>P2(DB2*R.VU64AE)SC[PR.O'
MUXZU8Q6%;)-"L\$Z%L7D9C9(]JDN4D+*&9S\CEF).1Z=,#=% !BL/Q,N]]/^
M1FQJ4!&TXQPV2?8#)-;E8'BWS!_9YCW<:I:ABN>%8E3G'8YQSZT ;XYHH%%
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MGY_B&/NGL16S/JLEP0P5+6.(94X8L[.<'OM 'Y^U &F*H>(_^07>_P#7I/\
M^BVK1 K.\2$KI=Z1VM)__19H 2+4;>WMO,>3*QE(V;#/ESM7 ('S'+ 9 Z\=
M00)H[^"01,KY$CE$X/+!68J>." K9SC!&.M8ME;W TSRA&6D2[CDPA&UP;A;
MDE&<J"-K8R2.01[U.+>XD1V>(HT^H02!<ARJQ>5RQ7*@E8B>N.0,DT#+$W_(
M5M3C_ETN\^G^L@K8K#N2PUJTVXP;6[#9] ]N1CUY-;= A:2EI#0 4AXI:@NX
MC<121ARA9&4,O#*2,9'N.HHW @DU:V18V+$B0,4PCMD#!S@ \8Y^G-/AU"&>
M2.-&)\R(RH0#M*#:,YQC^(<5AW%I<?9].:*UDD,,0R@F$+*0B@!B<;N1TQCV
MK0CMY99; O%Y;1H[N%^XO[ORS%P2.K@CG^&@#6 HQ2T4 8_BF/S++:55@;BV
M!W' YF0=?T_6M@5D>)TWV>._GVV.I_Y;(.@Z_2M<=* "BBB@ HHHH **** "
MD(IU% $3RHC(A/S-G ZG@9)^@]?H.XJK%JUI/*84E4N'9"HSG<H)9?J #3;E
M'6_MY K%3%/&2.54DHZDC/ (1AG'7 /45#I.G-#)/)*C F>0KN8.N/,E8,@&
M=N5DP>0>O [@&E!,EQ&DL9RKJK*>F01D'FI*IZ6CI;J7!!9I'VL,,H=V<*>O
M(!Q5R@ I:2B@ HHHH **** %HHHH **** "BBB@ HHHH :W44ZFMU%.H **2
MEH **2EH **** "BBD-  3MZUCR^+]*B\S=<K^[*A@ Q//3  RWOC..]:^,T
M;10!BGQEI&UV%TAVJK$<@G<,@ $<GU Y'?%*?%^D@'_2D.%#'&3P?H/S].];
M)13VHVB@#&3QAI#E0+I/F4L,Y' ^HX/L>:8_CC1HPI-VOS+D85SW(YPO!XZ'
MFMSRUZXH" 4 8J^--';!^V1\J2,Y!XSV(X/' ZGMU%9.O^)=+U!;-HYT?9J%
ML^=^S;M8$M@XR #@^F<]JZ\J*PO$FU#8$LP']I6PXSSPV ?8GK0 2>.M%A1G
M^UQL%D"':<G.<$C.-P'4D9XZ9XIB?$#0I,8O5Y_V9/\ XFIM;6[62(6UR8S*
MS1J-L94,(I7!.Y&/+!1QV[5(ES-;7GELR-')=&-1EBZ'R/.))+$=0<* , @Y
M[4M1JQ%_PG&BD@?;(^>G4=L^G'XTY/&&D/R+V+J1RP7H<'AL?@>_:G:3J4FH
M^4S!"DT+2*5R"N&4;#DG<1NY(Q@CD#(IWB&*=+.26VF,31I)(2JJQ;;&Y"X8
M,/O8)XZ"G;M^(GY#9O%VDP?>O(L[@N VXY/LN?Q/;O3&\:Z.A8?:T.U@IP&;
M)/3& <CW&0*+F>ZMDCB2:)G,4\GFSXVE4(V@B/9V898#  Z'-%I<7-S><%4C
M-K;2['C/F+YC2;ER&&&^49R".G'7*U0#O^$QTDAS]I&%VY.U_P"+ICY>?PI9
M?%^DP^9NND'E[=WWC][IC ^;WVYQWIEEJKW%ZT)1!&PN"K*.289$B;))!/)P
M<J,8X+#FK^GI$L02-RZJ[C)<R'[QX+,23CW/2GH#*,OC+1X]^;V+Y "<-NSG
MIC&=WN%R1WIL?C;1Y%=ENE(1-[?*_"YQTV^O;K4FO+-:PQM;"5G\X\(ZY.Y6
M.,S!E W8QD<=!Z5'J&ISZ?$%BVRD+.S2.538L9SDQJ 2H! )4'L<'-#\@)'\
M8:0A(:[C!$8<Y)^Z1GTY/L.?:FGQEHP_Y?8O]5YG#9X]/=O]D?-[5,9;EKTH
MC1%!%"S*=P==S."0=N#G;QR.G('<\V5;RYC4C(M(&0')4$M.,XR.NT9Y'2D!
M$/%^D$$B[C.(O,.,G"_@.O\ L_>]JCB\<Z-+TNA]TMRDBC ./XE'/MUI;#6)
M),>>% ^SF0[0Y.52)W(!W<?O0 .O'?.%=]KO;F&=(?+26&55)<,RLNT,6 #9
M4D'Y<YZ#(YX8$?\ PG>BCK=J/DW<I)T_[YZ^W7VIB^/]#;I=C\4D'\UJ]/=S
M6IB5PI=Q+D#=L.U=P ^4L6XX4=MQYQ575=1FEM[B.%561;'S"Q<Q[2^X#:64
M'*[&)+;<$#.,DJ:/H_O$*OC?16Q_ID?XY'\Q4@\8:0P)^V1#&>K8Z$COUZ5K
M)&H QT K'@EFE87#79"BXF5HML94A"ZA1A=Y?Y0?O'G.!C H^_[QB2^-M%A(
M#7L7)/W27'YJ#3O^$ST;_G]B[=\=1GTI+76)95#SI$HEMFGB_>' 550D2,5P
M.7^\,C'TR:CZI>RVE]E8A-#"K -')'A2#N#(P8'!1@I5V5L=AU6H_4MMXTT5
M1G[=#U ^^#U.*D7Q;HS=+^V_[_(/YFKNGQS>2HN1&'&<B+/ECDXQN /3%4M1
MO9+29O+A1EB@,DC,X5MI+?*HQU.PGD@=.:8: ?%>CC/^GVW&.DR'J<=C_P#J
MI/\ A+='&[_3H#M&3B13V)XQUZ=!39_M7]I06\>Q8%@=V )W<%5&1MP.N%&>
M>3U4"M984 Z#UZ4M1&4WC#1U#'[;#\JY^]G/7ICJ>.@YIY\6:0N[_38/E7<<
M2*1CG@8/)XZ#GVY%9L=]=+I2WL@MPSR6S@J2$_>2JKABRG;\K;2<$CGKC-7I
M-7%C$HEAQ(;GRF6,/(N63SBP"(6;Y>?N_>X.!\U,"7_A*](Y_P!-@X7=_K%/
M'Y\GVZTX^*-*Y O;<X7/$J'CGI@\].U3V$BWT"2M%L)'*LK @@D='56QUQE1
MQS@55EEDCNF\F&'9&%,C.VQ_FZD?*1@*,DD\D8XQF@/D"^+=(?;B]A^9-PS(
MHXXZYZ'GH>?;@T+XLTAMO^FP#<NX9D5>..N2,'GH<'\C3(=4D9DS&H62\N(4
MPQ+8B$I+G@#DQGCW!SVJNFL7-S;7#>4L<BV"3QE6,G^L63:""@Y!3ISFEJ%B
MS'XMTB0*1>PC<3C,@'3UST_&E'BS2?\ G^@_[^J/ZTM[+]BM4E$",XDB545@
M.9'5.&*\<GT'X5!J6HR:5;+));(S 2,40RNJE>5P5A/;JS!0#0!/_P )5I.,
M_;[;_O\ Q_\ Q5(/%VD'/^G6_# ?ZY.IQ[\CGKT_(T_[7<-,\<$".D4L<;DR
M;&&55B57800JN#]X$\CTRMM-+=W-Q$Z)Y<,JJK!SOSY<<G*[<?Q'G=[8[T?U
MT 0>*=*;.+VW."!_KD_QYI/^$JTH$@WUN,'O-&/_ &:KEQ:*\;@(A)#$!@-I
M;'&<#\ZSVNUCL$G$(D>01@HQR6.0&Y"$MM&6X7) X%,"<^)-, W?;+?'KYT?
M_P 52#Q/I1'_ !^V_P#W^C_^*JQITXOH%E95!;<"%+, 0Q4CYT0Y&,$%1@Y%
M1W:Q"1(I(D9)RR'(!R0I< J1@C"GG/7''/" B/BC2USF]@X'_/5/\:0>*=*8
M9%];_P#?Z/\ ^*J);IO/$4EM&L;SO;@@DEE6)I%."@&W *D9.#WI]E+)?;+A
M;6,*\!>-S)\X'!C1AL^7(8DX+ <CGN #^*-*A&XWL'+#CSD/7 '&[I^G<]Z=
M_P )3I/>_MA_VWC_ /BJHC5'^RP7#VB?OMGE+O>5@9$9V#;8F*@#(^4-Z$ 9
MPLNI1P6L,XM#O5)BJLDN5" @D'RF<;NQ95R#SSP78/E^/_ *=EXDTZ'5[Z0W
M5LJ-':#<9$C#864DAMQ$A&Y0>F!@=N=C_A*=(/\ S$+;_O\ Q_\ Q59CWSV6
MHW++&A'DV8Q\XV[GF9MYC5PO!9BQP!QZYJ4:JMO=+!#9 1K/Y.]5?"[@K,WR
MQ% N2!RXR>W%# NGQ3I)Z7]M_P!_H_\ &D;Q5I2C_C^MSQGB:/\ QJK8W37L
M]NWV?RHY(IG"\ DY3[RXP?O$@@GKR :T-3Q:0!T12?.API(12SR*@R=K8Y;.
M<9]* (H?%6ERC/VVW (!'[Y,X(!R0<$'/;_]59VM^*-.N["[B6[AR]I*4PX)
M8&/H<CAB<C;R<<]>EA]35/,\^%0$O(XY<,I"Y53',00/XBON.O:M&R9+^!9B
M@VN"5SSE,G8W3C<,-CMG!Z4 9MAXHTW[/$'OX6?R8V):11_" 2?0D]CS6[DC
M P?RXKB]+W>1I862,Q_9;(&,!'+$G8Y92-PP2""#P020>W<T 8EW;RS:K8S*
MK;$ANU9MIQ\QB(!Z8SM.#[5KC(XK+N=,OY=3BN4O)%@5<-$&CVG."?E,))&4
M Y;=\[;63;AS6=,O[VXMY+6\D@1&RZJT8!ZKT>&3)PY/S$KE5&T$[T [&I\P
MI>1_^JLK6=,O[VXMY+6\D@1&RZJT8!ZKT>&3)PY/S$KE5&T$[TV* *\TWD1F
M21@JJN69N% '+$DG@8[D\5ECQ3I>W)OK?.XC_6+VYX&[T[]^WI6VW(-0"&"7
M( 4E7R< <-@'GT."/>@#.3Q1I3' OK?.2/\ 7)V_X%2MXHTJ,@&^M^3C_7(>
M>O//'XU8U./[/;2/"B%D5V4-\HS@Y.=K=B>W/XU17[3I=LCO&DS-<+G,BKM:
M1@BD%($!Y;YCMSC)YZ4,"?\ X2G2NAOK?_O]'_\ %4G_  EFDY(^VP\$#_6*
M?ZU'?W[VH?%M$S06ZSR@R$ 9W_</EG<?D;DA>WKQ%-J4EI*L<UI$ \L>"LI;
M/[V*+>08UY!=2/H>1@9$!!X@\0V,MJ?*NX#MDB?B6-GS'*C@!"ZA@0#GY@?0
M'-:UOKVGW)6.*ZA=CG"I(K,<#)P 23Q5/Q419V3S(%!$]LY)'!*S1X)QUZ#\
M!4NB3RO)+%.Y:1-A8;4"@L"#M*X)7(.-P#8ZYR#1T"QH?;5RHP_(S_JW] ?[
MO!YZ'FI!+GL?^^3_ (5+12U[@,#YZ@_D?\*02Y['_OD_X5EW.F7\NIQ7*7DB
MP*N&B#1[3G!/RF$DC* <MN^=MK)MPY<Z9?RZG%<I>2+ JX:(-'M.<$_*822,
MH!RV[YVVLFW#L"_]MCR!MDY8C_528X./[O3WZ5(DP< X;GU4@_D0,5F:SIE_
M>W%O):WDD"(V756C /5>CPR9.')^8E<JHV@G>FQ2U @-TH4MA^&"G]V^<G'0
M;<D<]1P/P-*]PJ G!X&>%8_E@<GCH.:FI#3 Q_\ A+M(+%?ML.1MS^\&.>!S
MT/O@\=Z>WBG2D&3>P?A*A/Y FKZVD0;?Y:[L_>VC=TQU^G%.6WC3.% R23@#
MDGJ30!GKXITEAD7L';K*@Z_4TB>*M)?:/ML W+N&9%'''7)&#ST.#U]#5Y["
MV?):%#D@G**<D8P>1VP/RISVT,A):-3E=IRH.1Z?3VH H)XHTIP"+V#D9YE0
M'\03D?C3%\7Z.^W%_!\V<?O5!_$9X_&M.*WCA4(B*JCH%  ]>@I/LT7R_(OR
M'*_*/EXQQZ<<4 5K+6[#47*6US%*P!)".K$ $ G /O5[K3414X4 ?08IQH *
M**6@ HHHH **** "BBB@ HHHH :W44ZF'[PIU "T444 )2TE+0 4444 %%%%
M !1110 4444 %%%% "5B>* /+M#D#&HV9QG!/[T# ]>N?IFMRLCQ&0(8,IN_
MTVSP>/E_?I\W)_#CGGTS0!?DM8K@H\D:LR'*DJ"5/J">G2G?9HRP<HN0^[.!
MG=MV;L^NWC/IQ61K"HEU!+(TR+Y$Z[XA(V#NB8#"JP&0#U'./84/?2K>F ._
MFM,A2/;F+R  '8D+QU."3G< /N\$ V(X(X<[$5<DDX &23DGCN3R:3$=TF#M
M=6'LRD?R-,O&*02L%9R(W(520S<'@$<@GM65X2BCC@D:*)HT:0X+HD4K,OR/
MN2/Y005QG )[C(RP!JRZ?;SQB*2&-D4@A612HQQP",#K2SV$%TR/+$CM&<H6
M4,5.0<@D<'@=*L44 5(K:U2XD,:1"8JK2%0HD(.0I;'.#M(!/H?2FVUE96$F
MR&.*)W4G"*B,RJ0"<  D L,^F1ZU6M_#%A;7[ZBD2"9]V3Y<0P2.6!"!@QRV
M3G+;B&) 0*7'ABPN;]-1>)#,FW!\N(Y('#$E"Q887!SE=H"D N& L7IT@F=(
MI0C-S(BM@GY"/G /]TL.1TR/6H6T2QD1(VM82J;MJF)"J[CEL#&!D\G'6J]Q
MX8L+F_347B0S)MP?+B.2!PQ)0L6&%P<Y7: I +AM:@"">Q@NGC>6)':,Y0LH
M8J>#D$C@\#I4+Z/922&9K>(N0P+&-2V&!##.,\@G/KFKM% %0:7:+R((Q@8^
MXO3;LQT_N_+]..E$&DV=JCI%;Q(L@PX6-5##!'S #GJ>M6J*!%4Z39F,Q?9X
MMA?<5\M=I;^\1C&?>DFTFTN%1)((W5!A R*0HX& ".!P.E6Z6@+#4144*H
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MK@]LU/24 5CI]NQW&-<^;YN<<[]NW?\ 7'&?2B/3K>)MZ1*IPPX 'WCEN/\
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M79R%&/F8Y)_SVX'%5/%!VZ?*Q*C;L;Y\[>'4@8'4GH!T)P#Q6J.E "TAHHH
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MU=29L+L\XG[H&"?QZX%7M0T>XN7F5H#)YBP$3"1 RJA0M$H<=25+#@*2W.*
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MGW-3Z,\KF5BLRQ'9L6?_ %@8;E?J2=IPI&3U)QQB@#3HHHH *6DI: "DI:*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!IZTM(W:G4 %%%% "4M)2T
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MS;1N*J54G')"DL0">@R?J:<31F@ - HZTM !24M% !2444 %%%+0 F*,4M%
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M8Q[UKCI6-K)_T[2QE?\ C[EX_B_X]9N1[#O^%;(I@+1110 4E+10 F:6DH%
M"TE+10!E^(LG3+P=_LLW_H!K1C&% ]A6?XD.W3;P_P#3K-_Z :T5/ H 6BBD
MH =29HI#0 M+244 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 T]13J:>HIU !1110 E+24M !1110 4444 %%%% !1110 4444
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MTDA&-OWG)/"\#)P/3L0#0I::B+&H50     ,  =!BG4 %%%% !1110 4444
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MEG<V]Q<1-N$ E+J,%\1EAG&?X@N5R>1CI5I=5LWB:=;B(QJ0&<2*4!.."V<
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MG/'3%6+"S-C&8_-DD&]B#(VYE!.0NX\D#MDD^]6:2@"E=6)N9X)?-91$Y;8
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M%%% !1110 4444 -/6G4WO3J "BBB@!*6DI: "BBB@ HHHH **** "DI:2@
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M%#$9/3\Q4AU"V686YFC$I!(CWKYA &<A<YZ>U4M5TB>^,_DSK&)[80N&B,A
M'F<J1(F#^\/7/04O]DRM(Y:52DDL4KKY9#;XPF-K;\!<QKP5)Z\^B0%^.\AF
MD>))$9TQO4,"RYZ9 .1^-);7UO=LZPRI(4.'".K%3SP0"<'@]:R])T&33';,
MV]55UB+&5G5200,/(R#;C'RJ,\=.09=$T:32FD+RAPR1JJJ) %"%L?ZR60_Q
M= 0!C@4] -*XNH;1=\TBHN<99@HZ9ZGZ5'+?V\$:S231JC8VNSJ%.1D88G!R
M.E-OK+[88#D#RIUDY&0<*RXZCGYL@]CZU4CTJ6(HR/&&5[HC?$7P)I-X PZX
MV]#ZCTH T?/CWB/<-Q!(&><#&3C\14F:R8=%-E/!- V=EJEL0YQ\BL"&RJ\L
M,'C@'/;'.J* &K+EG!4C;CDC .1G@^W>E65')"L"5.#@@X/H:IQ6;Q3SR!(@
M) G0$,2 V2W'))/Y50M?#\D4$<+&,?Z#'%)A<AG4@DD?+N1N=P)R0>W- &X&
MS0SA!EB!R!SQR3@#\36"=%F:.;%M:(9);?*(6"%(F#89O+PQ)R/N# /).*=J
M&ARW<42Q+'%M21&B4Q^45=E8\R02#&5!QL'/?CD W,TH-<[J&A7EPT1213LC
MMUWDJ)"T;$DDF%V.>HPZ]3^-B#29X[_[3LB ,LC,X8M(P*;%7:T9*XP.DF#S
MQR  #:)I*P]'T.?3[CS9G#XB= ^Y-S;G#9*B%3DD9YD;!)ZY)K1U6T^W6LD6
MQ7R 0K?=8J0P!X/!(H L&4!PG.2K$<'& 0#SC ZCCOVZ&G@UA_V/YWV=&MXT
MACBG!AW93<6382  #T8Y(.#SUJA>:)J<TUOERX^SQ(S+*D9C9.78,\,C_.<<
MI@\?-P!@ ZRHXYDF!9#D!F7\58JP_ @BGBN;GT*6*VF@@ACC8RDQRHQ# -="
M51@)E0H/)!XP,9'0 Z-I%C4LQ  &22< #ZT"12Q7/( )_'./Y5SW]BRW%O<Q
M+"(5>.!4B+[TWQL79AM. &) SU.,L.Q2[L9M01(DM1"D<QP@\MMI\O*-L)\L
M#,C;L!CTP">5 .@:X1)%C8X9L[<@X.!G /3. 3C.< GH*DK'%O=!-,#H6:$A
MIBI3;D6TD9')!.688P*V*0!FC-<S+8ZC(+G".&>*;'S1!/-9T\MT(;>=@'#.
M01CY0O"U(-,O$$P <B:25I 9,[E%P-JC+?*6@^48QV#$8% '19HR*R!;S*$_
M<OM,[C9YB[UC="&).[!^?D88D C'3;5+[%J#0JQ2;SET]%4^>.)U)&6 ?:V2
M0V3G@$'GBF!T0D4L4##< "1GD Y ./0X./H:?6,+ VVJ272PR,)8X 623"AE
M\Q6+(9%R I7'RGU'-:ESYIBD\G'F;&V;ON[L?+G';/6@"0FBL%[>\%K<+$DX
M9[?"AYE:3S3D;@_F84#@G! ]!VK5TZ+RH1D2@L26$KAWSTSPS*,XSA>!V H
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M@BRHBAE?=L4[79@P/F21[2 I[-SUQW -RBD%+0 4444 %%%% !1110 4444
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M9Y!_+D4M%% !2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ$0N0R9W9 R.G8D8/MGD=:U%H =24M)0 4444 %+110 4444 %%%% !1110
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M!^7//E9')Z'BMVLC5E/]H:80S#]_/D#&P_Z/)UXZCM^-:] !BEHHH 2BEI*
M&0SK.H=<X89&1C(]<'G%2444 %%%% &)XRW?V1>; Y/DG.PA3C(W<D'C&=P[
MC(K80Y'X5E>+8_-TF\&W=B!FQNV_=^;.1Z8SCOT[UK(, ?2@!:6BB@ I*6DH
M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@#H*45DO?72/$'\I!LAWY60@O(VTJLF HP>F02V0/ESFM5:8#J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BDHH ***#0!B1 G7ICM.!I\//&T'SI, \
M9R>W(Z'@]MRL-$9===B/E.GQC/N)6X//O6W0 M%%% !36Z4ZD/- &-X19GTY
M6;&3<79.#D?\?,G? _E6U6'X,).FKSG]_=?^E$E;E &'J[?\332URO\ K+GC
M'S<0-T..!ZC//'7'&Y6+JQ_XF6F#</\ 73G;CDXMW&<]L9Z=\^U;- "T444
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M5?[4 +10*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH(K(TVQFCN [0^4/WC/F3S4+N=W[L$DIU8O@*,\#<.:V: "BEI* $Q2BEHH
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M>0^G(4D?K6@.E9_B#/\ 9UUC_GA)_P"@FM 4 %+110 4E+24 +1110 4444
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M< $@=NN3Z=:T1Q0 M%%% !24M)0 M%%% !1110 4444 %%%% !1110 4444
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MMN\Q)YKH8U95V;2 Q:0  +N. -H8FFW=WJ%M:Q.98TDBLFFG5E#,[HJDJ "
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M=$R%PH5@"V5 8DD#(. 2=NR>99I896+X5'#E0H^=G&S '\.WZ\\^]K-*#2T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 T=:6D'6G4 %%%% !1110
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MY =&Y<+C![<\<'#_ +.U*[:!66X18U@C;_23#N"-*KL?+=LLP,;'KP" V:+
M=?UI!&H); R0!GO@9P/U-8"0:@[*TJS&3]R582JL2@(F]7C5P"2P?)"-P1@]
M,/$MS)=K"T<X5;B8,^2(S&\;LHR&R?FQ@X^7ID="6 V8[.".1I5C0.X 9PH#
M$#H"<9-.:VAD5D9%*O\ >! (;@#D=^!BL*UL9Y;?[.YG5I]/(D>21I DF O
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MQ]=!:?3\%A_IR_=(#<0RD]>W][VS6S6-KI'G:>-K-_IZ\*<'_4R\_0=3[9H
MUUI:!2T )BC I:* $P*,4M% "44M)0 48I:* $P*,"EHH 3%&*6B@!*,4M%
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M"?3<L5_XF"<C)Y\F7CCUZ?C0!MT444 %%+24 %%%% "T444 )1110 4M)2T
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M24M)0 M%%% !1110 4444 %%%% !1110 4G04M(>E &)H2 7NIL0=QG@4D@
MD+;QD<CZG_ZV:W*R=(&+O4CZW<?T_P"/6"M:@ I*** %K.\0MLTV\([6LY_\
MAM6C69XC_P"07>G_ *=)_P#T6: )=$;=86IW!LVT/S 8!^0<@8& ?H*NU!8L
M9+>)CNR8T)W@*_*CJ   ?4 5/0!@I_R,;GG_ )!:<8XYG?OC\N?6M^L&-)#X
MAD)+;!IT>!_ "9GZCNW'!XXK>H **2EH **** "BBB@ HHHH RM;7?+8K@'-
MXG!_V8Y&ST/3&1[UJ5D:XT<=QIK2' ^W;1DG&6@E"\=,[L8K8H **** $HI:
M2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!HZTZFK3J "BBB@ HHHH **** "BBB@ HIKN$&3P*=0 4444 %)2TE !6+J
M_P#R$=-/_36;GJW^J/'0\'O_ )(VZP=8DVZMI:_WGN?TBH W:BFE>-D"H6W.
M%./X1@DL3Z<?G4U)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !24M)0 M%%% !1110 4444 %%%% !1110
M 4AYI:2@#+T=MUSJ/M>+_P"DT%:M9&BIBZU,\\WB#J2/^/:#_'_.*UZ "DI:
M0T %9_B LNFWA7.1:SXQUSY;8J_5#7_^0;>9S_QZS=.#]PT 3Z8S/:0,Y))A
MC)+$%B2HR3CC/TJR:JZ4ACL[=6!!$$8(8[F&%'!/<^IJU0!BQY_MZ4X?_D'P
M\@_NQ^^DX(_O'L?0&MJLB'/]MS_+Q]@M_FSP/WLW&WOGU[8]ZUZ "EI*6@ H
MHHH **** "BBB@#&UX@3Z=G_ )_U'3=R89<<?U[=:V:Q]>&Z73Q_T_IV!Z12
M'\.E:] "T444 %)2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 U:6D6EH 6BBB@ HHHH **** "BBB@!&4-C(!P<_C2T
M44 %%%% !24M)0 5A:QC^UM*Y&=UUV.<>5S[>G].];M8VJLW]IZ:NX;2;DD=
MR1'@'Z#)!^HH V:**6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *2EI* %HHHH **** "BBB@ HHHH ***
M* "D-+2&@#)T.,1W.I\#F]4\#!YMH#_6M>LG1EVW&HCC_C]'08'-M ?4\\\^
MIYK6H **** $K/\ $7_(,O?^O6?_ - -:-9_B#_D&WG_ %ZS_P#H!H LV*E8
M(@5V$1IE=V_' XW=\>O>IZ@L@!!%M*$>6F"@VH1@8*C)P/09/%3T 8T/.MS\
M+Q86W^]S+-T]N.?PK8K)@7_B=7)_Z<;4?^1)ZUZ "BBB@ HHHH **** "BBB
M@#+U4,US8=,?:FSQS_Q[RX_K6G69JO%UI_\ U]O_ .DT]:E !1110 4E%% "
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #5
MI:1:6@!:*** "BBB@ HHHH **** "BBB@ HHHH *2EI* %K%U(M_:^G 9QY=
MV2,\<+'S]1G ^IY[':K!U61DUC2P"<,;M3QQCRE8?JM &Z*6DI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I*6D% "T444 %%%% !1110 4444 %%%% !2&EI"<4 9>CY^T:B2<_Z:N.,
M<?9H!6K6/H/,^I'YO^/\_>Z\6\(_+CCVK8H 2BBB@ K/\1<:9>_]>L__ *+:
MM"LWQ+QI5[_UZ3_^BVH OP?ZM><_*.>/3V J2HX&WQJV0<J#D=#[CD\?C4E
M&7;_ /(6NO\ KSL__1EQ6I67 O\ Q-[DY/\ QY6@QV_UMQS6I0 4444 %%%)
M0 M%%% !1110!E:L<7>FCG_CZD[<?\>TW>M6LG5_^/K3?^OU_P#TEGK6H **
M** $HHHH 6BBB@ I#GM2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 -6EI%IU !1110 4444 %%%% !1110 4444 %%%% !1110 E8.
MJ@'6M*SV6]/_ )#0?UK>K"U-<ZWIAYXBONG3[L76@#=I:2EH **** "BBB@
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M **6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!JTZFK3J "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@ K)
MNF#:M9@$$BWO,_-@CF#L.IY'!^M:]9%WM_M:RR,G[/>8^4M@[H.<_P /'?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M2@44"@!:*** "BBB@ HHHH **** "BBB@ I&Z4M(: ,/PHP<7^&9L:G= Y[$
M,.![8QC_ "*W:P_"CHT=XJN6*ZE>A@1C:3*6VC@9X(/?K^ W* $HHHH *P?'
M3;=%N\?W4'YR**WJY[Q]&9M%N47.281QUYF2@#H%&!3J1>E% &18N'U:^&?N
MP68_68_UK7K$TR3=K&I+G[L=G^JR5MT +1110 4444 %%)2T %)2TAH RM5!
M%YIQP,?:9 21EN;:7&/3WK5K+U&)I+^P8*Y"R3$D'"KF%@"1U/H.PSUZ ZE
M!1394\Q"N2,C&0<$>XIRC ]: %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!JTM(M+0 M%%% !1110 4444 %%%% !
M1110 4444 %%%% "5B/M_MZ'CG^SY\G'./.BP/PYK;K$P6UX-MX73F&<_P!Z
M88&/^ GG\^HH VZ6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!*!10* %HHHH **** "BBB@ HHHH **
M** "D;I2TAH QO"VXPW6Z0/_ ,3&^P  "@\]_E..ISSSV(K:K*\-KBVE/K?7
M_I_S]2C^E:M !24M% "5C>+]G]FOO!*F:U# <$@W$>1^5;58_BI-]B5P3FYL
MQ@=>;F,8[T :X&.**%Z44 <_HH_XG6KG'>R'_D$_XUT%8.BC&KZM_OVO_HD5
MO4,!:*** "BBB@!*6DI: "BBDH R+Y"=5L6Q)@1W7*_=R0GW_;T]\5L5D7J!
MM5L3M)VPW9R.@_U8Y_/BM;- !1110 M%)2T %%%% !1110 4444 %%%% !12
M*NT8Y/7J<]>:6@ HHHH **** "BBB@ HHHH **** "BBB@!JTM(O2EH 6BBB
M@ HHHH **** "BBB@ HHHH **** "DI:2@ K#\@MXA\[<F!IH0+N'F',^=VW
MKM&.2>Y&,\XW*R41CK4C?NMOV&,=!YX/FN3SUV'O[@>^0#7I*** %HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0'(SC'M0 M%
M%% !1110 E HH% "T444 %%%% !1110 4444 %%%% !2'I2TAH R_#3^9:.<
M%3]KO<J<9!^TR\'!(S]#6K65X:C$5HRC.!=WH&26/%U+U)))^IK5H **** "
MLOQ&H>U0'O=V7_I5%6I6;KPS;)_U]V7_ *4Q4 :(Z44"BD!BZ,A&HZHQ&,SP
M#UZ6Z?XUM5F:2/\ 2M1/_3VG_I+!6G3 6BBB@ HHHH **2EH **2EH R[I<Z
MI:'GBWNOI]Z$5J5F7'_(4M1_TZ7?_HR"M.@ HHHH 2BBB@!:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!J]*=2+2T %%%%
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MMUQJ'3B\'3_KW@Z^_K6K0 4444 %%%% !124M !1124 9D__ "%K;_KSN_\
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MDX?6;P=UMK9>1@\F1N#Z<\^_TK:KG=(.[7-6]ELA_P"0R: .AI:** "BBB@
MHHHH *:N[+9QCC&.#TY!_'O^G&2ZB@!%4(  , #  X I:** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***2@ H%% H *6DI: "BBB@ HHHH
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M[2444 +1124 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M MX<?SS6Q6'X>8R3:D3U_M%QUSP(H@/T% &W12TE !12T4 )12TE !2TE+0
M4444 %)2T4 )1110 44M% !1110 4444 %)2T4 %)2TE !1110 M)2T4 )0*
M*!0 4M)2T %)110 M%%% !1244 +1110 5G>(7\O3;UL XM9S@]#B,G'%:-9
M7BEMFDWQ_P"G2?OCJA% #O#0QI=C_P!>=O\ ^BUK3JCHB[+"U7TMH?\ T 5>
MH **** "L?5,G4=.'FA1ON#LP,L?*(!SU^7)Z>M;%8NI@MJVG<)PEVV6^_\
M=1?E_P"^N?:@#9%!I:0]* ,;PA+Y^FQR%@Q:6X8D=#F=SQGG'UY]:VJQ/!N_
M^R+/>VX^5U/ID[1^ P/PK;H **** "BBB@ HHHH 2BBB@#(T\[M5OSOW8BM%
MQ@#;_K#C@<YSGG/6MBL?2SOU'46XX:W7I@\1!N3W^]6O0 4M%% !1110 444
M4 %%%% !1110 4C#<" <<=1C(]^<TM% !1110 4444 %%%% !1110 4444 %
M%%% !1110 @I:04M !1110 4444 %%%% !1110 E%%&: %HHI,T +129HS0
M5@>%6&^_!/)U*ZP. 2%V*2/8<"M_-8/A-@?M^ !_Q,[K.,Y/S#DY/7MQV'K0
M!OT4@I: "BBB@!**** "BBEH 2BEHH 2BEHH 2BEHH **2B@!:*2B@!:*2B@
M!:**2@!:*2B@!:*2EH ***2@ HHHH 6BBBD E%+13 2BEI* "BBB@ I:2EH
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHUW1R$$.,!03L&XGYL@D!?4C!CO/$(M)440F%9(T.98" O[X1,S,'  "X."
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M\QH6QC<5!;'IG&:GHH"Q2?1K&3&ZVA.!CF)#QG..E-;0=/<;3:PXYX\M<<@
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M HHHH ***3- "T4F:,T +129HS0 M%)FC- "T4F:,T +1244 +1110 44E%
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M))&",8YXP?USQ[TBS*YP-W3/*L!^9&/PK+DT!SC;>W(YYS*2<>@Z8/OS4/\
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M-M!/H/0D_D* '4E-5P_3^5*&!SCM0 M%-WC;N/ QGGC^?2E!SS0 ZBFYHS0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $S1FLFXT*20 17DZ^N79L_D
M5JLWAV][:C)^/F?_ !RC4>G<WZ6N>7P]J"_\Q%_^^7/\Y:>-#U)?^8B?^_9/
M\Y* T-ZBL1-(U)/^8AGD]8L]>>[FI1I^I#_E_'_?A/\ &@1JT5E'3]3[7X_\
M!T_QI?[/U'_G_P#_ "!'B@#4HK*.G:CGB_/_ 'XC_P *1]/U+M?'_OS'C^5
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F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exh3_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh3_1.jpg
M_]C_X  02D9)1@ ! @  90!D  #_X1?(17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  #T)    G
M$  /0D   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,34Z,3 Z
M,3,@,3$Z,#(Z,CD      Z !  ,    !  $  * "  0    !   "N: #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !:2
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !Z P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M,I*:> <=U$TVWY3=SG&PN U<=SF_H?19W_<6BW@?QY0SC8Y,FMA/B6C^Y$
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MR&,<T;'M^TN:YKOS/<&_SCZV?^C?TRM]-LII!]3(:][HK<P/=:18TG>&V/\
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M:W:&N;^Z[9L_0_S?Z7^<3_M/.-;]O4.G.>)],BV&EHC6SZ>W\[Z*FW+S7@6
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M^;_I/YQ-]AR8#?4]NYSI]2[=!&VOW>J?H_G[O9_Q:2FM9T2WT?3]=G+>:01
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M$E/_T/5 G0S:T:!S2?#< EZC_P!UO^=_L24S+0X$.$@\@\)-:UH#6@-:. -
MH>H[P;_G?[$M[^S0?[7^Q)21)#WV?NC_ #O]B<.=/ ^__8DI5H):(_>:?D'
ME24-UO[@\O=_YBD'6]V#_._V)*2)*,O@>W7N)3%S_P!S\0DI%=@XU]GJV!Q?
M &CWM&G\ECFM2HPL?'=OJ#@8VZO>X1I^:]SF_FHF^W_1_P#2"6^V?YO3XA)2
M1)1#GZRV/F$B7#AL_,)*6C7C\[^"FH"=WT8!,S/DII*?_]G_[1QB4&AO=&]S
M:&]P(#,N,  X0DE-!"4      !                      .$))30/M
M   0 &0    !  $ 9     $  3A"24T$)@      #@             _@
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))300*       !   X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -%    !@
M           #CP   KD    ( &4 > !H #D .0 S %\ ,0    $
M                 0             "N0   X\
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   X\     4F=H=&QO;F<   *Y
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ./     %)G:'1L;VYG   "N0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     $_\"E?K4"E
M?SA"24T$%       !     $X0DE-! P     %JX    !    >@   *    %P
M  #F    %I( &  !_]C_X  02D9)1@ ! @  2 !(  #_[0 ,061O8F5?0TT
M ?_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( *  >@,!(@ "$0$#$0'_W0 $  C_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M@0[U?<W][<C;K0"3;7'CM/\ Z441>X_1R*9^$_\ HU)3$VT%Q'VL@MY$L_\
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MMCYA(EPX;/S"2EHUX_._@IJ G=]& 3,SY*:2G__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P R     0 X0DE-! 8
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M24-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D
M!@ Q  !A8W-P35-&5     !)14,@<U)'0@                  ]M8  0
M  #3+4A0("
M             !%C<')T   !4    #-D97-C   !A    &QW='!T   !\
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M0S8Q.38V+3(N,0
M                    6%E:(        /-1  $    !%LQ865H@
M             %A96B        !OH@  ./4   .06%E:(        &*9  "W
MA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:
M  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M     $P)5@!0    5Q_G;65A<P         !
M H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" ./ KD# 1$  A$! Q$!_]T
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M8Y'F$I(61%5B6BJK5D7X?AQ56C\TZ&^NS:";N--7A5'%G(ZI(ZR(7#1H3RD
M5&+\5^'%7)YJ\M2+&\>KV3I-/]4B9;F$A[@4K"I#?%-N/W8^/ J^\\PZ39ZO
M9:3=7*0WVHI*]E'(0@E]$H'1"2.4G[U2(U^+CR;]G%55M:TI$O))+VW1-/\
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M*;G0Y9=<DU6.Y](OI[V"H%W5FDY^KRJ/L_R_\-BJ D\F!?(</E>SNOJLMM!
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ME D+S*I168#=@I+%1[<FQ5-."^'C^/7!:K949HG6-O3<J0K@ \338T.VV%6
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M1V4HNOJ]N7$+0O!?_4TC><^HLK.2!]A>;_W?PX"K,I+[S&#\.DQ-XUNP-_\
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MTA0]/AC0;5+=AXDG&RMHE8U4 !0 .@  &-JV>F*N5JJ"017>AZXJM4/5B6Y
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M8J[%78J[%78J[%78%=BKL5:Y#%6ZC"KL5=BKL5:V.*MB@VQ5Q.*K<5;Q0W7
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M\OMJ-W;+%I.DIZKVEW<2V$SG2(8K@Q0S3%Y/JTCWBLGHO+''_>>I^\AAPW:
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M:Y<FW6"]MEAD2-S,[S!81S!>-&B 6$HZH_IS-PD]&+ABEZ&.!%"*5P*UP3J
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M % I3:TZ4Q%=P_V7ZV/#YG_8MIY9U072R/YBOYK?]JVD6U4'K^W%#$P'V/\
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MFREL7Y0ZQ:W0FAU**^MQ*TQL-21I(V*W33(DC(.<T;1O\37'K/'/%&\7[O\
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M>--0KRT_5JN>( TN^._T1;=,G$$L#*E.X\^:7"T2/9ZH)+A^$2_HR])8@%B
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M_67'=2CAKVM%A_SK6H '[59-.K]'^EX5)6KK^N!5Y^6M0+?M<)-. ^BMYAI
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MB_NM(LH]J?#;0C]2X.(]Z&O\*^7.;']&6G%A1H_0BX$U)Y<>/VM^N/$55?\
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MM(VHR_"W\V*J]G=VU[;I<VLR3V\@Y1S1,'1A6FS*2#BJJLB-(\08%TH64$5
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M#N(CPX<59FXM]O"H#:_FA9F]TZR>U$=QJ45C+'"TU)!]=E,1^ H.2Q4Y\_\
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MT^%88V62>6_XJH9DV]4VX0*3LV_VU_R&QNDHBUUGS',TSVFDVKMU91?$*S$
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MJH);Z ,56M,5=8^#58,>0!*BE.K=NNV!5J7 YLG!QP8+R92 25#5![KO2O\
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M$3R3-\/[LJJ)\(9?MLGV<25M(-0_0<>F:O<S>5K"XGL)X;*U-O$\EN]S=2K
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M2,R_:]1N*(SX5>@+05Q5=48JZHQ5V*N.!6J8JWMC:NPJZN*M$C%7<@!C:M'
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M69?L\EW^+%3BD.BY?/GDGD5_Q%IG+N/KEO\ JYXL#LJ#SMY/8<EU[3F7Q%W
M1_Q/&PR$">0:_P >>2@Q4Z]IP8=OKEO7_B>-J82[E)_S"\D"0(=?TP!@:L;V
MWV.U!3G7?!Q#\ L4/_CSRDDQYZ]IJ1\@ 6NX-EZ\J\^A/P\?M?M?9QXA^ 4H
MA//?DXLP&NZ<%ZJWUR#<[UVY]L;O^PIX2J2>>O)RH#^GM.]O]+@_YKQ12W_'
M7DQO^F@TVOM=P=_]GAW[F-AW^-_*(+ ZS8<DZUNH!U%1OSVKCNJA/^8_DB"-
M6FUS3E)(!47D#D5%3]EC]GIAH]Q^2:*6:WYV\G7&M>63#K>GR^CJ,A?A=0MQ
M#V%U&I-&-.3NB"O[;*O[6 [=#\F/$.\?-.HO._DYXGF&MV*QJ0LI>XC3@S$@
M*X8J48T(XOQR(-FAS]Q3Q#O'S;_QIY/'Q+K5B[ 5")<PL6_U:-U)R9C+J-EX
MAWM'SWY55PGZ3MRQ8JW"5'"[$_%Q/M_P3+@(*17>%%?S$\D>L83K-OZO$.$Y
M5+!B110*\C\/V5^+'=7?\K#\F$ IJD;JVR\4E(/RHI\#B"GA7_X^\J,H87I]
M,[<_0N.(^9].@^G&T\*&N_S+\BVEW!;2:Q%+-=JSVB6R277JJI(;TS;K(K\.
M+<PI^#]K&T4AXOS9\BWC3P6&HM<W<"L7@2UO&*E=OB"0LP'+X3MA6D8OYB>5
MPPC>:Y5V'-0;"^%5%*D5@%0.0Q4"U@_,[R497C6_?G%0R)]5NJ@$ U(]+WR
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M@'%(D*U!WH&E7N?M4R/$>Y!+=OYVD:W]1M!U5Q'R6218( H9"58?W[<>)'Q
MGX<F+[F2K'YLO3(_+R]J@2HX4BC+<>(KR_>T#<O#]C" A<?-ET%4OH>I(*@&
ML48W) %*R]ZFG^QQX?,)I3?SK<+(T:>7=7<HI+M]70!32J[F7X@?\CDRX\/N
M32L/-MP!OY>U;Q $,73Z9</#[D,A1N2AJ$5WXGJ/8Y$(78578J[%78J[%4I\
MU\?\.:CR^SZ+5Q5-L5<>F*J-LK#U"PIR<D;UVV'T=.F*JV*NQ5V*O__0]2C
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MDW5&_1VNZ2K)6)'6X6&YM#<>L\4L(D;X/5MQ&]Q\:IRM_C^'XTPBU,0A+?\
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MI#NWI<?BX-D>*BI"C)KWY?F:TTRVN+ QHQL5E(A*)';O%*;9&H4$<G%E6/\
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MD?[MT^SR_P"+6P"5)Y*C^0O*+2Q22/.W!HU$*74X@$L$20*1$'*JXBB2-O\
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MC1O6+2M%\?-N3\L'$.5K15=+L/ROL=.M9-/CL+6SUADAM7A/%;DQR&5..]9
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M>-=I +M&NA-$'4Q>LVGDF*,V\O&!F_W5)_+AL^2T4&OY<V5G^D&O=2M.<EW
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MDG:8J3&KN[QJ\*PN.1FF<5Y<7?EP^SQB*2G_ )3_ "XLM UI[R"4R0F$*(Y
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MU6OYZ\EH:/KVFI7IRNX!_P ;X#*O[%YKU\[>3'-%US3R0*D"Z@.P[[/TQO\
M%%!(ZK#Y[\C@C_G8=,%?^7R#_FO'B'X#, E2;\PO)"P+,NNV$B,=O3N82=A7
MH7'ACQC\!>$JQ\\^3C'ZBZYI[1^*W<%=S3^?"#?)C+T\]EL?G?R@X#+K>GA:
MD-6[@K4$C^<]>N2(+$$'JM/GWR8/4!UNP7TVXU-U .7P@_#\>X_9_P!? 00G
M9O\ QQY0:$2MK-B!0-P-S 64FE 5#GXA7&I=RV.]L>>?)_QTUBS8ILP%S Q&
MQ\'QHLZ6O^8'DE+E+=M=L%F>G &YAWJ">H8CHIQ(12N?.WDX;'7=._Z2X/\
MFO(<2M#SOY,K_P =W3_^DN#_ )KQX_Q4D*C><?*2BIUNP /<W4/_ #5DO@5V
M4F\[>3@X'Z=T\GVNX/#O\>.]U10YO/'DQ!OKVG+\[N#_ )KQXF0B5I\\^3C&
M9%UW3R!_+=P-^I\!-) +?^./)=:'7].KU ^N6X(^CGA"**=6\\%Q"D\$BS0R
M -'*C!E93T*L*@C"A4IBKJXJWBKL5=BJ6:_4V* ;'ZS:[G_F(3%4SQ5QQ5:A
MJO?J>OSQ5=BKL5=BK__4]2C E4'3"AV*NQ5V*NQ5V*NQ53DCCE5DD171A1E8
M @CP(.*H<:3I0'PV< ^42#^&-E5GZ'TFCK]0MRKNLK+Z24+K3BY%-V7@M&^U
M\*XVM-)HVFQ5]"TCM^4OUA_141<Y>A=^''FQ'7GRY8JB%M8E556-0%V%14[;
M=3@I4'_AW0-Q^C+3>E?W$>]"6%?A_F9F_P!DV2M%.'EO0@W(:;;=:C]RGA3P
MQLK3S?S3YR\OZ/YCGL;S1;=SI5U8J)'2R5S'J%66> ..1] V\@X<EE?DS_#Z
M:X+9 !-_.GF>V\KF&6/1K2^LYK2:\DOTN!;2/]1XN558X'#%S(@A'K*KLS(W
M%?M.Z*8SJ7YL^7=-M]0EM_+O I=S&]5[A[65R\ES!+*R>EZQ?_10./#E%ZB\
M>*1>IC4EH)YK/GR[T[4=6M+#R_$R6<S0_67N^)<Q:>U^62'T)47]U&\?V_BD
M^U_/C1182*Y_YR T?3KO3[75="6";5$ADMBDJR1)Z\H3TY93#%Z;1Q<YV^%O
MY/VN6#=(X4RUK\V-,M=7O+%M!AOH+.>2&%%FC:Z9X'B21C;&-BGJI<+]3^+_
M $CAQ_=^HF'='I4CY^\L3>7]4U^+1$N],A57N[-'C:0V9,ADNX@P ^RB4CYQ
MIRX^G+ZO%7=TA-O,/Y@Z-HVK>7=#N[#T[O58#/SB?FEHY0I"LE%^/U9&])3-
MZ<?+XOC9<";26+\V[R".UF'DZ=5N--?46!N6/&RM@6]9O5A7C'R<AI)!$TG^
MZ_7_ '/-W8F11\WYG6<.MKI>F1VUZ&:SEXBX!41WRRM(/46*6ACD4%59_B^Q
MQB3CR'":94I^7_S(N-5T;S#K":?;37/EGF)[6.ZYK/"8S)')ZB0M KO&O-%B
M]5?CXNR,F$@A;3;1//RWGFA?+=UID$%UZMS&\D-SZ[+/;*9'YQF*$B)A_=R5
MY-\'*).>)BH+%M-_/%-26%[?24M7D*\/K]S':PL1;7$DL/J^E-Q$1@4QR\?W
MS2QK\*\L=TD)I#^<-O=BW>+38X4N%MG17N$-TGK"TE99;<QTC1DO?363U/\
M=;?9^' 06(0\7YQ22WNDV]QI$&G2ZII_U^/](7)MK50\K"/UIY+99$8QPGTJ
M1>G,\G%6^%9,.[+A"^^_-.WO6U^RL=(]7]"+;7 O8[GT(;E?@:;ZO<"&02>C
M))%&X*_&LO[ST\.[':UEYYOB2[U&3]$V4,]I<PVUWSF629))+R2U]2T4QAIO
MB0LW+T>"HGPOPX8+*T$1H'YEZ'?^76UG3M&6SE%_;Z?-;ZE-]6X7%W;QSNTL
MK)+Q"K(J*X1_4^'[*MC96@H>2/S$'F:#4[N+1ULO+F@VW..#F7N9KB&**XHK
M*M&A56^%F;]\LB2,KJ_PI3LJ)^;NF17;VS65E.YCAN;H6E_ZQ"W#11)!;@0*
M;BZ^,2/ GI\.2_O/CR7"4;('0?SC3S+J5@VG:64]*XM;.^MKAS$(IKYYXD=)
M$A9)XVB19DW3E\/#_=F)%*LL_P ^M.(L7O\ 3C;&]N[:-XXR7^K6DL$<[W4P
M,(D$/[Z)!*P]*3GRBF^!LC178)M)^8NK7/JR:3#ILU+BT@6%[A_5C%W=_556
M9%B8)(LBGFM6_:^UQ3F0.]!*46_YWW$T]S9KI=FMU$Y47+7"_5TC=E@@N)Y4
M5XTC>Y=5;@SNGV6BCQD$@A"Q?FO<V5[=1KHUL\D@N;PWXN@MC]=@62.2)6$:
MF9&2+U%8_$L+>MZ;>E@$9;[_ &*:1VH_GA)#=W5M%Y?69;"UN;J:\M[N-X2]
MO+<P)''6)6F64VO)9%7]O[&-'I2":5O)GYN'5-?T_3]4TNVTJ*\MVCN&DNXY
M9H[R.1^,+1*.4+?#+R^L"/[*_'_.+*BF3^;O-%_H=S=QVEO;77U6QCO2EPPB
M5O4F]#B"J,>7(#C_ *_'^7) 6$%B?G+\^M'\J>:;WRW=Z)-<WT,]N@>"12DH
MF@261D!7DK0\XU6+_=OV^<> "3.AS1$GYHVNG:9=M=:?8W04NUW+I]^\B2QL
M+;:T8QEYI^%ZM($:/XHF]-_LX[H-!)KC\YKFPL[W79-)A_1=GZ<5N9)+A7-S
M+ITFI!&(1HFV?T/M\H_A=U^)/3>';S_'])0F?E_\U!JGG_2=*FTZT@COK5A;
M7 G>21I'1YN"<(5_9A;U!<A$^'G!)^P\B$"Z3?\ Y6FMOM?:1&A]>[M_4M9S
M<P#ZE=06DDDLIAB]*/G<GXF'P^GQ_:^&-%(I V_G\2^3;'7EM;&$ZA=16D/K
MSN]K:)*AE62[=H@45>'%'X?&SQMZF$@_@)V0/_*VHX93=6FFV=_ZLOH>AITP
MDN))!+!5BIAAY13F[Y03<4?E]K^]QD"II%?\K?U"Y9WT_1;>2UFTH:M8^I)+
MZ[HUW]2$;PI%R#F8JW!?C5/@X-+\.  L;"G)^>5A#/#%+I1]6739[]B&D,7U
MB.5UBM?6,*B-W@BFF?U(UECX>F\/J8>$IL=$=<?F.?K:O+I5LZK#=2K<6FH^
MM!+]4*LD4++ D<KSRO J[K(G/TY%_P!UR-% *47OYY7MM%(B:):7-Q/)$UF;
M>26>..!Q-5+DQQ,WUI/JLA:*$?\ )B3)"!9;*.F_GU<W23JVB6BSHSB.EVLW
M K?0VI$P@B)X$7*M#*G/U?3PF!'-=NB>:+^;C7^N:AI<FDQQ_4["34%N%<\&
M,$,,DD862*)B#ZZ\67F\?^[T16CR)CW%4LM_STCO6A%CIEMZ<1@;44O)?J]P
M5D2V$D-M%P;UKE'N@]/A3T57]J5>(HI(3W7/S)T[3O,V@V<-J+R+6'FCN[J#
MU'2"V6OU:X)8)!&LLI^)F_8^S(V1I4IL_P [[:7RN-9?3+%9WU2UTP6K79C]
M 7Q+0R74CP$1A$X^HT?K1O\ O&1OAXX!:"D__*\+];>[NM+TRQ;3HS;KI]O<
MR2B=WNB@),I#+)'R=Y(^'[V1./PI]G+1$GK^/FQ)'<G$?YP7;Z<MY:Z;87%8
M[5883.QNWFG^K<I/JT<'J?5Q]:^!XP[.T?V/BR)!"1()1YD_YR#CTVVL[V/0
M[>YM[B)FN56X<D!4MF:-61*++RN77E(B>GZ?Q\7^#" 46$1IOY\RRZ38:G/H
M]D+?4#<2_5UNWCG6" VX"1B6/_2+HFYKZ47[ME3^\7]F)V6[3_6?S?TG2O.7
M^'&TI[BY$JPI)"PH#,]NBB5" $JUQ_>,?2Y<4Y_O,&Y2 A+K\T+]VU/4-)M[
M"33;']+(L,K/+([:1!ZOJC@5])9VD561DY(J_P"6N2HIV2NP_/T_I3_#VHZ5
M$VMO]7:.:P+FW$4\@CED/K)ZB&U#H_QKPE^+[/P\DQ6V3^8?S7MO+^MRZ;>Z
M21$FIV6G17(92&2Z4-)<-Q4K&L=>*(SJ\C<OV4R*0]"B:VF16C5'1]T<4(8=
MB".H.%"\VL'>-2?]48TCFU]7@'^ZE_X$8;13?U:#LB_\",;2'?58/]]K]PP*
MV;>#_?2_<,54VLK<TI"@(^R>"[8;6E--.@ 7]VO($,S!0A9AN2>-.IWP*BT4
M(.(% .@'3"J[%74Q5V*NQ5V*I9KW 6L!8*P^N68^*M*FY2G3N.V*IGBKCBJV
M.O'?K4_KQ5=BKL5=BK__U?4HP)5!TPH=BKL5=BKL5=BKCBJVHQ2ZHQM6Z@8V
MJU9D<&E?A)4U!7<&G>FWO@M#C-'6A8 TK0D T/?"K7,5IOC2%W($'%*67/E[
M1+ETDNK**YEB:*19)E]1N<((B9F:K.R<CQY?M?%]K%5==)TQ$B06L(2!#% O
M!>*1FE44$;+\*[8VJ"NO*^@7=Q%,]L@,,KSE4"A6E9N1D?;^\#[\_M_$Z_8>
M16-K2+_06DF2:4VL;R3N996<<B7,9A)J:T_=%H]OV/AP(I"V_E/RQ#"D5MIM
MK%"KF5%CC15#&NXX@>.*T%9O+^B&_EU![.%KN=8UDF9 21"Q:,[]T;H?]7^1
M,-HX4))Y2\MOID]A]5C2UEB>!BE%9(F);@L@^)50GDBU^#_5R-[LJ3#ZGIT5
MOO$KJD:*6"!W98A\->(Y/QZJ/^!QM:5_JUN>J*1P]/HOV/Y>GV?\G&UI C0-
M!42!+"VB]5_4=TB1"9!0<^2@'EL/BPVM.ET;1FL;NPEC0VFH!UN(MD#+*.+)
M5>+4/(T^+DO+BG[*XVJM;:1I5K<M=P6L*7<BB.2Z"#U61=@K2?;8"@^TV*NF
MTG298Z2V<$J4^PT4;J*;["F-*N73M.:87(MT]5D"%B@!*@@BJD?LT'&OV<;5
MTNF:7,ZO+:PNRIZ*ED1J1U#<-Q]GDH;CC:KDL+%!1(8PFX5.(XCF:L .@YD5
M:GVL3)0HRZ%HDMS'=36-N]U#S,5P8U]1#)7GQ:G(%JFN"U6-Y=\OR6YMY-.M
MWA:G.-XD96*A0"X(/(T1-W_D7%-(F"VM;6(1HB)$0$("JH:@"*"  .@XC_@<
M;52_1&CIZ)^I6Z?5F,EN1$@]-CU9-O@;_*&.Z*5H[2R&Z11@@@5"KU3[(V'[
M-=OY<5I:^FZ:THF:UA,HB,',QJ6])J$QUI]@\5^#[/PX;5M+'3P2Z01?&P<N
MJ+NP-0U0-S45Y8VM*#:+HZ1W'"RMU6Y#?646-$$O.G+F0-Z\1C:H+2K'172<
MB.VDYS/$!Z2(.$=4]/@1T3]XO_!?LMB2J8C2]*!6EG!6,%$_=I\*GL-MA[8
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M$D*G-M^6=I;>7-)T*WE:.+3;QKZ.[HID4RR2231C_)D]5XW92O)&Q04JT/\
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M/+\KN21P%U:A@!2A)+\=_;%5,ZSKJN)6T&Y5I>,80W=L5!'(B@#D MR^)O\
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M4J&+<KJ&BD= :5^U3]G!224,^M>:@D3'0XH3(0KK->Q *S;  JK<N1^%?\K
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MZY7\TGN;#S)<1J=.TE=6T?3G6V>2YM0J3IZQ172)&F9_02A65##+'_JKA&
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M7#/.!$L^J2(+>.:5(BUR)V!C54<7!AE62WEDX-$WV,>%EQ <UC^9-1>]=/\
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M4!C2J4GDJ>=Q(WF'6E85H%N8E'AT6+CTR5IM<_DNZ*D+YEU@$TW,T!IQ-?\
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M?[O_ ";#DCWA 4-:_+[5+O2WL]-BMXK=TNEM;:XO;M3&]Q0QW<CK&TDL\?\
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M]2I]L_,X$JAZ84.'3%78J[%78J[%78%6L U0?NZXJH16=I#'Z45O&D8K\"H
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MK<VJNX9B&;T"4;;X_M-\>**5=!\KZ?H<<D-@9E@?TU2&25Y4B2) B1Q!R>*
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M@AU28+$7M85A')."D?6XVFXE?3C3_7XXD!65:;H5[9>;=3U Q226^I")C/\
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M$)4.D@5DJ.2NNZ2.OQ+^UBI2Z/RE;+JD>IM<R-=1W7UDL>)YD6JVE&^']J-
M[\?]V?9QM4OTG\M]/T?1]-T_3;R6!])EDETZ[*1-(@G#B6-JKQ=6$C]1R7!>
MZ*58_P O-%AEA,<LRPQ*G.(%!ZCQV\EJLDC!0Q;T96'P\?LI_+QR0*D)'Y=_
M+O6X;F>35;BW>)KA1;QJJ7'*W@MGMXO7YQ1<VXNGP?L^G_>.LF2-#D@6?Z+.
M].LOJ.GVUD9&F-M%'")G^T_IJ%YM_E-3XL@63'KOR!8ZCH=WH^JW3WL4US)>
MV[T,+07$DCR^HOHLA;C+*S*K-DN*DVGD6G7%MH\5C;W%9H(%ACG8"K-&G%6(
MZ5J%.10\^U+\I]6M(=-;R_?JUQ#/:_I)KODRS);S/-Z_%S*GJ!I&_<*$A=W:
M3X,DD%DDOD0\],EAOD673I;FXY2VL4RM+>.7F9%8CT0>3A OV%; BTS30[Y-
M9OM3CU!%-["D B^KK\(A]0Q,7Y5<HTSUY?:^SC:J>D>7M1TS3-)T^+4N<>FE
M(IIO117FM8(FCCA.[!?C]-WD_:XM]GE@M4WN(99+22&&9H)61EBN*!F1B" _
M%OA;B=Z'%6+/^7@ET/\ 1MQJ3RRAK@_7C$OJ,+R)H;@R@D^I)(LDAY_#PY+\
M'!..%4RL_+'U2_T^XM[E8[;3;+]'PVHA4DQ#AUE9FDV])>(_9^+[6*HQ-+EM
MX+L6ER(KR[G:X>Z>,/NQ  *57EQA5(5W^RJM@5,: BO4?PQ5C!\F37'J)>ZI
M)<Q'4H]1BA,2!$6&2-UMZ?%^['I?\._P_P I5+E_+AOTO8W[7O%=/:&..!5=
M(6AMY&EC].&.2..*2LGI-R$W/@LG_%>(*60^9=$BU31+NPYF$2\90Z1B6DD4
MBS*WI_[LJZ#DO[>*L;T;RAJ%WI.CFXNT18],M(7D@A5)5:-Q*OH.3S@*I1"W
M[7V^"M@(W5-?\&D6-[81W8AMKZXEN)A'"JR-ZUV;F1#("& *,UN&7C(B_O8W
M615R(!'<MJ-KY0N=-L](@CO#<#2)7<32I(TLJ3F12C&,F3E&LWPOR;E\7J?M
M9(!";>:=%?6O+]]I,<J0M>Q&$RN"P"DCELI5OL_Y6$*"PFX_+'6VO;+EJL;:
M;:W3ZA#:O#),T%RUPERWIR$^M(LACDY_6)'_ +YT^+]WQF"$&U8?EU=W.I:Y
M=17,=F-8@93+ DR2$/)$\?JK-RC6BVYBDAB"_#+^\3[.1L!EQ$LE\IZ%<^7=
M#6PF<7 661SZ52J(^X6*-44!0?V$1?M,_P#-@)LVJ0>8_P OK_6+C7FFOY8K
MK5XQ;Z9) \HBMH"(TE#KQ*\G2/XJO^\66:*+T_B;&UM#67Y8WBVFG6ES!8/:
M07-U<74)DN&5DN55##&%])$1E+2>FB)#ZD</[MG_ 'N*+3:X\FZQ-=^966>V
M@AUH1^C(H<RHUNB*G.G'X9*/SXGFO[+_ ,J%2FZ_+*^O;">!C8QAS<);VG"<
M6=L95C FMX2P^(/$S\?VFDY(ZH[*\K5G&KZ5-?:%>Z=!<&TGNH)(5ND Y*[I
MQY[CQZY#JK$V_+[4)](DLKB+2PC7EI=QV"PR-9QBVH9.*$_:N"*/M]AOBY83
M2 SFS@,-G#"Z(I2-49(@1&*"E$!WX^&!+![3\MH%TR+29++3X+&"_AO)/3CY
M?6TAE>6DJ\55=I J*?4X\?\ *PDIM;9_EQ=0>8K76&EB4VL-I#;I \R"!+,L
MOIH6YR2)+"W%^<GQ?%ZGJ<EX KQ,D\Q6%[J-K%:6LK(RR)+- >2PSPJU)())
M%'PJX/+BIY-QXMRBYXA 8U?>3=1E:WBMYXK.V5(XDA+W,GU?T9V=W@+? \LT
M,GU?C(/[M.,'[GU$R5A*&;R!KLUGJUK//%-#JEG=J]I-=74R"ZFGE])T,A8Q
M)]3D6WF:(*W'X?V<C:$8WD_5[XZ%#+=S:;9:4TS7^GVU[?D312!A!&MR'A+B
M$A9/CY/%Q6+^[^U(2Y\BJ'A\H^93=:C?077Z.,\-Q;6Y@ENOCC,RO;<H)@QM
MVC FCD>'XF^LR7$?'!\;_P T>G_?(!/<IWWDC7KJ+2YK=)(IM(NI)%L9-6O@
ML@:W,:O]854;^\/QH$XO&\J<EYMDAPVN[/YUO7T^1$XK>-"54J2$$I7:AH:+
MR]LKID\VE_+_ /,#_#UC8#4R][#-(=1N!?7?*[K"%BN#(Q]2-HI%_P!Y@WU?
M_=GVLF %)7OY)_,6#7OKMIJ/KVHD9WAN+^Z,<JR0\'#6]&A3]Z[R\4'P\5X<
M/V!88M1^4OS+E\GZSI-]<HVH74D+Z7<0ZC=(T)")ZK-*RRR<4D3E'%R9)5?]
MYQQVZI!3I?+WFY_,DNH_67CMI&LQ&HOIF6*%8&6\'U7A]5>1I>/"3A\7]Y^[
MX<7&R;5/R_\ +_FK29;W].74EQ%(D:VXEO);MPP+%]W5!3XAQ;BK?S8=D;]6
M; UP*["KL5=BKL5=BKL5=BKL5=BKL5=BKL5=BJ7:W$)+: $5 N[5J TW6X0C
M]6*ICBKCTQ5 :7--)-J(D8L(KHI&#^ROI1F@^ECBJ/Q5V*NQ5__3]3#[9^>!
M*\],*'#IBKL5=BKL5=BKL50>K2WD.FWDMC&)KY()&M(3T>54)C4[K]IMOM8J
MQ23S/YHN)PUA:4M'EN!"TUI.KF..T]:.H9D*DW :&K*O/]E?YFZ4ATNOZW+-
M-#>&2T@D@)CMX+&[:9@UIZK2K=(_&!EFYQK'Z?J\D5?M2+C8I:W26X\\^<M,
MT4H^GSZAJ4%%1TL+@))_H*RJLGQLPD-R6C+IS5_39?W7)<8BTHY_./FMKN^E
MM+-I[&.>:"PMGL;F-W5+,S).TSL!P-R!!Q])>7+X<"2$)_C;S=)ITTMHJW(@
MOS:O?+8W"T1;2*<![4NTU6FE:+U/\G[/Q\E(""F%EYC\QW'F/28;U)+>%Y)A
M<6L5I=",(UL6BDDN6K$4:3HCK&\;,J/\:?$TK+-%UF'6-,M]2MHY8[2Z3G$L
M\;12TY$59&Z!@.2_S*V1*&.7WFC7#YQ.AV5NZVK1.C7<EI,RQS^CZJ.) PCD
MBZ+_ +KY2?N_4Y)DJM4P\E:MJ5]I/^Y.<S:A'Q-Q6RGL0I8?9I+42GDK?''\
M/^3_ # BE0&KS7 \[Z<D<]XEL8I_TA#$+PQ<?0D,;54?54 (_9Y7/K^BJK]K
M"FT;Y%U$W6CR(S7<C6]U=(C7T=PDIA^LR&W/*X5'D!@].C?%\/V_BQ.R&+7V
MM_F#;^9IFB5V\M6^J SJL#RW;P+"Y:&("/BT#%5E253S5_W'/XTP\-I4K?\
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MAB4)'&@"JJJ**JJ-@H'084JG+%7$XJZM<4M-TQ59'+$[.BNK/&0)%!!*D@,
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M:PD<1S'_ $E 2\2J$+.4"L69 RJJMC:\*DGYE>16N1;?I>)96;TUY+(J,]0
MJR,H1^5?@XM\:_$F%4)=?FY^7]K(JS:HH# MZB))(@4*6#%D5A\:[QK]MOY,
M%IX2KG\S_)["X:.]:>&V6U:2:&&62,B]E,,)1E4^K5U^+TN?'_@L04<*]_S,
M\BIZG^YF!_2KZGI<Y:!1R+?NU:JBA7FOP>I^Z_O/AP\21$E6TSS_ .4M2NHK
M.RU*.:XN*>@M& ?D"RT:G"KA7X*WQOZ<G%?@;'FIB0A-6_,GR1I%ZUK=:@@O
MS(L<ENH(EYT8#X&XU^QQ^'^9/]^)R:12YOS,\EL\L2:Y:1W%O))%-!</Z$@:
M$@2+Z<@60LO*@HOV\;4A?%^9/D=A<M^G;&EKP^L_OD^ R,$6IKW=N&(W8[=Z
M/N_.'E>RNI;6\UBQMKF$*TUO-<PI*@?[)9&8..7[.V(W.S*EB^=/+#FZ*ZG;
MF"R,0NKOU%,"--RX*TH)C4_!^TR_L?SKAHH#O\9^5/AXZU8/S9T2EU#1FB7G
M( >76-#S?^5/B;(\2:0-M^9ODJXNC;Q:K S>IZ<;AU,<E#&"R.I*E.4\8Y_9
M^UQ^P^#C4Q3&/SIY3D0R1ZWI[(%5RPNH"H5R K$AC\+$CB</$O"574O,VB:9
M*(;Z_@MYCZ?&%Y%]0^M*(8CZ8^,AY6]-?A^UAHH4V\W^7%OIK!M3MDO8 QDM
MY)%1P(Q5Z<^/+@/M\?L_M8.)-%N;S9H5LEL]UJ%O$MX\:63<ZK.9VXQ>DU*2
M\MN7I\N'[7P?%CQ(1EOJ^FW*Q-;7<,RW*-+;F.1']2-2 SIQ/QJ"0"RX@K3A
MJ>G&=X/KD)G1"[P"1>80 $L5K4+1E^+_ "LE:TU+J]C'1?K$7J./W2EA\=06
M'$"I;96-$&*K;[4].MH!=74Z1Q(ZH92=@TCB)1M7J[*N!56>;@5)F],48$_"
M%W( -2#\0_9_9_FQM(W:,ZMZ?^D!2IJ0"A+@ BAJ/?E\/'!Q!:*VZUBPM #<
M7"1\@[(":DK&A=R *D\4!;'B0J27]I' UQ-/'%#$*RRNP14![L6-%PE5\EU"
M@JTJJA(4.2 *MLNY[DG;&UW2W4+M8'AM%NXHK^X+M;6[2(KSE!]DJ59O3/\
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MM)IH[\6'.-I+;3C<.'3]WQ^LR^C)!Q^W')*O^ZN3O".:^*>]?J5ZFEWC&_\
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M6M01XRITI\\4>)'O"&_Q?Y)BK(-9LPCD$<IU(J.G&K;+_D#X>6$"^A9@J?\
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M^O:U<N[K'<BWHJ6B22-),3.97=HY7^S"J^O%@I-TPCT/SSG_ $78F"]L;&S
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M =E%=CO0 4K_ ).*5?D,4)/KMZ89])18T?ZQ?K"Q<5*5AE;DG@_P4K_*S8I
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M-^+/4DP=.*TV5OB_R<(![Q^/BQ/DZ6]\WBX01Z3:M%5QS^ONHH.G-?JI;?\
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MUK7K3S)YS6""3303HVA6<KRP6\C_ &IYI&"B>Y ^")T2-(T_9YX*2&=+4?+
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M-YNT%>LLO_2-<_\ 5/!:VL/G7RZ.LTWT6MU_U2PBT<0:'G;RY_OZ?_I%NO\
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B8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exh3_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh3_2.jpg
M_]C_X  02D9)1@ ! @$ 9 !D  #_X1#R17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  #T)    G
M$  /0D   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,34Z,3 Z
M,3,@,3$Z,#(Z,3<      Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   ^\
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MSP#$M:2)3-IR63MN;K^\U[O^KO4MN9_I:_\ ML_^EDE*^T-_T=G^84OM+?\
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MFD0/!22224__U_5!PAY7]&N_J._(40<(>2?U:T\>QVOR*2E-H(U]5Y\B0?\
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M ^T      !  9     $  0!D     0 !.$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-! H       $  #A"24TG$       "@ !
M      (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      T4
M   &              ./   "P     @ 90!X &@ .0 Y #, 7P R     0
M                       !              +    #CP
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   #CP    !29VAT;&]N
M9P   L     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   X\     4F=H=&QO;F<   +      W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     3_P
M        .$))3004       $     3A"24T$#      /V     $   !\
MH    70  .B    /O  8  '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MSP#$M:2)3-IR63MN;K^\U[O^KO4MN9_I:_\ ML_^EDE*^T-_T=G^84OM+?\
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MFD0/!22224__U_5!PAY7]&N_J._(40<(>2?U:T\>QVOR*2E-H(U]5Y\B0?\
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M(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, ,@
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M65H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M     /;6  $     TRU(4" @
M                           18W!R=    5     S9&5S8P   80   !L
M=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP
M   48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9
M TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C
M:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,
M=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O
M;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M   2<U)'0B!)14,V,3DV-BTR+C$
M                                 %A96B        #S40 !     1;,
M6%E:(                     !865H@        ;Z(  #CU   #D%A96B
M      !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@
M                9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                 &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<
MG@    %865H@      !,"58 4    %<?YVUE87,          0
M              */     G-I9R      0U)4(&-U<G8        $      4
M"@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W
M 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4
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M(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/
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MM@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7
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M@EW,7\U^;O*LWF3RB\6M63I!?S23LMS"5539RJ"YY;#DU!D3ECWKPED!UO\
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MA^5GY>#IH5L/H;^N/&5\,-_\JP\@#IHEN/H;_FK'B*?##?\ RK+R%_U9;?\
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M+_N*0?\ 5/!1\E]']+Y1_P"+7?XB_,?OY.C_ .XG!_S1AX?ZO^R_4BX?T_\
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MW@5W7%5C1Q\2.(HWVA3K7KA5#);Z;$%1(H8QR(5555JW0T [XVJMQBH(RJD
M#X*#H/L[?1M@5T5O;Q%S'$B-(>4A50I9O%J=3A54'7%6,^0S6RU4]_TQJ/\
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MP@B%*(H"L7&PV8UJ1[FO7 K$_)EC92+J<TL*//%K6I/#(P!=3Z[#DM?#D?\
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MSUIG_5OU;_N%WW_5+&BCB#O\=Z96GZ/U:H_[5=]_U2QHHX@[_'.G?]6[5_\
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M=$RD,W.ZF>>05 7X0\C<?\G%4QH,5=3 KL*N.*L:\M4'F7S=_P Q]M_W3;;
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MC*[L(TA?TW=R%6NW0DT_:I_K85;^NV9C]03QF.O$/S7B2=Z5K2N*7->V:3+
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M922):@5^&W$\7+_BS&DVF?E"*[2SO6G@>VC>[D-I!(Q?C"%50%)WX<P_$?\
M ?!QQ0IZU87:ZQ%J,%LMS']5DM9JN(VC#.K^IO\ : X_9^UB$AAWY2V.HS?E
M%H4=DLEK<WFF7$<=Z9V(A:0'T9!'4_M4:-5_N?V?MX2I9GY4L+FSAN?7LGL9
M)I!)(C3K.KR%?WD@"_"A=MW_ )LC2&O,FB_79[%H[*.X5KF/]),Y4<K9(Y4X
ML&!]0#UW^#_6PA5:"UU9;MVF<LK7C21R!SP%L8Z*ACJN_P"S^U\?[[XL2E=)
M;Z@+)X+.,VTGJF1)9':4 M<EV)4.C,K+\?#U/LMZ/^3@0E0M/-0L=,$]NEW=
M6M])<3$RJE(5,JQ**\ZN4=.K-_E/A96&6AJTVZXL6\5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BK_]?U+7XQ@2J84.Q5V*NQ5V*NQ5V*NQ5V*M=\58AY6,S:
M3KP@F-O*=9OU28!6*DW%-@X*_P#!8E*).K:QI^E@F*75;\W!C:)E2.6*-J\3
M*MNLOP_#R#1Q_9=.7[6 !5:'7-5N=5LX+6WMI+&XM!=2RF=N:GU K<.,;+(
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MO>WP.W86$A.$*SA<5;.%6L5:Q5L#%6\5=BKL54+W_>2?_C&W_$3BK$?R7_\
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M;3R+>)(8FM6$+^HZ. [2N%"B)%^TT(C_ ."^'%*>?68/K!MO40W 02F'D.?
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M3IR%1\4;%'&].C*1@55]11L3OT ]^N-JWZB;U[&A.-JHSWMO (S(U!*ZQQD
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M>G+_ %^>*H_]$VGU]+]@[W,9<QL[L0OJ *P4?RT&R_9P6M(FRM/J\7I^M),
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M=W$4D'IV\8C,-P'!]3D#R'$49.!'?[7+ JQ-<TAK(7JWL+6A<1"X$BE#(S!
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M(&V]5U90@#\$"*BI_=_']K_6;8\.]J-AY6CL_+MGHR3+2S:V<3K&%YM:R1R
MLM3]OTN)^+%D45>0ZL^H:<+>58K*-I)-1H%/J#AQCB4,&9?C;U&9?Y/M?%BJ
M3^5X!<1^9X&=D6;5;N-G0T=0T42U4]F';%5*W\DL6E%R;6&)[>*S(M(FC>1(
MIEE,KR!E82/QHJ#EZ3?%ZDWV<(-( ;B\E/;V=HA:'4Y[*ZN;F-;T-P*W1;X"
MS?6'_=AAO^VR_L9(3-]W]5C*%CE?]9%7?EAYM<BU%7/'UHYI:S3+P]$? JQJ
M>$E3R^UZ:IR^Q+D65;HS2M"2RNVN1;VD3^GZ+2P1E99!4-R=B3^UR^ ^I_/Z
MO[.*(BN@83H>F_7OS@\Z%F40VQT6?B54DR+:3"-A4&G!FY?#Q_X'(D,[98^G
M^8O1LHE@L)'A,;W$\\DLDA:%J*5;TJLYC_W<QY([-\#_ +1I MA7FNQD7\R?
M)\,EE"D#ZI?2BY1"!<&6PE($O*O)TKP^TZM_+'_=8:3;,&\O7U[:W\6H6EE6
M\EAG]."250TD8"LTDGIJS'X%WXMR^PV.R 2Z#RW?VUOIC\+6[O+%)XW2:J1T
MN)%D^%E1C6+@$!]-?4_O/W?V,"EDA5B.F].A.U<58^^@ZK=6=\+QH!?W0A83
MHSLM8)#*D-"J<(DZ*WQORDDD;%41#:ZM9!3;QQ/<:A?^M?L6+111$?$4V1BW
MIQ)&O_%TG+^[Q5/#TQ5*DLM4^L373K;_ %IHI([:3D[+'\0,:\>*_"U.4S<N
M7PJJ_P"2JLU33M5U#1;^SD:!+BY!2!EY\%2@^T34EJ\N@_EQ5VJZ0]W=Q720
M0_6X8S'%=L[+)%ZCKSXT5E8<*LO(?WBI\/\ *$VEGY80F'R-IL1V,?KI3D7^
MS<2#[;?$W^LWQ-A0F2V+7'UZWFC^K1O=),)(/A,Z 1L>9-=WX>E+]G]WC:J^
MB6$VGZ1:V4SB26!.+2+T)J345QM4H_1@G\P7$MF?J\D=U;SW4_*XY.$C96C5
M'40A7KQ;TG_:9W^/%*71Z'K]O-J]Q,[)9RB.;TRRTEEBN#)+2.%2T<=Q%2,<
MFFD56^+[/Q*[+?T)J%]HT#1I<" 7=Y,ED)$C9HY)G:"0_6$<_NU^RG)./+[+
M8!LMWS1SZ!J3ZY87+K*XLA INGN%9'")^\+*%CE]1F\/W,GVY$PK:?Z='Q>[
M?ZN+?U;AGJ#5I:(J>JP_9Y<.(_R%5L4(_%78J[%78J[%78J[%78J[%78J[%7
M8J[%7__1]3#[8^6!*_"AV*NQ5V*NQ5V*NQ5V*NQ5U<58YY)/^C:O[ZQJ'_)\
MXJR(]<5;.*M#%6STQ5;OBKL5=BKJG%7;XJNQ5V*NQ5V*N.*K<5=BKL"NQ5V*
MNQI78TKML:5K?PQI6]\*MU.*M'%78*5V*NQM78VKAUPJW05Q5Q&*MXJ[%78J
M[%74Q5C'DC>3S%_VVKK_ (A'BK)Z#%74&*M<1BK?;%7G_E#_ ,FS^8/M'HO_
M %"RX>B6?@=\"VP?STO_ #NGD'_MIW1_Z<)L4,YH,5=3%78J[%6B-ZXJX' K
M>%78JT32O8=SBK&?RX99/)=BRD%6:X*D;@@W,FX/OB59(%I_'!2MTPJUQJ=\
M57<>W;%6N&_7%6RN*N"4%,5;Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]+U
M,/MCY8$K\*'8J[%78J[%78J[%78J[%6AUQ5C?DQ@MKK#'8+J^H$D[?[N8XJR
M&.:.4%D8,!UH0:8JOK7%4);ZI:37-S;(S":T($X='0"HK56<*KBG[2%L"TM7
M6M-:TBNQ<Q_5IS&L4M=B9:<!_LJX55_K<-4!D0&3^['(?%\M]\5:-W KE#(@
M=069*CD -Z\>N*M"]M67F)HRM:5Y+3EX5KUQ5=]9A 6LBT<\4-1\1\!XG K8
MN8C(8ED4R#[2 @L*?Y/7%5EEJ-G>HSVTR2JK,C<&#49&*,#_ +)2,*KKN]BM
M4YR!R*,W[N-Y#114[(K8JJ0S130I-$ZR12*'CD4@JRL*@@CJ",567EY;V=I+
M=7,@B@A4O)(>@ [XK2'_ $Q8^F7,E")/1,?%O4$G$/P].GJ<N!Y\>/V/C^SB
MDAI-:TJ2,RQW<+QA4<N'4CC(YC0UKT9U9%_REXXH5EO(6NGM5:L\:+(Z4/PJ
MQ(6I^SO3I7%5 :WIS1W<D<WJK8R&"[$:M(RR@*QC"H&9GHZ?"@;^7[6!--?I
MO3O2@E$U5N"5C 5^0*_:YK3E'Z?^[?4X^G^WQQM",:154N6 0"I)Z  5)Q5#
MP:OIT[6ZP744INXS/:A'#&2(4JZ4/Q(.2_$/A^+&U17([[;C%7!P? ^XQ52^
MN6_U@P>HGK#K'4<NE>G7[.%54N>E,"K3.BR+$S#U7!*)T)"TJ0/:HPVJ[G]%
M.N"TK7F6-&D<A8T!9V.P &Y)^0Q0Y'Y@%34$ AAT(/3%5U?NQ5HN%!+$ #<L
M=A3QKBJR*>.9 \3JZ'HZGD#WZC%50/BK88_V8JWR[=\*N!\<5;Q5HMM[X%6A
M^2AE^('N,-JQCR)(I;S'0UIK=V#[46/!:TRD-MUPJM$BDD*0:&AIXCJ,56K<
M1-*8A(OJ 5,=1RIXTQ54)%,"L#\HI3\U?/[>*:,/NM9,*6>$TQM#"_.@5O.'
MD9BQ!&HW5$X]:V,W4UVIBEF4DT<:%Y'5$'5F( ^\XH:,Z +5E <T0D]2=P!@
M5<&))!ZC%5K2*@+.0J 5+$T 'B3A5;]8B],2&11$:4DJ.)KL*&M,"KN8#4)
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MS9%5'6X;B6")$,YA]2MP+5_3F*!3L&V-.5.2H5?_ (;"%8GJ-EYNB.DPVIO
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MX^KQ$+0(LP(XS1NW+DM?4_E^UBH1,6ORO>&)E"Q374<=D#'('DADM4F+MO\
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M030 FI-*D8JQ*U\]F72K:_DB@_TNW>6*&"9IF$PF$,43T04,CND5?V9_W?\
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MZC%75&*M$XJM&*MX5=@5U<57#IBKL5=BKL5=BKL5=BKL5=BKL5=BKCBKS_\
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M*-2Q56!V*CU'_P""PJA['1;6Q+-#S9W(!>1V=@@KQC!8U$25^%,51%I86ME
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M3#+9 -I^<"6)^0#\7F;_ +;MY_Q&/%668J[%78JXXJP/RG_Y-3S_ /ZND?\
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MO^4C\F?]M67_ *@;C%66_LC%5O? EL'?$(785=BKL5=BKN^*K.H)\*XJQ/\
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M@37A04K\L5=Z$7PG@M4^QL/A^7ABJ_ JWTHQ7X1\7VA04/SQ5M455XJ %'0
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MZL1,?(-$15:\N)Y(RRJP/#BWVN?PXK3;>88EU9[![>41I,EJ;NJ>F9Y(EF5
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M( T8#J2P/0KO\0/M@5N&\@F+"&5)2AI($8-Q/@:$TZ8JJ2SQ1+RD8(M0.3$
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MXI/WG/\ :Q*IQ>QWS*HM)D@8'XS)&901X !XZ' JWT]1]9&,\9A '.,1'DQ
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M5=BKL5=BKL5=BKL5=BKL5=BK_]#U,/[SZ,4K\4.Q5V*NQ5V*NQ5V*NQ5V*M
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M"K4F@%!4FI/S)-<5<UO Q!:-684H2 2*$,.ON*XK2V.U@C>5T0*\S!YF'5F
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MNQ5V*NQ5V*NQ5QQ5V*NQ5V*NQ5V*NQ5V*NQ5V*M$?KQ5CGD ?\ZX/^8W4O\
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MSTUBQ/\ T<P_\U8 ;187?XJ\L?\ 5WL?^DF'_FK)45:/FGRT.NKV0'O<P_\
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M5: 4%?J+'Z2;4DY 0 _MG_Q2"7/Y:U4_9\SZHOOPT\[>&]IDPA+QY0\XBO\
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M6%F^S+-]M$G2'^YQ5,_+^F^8(?.EE<:E/J,\,$6L6<,TRAHS%]:MWMS*R1J
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M2XYR3?NF53?R1%YJ47OZ;GO)A/:031+=J@].X>:[66./@J4XQ);? >7'DO\
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M4@*3Q5OJP]#F%Y^E\'+%43=>4?+EU,9[C3XI)><KEC7=KCAZI-#OS]&*M?\
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:%78J[%78J[%78J[%78J[%78J[%78J[%7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exh3_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh3_3.jpg
M_]C_X  02D9)1@ ! @ !* $J  #_X0N117AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +7B@   G
M$  M>*   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,34Z,3 Z
M,3,@,3$Z,#(Z,#@      Z !  ,    !  $  * "  0    !   "Q* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   I;
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M%+^G>B]IK@A[VEXK]P)<Z/?M^DF>S#--KFU.>0TMV["]O]:',_G%H8WT'_\
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MQY@@_<Y22224_P#_V?_M$"Q0:&]T;W-H;W @,RXP #A"24T$)0      $
M                   X0DE- ^T      ! !*@    $  0$J     0 !.$))
M300F       .             #^    X0DE-! T       0    >.$))3009
M       $    'CA"24T#\P      "0           0 X0DE-! H       $
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      T4    &              ./   "Q     @ 90!X
M &@ .0 Y #, 7P S     0                         !
M  +$   #CP                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   #CP    !29VAT;&]N9P   L0    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   X\     4F=H
M=&QO;F<   +$     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     3_OR6+\EB_).$))3004       $     3A"24T$
M#      *=P    $   !\    H    70  .B    *6P 8  '_V/_@ !!*1DE&
M  $"  !( $@  /_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MRGX'V:TC'YK+@?3''$\?O(60W":PRU\[ZW PZ TO8 [Z*OY/K?9K2\MCTG2
M#.Z/&?HJ>3_-C_C*_P#JV)*:%+^G>B]IK@A[VEXK]P)<Z/?M^DF>S#--KFU.
M>0TMV["]O]:',_G%H8WT'_\ &6?]4Y++_HUGP24AVX4_T7_P'_S%0%&-ZN_T
MG[>2TL,>&T,]/Z*O.W0=L;NT\*'Z?6"S^3H=/BDI:D5 'TF>F)U&W;_ (JBW
M=KNCRA224__1]53'A.F/"2D>+/V:J>=C?R!%0L7^C4ZS[&Z_((J2E))))*4D
MDDDI#E_T6[^H[\B63_-C_C*_^K8EE_T6[^H[\B63_-C_ (RO_JV)*5C?0?\
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MZMJ;+_HMW]1WY$LK^;;_ ,97_P"?&)*5C#V/_P",?_U3DLN/LUD^"6-]!_\
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MC?:]PU[%KG;7;?S4E)V.#QN$QY@@_<Y22224_P#_V0 X0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
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M#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  (
M"0 & #$  &%C<W!-4T94     $E%0R!S4D="                  #VU@ !
M     -,M2% @(
M                $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H
M  )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I
M97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M#')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D
M97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@
M245#-C$Y-C8M,BXQ
M                      !865H@        \U$  0    $6S%A96B
M                6%E:(        &^B   X]0   Y!865H@        8ID
M +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT
M=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C
M+F-H
M     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:
M(       3 E6 %    !7'^=M96%S          $
M   "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D
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MK@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS
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M 0$!          $  @,$!08'" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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MBKJC%7;8JUMBK=1BKML5=7%75Q5V*NKBKJC%78J[;%78JZN!785=7%7;8J[
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M1B,RJRE2P+,I@D^QR7]KEQR)R21X<>[[%0:UY=:ZM[0V""2>+ZPH(M2!&7*
M[2'F>2G:+U,>,J,<>[[$)9^9?*]["C66E?69Y#'Z-K'';,["6,RUY!_27BBM
MS#R*R_[-.2)GHR, %:RU[RE>ZA!9P62,\Y58W,4(^)H1. 4KZPHAW;T^"O\
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MD+QI*$1HG0MPD9.[#I_P.*H"31KJ.]_=12/;PO8!:K"?4$!/)ZL>8],?ZO\
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M]TO]BU^D/S*H/]PNDGQ_W)3_ /9'DJ'?]B+'FXZA^9%131-*(\?TE/\ ]D>
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M_P!Y<:/>%L>?V?K6G6OS'%/^=8L3_P!O4_\ 9)CPGO'VKMYM#6OS)+4/E>Q
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MY0U\^XAM"/\ J)PU+N_V44[?BUI_,.^K3_!WF#Y^A:T_ZB<(C+N_V44[=_\
MNEQ_,"]4$_X0UXT--H+8_P#8QAX3^)17T]_^QE_Q+%OS,\]7,_DRZ1O*^MVZ
M_6+%C)-;P!1PO86I\,[-5J<5V^TV/"?P8HL=_P!D_P#B63_\K#N?^I0\P=*_
M[RV__91CPG\$,>./XC/_ (E</S N=O\ G4]?W_Y=H/\ LHQH_BEXA^!+]2\>
M?;@JS'RMKHXD"AMH:FM>E)^V"CW?;%/$%H_,*;B&_P *Z_0[?[R1U^[UL%'N
M^V/_ !2=OQ:3>=/.MQ?>3M=LXO*^NI+<Z==11E[1 O*2%E%2)3M4_%AH]W^R
MA_Q2[=_^Z16@_F4D^@Z=<0^6]=FAEM87CE2R4JZF,$,O[P;-U&/">[[8_P#%
M*:[_ +)_\2C#^8Q#$?X6\P$#O]1%/^3F'A/X,?\ BEN/?_L9_P#$L6\N^?N'
MG;S=<#RYKCB5[!#&EE5XVCMMPXY[%@ZLO^3@H_@Q_6CB'?\ 9+_B65M^8G$+
M_P ZQKYJ.6UC6G78_'UVP;]W^Y_XI;'X$OU-?\K&%/\ E&/,'_2 ?^:\1Q=W
MVP_XI.W?_NOU-?\ *R!M_P ZQYA^7Z//_->2X9=W^RA_Q3*AW_[K_B5W_*Q
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M1PIV0</LX5W1?F6"">QB26S:] GA<1K&)2.$BLS4;I\(.*T"HW$#Q^8H;O\
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MRN8U)-L9U/)T604''X?2Y?['XL053"VU26Z73K@'T%GDDBGMS1JLBR \7VJ
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M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L2_-?\
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M5=BKL5=BKL5=BKL5=BK_ /_3]4XJ[%78J[%78J[%78J[%78J[%78JQO6"/\
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M%78J[%78J[%78J[%78J[%7__U?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L2U_\
M\F-Y2]K?53_PEOBK+<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK$?S8_P"4
M!U,>+6P^^ZB&*LNQ5V*NQ5V*H?4333[H^$3_ /$3BJ2?EL*?EYY8_P"V59?]
M0Z8JR/%6*>6%9?.GG,%2 US8NK>(-C$OZTQ5E>*NQ5V*NQ5V*NQ5V*NQ5B?Y
MIL%\CWQ(K2:SVJ1_Q^0]Q0XJRS%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%7__UO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L4UU2?S%\J
MGL+75:GZ+;%65XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%6)?FMOY$OQXRV
M@^^\A&*LMQ5V*NQ5V*H75332[P^$$A_X0XJE'Y=BGY?^61X:59?]0Z8JR'%6
M)>6J_P"//.7^OIPI_P!&E?XXJRW%78J[%78J[%78J[%78JQ+\U=_(]X/&>Q'
MWWT.*LMQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_
M_]?U3BKL5=BKL5=BKL5=BKL5=BKL5=BK'-8%?._EP^$&H_\ $8,59'BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL58G^:8KY(O!_Q?95^7UV'%668J[%78J[%
M4/J,?JZ?=1?SQ.OWJ1BJ2?EO+ZOY?>6G"\0=,M %K7I HZ_1BK(\58EY8_Y3
MKSF?^+=/'_3FI_CBK+<5=BKL5=BKL5=BKL5=BK$_S2W\E7(\;K3Q]]_ ,599
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_]#U3BKL
M5=BKL5=BKL5=BKL5=BKL5=BK%/,$C+^8'E)!T>+4^7R$41Q5E>*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5B7YKDCR!JI'4" BOM<1XJRW%78J[%78JI7AI
M:3GPC;_B)Q5C_P"60I^77EG_ +9EI_R97%62XJQ/RO\ \IOYT/\ R\6 _P"G
M&,_QQ5EF*NQ5V*NQ5V*NQ5V*NQ5BOYGJS>3YE4$DWFG5 \!J$!)^[%658J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_P#_T?5.*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*L2\P;_ )B^41_Q1JI_Y)P#^.*LMQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*L2_-C_E -4'B;<??<Q#%66XJ[%78J[%5"_-+&
MY/A$_P#Q$XJD7Y:BGY>>6?\ ME6?_)A,59)BK$?*X9?/OG52:J\FG2*!VK9A
M/O\ @Q5EV*NQ5V*NQ5V*NQ5V*NQ5BOYH2F'R5>3 !FCFLW4'I5;R$C%658J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__2]4XJ[%78
MJ[%78J[%78J[%78J[%78JQC75B_QUY6=A^\$>HHC>S11$C_A<59/BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL58E^:__ "@6H_Z]K7Y?6XL59;BKL5=BKL54
MKR/U+2>.M.<;+7YJ1BJ0_EL0?R]\M4Z+IEHOC]F%1_#%61XJQ+RU_P I_P"<
MC[Z:/^G8G^.*LMQ5V*NQ5V*NQ5V*NQ5V*L2_-;_E!KX>,UD/OO8<59;BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_3]4XJ[%78
MJ[%78J[%78J[%78J[%78JQ/S(Q'G[R> 2 ?TE4>(%LN*LLQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*L5_--^'D#6'I7A&C =-Q*A'CBK*L5=BKL5=BJR<T
MAD/@I_5BK&ORN%/RX\M?]LZV_P"38Q5E&*L2\L_\IWYS/_%FGC_IT!_CBK+<
M5=BKL5=BKL5=BKL5=BK$_P TQ7R3=CQN+ ?]/T&*LLQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__U/5.*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*L2\Q_^3!\GC_(U,_\ )",?QQ5EN*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5B7YL?^2]UGWCC'WS(,59;BKL5=BKL54[HTMICX(WZL58[^6(I^77E
MG_MF6O\ R97%638JQ7RXJ+YX\WT:K.VGR,/"MKP'_$,595BKL5=BKL5=BKL5
M=BKL58K^9_$>2[QF)"I-9.:$#[%Y"U-]NV*LJQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__5]4XJ[%78J[%78J[%78J[%78J[%78
MJQ?7TKYZ\J/M14U$>^\*?TQ5E&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MB7YL?^2_U4>(@'WW$8Q5EN*NQ5V*NQ51OC2RN#X1O_Q$XJD/Y:"GY=^6?^V7
M9_\ )A<59)BK$O+I)_,'SAX!-,'_ "1DQ5EN*NQ5V*NQ5V*NQ5V*NQ5B7YK_
M /*!:D/%K8??=1#%66XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J__UO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L:UYU7SIY7!(!87X'_
M "(4_P ,59+BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL58O^9T22^1=55ZT"
M1O\ #UJDR,/Q&*LHQ5V*NQ5V*K+A ]O*C;AD8$>Q%,58]^6K(WY>^6^%. TV
MU"T]HE'\,59)BK$O+?\ Y,#SD?\ MFC_ *=F/\<59;BKL5=BKL5=BKL5=BKL
M58E^:W_*"7X\9;,??>0C%66XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J__]?U3BKL5=BKL5=BKL5=BKL5=BKL5=BK$O,I/^/?)P!Z
MG4:_1:C%66XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%6*?FL[)^7FN,I*L+
M?X6&Q!YK0C%65XJ[%78J[%5LII$Y\%/ZL58S^5@I^7'EK_MG6_\ R;&*LHQ5
MB7EG_E/?.1_R].'_ $ZU_CBK+<5=BKL5=BKL5=BKL5=BK$OS4W\D7@\;BQ'W
MWT&*LMQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__
MT/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L4\Q1NWGSR@X^PGZ1!/N;=:?J.*LKQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L2_-C_R7FM>\2#[Y4&*LMQ5V*NQ
M5V*J=R:6\I\$;]6*L<_+ 4_+GRU_VS;7_DTN*LGQ5BGEM./GKSA4BKOI[@=^
M/U7B"?\ 9*V*LKQ5V*NQ5V*NQ5V*NQ5V*L6_,YE7R5?.WV4DM';IT6[B8]?E
MBK*<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_]'U
M3BKL5=BKL5=BKL5=BKL5=BKL5=BK&M? _P 9^5COR!OZ;[4^KC%62XJ[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%6)?FQ_P"2^U<>*PC[YXQBK+<5=BKL5=BJ
ME= FUF W)1J#Z#BK'_RRI_RKORU3MIMJ/NB48JR7%6)>7O\ R87F_P!HM+'_
M "2E/\<59;BKL5=BKL5=BKL5=BKL58E^:_\ R@.J#Q^KC[[F(8JRW%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__2]4XJ[%78J[%7
M8J[%78J[%78J[%78JQG7V \Y^51XF_[T_P"/<??BK)L5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BK&/S.('D/66*\N$ <* "25=6 W^6*LGQ5V*NQ5V*M, 5
M(/2F^*L7_*QW?\N?+C.2S&PAW/AQVQ5E.*L2\N;_ )@^<?9=,'_3NY_CBK+<
M5=BKL5=BKL5=BKL5=BK$OS7_ .4#U >,EH/ONXABK+<5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_T_5.*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*L2\S?\IYY,'^7J)_Z="/XXJRW%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78JQ/\V/\ R7.OCQM2/O8#%668J[%78J[%6I#1&/@#BK%_RK%/RW\M?]L^
MW_X@,593BK$?+1_YW_SG['31_P!.IQ5EV*NQ5V*NQ5V*NQ5V*NQ5BGYI\!Y#
MU1W%4B$,I'_&*XC?_C7%65XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J__U/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L3\R*Y\^>3V"DH
MIU$%AT!-L*5^>*LLQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L2_-C_ ,EW
MK?O !]\BC%66XJ[%78J[%5DYI!(?!3^K%6-_E<*?ESY:_P"V;;?\FABK)\58
MKH#+_C_S9&!3]UICL?$M%*OZD&*LJQ5V*NQ5V*NQ5V*NQ5V*L2_-C_R7NLCQ
MCC'WS(,59;BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBK__U?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L;U_\ Y3#RL?![WM7_ (]CBK),
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5:+$,J\20:U84H*>.*MXJ[%78J[%78J[%78J[%78J[%6)_FO_Y+[6>M
M/32M/#UDQ5EF*NQ5V*NQ5;(H:-E/1@0?I&*L7_*N0O\ ESY=)VXV,2"G@@XC
M\!BK*L58EY?_ /)A^;O:'2Q_R2F/\<59;BKL5=BKL5=BKL5=BKL58E^:_P#R
M@&JCQ$(^^XC&*LMQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5__];U3BKL5=BKL5=BKL5=BKL5=BKL5=BK%O,DI3SIY12E?4DOU/M2
MT+?PQ5E.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5BOYJE1^76OEAR"VCL!
M[BA'XXJRK%78J[%78JYMU/RQ5BGY4"GY;^7?^8&(_>,597BK$O+G_DPO.'LF
MF#_DA(?XXJRW%78J[%78J[%78J[%78JQ+\U_^4"U(>+6P^^ZB&*LMQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__7]4XJ[%78J[%7
M8J[%78J[%78J[%78JQ+S/OY[\F#_ (MU _\ 3FP_CBK+<5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BK$_P V/_)<>8/>T8?>0,599BKL5=BKL5:;93\L58M^
M50_Y!OY;_P"V? ?O08JRK%6)^7>(_,'S>M1R,>F.5%:T,,B@FNW[)Z8JRS%7
M8J[%78J[%78J[%78JQ3\U']/R!K$M*F*))%%:5*2HP_$8JRO%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_]#U3BKL5=BKL5=BKL5=
MBKL5=BKL5=BK$O,HKY\\G>S:B?\ IU Q5EN*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5B?YL?\ DNM=][>GWNHQ5EF*NQ5V*NQ5;+7TGIUXFGW8JQG\KE*_
MEUY;4BA&G6]1[^F,591BK$]"W_,;S7[6NE#\+D_QQ5EF*NQ5V*NQ5V*NQ5V*
MNQ5B7YL?^2\UH>,*C[Y4&*LMQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5_]'U3BKL5=BKL5=BKL5=BKL5=BKL5=BK&]? _P 7>5C2
MI$E[]WU4XJR3%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78JQ7\U(VD_+[6E45
M/H@GY"12?PQ5E6*NQ5V*NQ5QK3;KBK&/RP='_+[062O$VD?6O4;'J3M7IBK)
M\58GH&_YB>;?:#2Q_P DYS_'%668J[%78J[%78J[%78J[%6)?FQ_Y+[5QXK$
M/OGC&*LMQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
M_]+U3BKL5=BKL5=BKL5=BKL5=BKL5=BK&?,,R)YR\IHW662^5/F+4M^I3BK)
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK%OS1<I^7VO2 !BEJ[<2: \2#2
MHQ5E(Z8J[%78J[%78JQ3\J?_ "7/E_WLT/WU.*LKQ5B7EW_R87F\_P#%>F#_
M )(RG^.*LMQ5V*NQ5V*NQ5V*NQ5V*L4_-((WD35 W0B'IX_6(Z?CBK*\5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_]/U3BKL5=BK
ML5=BKL5=BKL5=BKL5=BK$_,SNOGCR:JF@>74 X\0+-C^NF*LLQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*L4_-?_P ESY@KT-FX^^@Q5E>*NQ5V*NQ5S=#B
MK%?RJ_\ );^7/>PA/WK7%658JQ+RY_Y,#SB?;31_T[OBK+<5=BKL5=BKL5=B
MKL5=BK%_S-56\C:JK5 9(QR4T(K,@Y5_R>N*LHQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__U/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*L2\S?\I[Y,'^7J)_Z=*?QQ5EN*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5B?YL?\ DN=>][8C[V48JRS%78J[%78JMD-(V/@#^K%6,?E8*?EQY:_[9UO_
M ,FQBK*<58IY=Y?X\\WD]/\ << /E;L?#WQ5E>*NQ5V*NQ5V*NQ5V*NQ5BOY
MI$#R#K!-"/238]/[U/EBK*L5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5?_U?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L2\R;^?_)P_P"V
MD?\ IW4?QQ5EN*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5B7YL?^2[UOWA4
M??(HQ5EN*NQ5V*NQ59<&D$A\%;]6*L;_ "O%/RY\M?\ ;-MO^32XJR?%6+:
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ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL58E^;'_*
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M:D]?[I<59-BK$O+/_*=^<S_Q9IX_Z<P?XXJRW%78J[%78J[%78J[%78JQ/\
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MBKL5=BK_ /_6]4XJ[%78J[%78J[%78J[%78J[%78JQR8C_E8UF*[C1[K:O\
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M4Q5=BK%?R_F>9/,,C@ _IV_04[B-EC'X+BK*L5=BKL5=BKL5=BKL5=BK$_S
M7U)/*\/3U->M#6E:>DDLWX^EQQ5EF*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*O__5]4XJ[%78J[%78J[%78J[%78J[%78JQ-2?^5L
M2BNPT&/;MO>/BK+,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK$OS$_N_+@\
M=>T_\'8_PQ5EN*NQ5V*NQ5C_ .87_*#:[[V4P^]",59!BKL58E^7/^\NOGQU
M[4_PN",59;BKL5=BKL5=BKL5=BKL58MYX4&^\I^VN1$;5_X]+G[L593BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_6]4XJ[%78
MJ[%78J[%78J[%78J[%78JQ2-3_RM6=]J?H*(==_][).V*LKQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*L2_,/\ Z9D>.O6/X<S_  Q5EN*NQ5V*NQ5C'YGN
M4_+OS&Z_:73[@CY^F<59+$28D)ZE17[L578JQ;R%(K)Y@15X^EK=\IIW)97)
M_P"&Q5E.*NQ5V*NQ5V*NQ5V*NQ5BGG]W23RQP8J3KMHI(\#'+4?2,597BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_]?U3BKL5=BK
ML5=BKL5=BKL5=BKL5=BK&5],?F8_P_O&T5*MM]E;IJ#_ (;%638J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%6+>?(@_^'7+<1%K=D]/&O-*?\-BK*<5=BKL5
M=BK'/S'@$_D'S#$30-I]Q^$9.*LAB_NT^0_5BJ[%6)?EYT\RGQUZ^_ H/X8J
MRW%78J[%78J[%78J[%78JQ+\P/[_ ,JCQUZU_"&<XJRW%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_]#U3BKL5=BKL5=BKL5=BKL5
M=BKL5=BK%UX'\SI*_;&B)Q'L;MJ_J&*LHQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NKB
MKL5=BKL58E^8N]OY?'CKVF_A.#_#%66XJ[%78J[%4@_, T\C:_\ ]L^Y_P"3
M38JGR[*![8JWBK$ORZ_NO,1\=>U'\) ,59;BKL5=BKL5=BKL5=BKL58GY]%;
MKRI_VW;?_J'N,599BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BK_]'U3BKL5=BKL5<<58S>VGF?Z_,(O,MO;(Q,L=H]E&[1Q,W%*L9E
M9A7X>=/B;';S_'P3?E]Z#@7S5< M;><-.E7<[6"MLI"G[-UV+*,=O/\ 'P7B
M/='_ &7ZVE_Q>)&A/F[2VG1Q&T9T^A#M7BI7ZW7D>+8#7FO$>Z/^R5!'YX%P
MEO\ XETEIGY<8?J#B1O3V>B_6Z_!^U_+C0[S_L5L]P_V2ZW3S[*S>GK^C3!7
M:)@EC+42*-T-+L_$O[2_:QH=Y_V*+/=][I!^84+*LNLZ(K.PC17LKA2SD5"C
M_2_M'^7&A_./RBN_<@5T_P XG4%UZ/5=">YE@%BMQ]7NA&R>H7""EV5+>I7_
M "L0!_.^P(HH@W/YC $_I/R\15A_=70WC^V*^N?L?M?RXV._\?Z9-'N5(V_-
M.1 \5QH$B-NK+'>4(]B)#A%=_P!G[46>[[?^.KB/S8 %#H)/?:\'\3AH=_X^
M:WY?[+_CK0;\V:BL>@D=Z/>#_C0XT._[/VIOR_V7_'&Q+^:^];?0B/V?W]X/
M^91QH=_V?\>7B\O]E_QQWUC\U@/]X=")]KN[&_\ TCX*\_\ 8_\ 'D\0[O\
M9?\ '6Q>?FF#OI6BL/:_NA^NUQX?/_8_M7B'<?G^QQU'\T%_Z4>D/OVU*<;?
M39X\/G]BV.XM_I7\S0=_+VEL/\G590?QL\'">\(L=Q<-:_,CC4^6+$FM*#53
MT\=[08:/>$<7D?\ 8_K:.N_F(%!/E2U)K0A=57IX[VXP\/F/M3Q#NE_L?^+<
M/,'YA4J?*4(]OTI'7_DSCP^8_P!E_P 2MC^E_L?^+;_Q#Y] J?**D^"ZE ?U
MH,%'OC_LO^)6Q_2_V/\ Q;CYD\\@D'R>Y .Q74+4_KXX"#_1^<O^(6QY_P"Q
M_P"*;'F?SGW\G7'T7UB?^9@P5+^C\Y?\0MN_Q3YM /+R;>U!_9N]/-?^2XP@
M'R^?_'4<0\VCYN\SC[7DO4O]C<:<?^QD8:/DO$//Y./G#S"OVO)FK?[&73C_
M -C6/"5XH^?^E6_XXUD$AO)FM"G<?4&_5=8>$^7S3<>\_P"EDV?/>H D-Y1U
MS;N(K0_JN<'#+R_TP3MW_87+Y^N2U&\JZZNQ-3;0$;"O[,YQJ7=_LHHV[_\
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M]:F/"/ZJ_)_5Y1\56*7.B_F!%KEQ?:S;7D+RW^FW5U?Z0[WS*%MKV.46L3P
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M_P *JB=6\S^:?\%:+YBTQK&&:^CT]KN"Y@FF7EJ$D$0],I-"56,S,WQ<^?\
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MII$T;\7'J12)#'ZL4G*.;ASE5WQ5,#Y3T+U?66W*3>I<3"5))4<27=/78,K
MJ7H.GV?V<53>F*NQ5V*NQ5U,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5?_U_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O\
M_]#U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
GBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exh1_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1_1.jpg
M_]C_X  02D9)1@ ! @$"6 )8  #_X1<B17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  6XV    G
M$ !;C8   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,34Z,3 Z
M,3,@,3 Z-3 Z,S$      Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !7L
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MG_GM'24Y#,;(8][OL[W[I=%C:GMG_@V_:6^G_)_,1Z<>ZUI+Z*:#^Z^EKO\
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M_P#_V?_M&[Q0:&]T;W-H;W @,RXP #A"24T$)0      $
M       X0DE- ^T      ! "6     $  0)8     0 !.$))300F       .
M             #^    X0DE-! T       0    >.$))3009       $
M'CA"24T#\P      "0           0 X0DE-! H       $  #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T4    &              ./   "P     @ 90!X &@ .0 Y #$
M7P Q     0                         !              +    #CP
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #CP
M  !29VAT;&]N9P   L     &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   X\     4F=H=&QO;F<   +
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     3_P        .$))3004       $     3A"24T$#      6"
M  $   !\    H    70  .B    5[  8  '_V/_@ !!*1DE&  $"  !( $@
M /_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)
M#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1
M 0,1 ?_=  0 "/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M7.<2UU;CZ=[=S-GM?6[_ (M#H-U@8]U V;O=^M6-<0/8_P!EF0WW>W]&Q_\
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M[ZS +H>WU?TGMW._FWL24WJK<BMCZZ+6TTUD,K: '!IAEGTA6W=N]3_K;_\
M2(V._-=<UEN7[2/<UM;9X]OZ5WT?=_P*#7TSK+'$MR*!ZAFS]&3$M#'>G)]W
MT&.]Z-1@=2K>2;J9:(9;Z;BX\_39ZK*OH)*=1"_PG]O_ +XB#S0]/4_M_P#?
M$E/_T/54DDDE*22224I))))2DDDDE*22224I))))2DDDDE*0H_2?V_\ OB*A
MR-\3^?\ ]]24_P#_V3A"24T$(0      50    $!    #P!! &0 ;P!B &4
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M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(                  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
M"Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-
MPPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F
M$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2
MXQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]
M%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48
M^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2
M''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@
M%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P
M)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH
M/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB
M+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ
M@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R
M-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[
MZ#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J
M0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'
M>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV3
M3=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_94
M0E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU
M6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B
M26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF:
M:?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQ
ME7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)
M>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V"
M,(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*
MBS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4
M()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUD
MG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG
M;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@
ML=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\
M(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#
MQT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2
M/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6
MWAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;I
MT.I;ZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>
M]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X #D%D;V)E
M &0      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,# P,
M# P0# P,# P,# P,# P,# P,# P,# P,# P,# P,# $'!P<-# T8$! 8% X.
M#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,_\  $0@#CP+  P$1  (1 0,1 ?_=  0 6/_$ :(    ' 0$! 0$
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MT#H?_5NM?^1,?],5=^@=#_ZMUK_R)C_IBKOT#H?_ %;K7_D3'_3%7?H'0_\
MJW6O_(F/^F*N_0.A_P#5NM?^1,?],5=^@=#_ .K=:_\ (F/^F*N_0.A_]6ZU
M_P"1,?\ 3%7?H'0_^K=:_P#(F/\ IBKOT#H?_5NM?^1,?],5=^@=#_ZMUM_R
M)C_IBKOT#H?_ %;K7_D3'_3%7?H'0_\ JW6O_(F/^F*N_0.A_P#5NM?^1,?]
M,5=^@=#_ .K=:_\ (F/^F*N_0.A_]6ZU_P"1,?\ 3%7?H'0_^K=:_P#(F/\
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M^@=#_P"K=:_\B8_Z8J[] Z'_ -6ZU_Y$Q_TQ5WZ"T/\ ZMUM_P B8_Z8J[]
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M01122%8BC_6YC!%R"+ZTL8DD3[,C8JS"VECEMXI8A2.1%9!2E%85&V*I3?\
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M9!R]4213Q1<3^SPXR_ZV*IWBK&?S/_\ );^::_\ 5IO?^H=\53S2?^.59_\
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M6_\ $7YA4K_@^/Y?I.'_ *IXH:_Q'^8?_4G)_P!Q.#_JGBEW^(_S#_ZDY/\
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M>E'^[5<58!?_ )&74_HW$%U;Q7WURZNKDD-Z+1/-+-!"J*JE=YN$TH;U^/\
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MMYT62&9-*NV5T<<E92$W5@:C%53_ )6=8?\ 5A\P?]PF[_YHQ5O_ )6;8?\
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M5E2OZ!U^G_;*NOU<<5:_Y698_P#5A\P?]PF[_P":,5<?S,L1UT'S!_W";O\
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M;"M/T#Y@_P"X3=_\T8JX?F;8'_I0^8/^X3=_\T8J[_E9EC_U8=?\?^.3=_\
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M%-:_\F3Y7_Y@-6_XE9XJRO%78JP_\JI(U\DVP:1:_6M1-"1T.H3XJRWUX?\
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MQ_=8H8YY;_.'S1?1VDK7>CZR;K39[V[M=,BN$ETYH[1KA&NF>65/2:1?J_\
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M[N/XE=V@%PR0UJ&DB26!I/\ 7D_>?N_C52JZ7RNNFQZBGDO0/2?3;C62LC2
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MUV\M-.M_+[^9KJ6[UNVLF76+7CJDIA=[DO\ W$LJI!+($_=02?99>3*JRO\
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MIG?_ *.L56_XJU\;?X&U$?\ /;3!_P!C6*KF\U^8F#!O(^I,&^T#-IAK\_\
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MX_ZFG2?^DVW_ .:\58SJ?YA>0W_,70;M/,>F-:PZ;J4<TXNX."O)+:%%9N5
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M-+?JQ'(R?WG+]O%*&M/*>MV8_P!%\JI$_&W1)%U^XYHMFK);A"8/A])'=/\
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M32VUB4\(HC)"GQ,L:>JZ\T!56_><>7[2\DY*H34?SOT2UTZ\N4TZZ>:R#)/
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M <54],U6PU.V^LV4OJP\Y(^5&4\HG:-QQ8*VSHR],51(=#2C UZ4/6F*H/\
M36F_5KJZ$W*"S:1+AU5B 8?[VE!5_3Z/PY?%\/[.*H;5_->@:0MNU_=>FETC
MRP.B22J8XE#R2$QJX6-$8,SM\"K\6*IHDD<BJR,'5@&5E(((.X(IBJ[%78J[
M%78J[%78J[%4'HW/]%6O, -Z8J!TQ5__T_5.*NQ5V*NQ5V*NQ5V*NQ5*?,.D
MW.H+I\ELZI-I]Y'=!7'PLH1XG'0T8)*SIM_>*F*L:\H_EK-Y=U"T;Z^;JULW
MNKA6*"-FENXXHC'P!95C40F3_C))]GX,52_5?REFED>[M[P/J#RRM!<(HMS
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MT*<7E)/2XDD_?+.HY12<N.*6.ZU^58TNZLGN=7L_T4TR\VOHXHU:?C BKZ0
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MBGVD57X2HS4E9F^/^;%4D7\L]7-WZ<6NV\5P_P!6%Q#%-=>JZP)+4%_6]?\
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ML?!(V*II/Y)U;]"SPI:VDK3ZY!JT>E<Z6UO!$\3/$C&,CG)Z3R/2-4]6=_\
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MJ[_!WF;_ *G75/\ D1IO_9+BKAY.\STW\[:I7_C!IO\ V2XJX^3O,]-O.VJ
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M:G_TBZ;_ -DV*N_P7YO_ .IZU/\ Z1=-_P"R;%7?X+\W_P#4]:G_ -(NF_\
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MG"ZO;:-PTMH]G8QK*H_9+QQ*ZU_R6Q0RG%78J[%78J[%78J[%4!H'_'$L?\
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MNQ5A7F[\I/+7FG5_TKJ-WJ<-R8TBX6=]/;1<4)(_=QD+RWW;%4E_Z%X\D?\
M5PUS_N*W7_-6*V[_ *%X\D?]7#7/^XK=?\U8K;C_ ,X\>2*?\=#7![_I6Z_Y
MJQ6W?]"\>2/^6_7/^XK=?\U8K;O^A>/)'_+?KG_<5NO^:L5MW_0O'DC_ );]
M<_[BMU_S5BMN_P"A>/)'_+?KG_<5NO\ FK%;=_T+QY(_Y;]<_P"XK=?\U8K;
MO^A>/(]:_7]<K_VU;K_FK%;:_P"A=O(W_+=K>_\ VM+K_FK%;=_T+OY&I3Z]
MK=!N!^E+KK_P6*VT?^<=?(A-3>ZV32E3JEST_P""Q6VO^A<O(/'C]<UKCX?I
M.YIM_LL5M*+G\EORO@U>?26N-?:^@LSJ!1+Z[8/"K\#P()YORVX+\6*J^B?D
M9^7&LV1O(9M?A*2202PW.H74<J20L4964L>A'52RXIM(Y?RW_*N"2\66'S2I
MTZW%[>5N[@>G;L)2LC#U.0#?5I:;<OL_SKBK5_\ EU^4MDKO.?,IXV4&I.%O
MIR1;W4GI1FGJ?:]3X63[2XJF6G?E)^55]JCZ9;OKTDD5Q+;2W)U"Y,2SVZ+)
M+ S+)\+*LB]5^/\ W6[8HM!7OD#\H[2/4;B2V\QFWTRZ:SO)4O;ID24-$H4'
MUMP3<1</^;'XJ43;_E7^6,^HRZ8MIYD6[M_0>Y#7UP/32XD>&,G]]NK/%(QX
M!OA7G]C%%J$GD3\DHM!N=:DGUI+?3[]M*N8#?WOK_7!*(?1X"3?XG5E93Q]/
M]YRXXI3GS!^3OY1Z!I:7VK7&IVEO)+!;+*VIWA/JSR+&G^[2OVF^,_95.38J
M@M7_ "X_)[2=:_1-[%K*S!;9VF74+UH56]G-M 683[<[@>E]GX6^U\'Q8H2V
M+RO^2,D2N(-=#R"-H86OKT/(DMW]1#J/K%.*W7&*3?DG-&^PW+%*;>8/RP_*
M;0KCT+VVUIF%E<ZB6BU"\=1;V84SG^_'Q)ZB?#^UR^'%5DOY:_E1"EMZ]EKL
M,M[-%;V,#ZA=!IY)HGG41GZSZ?\ =QN6Y.K?L_:9<4(JX_*;\IH-.TV]>/5R
MVKM''I]G^D+X7$DDJ&0)P:8<65%9Y.;*L:HW-L5M 0^0?R5DU"RL'.K07-_<
M3V,(FU&]0"]MA62U<^O\,W'XX_V)5_NG?%*(TK\L?RGU/58=,AM=;CN9[:2\
M0RZA>*GHQ3>@Q)%PU#ZNP7_9?9Q52B_+C\HY;FXM%M=<%[;:@FERVAO[P2^M
M(GJJX7ZQO 8OWOK?8]/DW[+8JKZI^5?Y7Z=J<>G/IVOS3S%Q T-]>LDACB]9
M^!,ZEN*> ^U\"_'\.*J=I^6WY.W5U;11KJXM[VYEL;&_;4+X6\US!R]2)'];
ME7]U*$9D6.3TW]-VQ0J#\L?R;&L:OI$K:I!>Z+;)>WJR:C?!?JTBLPEC83$.
MJ\?C_:3]K[6*H"V\D?DQ=:>E_:P:Y/ ;%-4N E]?%X+.6ICEF7UZKZBH[I$O
M.;@C-Z>*5TWD7\EH9+LR)K/U*Q-M]:U%=0O7MD2]4/!(76<MZ3JZDR<.,?\
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M"MPK<O69N'I,A5^/#]Y\7Q8JI2?E)^57U^XM8I/,$\=M=1V5W>0W]RUO!<2
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M+(EC]7F\RW,E_<W5G%!'>W/J+=67+ZQ%(K.O%XQ')O\ 9;C\#M\.*&X_R_\
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MC_C;%4!K/G_S9HNEW&J:EY/ECLK5><[I?VKL%J **#ON<51G^)_/E:?X,?\
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M9*NO+@U:LOV?YL51D6N^:4*/#Y-B'P"W61-0M*A$Z1UI]E?Y<52ZMXT4-O\
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M+):.3Z5:VU&_U>7[O%4'/^4GF5K1XK.]M[*:2RN+&XE21JW$=S&JNC^E!;A
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M3EHFE*(F"2<M: *N14*W^B[$XJU)YR\YQ2&.71-)21: HVM@,*[[@VN*K?\
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M>3JLI+-RXOZ+<N'JR*IAJ?D'S3=V6EV\7F.6"2QMY8Y[I3-ZTLTLBR<^8D!
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MK(?*-K%HT=W'<ZK!<+/(C(SRJTA]&"*W$CO6A>80^K)\/VW^VV*L@_2NE_\
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MNQ5(=7\A>2M9OFO]6T*QOKUU57N;B".20JHHH+,"=L50?_*J?RS_ .I7TO\
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MZ0K?_FC%7?\ *K_RV_ZE;2?^D*W_ .:,5=_RJ_\ +;_J5M)_Z0K?_FC%7?\
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MV*NQ5 Z$"-%L >OU>+_B Q5__]?U3BKL5=BKL5=BKL5=BKL5=BKL58E^:_\
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M!L?^K/K?_<+N_P#FC%7?\K!L?^K/K?\ W"[O_FC%6C^85@!4Z/K=/^V5>?\
M5/%6_P#E8-C_ -6?6_\ N%W?_-&*K?\ E8>GU_XX^N?]PJ\_ZIXJ[_E8FGUI
M^A]<KT_XY5Y_U3Q5;_RLC3/^K1KG_<)OO^J>*N_Y61IG_5HUS_N$WW_5+%7?
M\K(TS_JT:Y_W";[_ *I8J[_E9&F?]6C7/^X3??\ 5+%7?\K(TS_JT:Y_W";[
M_JEBKO\ E9&F?]6C7/\ N$WW_5+%7?\ *R-,_P"K1KG_ '";[_JEBKO^5D:9
M_P!6C7/^X3??]4L57)^8VEN?^.5K8!WY'2;ZG_)K%6E_,C1F7D-.UG;=@=)O
MZC_DCBJ[_E8NC5(_1^L5'7_<3?\ _5'%5@_,O0S3_0-9J>QTC4/^J.*N_P"5
MEZ%_RP:S_P!PC4?^J&*N_P"5EZ%_RP:S_P!PC4?^J&*N_P"5EZ%_RP:S_P!P
MC4?^J&*N_P"5EZ%_RP:S_P!PC4?^J&*N_P"5EZ%_RP:S_P!PC4?^J&*N_P"5
MEZ%_RP:S_P!PC4?^J&*MC\RM"I_O#K'6E/T1J/\ U0Q5%Z=YXTC4+Z*SAMM2
M268T1Y]-O8(@:$_%)+"D:=/VFQ5D&*NQ5V*NQ5PKWQ5V*NQ5!Z*S-I%DS"C&
M",L/<H,5?__1]4XJ[%78J[%78J[%78J[%78JM,L0%2ZT\:CMBK$OS8/_ #H=
M]O0--9+4"NS7L(Z=^N*A Z%:^=;?S9-/<)>?HI[N^%P)YTFB>"65/J1MXS*Y
MB$2B5I/AB_=MPX2-QX*L]Q5Y;JFB_F%/'J7IOJ"W:1:@[/#=B..XF><'31:@
M2+Z210<O65O17_?OJM\6*H7S!H?YAJ;Z+1_TJ;<W4C6)-X3,(C:1A29'NA6,
M7/J?NV7G^USXXJF/E[3_ #[;><X;NY346T#B(I(I[E7^-UD_>&)[BXI"IX<O
MC:X5_3XL\?K+BJ%M;O\ ,_3]=GM+:&6Y^MO<W, OBKJR(R\49A,T=NB>KQC:
M+_>CC'_H\/&9\55Y[G\W[BU*3V3)*L;>G) MO&:M:RA9#_I34F]<JK1'G!QX
M2JW\JJ+TU_/8\LZA#:SL9+"X@M]/N&CY3R1).KW3N+ER&:.)GM_[QE=X7>-_
MC3%4 OF/\U[AN.GPPW,IM!.(S (DX,TT2RJTLD;>K+Z,=Q#;LOV)N$\B8JF/
MF5OS0N;2&TL8>"SV4 O)X/2219F/^D<.4O[N1:!456>/TWD;UO41,57ZM+^9
MUEJ<UOH=L+G2K=(X[+ZP(V,@6*-29)GF$Q;FTS%F3_=2_:YXJE]S)^;%Q?6+
MRV4GHPL:-$UN@:)IUI)<()Q_I"1+7TH_4@_R_C:/%5+2E_-G2M-:VBM);J7@
M\HGF>&5WN'ABY!_4N#Z<:RF;T_2^%N''TU1N6*JUO<_G")S</8@R2( 5D^K@
M1MNPC54FXM$7XK)(W[Y(_4X>I\"XJC?TC^;$?EMY#8)/K?UV/A&! J_5#&&D
MV,W$\9 T:GGS_:XXJMTR7\T)]3TI-7M66SBN1+<S0>A'R1H*,LRK,Q]..5_@
M]/U/4X_']E>2J$.I?G/(EU&^GB#E+*+6:(6C,L2ABA(>:G(UC5-OV?CQ52L9
M/SIM-,^J16JR2PQR?5IKDPN[DQ@A9F]8[HYXQ,#^\;^]X)\>*HB.?\S+35DM
MYY!]5NI_20/%&RM&99C-<\D=VB:.+T)/2;A&W]W'Q?%69>3WU)_+=DVI<_K1
M5MY?[PQ<V]$R?\6&'T^=?VL53C%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J@]&0II%BAW*V\0)
M'L@Q5__2]4XJ[%78J[%78J[%78J[%78J\ \Z0:%I'YA2>8K.V-[Y/U"[M].\
MZV4:B1/K:L9H9XX@K.R1NJM>>F.,G^7^^XJO4?S-2.X\BS)"P$<MQIPC==UX
MM?04(IVQ4,NQ5Y%KWYG>:=+B\Q:<HA?4K>[:31KQT_=C34G$%P\H'PM+:R?N
MOV>;3VW^7BJ>7GYIM#J$&G6]G"\_UJ6VG::Y5:+!<7%NQ^%-G=K7DE5_W9BJ
MG;?G+IMS=V=M':!?K<EHCR?6(R8UO8K9U?C0U]-KQ$DKQ7X/M?$JXJKR^;_,
M _+?2KZR*7GFG5K=!9CTBZ/-Z9DDD:**I]-45OL_M<,5:D_-NT:VT^XL=/:Z
M2]TYM3D!E6-HDCCF>5&JK#E ]NT$O(KQE>/BK_'P56W'YL26TTL$^C$2PF&&
M0K=P%1<7*Q/$AY^F_ILDZ_ON'#DK+_*V*J;?FW< SG]" 1VRLTQ:\BJOIVD5
MY*/A5T/&*;BI5V5W7^5N>*M77YPK'ZKPZ.TENCW0CE:ZA7E'9QSRRL4'-XVI
M:R 1NOVN'Q?;X*II:^?Y&TB6]GMH1,=8DT>UB6<^GR$YAC:>0H?2Y<:_8?\
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M#T^7J2<L51[?F#>W7D]]:L+%(KQ+^VT^6SN7D0Q-/<0PL) T:2)(GK?8:/\
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M;SA^2\TCS2QHTCO#(['3;RI>W%(6_N.L('[L_P"Z_P!G%6HO-/Y)I/;7"6\
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M?3;N;2YK:PU.>X@BNI)8BJ?5$G>=W"DL%1;23_6Y1_Y7%5>_YDQI8VMZ^E7
MBU.SFO\ 1TY1\[F."/US&5K^ZF>W_?1HY^)596='7CBJ9Z!YST_7IK3]'(TE
MI>6?UU+AB%*\9/2>&2,_&DT;U5U/V65E^UBJ#@_,*TG^HS)92_H[5KB:STF^
M9E"3SPJ[*"OVHXY_1E]"1OM\?B5.:8JB?)WG*+S1:1WEO:&&VEMXKA',T,K+
MZP)$4B1L6CE"_%1OA_RL549_S T[ZKYEFL[6>[E\L_[TVZ *TX$?,FW+;/\
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MA&61&]>-S-+P$O\ =<_AQ55N/ROAEF>3]*3 ---.J^G%LTVG#3*;!=A .?\
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M+<P\";CTQP4R2)T]56^+]CXL5=:_FGI]TFI7D2#]&64EDD4M4,C"Z=T<LOJ
M)NGP<CS_ &F3CBJV^_-.']!V6KV%FP@EN)8[Q;@Q\XHK:)IY2%20J[M&OP<'
M;C^WBK>F?F<FHZA?K;0QR65K;7ES$ X$S_4TMF(-"T8#-<2+RY?LHV*H>R_.
M/2TLD;4[647:AS<&V$9A58UE=VJTG+]VMN_+]IOMQ\XFYXJF0_-/R_\ 5]3F
M:&X5=)BCENJ>BP)E*J(T=9"CM61/VN#\OW;OBJ5R?G7H-QIYGTV"0SN\0M1<
MF*..1'D*.]1(2.'!_@_O>7V8V7%6_-GYNQZ=<W%AH]D;N^LY9DN3<,L,/&V@
MDGE"L6#<OW7$?#^US7FN*M?\KIT>WLIQ<VDTNI6<;M=PQ&&.,F(A',32RJ63
MU#P_:D7[3+P^/%7HD4JRQ+(A!5A44(/X@D8JNQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ53N32VE/2B-N/EBJ$\OL6T'36)))M822
M=S_=KUQ5_]?U3BKL5=BKL5=BKL5=BKL58GK]AK[ZI$!KUC:PW<ACT^UN--%P
MX98S(RB4SIR-$=_LKBJ4VHUB]AM9H/->F/%?RO;6;MH_$32"-BZQ\K@<QZ4;
M?$OPLBXJOGT/7?+MK+=2>9-.T^VGN?4FN#I)"_6+AN'-V-T0G-VX\FXI\7'%
M5"33]2NP^G/YFTQCJ'UFR>W_ $04>?ZN"+F, 7*LX3]OCBJ@=3GAL;&['G/2
MOJEW$;FQ9-(+<XK<JAD4+<%@(C(J<OV6?CBJ8RVOF)K!+ZY\SZ<EI+*D"O<:
M.8_WKS>DB%9+A6#&=N-&'V\50=S>7]JMU+-YNTR,Z9,\5X?T,Q:WE,?K/S N
M.2<H_P!YS/PR+\7Q8JMEN=0ATR349/-NG):6\C0W$AT1N43JGJ,LJ>OSBI&O
MJ-S1?@^+[.*H:36+OUV4^<;,3\QZB_H&4L&<T ;]Z2&<B@Y?$V*JT'Z132K:
MXM_-5A]0>>6UM?3T)C6X#,TJ)&)N7/FDG*B_:5\55;UM<MA;Q7?G.P59XEFB
M1M&!589F"*[TF(B21V"!I."L_P /VL56QOK<]C+?IYPLS:Q,B-(=#(JTK\$5
M%:4-(7D/!0@;X_AQ516ZU1XTB3SC9R"-E2*W3069^3P_6*)$)2Y_<GU7XK\"
M_;Q5H:EJ*0R7J^=['C;MZ,SIHA+QDQ?6.+JLO- T1]4<AQ9?BQ54BFU<W\.F
M_P",;*.\FI'#!+H1B->4@5/CE4*Q:*;@C?R/QQ5,=0T+S;IUG<7][YJL(+:)
M2\\S:/'T'RG)8D_94?$S8JA=+@\PZJDSV?FZR=8Z"4OH@BZ%HQ_>3)7B8W3_
M ">/'%4Q3RYYV<1QIYKL&"#G$@TF(\5:HY*!<; [[XJM'E_SG(%(\V:>ZHIX
M4TF(@+WI_I&RXJI3Z/YLBMZR^;]/$#.II^B8BI=VX@T%P=RQ^UBKI-(\UI)'
M _F_3O4E)$<0TF(D^J>)V%QT=OA)_:;%42/*?GH;#S-9 >VCQ_\ 91BK:^5?
M/BD%?,]DI6G&FCQBE.E/]([8J[_"WGVH/^)[.J[*?T1'M0UV_P!(\=\5:'E3
MSX%XCS/9<000/T/'2H)(/^]'OBKCY4\]D4/F:R(H5I^AXZ4:E1_O1T-,5;_P
MMY]JQ_Q/9U<AG_W$1[D="?\ 2-\5<?*OGPKQ/F>R*BM%_0\=-Q0_\?&*M?X4
M\][_ /.S66Y)/^X>/J>I_P!Z,57_ .&OS!K7_%5I6H-?T0G5=@?]Z.V*K?\
M"WGTA0?,]F0E>(_1$>W+[5/](_:[XJN;RS^8#?:\TVA^'AOI"?9/;_>CIBJE
M/Y0\[W"\)O,EC(@<2A6T>-AS5@P;>X^T&4-7%5X\J^>Q+ZP\S60GJ3ZWZ'3G
M4BG7ZQBK7^$_/6W_ #LUEL21_N'CV)%#_P ?&*I7YJTWSYHOEW5-8_3]A=/9
M027)@?2442,BAJ,WKG[7$;XJJ3VOF.W:Y^L><-/CFM#$MRIT="RM<$&-0!/5
MS*WV53ER;_*Q57M]*\W75S=6$/FZPDN+1HY+RV_1"<HWF7U(V=3<;,P^+?%4
M)J%OKMA>-:7GG#3XKR*W:\]$Z*I?T%8(\B 3$N%;CSX?9_:Q5"'2;G3;F^O?
M\6Z9;W$=U#:ZA.=)!,=S<>F\2/6X*Q-(9(6_9^-D_:Q5<?KEKJ5S:CS;IQU"
MOU:Z$6AEVK"%E*.8YF7]S]821J_W?J\F^UBJ97ECYCL[B2&Z\U:<LX@DO9(?
MT.&<P1D"27BMP6*JS"N*I?-J$\*13/YMTPQ7$8N8)TT5GC>-HS+ZBR).RLOI
MJSEN7PJK8JB+V?4[(06EQYKTX).@GMXTT5I(W5@7#KZ<[(?A5G_U?BQ5!2:Z
M1")V\XZ;Z7 2K*=#D*\'IQ>OK4XFB[XJC[G3]7_2'Z(G\Q:<;N:- \!T1MXY
MN2IR87'%0_INJ\F_8Q5+(8)-)6:RM_-.DPQH\B.GZ%EE+N'2&50YNG]9D<Q1
M2A&?A\"/QQ5&WWZ:M([:XNO-.E*)X3+;_P"X)VD]"$#D_!;DND<7(<F956/E
MBJD][?1.T+^<M&C$DT<1+Z,5C>1Y##&0YN@CCU5,*R!N'J?N^7/%5*ZU:^MW
MDMKGS?I<9A]7U(WT&:BA"(YC_O12B\E60_Y6*HVT37&MH+BW\W:.L-U.;"$C
M1^!:XW4VY4W082? 08V'[.*H*ZU2\L9IHY_.&DQ.AD$K#0Y"I, ].;XUN"K^
MB/W<O$_N_L/BJZ"\O9IWL8_-ND":5/3>W;0G0NL$1E$?%KE>9CBK(L7VE3]G
M%52TM]3U":"PMO,VCSM)Q:&,:"QCY"/UU'(W/!9%C/J^G7U%7XN.*J-Q=7,S
M2S3^;=&G<.H9VT)I&<LQ@5D/UDF52P:$21\TY?NN7[.*M175Q,ZJOFO2&:27
MTE)T%P#--2(K4W%.;U2-_P#8JV*HJWU_5($CAB\Y:6(S\,"1Z-,%849^4?&Y
MHR\4=@Z?N^*LV*H_2K_S7J\D\.E^;]*NI[7:>,:7+R7XFCJ1]<4T]2.1-OAY
M(Z_:7%6M8O\ SCHHA;5O-NE6RS%O3'Z*G9FX*68T6\8\54?$V*HJRC_,"]MX
M[FW\S:4\,I/!OT5,I-#Q.S7@->0(Q56_1WYETK_B/2J5I7]%RTK6E/\ >W%7
M?H[\RZ5_Q)I5/']%R_\ 9;BJPVGYC"<0'S-I/K%2X3]%RUXJ0"?][?$XJMBM
M_P PY;B2VC\SZ2\\2AI$72Y25!+**TO?YD88JK_HK\SO^IBTO_N%3?\ 9;BK
MOT5^9W_4Q:7_ -PJ;_LMQ5WZ*_,[_J8M+_[A4W_9;BK7Z*_,[_J8M+_[A4W_
M &6XJN&F_F:&K^GM**TH0=+GZ^/^]N*MMI_YF@'CK6D$]BVFW _5>XI6FP_-
M&NVLZ-3M73;G_LMQ5&:1:^>X[Y'U?4M-N;$!O4AM;*:"4FGPD2/<S**-U_=X
MH3_%78J[%78J[%78JI7?^\LW^HWZCBJ$\N_\H_IG_,)!_P FUQ5__]#U3BKL
M5=BK@*#K7YXJ[%78J[%78JE^JZ5)?36$J3^C]1N#<4X!^=89(>)J13:4G%6+
MO^5UJT5J%OWBEL)OKE@T4:QQP733K*[QQ*1&(W6,1>C3@JM(WVY&Q5DFK:(=
M5TI-/O)4E0R1/=<XE9)DC<.T;1L2.,E.+8JQE?RLAA>RDMM7NDETJ?U]*DD_
M>F$-++)+&]6'KK*DOH,9?C]*-?BY_'BJ!/Y*V*0B*WU6:(-!+;R*T:.G&?TF
MD]-2?W2O+$9F4?#ZDTG^1P53O5OR^@U;R_#HE[>O]5A,S@0H(0)9 PB9 A!4
M6Y<LB,S\F_O.6*H2_P#RQ74$O);O59?TG>QS03WT421EX9X?2X21U*/Z7Q/"
MQ_NVD?\ 8=EQ5,)O(R3Z-K]E-?2->^8U*7]^$0%5]$6ZB.,? H2):"O+XOB;
M%72^2I)-1DOFU%O4EGL+AT$2TKIZD!>O24FK?R_LXJ@+K\MKBZLXK*;6#)90
MWD]^ML]M$R-+<22R.)-^3*#.X7XEQ5&ZKY"BU#DKW\B1W5E!I^J($3_2(;9V
M=*&@]%R9)%;A^P_\W%\5=#Y"L(/*MSH7J1N+N0S7EQ+ CI,Q<.?4B)XGX5"5
M4HW[:LK_ !8JQ5=)\FV=^MNGGBV36)!]6A6:>VDE9'M8K22-T9^<CR""&16K
MZBRK^TK,N*IK=?E-IDEH(1J<T5PT3V@N0$Y2P/"(@DRGX9G2CR)(?B5I9?V7
MQ57A_+&./6;36%U)DN["GU18H(TA0>K+)(OIU(99!<RKO\2?"\;*V*LGUK2W
MU 67%@OU6Y6Y^+<51'5#3]K@[+(%/[28JPO5ORQO;JQM;&":#T[.!+/UY!5K
MB.:9);J6>/@5YCC+Z40?@\DS2.R?9Q5,=,_*W1].M]6AM[J?_<I;_5?4/#G#
M&5 =(V"@K&SCGZ0^#XL549/RSMK/3=9;3#'+K6K0-:+>W"J@@AF),RQ"-3P3
ME)+(L:K_ +[3[*8JHO\ DSY<:)N$KQW-$6.Z6.+E$BB5N$0X\8T,T[3?!^TL
M:_93%41HOY76&CZG#+9S4L$=)F@X(IY023201KP"TC5[CF_(LS-!#_EXJSC%
M78J[%78J[%78JIS7-O#3UI4CY?9YL%K\JXJJ UW'3%78J[%78J[%78J[%6-?
MF9_Y+[S%_P P$_\ Q XJI:]Y#MM;EN9;FZ91<&W>)/31A&T$<L5?BKSY)<2<
M>7]W)PD3XDQ5VD>1#I6LMJUMJD[W5Q%Z-^9AZ@N%67G$6J?@>*/E"K)]KGS?
MD^*JWF3R-8:_?"[NIWC>.%([9H@%DB=)"Y=).O[Q&:&6/[$D3<6Q5*;C\K+:
M>2^,NI3/#J_IMK$+H&6>2*=YED6I_<MQ?TOW7P\%7]K%4/!^44,%TDZ:M+(8
MY9+A#<0QROZ\T4$;S,[?:E)M4EY'_=K/\/'X,5337?R_75=9;6?TC+;ZAP>W
MBD5>2K:2P-$\!0MP8,[F?GQY^IP_87%4./RS2WEBDTO5);#TW>7TTBC>-7EM
MS!*8D>JQ*_-YN'Q)ZS\^/[.*IM_@^"!- AT^X:VM_+T;Q6L3*)>:FW-LO-B0
M?@4\O\IL52>7\M'DT8:5^EG$0TN'2?4$*\N,$OJ"7[5.;#X&'V<51T'DN_'F
M9-?N=6^L7(2.)U^K(E$C:4A(R&/!6]=E;EZC<?VL52Z__*N"[BCMCJ3K96LL
M\UA;F)6]/ZU<">=7:H,JL0R)7CP1_P!MN+8JGE[Y5+:M::IIMX;"YMK0Z>RF
M-9D:V+*X4!R.,B,GP/5O^+$DQ5)1^56G-]5AN+KZS860:WMK2:%&7ZG)(998
M'-?C9VX+ZM/@2/[/+F[*J\OY=5LX;2/5IRD&G7^F++<*L\K)J$B.TCR$J7>,
M1JJU^W]I\503_E.#81V":S-';6DKW>EA8P'M[MY4F$Q<-RG]-U?TUFY_!)Q=
MGXKBJ8GR)<_X>U'0!JK"PO$N([?]PG.$74IEDJU?WG$LRQ_9^'^\]5OBQ52U
M;\MH-6U'4+F]OF,-\PE6.*,1RP3);I!'-#,&Y))'Z0D5J?S)_=_#BJ_1?R\3
M2KZTDCU&22QM)Y;M+0H%+3W$/I2EI WQ1%BTRQ\/@D_W9P55Q5+Y/RCMI8;"
MWGU)I;;2XXK2QB:("EG%.DYAD*N#([F&&/UO@XHGV.;\\51S_EM;-;WL"WA3
MZ_J*W]PXC^(Q(3QMZ\]J!F7U?MXJI3_EU>S6&DV;ZPKQZ*/3LBUJO]V(#;KZ
MG&1>3JC5Y#BG/_=7'DK*HORCY"'EO4KR^CU![IM0]1KQ)(P.4CW$DZLC<CZ0
M7UG1HT_=/_><%DYLZJOKOE!M6O[B=IQ$DZV*.>/-FAL[A[B2"A*A%G8H'<?L
M_P"QQ5BD_P"4UWJNMB\U*1+6W9I[NMJP:6"XFF$B1P.42@C823-.5YO)/(O%
M%XMBJ<_\JOMAH6FZ0NH2+%922RW+A ?K#S AI&#$\9EK^[EJ[(WQ_;X\54'J
M'Y5VTFGZ5H%J(UTA+B:^UFZ<!IY[EXFC#A3L'8R._/E^YX1<4;CBJ&N/R+T.
M6W,"WDD8DB*SN(U+R3L)^4[,34GE<\N'V/W,2_9Q3;(O)/DQO+OUCG,):@Q0
M$ *2AFEN&DD V]222=A_QCCC_P K%#*L5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BJE=?[RS?ZC?J.*H70 HT+30IJHM8:'Q'IKBK__1]4XJ[%78J[%78J[%
M78J[%78J[%74WKBK$'UW4['\T4T>^N/]Q&LZ;ZFCQ%5 %W9NQNE# <N30R12
M<6/V4;C^UBK+\5=BKL52?S;YFL_+6A3ZM=1O,(S'%!;1TYS3SN(H8EKL#)(Z
MKR/PK]K%4F_1'FF33SJ?F+S%/I]PD1EELM)2!;: @5XJTT4TUPR_S,RK)_OE
M?LXJG7E*[UB\\MZ?=:Q$8-1FB#S1L K@$DH9% 4)*T?%I8Q_=R<D_9Q5-\58
M;^;6A:QK'D^2+2HC>3VD\-W+I <Q+J$,+5DLW<,A595_ROMJJO\ !RQ5$^7]
M#\AZMY:B^I:%81Z9=Q@36!M85".-FBEC"T]2)OA8']K%6.^;=%C\MZ1Y*TJP
MGE>*'S+91PRW+>K(D4C3,8D9OLHL9]",?LQ?!BKTO%78J[%78JDN@:Z^J:GK
M]N /0TJ]6SBD'4M]6AFD!_U7EIBJ=8J[%78J[%4G'G#RN=<_0(U2W.L T-D'
M'J<N/+AX<^/Q>G]OC\7'%4XQ5V*I/YQ\PKY<\L:CK1B]=K*$O% #3U)6(2-*
MBM.<C*M<52C1?RXT=%6_\R0PZ_YBF_>7>HWD8E57._IVT<G-;>"/[,<<?^L_
M)_BQ56\V:KYDTVXTZVT8:?%#>RI:QR7GK22&=R3QC@B],,J1*\KLTZ_"OV<5
M43I_YL<U<:WHI %&C_1MR 2>_+ZY7;%5'SAJ/F;3_+&GP7-Q"-1U+5++3KF\
MLD>%(X+JY5'9!(\C*_I?N^7/[;\DQ5.-2T'6[JYBDM?,5WI\"2!FMX(;1@R!
M:<.4L,C==^6*J;:7YSMI#+::W%?(*_Z+?VRKRVV_?6WIE#7]KT9?]3%4;Y;\
MP6VN:>US$OI3V\TEI?6Q-6AN8&X2Q$T'+BW1OVUXMBJ:8JQK\S/_ "7WF'_F
M G_X@<59(OV1\L5;Q5V*O,M?UGS/9:_J][HUO=&UEDAM/K$D$\T<<T%O<.1%
M;&G)+B=;6![B,>G\?V_VT505MYB\]6TLMO'ZL#7UYR*2V-Q<BS]2\B2:DE0L
MD8BEF>/[,:I#\/PXJFSZKK6H6?E/4-=ANK?2I[6X;7(K>.>-EO>*+!ZL<?\
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M-7\N"W'_ !'8<O\ C,N*JB_F=^7K*&'F*PH>G[]/ZXJV_P"9GY?(Y1O,5@&
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M\O\ _J9M*_Z3;?\ YKQ5=_RL#R'4#_$FEU/0?7;?_FO%5W^/?(W_ %,6F?\
M29;_ /->*N_Q[Y&_ZF+2_P#I-M_^:\51&G^:_*VHW(M=.UFQO+I@66"WN899
M"%W)"HQ;;%4UQ5V*NQ5V*NQ5V*J5V:6LQ\(V/CV.*J&C&ND6)\;>+_B Q5__
MU/5.*NQ5V*NQ5V*NQ5V*NQ5)M=U":RO]*2-XUBNIIDN%=*U5+:653R&Z4DC2
MNV*O.[3SSYO74]*CFD2XBF:(7J) I1UDO3 TMO14E>#T/WL9/!U5?5EY1XJS
MOS9JLUK8:=)93I:VU]=Q0W&I^F)5@@='<24(*#FZQQ"23]VGJ\FQ5AMUYO\
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M-I/:GT9XV$D;AF"@JRD@[XJS'%78JEWF#7]/T'37U&_$QMD95;ZM!+<R N:
M^G"LDE/$\?AQ5XO<>6/,NO\ E'S?KUGI=P!JOF*UUFPT>Y3T;B[LM/,')6B>
MA1K@0NT4<GQ-\'\V*60ZYJX\_>9?)T.@:??1IHNIIJVJZA>VD]FMM'#$ZFVK
M.B>I-.S\"D7->/Q,W'%5+R=I-_'^77YC0364L<]YJ>OO!"\3*\RR(1&R*161
M7_8*_:_9Q5#>6M*U,:G^3;SV4X%CHUXEXSQ./0D-E"JK*2/W3D@JH?CBK*/+
M-E=Q?G#YVNGMY([2YL])]*<HRQR/'',&XN1Q=D^$-3[.*&->?;?R_'^<MI?^
M9]%EU70_\/F"-OT=-J,2W1O"RCC'%,%?T^6^*67Z-YQ\L6EKHEAH&B7T.FZC
M=RV4$<&G2VD-JZ*9G>:.1(3%$Q;:3AQ9^7^5BA#_ )I:1K?UCR[YKT2T?4+[
MRO>O<3:;%3U;BSN8C#<K%RV:94(>-?VN/'%4D\[^:6\^^7)O*'E;3]0>[UOC
M;:A>7EE<V<%C;,P,\DSW"1AI G)8XHN;,^*5]U/_ (,_-:ZU.]L;V;1-6T6T
MLK*[LK::["W%E))6"18%=T9TD5HV9>#8JQ*?0_,=U^3?F;EI-U#?#S1+JC::
MT9:X,":A%.W!5KZA$88_N^2MQ^#%4_\ .\K:AYF\N>=[:;6;?RTUC=V$]YIE
MLZWEK)),CK)+;3023^A+Z11V2#E\,?[#8JE?F;R]IEU^7GF'4-!EUG6KK6-3
MTKZ[)J5M(DTGU6XA7E'$8+=C&L1H[^GQ^#_(Q5FOG:QO)?S4_+N[@MY)(+9]
M5%S<(C,D:O: *)' H@=OL\OM-BAD_F3RM#KRVXDU+4=/^KEB#IMW):%^=/[S
MTS\=*?#7[.*HC1[6.S#6:S23BW1(UEG<R2L%%"SN=W<G[3'(CFW9/I##$N/S
M!9M-:S-R1R1]16ZB"AID6=FA')5*PRA8T:1?@1V@]-O[S)-*>:=JWF4:-H[S
MVTGUB<HFHR2P.98:P<Z-$A'-FE_=M(G[J/\ V.*J.H:AYT]$N;.2W8PW4426
MX64F=XA]69N+2\0) PY-Q1?V\51.E7^MV]QJ5K=1RWEQ\<NGS,K11R%>1]"C
M*%C]/]VGK+RCFYJ_V_47%5.QUCSG<A>6F*L995,[+Z)H40N?3DD#KZ<C21]'
M]3T_47[6*H6.\\TRZ7.LC7,%U]7M$B=[=VK<0KRNP?30NJRD^GZJJW\\/+AB
MJ3_FA?:Y-Y:T&2*TN(HAJ>GG48.LXE2>)HHU8*Q93+\/JQ(WQ\/V>>*IV/,/
MG0Q%UTCBWPJUNZ.6C:5VCBK(&XS*M8I[AXU_=1^JOVL54QY@\_L#72H495G+
M+Z<SD/&RK&G5%8.']171GY\67X>.*KKG7_/44LPCTQ)(X/7 (AEK+Z(E9"OQ
M_#Z_IQJOVN/J_M8JVOF#STTOQZ5''&#,7C"2NX]-T58^7PH?41RZRIZBM\7P
M_#BJ(L]9\R)Y>MS/ \VKQ2K%J;FW?]VK,U9$A0CUN*<-HF_:YXJIVGF#SM-^
M[DT417*J[.E#P&\7IA96=$8D/+RHW[&*I=>7GYBEKAHX61?K;B% M6"?5XBH
MV#+Z/JF7XP[-BJ)L-1\U6NJ^OJJ336AN;J)K>*-PL40D?T9E8)2=''IQ>F>,
MJ_#(G-?4Q5FV*NQ5V*NQ5V*NQ5V*NQ51OB5LKAAL1$Y!_P!B<54-$).C6!/4
MVT)/_ #%7__7]4XJ[%78J[%78J[%78J[%78J[%78JDGF'S5;:3+#8P6\FI:W
M=@M9Z3;<?5=1L9)&8A((%/VII65/V5YR?!BJ37?D?4O,]JT?G:]]:REH6T#3
MV:&T4@\E]2?X;JX=" >7.&+E_NC%6$V.FGRE^8/E70-7M(9;9I[R'1]?,*^I
M=126Q,<-U(%_WL@:/AS8_P"D(RR+\?JXI>U8H=BK&?-MK<ZC;I:3Z+=:E:*X
MD,5G>);+(0*!9>4MN73?^[/)/YL52^PA\VVUK]4\N^5],\NQ= ]U,K #Q]"R
M0AS\[E/];%4@_*CRK9R3ZX^K.=3N-"UV]M]-$@XVENS\+B1[:VJT<3&6>2CD
MR2(OPK)BDO5<4))YI\J66OV\):1[/5+)C+I>JVYXSVTQ%.2'HR-]F6%_W4R?
M"ZXJE_E_S7?Q7T?EWS9''9^8"*6MU$"+/4545,ELS?8EVK):.WJQ_:3U(OWF
M*LKQ5V*H+5M:TK2+0W>I726L V4N?B9NRHHJ\CG]E$5G;]G%6-7=KK?G2(6U
MW;R:/Y4E_P!Z8):I?WT?41LH/^B6TG^[5;_294_=,D'Q<E681QQQ1K'&H2-
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M5LQW_P!Z(O\ FK%7'S)Y=%*ZI9BO3]_%_P U8JM/FCRT" =6LJG<#ZQ%N/\
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M_*=A1M,N&'<&^O"/QEQ6V_\ H7;\JJ<?T?<\>E/K][3[O5Q6V_\ H7C\K/\
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<1P.*KM/NHI[=/3610J(?WD;IU&U.8%?>F*O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exh1_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1_2.jpg
M_]C_X  02D9)1@ ! @$"6 )8  #_X1BU17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  6XV    G
M$ !;C8   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,34Z,3 Z
M,3,@,3 Z-3 Z-34      Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !=_
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MR[7A[&M;:  6MR+FR)AL5XYH_.*3F956*UCV-L<;&^H:[GD[M&N%?J!UC/\
MMWZ:#U:FFRYHOR**[VCAU#3(=[9+[O6_FV[W-VHI9NQME+Z+6>JUCV^D6AQ.
MWVOVOV_S7IL^A_-I*0@-?62S%RP6- V?:+VF /;M:7M:Y_M_ZA3%MC+Q=]DR
MP6G=_/6O8=P(_F=SV>W=]#TTS,&Y[1NZ9B5N8V& L88T>X,]I]OZ3_SZC8U?
M4,<[*L/'QV/]Q-4  [?\(UIKW?N)*9U=4OL<UGV*UA>8EX< /-[_ $RUJ?-%
M]OI5VUM#'N<'%MKFF/3L_P (RMCV?UF.2]7K.XM]&KO#YTX);+=^_P"E[$.Z
MS-+&V9K:J6,<\N:6FP%@J>YSSML_\#VI*7;34+&N:&EX/M'VNT]V_FG^4U1^
MS4 ;"&B'3KF6SN)GZ7TOI(5=_32\%C\8.DP?LKAK#''W;_W?32]?IKH._&.X
M@@_97<[B/W_WV)*;>(<EKKVUU5EHL:!^E)T]*F/=Z7N35O#8+6TF/<"<ASC#
MG%TRYA]N]R6$S(!N%3ZF,#V[6^DYH ]*G;#/5;L0F86)<RMS*L9S'L;Z;OLA
MC8[WM_/]K4E-F]^2YC-U; PV5>YMA=IO9P/3:KBIW,R&5L#GUFL65#:VLMTW
MLC;^E=M_S5<24I#UW_VO^^HB'^?_ &O^^I*?_]7U55\_^@Y/_%/XU_-*L(&<
M8P<@\_HGZ?V2DIS,YF?:02V6,D!SO48?=#?HXKV[_<I6.SJZ1ZLMVVM+=K-S
M8G<XOWO]3Z>Y/U&G-LL;;4SWB ]C;[FR"=C'-9CFKZ+G;G[E-S+F4-9M#@;F
M[W>N]T&=K]KWM=8S_.24UF]8O?47LOI>6B8;+A^>[EC"YOL9O_FW_P"$4V=5
MN#WMR;V5M:2T%K3.YH#G,>;FUU[F,_<1SC;-CW-,,.YI=EVQ+?TONGVO:W;N
MV/3-J:QS3)EAW#=FVGB#[FN]KF_UDE(QUC&/&:# )/M9H -SOSOS6_24_M%M
MSL:VJRRRMSGEKVUL(,,>-#N5P7Y!<&BNK<9('JZF-'?X/\U!R77/=4+*V!AW
M@D6D0-CMWO;6-J2D?J]5W&&^S\TEH#CS])L._DIF7=9+V^HP-9^?M&YP_J;F
ML:Y/736VUKJVC>V('VJPCF=6?1=[GJ+J*B-0WF?Z78-1N\/BY)3*E^5OO@VS
MZNOZ-G^CJ_E*7J=1]4:N]#:9)K'J;YTCW>GZ>U3Q3DM-X94P@6 ";2=!75M]
MQK5<83"1#2=S&L &;=JUL%D?RO\ A?YW^6DI*]^2?3#S9M]2N=U;0/IM_.#E
MHJG8<@5UL=4UK ^H;O4+C >S]YGO_P Y7$E*4-=_]K_OJFA_G_VO^^I*?__6
M]50,^?L.1'/I/B?ZI1T#.G[%D;>?2?$^.TI*<OJS,=]C'9'V5E[2/:Y])>YK
MO;[OMF._VL;N=[$1Q_5 RIV.ZIMC667->WEOL<;-E/H^HQ@9])B747['M%F1
M6V]NK& .JW!WM=OL+[6_04K39]E_0W,>RMX:YQ8\.EHU<ZPV.=]'_"['I*:>
M-B8X]F-F8_N&TM9]F]T!SH.S$]VVL7?V/51:S@5M<;K,"][FRZVQU37&M^M;
M7^G2QKJ_9_;5>BT03ZS:M.^0XQ < UHK=M^G_P!7O5IV)U4..CW-^E O,2Z-
M[/>/H-WV;-[DE,@.FY$,%73[?4<=K=S7;G@ NC]'[G_15C)]5GI"VNAM(]3>
M'.(9MV/+]\U[-G[Z!C-ZO6\DT[MY$FQ[;-L>W>(-;MVWZ?\ X&B.LSSZ-V2*
MZ-I>2TM+R &NU<ZNW:DIB+,(VL ;@FW3T_>W=,C9L_1[OI[-JB;>GZ$MZ?\
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M_]G_[1U04&AO=&]S:&]P(#,N,  X0DE-!"4      !
M    .$))30/M       0 E@    !  $"6     $  3A"24T$)@      #@
M           _@   .$))300-       $    'CA"24T$&0      !    !XX
M0DE- _,       D           $ .$))300*       !   X0DE-)Q
M  H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      -%    !@             #CP   L     ( &4 > !H #D .0 Q %\
M,@    $                          0             "P    X\
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   X\
M4F=H=&QO;F<   +     !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   ./     %)G:'1L;VYG   "P
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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MEV7:ZMI'O<V'F&^ZYK=C'_0_XM)3H[&?NC[D/:-\0(W\?V$4" !X*'Y_]O\
M[ZDI_]#U59G6<'+RS2<>UU0KW;RV^R@^[;_H66-L^C_A%IJGU'IU>=Z?J;2*
M27!KZZ[-=(+?7:_TWZ?FI*<4=%ZX&EOVW<'-A\Y5_('L-;MNYGN=[_WV)7='
MZZYY RVAN\/#79-^Z6R*_<T,_P %Z?J,_F[;?TRMW4=,Q133=@X_NIWG?Z3"
M"S]+MV;?1^FS?^A?]-!^U='R'O-N%AV.(FPNLI>X[6^V6D;W.VUI*85])ZT
M-^8"^IVYL9-T Z3ZNX/]5OMK_1V?\)_IDF](ZRV2<P%A#6O(R;P06G?N9H]K
M7.]N_P#TG^$_G$47=':\..%AMB&V.WU;AN;ZC6_0_2->QOYKT2O(Z>&-I^Q8
MS*6GU&-:ZIS=-GO:RMI;NVN8Y)34'0>KG=Z>6[:72/UO()$CQ;])SE-_1>N.
ML=;]H8;'/#B3?; :0]KF"MK!7W;]!GI?\ K^-7TS)#658N,9:UUC T:3&_\
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MT.;5_-M<\O\ S6C9ZCTE,G]4H;8ZIV%>7L]I I<X?R=KV-=6YKOS/<F/5L>
M3AY&HD?J]D^'^C0#UZT#<?LX 'O!NJ!:?Y7Z?;[MW[RD>MV>_:[&>& $N%S(
M!.QNQ_Z7<S])9Z?T4E)3U;'9+CA9#2'$$>@^=Q);IM9[_4=^>Q$?GL] 7'#M
M?6XD-:&#>2W=_@+-EOYCOS/_  -4SU^T :8Y>6[]HOJB#JSW.M;])CF/W,9L
M]Z*+K^I-K:^NDX[WN8=VVUCQLMW,_0VV-]L?I-Z2F7[:IVE_[/S( !/ZNZ8[
M>WZ6[^0I/ZE26D68.06F"YIH<[1QC\UKMW\MO\XJ]N'TRBPTW-PVO< ]S'L.
MH)=2UQW/_.=8]G]M*CIO3LD;J&8CP"22UCN3]+_"?R4E-P]2'I&_[)<6@M!A
MDO\ <&N!=1_/MVML_2;Z_48A#J]!&[['D0"&R:+!SNX'I[]OM1,6O)J]>NMU
M3&5O#0-KH %5,?GHC;[WM8YEM3FV-:YC@QY!#OH.G?\ G)*84YU=S0X8MC:P
M\5EUC/3@N+1HR[TWN9[V^]C5=:QK9+0!/,#P56\9>UGJ.K+/4KD-:X'Z;./>
MKB2E(7^$_M_]\14+_"?V_P#OB2G_T_54#/\ Z#D?\4__ *DHZK]0_H&3_P 4
M_C^J4E-3/9F6['LKAS 06"^QDAQ:/HXQ9N_MJ-C<NK 92^O<]K@"YMKG&2?S
M'V[KOZN_](EU&C%R2++:'AS=#8:*["1PUOZ9EGC^:FNV4X0J]&T^YH>[TV N
M_,G8V*?H-V?S>Q)338>H&MSVTV$C5P<_+#HCVBK>=WTO4W_]93"[-W#=5>:P
M 8!S0[W#;=[M=_N;^AW?S/\ Y[JTV4,_34T .J  ?6S%EL"P^MN;2STOH^W^
M=_XM6_VO>VN?4N-I(_1V/QQMWM+F;WLJ_1_2]K;?W$E):_M;LGTKJ[6UO=H:
MW931(W-;[S^BJK]ON_FZ_P#MRM:%]EPMH<ZH- >XD[QVKLY]JSJNI5N<P.ZE
M8;'$ U!M!U,?HQ^B:Y%KR*<H-:76]0I?:YKQ8RLM$5.W4[6-J:]OY_OWI*;E
MH=;8'.:0Z( ;>YH(G]RO:WZ2:F:"=C2XN,'?>7]S]'U-VWZ7YJ84X+7![>GP
MX&0X55R#IWG^2U,,? #=HZ< V9CTJXF=T_YR2F>/;<7Y#FUM(-@,AXC^;I_D
MHOVBV0/3;K!'Z0:SQV0,:\-?DM&/9M]0#:&M@ 54B(W(K+6,:UK,5[6L :P!
MK0 !]%K?=[=J2ELA]Y8P/J#6^I5)W3^>SR5M4[\@O:QOHV-FROW. @?I&<^Y
M7$E*0]=_]O\ [XB(?Y_]K_OJ2G__U/557S_Z#D_\4_\ ZDJPJ^?/V'(CGTGQ
M/]4I*:74*,NUX>QK6V@ %K<BYLB8;%>.:/SBDYF55BM8]C;'&QOJ&NYY.[1K
MA7Z@=8S_ +=^F@]6IILN:+\BBN]HX=0TR'>V2^[UOYMN]S=J*6;L;92^BUGJ
MM8]OI%H<3M]K]K]O\UZ;/H?S:2D(#7UDLQ<L%C0-GVB]I@#V[6E[6N?[?^H4
MQ;8R\7?9,L%IW?SUKV'<"/YG<]GMW?0]-,S!N>T;NF8E;F-A@+&&-'N#/:?;
M^D_\^HV-7U#'.RK#Q\=C_<35  .W_"-::]W[B2F=75+['-9]BM87F)>' #S>
M_P!,M:GS1?;Z5=M;0Q[G!Q;:YICT[/\ ",K8]G]9CDO5ZSN+?1J[P^=."6RW
M?O\ I>Q#NLS2QMF:VJEC'/+FEIL!8*GN<\[;/_ ]J2EVTU"QKFAI>#[1]KM/
M=OYI_E-4?LU &PAHATZYEL[B9^E]+Z2%7?TTO!8_&#I,'[*X:PQQ]V_]WTTO
M7Z:Z#OQCN((/V5W.XC]_]]B2FWB'):Z]M=59:+&@?I2=/2ICW>E[DU;PV"UM
M)CW G(<XPYQ=,N8?;O<EA,R ;A4^IC ]NUOI.: /2IVPSU6[$)F%B7,K<RK&
M<Q[&^F[[(8V.][?S_:U)39O?DN8S=6P,-E7N;87:;V<#TVJXJ=S,AE; Y]9K
M%E0VMK+=-[(V_I7;?\U7$E*0]=_]K_OJ(A_G_P!K_OJ2G__5]55?/_H.3_Q3
M^-?S2K"!G&,'(//Z)^G]DI*<S.9GVD$MEC) <[U&'W0WZ.*]N_W*5CLZND>K
M+=MK2W:S<V)W.+][_4^GN3]1IS;+&VU,]X@/8V^YL@G8QS68YJ^BYVY^Y3<R
MYE#6;0X&YN]WKO=!G:_:][76,_SDE-9O6+WU%[+Z7EHF&RX?GNY8PN;[&;_Y
MM_\ A%-G5;@][<F]E;6DM!:TSN: YS'FYM=>YC/W$<XVS8]S3##N:79=L2W]
M+[I]KVMV[MCTS:FL<TR98=PW9MIX@^YKO:YO]9)2,=8QCQF@P"3[6: #<[\[
M\UOTE/[1;<[&MJLLLK<YY:]M;"##'C0[E<%^07!HKJW&2!ZNIC1W^#_-0<EU
MSW5"RM@8=X)%I$#8[=[VUC:DI'ZO5=QAOL_-): X\_2;#OY*9EW62]OJ,#6?
MG[1N</ZFYK&N3UTUMM:ZMHWMB!]JL(YG5GT7>YZBZBHC4-YG^EV#4;O#XN24
MRI?E;[X-L^KK^C9_HZOY2EZG4?5&KO0VF2:QZF^=(]WI^GM4\4Y+3>&5,(%@
M FTG05U;?<:U7&$PD0TG<QK !FW:M;!9'\K_ (7^=_EI*2O?DGTP\V;?4KG=
M6T#Z;?S@Y:*IV'(%=;'5-:P/J&[U"XP'L_>9[_\ .5Q)2E#7?_:_[ZIH?Y_]
MK_OJ2G__UO54#/G[#D1SZ3XG^J4= SI^Q9&WGTGQ/CM*2G+ZLS'?8QV1]E9>
MTCVN?27N:[V^[[9CO]K&[G>Q$<?U0,J=CNJ;8UEES7MY;['&S93Z/J,8&?28
MEU%^Q[19D5MO;JQ@#JMP=[7;["^UOT%*TV?9?T-S'LK>&N<6/#I:-7.L-CG?
M1_PNQZ2FGC8F./9C9F/[AM+6?9O= <Z#LQ/=MK%W]CU46LX%;7&ZS O>YLNM
ML=4UQK?K6U_ITL:ZOV?VU7HM$$^LVK3OD.,0' -:*W;?I_\ 5[U:=B=5#CH]
MS?I0+S$NC>SWCZ#=]FS>Y)3(#IN1#!5T^WU'':W<UVYX +H_1^Y_T58R?59Z
M0MKH;2/4WASB&;=CR_?->S9^^@8S>KUO)-.[>1)L>VS;'MWB#6[=M^G_ .!H
MCK,\^C=DBNC:7DM+2\@!KM7.KMVI*8BS"-K &X)MT]/WMW3(V;/T>[Z>S:HF
MWI^A+>G_ $O;[V_2]W'Z/Z?TT9N8'6"L7U>H2&@>A8-9VQ_.?O.3.S6@![KZ
MH)@'T+.=?^$_DI*28[LS?D;65&;!^>Z(].K;_@TJ;7;6,H;C;0-M88\Q#?;M
M9MK_ #=NU+%^U/-SV6U[7/#@?3=J#746G^>0AU%H8'#)J#'-WM_06:MD3M_2
M_P I)38N=E[6>HRL,]2N2U[B?IM[>FU6U3L&2ZNM[K&.K+ZS K<TD%S=OTK7
M;?\ ,5Q)2D.??_:_[ZB(7^$_M_\ ?$E/_]?U5 SP#@Y .H-3P?\ -*.@9XG!
MR!_P3^-#]$I*<_-9&3]GHQ&;"&S8*[&P2?\ 3TTV5_F^_P#\$3.91?C>K]E;
M6\6@-!I?6Z -_#JVW^V?IU-_XM+/NJHR1BM-HL> YI;D@.B3]&F^YN[Z&U-8
M<3+P3?6][J2^-S<ASVN;!_/-CJOZV])2"AC@PBRNRV!])S<F3J6N]GV7VN])
MW[[_ -+Z:>GIMEH+JJI8'0!:^REPT]WMLQ=UC6._F[/S_P#MQ4\6GIOT[',]
M5GN%C+J1!DASF/&3N]G\_P#0_P %Z:>GI>/>'.QZ?M-;7;=]1I> 8WECYRV[
M7L_PC&?^JTITJ>D7,?27,I<QKIL#WNLTU;[?T=7J>S_2?X7WJQE86.'U>A12
M+??LW,&W=L=]/:-VU5L?$SJS16YMYJ!AP]45AK1[(<*KK/:W^<9Z7_%JSEXS
M6.J-8ML>-Y;7ZU@W'8[V[G6>U)2U6)E;QZU&'L_.V-,\NXW-_<V)OL>; /H8
M4Z2-KO#WZPE57D/>!;BW5M,R[[4YT:N["WRW*.S*@'['=VD?:W3J/=_A/S4E
M),7"Q7&_U,>GU!8-T,!&[TZMVV6_O(M6$W:PVU4!T V!E>FZ/?L<?Y7\A#Q<
M2MQN+S:T[P2WUK)!-=4MW-L_-4ZL9S@TO997/T@<BPD?YKMKO\Y)2]V)B,V/
M936QXL80YK0#.X?G *VJ=V+77Z;VNL)%C-'6V.'TARU[W-5Q)2D+_"?V_P#O
MB*A?X3^W_P!\24__T/55"ZH74OJ<2!8TM)'(!&W25-))2#T+O^Y%GW5_^DU"
MW"?:W:[)M F06[ 1\'"I6DDE- ]*D0<S*YG2R.8T]K?H^U%IPGTLV-RKGB29
ML+'G7^4^M6DDE(?0M_[D6?=7_P"DU%V*]SF..19+"2W2ON-O^B5A))2'T+?^
MY%GW5_\ I)-Z%W_<FS[J_P#TDCI)*:S<2QA>6Y%DO.YVE?,-9_HOY"EZ%W_<
MBS[J_P#TFCI)*:_V9Y+=][WM:X.VD, ,&6_1K#E82224I"_PG_7/^^(J%(]2
M)UW\?V$E/__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '  ( !# %, ,@    $ .$))300&       '  0    ! 0#_X3EH:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[
MOR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A
M('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2(S+C$N,2TQ,3$B
M/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y
M.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX87!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(^"B @(" @(" @(#QX87!-
M33I$;V-U;65N=$E$/G5U:60Z-#4S1C=#.$%$,C<Q134Q,3DU-T$X0C0W.3)!
M13$W13<\+WAA<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX87!-33I);G-T
M86YC94E$/G5U:60Z-31#-S5$141$,C<Q134Q,3DU-T$X0C0W.3)!13$W13<\
M+WAA<$U-.DEN<W1A;F-E240^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX87 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@
M(" @(" @(" \>&%P.D-R96%T941A=&4^,C Q-2TQ,"TQ,U0Q,#HT.#HU-2TP
M-SHP,#PO>&%P.D-R96%T941A=&4^"B @(" @(" @(#QX87 Z36]D:69Y1&%T
M93XR,#$U+3$P+3$S5#$P.C4P.C4U+3 W.C P/"]X87 Z36]D:69Y1&%T93X*
M(" @(" @(" @/'AA<#I-971A9&%T841A=&4^,C Q-2TQ,"TQ,U0Q,#HU,#HU
M-2TP-SHP,#PO>&%P.DUE=&%D871A1&%T93X*(" @(" @(" @/'AA<#I#<F5A
M=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,R(%=I;F1O=W,\+WAA<#I#<F5A
M=&]R5&]O;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @
M(#QD8SIF;W)M870^:6UA9V4O:G!E9SPO9&,Z9F]R;6%T/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO
M<#I#;VQO<DUO9&4^,SPO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @(" @
M/'!H;W1O<VAO<#I)0T-0<F]F:6QE/G-21T(@245#-C$Y-C8M,BXQ/"]P:&]T
M;W-H;W Z24-#4')O9FEL93X*(" @(" @(" @/'!H;W1O<VAO<#I(:7-T;W)Y
M+SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G1I9F8](FAT
M=' Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C O(CX*(" @(" @(" @/'1I9F8Z
M3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @(" @/'1I
M9F8Z6%)E<V]L=71I;VX^-C P,# P,"\Q,# P,#PO=&EF9CI84F5S;VQU=&EO
M;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I;VX^-C P,# P,"\Q,# P,#PO
M=&EF9CI94F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z4F5S;VQU=&EO;E5N
M:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(" @(" @(" @/'1I9F8Z3F%T
M:79E1&EG97-T/C(U-BPR-3<L,C4X+#(U.2PR-C(L,C<T+#(W-RPR.#0L-3,P
M+#4S,2PR.#(L,C@S+#(Y-BPS,#$L,S$X+#,Q.2PU,CDL-3,R+#,P-BPR-S L
M,C<Q+#(W,BPS,#4L,S$U+#,S-#,R.T,Q.#="-SA"03,T041&03-#04,T-#0S
M1C8V0D$W0T0V/"]T:69F.DYA=&EV941I9V5S=#X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO
M97AI9B\Q+C O(CX*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C<P
M-#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.E!I>&5L
M641I;65N<VEO;CXY,3$\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@(" @(" @
M(" \97AI9CI#;VQO<E-P86-E/C$\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @
M(" @/&5X:68Z3F%T:79E1&EG97-T/C,V.#8T+#0P.38P+#0P.38Q+#,W,3(Q
M+#,W,3(R+#0P.38R+#0P.38S+#,W-3$P+#0P.38T+#,V.#8W+#,V.#8X+#,S
M-#,T+#,S-#,W+#,T.#4P+#,T.#4R+#,T.#4U+#,T.#4V+#,W,S<W+#,W,S<X
M+#,W,S<Y+#,W,S@P+#,W,S@Q+#,W,S@R+#,W,S@S+#,W,S@T+#,W,S@U+#,W
M,S@V+#,W,SDV+#0Q-#@S+#0Q-#@T+#0Q-#@V+#0Q-#@W+#0Q-#@X+#0Q-#DR
M+#0Q-#DS+#0Q-#DU+#0Q-S(X+#0Q-S(Y+#0Q-S,P+#0Q.3@U+#0Q.3@V+#0Q
M.3@W+#0Q.3@X+#0Q.3@Y+#0Q.3DP+#0Q.3DQ+#0Q.3DR+#0Q.3DS+#0Q.3DT
M+#0Q.3DU+#0Q.3DV+#0R,#$V+# L,BPT+#4L-BPW+#@L.2PQ,"PQ,2PQ,BPQ
M,RPQ-"PQ-2PQ-BPQ-RPQ."PR,"PR,BPR,RPR-"PR-2PR-BPR-RPR."PS,#LW
M,3E%-#4X0S0W14(Y.44R-T8W034X-C V-S W14(P03PO97AI9CI.871I=F5$
M:6=E<W0^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^
M"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H\/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X #D%D;V)E &0
M     ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,# P,# P0
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $'!P<-# T8$! 8% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@#CP+  P$1  (1 0,1 ?_=  0 6/_$ :(    ' 0$! 0$
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M^@=#_P"K=:_\B8_Z8J[] Z'_ -6ZU_Y$Q_TQ5WZ!T/\ ZMUK_P B8_Z8J[]
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M=#_ZMUK_ ,B8_P"F*N_0.A_]6ZU_Y$Q_TQ5WZ!T/_JW6O_(F/^F*N_0.A_\
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M2R#\F-6CBALOKMF(:%Y-4$3_ %^)SI\EAZ4#; 0+S$ZU;[7J)Q^+U,55;/\
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M73="%.G^FW=/^H3%6_K7YK5_XYNA4_YC;NO_ %"XJ[ZU^:W_ %;=#_Z3KO\
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M+**?N^'-)?V&Q5$S_FBEMK6G:;/I,RQZI<:A#9WB2QNC)I:EYYN(^/@55O2
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MO^IJTG_I-M_^:\5=_P K/_+?K_BG2?\ I-M_^:\5</S/_+<]/-.DG_H]M_\
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M-&E_])47_-6*N_Y6K^6G_4T:9_TE1?\ -6*M_P#*U?RU_P"IHTSQ_P!ZHO\
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M?EI_U-&E_P#25%_S5BKO^5J_EI_U-&F?])47_-6*N_Y6M^6?_4T:7_TE1?\
M-6*N_P"5K?EG_P!31I?_ $E1?\U8J[_E:WY9_P#4T:7_ -)47_-6*N_Y6M^6
M?_4T:7_TE1?\U8J[_E:WY9_]31I?_25%_P U8J[_ )6M^6?_ %-&E_\ 25%_
MS5BKO^5K?EG_ -31I?\ TE1?\U8J[_E:WY9_]31I?_25%_S5BKO^5K?EI_U-
M&E_])47_ #5BKO\ E:WY:?\ 4T:7_P!)47_-6*K/(6KZ9JUWYFOM,NH;VQDU
M1?2N;=Q(C<;"U5J,M1LP(Q5EN*NQ5V*NQ5V*NQ53NO\ >:7_ %&_5BJ'T4$:
M/8 FI%O%4^/P#%7_T?5.*NQ5V*NQ5V*H6YTG2KJ3U;FR@GEI3U)8D=J#M5@3
MBJC_ (>T#_JV6G_(B/\ YIQ5W^'M _ZMEI_R(C_YIQ5O_#^@_P#5MM?^1$?_
M #3BKO\ #^@_]6VU_P"1$?\ S3BKO\/Z#_U;;7_D1'_S3BK8T'0QTTZU\?[F
M/J/HQ5>='T@FIL;<D; ^DG?Z,5=^A](V_P!!M]NG[I-OPQ5O]$Z5_P L4'_(
MI/Z8J[]$Z5_RQP?\BD_IBKOT3I7_ "QP?\BD_IBKOT3I?_+'!_R+3^F*N_16
ME_\ +'!_R+3^F*N_16E_\L<'_(M/Z8JV-+TP5I9P"O7]VG],5<-+TP&HM(0?
M$1I_3%7?HS3:U^J0U'0^FM?U8JX:9IH-1:0@GOZ:_P!,57?4+'_EGB_X!?Z8
MJW]1LO\ EGB_X!?Z8J[ZC9?\L\?_  "_TQ5WU&R_Y9X_^ 7^F*N^HV7_ "SQ
M_P# +_3%7?4;+_EGC_X!?Z8J[ZC9?\L\?_ +_3%7?4;+_EGC_P" 7^F*N^I6
M7_+/'_P"_P!,5=]1LO\ EGC_ . 7^F*N^I68Z01_\ O],5;%G:#I!'TI]E>G
MW8JU]2L_]\1_\ O],5;%K:@\A"@;QXBOZL5;-K;&M8D/+[7PC?YXJTMK:K]F
M%!\E'],5;6VME^S$@^2@8J[ZM;5KZ25'3X1BKC:VQ-3"A/2I48JX6ML.D2?\
M",5:6TM%IQAC%-Q11_3%6VM;9OM0HWS4'%6_J\%*>FM.E.(Q5KZM;U!])*C8
M'B-L5;%O .D:C_8C%6A;VXZ1(/\ 8COBKA;VX)(B0$]?A&^*M?4[2@'H1T!J
M!Q7K]V*MBUMA6D*"O7X1OBKC:VQV,*&O7X1BKA:VP%!$@'@%&*M_5X*U]-*^
M/$8JT+:V!J(DJ>IXC%7&VMSUB0]]U'48JT;2U-:PQFIJ:J.OW8JW]7M_]])_
MP(Q5PMK< @1( >HXC%6_0@_WVOC]D8JT;:W/6)#_ +$8JX6UN  (D '0<1BJ
MT6=F.D$?_ +_ $Q5LVEJPHT*$#< J/Z8JU]2L_\ ?$?_  "_TQ5WU&R_Y9X_
M^ 7^F*N^I6?^^(_^ 7^F*N^HV7_+/'_P"_TQ5WU&R_Y9X_\ @%_IBKOJ-E_R
MSQ_\ O\ 3%7?4;+_ )9X_P#@%_IBKOJ-E_RSQ_\  +_3%7?4;+_EGC_X!?Z8
MJ[ZC9?\ +/'_ , O],5=]1LO^6>/_@%_IBKOJ-E_RSQ_\ O],5=]1LO^6>/_
M (!?Z8JJ1Q11+QC147K10 *_1BJ[%78J[%78J[%78JIW/^\TO^HWZL54-'_X
MY-E_S#Q?\0&*O__2]4XJ[%78J[%78J[%78J[%5DLT,*<YI%C04!9R%%3TW.*
MK;>ZM;E"]M,DR T+1L'%1VJ"<55<560S0S1B6%UDC;[+H0RGML1BJYW1$9W8
M*B@EF)H !N22<5:CDCEC62)@\;@,CJ0592*@@CJ#BJ[%78JI+=VK)+(LR,D)
M99F# A&3[08U^$K^U7%5\4T4T:RPNLD3BJ.A#*1X@C;%5LES;1RQPR2HDTM?
M2C9@&>FYX@[M3VQ54Q5V*H)-<T5W6--0MFD>0P(BS1DF5>L8 .[C^3[6*HW%
M5)KNU2XCMGF1;F96:*$L [JE.95:U8+R7E3[.*JN*K)IH88GFF=8HHP6>1R%
M50.I).P&*MQRQRQK+$XDC<!D=2"K*=P01U!Q5<""*@U&*NQ5#PZEI\UW-9PW
M4,MW; &XMDD5I(PWV2Z \EKVY8JO6\M&N3:K/&;D)ZA@#+Z@2M.7&O+C7:N*
MN@N[6X,JV\T<S0.8IQ&P8I( "4>A/%@"/A.*JN*NQ51N+VSMC$+F>. SN(X1
M(ZH7<]%6I')C_*,50LWF/R]!;)=3ZI:16TKM''.\\:QL\9(=58MQ+(5;DO[.
M*HZ*6.6-)8G$D<@#(ZD%64BH((Z@XJN) Z]\54K6[M+RW2YM)H[BWDKPFB8.
MC4-#1E)!W%,55<5:DD2.-I)&"1H"SNQH !N22<506H:[H>G",ZAJ%M9B8$PF
MXFCB#@4J5YD<NO;%5.?S-Y;@C@EGU:SBCNE+VSO<1*LJK]IHR6^-1W*XJL@\
MV>5IY(8H-9L99+AN%NB7,+-(PV*H WQ-OT7%55O,7E]+R2R?4[1;R'^^MC/&
M)$VK\2<N2XJNM]=T2XL)-0M]0MIK"&HENXYHVA3C]KE("46G>IQ5K3?,&@:I
M(\>FZE:WTB*'=+:>.9E4F@8A&:@KBK4?F/R])>_48]4M'ON9C^JK/&9>8ZKP
M#<N0_EIBJO<:GIMM<P6MS=PPW-T2+6"214DE(ZB-20ST_P G%52[O+2SMI+J
M\GCMK:(5EGF98T4=*LS$*,50-MYH\LW44\MMJUE/%:H)+F2.XB=8T-:,Y5CP
M4TZMBJV7S;Y4ABCEFUFQCBFKZ,CW,*J_&E>)+?%3DM?];%6E\W^4W*!-:L&,
MO+T@+J$\N.S<?BWXTWQ5$?I[0OT?^DOTC:_HZH'UWUH_0J30#U.7#<FGVL51
M,=W:2+"\<T;K<"MNRL")!3E5"#\7P_%\.*I=<>;_ "G;3R07&MV$,\+%)8I+
MJ%71EZJRE@58>!Q5N'S9Y5GN5M8=9L9;IV]-($N86D+_ ,H4-R+>V*JMAYB\
MOZC.T&GZG:7DZ@EHH)XY7 '6JHQ.*J^H:GINFV_UG4+J&SMZA?6GD6-.1Z#D
MY J<54)_,?E^WLUOI]3M(K)VX)<O/&L3-UXARW$M[8JW<Z_H5M!;W%SJ-K#!
M=T^JS231JDM14>FQ-'V/[.*H:;SEY0A=DFUS3XG3[:O=0J1M7<%MMC7%4W1T
M=%=&#(P!5@:@@[@@C%4#?:_H5A<Q6M]J-M:W4]/1@FFCC=ZGB.*L035OAQ5J
M3S%Y?CU :;)J=HFHDA19-/&)JL*@>F6YU/RQ5#CSEY0+\!KFGE^7#C]:@KRK
M3C3E]JNU,55D\S>7)+*:^CU6S>RMVX7%TMQ$8HV/17<-Q4[]"<5;/F3R\+:W
MNCJEH+:[?T[68SQA)7K3C&W*CM7]E<514&H6$]S/;07,4MS:D"Y@1U9XRPJO
M-0>2<ATY8JO:YMU,BM*BM"HDE!8 HAK1F_E7X6W/\N*H/_$7E_ZM#=?I.T^K
M7+>G;S^O'Z<CTKQ1N7%F]EQ5=I^NZ'J3O'IVHVUZ\8!D2WFCE*@]"P0FF*HN
M6:&(*976,,P12Q JS&BJ*]V/08J@[W7]"L9A#?:C:VLQ( BFFCC8EOL_"S _
M%VQ5;=>9/+MI<M:W6J6D%TBB1H)9XDD"$5#%68-QIWQ54M-=T2\D$=IJ%M<2
M,GJJD4T;L4H#S 4GX=Q\6*J,?FGRS(C21ZO9.B'B[+<1$ @\:$AOYML514VJ
M:9#:K=S7<,5H].%P\B+&U=Q1R>)KBJZSO[&]C,MG<Q7,:GBSPNLBAJ T)4G>
MAQ57Q5V*NQ5V*NQ5V*NQ53N?]YI?]1OU8JH:/_QR;+_F'B_X@,5?_]/U3BKL
M5=BKL5=BKL5=BKL587^<]M+=?E9YFM887N;BXL9(H+>-2[O(VR*JJ"2W+%7C
M&DS>>?+DFL7^D6-SZ-VFAP7FL6]G) L,"1\+E([-DE::>#_=MVB2_P"IBE/'
M\_\ G%/.FFZ%J_FVVLJ+IYN?W"V?KPRQR&8""XBDE^M7#B P_%&D:,R<4?X<
M52>P\V?FCI^A:;#IPN[ 6FE0SMI]OID:1-?'5BDL3((/@_T)O59(^'^_,53N
MZ\V?F)+K^JV\T][<:1-)YAM8;5[%3"+>&W5M-8-Z'Q^M*7C4R,ZR_8XXJHZ-
MYL_,2VO]!@BENK?3(#H$$]BM@J6RQSVKC4@W&%61+>18OA1T6'EBJ=?DMY]U
M?S#KUZ-6\TVM\L=H6.E*8U<7 N&$DZKZ4;Q6ZQ^BD<3R/(K,WJ8J@[_4_P Z
M$\VRZ5!?O)HHU1[!-0"P _5+V S6]S41_P#2O"LDA_W=+PC?%4 C^8!KK+*U
MY'IGZ0\R(5BM@D=R6@C%E)<B*(>K]84S#ZP_V_\ ?G+%4[_(.^\PV$,.A:J]
MS'IEMHFG26T5W"(4@NZR)<P(_".O >C\#EV_:Y8J6'ZA;^:7OH9I)]4.I6/F
M36[E+LPF1H8/J<L=F\3&)X_3F_=1_#S3^7ABK+O+GFK\R[_S;H":E<36%@=.
MTV>:-K0M%=220D:BDS**6\\<Q#+ZCQ\%C^"-_4Q5%^:]<\]3?F%?Z;!>367E
MZ.S5[(P6YFBNHW@D%T/60$0W,4IC:)I'_8^"*3U,5>8^7O*^M:/I^EZGI>E2
MR:_:>57G2&XMD(35DO%"_;C%;J* -)"';U/W47VE^%E6?:1K?YA2ZKHUEJ&L
MZA#I,T;SVFJ1:?\ O))OK*'ZI?1RJ63C;%XDG=($9_WWQ<<52/RG;><YKC1+
M$7>H6FIO8:\EQJ=[ A-K?27 DM2EQ+$2$EIS<<O3F_X'%4?=^8OS<.C>7+F6
MZN=,EU(RC4RD(O&M)[:*.*V$D2*K>C>2QSSO7BG[Y$:2.-,59'^<6L:]+;6>
MG6<\@T>]T_4TU1M/5993>?5:6D#JHE9(99"ZG]EF^%WQ5BOEGS'YYAU[0-'5
M[^UT&+3H;"Y!A6*.%_T2.(5N+;I>+_O0[JW/]UZ?IKS95#>2]8_,*UM_)NF+
M>WUA9K;>I?RW-O\ 6/4U 75;FWGY%&CA:W/[F:1ECY-))S?X<59E^8WF3SO#
MYIC3R]<,;-+:T?2T@*/!/>-?*EW'=O1N$:67)UYM&OVG5O4Q53_+G38['1?/
M%R)&AUN^U/5!I][.42ZD@8EK9XY'"L5=VYI7X.>*O,;>7SUIMGH^JZ2VIQZW
M:>6[>WFEDB$DCW8U-7FMGYHQ:(0M+)Q^'EQ^WBK+_P!.><[3S#='2WG^HR^9
M;B:6W2(0-<V4OU58Y5G]/@WITF^&XX^I!S_?<XX\53W\Y-?\W0ZE;CRIJ-W'
M&-*OY6%BJ3(U[$8S9HY*24,A,OPCCS7[6*A)QYH\_?5I+>:_OVTM=<G6YU!8
MU%\-/-B)+?TE6,$Q-?<HV9(N2?8;BF*I5J.I^?=7O= 'FE+DW-EJ'EZ\%M:1
MJUJ(T4O?SR-$&5;B*?[2^I^[_P!UKQQ5*&TO5K[3]/EO[:XDNK/2O,@CMVMH
M_26[>X]33^4/I^EZMQ\+_9_>,B<O\I5DMGYH\_0QZD]S=ZC8RZ=IEN=%L[&T
MAGM[B(Z> _)7"HEU%>?$R,R-_NI(_3Q5!6NJ^=]0D\K2ZW/JBVUCY@OQ=B$G
MU5M3;!K-VJB/*H=Y(UF=/A7DK\6XXJUY;UW\S[6PT2V436PAAMQ9VRQQPPR3
M/J;B^%Z%55B5+#XX^7I_[\CYRXJF7DWSWYTT>^N-3\Q3:IJ6E06>J37%F\,9
M<&"]46?I56'XWLR\GQ2?&F*L^_,#4TU_RU!H6ESJA\QQF.>X:1H5AM6B+OZD
ML:3>D\GPQ!67XN;8H>5SW_FG5?*/Y?6-U;O%YA\MZVD=U=3V\DD AM8Y(H;Q
MP.!:!U,7*C<_MXI:;2.7Y >8M&ETF6/S>);B"6W*"0S2W%XMQ(UD5%/JDG'F
MJI\*<?B_F95DOF6SB;SEY N](A6!XK/43>W\<?[NWN;K3TM[=YR!\#>HBK\7
MQ+P^+%4P_*J72-,\D:-H/F#3Y%\P:?<23Z@SQ\P+I)7D-[]9_NY!(-Q(LCR/
MR]/A^SBJ4^0M;&D_E0/+=Q87(U*[_2ZS0M!(JQ1RM<2QNS%>+>KRC2-%;DS2
M8JB_R%=M)T;3-.U>-EU&/3PHGGA-L+*!/3'U)G<!9G>;G-\#-\/Q8J6'>;-(
MU:__ ##\RW5E927<%QKFB7-I;F+TX;M+)"LTGUSX?JZ6Y^+FK_O?\O%65?F#
MK>@>9-2\O2?X9U!KE;V*YN-0^JI]9B2QN&]" 3%Z01W,O[QWY_!;?&R<W7%6
M9^:_,=IKWY;>9EAMYH+F6TO[*"QN%43RR!'B1HXU9RR3-O$W[2_%BAYCH=GS
M_+^UT+4UOTU-HK C5[.W:&;3DMC!]7A]-Q2Z^JW"2SRK'RY1\I/MR<<4JFNV
M.L7OY/\ FJ+4;6UU#S'=WBPV%_:6Q@GU" 302?66MA5HG;TWYU6-7]+G_E.J
MR+S&+"+\U?)6K64%--MK34YM2N88F,<<]Y;JB&3B-I)"E*?:_GQ5YQYC\EZQ
M%Y+\QZ3I\9F\OW(T_6-%TR./][^D;HHEW%Z8^)%MQ%-(RL/A:2/%6;?F%K'F
M&XU;1O,_E^*2>'RC<VR1V"&6.>[2YCXWO"!HP)$]-DC63U%X-'-\+<EQ5,_-
MD&CW?YJ^1+RUM%?2%CU235)1%^Z0W\-!]8J**TKEO4Y_\],58]Y09M._,/S1
M?S6[SZ/=ZT'TZQ6W;A))^Y2"]6X"E$BM@DO+EQXK\2\N6*I=I>CZG=O8VVG6
M3V>JV_G>[UE=3FC]".#2W>KN9'X<ENE^%84Y,_[:XJ]"\VS&+\VO+7F&Y=;_
M ,KVEA=0#T")_J=](P(N'B0LY$D?[D2HC>G_ )/+%4JN(]/L_P U=&\UBR9?
M*ALKZ-(TCY-::A/+RDNGMH^<J_78QQ$GI\_]^*G+%6&6OE_7;*P-W:75QH>I
M ZI-I-C);B_L9=.OKHNFEW4"\_0D?B)5_919.#\63%66W&GV9\\?ENT^F6]M
M;PZ?J"Z]#;J)+6">\M41HI''-3RD#Q_$S?Y38J](U/5=3MS;P^7GT=[-(^!%
MW=O"5*[*J"*.4%0OOBAY&]MJ=FGYG6_F2P&J:OYIC!T=[,&ZMYHV@,<-O',P
M7TOJLA!/K>CQ_O5Q2E]IY!N-:\[Q:5YCOG@LX_+ND6FHZJBJPN+RPE69X8KI
MJJC\E7E,OQ-\7'XL59K;Z?HB_G;=.UI%_A]?+L-G'*8Q]5]>*[]<1AJ<.:K1
M_P#6_P O%6$:!INHQ1>7;^ZM)FTK2/-FJZCJM@R$2>C=LQL[P0&C31Q$\_@5
MW3E]G%4R7RM8:_>>:H=7C>#RGYHUVWETVVH4D3TK:19;\(-[=99_396E5.7'
ME)]K%6:?E*VN:1;Z[:^;+Z"XN[2YB@M=34K_ *9:06R+#.:$EY"OP2?M>HN*
M&,:1K7F2P_-:T\V744CZ'YKMY+2_MT,DKV*6SL;)YXS&GU?X3QD6LGQR328I
M4O*OE:Z\N>8- U'1YT_PIK,JW>OZ5-L]CJ$-O+_I,:.0T:3O\$@X_:X_S)Q5
M2/R%HNL&;R"EM:R:9>Z'J>J7.M7TZ_5D73[B9V6 L_'UOK 8<(UY\/M/PQ5F
MWYX3ZWK>GBQ\M7"I<:(L>M)*'8":Z@E!MX8N*.)G'&1FBY)\3PMBK"/S(F\Q
M^;=>M-7TC3C!<W/E.YL[VWO8&*K<3.6ELPQHJ7#)R]"1N2<N'\^*I[KUMI<]
MI^5MSI>GW$266J6DVJI<QE[J"*VMQ;<KQJ<JIQ1.9^TOQ)\&*I3YY\O:G<:W
M^8%GY5M_0@N=*TJVL!#2&.XBM)2UW:P2GBG(QMQX\OC^QBK*?S'N/*^M_EIJ
M]OH.E2#5!HK65E&+5H7C65XB+,*P4LW*)6XHKI'Z7+FG+XU4M_-'6TUS\K(_
M+6EV%S<WD$&F.];>5.,L<\7*)$=4YO'&DDDE/A15X_MXJ'HOY:WL4UI>P<3+
M=Q2*]]JGH-:I>3R _O$A<!U"1+%'7^9>'Q>GRQ0S/%78J[%78J[%78J[%5.Z
M_P!YI?\ 4;]6*J&C_P#'(L?^8>+_ (@,5?_4]4XJ[%78J[%78J[%78J[%6*_
MF?=>4++R9>ZAYLLUU#2++A,;1E#M)-RX1*BDBLC._%=\58MI'Y:^6)[^TAU3
M\O\ 3;2WNK=Y_K4$QN!"Z\.,$P:**DC!V^)"Z? V*I;%Y4_+!OS+_P '7'D?
M34=[.2]AO$FCDD"1.$'K6] 8_4KRAH\C<?M<,4I;K=AY$L=;\T:59_EY8ZA<
M>6H;.X"),5>Z^OGC''&OIMQD'^4WQ8JAWE_*ZZ\JW?F?0/(MAJEE8V"WUS:%
MS%=(RR-'<0/'Z<BK);\&=JM\:_9Q5%:U'^3NE:)^G!Y0T^]TQ[.RG@,!K)-=
MZBU+>U5&4+\2CF\CO\"?[KQ51UFS_+KRY-K%CK'Y?:3'K%AI+:]!#"PE@N;:
M)N,\:2O$C1S1']GTN#_:Y8JB]#TG\N]<U2VT;1O(6DO?C3K;5=6>XHMO:I>H
M'MX%<1.\TSK\34C1$^U_DXJAM2M/)UEYCMO+S_EQHL6J75A]>@M[B9(S)(+A
MK?ZM&1 W.1ROJ1O\*>G\3<,53SSWH'Y1^4QI"W?E32(!JTS0+>7L8@LX76/F
M%FF6.7@TA^".J\?M?%\.*H'3-%\B7GFJ+R]+Y T>VGET0:YZE4E"UD,(A^"+
MBWQ_%ZRMQ]/XN'[.*I!YDU+\N]!N!#<_E]HCDZ-;ZYQ]54>59Y!%]6@5H/WM
MQR/[M?A]3_)Q5-XU_*B#SC<>7M5\AZ?80&Q:_P!,O&B0M<-'#'/+;M$47T[B
M-)E^#F_Q8JEOE^Z\@:O#Y:E;\NM)M1YBU2ZTKTG*L]NUF&+NU(>+U]-QP7_@
M\56V^K_E-/H.IZY%Y'T>:VTU'-Y:1@?7+21;A(52]MS"'B7B[2R2Q>LJ+$Z_
M'^TJC73\N!'H,MOY)T"_M=?U9-(M+ZTD26!A)")1<"D/+X3SC>%PCJZ8JL^L
M?E@-"?S>/(6E_P"#X]3&FF\9$^LF,3?5S>>CZ?I^B)]N'J^IZ?[S_(Q55M6_
M+L>8-1\L7?Y?Z/8ZU!*OZ*,T<9M]0MOK MY989/2Y!XFJS0\6_UL59%YZT7\
MH?)\$-S?>4=,>T$-S=7KK:0\D@MD&ZKQ^)Y+B6W@C4E?BE^U\.*I7J>E>3]!
M\K_XI\P_EWHL&D?5'NYEMDBEG@)4&""16AC5WF9ECYHW".3_ "?CQ5#WEGY.
MTNZL;'5_R]T.&\UK3;G4=)$*1O'ZMG$)Y;2=FA0H_I'X9D5TY?LXJI^6_P#
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M4[)'XR.TE&5!Q;BSG%4@TCR;^8&F^2-5\JIY1DE&K+=1R:F=0L%G2.]<O*M
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MBJ(L]1T^]5FLKJ&Z5" YAD60 D5 /$FF*HC%4&FM:-(9Q'?V[FV%;GC*A],
MTJ]#\&X_:Q5K].Z)]7%Q^D+;ZN6],3>M'PYTY<>5:<J;TQ5T6N:+,Z1PZA;2
M22GC&B31L68=0H!W.^*N_3>BUG'Z0MJVP)N1ZT=8P#0E]_@WV^+%59[^Q1H$
M>XB5KG_>92Z@R=_@%?CZ_LXJW#>V<]Q/;PSQR7%J56YA1@SQEU#J'4&JED/)
M>7[.*JV*NQ50@O[*>XN+:"XCEN+0JMU"CJSQ,ZAU$B@U0LAY+R_9Q57Q51M+
MVSO(C-:3QW$(9HS)$P=>:,5=:J2*JP*M_E8JK8JHP7MG<2SPP3QRRVKB.YC1
M@S1N5#A7 /PL496HW[+8JK8J[%78J[%78J[%5"*_L9;N:RBN(WN[94:XMU=3
M)&LE>!=0>2\^+<>7VL55\5=BKL50NI:KIFEVWUK4KN&RMN03UKAUC3DW0<F(
M&^*HH&NXZ8J[%78JH+?V+7SV"W$9OHXUF>U#KZJQ.2JN4KR",RLH;_)Q5NTO
M;.\A]>TGCN(>3)ZL3!UY(Q5UY*2*JP*M_E8JZ[OK*S1'NYX[=))%BC:5U0-)
M(>*(I8BKL=E7]K%5;%78J[%5D\\%O!)<3R+%!"K22RN0JJBBK,S'8*H%2<5=
M!/#/#'/ ZRPRJ'BD0AE96%592-B",567-]96IA%S/' ;B188!(ZISD;[*)4C
MD[=E&*JV*H:\U33;)HTO+N&V>8\85FD2,N?!0Q'+KVQ5$XJHK>V;7CV2SQM>
M1(LLEL&!D6-R51V2O(*Q1@K?Y.*JV*NQ51%Y9F[-F)XS=JGJM;\AZ@C)XARE
M>7'EMRQ5UK>V=VC26D\=Q&CM&[Q,K@.AHRDJ3\2G9EQ56Q5V*NQ5V*NQ5V*N
MQ5V*NQ5V*J5U_O+-_J-^HXJA=  &@Z: * 6L.Q_XQKBK_]#U3BKL5=BKL5=B
MKL5=BKL52KS3K3:-H5U?1IZMPJ\+6*C$-._PQAN(8A.9'-J? G)L5>"7;^8=
M/_+W\R?(6JV]W>747JW6BW'"2Y-P+YA*\22*G!YHYF+%$^+]Y_D8I3C\M=)M
MXO,NO#S+I(C:6PT^]TEH;5QIDL-I;,HEXL& U"-I'697//\ D7X<5+'!Y;X_
M\XWV"#1Y1K_UV*"XA%K)]:]--4-P5>,)SXK%^\Y,/A7_ %L59YY?M[.V\Y>=
MV\YV$EV=7FC&A326TES'/I1BI';6Q5'"\&)]6#X&YMS_ ,K%"EY:U73_ "QY
M\\_WATZ[]&8:7%I,45I.S7!MK3TFBC=4925DXI(W+BOVFQ2E'D.WCMOS$\QW
M&H64DEG=>8IYM*M_J,PD,\IA2*]2XX!!;)&+A7^)%_U_4XXJU^=VEW>H^?Y5
MMX)#&WE>\M#,NGRWRO<2S!H[9>"D)-*!^[D_W5]O%0K^9;W2[S\I[/RSK'EG
M4AJ]I9VEBMM-9W.HBTDN+<<KA75?W\EK"">8^-)N,/P\GQ5ZCY*UFSN+&'2;
M>TU"W&F65E274(6C+I+#6,>H=GF55_TA1_=R?"V*'F_Y@6JR_G(EU-;L^CQZ
M$EMJS&PGNDN$-WZLEHC1HP]>2#=?M?#^[^'GRQ2AGTK5I?."WFG6DMSI>KZE
M;'5O*^K6<G.%4BCA^NV=\!14BA'QQM)P^!X?BY\<53?R_P"7]/B\_?F')-I'
MIV7IZ?+HTIMG6(FSLVAD^K'AQ;TG/I_N_P#5Q0P;3O)OF%_RW\GS:=IES!YP
M\HVCW]C;2020L9DOU:6V<LJT]>W+_!^WBEDOE>RUSRYYO_,"Z6RN&U+5AID5
MG?&&?T);N9"MS(LWIN/1MIY26;CQ2-,517D+2]3M/*7F3REYBTZ:YE\MRWDF
M@7TL4LR30W,4G$PRM&@FFC::6%N*\OC^%<4,=F\J7T7Y,^08;?2)[?S##?:8
M+]OJ,LL\$=G)*Q>>(*&*0&4M1OM\OA^UBE./,%F)[[R \6CW4EOI.LRR:S<+
M87'"0FS N+OTO3YK%-<.1\4:^H_)L55=)\H^?XOR*\SZ1IT4UAJE]<WTV@Z>
M[<)X;"68,ENN_P"Y=XO5]-*_N_4_9Q5&>:M'AU[\K)=)\I:1/9^8;72C!;(;
M:2T>!2(Q<V9D=8QZEQ&'CXKRYM\?^7BJ5>:- _36I:+)H^CZA9:/8^7KVP\P
M?5[>2VF,-S$D<%E$C*IFN(I.4JHJNB_S?'BJ+TS0]>;RKYUBUNVCUN6"Q>WT
M+7EL'MKN[,EK)#Z;VQ7EZ\7[N(RHGQ\N/+X&Q5F7Y<Z5?:9^6VB'3].A@U[]
M'64%W#>![4EX(PC+,5C>0-&.87]W_P +BA&:]:^?=2\H:_8B.SLM5N+&:+2I
M;*YE<^N\; <FDBA]/?CQ<8JP_7;$7>F>7ET/1KJS;2=/O(]3A-K)&8[:2P>'
MZB:K^_DENFA*I%ZO]UZW\O)2[1?(!M/(.I:Q>JUWJ^H^7H+*/3TM3"87@LG@
M"+%^\D:Z<R-%)+]IEXIP5,4++_R_J#Q>3QHMG+9:H="O[=[ST'3T+R33XK>W
M^L-Q_=N)$X?'_)BE=)IC7.A>4+/3M&N;*ZT6VE&L)+;.OI0?4)()[5F*TN6N
M;AHN*Q>KZO#U_P#*Q0FGE30M?T'6=#TF.*2]\HA9+G2KJ7EZ^G'ZNR-93<QS
M,/Q_Z*[?%'\5O)_NO%4%YJU'SO!J>N_HHW?II?Q-:Q);NAN(!IZ\DAN(X)0K
M+<U]-ID>.1T]"26-,53WSI+YO?6K"/1)[V!!IE]<M##%&89+V'TFM(9I7CD5
M/5/K*RATYK^UBK&K&_\ S&&EVVJV,^J:@3=1P76EWME]2D3ZW T+G][RDD2T
MNVBN'=.,*Q>JL?-%^%2NUNX\]:?/K$-C-?W7U>^M1;R"W9);R%-/42K%/% Z
M!S=596F1H6=?J\DD<>*%KZW^8HGU6>;]*(R71BO=/AL.206)OD"W%E<5=)YA
M8EOW<"2-]MW7U(TY*KTT[65_)[5[>T34X[S])W<T1$4D5]+;OJ9E,G HLC>I
M;MS;BG)_Y?V<4IOY<U#SE/YHM?5^O" W-_%JMM=PE+=+*.ITZ:%RBUED7T?4
MXNSLSS>JB>G\"A*?,5SYY_Q#J<&G3ZE;61O+QDEM;5?BB328W@I(86##Z^K1
M(WVG_N^6*5,Z_P#F1+;WD\,.J+KUO:*]O9"U7ZC- ]G$QDYR( +N.X]?C#S]
M5I^,31^ABA%0-YSO-=L[&#4M8A\O27<Y@OV@5+@P+91RA9VF@/!1>>I%&TB(
MS_$G[*MBJ1^5M?\ /][8Z/>RWVJWGE_4;:S?7;U;<"XMIY%GY"TX0J[P56V]
M=XTF]-?B63XWXJ4:EY^91MM0O+^ZU=;BQTVT:WM+6VC"S32SS0RNP]&0F5;;
MZM/-'%R>%V;A$S+Z6*I;#J/YC1F>_,>L37\5@UK'_HTQ0Q1ZLZS2)&ZQ\[C]
M'&*2+DR2SM_-)BK-9=0\T6GD"UN(Y-0U!Q>QK=W/U1H=1_1S7%'=+8\Y?42'
M;XE]=H_WO#U<4,9@3S7;>:_TM;MJ[EUT*WFDEM%5KN 7%TMRUPBQ\5:*WEC9
M@K1M%S7U?C^RI0VB:S^9%W<6]G>3ZU:VUQ>6;S7)LV$B6\MK.;M6=[?TT*7*
M0#]V.$;-^YYQ_%BJMI_FOSW+J6CI?7MU9NEMIRWJRVLB1-=2P2"6UN"('BBG
MN+HVIYO+#Z:,RI]KXU5&'6_S,_0=O<&;5YKYY(WO=.DT^2UD6X6(B>"WG"SJ
MP]3C)%ZD:V,O]WZZ8JRG\T[/6Y]9T"?28+BYGMH=3<6RH7MC,UDZVZW'PM'Q
MEE/H_O&XLKLN*$G67SU=WVGVEG?ZQ!H=W>VBR7CVX2[B62SG:[5O5@;A#'<+
M:A79."22/&G[M?@4LH\PW_F&/SE9V2?I*.P].UDL)K&%98)I?787<5XY1DB7
MT?2*L[1_#ZC1?O?AQ0EWYB'\QK36&E\M&XNK2YM!<"%"@2"?3Y5EDB'PDM^D
M;=C;HA_W<O/X,5276H?-\KS"[;5/3^JZ+>3?5HBTB2-J;27L"21Q\I?J]L\=
M8JO]CE_/BE-?RZ'F"S\RR6KB^&BWBZM=-#=0,D44YU1FM^#F-2IFMI'EHSMS
MQ0E&MMYJU9+FVO8]72[CUBV$]NMH&LXH8-5C>WN;27TVYTLEYOQ]1/A=KCX^
M&*4/'K_YAV]QHL<IUEXK6X>.\E^IN_K6OZ1FA#.$A/.7ZEZ,C._I_P"ZY(4=
MWEX*J5OK_P"8=AHT1U"YU6:>^L])>Y26V99A=R7;I>VML8H 4D^JA6^%)73^
M\_F=541IFN>?KBXTU6U34)TB@5TN[;3GFCFNDN)5O+6Z5EM?J[PQ")%]=(^7
M'U(OWC8JR'RQ>><)O('F(:B;N75HHYA8W+Q,3.QM%96@@FB25:S$AK>2*18Y
MO4BC>2+ABA+_ "_J7G@>9+.2XGU']'M?VEL]F]H$MEM9-(#S.:0JR\-1_=\N
M?%&^#%4)YJTS7I_.6IH6U06[:SHEQ93Q1/)%#;1Q$7$L#^G)$GIN9%<?Y7Q)
M^UBE4\MZ[^8=WJ^A0ZI)J5LOHVY'^X]FCNN,TL=V+MSZ<=LXC$3\G5?AXO!R
M9V3%";ZE EEYN\V3:_IL^HVFL65O#HSQ0/<AX4A=9K)>"MZ,C3EI:/P23U5?
ME^[^!5B'EV?\RK>Z@\N/JU]+JFF?HFUN;)(XY(%MY[(->-)<F+:6&O*-S/S]
M5?A63GBE%:+J?FZRT_2T1-4%E^C]&CU>YDM&-Y HDN5OC&S0^I(8V^K\Q^]>
M.%WFC7]O%534=:_,F'G);W>IR0VP:73J68/UJ :G$D1N!Z//U&LVGY1CTF:&
M-)_AQ0GGYF3Z[8^9['4]/?4S"NDWR+'81--&+CU;<H641RA#Z1E8NRLW&/\
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M;".U-N=%']PSMUE)KUV7X?LXJX^5]2/G@>8OTQ.-/%M]7_0M/W)?_?O*M?\
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M1*)5^%1_QDXXJRVWM='AO7^K0V\=\(D1_35%E$*[(II\7IBGP_LXJE?FB_\
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M6M]#-J%E0W5JC@O'7;<#P.S?R_M8JZS\P:)>ZC=:;:7T,]_8T%W;(X9XZ_S
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M&*JN*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*J5W_O+-_J-^HXJA/+O_*/Z9_S"0?\
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MFY-^X]+]SBA,_+]TL?DC\Q[VPO)KXO<WEQ:7LUNC-/73X?3;TC$L4W-U]/\
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M6AU& +K-W:W$L)MV)6&VB6!H@WJ[M)&B_O./P/\ L-BK>D^6-9TRZUFX@U&
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M9"%]5'CC-5XR</45)./)<52F'\F?+\=K+:-J-_-:W#0/<02-;E&:VB2*-@!
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MY6:#(;]7O-0:UU2W:#4+0W),4TC0?5VNGJ.7UDQ;%^?#[+>GR7%5%/RB\O\
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MJ[%78J[%78J[%78J[%78J[%5*Z_WEF_U&_4<50OEX4T#31_RZP=>O]VN*O\
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M#S-9EO %Z_=QQ6E__*Z?RLZ_XCM:=S^\_P":<44[_E=/Y65I_B*VKX?O*_\
M$<5IW_*Z/RN_ZF*V^Z3_ )IQ6EK?G;^5BFA\PP'Y),?U)BM+?^5W_E7_ -3!
M#_R+G_ZIXK3O^5X?E5_U,$/_ "+G_P"J>*T[_E>'Y5?]3!#_ ,BY_P#JGBM.
M_P"5X?E5_P!3!#_R+G_ZIXK3O^5X?E5_U,$/_(N?_JGBM._Y7?\ E7_U,$/_
M "+G_P"J>*T[_E=_Y5_]3!#_ ,BY_P#JGBM._P"5X?E5_P!3!#_R+G_ZIXK3
MO^5X?E7_ -3!#_R+G_ZIXK38_.[\K#TU^(_\\I_^J>*TV?SL_*X;G7HP/^,5
MQ_U3Q6G?\KK_ "OH#^G8Z'H?2N-_E^[Q6G'\Z_RO ).NQ@#J3%<?]4\5IW_*
MZ_ROJ!^G8ZGH/2N/^J>*TV/SJ_+ ]-=C/RAN/^J>*TU_RNO\KZT_3L=3T'HW
M%?\ DWBM-_\ *Z?RQ_ZOB?\ (FX_ZIXK2P_G?^58?@?,$(D.X0QS\ON].N*T
MV?SL_*X==>B'_/*?_JGBM./YV_E:.NOQ#YQ3_P#5/%:</SM_*T]->B/RBG_Z
MIXK3C^=OY6@5.OQ 'H3%..O_ #SQ6FO^5W_E72O^((:?\8Y_^J>*TW_RN[\K
M*T_3\5?#TIZ_\F\5IP_.[\K#L-?B)Z?W4_7_ )%XK38_.S\KCTUZ,_**X_ZI
MXK31_.[\K!UU^(?..?\ ZIXK3A^=WY6'IK\1[?W4_P#U3Q6FQ^=?Y7D5&NQT
M\?2N/^J>*T[_ )79^5W_ %?HO^14_P#U3Q6G'\[/RN J=>B _P",4_\ U3Q6
MEO\ RN_\J_\ J8(?^1<__5/%:=_RO#\J>03_ !##S(J%].>I'C3T\5IW_*\/
MRJ_ZF"'_ )%S_P#5/%:;_P"5W?E9T_Q!%7_C'/\ ]4\5IK_E=_Y5_P#4P0[=
M?W<__5/%:=_RN_\ *O\ ZF"'_D7/_P!4\5IW_*\/RJ_ZF"'_ )%S_P#5/%:=
M_P KP_*K_J8(?^1<_P#U3Q6G?\KP_*K_ *F"'_D7/_U3Q6G?\KP_*K_J8(?^
M1<__ %3Q6G?\KP_*K_J8(?\ D7/_ -4\5IW_ "O#\JO^I@A_Y%S_ /5/%:=_
MRO#\JO\ J8(?^1<__5/%:=_RN_\ *O\ ZF"'_D7/_P!4\5IW_*[_ ,J_^I@A
M_P"1<_\ U3Q6D?HGYI_E_KFJ1:5I6LPW6H3\C#;JLBL_!2[4Y*H^%06Q5E6*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*J=S06TM=QP:H^C%4)H!4Z%IQ444VL-
M!X#TU^>*O__5]4XJ[%78J[%78J[%78J[%78J[%4-JG_',O/^,$G_ ! XJQ3\
MG((?^55^5"8UJ=,MB305)],8JA/SC\S:KY7T#3=0TEXX9KG5+2PFYP"<&*Y<
MJY5-F,B@53C_ ,"V*L%U?\SO/.C?X>_Q&8M#BU']+F\F:P,DGU>P'*TN#;AG
MDB:<$>M$W+@OQ?N\4IO9>?\ SG/=_ETES':6TOFBPO;K4[9$1HR]K;^O"8YJ
MOZ2S57U?M^FO^5BJ#T?S]YSU>TU'38[D:7YSM;:(OHNI6"Q\+J6YCB#P.IX7
M-BWJ<%;GZJMZ;L[\L4.\O?FYKWF&Z\C0V\,5F-1NIM.\T*\ +K?6\#RR11<O
MA2GH\G^U\$\?[6*41K/YB^<]/DMO,]K;17_E O<7&H620+]8CTM+@6T-W XW
M<T#73JW+]TV*$N\Q_F5YJM'T9]*U#Z[9ZIHVHZK'-!81S.[6KUMR(QPXPM&R
M^K^U^UR7%*(/YJ^8DN-'EU0Q:?IFJV^FM8ZS9VZWNDRW$X4W<-Q,*S6[EF].
MW_93X6?U,5>V>C#_ "+]PQ0P[1H(3^:_F=N"\ETO25!H.ADO#_#%69\$I3B*
M?+%6'_FOYON_*/DVXU:P@CEU"2:"SM&E!,4<EU*L2R24H2D?+EQK\7V<58UK
MOYDZIY'\U76E:Z[:YIT>A_IH7$,44-S&T$P@F3BI2)DDKZD=>++]CD^*49+^
M;DDOF+3] LM$E&HRZDVGZA#-)"#$!9?749&5F5_4B(WK\/%U^UQQ0A/+?YSZ
M:^E:4+U+B^EF2U;4M0,4-OZ/Z0O9+.TYPH[UY2Q_'Z1;A'^\_P G%-(BQ_._
M2K_Z^D>DW5O);V-]>6K3&(K.]A<_4WB41L[ M<%$CY#X^6*$LL_S(\Q:%KGF
MR+S%(^K6OE_]"VT=M;16\<C7&J(HD;E^[5E$[40<E^#^;%4XM?SHTZ\2SAL=
M$O;O5KAKTSZ5#Z1FBBTZY%K.X)8)*?4/[M$/Q_']GCBK5_\ G1IUE)J/K:)>
M+;6&HMHJWI:#T9=0#HJ0K1S(%97]0R&/BB(W[?PXJHC\\M-:[M;:/R_J!DN?
MJ"E9!#"\<FI/)#!&Z2NC\O6A=6VX\?WG+CBFFXOSV\O2V^AO'IEY)<:PDDLE
MI$@EDMXHKOZD[L$Y>H!/7['^Z4>3_)Q6D%-^?ME)I&K7=GH5P)[#3+K5+99Y
M(1'*EG=&SEJ49V4+*.73DZ8K2:?F/YM\R:5Y5\LZC8.-.OM4U33K&]C*13 1
MWAXR4Y!UYK^PP_X;%"1VOYVW&BW^O:%KEL^KZII6J&PTUK&,++=Q&W:Z):,5
M0311IP98_P"]D:/BB8II.1^>6A//J,"V$XFLYK>UAMIF2&>2>[E2*W5HI>+0
MQRM)R69OW?IH_P"W^[Q0B?\ E:EU+K$>B1>6=134C91ZA=)(;9/JD$DCQ,\O
M*05]-X_LIS]1.+8JDNC_ )YVD6D6;W]G=WJQ:=IVHZGJA6WAI!J,OH))Z".W
MQK+_ 'D<?V4^)6_9Q335O^<=W+/;W>I6[Z3IT6M:GI\@C6*X]2'3;621Q(2P
M>,UB:3G$K?LQ_9^/%:1Z_GCIY$42Z-=-?SS6D4=F)(:\=1M7N[20N65 'CB=
M91]J)_Y_M8H9MY1\R6GF?RSIGF"TC>&WU*!+B.*6G- X^RU*BHQ5-\58/<(#
M^=EBQ&Z^7+JA^=]!BK&OS-\X?F'IWGD:#Y3+7,TVBOJ%G8BWBE#W:72PA9';
M@4MV0MZC>I\+?M?LXI2'S#^:WGC3/.&JZ(MY$NH0WNC6VEZ?+!']4>2^B$EW
M#-=\4]-4^+ZNY=7;C_NW%4ZU/SOY_BUCSM:Z7RU(:%J&FPVEE!';BZ-I<Q?6
M+OT R\9KE4#>BK\O@_8D;%4LU#\V/,4.@:?YITS4C?:/9ZA,/,-E=V2V]W%8
MQS6\+I*H4>E<6WUCE(R?!(GQ_#BJ8:?^9OF>Y\P^<E,D9L;.TL)/+%F(E4M)
MJC&*T,K$%V,C^E)Q_963_)Q5J?SYYWT3S(V@Z[=AK+6;Q;7RSKT,$0/KPW"P
MS6ERG$QAY4Y21.$_YM4)>OYI><K?SI>6$MZGZ-M/,Z:,9+J"*.T%I)#SXR7*
M .EV6_N?A]-_V\4L@_+OS]YBU+S1%H7F5I]-UD6UQ-<:7<VT:V]QQD7TY].N
MHA26!4/Q)(SO^WSQ0G'Y>>9]6U*\\X_IF\62VT769].LBZ10JL,2(REW4+R<
MF2A8_P# XJQO3OSUM[+1;.2_L+W4I&@^NW5Z$MH.$$FIMIZUB63[<<G%0J<N
M:?'\.*:9EY<_,G3->\T:AH5G970CL)+B#])%*VSS6CK'/'R%0C<G_=<C^]57
M;%#![7\T_-=GJGF6VE0:K]4\SV?E_2X:10!([JAYR, OJ/\ L+]E?LLV*II-
M^?\ H"K=RPZ3?7-M!<QVEO<1J@CF=[KZFP5W*QHRST^!WY-"WJ_Y.*TFWDW\
MU['S-KB:.-*N+&:2&[D665XG0OI]T+6X0>FS'X9&'!_V\55IJ?\ *ZK04Z>7
M+C_J.AQ5FW%? 8JEOF:XN+3RYJEW:OZ5S;6D\T,@56H\<9==F!4[C%7E'DW\
MV=:'EK3?,6O&XO(+P:=93VWU>"#_ $W4G'ISVY 0M:J#P;DS_%]C[.*4UU#\
M_-)L].%]^@KR2/TM0GD4- I1-*N1;7)-7W^)@T?'[?\ D8K2GY@_-Z1O,FDP
M:.IAT2#66TO6KV58V63A9-=RHB;RKZ2A?WH^TWJ+_*V*TKV7YWZ?K%A"NF:1
M>IJ6I,R:5'(L:+)']5:[^L+*_P"Z/IQ)^\C^/C-^Z_R\5I-?(GGBYN_RBTSS
M?KSQR7DMF9[AP%A1Y2Y1% ^RG-N"8H2;RO\ G-]8\@6>M:E8F[UE=470M2LK
M-HQPO9)O2C*F1E3TGY1MRY?MXII?:?G]Y>>RNKV^TJ[L;>VTZ34HV8PR&40W
MGU&2-!&Y^+ZS\"%^/-?C^'%:1-Q^=ND6OK0W&DW O;3])+?6R-$WI2Z3 MS,
MG,LH?U(75HG7]KX7X8H:C_.[2)-?M-(31[LFZET^$7-8."OJMJUU:J1SY[A&
M23;BF*LA_+3S;=^;O*<&O7=@M@;J6<0Q!UD!CCF:-34=_AXM_E+R^SBK*>*^
M Q5B'FV@\[^1@!UO+[_NG38JS#%78J[%78J[%78J[%78J[%78J[%78J[%5*Z
M_P!Y9O\ 4;]1Q5">7O\ C@:9W_T2#?\ YYKBK__6]4XJ[%78J[%78J[%78J[
M%78J[%4+JO\ QR[S_C!)_P 0.*L<_*->/Y7>5!_VJK3IM_NE<51/F?0_*/FR
M2#1M5N%GGL9DO8[*&Y,<J2Q;QRLD;"3]W6J\OAQ5VI>4_*?F#7+74[IOKNHZ
M&)+9$6<E8OK"4FCEB4\"9HF D65?BCQ5+;/\G?(UF-/6WM[A8M)6XCTV(W5P
MR01WBE;A$5G(X2J2I7_@<55(?*'D=-06Q2]D;5;=(T@B:_D>[A@A=9TB3DYE
M2'FD<C+^WP3GRXXJB+[\M/)]]+!/]6>W>"YN;^%[6:2"ES>J5GF_=L*O(C%:
M_P# XJF=IY5T:TN+>:"-E6ULAID-N78PBU6E$](DH?LK\1'+%6-W?Y<_EM/?
MVEDS>A>:;8R6=K907LL#Q6,N\L8BCD1O2<;,:?9Q5&Z?Y \AS6D3Z9$&TAS"
MPM+:X<V,OU4(D/*%7,+^EZ*=OM)\?+%678JP[1?_ ":GFC_MF:1_R<O<59CB
MJ#UC1]+UG3+C2]5MDO-/NEX7%M**JRUK^!%0?V<58AYH_*C3-1\LZWIVF2&#
M5M:M4L9=7O7FO)5MT<,(PTC\_37XN**ZKS^-N6*HZ#\KO**I;R36TCW\-R+]
MKX7%QZ[77HBW+M-S]1E]$>GP9N'#]G%76?Y4^1;/ZB+?3N*Z>(Q AEF92(9F
MN(?5#.?6]"=WEA]7GZ;M\.*J=E^4?D2SN[:[M[&036KL\/*YN'4&2X%V]4:0
MJP>Y59F5A]O%5:^_*[R9?7>IW=U:S//K,D$VI,+FX42O:,'MS19 %]%E'I\.
M/'%5D/Y4^1X7MI(;&2.>TN+BZ@N$N;A9A)>'E<@R"3FT<[?%)$S>FW\N*J]U
M^6ODZZTS4=-N+)I+35+S])7:F:;E]<J#Z\;\^<,@XKQ])DXXJI7'Y6>2[B]%
M]+:S-=AK5_7^M7/(O8LSV[D^I\3QN[OS;XF=V9^6*NM/RK\CV9T\VU@T3Z69
MOJ3K/.&5+E_4FB9N=9(9)#S,,G.+E^SBJA!^3OY>PI-&FFL8Y[2XT^5'N+AU
M-M=R&::.C2'[<K>IR^USQ5,]7\A^6M7TO3]+U"&6:RTN2.>R3ZQ.K++#_=R%
MU<.[IU5G9OBQ51G_ "U\DS6L=NVFA/2O#J2W$<DL=Q];84:<W".)VD=3Q=FD
M^-/A;%5*Z_*SR)=I=)=:8)UNHQ$PDEF;TT$OKA8"7K;@3#U%]'AQ;%4=;>2/
M+EMJ,NI102?7Y[/]'37+SSN[VW(OQ8N[5;F6;U/[SDS?%BK%;+\EM!M_-$]Z
MR(_E[ZC96-EHW*<"/ZA,9X^;>I2:/U&J(I595X)BMI\OY8>1UNOK TT%OK<]
M_P"F99FB^LW2%)W](N8_WJ.ZNO'A\;_#BJR'\K/(T*1*FGDF&:.XBD,\YD5X
M(C!!1^?/C!"QB@2O")/L8JGVA:'I>A:3;:1I4/U;3K->%M;AF8(E2>(+EFH*
M[;XJCL583/\ ^3IL_P#P'+G_ *CH,51>LI^7^E^:[?7]9O8+'7S;FWM9[FZ,
M-;:M71(V=8RG+XG^'[7Q8JZZ_+7R'JWZ3NKJP2_7S 89=0D>:61)_0H;=U^.
MB^D/[IHN/%?];%5%O(GD"RU+A)SBU76)4FC9[VX^L3SV415)(RTO,R00D_$G
MV4^UBJ,G\D>3[>QN?K5O_H;P7*:@T\TK++'<@&Y>X+-^\9PBEY9/B_=I\7P+
MBJEI_DGR->:DGFG3XEN)[LP3K>0W$DD$PMU(MFXAS"ZPAOW-%XI^SBJKJ&G>
M2+=K71M3GA$U]?"_L+6[N"TS7B2"4/!ZC%PPD'+C'_E+^UBJ0V7E?\G;CS%<
M10SVMYK4UXU]<6,E\\S&^12/6-L\K+Z\:_9/I\HU^SBK*=)\F^7])G@GL[=_
M4M(C;V7K32SBWB;CR2 2LXB5N"<N''EQ7%4C@\I?EO%KEWI,4]-7O)1JM]I@
MU"?U)90R,+F6W]7XJ,L>[)Q^SBK;_DU^7;P>@VFOZ'I"W],7-R%](7'UKAM)
M]GZR?6_XR8JG6D^3/+FD:M>ZKI]J8+S4',UT1)(8S*] \BQ,QB222@]61$5Y
M/V\52T?E7Y(I?@V4C-J5Y'J5Y(US<%VO(6Y1SJ_J<HY%\8^/P_#BJV;\IO(4
ML5S"VG,L%U=+?20)/<)&MPKB3G&BR!8N4H61_2"<Y%5G^SBJ)T3\M_*.B:I'
MJFG6LD5[$MPJ2-<3R"EY)ZUQ59'93ZLH]1JC[>*I?,?^0U6@_P"_<N?^HZ#%
M6;8JA]1T^VU&PGL;H,;:Y1HIE1FC8HPHPY(0PJ-MCBJ1G\N_*3>5;?RLUFS:
M):-&UI;F:;G$T+^I$8Y>?JIZ;CX*/\.*I;+^3'Y=R6GU1].D-MZ=S#Z7UJZI
MZ=[();E?[RM)I%5GQ5$_\JJ\B'4DU$Z<3<),ET 9Y_2-PD/H>LT7/TVE:']W
M([)RD7[?+%5L/Y3^18-.M]/AL)([:SF-Q9<;FX$D#,K(4AD$GJ10\)'3T8V6
M+B_V,53*T\D>6[+1=-T2SMWM],TF5)[&VCFF4*\3%TY'GRD4.>7"0LF*I;<?
ME/Y'N+R]O)+.43ZC>1:C>%+FY17N[=N4,W!9 H>-OL\1BJRV_*#\O[=9$736
MDBEM9K&2&:>>6,V]Q*9Y4X.[+\4Y];E]I9/C3%5UY^4GD.]LX[2ZT]Y522XF
M>8W%P)I7O$$=P9IE<22^M&%1_49OA55Q5T7Y2^18M0AU!+*7ZW;R6DT4ANKD
MTDL(_2M6(,E&]&,E%Y?LM\6*IWY;\KZ+Y;T\Z=H\!M[(R/,L)D>0*TC%F">H
MS<$J=D7X5Q5-<58=YN_Y3CR+_P QE]_W3IL59CBKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BJE=?[RS?ZC?J.*H3R]OH&F'_ET@_P"3:XJ__]?U3BKL5=BKL5=B
MKL5=BKL5=BKL50NJ_P#'+O/^,$G_ ! XJQW\I?\ R6'E3_ME6G_)E<58Q2XT
MO\Z_,7F&;3+Z:S?0[:UM;BWM)YEFFCD:22%&1&!>GI]?A_RL4L4NG_,IO,%^
M]I!JVEVE]K$\MP;2V^+ZLVE*R5D]']X%OE]%9OM_[#%4W\HZA^;=YYB\O+K;
MWUE;)IVG27"M9EX;B4QNNH1W+#@MO.LG!U=_]]_N4?U&Y*J'G_0O,]QY^\YW
M^CV5\)9_*)LM-OK:-U#WB3&;T8Y0*<RE.C?Y'V\50,;?FI!;S6M@^L6EG8Z%
M$-(@-H\C3R_4G]17D-/1N(KT1^FLBM(T7!%C])I,55M!N/S5A\Q:89Y]<GLO
MK^DBY6Z@/I&"XL'.I&2D2?#%>>FH_P!]_L_S8JRK\QO(]]YA\P_I316DL?-6
MA6D%QH&IE'$!E668RVLDA'!XYT9%E2O^5_-BA(HYOS4@O-'6"UN[81VVB&VL
M8H_]#_>.WZ96Z.X5XD^&+U&_E]'E)BKUO0]5.JZ7!J!L[G3S.&/U.]C$5PG%
MBO[Q 6X\J<A\7V<58YHO_DU/-'_;,TC_ ).7N*LQQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5A,Q_Y#3:"G_3.7&__1]#BJ3?FQY=
MU;7/-_DN.RCN8[6"34$U'48(/66WBNK7T 6Y*R?'4IT;A]ML52>#R]YVT'S2
M-!TN34[?RGHVGQ0Z(($]>"X@6TD29)Y!)'Z5U]8*R1OZ3R?"B0<4Q2EUMI'Y
MJVVC^4[^*;5;[S)<6&I2:BNH!7CM;TV!BMD(**L*M/XGXW^)VX8JV8_S1>/Z
MO<IK,OE>6;A)]LZD7;2:,&W];ZK^DJ_Y'_1MBJ=Z7IOG73?R@\DZ;;6UW9S6
MTEC#YDM[<,M['9(2)Q$(_CY<@G+TOWGI\N&*J'D'RYYKG\^:3K/FVTN9+R/R
MXD4US,"T2W:7KM$K4K&LZVW"1Z?[MY_[LQ5":5^76J:G^8/G'6KJ&YMDM=5@
MU;R]%+%Z4%U=V]HT,,C2L.?IQR,P:-3'S^TW-,506D6GYNW6AZ2E_?:[!=WN
MJV*:POH^E+:Q\)4OFCEYS"2W<^E(I]-88F_N%^VJJK8_*7F_2?,^NW-K#JLN
MGS:[9+?ZG\;W\^F)8\)9+>10)#RN41)V@XR>FJ</W>*IAIVF_FI?/SUR]UFS
MEM/+4-P8[)@J3:JC3#TV(5U:4Q&#U(XV3E)_JXJE/EN/\WX-2T::\EUZ4+/H
M;7\5P':$B6*0:KS!6G"-Q%M]E?MQ_P V*K(KK\ZWM/,O[O7(WGLH)=),J?OA
M=KJ)#\?3K#&QM#\42?N/3X_:;DV*IJ!^9SQ6=C<R:]'HQU76(I;^U7EJ,</P
MG2Y6YCE);[R5Y*R_9];X5Q5DWY=_\K#?SAK4OF26]CMEEN8XK6:%?J;1>JIL
MYH)A)QY^CR22.*+[7Q2MRX8H3.5J_G=;+V'EJ<_??Q?TQ5G&*NQ5V*NQ5V*N
MQ5V*N[XJ[%78J[%78J[%6'>;O^4X\B_\QE]_W3IL59CBKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BJG<BMM*/%&_5BJ%T !="TX"M!:P@5I7^[7PQ5__]#U3BKL
M5=BKL5=BKL5=BKL5=BKL50NJ_P#'+O/^,$G_ ! XJQW\I?\ R6'E3_ME6G_)
ME<599BKL5=BKL5=BKL5=BKL5=BK#M%-?S5\T^VF:1_Q.\Q5F.*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L'E:OYW6R^'EJ<_??Q?T
MQ5G&*NQ5QK38TQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L&DK_RO"W\!Y9F_P"H
M^/%6<XJ[%78J[%78J[%78J[%78J[%78J[%78JP_S=_RG'D;_ )C+[_NG38JS
M#%78J[%78J[%78J[%78J[%78J[%78J[%5.YH+>4GIP:OW8JA= (.A:<5V!M8
M:#V]-<5?_]'U3BKL5=BKL5=BKL5=BKL5=BKL506ML5T6_8=5MIC]T9Q5YE^6
MOGC7K7\O?+=O#Y+UB\BBTVU1+J%K$1R!8E =.=RC\6ZCDJMBED'_ "L/S5Q)
M_P"5?ZU7L/4T[_LJQ0[_ )6'YJI_Y+_6J^'JZ=_V58JU_P K$\U_^6^UK_D;
MIW_93BKO^5B>:_\ RWVM?\C=._[*<5;'YA^;":?\J^UK_D;IW_93BK:_F!YL
M9J?\J_UD>YFTX#_J)Q5?_CSS;_U(.K_\C]-_[*<5<//GFT@'_ .K[^,^F_\
M93BKO\>>;?\ J0=7_P"1^F_]E.*L1T/SGYG3\RO-5P/)VI33RV>EJ]BLUAZD
M"H+@JSL9PA]7DW'@[M\/Q\<4LN_QYYOH/^= U;W_ -(TW_LIQ0M?S[YR ''\
MO]5)[@W.G#_L8.*K/\?>=O\ RWNJ?])6G?\ 91BKO\?>=O\ RWNJ?])6G?\
M91BKO\?>=O\ RWNJ?])6G?\ 5?%5Z^>?.Y7D/R_U&G@;S3:_]1&*M_XX\\5
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MO.P-/^5>ZI]%UIW_ %7Q5K_'WG;_ ,M[JG_25IW_ %7Q5W^/O.W_ );W5/\
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M5/6OS)\Y6:WB6VH64D6GPZI<P7[6_-;Z.P2UDBX<9 J\FN)K=VCY*S0LT?\
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M:A]_U"3%67XJ[%78J[%78J[%78J[%78J[%78J[%78JIW)I;RGK1&-/HQ5"Z
MW+0M.:E*VL)IX5C7%7__T_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5 Z__ ,<+4?\
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M_P!4:1I;5YEMXN;JA]0>JJ [_!P5W^SBJ=S>1O)LZ>G/HME*@N!>!9($8?6
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MJMIP86!$*#T [!V$>WP N WP_M?%BJ;8J[%78J[%6# ?\AP8TZ>60*_._/\
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M>-U7]EF51=W+_P X]V\%VZ:79SRV4$\[01V<I9Q;())$0E K2*C*[+R^&/\
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MO_2-%_3%#O\ E5GY;_\ 4LZ;_P!(T7],5;_Y59^6_P#U+.F_](T7_-.*M?\
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MRC]J,MTC_E_X%0H:3^7NIVGF6/69!8JPU+Z_(T0?U3$=,&G^ER*"OQKZV_\
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M."LR?;7[2J#3\P]?6];1)M*MAKYU!["#T[AWLW6*Q^OO)ZIB63DB%86C]/\
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M"+<?Y?\ /\*J;:+HJ:8+YO6:>:_NY;R>5Q0UD("(/\F*)(XD_P E,58E;?\
MD^+[_P !FV_ZCIL59]BKL5=BKF%014BNU1UQ5B/E;\OSHWF*^U^[U*34M1NX
M5M1*T<<1,"<*&;@/WTU8_P"\^%>/V8UY-BK+L5=BKL5=BKL5=BKL5=BK#?-'
M_DQO)'_;T_ZA5Q5F6*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*M/\ 8;Y'%4+H
MY4Z18E35?J\5#TVX#%7_TO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5(O/O_*#>8O\
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M_>/BJM9^4/.%]'Y2B95T"3ROI[1"^9HKJ5[N2T6UI'$I:,P*.<C>J_)V]/\
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M%W>7;^K-*(UX(KL0/A1>BT_:;]IFQ5O4?+>F7SZ<SAH5TRZ%[;1P$1IZRJR
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MJ@EF-_&  .I)]'%;27RIY=M?,]G+?:?YH\V)8J_&WNYKV 1W"_[\A*(_*/\
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MUG^LC49Q<$M=S+P,M>1B''DL?V>7+%+,?^56VF__ #LGF/?_ +6MQ_7%#O\
ME5EG_P!3)YC_ .XM<?UQ5R_E;:*:CS)YCK[ZK<']9Q5L?E=: U'F3S%7_MJW
M';Z<5=_RJZTW_P"=D\Q;_P#:UN/ZXJW_ ,JQ@ I_B;S%_P!Q2;%6A^6$   \
MS>8MNO\ N4FW_#%7-^6$)K3S1YC'RU.3^(Q3:W_E5T?_ %-7F3_N)O\ \TXK
M;O\ E5L?_4U^9/\ N)O_ ,TXH=_RJV/_ *FOS)_W$W_YIQ5W_*K8_P#J:_,G
M_<3?_FG%7?\ *K8_^IK\R?\ <3?_ )IQ5*!Y5&A?F7Y4*ZOJ>I_6(=3!74KM
MKE4X11;Q@@<2:_$<5>FXJ[%78J[%78J[%78J[%78J[%78J[%78JLG!,$@45)
M4T!Z$TQ5"Z(KKHM@KJ%<6T(91T!],5 Q5__1]4XJ[%78J[%78J[%78JXD@&@
MJ>PQ5V*NQ5COYC_^2]\S_P#;)OO^H=\51?D]$3RCHB(0473[4*10"@A6G3%4
MWQ5V*NQ52NA,;680*CSE&$22U$9:AXAZ GC7[6V*L?\ )?EB313J5S);6MA)
MJDR3RZ=IY8VD;I&(V=*I#\<W'E(?23]G[7VV59+BKL5=BKL581Y0(/YD^?MZ
MTETL?].(/\<50M[^7^NG2O,'EJSN+<:#YCNKBXENY"XNK:.^;E=Q)&$,<Q9C
M)Z,C2Q^GZGQ(_I_&JQ&P_+"XUZ/7OJ]K;:8(KO7;:SNI(Y%N+@7J^C#ZH,:?
MZ,G]ZLBO-ZG&/BJ\<4LC/Y=^9OTW/K)&FR-+<F8Z6S2_59$ETV.QDYGTR5>-
MHN<?P-SBDDC_ '?+EBA#>7/RDU?1-5L[A9+*Z2TO;&<7LA<7306>G-8NO]V?
MB=F]15]7CP^!F_:Q5D.N?E[/J'FO3M<M]5N;=(;B2>\A#K6C6CVR+;GTRT=.
M=6JW[4C)^\;EBJIYC\D7UWY!U/RQI]_+=7&H(T:WFJS/.R!R*U8*695I\*?\
M-BJ67GY<ZMJ.O_IFYF@M)?K+M<16[O(MU836\4<ME,6C2B--:POS'+X&E^'^
M95Q\@^86_*B\\FM)9_7[H7,8N \OH!+F=YZD<.=5]3AQ_P!ER_9Q5;YE_*\W
M\5FFEV=A:JMMJ(O4D+N&N]0M1;K,&,;-(8^/VWXOP^'%4FG_ "F\V3:@+B67
M3IH/J[VTD/J74)=)+:UB8\HE!297M.2W7Q2_W?\ OE8\4VC],_*W7X-<TV_U
M"[L]2CB2W^M/<+(9X9+.XEFB>W,?I0RR,LW"26:)&]1?K''D[1XH9=?:%JD_
MGC2]<C:'ZA8V5U:2QLSB9FNGA?DH"E*)]7 W;XN?^3\2J&E\NZY8>:]1UW17
MM9DUF&WBO[:\:2/TY+0,L<L3QK)R#))Q>)E3["LLF*I/?^0O,=SKUQJ1GLI5
MFOK&\'+U$)%I9R6SU4*X4R-)R7XFXI\/Q8JE.D_E-K^G0V$41TU5M(M!1^!E
M7D^BSO-*_P#=_:G]3BO\G^5BJK_RJ_S4MC!:_6-+E:QN4^KWA@>.[GM%DEDK
M-<J#+#<)ZY^*#[?[[XT];X%4\_+GR7KOEN2;])36LROI^FV,9MC)6NGQO%R(
MD'[8?^;%4-K7D+7=2A\\Q%[,)YIC@CLP[2,(_1A$!]8</VE7G\'^K_EXJ@]<
M_+'6;J_U"73?T;965Z;$K;*LB%1;0W$4O%HE4Q%C=55XOC9$>-N'K-Q4I>/R
ME\TG2S:R7%B9UMM,M[>XAEN(7BDTZTFMO60A'%3Z_P#=NKQ2Q>I%(O[SX5#U
M33K>6VT^VMYI%EFAB2.255$:LR* 6"#9 2/LC[.*L.M>1_.[4? >7+3\;VXQ
M5G.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5Y_IX/\ RO;63V_P[8_]1EQB
MKT#%78J[%78J[%78J[%78J[%78J[%78J[%6&^9/_ "97DO\ XPZM_P FH<59
MEBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BJRX+""0J*L%8@==Z8JA=#9VT33V<
M<7-M"66E*$QBHIBK_]+U3BKL5=BKL5=BKL5=BKL5=BKL58[^8_\ Y+WS/_VR
M;[_J&?%4=Y5_Y1?1_P#F!MO^32XJFF*O.OS \[ZMI%SKSZ>-O+>CIJ/I'[,M
MQ>220Q-)3<P6R0O*ZCCRY?Y&*H;S-YLUCR->Z=(;N;S%:WNG7ES=P2F)&]2T
M$3+/$\:!8HY?5,;)1H_BBX8JJ3_F/YBFUH:.^E1V<D":FNIJEUS<&SMX)XC!
M*(N/QQW<;5=/AD^']GDZJ[2?S/*:1IKQ6,MU:>G96DT\]R&NOK=W8+>1!P(P
M'0JR1RW'P?O'Y+#P5L53?R;^8$VO074U_IOZ-6WL++54"2_62UM?1/(M>*(1
M(GHOR10_[/%L58?:?F)K-Y:^<]7BO@SZ%]5U.PT[TWB2.T$ DEMIN:*6>1.?
M+^6?^[^%%Q2]?BD62-)%KQ=0PKL:$5Q0NQ5@_DVG_*QOS _F^L:97Y?4$IBK
M.,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL58/:)7\Z
M]3?P\NV2_?>W)_ABJI^8.I:C'J6@:1;7DFG6NIR7IO+^(A73ZK923QJ&/2LB
MB1OYDB9/LLV*L$T3S]YDNO./E^YU+4V@TJ[M+)KUU%+9+B73)+J6SEBIM-/\
M-[%<U_=PI]7_ &L4HV/S9YICUU9YKR5/2U+1X$TZO[N2#6F>2;DK"I]&-UCC
MW_=_5'_FDY*$-Y \W>9M2BU6RO=3FGO;\6J::YKQGBN[F=#J=JU%,,!@3X;;
M[4+VW/\ W9BE,=:U'S)I%UJ9T_7KB\TZXET[3YKFX,9$-Y<WZ0736G%?W:06
MTH1_MI'.\?\ NU)<4)AH^N:W-)H$3:A,88O,6I:2\K%&^N6MK%=F(R-3DS(T
M")S#?&\;,W+EBJ'T_P#,TOY^U(W;WHTB#3N5KI<5C=M*K1W9B:9D$7-WE^T.
M/P+%Q_;]3%4!J7YAZS:ZA?>84DGDM;/53IT6B,C1\[)=(-^7>)U$B3F3][S;
MXDC7TL4H[ROYGU?4XOT'=W$Z^9;J6QGO[D2AK<6UQ!];=K0( L2+&C6_"G/D
MT;O)+SYXH4+C5]?M->G\M/J6H)%=ZW8V[W%PT1E6TN;6>8O!/%_=K<SVQC6.
MB/;_ +''U%XJHCR[KNI^9?+%E<ZEK,^FPV-BSZIJ-KQC>?U+AXHBIH0LCPV_
MJ?NTY?Z0OI?$R8JD=WYH\[:?;&"\U27Z[H>E1ZE"C</5N99]2:"."\$8XR2Q
MVJQ03(G^[Y^?V_3Q2S>U_2^I^9/.FCMK%S:V\/Z/^J3Q>F)+5)HB\HA)3BO*
MGVW5^/\ L<4(S\LUOF\L_6[G4+K48;ZXFN-/GO6#S"S9N-N&950?'&HE^S_N
MS%4KT\'_ )7MK!IM_AVQW_Z/+C%6?XJ[%78J\Y_.'4M;TZ/2[VUOIK?2+:1Y
M-8BL7"7JI51'=(I_OX;<\_6MS\+\_P!OCPQ5Z!8S)/96\Z2^NDL:.LX'$.&4
M$/3MRZXJD/F#3/.5SYCT6ZT?4XK31;9V;6+1TY/,IV 0T/8G[7^Q^+%7:YIO
MG*X\T:-=:5J45KH5L6.K6;IRDFK]G@:4^?+_ &'Q8JWKNF^<;CS/HUWI6I16
MNAVQ?]+6;IRDF!^SP-*?/E_L/BQ5D>*NQ5V*NQ5V*L-\R?\ DR_)?_&'5O\
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MC_J0W_[BEEBKO\6_F1_U(;_]Q2RQ5W^+?S(_ZD-_^XI98J[_ !;^9'_4AO\
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M%N;>33(4>>2[C99(@L-2[\EJ/W?%J_RXJD-OYVDGMHM07R]>K87<$ES97;"
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M *6ML*_+3K?%5NH?EY>:@R7QN(['6+;4)+BWN[<LXEL9YUEFL[@,J\DD4?\
M/.54ECQ5)-4_*'6+^R^I/=6;I:M=BTN'5_4GCOKV.[9;L4H?2$95>);U).,O
M[O[+*4XC_*V.ZLM2M-2O[BWMKZXU!A9:=<20VI@U L>,T- DCIS.]..*%&7R
M'YMNQHL=_>6$IT&VNK>&[1)5DNC-:M;1&5-UAX<O6?@\O*1?@5,505]^46I/
M:7XM+V!);V>RNH[5PWU>VFBD@EOGB(',F]>UBZ\?3_>?SMR59#Y/\BII.JZM
MJ^I06D^IWNH7-[:7409GABN@H:(,X%#\'Q.G'GBJ"\T_E]JNNG4;[ZW'!K(N
MK2?0;@23^C;I8N)8?6A!"R-ZC3LW_&;C\/'%4'J/Y:^8[ZWU^REO=/\ JFJB
M[N+29K=I+J&YO8E22/UBW^\RNG["K*\:QQM]C%5]Y^6>MWT5Y/)J$%CJ\NKI
MJMI?6:,/222UBL[N+B_^_H$DI\7VFC9O[O%5>Z_+W51YA.I6$UG!;0W^GW5I
M;LLA(ALK.6T>-Z4^(K/RB(^SQ^+%4JTO\HM7M)]+>>XT^ZBM;>*"YCFAFDX/
M:W,UQ!+:_&B*Q]?C()4?BR^I'BK+O('E>_\ +FDS6-U<)*C2A[:"-GD2"(1)
M&(DDE_?/&&1C&)6=HH^,/-ECQ5DV*NQ5V*NQ5V*NQ5V*NQ5V*L*T:*OYN^9Y
M?#2=)2GSEO#BJ;^<=$U'6]..EP+9/87B2P:BM[$\I$<B\0T(4A>:'?X_^%Q5
M*M2\H>85T6?3M(O+9'O9@+V:[$K,]I'$L$<(:)HW#-%&@EDK^U)P^)^6*K)?
M*'F2[FT^2[ETN*31XR^EW-I;RQR1W#6SV_#XG<+:KZE> /)U1$;^;%52Z\J^
M91J.CQ6-Q8#0=(2%8K>YBF>;F@X2351TC,OI<EAYJRQNS2_$W'BJEFC_ )7:
MC86%_:O?Q2D:,_E_2"$90ELSR.LD^YY2_O(T*I\/[K_BSX%5VJ?E5-J4&A2O
MJMQ:ZAIC:<MUZ$K""2/3F+#TT(^"1BS,K?LM_-BK,KC0K:?6[;5VN+M9[6,Q
MI;QW,R6S!N6\ENK"&1OB^TZ<OL_RXJE=YH&N?XMNM?L9K9>>E?H^UBF61N,P
ME:99).)'*.K<2B_%_E8JE_EWREYHLYUN-4O+&:6 W%S#]6BF02WLZ!/K%P7=
MRYXF1.*>GP1N"?9Q5!W7Y<ZE<^6_,UF);2TU'S.4:XC@$GU*)U4(\JH:.TDO
M'E+]CE\/\O-E4YU70?,TL.I3Z;=6UMJFHM!"9I!*R1VD*?%&A0HPD:1YBLG[
M'J?S+BK'I?RNU:X BFO+.&UO[:RLM7MK6&2-$@TZZ:>!;3D[D%HW,$AE/_%J
M_P F*I[%Y=\R6FH>9M1M);&2?69[:6TAN%E:)$@A2!DEXD$ET3DK+]EV^RV*
MIIY2\O1^7]%33H^ 'JS7#1PJ4A1[B5IFCA0D\(49^,:_RXJQ[0%/_*X/-S=O
MT9I K_LKK%6<XJ[%78JP;\SO).N^:XK&UL;BVM[>&593<2+(MS:S+RXW-M)&
M0>:U_NSQ5OVFX<D95&7VC^9;/6-;UW3_ *K<W$VF6]KIL4JNTAN+5IG4R\3&
MO"5KA@>#IQX_Y7PJL?N/RP\QW?F?4/,/Z633K[4;2>W>YMP[3*)[1(8[=@2(
MG@M+A6N87X^KR;_6;%*6VWY(ZA;Z3%;1SV-()KPVVE2)++800W]HEO,(N9,@
M;UD^MK^SSDDB_:]3%;3^[\J^:K[0+GRC/'87.A0P0Z?;WEZ)3<21):JAG(5F
M#3QSCFO]UR_R>'J,H4G_ "JNVU,QG4R=%FN[?4[E_B%\;NVL19+QE^RH8I'<
MF3[:RKQ_RL53CR1Y$?ROJ.LS#4KB]M=0>W^JQ3L&,<=O;I".1"H"_P %*C_=
M?#]K%66XJ[%78JP_6O\ R:GE?_MFZO\ \3L\59ABKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BJV7^[?H-CN>G3%4-I'_')LMP?W$6XZ'X!TQ5__T_5.*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5BGYL_P#DL/-7_;*N_P#DRV*LBTO_ (YEG_Q@C_X@,51.
M*NQ5@/G3S/JOEKS?INI2W17RGZ2P:Y"X7C ;F0I!=\Z<D2.5%BEWX\9N7[.*
MI9Y<\]>8Y/,FJ6]ZOK76H:A#;:%ILK?5H;:W;3_K_P"^8)(_K>EO)\+MZK<%
M547%5LOYF7>OR:&-*ADT\)JFGPZP&E7FIG>>.2W"A&$L?*#^]YQ\OAX?MXI9
M%YONM7T[S)Y=NX;V[CT^ZOH[*ZAC2![0+*CA1,I_TCG--Z:1RQ_!%^U_EJ&8
MXJ[%78JPCR&/^=N\_FO_ $MK?;_MVVV*LWQ5I>5/B()J>@IMV\<5;Q5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5AVB_^35\T?\ ;,TC_DY>
M8JS'%78J[%78J[%78J[%78J[%78J[%78J[%78JPC0!7\W/-Y\-.T@$_3=G%6
M;XJ[%78J[%78J[%78J[%78J[%78J[%78JP_6O_)I^5_^V9J__)RSQ5F&*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*K)U+0R**592!7IN,50NB1F/1K",TJEM"I
MITJ$ VQ5_]3U3BKL5=BKL5=BKL5=BKL5=BKL58I^;/\ Y+'S5_VRKO\ Y,MB
MJ4Z;<_G7]1M0FG^7?2]*/BQN[VM.(I4"#%*+]?\ .G_EC\N?])-]_P!4,4.]
M?\Z?^6/RY_TDWW_5#%4KO]!_-"^N)KF[TGRQ/-<1"WE,UQJ$B-"K!PC1F+@1
MS'+I]K%*"NO)?YAW$MU//HOE5IKR5+FZF,^HAVFC%$E#A R.BG@KKQ94^#[&
M*$-;>6/.&JR66J6FD^2[QM."16-U;S7CK']78E%4QIQK$Q/&OV.3?S8I35]!
M_-=]7&L/IGE9M1 4"=IM0-. (5N)3AS4,RA^//CBA,?5_/'_ )9_+/\ R.O_
M /JGBKO5_/'_ )9_+/\ R.O_ /JGBKA)^>-=[?RS3_C-?_\ 5/%6*^37_-K_
M !+YS^JQ:"+C])0_7_5DO. E^HP4]'BG(IZ7IUY_%SY?LXI9:'_.PC>+RT/^
M>E^?^-,4-\OSK_WWY;_X._\ ^:,5:8_G;MQ3RT/&K7Y_XU&*K#_RO*NW^&*?
M]O#%+O\ D.7_ '['_<PQ5W_(<_\ OV/^YABKO^0Y_P#?L?\ <PQ5P_Y7EW_P
MP/\ N('%7?\ (<O^_8_[F&*N'_*\N_\ AC_N88H7 ?G=O5O+0\/AO_ZXJNX_
MG70_'Y;KV^"__P":L5=Q_.K_ 'YY;_X"_P#^:\5=Q_.K_?GEO_@+_P#YKQ5W
M'\ZO]^>6_P#@+_\ YKQ5W'\ZO]^>6_\ @+__ )KQ5W'\ZO\ ?GEO_@+_ /YK
MQ5W'\ZO]^>6_^ O_ /FO%7<?SJ_WYY;_ . O_P#FO%7<?SJ_WYY;_P" O_\
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M7$Q7L$$$T? CC_QZPR1O^Q)_,GP8JNT?\L[#1]0LY[2_D6&SO3>VUJRH0/\
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MCR9;Z9;:T(K@_7-=D::\N$C2-!(8A#R2%?@!XJ&8GDTDGQ/BJ5V'Y6V5E%#
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M(B:?ZLC:?'-"K%)09IIU1K-:TE@9AQU3X6X0^CBKU_%#L5=BK!_(#5\V^?\
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MI2I7DAZ'BP##Z<50WF'S7HOE^.)]2E=3,)'2.*-Y7].%><TI5 S>G"GQ2/\
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M #3BMN_Y5-^6'_4J:5_TAP_\TXK;?_*IORP_ZE32O^D2'_FG%;=_RJ;\L/\
MJ5-*_P"D2'_FG%;8;Y>_+7\OKC\R?.-C/Y=TZ2SM(-+-K;M;1&.(S0RF3@O&
MBERJEJ8I9C_RJ7\L/^I4TK_I$A_YIQ1:W_E4/Y6TI_A32]C7_>6+O_L<5MIO
MR@_*UA1O*FE[[_[RQ#]2XK:W_E3?Y4_]2GI?_2-'_3%;=_RIO\J?^I3TO_I&
MC_IBMN_Y4W^5/_4IZ7_TC1_TQ6W?\J;_ "I_ZE/2_P#I&C_IBMN_Y4W^5/\
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MEQ5*_(2Z#?R/I_E^6FDW>J'5I;"#EZ%I;V\<7I0?$."R3W"Q7$T4?V&:1?\
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MS;]?]REA_P U8J[_ !C^9/\ Y;V;?K_N4L/^:L5:_P :_F-M_P Z!+\1HO\
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MN+8JE"?EGJK7Z32WMI';7C:7+J]M;P/&@?1Y3)!':J7;A$Z^E$_,\E6+DO\
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M6*VRL?DY^5(_Z9/2_#_>6+^F*VN'Y/?E6'Y_X3TKE6O^\D77Y<<5M;_RIO\
M*G_J4]+_ .D6+^F*VVWY/?E6QJ?*>E=2?]Y8AN?]CBMM?\J;_*G_ *E/2_\
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M&NK7$=M;6[V[Z2"WH2%ZDR'XMC41_#QX?!\7)N+(JR'%78J[%78J[%6'2?\
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MJBBR/9W$EN9!T_O/2Y_[+%608J[%78J[%78J[%78J[%78J[%78J[%6$^4O\
MR9/GW_7TO_J"Q5FV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5A/E+_R9'GS
M_7TO_J"Q5FV*NQ5V*NQ5V*NQ5V*NQ5V*K8XTC!""@)+'YL:G\<578J[%78JP
MZ3_R<$&__3/3;?\ 1[%BK,<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL50^H_\
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AXP2_\0.*J.@723Z5:<4D3C;PU$D;Q_:C!VY 5]Z8J__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>exh1_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1_3.jpg
M_]C_X  02D9)1@ ! @$"6 )8  #_X0Y[17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  6XV    G
M$ !;C8   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,34Z,3 Z
M,3,@,3 Z-3 Z-#0      Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   U%
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M#OR<N65CN\U.#9,>UUE%C_\ @_W%+T;\5@+MSV&RLG>:FANTZO\ T%-/YO\
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M[0      $ )8     0 ! E@    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M   )           ! #A"24T$"@       0  .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #10
M  8              X\   +     " !E '@ :  Y #D ,0!? #,    !
M                      $              L    ./
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   ./     %)G:'1L;VYG
M   "P     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   #CP    !29VAT;&]N9P   L     #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    !/_
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M=X>7I[?'_]H # ,!  (1 Q$ /P#U1SFM:7.(:UHDDZ  =RJ^3F,IH=;7[W-
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MJ)>UKZG-81)+7TD Q^<#C-_/_<24U*LJL65,N%+MS]M@!HK+1.SW?KE_CO\
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P R
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M6B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M    ]M8  0    #3+4A0("
M                         !%C<')T   !4    #-D97-C   !A    &QW
M='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+
M !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #
M3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT
M97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M
M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M                                6%E:(        /-1  $    !%LQ8
M65H@                     %A96B        !OH@  ./4   .06%E:(
M     &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:
M              !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                 '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M     5A96B       $P)5@!0    5Q_G;65A<P         !
M             H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '<
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M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" ./ L # 1$
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M1_T:Q?\ -.*KC^6GY>L0Q\MZ:2.A^JQ?\TXJT?RT_+TN7/EO3>1%/]Y8O?\
MR??%5(?E5^6HI_SK.F[=/]&C_IBJ\?E?^7(Z>6=-';_>6+H?]CBJ\?EK^7H_
MZ9O3?^D6'_FG%5-_RN_+EVY-Y:TZOM;1CW[#%4)JOY7_ )<IIMY*OEK3@ZPR
MNI^KQBC!2:C;;%4#Y+_+;\O[KR9H-Q<^7=/FGFTZTEED>WC9F=H$9F8D;EF-
M3BJ>'\LOR\(-?+>G;BA/U:*M/GQQ52'Y5?EL(O2_PUIWIU!I]73J"3UI7OBK
M0_*C\M!T\LZ=MT_T=/Z8JO'Y6_EPO3RUIP]Q;Q_TQ58_Y4_ELZJK>6[ A*\?
MW*CK\L56?\JC_+*E/\,Z>1[P+BK:_E)^62[CRQIP_P"C=/Z8JO'Y4_EL%*#R
MUI_$]O03O]&*J9_*+\LCU\M6'_(D8J[_ )5%^6/_ %+.G_\ (E<5=_RJ/\L?
M^I8T[_D0G],5;/Y2_EH13_#5@!X"%1^K%5O_ "J'\L?^I:L?^10Q5W_*H?RQ
M_P"I:L/GZ0Q5=_RJ7\M/^I<L13?:(#]6*K3^4/Y9$[^7++_@/[<5=_RJ#\L?
M^I;L?^1>*N_Y5#^6/_4M6'_(H8JN'Y2?EFNX\M6 /CZ*XJ@O(>C:9HWF_P X
M6&EVR6=BDE@\=O$.**SVU6(7MR.*LZQ5V*NQ5V*NQ5V*NQ5":0JKI5FJFJB"
M.AZ[<1BK_]7U3BKL5=BKL5=BK$O*BC_&OG9NYN[$$^PTZ'%6!^9-3U2U_,J2
MX,T>LZ+)J>GV4L%O=/;ZGIDS>D!&L ;A<V4]?5F7AR=7EY?W>*6,>0=-\Q7^
MA^8O,7Z7>/2-+?S#:W41NYY7N: _54XL?3@2SISAE5O5^+]E<56^7O,NM67Y
M0W6JZ7<M-YTFT='@-O<R7LSVBF$W%]-$Q?A<PM+*J_#_ )/[WCBK*_/UMY3M
M/RNU74?+VL2&_@T66X@DAOY7:3GZ9%S(>9/K!_L2?"_QNG^3BA2\^><M9T?R
MWH%[Y>DDGL?*\>GZGYA,;!Q+;S+P,4DA?EO$TD[?"_/]TV*47IGFSR^GYU:W
MJ,NK1IHH\NV=] \EQQMPTLC%I45F]/FT03D0.6*JOYS:@UQ-Y!:P=T?5]5CB
M$9N);198)8&?TIFBJX0MZ;-\+<67%0P/SO!YM\L:EH^D7E[=>8=7M_*^H2WS
M6]W-;M)-%+^ZN5"GG+)9QM\'+][*D>*L@\OZU;Z[YDTZV\SZZU_Y73RK#=:9
MJ+2M:Q7ETIX7MRY1U_TF"E/39N<'V_M?%BJ56>J>=K#RAY$_,?4&OKYK*Z>R
MU:S+2<[S3[F5X;*Y>*JH\Z\TX2.O)_41FQ5/]=MY-$\]:#:3ZI+ITLN@ZSJ-
M^R322(ET KK*(F8K)]5YR_5UX_9C^'%6(Z[JVMV'D;6['4I!'JEI#I<UKK^E
M:A-+9WD,MZ(3/N_."[F3U/57E^^CY-]E,59%K6I,\WYER:YJ,VGZAH$48\HQ
MQSR1&&V$'*UGMD5OWSW%QQ61^,G)OW/^1BJ!UFX_,&PL;_SA'+/=M%IUK;^<
M?+(=AQ^LZ?'))=P1@_N+B"9_4D"*OP<OY6Q5-)-0U?3O.%E)ZHUC0Y+O2K$+
M:W<D6HZ;-Z<-(FMRW&ZLYR?6E^'FRR2.[?N\4/=,5=BKL5=BKL5=BKL5=BKL
M58O^8!(M-%]];TVO_22N*LHQ5V*NQ5YAJM^U[^<CZ'YCN&MO+T&DK=:+;-(T
M$%U<F2EQ([AD]62W3B$B)^!6]7C^UBJ$N_S'O=$UR#1-*XW^E0RZ?##+<.]Q
M=7B:J\Y,\$I<<H;/TOBY+)S7GRD3[6*L2E_//SO?^4]1N4?3K2Z.B6^K6\]M
M'(S0^KJ)L95822,"0H]4/_NO^5OM8I9;J/YG^:[6]\U-;W&BS:1Y5M[2::[D
M%PAG-Y:^HA0QO,JH)?\ 7YHW#[7[S%4OTS\[/,6I0:5;1+I=G?WUWJEM]>O6
M>.S<Z8Z<(24D?T9KB-R_]Y,J\/@63GBM)]Y-\Q:IKWEOSL=<OK>X:QU#4;6.
M& &%H(;<,B<B'+(K<.<9^%OM/S?]E0PW3-8\W>3I4M-72Z\QVFEZ3>:[Y8U9
MI':2YA%NA>SN""?4EA=PR.W+]U\:XI9]Y#_,U-6NI]+UJ>U2_P#K*6VF3V]4
MBO2UE'>2+"K-(>=NLA27]XW[/V>7#%"!_/J]N+/1?+<EM<-;S3>8-/MV"3O;
MB2&5F$D3LAKZ;T'/9L5>:>9-4OX=*\^R?79(+FR\U:;:VB17LW"**0Q>I!%)
M5&2)^4G-5C7]OX/@Q2F4USK4VM>?[2'5H-+U./5=*M["SN;N:6P*M"9GLS)^
MZ>&&\9.+NB1_'^ZQ5%P1^;==TZSO/+<D^A>;]#EU!QI$MZUU9W3VLENKVR.2
M5GLW62183_NB3]WS^'X55#5=?T.Y\J^6]2?6KCRSKVI:E+=V]G->R1"UCAOG
M^N>I"&_?MZ:?4XHG5N;^G'%&G[W%65ZCY<T.Q\U:QJ5[KFJVVEV-A+>ZY=RZ
MA.L:O?2DI#''41P>E!'*JK"B2*LT7#]YQ;%#!+K5=$_Y59IT;^>98-5?4)AH
M5T=1=8[1#,LU)YE/^E_4K-@C\VE7UI/JZ?O,4I_Y>U_S#>_FT(Y+NX,=SJ6J
MVMU"7= NEPZ=;2V<GI[+&/4D]5'XJWJ3/\6*H:+S#?O^1NFZFVLW*WI\P)!)
M=_67,DB/K!C:.5^577T/V6/V,50_FWS-YZM_S"U5M,EG;4X=0N+6RL5=F4Z<
MNBM<(X@KQ*_6?WJR\/[[X.7[.*L>L?,?F!HK2REU2YD\J3R6,M]J#7$@I=R:
M%)=2HUQRY)RNPLSQ\_[[_@<59/I>O:KJ.L_EW>?I62?7'BBLO-&G0WLBWL<E
MU9<EDELCRB]",#ZQ*WIJ_J-]O%6]=L;ORM8W\VD:OJHT"36].T35-0N+R>XE
MM[1"6U"X21V;T/4FD2V>5./I^D_V<5>O^7=.\NVE_=+HUX9%6&%)K%;AYXHM
MW9' 9G]-Y0?B_P!^<%;%"?XJ[%4%KG_'$U#_ )AIO^39Q5+_ ""I7R+Y<4]1
MI=D#_P!(Z8JGN*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5X;YKTKS+KWYRZMHGE[
M5VTR>'3]-OOK/UF95MB+EO7>.W2J2R3PJL3))P3C]K%*FOY^>8)-0\Q6L$>F
M3C3E!LGC9R %U'ZE(?B=&N2D1]7TT2%GE_=1<UXOBM(B3\Y//UM<:)9W.GZ:
MMWJC7=Q&T[_5(YK6VN4A1$:29A'<S0E[CT_WCK^[B]'[3XK3+_S*DABO='O+
M:5I-1M+^P]6U@O6AN4MY;D(QBM5JEQZW]W*)1\4*OP^)<4(3\TOS.UCRGJ26
MMA:PO'#ILNJ2&X#'ZT8KF& 6=N59.,S"8ORI+_NO]W\6*4%Y*O#-YG_,/7M>
MU=T@TF[DL48321QVMF+:*9N4?-HE,7[+^GS63UVY?'P50J_DK<SG4O-]JEW^
MD-*6^BNM+O8;R2^L_1NHN?I0R2EI!)'QY7"F1_CD_9Q5E'ELU\\><!X/I_\
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MU4\E65%< ^(# XJVUI:/(DCPQM)&I2-RH+*I%" :; XJHC2-* =190 2*4D
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M?'%7H>*NQ5V*NQ5V*NQ5V*H'76X:)J#=>-M,:?*,XJ@?(?\ R@_EW_MF6?\
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M"21FMDN*>GRY*X$J_ _'_@N2JJDN@_FQI4R:197,=]=7%[%IQDU,VT<,'+5
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M_LIQ5KZC^=W_ %=_+P_Z,;S_ +*<57K8_G4*5U;R^:=?]!O-_P#IYQ5MK/\
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MIMM39'D1!ZGPRQ,G[N4\D^+XXF^'%"+T?\NFTS6;>_CU'G!;7UY?);&'>EW
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M2XO)O5E:OV(U-%I%&NT2*/\ C;%43+I>BF0M+:6QD=BQ+1Q\F9]B=QNS=/\
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MV>J627EHQ:)F=&5AQ=)(V*21NI^R\;JR.O\ -BJ+Q5V*NQ5A 4?\KM+=QY:
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M'=Q0R":))5Y!9%!"N ?VEY'BW[.*NU71=)U:**+4K2.[BAD$T22KR"R*"%<
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M200W,4DCF(#ER]#TOY/WB_R8JCXOS*TA[N:3G+]1%M!+!:-8W<=XTD\TL2L
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M42KS1D$L)=HQ/"6 ]2$R1R)ZB_M+_J\E4\Q5V*NQ5A?FQ:_F'Y$-:<9=3/\
MTXL,4LTQ0[%78J[%78J[%78J[%78J[%78J[%78JHWI LYR>@C>O_  )Q52TB
MGZ)LJ=/0BI_P Q5__]'U3BKL5=BKL5=BKL5=BKL5=BKL52_S"*^7]3'_ "Z3
M_P#)ML52G\L37\M_*Q_[5-C_ -0Z8J638J\^\W>3YM8U_6K.>1XK+S/HB:9;
MWJJ7%O<6TDTG%AX2+.)!7CS]%TY?9Q5(_P T= \RZOY5FO\ 6K6W@_0>FW@B
MALY'G>ZO;F#ZNI0"-6CA 9F5/CD9V3_??QJ0NT_\LK^/4[+6K/2]/AM6N[FX
M724EK%;PW-A';!XG]+BS22Q^N\82->4GVN7+%5+3?RN\U0Z?I]G=1VCS6L5B
MPOQ*QEB^IV9MIK-*I\<%R:FOPKQGFYQ\U7DJGWY;>0M5\MP75M-'!8QW&EZ;
M:&6S?DWURTADCN+BC(J\G9T97;DS</WF*$GU/\O=;TW1/-FFQ7CWX\Q16>GZ
M.A2,2!UA6)YYC'&@4QT>5GKQXIS;]ZV*7K,:E452Q8J "QZFG<XH;Q5@_DEB
MWGW\P/ 7U@/NTZ'%6<8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78JPE/_)UR^_EN/\ ZCWQ2AM4\AZS=>;Y;N*2$:1>ZEI^L7,S,?6C
METV'TU@6.E&65XX6Y\UXKZR\?LXH2OR'^6OF30[J6*]-NNF75W;WU]#%)SYW
MEN)'>XC'IQ^E%<3_ %9UM?B6#TGX?:Q5!Q_E/YE&D7%A(UI(MKIIT>S1F8B[
MMI-0%W,9#Q_T=WMT6!&'J-',SS?R8IM/?+/E;SEH6A(JBVN]1TZSEM=$MY92
M(T$]RTE)Y1'R=HH%MHVD5.4S1O\ S\\4)7>_E]YNN+*4Q6]G;W5_I^I:1>J]
MT\U%U)XY7OFD]&/U)O564R0A$7AZ2(_P8I9!+Y-U6?7-203&TTNZT6TTF&^B
M=6N.5O)*[L8W4J%=)N'5OVL4*'E/\O\ S!I?UH7&OW$$;:O/?QPVB6RQSP2<
M.,<ZF#X:\/B6'AQ_8;%5GF/R#J^H>:+FYMGB&F:K-I-S>S,Q$T+:1,\O&-0I
M#^O6-5^)?3;U&Q5*O)OY8>8-&N;:WG>&'2X4MH+U()7<7KVD\MRMV\;@+')*
MQA21?B;^]^/BJ8I1NL>1O,6LW>IZJ8X]/NYA8O%8M=R7,$]QIMX+J)V)11 C
M(OHTC3_=C,R_!\:A%:'Y5\S:4^I:J(+:?5)GO;ZPLVF80K=:C,&:-Y G+C%#
M# OJ!/C9YN*KBJ1WOY>^<;RS^L"ULH-4GMM5T^\4W32A_P!+QQ<[UI!#'\<<
ML7]PL?\ <<$63X<4LPT7R]J6F^:FN."/I46CV>F6\_/]ZTEI)*Q+1TV5A*./
MQ_LMBA,/*.D7>FZ4WU_A^D[Z>:]U QDLGK3N6XJQ JL2<(4_R(\58^*_\KS;
MP_PP/^Z@<59UBKL5=BK!_P U?+.L>8-+L[;3+&*XN()UG@O/7^JW5G.CH8YX
M)>+THOJ++^UQ^SS^QBJ^/1_-%GYCM=<N%AOY+3R^UC<SAC&9KX.DQ81JC%8G
M:,_9#,O/^[Q50N=(\U>9-1T?4YH)/+DMK!(9+B*[,S<;NT*/#]7*+&)8IW5Q
M*Z_[H7^?TU526#\I/,$=IY@L_P!,TM[J>.;38UAM^$OI6"VR?6%,9X\9%_8_
MWVDW]YBE.=/M_.T/E>X\J);H+ZRTFTMK;6O4XQM<3(8I@%$:4-HHYQ\.?J?!
MSX/BA+-:_+366\[:!J6D^C#I^BP6=I:3%@&BMH6D6[CEC*M]8,T+H+9^2_5Y
M59_AY-S4HW\NO(FMZ'J5O<:GZ*1Z3I*:'9^BQ?UT2X:;ZPPHOI\D])>'Q-S]
M7_)Q5Z'BAV*NQ5AOFO\ \F#Y&_XRZE_U!-BEF6*'8J[%78J[%78J[%78J[%7
M8J[%78J[%4/J/_'/NO\ C$__ !$XJI:)_P <6P_YAH?^38Q5_]+U3BKL5=BK
ML5=BKL5=BKL5=BKL52WS*2/+FJD=?J=Q3_D4V*I5^5QK^6OE4_\ :HL?^H=,
M5*GYQUO4H==\N>7K"?ZD==FN!<:@ K/'#:0&5HX0X9/6F)4*75N*+*W#%4%J
M/FK4?*S7EC.9?,$MK;S:O([-#!+#IL(16!XJJ33\_5* +'S7[;JWVE4OOOS:
MN7NY++2M,1[A;^RM(TNIS#(\%W,(UN/2,?+TI%W@D4R1MR^+BZ^EBJ;ZMJVJ
MWWGZ#RI;W<FF6BZ6VJ7%U L9GE<SB!(HVE61%2/=Y?@Y?%%]G%4BT;\T]4BE
MFTC4;'Z[?PW%[9:=>K(L*W\UE>I:^F$"E4EX3QR24^#X9>*JJ?"I1?\ RMJ:
M0/)9^7;RYMI+F.TTZZYI%%<.]R;0T>3B%XRT.W/]VW)N#_N\4+[+\TM0GGC2
M?R]):Q2WEUIJRO=0M_I=E%/+*G% Q]/_ $9E]7_*Q5VD_FR-0U/3[8:--#:7
M[6,?UQIHSP?4;-KR$>F/B:BH4<_LXJ] Q5A'DE:>>OS /CJ%C_W38,59OBKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK!T)_P"5W3"N
MW^&H]O\ H_?%+.,4.Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5@U#_P KQ)IM
M_AD5/_;PQ2SG%#L5=BKL5=BKL5=BKL5=BKL5=BKL5=BK#?-G_DP/(O\ QGU'
M_J!?%698J[%78J[%78J[%78J[%78J[%78J[%78JA]0_W@N?^,3_\1.*J6A_\
M<33_ /F&A_Y-C%7_T_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5+?,V_EO5O^8.X_Y-
M-BJ4_E9_Y+3RIW_W$V7_ %#IBI3K6-#TK6((X-2MQ.D,JSP-5D>.5*\9(Y$*
MO&XJ?C1E;%4!<^1O*UR(OK%B)'B$B^HTDOJ.L_$RI*_+G,DG!.:2LZ-Q7%5E
MSY!\HW3S/<:>)7F<2,SR2DJPF^L?NCS_ '(]?]YQAX+RQ5'ZIY>TC4Y;>:[@
M)N;7D+:YB=X9HPX =4EB9)%5Z#FO+BV*J</E7R[!'IL<6GPHFCR/-IH"_P!S
M)(CH[K_ENLDG-F^USY?:Q5 1?EQY)ANYKN'2TAN)[E;V1XWE3_2$D]4.H5@$
M_>_O&5.*O)\;_%BJK<>0_*=Q9O9S6 >W>[DU!E]24'ZU.&660,'# R+(X< \
M6YMBJG9_EYY/LWA>VL/2:WDMY8:2S45[.(PVY +T_=1$QK_DXJR/%6$^2O\
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M:;%59/S?\E2*QAFN+@^M%!"D%O+,TS7 <PF,1AN0E]*0+7BWP_$J\EQ54?\
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MW:N0UO!<6R1QW5O(8A);FX02""0@E0Q#;HK,N*H6#S5H2)K[Q6C12Z"TL5W
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M%5_RL5M4;\I] /\ TM-='C36+_\ ZJXK:W_E4GE_OJFNG_M\7_\ U5Q6W?\
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M /ZM%U_P=K_U6Q5I=4U!BP_0]TH4T!+VN_N*3'\<57_I&_\ ^K7/_P ';_\
M57%7#4+_ +Z9.!_QD@_ZJ8JN%]>FE=.F%>OQP[?\/BK7UZ^XU_1LU?Y><-?^
M)XJV+V]/'_<?**]07AV^='.*MM>7HZ6$AV)^W%]WV\56'4-0X%OT7,2/V!)!
M4_+]Y3%7)J&HL-]+F3V:2#_C61L54-0N+Z6UX-8M'R="7:6'B.+J14\OVJ4%
:/VL51?UN\!6MD_$LH)#QF@)H32O[/7%7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>23
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`#&%9D?6X#P>EP$``+H1```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,V874_",!2&_PK9K6&E5?$CP(UXJR3Z!^IVQAK:M6G+@']O.]#H,@TH
M2\[-/GA/S_MNIWLNF+SN#+C!5LG*39/2>W-/B,M*4-REVD`5E$);Q7VXM4MB
M>+;B2R!L-!J33%<>*C_TL4<RFSS78*W(8?"P%V+O:<*-D2+C7NB*U%7>ZCK4
M12$RR'6V5F%)ZH,U7`0]&2RX]4]<A19D*TDC[(\TC3HYCZ$S%GCN2@"O9.K\
M3H+K\M\K'\YS*/A:^I.,#^\NM2";&E<*<[!ZW(8N+OPV38+JCG)H+_PMF5!Q
M:*9:?EL1[__X+*V76"LYMWPC6@9U;V.*YU1Q476-:J/MZDWKU3FW"<2GRB$?
M&AL*K1<=NR04+X+J2&C]+^^/G9)I"T<9QL(>/XJ26\A?O`WS[?XVOA;TER/.
MM;G^:>B-Z$ASZA$2)^5@2')<(LEQA23'-9(<8R0Y;I#DN$62XPY)#CK"$@0+
M42D6I%(L3*58H$JQ4)5BP2K%PE6*!:P4"UD9%K(R+&1E6,C*L)"582$K^R0K
M:?ZRF;T#4$L#!!0````(`#&%9D=(=07NQ0```"L"```+````7W)E;',O+G)E
M;'.MDLMNPD`,17\EFGUQ2B46$6'%AAU"_(`[XSR4S'CD,2+]^X[8@,)#K<32
MKWN/KKP.J:P.-*+V'%+7QU1,?@RIROW:=*JQ`DBV(X]IP9%"GC8L'C67TD)$
M.V!+L"S+%<BMCMFLY]K%SM5&=N[3%$>4EK0VTPAGEN&;>5ADZ3SXB?078VZ:
MWM*6[<E3T`?^LPT#SWF65Q['=B^<KRT+_8_H>13@2=&AXD7U(V8#$NTIO8+Z
M>@"%,;X[)9J4@B,WHX*[O]C\`E!+`P04````"``QA69'>Q>T)50!``!8$```
M&@```'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSQ=A+;H,P$(#AJR`.$#.3
MA"0H9)5-MFTO8,'P4``CVU6;VY>RJ.C#HRZ09@,"2^-_PR>+\^"2[(DZ[5LS
MN*8=7?3>=X/+IO=YW'@_9DJYHJ%>NXT9:9A6*V-[[:='6ZM1%W==D\(D295=
MSHDOYY^SHUN9Q_960AR]:%N3S^,W8^^N(?).S3?83!M,RX^1_K.]J:JVH*LI
M7GL:_!\5ZFN#6(6#,!R$(D';<-!6)&@7#MJ)!.W#07N1H#0<E(H$'<)!!Y&@
M8SCH*!)T"@>=1((@861,9)(XK&6T!H9KD/$:&+!!1FQ@R`89LX%!&V34!H9M
MD'$;&+A!1FY@Z`89NX'!&V3T1D9OE-$;&;U1Z*S-';9E]$9&;Y31&QF]449O
M9/1&&;UQH;=KM*7RV=MVJ-W:-=^&LT4+O)U_=+1^RCR5;5AH[:>=2,W7U3_W
M>>IGB/KU$^'R`5!+`P04````"``QA69'+Z?7KY`"``!K"```$````&1O8U!R
M;W!S+V%P<"YX;6R]5DU3VS`0_2L:7YH>P(F!'C+!,R&A4V9*R9`4SHN\MC7(
MDBO)'L*O[]HFQH$DU!R:2U:K??OQ=E?)1-GA>&%TCL8)M.PID\J.27GNI<[E
M8]^W/,4,[#&9*+J-M<G`T=$DOHYCP7&N>9&A<GXP''[S\<FABC`ZRENG7CBI
MHDSS7`H.3F@57@MNM-6Q8Y=/'.7$?VM0(\CS$GEAA%N'P\:FJZIMEAPDSBA6
M&(.TV%B]*FN;F<YR4&N_.?T4ZM'^SE=Z#@Z[J.V+QGL*!B,*NN6]5=8V/]94
MIZRPLQ14@E'7]OWEAHL[-+:J=!0<#^G34K#1-[X1(J&2!0ACPTGIQB5RI\U+
MFTKWV2Y%FE=-MW<KRL]Z[`$L5N*Y5X(1H)S'K'BF8^`U81MM+<O<.A/>:_-H
M4T1G)WZKK,6N;5<6IV%P5EN0M&WIMY6%+[1MU5UI5L))M#?Q`HS[3U34-;5$
MG'F=ZC<NV%1%[%(Y&D=VI9I0U+PN):TTT\IJ*2(:KHA=@`3%D2UK"ME@5GP"
M<_(Q9NGHJ\K4,AVS:A%Z8\"F.S&_M$,V8D=L*1(EB%BH^.!<%\2'2O9C@@KC
M-'\\NB"NHSHK5):8VX\Y(<Q,2PD/VI!AB0R(^1N7XG[,*6%N]1HD->=:*W3B
M>7]W:L39)K-4RXCV\`N[_%-0;W<B=I?-%L0CIU>O/V>CH#]GH]TS<#C.Z6',
M=]HZ=@>RP*K_1/'^N7F-0TL7%9(RNP97/\^,MN$#3)%E8-95D%OD*$IXD!_Q
M=J5*&DQ-J,$<'0AIO_8(0MB"?N0&\_Y$!\-_P%!ZG-*KQG-!N\JFAS'W*)*T
MVKAIB0829%-KBZS_$@0'AF#?$K!!_S78QKQ[M-\\T?[V7XOP+U!+`P04````
M"``QA69'PBY5/SX!``!I`P``$0```&1O8U!R;W!S+V-O<F4N>&ULS9--3\,P
M#(;_"NJ]2[/!#E'7`R!.3$)B",0M)-X6UGPH\=3UWY-E7<N`2V_<ZMKOX]=Q
M4@K'A/7PY*T#CPK"U4'7)C#A%MD6T3%"@MB"YF$2*TQ,KJW7'&/H-\1QL>,;
M(-.BF!,-R"5'3H[`W/7$K"JE8,(#1^L[O!0]WNU]G6!2$*A!@\%`Z(22K'HQ
M.V,;4Y)!7Y71<<T#+JU4:P7RMAW*?J=B9P2OPTD.LF^?_O[I(65(UE4>@NJK
MFJ:9-+-4%P>FY&WY^)S.)E<F(#<"HBHHAJV#17;N_#J[NU\]9-6TH#<YI7DQ
M7]$YNZ9L1M^/DUWX&PSK;HA_Z_AL,&T7%=8P<K=)(]-RTV<"20C"*X?*FE&X
MA/DF3K"P__@$@>-!G3!=MAVTC?4R5.E^#='QY<25;:QO3ZD?T<6KJKX`4$L#
M!!0````(`#&%9D>97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM
M;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'
M-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D
M$4$P&:>O\,`*I4Q>M5II`,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$
M:6RA&$=D8'U>+&A`T%116F]?(+3E'S/X%<M4C66C`1-702:YB+3R^6S%_-K>
M/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:C
MTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D
M00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'
MPZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:
MV1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0
MUL\IM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CD
MGZ>3UTU"SG"\+`GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E,L_O^0KK3CQG'U:6
ML%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&
MF&I0'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F
M<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\'1,2S90+!D&&ER0F
M$JDY?DU($_XKI=K^G--`\)0O)/I*D8]ILR.G=";-Z#,:P4:O&W6':-(\>OX%
M^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:<K46@;9QJ81@6A+&
MT7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY`1OQZ&.$J:[:)Q6`3]
MGE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR-`>CFED)O816:I^JAS0^
MJ!XR"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK<W
M(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?P.S]:#Z>\>WZV22$
MKYI9+2,6D$N!LT$DN/R+RO`JQ`GH9%LE"<M4TV4WBA*>0AMNZ5/U2I77Y:^Y
M*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL<QP3A[+##MG/)(=
MMG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9
M!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&UL
MK"0L1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2
MX]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,
M$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'<4Y3N!)VM@\",KF[
M.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T
M74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0!A,!S93)1/`"@F2F
M'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L`P%(1=RX^_ODVIWC-?Z+(%M
MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+PWING2TG_]M>U#VT
M%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MB
MOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\4
M8JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%
M7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`,85F1QP$3&->`@``
MT@H```T```!X;"]S='EL97,N>&ULS5;M:MLP%'T5H8S1PHCM;'6[U3:,0F"P
ME4'S8_^*;,N.0!^>+&=.WV<OLB>;/AP["4W3I.W6_-'5T=6Y1U?7N8IJM:3X
M9HZQ`BVCO([A7*GJD^?5V1PS5(]%A;E>*81D2.FI++VZDACEM=G$J#?Q_=!C
MB'"81+QA4Z9JD(F&JQA^Z"'@]E^)',?P]N3MST:HRS?`C:-WHY%_>WJYC9_8
MA5,(',>7/(9!>`:]QY..?7\WL5G<(@\/)'^(>XOZ?`_UG]\[LM$OW)N."T/K
M=7E/HD+P(?T3Z(`DJN_``E'M'QCW3%`A@=+WJ^-;A".&G<<5HB25Q(`%8H0N
M'3PQ@"V)SH\1+J2-[2)LQQG[0R19IC'TN]_CPZ4#NQW,\0BEF\?30!)52"DL
M^51/0&?/EI4^'!<<.Y'6;X]W*=$RF)RM;;"#CIL*F6/91P[@"DHBB@NE-TA2
MSLVH1&6D"Z4$TT9.4"DXHH9RM:,S-&V&*;TQ'^"/8H.[+8#S,7?L0V!4K$R=
MB,X<RL`FU5MG<]SKM,?Q@K;H`^C=J*KH\C,E)6?8B7705'2S??3!#OHD0BM6
M,!>2W&E_4PB9!K"$8(&E(MDZ\DNB:H9;U56PUQ:[%!Y[Y->N:8BOB^Z0X!:Z
M;EB*Y=3^$QTNZ?WY_CS93P)NR?RW5W6$A.>OY_]Y3Z9?OEB6GBHM?+W27J:\
MGT7:Q1.E>5UG6&L_&\VG1T':$*H(7VE`YKEP;733C;XP-![-F;=#S[&K"J7Z
M@;D119/EN$`-5=_)0BB[&,/!_FKD!V'O->LI8CC8WW!.&O;1*AA>L<E?4$L#
M!!0````(`#&%9D=,3W\10`,``+()```/````>&PO=V]R:V)O;VLN>&ULE9;;
M4MLP$$!_1>.7T@<:VR0!,H092*!EIEP&&'A6[$V\@RRYDIP`7]^50V`#,2U/
MMGPYTFJ/5CIP@X6Q#Q-C'L1CJ;0;V&%4>%\-.AV7%5!*]\-4H.G=U-A2>FK:
M6<=,IYC!V&1U"=IWTCCN=RPHZ=%H5V#EHA>:^Q^:JRS(W!4`OE1+6"E11X<'
M;C!%!7=@'8&%K*H+6<(P>E214-+YDQP]Y,.H2TVS@+4'MJZ.:U2AT8M[42?`
M5J%>69&9'):PVP+=_<N+2.0PE;7RMS385;_#*$F[:=I?,L)G=P@+QX'A@9"9
MQSG<RLDPBB,A:V].47FP8^GAIS5UA7I&K$A,T3I_$\)MOBQ18XG/8=S4<H59
M_#(6GXWV4MUDUBC5_!5>-#]1#^[U"8W18[;VH9>3ZY")8=2/"3A'AQ-4Z)^&
M47.O($32>1=*,_UO=T(WD[-*L3C2N3C1GBCB3"^31U,3QD`?G^5-QW:`=&//
M\F0Y51PT(C&,PISF(A?'4DF=@6C"<6)K5#-0RD#I5T$[#+3#0#O_`-UXNH1`
MG3!3,3)EQ4!=!NI^#21=P4`]!NI]!%T8#R(1V^(&9QIIA<DP\5EF:IIX/6.@
M/@/U6T!I`'F3/6P?2T<C"T&!=I0W!MIEH-T6T`Z!1B27G!@K@^)"D@R7O@`&
MVF.@O190ET#7YDDJDNC<:/#X_-ZB?8;9;\'T5H$51N6T1+^)DS\UB<EEC+F-
M\4?0YAD65Y3'#,%QU)K8&\S^-&M)RE%<[62#VY_F+>%N)USN9(/=GX^JRU%<
M[V2#WZ^H4XE6W$E50W";\O]^H21<\.13PVDWR&M%X9U+7]M05JBH<!17/&ES
MO$'592GM4QC2-62`<TD5;BV#7/*DS?*`.M-S6KF&8%MC\!*5^\XYW/&D3?(/
M0R)D#52;QAS%/4_:1&\S(8UYN>2JIQM47T=1C!G%&%;Q%=5.<<117/6T3?6`
MN@><%:'<'<W!RAF((^?JDJ/6JGB;ZFV5)>6JIUSUM$WUMMHBMCB*JYZVJ=Y6
M7]917/6T][*COFVB=(Y`#7DX8KBF&]JCLW#NH,NR%G1[P8+0/J>SR#`*!P8Z
M&]1*C>C9I?YM9+.M+LFKD\;A7U!+`P04````"``QA69'*I''<VH"``#B"```
M&````'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;'U679.;(!3]*XX_8!7\3,8X
MDZ33:1\ZL[,/[3,Q)#JK8H$DVW]?0.-:N/9%`<^YARL<+L6#\7=14RJ]CZ[M
MQ<ZOI1RV02"JFG9$O+"!]NK+A?&.2-7EUT`,G)*S(75M@,,P#3K2]'Y9F+%7
M7A;L)MNFIZ_<$[>N(_S/@;;LL?.1_QQX:ZZUU`-!600S[]QTM!<-ZSU.+SM_
MC[9'E&J(0?QLZ$,LVIZ>_(FQ=]WY?M[YH9X#;6DE=0BB7G=ZI&VK(RGEWU/0
M3TU-7+:?T;^:=-7T3T30(VM_-6=9J]F&OG>F%W)KY1M[?*-3#HD.6+%6F*=7
MW81DW9/B>QWY&-]-;]Z/\4N")QI,P!,!SP2\^2\AF@C13$"QR72<F<GK"Y&D
M+#A[>'Q<C('H-4?;2/VY2@^:'V6^J<R$&KV781'<=9@)<1@1>(%`,R)0L6<!
M#`D<L$/'_PH<740$"T1@!I&A1PMZ;&7@(A)8(`8%8H>>6@(C(C:(WB#R'&>;
M%%9)0)7$4<DL%1>1PP(I*)`Z](TEX")0""MDH$+F\I$E`4`P+)&#$KG+CRP)
M`!+#$AM08N/R$TL"@*RLM3Y"(->%;@1[N2',2B)HQ=O(C9!;YILPR[V;15&4
MYMF*RQ%H\SW"KI:]OP`,7ME@"/8Z<JV,[2T&85;V&((-CUS'8WN7(=?S.$0K
MYPJ"+8]<1V/[[)HPR1*SI@+['KFVQO8!!F$R2R58E)2.\JLIM<*KV*TWE7TQ
M.I?SO2EZP2>\+`9RI3\(OS:]\$Y,JL)FRL^%,4G55,(7E6JM+AQSIZ47J9N9
M:O.Q!(\=R8;GC6*^UI1_`5!+`P04````"``QA69'I"-BS$H$``!W%@``&```
M`'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(V83V_C-A#%OXKA^Z[(&9*B`L=`
MDT71'@HL]M">E9B)C94LKZ3$VV]?27:\#N=130ZQ_KPA'T>:'RFNCDW[O=N&
MT"]^UM6^NUUN^_YPDV7=XS;49?>Y.83]<.>I:>NR'T[;YZP[M*'<3$%UE9%2
M+JO+W7ZY7DW7OK;K5?/25[M]^-HNNI>Z+MM_[T+5'&^7>OEVX=ON>=N/%[+U
M*KO$;79UV'>[9K]HP]/M\C=]<V_4*)D4?^_"L;LZ7HSF'YKF^WCRY^9VJ48/
MH0J/_=A$.?R\AOM056-+0\\_SHW^ZG,,O#Y^:_WW:;B#_8>R"_=-]<]NTV\'
MMVJYV(2G\J7JOS7'/\)Y#'9L\+&INNG_XO&EZYOZ+62YJ,N?I]_=?OH]GNYX
M=0[#`70.H$N`-K,!?`[@*"`[.9O&]:7LR_6J;8Z+]O0P#N7XS/4-#YE['"].
MB9KN#2/KAJNO:_*K['5LYRRY.TGH6O)><0\4Q462#?U?3!`T05,\7\6SPO$,
MXWF*=]?Q&L<;&&]D_]$0[TZ2?)+L)TEN"JN4BE(A=>Q-<:U[Y\="/U;Z81SO
M8+S[<#YR&)__?SZ`Q$2I.$G,52JL,SJ9"@^M>-F/Q?$%C"]D*AR.'ZL=%8B2
M#O*X0I1XZJ05R;?C++S.B38^G1.=*%HM/?E$"[CB-'T\+[CF-'\@+RR'ZT!6
MI,PZ9=-9P56L01D7L2,CNC+.40Y,2:4UUJBT*US+6A:S4;$K"_)$Z/T!0CMC
M">-!.VE)QY:<?*5Y3)/TY*0G3TQI5Q@Z6B+%Q-0!&H$=+;GC/*?=8.YH"1[#
ML1LO<F2*'*7(2TLZG\D09IDNI"<3>RI$5]X#1U*6NZ0?PF@DB49C(S\DB>>-
M16Q$RH)-^LD1AB-).(JW^ZQYAX$\]P`#2*FUGLE58HDCUSC&Q:Y(5I(V`)A`
M2"I/6\($)TEP\3J11#-Y]/``Z?,91YC@)`ENXCF%`)>)"V!)"IWB]%Q+F-\$
M^!VOD`E@F7UAT:-#4N=SD_:%(4X`XO%L1Q+-G,/')X4TMVPEC'"2>+;Q7$<2
MS\0*S<!`J373C"N,<I(HMP((DM#6:F0*H%S-><(H)XER&T]V)!G-2J$I^"/*
M]Y]1&.@L@6[C28\EIIT9_J0KH+0Y%6F@,P8Z2Z#;F%,L,:V51DLHH&1KTW,Q
M8YZSY+F-YSZ6F&8#OAF1KD@#@1,?P?(KV":6](SQRQ*_-L8O2ZJ*X<Q)WOO`
MR&6)7!LCER5'<V:06Z"CF<+`L&4)6QO#EB5#[3`#H$T")#54S*QU&`.7)7!=
M#%R6&/VD@2<DXYE,8=BRA*V+8<N2H9],07!F@EJ7^\*GG6'DLD2NBY'+$J3.
M*%BS8`%M':<_6@U&KI'(=3%RC=Q>2"TOH!0O+[*K+<)#^1S^*MOGW;Y;/#1]
MW]33GN!3T_1A:%9]'JIH&\K-Y:0*3_UXF`_'[6E?]'32-X>W;=[+7O/Z/U!+
M`P04````"``QA69'(#:2C1L"``!*!P``&````'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;(V5RXZ;,!2&7P7Q`+&Y!8@(4I.J:A>51K-HUT[B!#0&4]L)T[>O
M;0@%VY-,%O'M_\_Y#K;LHJ?LC5<8"^^](2W?^I40W08`?JQP@_B*=KB5*V?*
M&B3DD%T`[QA&)VUJ"`@A7(,&U:U?%GKNA94%O0I2M_B%>?S:-(C]W6%"^ZT?
M^/>)U_I2"34!R@),OE/=X);7M/48/F_]+\%FGRN%%ORJ<<]G?4^Q'RA]4X,?
MIZT/%0(F^"A4!"2;&]YC0E0@F?C/&/-_2F6<]^_1O^EJ)?T!<;RGY'=]$I6$
MA;YWPF=T)>*5]M_Q6$*B`AXIX?K?.UZYH,W=XGL->A_:NM5M/ZQD<+2Y#>%H
M""=#$#\T1*,A,@Q@(--U?44"E06CO<>&O>B0VO)@$\DO=U23^D/I-5D9E[.W
M<AT7X*;BC)+=(`EGDG"IV#L4^20!,O\$$3HA0NV/YA")`3%(,BUIM02N(`P,
MD&>J!4OD9(ELEK7!,DCB698$ZI]!\URWX(F=/+'-DQH\L97')'FD6#`D3H;$
M9L@,AN0IPR/%@F'M9%C;#+G!,$CRY>Z;1^2):$&2.DE2BR0U:MVE5JTAA,XS
M\AGE@BES,F4VDU'X+K,RI5$4I3:20QCD2?(A4>XDRFTBX]K8Y9\E<@C=1&!V
M[77H@G\B=JE;[AVHD#>HON?.E`HL@\*5/)"5?-BF`<%GH;JI[+/AKA\&@G;W
MEVMZ/LM_4$L#!!0````(`#&%9D<G-'&V700``,H4```8````>&PO=V]R:W-H
M965T<R]S:&5E=#0N>&ULC5A-<Z,X%/PKE.\9>!+Z(.6X*K:9VCULU=0<=L[$
M5F+7@/$`B6?__0(F#N@UV;W81N[74NOCO4;+2UG]K`_.-<'O(C_5#XM#TYSO
MP[#>'5R1U5_*LSNU_SR759$U[6/U$M;GRF7[/JC(0Q%%.BRRXVFQ6O9MWZK5
MLGQM\N/)?:N"^K4HLNJ?M<O+R\."%N\-WX\OAZ9K"%?+\!:W/Q;N5!_+4U"Y
MYX?%(]VG0G20'O'WT5WJT>^@&_Q36?[L'O[</RRB;@PN=[NFH\C:KS>W<7G>
M,;4]_QI(/_KL`L>_W]F_]G+;X3]EM=N4^8_COCFTHXT6P=X]9Z]Y\[V\_.$&
M#:HCW)5YW7\&N]>Z*8OWD$509+^OW\=3_WVY_F.C(0P'B"%`W`)N_>``.03(
MCX#XTX!X"(C_;P]J"%!>#^%5>S]SVZS)5LNJO`35=;G/6;>KZ%ZU:[/K&ONE
MZ/]KYZYN6]]61B[#MXYG@*RO$#&&Q%/(ED/HA@C;_F^#$&@0:\'"Q;2##4<8
MY8WA/TG23TDFPY1PKF0?K\?Q&L?',#[NX^4XWGAS?868'G+J(4HG211%WGQP
M*NFO":?20FI&E7Y*-5&EH"K%55E/U142CX9"@H]DH[AX!MH"+F.`+$Y&B:(Q
M;J)-0VV::TL\;9J-1Y$67!S'22$EUP=P2L<<F'*@%C0OT$"!A@FT7C]KPR<\
M2JSA"@V;\5:AY0HY82RUXDN=<D+K3>U$H84*+3NT=B8W)3`^X3/DY95UPF=(
MQF!_<RIV:!&5)CXUGU)-5'5E$N7]B.MBB3]BH^D,!ECZ`3DY;3("V68+.)4T
M!"0"3BF%U;/K3S,5CKC2V%=*7*F1?%";`3@1:HD?]RU@I$B"K)<"I(I)SLN$
M-?21!)>I?)F"=P4T<B:V3R$3WQ@IP!D[+PW779)<FO:E2;Z",<6@=`[(R1+&
M-@:)"G!JE40@4P&DM,:8>:78(1`OQM:W"`-FW-<=25AS()3Z?,*T`J@00G%H
MBJ`RTJ3FU6+G0-PZ6-\Z$*CW,@92`8[#M@`F04)+`6XZ%5-]V#T0MP_6MP_$
MR_@=M3L7*(1(XH/?(J2T8(.D$*EM/*\4VPCB/B+Q?03QNG\G%=JUP"!$%N58
M#K2H6`*<D?,^@K"1(,LUDJ_1LMQR1W'KRX!*`+6HYFP14L36\NV=(JB4BCY)
M1-CU$#<8B6][!DPR[BSZXK^Y810)7R2$^74GQ3`EL#B!O8_@WB?QO8_@/J7=
M,YJ]EP(8V<C;%UL$$T:Q%U0.TRI29D8=]CN"^YW$]SN"VY@$[%$`NP,;%,!(
M\,J;(KKY8RBPSQ'<G22^SQDPWC%4DA>S#8):+SL,*@%2Q`:]N"!H=PP3+C8<
M7=04KGKIK\CJ8%>^GII.Y:CU=@WWV-_">>UKNM\0:-_2?7J]9/N@7RW/V8O[
M*ZM>CJ<Z>"J;IBSZ2Z#GLFQ<JZ`]4HO@X++][2%WSTWWT[2_J^M5V_6A*<_O
M-X>WZ\O5OU!+`P04````"``QA69'+M8PNA,$```[$P``&````'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;(682W.C.!2%_PKEO1NN'@A2CJMB3W7U+*:JJQ<S
M:V++CVH>'L!QS[\?@8ECZQZELP@@SI7.%=(G68M+T_[L#M;VT:^JK+OGV:'O
M3T]QW&T.MBJZ+\W)UN[-KFFKHG>/[3[N3JTMMF-05<8B2=*X*H[U;+D8R[ZW
MRT5S[LMC;;^W47>NJJ+];V7+YO(\H]E[P8_C_M`/!?%R$=_BML?*UMVQJ:/6
M[IYG+_2TEF*0C(J_C_;2W=U'@_G7IODY//RY?9XE@P=;VDT_5%&XRYM=V[(<
M:G(M_SM5^M'F$'A__U[[US%=9_^UZ.RZ*?\Y;ON#<YO,HJW=%>>R_]%<OMDI
M!SU4N&G*;OP?;<Y=WU3O(;.H*GY=K\=ZO%ZN;[)D"L,!8@H0MX!;.SA`3@'R
M(T"-F5Z=C7G]4?3%<M$VEZB]?HQ3,7QS>I*NYS9#X=A1XSN76>=*WY9YNHC?
MAGHFR>HJ$7<2NBEB5_FM!8%:6`D6+AX;6'.%T;@%"7.08WQZGX/!\0K&JS%>
MWL>3UP=7B1DE]2B9"Y5E*DD2+QF@E%*3N5<^>-+0D^8Y93@^A?$ISRGW<KI*
MU)U3DH8G]%O9@QL#W1CFAOQV5H:U8XR1W`_7I5HG04,9-)0!0_XWSUA#4N3<
MSV]E#W9R:"<'=KQ9LLIY_^2@>[AL;J0(^AD8A["0L/%'B0Q4$2`+L:2DG].D
M>1A<>:YY5I/P85H1"1G."\+HA00SI9@IP4=8!GH:U"55P`T&%TGPW95O1X()
M*`GXD0!2X9%(&(;$::B8)<4'&1%@!Q`J'7:$44@:])+V+6G>2T)G`GCB2IDF
MG\P0#%CBA-4^08BS<ZX)>>+"7(<A2YBRQ#$KC6^)XY.\["=+7#C/LC!G"8.6
M$&G9#H,SE`SL)RYTZW":4M@6!B[E@&^!38/`B!0)R"SS,IM$CS,E,2E/#2E5
M."^!H2LX="GQ%W[!J3LG94!_`^4GEC!R!<<DD;_X"\[<N<JD`MA%4M*9#L]@
M@>DK`'W)G\*"TU?JS("-'U".]`W;P@`6',!NI?-M(0+K!#$82,DM'UG8%\:P
MX%M2HL"60&!F"LY,(G]Q$6##20;L"9`P2=//>AQS4X#M*?D+C.`\E%D*EF$@
M5*E,PZ8P.`4`)_G@%&#SJ1%<@(X^Z2<,30&VJ>0O,()O0+7,$5NXT$T_K<(]
M)3&()0`Q^2"6`*\F)\`7H,S=7WBK*3&*)4`Q^2B6'+!::94`6UPIW(!085L8
MQQ+@6/@XGD3F80RG`M`%*,GY0IN7^.Y,HK+M?CRKZ:)-<Z[[X>?_7>GM/.AE
M/`[RRE?TM+Z>ZGQ4LUR<BKW]JVCWQ[J+7IN^;ZKQ7&/7-+UU3I,OCE\'6VQO
M#Z7=]<.M<??M]6SG^M`WI_>CJMMYV?)_4$L#!!0````(`#&%9D?=TVUPH`$`
M`+$#```8````>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL=5/!;N0@#/T5Q`>4
MA$F[JU$F4J=5U1XJ53WLGIG$25`A3H%,NG^_0"9IVLU>`!N_YV=C\A'-FVT!
M'/G0JK,'VCK7[QFS90M:V"OLH?,W-1HMG#=-PVQO0%01I!7C27+#M)`=+?+H
M>S%%CH-3LH,70^R@M3!_CJ!P/-"4SHY7V;0N.%B1LP5720V=E=@1`_6!WJ;[
M8Q8B8L`O":-=G4G0?D)\"\93=:!)D``*2A<8A-_.<`=*!2*?^/W"^9DR`-?G
MF?TA5NO5GX2%.U2_9>5:+S:AI():#,J]XO@(EQ*N`V&)RL:5E(-UJ&<()5I\
M3+OLXCY.-]D,VP;P"X`O@)])%#XEBC+OA1-%;G`D9FIM+\(+IGON&U$&9ZP[
MWGFAUGO/1<K3G)T#T27F.,7P=<P2P3S[DH)OI3CR?^!\&[[;5+B+\)LO"O]#
MD&T29)%@]X5@]ZW$K9CL6Q*VZJD&T\31L:3$H8N#NO(NTWG+XYM\AA=Y+QIX
M%J:1G24G=/YE8_]K1`=>2G)U34GK_\]B**A=./[P9S.-U&0X[.</LOS2XB]0
M2P,$%`````@`,85F1YR]O`VA`0``L0,``!@```!X;"]W;W)K<VAE971S+W-H
M965T-RYX;6QU4]MNY"`,_164#R@9YE:-,I$Z756[#RM5?6B?F<1)4`&G0";=
MOR^03)JVV1?`QN?XV)BL1_-J&P!'WI74]I@TSK4'2FW1@.+V!EO0_J9"H[CS
MIJFI;0WP,H*4I"Q-=U1QH9,\B[Y'DV?8.2DT/!IB.Z6X^7<"B?TQ6257QY.H
M&Q<<-,_HA"N%`FT%:F*@.B9WJ\-I$R)BP+.`WL[.)&@_([X&XT]Y3-(@`204
M+C!POUW@'J0,1#[QV\CYF3(`Y^<K^T.LUJL_<POW*%]$Z1HO-DU("17OI'O"
M_C>,)6P#88'2QI44G76HKI"$*/X^[$+'O1]N]KL1M@Q@(X!-@-LT"A\219F_
MN.-Y9K`G9FAMR\,+K@[,-Z((SEAWO/-"K?=>\A7;9O02B,:8TQ##YC%3!/7L
M4PJVE.+$?L#9,GR]J'`=X;LO"O]#L%DDV$2"]1>"W;<2EV+VWY+064\5F#J.
MCB4%=CH.ZLP[3><=BV_R&9YG+:_A+S>UT):<T?F7C?VO$!UX*>G--B&-_S^3
M(:%RX;CW9S.,U&`X;*\?9/JE^0=02P,$%`````@`,85F1V@?7-*C`0``L0,`
M`!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6QU4\%RVR`0_16&#P@R=ES7
M(VLF3J?3'CJ3R:$]8VDE,0%6!62E?U]`LJ*DZ@789=_;M\N2#VA?7`O@R:M6
MQIUHZWUW9,R5+6CA[K`#$VYJM%KX8-J&N<Z"J!)(*\:S;,^TD(86>?(]V2+'
MWBMIX,D2UVLM[)\S*!Q.=$-OCF?9M#XZ6)&S&5=)#<9)-,1"?:(/F^-Y%R-2
MP$\)@UN<2=1^07R)QO?J1+,H`124/C*(L%WA$92*1"'Q[XGS+64$+L\W]J^I
MVJ#^(AP\HOHE*]\&L1DE%=2B5_X9AV\PE7`?"4M4+JVD[)U'?8-0HL7KN$N3
M]F&\V1\FV#J`3P`^`PY9$CXF2C*_""^*W.)`[-C:3L07W!QY:$09G:GN=!>$
MNN"]%AM^R-DU$DTQYS&&+V/F"!;8YQ1\+<69_P/GZ_#MJL)M@N_?*?P/P6Z5
M8)<(MN\(/G\H<25FFWU(PA8]U6";-#J.E-B;-*@+[SR=#SR]R5MXD7>B@1_"
M-M(X<D$?7C;UOT;T$*1D=_>4M.'_S(:"VL?CIW"VXTB-AL?N]D'F7UK\!5!+
M`P04````"``QA69'_N@+?Z(!``"Q`P``&````'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;'53P6[D(`S]%90/*`F9=E>C3*1.J]7V4*GJ8??,)$Z""C@%,NG^
M_0+)I&F;7@`;O^=G8XH1S8OM`!QY4U+;0](YU^\IM54'BMLK[$'[FP:-XLZ;
MIJ6V-\#K"%*2LC2]H8H+G91%]#V9LL#!2:'AR1`[*,7-OR-('`])EEP<SZ+M
M7'#0LJ`+KA8*M!6HB8'FD-QF^^,N1,2`/P)&NSJ3H/V$^!*,A_J0I$$"2*A<
M8.!^.\,=2!F(?.+7F?,]90"NSQ?V7[%:K_[$+=RA_"MJUWFQ:4)J:/@@W3..
MOV$NX3H05BAM7$DU6(?J`DF(XF_3+G3<Q^DFW\VP;0";`6P!_$RC\"E1E'G/
M'2\+@R,Q4VM['EXPVS/?B"HX8]WQS@NUWGLNLSPKZ#D0S3''*8:M8Y8(ZMF7
M%&PKQ9%]@;-M>+ZI,(_PFW5V]@W!;I-@%PGR#R6R3R5NQ>2?DM!53Q68-HZ.
M)14..@[JRKM,YRV+;_(>7A8];^&1FU9H2T[H_,O&_C>(#KR4].HZ(9W_/XLA
MH7'A^,.?S312D^&POWR0Y9>6_P%02P,$%`````@`,85F1V+\[A*B`0``L0,`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL=5/;;MP@$/T5Q`<$+WMI
MM?):RB:JVH=*41[:9]8>VRC`.(#7Z=\7L-=Q4O<%F&'.F3/#D`]H7UP+X,F;
M5L:=:.M]=V3,E2UHX>ZP`Q-N:K1:^&#:AKG.@J@22"O&L^S`M)"&%GGR/=DB
MQ]XK:>#)$M=K+>R?,R@<3G1#;XYGV;0^.EB1LQE720W&233$0GVB]YOC>1<C
M4L`O"8-;G$G4?D%\B<:/ZD2S*`$4E#XRB+!=X0&4BD0A\>O$^9XR`I?G&_NW
M5&U0?Q$.'E#]EI5O@]B,D@IJT2O_C,-WF$K81\(2E4LK*7OG4=\@E&CQ-N[2
MI'T8;_;9!%L'\`G`9\#7!&!CHB3S47A1Y!8'8L?6=B*^X.;(0R/*Z$QUI[L@
MU`7OM=AL=SF[1J(IYCS&\&7,',$"^YR"KZ4X\W_@?!V^756X3?##,CO_#\%N
ME6"7"+8?2MQ_*G$MYO`I"5OT5(-MTN@X4F)OTJ`NO/-TWO/T)N_A1=Z)!GX*
MVTCCR`5]>-G4_QK10Y"2W>TI:</_F0T%M8_'+^%LQY$:#8_=[8/,O[3X"U!+
M`P04````"``QA69'\<S`1[("```K#```&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6QU5]&.HC`4_17"!PRT".@$270VF]V'32;SL/M<M2H9H&Q;=?;O
MMRWJ..7T16@Y]]P+/>?F6EV$?%='SG7TT;6]6L9'K8?G)%';(^^8>A(#[\V3
MO9`=TV8I#XD:)&<[%]2U"4W3(NE8T\=UY?9>95V)DVZ;GK_*2)VZCLE_:]Z*
MRS(F\6WCK3D<M=U(ZBJYQ^V:CO>J$7TD^7X9K\CSFN86XA"_&WY1#_>1+7XC
MQ+M=_-PMX]36P%N^U9:"F<N9O_"VM4PF\]\KZ6=.&_AX?V/_[E[7E+]ABK^(
M]D^STT=3;1I'.[YGIU:_B<L/?GT'5^%6M,K]1MN3TJ*[A<11QS[&:].[ZV5\
M,D^O83B`7@.H%Y",B5R9WYAF=27%)9+CMQV8/4+R3,V'V-I-]][NF2E4F=US
M3;*R2LZ6Z(I9CQCZB+DC$L-^3T%1BC6=A%,<GL$*,Q=>?*EPC@EFD&#F"+(O
M!`OO%0%FEN(D.4R2`P+B)4&8P*<H8)("$&1>$H29X20E3%("@MQ+@C`%3C*'
M2>:`P)<=P@0.?@&3+`"!?_``DP<.WKH;.2@%%/[10U#@[$G`J010^*</08'C
M)]"N*T(!A2\`"`HH@&!?DPQ03%H/`@5$0+#]"?!V[LL`@8J0#G`'(,#>Q40'
M"!32`6X"!#B\F.@`@4(ZP'V``),7$QT@4$@'N!40X/-BH@,$"ND`=P,"K%Y,
M=`!`94`'%/<#"JQ>^CJ`H(`.*.X'%%B]]'4`00$=4-P/*+!ZZ>L`@@(ZH+@?
M4&#UTM<!!`5T0'$_H,#JI:\#!)J'=(#[`056GT]T@$"^#I*'8:[C\N!F5A5M
MQ:EW(_+#[GTN7E$W#'["ZVI@!_Z+R4/3JV@CM!DIW>"W%T)S4TOZ9&HYFLG]
MOFCY7MO;TMS+<98=%UH,M]'\_O^@_@]02P,$%`````@`,85F1\IAU6?7`0``
M104``!D```!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL=53-CILP$'X5BP=8
M$Y(`&Q&DS595>ZBTVD-[=F#XT=J8VB9LW[ZV(2Q+IQ=LC[^?L<U,-DKUIAL`
M0]X%[_0Y:(SI3Y3JH@'!](/LH;,[E52"&;M4-=6]`E9ZDN`T"L.8"M9V09[Y
MV(O*,SD8WG;PHH@>A&#JSP6X',_!+K@'7MNZ,2Y`\XPNO+(5T.E6=D1!=0Z>
M=J=+ZA`>\+.%4:_FQ.5^E?+-+;Z7YR!T*0"'PC@%9H<;/`/G3L@:_YXU/RP=
M<3V_JW_UI[797YF&9\E_M:5I;+)A0$JHV,#-JQR_P7R$HQ,L)-?^2XI!&RGN
ME(`(]CZ-;>?'<=I)XIF&$Z*9$"V$-/2)3T8^S2_,L#Q3<B1JNMJ>N1?<G2)[
M$84+^G/[/9NHMM%;ODOW&;TYH1ESF3#1&K,@J%5?+"+,XA+]0X]P^A[-<._I
M\:<,#[C``14X>('])X'CYH@8)L9-CJC)$1%(-B88)L5-8M0D1@0>-R8(YC'$
M31+4)$$$=AL3#/.?1TU1DQ01V/YV&&;[\'3UGPM0M2]G30HY=+YYK*)+QWB*
M?)U\P/.L9S7\8*IN.TVNTMAJ\S5126G`IA(^V*=K;$];%APJXZ:)G:NIS*>%
MD?V]:2V=,_\+4$L#!!0````(`#&%9D>VT]C0K`$``!8$```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;&U4S6[C(!!^%>0'*([STS1R+#5=K78/*U4]
MM&=BCVU48+R`X_;M"]AQO5DN`8;O;PPD'U"_FQ;`D@\IE#DFK;7=@5)3MB"9
MN<,.E-NI44MFW5(WU'0:6!5(4M`L37=4,JZ2(@^U9UWDV%O!%3QK8GHIF?X\
M@<#AF*R2:^&%-ZWU!5KD=.957((R'!714!^3Q]7AM/6(`'CE,)C%G/CL9\1W
MO_A='9/41P`!I?4*S`T7>`(AO)`S_CMI?EMZXG)^5?\9NG7IS\S`$XHW7MG6
MA4T34D'->F%?</@%4PLA88G"A%]2]L:BO%(2(MG'.'(5QF'<V:<3+4[()D)V
M0Z"C48CY@UE6Y!H'HL=/VS%_@JM#YCY$Z8NA[[#G@AI7O12KAVU.+UYHPIQ&
M3+;$S`CJU&>++&9QROZC9W'Z.IIP'>B[I?M^$Q?81`4V06#]3XN[FQ9CF/NX
MR39JLHT([&],8IB'&Q.Z.#@)N@GWTY`2>Q5>PZ(Z/X''+!S\-[S(.];`'Z8;
MK@PYHW77)QQRC6C!14GO7);6/=)Y(:"V?GKOYGJ\M^/"8G=]A?-?0?$%4$L#
M!!0````(`#&%9D>[6"(4<@0``%,8```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;(U9VVZC.A3]E2@?,&!O@Z%*(YW>TE8::30/<YYIXC1H(.0`;>;\
M_7!K6NRU$UZ:0-:^>J]E0Q?'HOQ=[8RI9W_R;%]=SW=U?;CRO&J],WE2?2L.
M9M_\LBW*/*F;R_+5JPZE23:=49YYTO=#+T_2_7RYZ.[]*)>+XJW.TKWY4<ZJ
MMSQ/RO]O3%8<K^=B_G'C9_JZJ]L;WG+AG>PV:6[V55KL9Z797L__$5?/BEI(
MA_B5FF/UY?NL3?ZE*'ZW%T^;Z[G?YF`RLZY;%TGS\6YN39:UGIK(_PU./V.V
MAE^_?WA_Z,IMTG])*G-;9/^FFWK79.O/9QNS3=ZR^F=Q?#1##4'K<%UD5?=W
MMGZKZB+_,)G/\N1/_YGNN\]C_TOD#V;80`X&\F0@U%D#&@QHJH$:#-14@V`P
M"*8:A(-!.-5`#P;ZTR`\:Q`-!M'4"/%@$$\U:->\7SG?,O'Z)>\&YBZID^6B
M+(ZSLI_R0]*225R)=B;7[=UN!+L?FYFIFKOORX8["^^]]31@;GJ,'&'$&'.+
M,'*,N4,8&F/N`6:,>'`1.AA#5A>=/%YV\@2<Q&/(,RI(G3!>T_E3^R5NO^P\
MT,A#@#T0]D#`0V@UM<?H#K/O,-82KRXBGLXA1GDJG*<">6KL(<`>`N`ALNKH
M,>I+ECHFWV=2#7&@$`2REGX5.H%$&"C?YLYCZ+1-DV03TC@A[28D&`\1]A`!
M#Q:%GR,GU;9S/IMLC$/%()3$'EKU@J+D`Q^.4OCN$@2^LP*KR[AQ3IQ0"I`3
M0W;!L%T`NKMU27>&45F78..,&/400#X$(T""8;8`U!:V!`V@T2HH7X*ZE#.&
M-G"<%:,6`LB%8`1',$(@@!((6W(@*&8",007@.'2Z0P""280HP,""(&4=B`$
M(B80HP("R(!4=B`$8J9/,EHA@5;(D/'!<%L";CM=02!NG26WW0,!D-H.A$!,
M^R7#:PEX+2/&!\-K"7AM'X'NI$M7?6[3D`Q=):`K<3X8NDK`1!)VPN[.35J=
M29BAK`1L)&:?DPP;)2":FW#D*F<S#WS"#",E(!LQ8T4,V0B1S1X)<C=<.MMB
M8FA)+N-T:`<33K!&YK7F@S'4),`Z4G8TZ6Y.\MRX$W=J!_PD[N#/\),`/\GJ
MSPJ"F&V0&&X2XJ:]#0Z@"0\(Q-"7$'WM<S>!@S>YQVX`X[)A^$V`W\H*<S^`
M1MD(][#V,.#T!=P*^",9@_(NXL8U,OI#0'^4L&L$^B-B32%(?PITG!DC5@3$
M2ED[\LT`&G4UL!]9^M<3"'KVX48Q"JBF/)HH\,@12G#8G0I\&H!NJ4SVC**J
MRXIZKUQ%%7X<:7>J`9(:80!END!%81"X@PV04=,1OE!&S150<^4L$U)S)4"A
M""C<CJP`D*+07<]'!`PCQ=?)[",*["-*V762NTZ1%':1+DHYBK="OD)-=GD`
M%4?VJ=S[\I;RD+R:[TGYFNZKV4M1UT7>O97<%D5M&H_^MV9[V9ED<[K(S+9N
MO^KF>]F_\^XOZN+P\0K_]'^$Y5]02P,$%`````@`,85F1VQ_0#PY`P``J`X`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,34N>&ULC9?+;MLP$$5_1=`^$8=Z
M![:!QD71+@H$7;1KQ:9M(9+H2G*<_GVI1UR;<UED8TGTG=$E.3PB%V?=OG0'
MI7KOK:Z:;ND?^O[X$`3=YJ#JHKO71]68?W:ZK8O>/+;[H#NVJMB.07452"&2
MH"[*QE\MQK:G=K70I[XJ&_74>MVIKHOVSZ.J]'GID__>\*/<'_JA(5@M@DO<
MMJQ5TY6Z\5JU6_J?Z&$MHT$R*GZ6ZMQ=W7N#^6>M7X:';]NE+P8/JE*;?DA1
MF,NK6JNJ&C*9-_^>D_Y[YQ!X??^>_<O876/_N>C46E>_RFU_,&Z%[VW5KCA5
M_0]]_JKF/L1#PHVNNO'7VYRZ7M?O(;Y7%V_3M6S&ZWGZ)Q-S&`Z0<X"\!%#T
MWX!P#@BM@&!R-O;K<]$7JT6KSUX[3<:Q&.:<'D(S<INA<1RH\3_3L\ZTOJYD
M%"^"UR'1K'F<-/):<ZM8`T5^D03&P,6%A"[D&!_>N$AP@A`F"$&"U.K&I$E'
M33-I0J+<Z@I0B5"DV$P$S43`3&:9F331U6LB>U`C[D1B&S&T$0,;5F\?8V9#
M6D[7/$T881L)M)%P&[&P;"3,QIT]&@D;C3L98A\I])$"'V3Y2/EPA)19A;0&
M*E,BCGK-H)D,F'%,;@X3Y!\H^)S[3%D)K)&*7&8&)"**B`^4_"RZ?A-%9),$
MB*ZFZ=:,`VGT@<*?13?=3FPO7!,[G&"L$>`:J_U9=%/\%-E6@"AR0(DP(@DP
MDBV`671;#9%@O$<RF;CF"6.2`"?)57<8<8089R\#`I`3N;#7`9`196'F,(1A
M1X!V?"%PW#'J$N>=`S"$<4>`=WP5<)21L)WP1*X/`&'8$:(=6P89J'`V1QG_
M"B2.KP!A<!(@)U\&`(HBR]DD<1E1FCF6@<3LE(B==@U+CL649&I_F8`LSF7N
M`(7$_)2(GW8-2\!/LF$.1)2Z-H:.G2':&MIE+#D=$YN@0..`N<3\E(B?=A5+
M#L:[)+:M`!&%CC*6&)X2P).5L>1;R)0BMI\!LC@/(YM\P=69XECLU?>BW9=-
MYSWKWAQ/QD/$3NM>F93BWL#T8(Z-EX=*[?KA-C7W[720FAYZ?7P_%UX.IZN_
M4$L#!!0````(`#&%9D=P1?YLW0$``!D%```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;'V4WW*<(!3&7\7Q`0+^834[KC.-G4Q[T9E,+MIK5G%U`F*`
M7=.W+Z!K#=+>"!R^[_#C(!03%V^R(T0%'XP.\A1V2HU'`&3=$8;E`Q_)H&=:
M+AA6>B@N0(Z"X,::&`4QA`?`<#^$96%C+Z(L^%71?B`O(I!7QK#X_40HGTYA
M%-X#K_VE4R8`R@*LOJ9G9)`]'P)!VE/X)3I6R"BLX&=/)KGI!X;]S/F;&7QO
M3B$T"(226ID,6#<W4A%*32*]\/N2\^^2QKCMW[,_V]UJ^C.6I.+T5]^H3L/"
M,&A(BZ]4O?+I&UFV8`EK3J7]!O55*L[NEC!@^&-N^\&VTSR3P\7F-\2+(5X-
M4?I?0[(8$L<`9C*[KZ]8X;(0?`K$?!8C-D<>'1-=N=H$;:'LG-Z9U-%;&:.D
M`#>3:-$\S9IXJ_FLJ#R*QU4"-,!*$7LI8NM//E&D#L6LR:QFF#5)!J%#LE=%
M>9S$?IC$"Y-X8)`#,VO2+4P6Y4[A*H\*I>@?E4F],*D'YN#`I/MEX`$Z]:OV
MJ@@=4.:'05X8Y(')'!BT.X`L2G-'5>U5Z#%)<P<&;/[B$5_(#RPN_2"#,U?Z
M0MC?MN5<$9T1/NB4G7ZGU@$EK3+=3/?%?'7G@>+C_2%:7\/R#U!+`P04````
M"``QA69'('#Y&<X"``!K#0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6R5E]&2FC`8A5^%X0$6\@.B.^I,UTZGO>C,SEZTUU&C,@O$DKANW[X)H$4X
M6=D;@7#^DY/(1\+\+*M7=1!">^]%7JJ%?]#Z^!@$:G,0!5</\BA*<V<GJX)K
M<UGM`W6L!-_6144>4!A.@H)GI;^<UVW/U7(N3SK/2O%<>>I4%+SZ^R1R>5[X
MS+\TO&3[@[8-P7(>7.NV62%*E<G2J\1NX7]ACZLHM)):\2L39]4Y]VSXM92O
M]N+'=N&'-H/(Q49;"VX.;V(E\MPZF9[_M*;_^[2%W?.+^[=ZN";^FBNQDOGO
M;*L/)FWH>UNQXZ=<O\CS=]&.(;&&&YFK^M?;G)26Q:7$]PK^WARSLCZ>FSO3
ML"W#!=06T+6`Q1\61&U!U"L(FF3UN+YRS9?S2IZ]JODSCMS^Y^PQ,C.WL8WU
M1-7WS,B4:7U;4C*=!V_6J-4\-1KJ:FX5*Z"8726!"7!-03`%U?7130J'000-
MHH%!U,OX!"1Q;Q@?2FY2Q#!%/!S&),0&"31([@^CD:2UI*PES#77$]C'!(1D
MV""%!NG=D*MT&#),'9U,82=3D)*PP0P:S.Y/92.)NREGY.C$O@L0/B'(&3DL
M'`2R^TE;33<JA0GK4SA4N:>=81(90''B@(!A%MD(&%M-]PE)XKC/(U!1FDX=
M:3"3#$&9."PPE6P$EDCCFC;,)4-@3AP6F$PV`DVD<07%:#+$9NJPP'"R$70B
MC2,H83@)P>EX>@C#22/@;#5WGF6@<C_+Y%@F$9RNA1;#22/@;#7QG0$-51\,
M",-)`,[4L6(2AI-&P-EJ;EZ,S@T*II,`G:Y7*V$Z:02=K6;<*YPPGP3X3!W+
M&F$^:02?])GE,\*$1D-"A_NV<`!.&L^2WL0!532-^_]QT-D6'_E>_.35/BN5
MMY;:[+#K??!.2BV,8_A@'IJ#^?*Y7N1BI^UI:LZKYEN@N=#R>/FTN7Y?+?\!
M4$L#!!0````(`#&%9D=CWNCWO`$``(8$```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;'V4WW*<(!3&7X7Q`8**ZS8[KC.)G4Y[T9E,+MIK5H^K$Q`+
M[)J\??CC6J,F-\(Y?-_A!P+9(.2+:@`T>N6L4\>@T;H_8*S*!CA5=Z*'SHS4
M0G*J32C/6/42:.5,G.$X#%/,:=L%>>9R3S+/Q$6SMH,GB=2%<RK?'H&)X1A$
MP2WQW)X;;1,XS_#DJUH.G6I%AR34Q^`A.A2)53C!GQ8&->LCRWX2XL4&OZIC
M$%H$8%!J6X&:Y@H%,&8+F8G_C37_3VF-\_ZM^@^W6D-_H@H*P?ZVE6X,;!B@
M"FIZ8?I9##]A7,+.%BP%4^Z+RHO2@M\L`>+TU;=MY]K!CY#[T;9MB$=#/!FB
MY$L#&0UD8<">S*WK.]4TSZ08D/3_HJ?VET<'8G:NM$FW46[,K$R9[#6/]R3#
M5UMHU#QZ33S7?%04&XK[28(-P$01;U+$SD\^4"0+BK6&+"2%E^R=I/-ETGT8
MAMLH9!.%;*#L%BAKS0K%2Y(92A*EGZ(DFRC)!DJZ0%EK5BC):E?2;V2-@F='
MIJ=G^$WEN>T4.@EM3I\[([40&DS)\&X7H,8\"E/`H-:VNS=]Z>^)#[3H;[=^
M>GKR=U!+`P04````"``QA69'U,T8EQ@#```?#0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6R55]&2FC`4_16&#R@D(0GLJ#.K;J=]Z,S./K3/K$9E
M%HB%N&[_ODE`%W*CI2\"\=R3>TYN+F%VELU;>Q!"!1]56;?S\*#4\2&*VLU!
M5'G[11Y%K?_9R:;*E7YL]E%[;$2^M4%5&>$X9E&5%W6XF-FQYV8QDR=5%K5X
M;H+V5%5Y\V<I2GF>ARB\#+P4^X,R`]%B%EWCMD4EZK:0=="(W3Q\1`]/*#40
MB_A9B',[N`],\J]2OIF'[]MY&)L<1"DVRE#D^O(N5J(L#9.>^7=/^CFG"1S>
M7]B_6KDZ_=>\%2M9_BJVZJ"SC<-@*W;YJ50O\OQ-]!JH(=S(LK6_P>;4*EE=
M0L*@RC^Z:U';Z[G[AR5]F#\`]P'X&G"=QQ]`^@#R&7!_AJ0/2*;.0/L`ZLP0
M==JM<^M<Y8M9(\]!TRWW,3=5A1ZH7IN-&;1+8?_3WK5Z]'V!.9]%[X:HQRP[
M#!Y@>#*&K"$$71&13N":!?9EL<0@'(\G6$$$ITX._R1YNDLR2I-XS2(VG@QG
M8)F?(/$2)):`C=Q._0342T!A!CQSEJO#<(NI+2:AJ>LG!.&,.`N_AB"D\TT=
M5R&*$DS\JIA7%?.HBOT$W$O`I_N:>@G2";YVF&3H!G%MA3S$W2H3:)[NTHSD
M9%XYF4?.C0UIVJBO+\33+44W6@N:8&H/2D:%R!Q7>Q"_!UI[F%)0JQZF(6@L
MR]NK'A&&LM(;U8K\?021_S#7WTE0,L7<!-8:=4O6PP1JUD.$44JHZ^Y=JK$L
M?W]#L,'!UQ$%R5"69:XLR`1E02:&"7-5W64:J_+W-P0;'$]=50RN%08;@<%>
MZVKR\'`.-$$BE-%;+<+?=!&?4H(<+A9BH`8A2K]"B"O-@Z(L(:XV"&,8W=+F
M?Q\@V(%=#Y<]9N1AG*7<U09A6EOJ:H.HA#`*=AB$I4,[.VW1X/17B69OS]UM
ML)&G6AE1@]'KV?X1F].C,[Y$#ROD&5^;;P%[VORD7\R.^5[\R)M]4;?!JU3Z
MS&I/ECLIE=#)QU_T1CKHKY7K0REVRMQR?=]TY_?N0<GCY7/D^DVT^`M02P,$
M%`````@`,85F1XU`@"-8!```HA8``!D```!X;"]W;W)K<VAE971S+W-H965T
M,C`N>&ULC9C;;J-($(9?Q?(#A.ZJYA0YEA([H]F+E49SL7M-[/9!`\8#.)Y]
M^P5,'-S]EY4;`^V_#D!_U47/SF7UJ]Y9VTS^%/FA?IKNFN;X&`3U:F>+K'XH
MC_;0_K,IJR)KVLMJ&]3'RF;KWJC(`U(J"HIL?YC.9_W8CVH^*T]-OC_8']6D
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MOL\IT;/@O7,T:%XN&KK1T*UFX6L<+Z_("U\U09OE-55"J;X0<&"<-)`FO-4L
MD29RDD6:&"?+\+ER[X!O'"38@8$.#'"0.G=[T<2]YM!K%`X1PA"A'R(5'$30
M000<.*]]@32$@\0P2`P<L!,$:0P.DL`@"7`08@<I=)`"!\ZD6J3>Z](FX50I
MX:%W%0XAJT"LV.7Q(C+C8'%"<BRA/&@0*W%C:2]6&/&=6)#O9TT@ECOE!]$X
MEHDHEF-A/+7/)X]<#+'8BT6A2N18F&3MH\S*Q43[+%,W,Z10F&CM(\U*H$UC
MIO57H`8B5D(QUQAK[3/+RBWG@VC\!J0HF&OM@\TJ=*,@423$P?AKGW]6PH)!
M&&ORL?93A2)A72&,-/E(LTH%%YA4\DEE[=#S0CZI6K'3-[PB50N9D`Z&F0#,
M6@LN,*,$EENO?I//J-;IG:)*F%("E&J!4L*4TE<H!2)Q7A.FE+ZR^@(1:ZFU
MPYP20%`+*SAA!`D@J#U^D$AX)(PY98"@EGI#C"`#!+6[JD*1P"EC3AEP2L)<
M9:&/16QYJ0(1"0`R!I#!(DD"$XRQ8M#/>BWS(!HS'(<A*W?Q7P)AQ(F\^#,&
ME0&#Y`(TB-)1K.3!G;M+K))F!.:9`:HD<,8850:]LO^8$[^=(06>LJ_3D5Q0
M&://@&IRT1]$-RN-B84FWV#V#6"?W&7"^*VW284"87"!,(!]<EM\*)*^,7&!
M,*A`>%^90,3""S*XBAA0(-A=KJ!(BB-\-(,JXK8<BT'TA:;2X$)CP/K-+M/&
MKQ]M7R--;(.KAP'5@]TF>1#=S#>A^!I<%0Q8Y?W-AMBOG'$,*B<01F$H?\L8
M7&<,:`G8A7H0W7RB"5%PZ3"H='A$^Z4CU0Z.KT!$'+G9!*.-N<)6VWY+M)ZL
MRM.AZ3:<1J/7;==GZC;VG/&%?EQ>-D\_W<QGQVQK_\ZJ[?Y03][*IBF+?G-O
M4Y:-;9-4#^VLW-EL?;W([:;I3N/VO+ILH5XNFO+XL2-\W9:>_P]02P,$%```
M``@`,85F1WVB^ZF2`@``D@D``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N
M>&ULC99-;Z,P$(;_"N)>\)BO4!&DIJO5[F&EJH?=LYLX"2K@K.TTW7^_MDDH
MQ8/4'()M9N:9,9K7KBY"OJHCYSIX[]I>K<.CUJ?[.%;;(^^8BL2)]^;-7LB.
M:3.5AUB=)&<[Y]2U,24DCSO6]&%=N;4G65?BK-NFYT\R4.>N8_+?AK?BL@XA
MO"T\-X>CM@MQ7<6CWZ[I>*\:T0>2[]?A`]QO8&5-G,7OAE_49!S8Y%^$>+63
MG[MU2&P.O.5;;4,P\WCCC[QM;21#_GL-^L&TCM/Q+?IW5ZY)_X4I_BC:/\U.
M'TVV)`QV?,_.K7X6EQ_\6D-F`VY%J]Q_L#TK+;J;2QAT['UX-KU[7H8W!5S=
M<`=Z=:"C0T)<X@/(I?F-:5974EP".>SMB=E/"/?4;,36+KJZW3N3J#*K;W62
MY%7\9@-=;3:##9W8P&@1F^@C@F*(#?7<DZ3``R1HCHD+D'P*L)KE.-BDSJ9W
M-C3)*4Y)44J*4,H9)?4H94XRG)*AE,RGI&1&&6S*"26/Z,*6YR@E1R@PH^1>
M+7>0+=12H)0"H=`9I?`H"X6L4,0*020SQ`HI)($2QY0HIOP"IO0K6:18(<":
MC2"<=-YMQ/O\`%&Y1%IH:T!(V9P$R,X!6>@:0+O[`2A"\A2$>C6ET41G/H-P
M%0!$!M)B#D)T8+6`P64`$!WP,;X0W"UR<"$`3`GFJ@:^%)01R<CDM]!.@`L#
M8,HP5SGPI:&$!<4&7!H`TP:/XXM#693I`@@7"$`4(IL+ZM5HNHU%Y/5N/#DS
M.RX/[FJ@@JTX]^XF,ED=KQ\/U)VY'^9U=6('_HO)0].KX$5H<W*[\W4OA.8F
M&1*9;WHT%Z1QTO*]ML/"C.5P91@F6IQN-Z#Q&E;_!U!+`P04````"``QA69'
MG5J9P>D!``";!0``&0```'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q]5-N.
MFS`0_17$!ZRY!+*-"-*25=4^5%KM0_OLP'#1VIC:)FS_OK8AA'BMO&![?,Z9
M,\:>;&+\0[0`TONDI!='OY5R."`DRA8H%D]L@%[MU(Q3+-62-T@,''!E2)2@
M*`A21''7^WEF8F\\S]@H2=?#&_?$2"GF_PH@;#KZH7\-O'=-*W4`Y1E:>55'
MH1<=ZST.]=%_"0^G5",,X'<'D]C,/>W]S-B'7ORLCGZ@+0"!4FH%K(8+G(`0
M+:02_UTT;RDU<3N_JG\WU2KW9RS@Q,B?KI*M,AOX7@4U'HE\9],/6$I(M&#)
MB#!?KQR%9/1*\3V*/^>QZ\TXS3O/P4)S$Z*%$*V$</^0$"^$V"*@V9FIZQ5+
MG&><31Z?_\6`]2\/#[$ZN5('S4&9/5694-%+'B=AABY::,$4,R;:8&X(I-37
M%)$K11%]H4?W"4Y?$?O$G2%V%A$;?GQ7A)6C<&%BR\=CS)V1G=/(SB&PLXRX
M,(EEQ(5)W482IY'$(;"WC+@PSY:1QY@[(ZG32.H0^&89<6#2P#+BPMBW$&TN
M/07>F&8@O)*-O=37:Q-=^\U+I!^-%2]4'YK;QDTFSP;<P"_,FZX7WIE)]23-
MPZD9DZ`L!D_JL%K5*=<%@5KJZ5[-^=P\YH5DP[45KOTX_P]02P,$%`````@`
M,85F1^(I9@JU`P``6!(``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
MC9C;;J,P$(9?!>4!B@\<3)5$VJ2GM%JIZL7N-4V<!!5P%FC3??LUX&2#/1/1
MBP;(_\\,MK_!9'I4U4>]E[+QOHN\K&>3?=,<;GV_7N]ED=8WZB!+_<U6547:
MZ--JY]>'2J:;SE3D/B,D\HLT*R?S:7?MM9I/U6>39Z5\K;SZLRC2ZN]"YNHX
MF]#)Z<);MMLW[05_/O7/ODU6R++.5.E5<CN;_*"W+SQH)9WB5R:/]<6QUQ;_
MKM1'>[+:S":DK4'F<MVT(5+]\267,L_;2#KS'Q/T?\[6>'E\BO[0W:XN_SVM
MY5+EO[--L]?5DHFWD=OT,V_>U/%)FGL(VX!KE=?=?V_]63>J.%DF7I%^]Y]9
MV7T>^V\$,3;8P(R!G0TTN&K@QL#'&@)C",8:0F,(QQHB8XC&&F)CB,<:A#&(
ML8;$&)*QAG;.^YDCHRWGR::6Q>]72;?&[M(FG4\K=?2J'HQ#VO)';[5+!V^O
M=JNV^U(OLUI?_9KSB$W]KS:2T2QZ#1MH^%"SA#3!4',':<*AYA[21$/-`Z2)
MAYI'2".&FB=(DPPU*U=CC<[SB+MZ`30Q.6M\/47G>6+P/+$N`K^LXZ+6000.
M1^!.!!Y3:]0`#>5PE@#.$@!9K!%[[#5QIRD[#24LBB@AR)B$<*X0R&6MR[O0
MR16&I/NS%I4KC&.:X#5%<$T14)/%P7/DI&(\$"%#<\5PKAC(%<(1!!Q!`!$L
MVI;"'4%H`%>NCB4"JR>!ZTF`>BRR5XF3AP>$X(/7=E6P\Q$@F;#Q!T04X8YB
M+98"B;`8"/[4Y9\+>P9`$442(5V"`BU`,#L1U">P.T(:!04ZA4!Z#44:``4Z
M@`CLWNN233FG`;Y@$+0IP+9`UC=%D*4`LV[%O2BX1(F)KF\AV1"\*<"WB)`8
M")(48-*M&(`RHE&"5LP0*!D$I=615D8TF-&(#WO2,!M")G/)9.AS&7LP`T]F
M9NTBGHQHT!S#*_4B<#((SAB)@7#'7.[TT\<>X<!9@0&Y-L`(H`P"U.ZQ1G29
MC`;7DB%\,HA/>S]G1(-DUV8"X9@!'"=V/S8B]]&)Y$(H9@#%";5S02*&)$)0
M9P#JB;6ANF<NZF%"\7T21TCG`.F)M0[ON4MZ@@\@1S#G$.;(V'`$<SX"\P5W
M,>=Z^W>E8FRO[H+N0+HPHD$;9-<HY4A+X,"C.`GM;("(V9L+_^*]\Y#NY,^T
MVF5E[;VK1K_$=N^96Z4:J0.2&XW]7J:;\TDNMTU[&.OCJO_AHS]IU.'T.\[Y
MQZ3Y/U!+`P04````"``QA69'J'Z"VDL#``"5#P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6R55TUSFS`0_2L,]P1V^<[8GJD_$O?0F4P.[9G8LLT$
MD`MRG/[[(L"ND19#+P;DMV]7*]Y#FIQY\5$>&!/&5Y;FY=0\"'%\LJQR<V!9
M7#[R(\NK?W:\R&)1/19[JSP6+-[605EJH6W[5A8GN3F;U&.OQ6S"3R)-<O9:
M&.4IR^+BSYRE_#PUP;P,O"7[@Y`#UFQB7>.V2<;R,N&Y4;#=U/P&3VOT):1&
M_$S8N;RY-V3Q[YQ_R(?OVZEIRQI8RC9"4L35Y9,M6)I*IBKS[Y;T7TX9>'M_
M87^NIUN5_QZ7;,'37\E6'*IJ;=/8LEU\2L4;/Z]9.P=/$FYX6M:_QN94"IY=
M0DPCB[^::Y+7UW/S3VBW870`M@%X#4"X&^"T`<[8`+<-<,<&>&V`-S;`;P/\
ML0%!&Q",#0C;@%`)L)KEJ!=S&8MX-BGXV2B:-_`8RQ<=GL+J==G(P?KMJ/^K
MEK.L1C]G3N1/K$])U&+F#08[F*"+65"8L(M94IBHBUF-X'D>P?.B8US;[F+6
M%`:N&*OJV[5Y2#8/:P*G0X`T@4,2.!H!VDKW%PTFJ#%YC5'FL1I$O-Q#=,IT
MR3)=8IZ.4F:#<6]2/+B^;:M-7[I:*:X=HH9;$7Q!Y&BX9YTO<#ITG?EYY/P\
M8GZN4H^GU0.^Y_8F\LE$/I'(4QKI:Q.*`D]OY&H8URDH(`L*B()\FB`D"4*"
M0/&&>:A5*M>QO]2(S!01F11GF%.8B$XBOVB4']HZ!?34"3V6"KJJ`51/A?]L
M"M`6!(0'Z<E0>WD1_0CZD]%V!;I?N8!J,D=+YCIVU)^+]AP@3`<<-9?N$L[=
M)M+Z!\(`P.VAH)4-A+1!E78+ZIB(INL!4+<86M5`R!IZ9`VTKH$0-@1JJ;JR
M(;KC04`K&PC9@B+M=0N2^ASN"]+B1DK</?Z`M+A1%[>+RA(N"!!&BDY6`Z!N
M,3W[#UW\>/,]Z5+0DL8Q6Q`<WH,,0U[N0KJUTI:`NB5@GS<CK734E:Y[<PL:
M[\U(>P)2GWMUWX3Z=_S!\?0-T9(`TCLG`ACZH.^<"!RY=;)NSA+'>,]^Q,4^
MR4OCG8OJ6%(?'G:<"U9QVH]5ZP[5&?GZD+*=D+=!=5\TI\;F0?#CY1!\/8G/
M_@)02P,$%`````@`,85F1V*GEM2=`0``U0,``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL?5/;;N,@$/T5Q`<4&YI&BAQ+3:JJ?:A4]:%])O8X1N7B
M`HG;OR]@QYOU6OMBF.&<,V<84_3&?KH6P*-O);7;XM;[;D.(JUI0W-V8#G0X
M:8Q5W(?0'HGK+/`ZD90D-,ONB.)"X[)(N5=;%N;DI=#P:I$[*<7MSPZDZ;<X
MQY?$FSBV/B9(69")5PL%V@FCD85FB^_SS9Y%1`*\"^C=U1Y%[P=C/F/P7&]Q
M%BV`A,I'!1Z6,^Q!RB@4"G^-FG]*1N+U_J+^F+H-[@_<P=[(#U'[-IC-,*JA
MX2?IWTS_!&,+JRA8&>G2%U4GYXVZ4#!2_'M8A4YK/YRLZ4A;)M"10"="?OM?
M`AL);$8@@[/4UP/WO"RLZ9$=9M'Q./)\P\+-53&9+BJ=A<Y<R)[+6YH7Y!R%
M1LQNP-`K#,UFF/T2ADX8$CQ,1NBB$9H$V%]&Z,S(@%DGC$Z8?)7-C"Q@Z&K9
M"%LTPA:,L%D1]F^1;%:#7$V@XT=XX?8HM$,'X\,PTY4WQG@(<MG-"J,VO+$I
MD-#XN%V'O1U^NR'PIKL\HNDEE[]02P,$%`````@`,85F1R`0ET.Y?```[](!
M`!0```!X;"]S:&%R9613=')I;F=S+GAM;.R]VW(;V94F?#W_4V14R&,J(LDB
M`!ZKW(Z@*,F6K0-;E.QV..8B"23(K`(R49D`*53,1;W#/S<38=_,`\Q#S*/4
MD_SKO-?.`T6JJ]L]'?]%J4`@#_NP]CJO;_VF:=;)IBQ^V.3GU:9<_]-7!^.#
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MSLA>9_5UGIQ-ISE<!=?,^/JAB<JHWN>KJE[3C-;9>M/9P;]T-U6>\*=J`926
MU3*NSF5OJX$;_YPO%KO?E]5=F5SF65.5,-173;,9'FNU7`*17:ZKZ?=I<DF4
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MS*1.@#(W^;?"P)-LL[ZIZN)'N/3GG_Y'<ICN[^]_"_/6WPN4%#.FJ2`"NFR'
M1(9[F7O7-P/O`KV'WW;OJ^C2XTDZF1PG('>0^=,EQZ/T]/!0ONKPP;,9L%%8
M9-@@/!R[<-DT6Q6P83WTLEEN%L2=Y=142V!3-T`]R'\65=-'@W;/+)\7TZ*S
M44P<3>]V]5^[:#&RA]W[A=)EYR+#7V[R=0%"L$%Q\R3Y>D"M;%%3V%G2!&9(
MU#6<$E@ZNK\CL3K4V*6'>U2*H;NKAVDD0[<+M=US9TS4CYUT?/>C9MQ[ZV/'
M^[A5BL@(5=.<A%!2S5$==,?A50G'`];@-1P+(*,^A<5&7"8?;JI-`V_OD-3D
MP99*YVB+0M!#I2RI&Y34O2+G?;7-%J#@#C#>6.\(4A15EJR>LH"?P;V+BL1:
M_S&N!X;W8D`>G5<@BV"95SS\)H%]Z"S(^P<.X1)T?=CI-+G.RQP-*[P^FRV+
MD@PWG-C`HO1/!FQ7O`MH9TB<(ATD\[I:ZK5`2(,B-ZQI060T>.&`#B)4=PVV
M<@*4#@9Q7ER7(H*G6UB9&A2OOEF^S=>]G/Q9UA137M5BL4'B+^5*.MI3.5)(
MT`\\]W^&(=W@@[);6`\P$1]W$#^6=9XMB$/0-'<6-&481':;%0O2LV'>1.6P
MBH/JXOEGA=A]1QZUV)>+ZJ[I/^$=7<[())O"ZO<J06>S[S8RUF1=):ABE5.P
M9,."P[?XF51H.`VW!7"&Y&J;[&P:^%"43QTYAO=T=)_G.4Q\6K".1?2_1)/[
M1_JB5Y_:O<H:TLZ62'7W:L%G[EFX4K/\:DVLF>3N%,YR=YUOLO(:]RJ99X7*
M$+CU$=3+CR".ZI:`U&.:H5,=^E3!(?/@80HVK^%GM.JWC]^X?MOG,T0T!26H
M(<V."'7>;W`,;T%]O_UUL0$FF^$JP</O.5UL#>([EQF\GI6V^V^Q%0JKXM>J
M>,#L7Q8ED-G]U^#(<"332!GH$88O/N7UM&CH8E;KJE4O]WZQ7"VJ;9ZK\B=+
ME*Q`UV1A^R!BF#]@\#O/\RFPOR9_BGH&?4I(<W^@=3UHAB?9.KG*KXNRQ`&@
MM"6-^%'WYWANANY\"X9B,@(.>0E'N@"+`)VD<I+PE1?`::<],WY+!B9P/ME;
MD+F!%7?V]OYG)W_]D']:)\\6L$T=#X4,$(VISSWFPTU.2E]6;I-G175>;T$B
M7X"X6F;3?,,&0XH;M)?L`!^!9_Y-+O_YI[\_!6Z89,E5`>^;WI35HKK>$F?%
MIZUO8!UG>0,#@"<@O2U!TC5>JVG`]H0/2;/,%HMD62WRZ08H>E9OKAN^_PKG
MEWR?;V%'?MPNB2W>5HM;.E0)#FB5@9:-&E!3T*F<`9GCH=Z+IC9'CQ\>6[YI
M#>1&)Q?OJ%'>ZVWXV+N;`K2OQJW<IEP"F2_S&:X''+!\U@!W+$3+`1$.K/VN
M6-\D!9`/V)ZQ<8=\%`1)D\=CNLL:4HWJ5<4^97CU\WR1W>%XX//H].2([L>'
MWN39[(=-5H/.A.8!"-&IW;.I;[)EFKP%:74#XKR&O2VS^%T%*%O7^):&Y@^S
MG18KN(PY&6P@;EV:3''[82\JN'9U`U_0E`NTK#'`@7KEEL\,/!<TJ!HV;9:C
M%HIDC4^%_:S]%K?W=A63%HRFKC;7-[R5=37-03=@_S6L#KP.M&3@^+O7&V(M
M2!E"4WN!7&]X(3=D^*%V(>M>YM>LWM,)GY.*T])>89=1EN,_Q!#AJ:0>`)W0
M5HI-'40:,D(@Y[5;6]Q>U.4+'DFSF:.3@-U$P%5`GX*%-.H@LL$G&:-S<@0W
MX\EH=)H>3XY27%+0F^!BT"'P5GPW.O3=\&%?*S2<CJ/M_OFG_]F$ES.]IDRJ
M1)A;?'0VF]6XVG!\T/G%U]P5L%D+C'8LML!$8:UAD\&B8+:.LVXV4]HD%(`X
M)C'$IJCMSHC`\#UX8IWI0M_5^36Z42H@(32;UHT>X?D&]W@/N$Q2U:`8=2;N
M]VMSA9KU&I@GC7!;P9-Q`7#Y:?0X$WC"-\G.Z*F.=K[!JQL@03A:%5DD+'`^
M[EWN);]#HBUIG/,-*^UA=G`2EK`P<,=B0S\AE<)CZ'(<90TBKODVV1D_1;5_
M%_@J*DU)C98!<?LI''XR8J(5:W`<W=5+4>:BAKG&6YD3>6*[JS8+7$KTPPMA
M+T&Q!G$-9QE&,7D*_`PE?1:<8N(,L[/&SB5\/VFT)JQI2'Q`2&5L*A#_]-0#
MF-L53<(]MC-XO\/9"O4!$AX\"1XXFZIT*7OZ30#C\80W'<+X<W@L$!HHG[P7
M:/_1MH$^G@]:Z+99W^(O7\/E.T=/60=D)N+(*&:.=8Y38\[H#D@UG\,BF/U%
M,_I4@`Z(9^/)Z)`<FJ11(5T1N_=T$BMEJ[9G:I:O*E!N,<;'UF':UKF,N&`)
MLQHCL7*(-R72$6T4<108YY3X7'.3+^;)Y>X$=T*<`#0$43)T+PK<]`6,A;@2
M3OO2ID!O>/%IREHTNIG`XB$#J$S>T+I/.&Z\EP2_ZV(;L\0O6]%_P(+^8]?S
M+3`>##$E1[2DDY9^@-S,^"`L'\DX)XL^(^I0U0LN*OB0X:%)%CFI7$%*P9.;
MS0I#U3"FZXJ.G#LIZ#4A=G^!)Z]<\QK@0*?>J3`WG;8)[@7>O)SI0$U->)2G
M%=5P[FXJH*-=$/VXI\#F07C!9J;)'R[>)^K-N]Q<):]?GR<[H(>Z[U`7W8LN
M0N4*<RA818*1EKBGE:AI6?)DPM06+!7,=6@ROLB/#U6=1;YFI8!/P"EMUV@/
MMCE/2-D^2.WM;X!9J=<@)6+/T'0EC@JJR[0N5NI06-_`RKKWPI&"+4==K38M
M.OS*.WW%;G_0"#/8[JL\+Q-0P$!$XRYTM8#/[U%XS@J]!S6O&.Y6/2-'!Z]8
ML!U6-6PK:(\P!O$\PNF%WT&#"FKYQ[(P5U-#V\6B]NSL@@R'.4EAF&BQ=,.J
M+6,"IXK/`2Y"_)OFCZ83[&F"N07,_BN,VAF9H:8IU%6X#!J\<EY5:P[PU2C^
M:E9H;$PT'MWIWG6"S=[`UO<N(;`B4&_7]/[,N[[0A($512Z6++,RNZ8;:&.J
M55$2A0!A@H:";`NFM^(S1MXC9*JX$Z@^9[A2M$`-*9L1N[UOHXDGTGO@ULV"
MCU\XWFDL@%DP@JB\PW_**IH-*P4PIQ)^@;7%T:""3-L5KJ-'-/V+"!R5U(`K
M%..9'LWO-J4[FZ01]MV+6X0_;C'=(\=0`IA+4V:@FB)A=,-[C2/.F7,B@1AU
M^H6CV\[*<@-OXXP=/.A*9W]$M93)-#!>7<J,%FEM6U@LT-)"(Y%X<5AI=X_.
M`E52F@J?63G6">6)H>T#-W=GA_8%'55R'^)&H]`B[LI^VX?SY-ZU6&)\`I5+
M2D<;7I+W^721@1B;TU3Q:)Z+DMN:QY)9_O!\E/?4]D32WG$>>(#Q(PZ2(L$K
M)X#V$O/?T(<7SG_CA6C@4+@R!<97NPX?>,D5<P_Z":2^D.9RB7XSMGZGW[,_
MBZ582FH]+P`;T:)_@,T,`F`+1[;^'E?`I%X=&7H87B!W,O$W_H[(/_8Q@LH.
M(F;)X3-XQ`)-+V`JY,0HED1CJM\P(4U!L]GB2,WW/.A1\PI8XQW6,]8WR-R[
M@=W?12,P*3/6HHG!HK,.**I!6C`O*^U$*^M%]OX2I0-OOB0E*M=L2)>.1&[A
MN#2,`],EB;B0&Y8L-C!P=`6GAQ3#L!-N(TBOP?0C'`$E8ZPI2L82V=PN"5B"
M<'1PW69J0J3)D^-]\B#'041*+T"Y<7D#)%A=%\E_S9:K;V'<>VGR>@WB%P6=
M_DARCIT5?!I5Y.'81<FXN,G>OSE+V#.X@^D%)9],UBJ>TKX]&:4'^^,'K5#?
M5$&DH:<&*8&G"N>LPIB)5U@79`[GGX"CF\R\VA2+V2X8M6JZEOE=\JQ`?\#U
M3;8,EM@\FXJ_"[EE(/+8`X7?$^'?@&FL8_D!>`Q:!ZVST58_"OI:+P&I!F;V
MUM3O1I99%@,$*[H:V:<$.G(A%@C,`E5F/B?5U7>BY<?Z*/'!SJOP'?!HL.SQ
M"-#!R.;YFK57R7.S.!'?C3N^*<GQ`D<[1]6@L8TB]=T<-+$ROLS5I8XB6?<Y
MR%9;TM4B0T60O4KDE*&[:,'ZUCB(`^0ZQ7HC*H#G<_1H,KQP9M?!,P*Z2TD>
MX\)Y:5#Q9&;$G%X)15Z<?X+E5]=.WY;J/K9(FR)1)+9Q(5EY0FY*WQ/;#!8B
M*UG+3!@\Q]?;;IV^N6PC,S-FVACKV:Q1_.$6>N*$*\%<!/57XNV!C[#&0>>F
MHFUWR[K*5N(6I3"<^#+6US"0W:ML^CU:/&XPL)AHA*'VTG15^BYQ"HF0"Q*5
M2#5XD0AV=??=$KK5$W-HF8$8V"Q)>[DM9CAS$43;((906VG$E2<OS$H+?:.:
M,(?Q5-&=H$.2UX;4QM&)B#)0IJNEG;QH,WLY!FXOZ0JR0771?(\+`[2RS+-2
M->UD:K$_.),80L=S9CR7_=]$*MFF$?[`Q@SNIE$PVP^VR+"B\P6ZD.!V>&G$
M8)`/PUAB"L9B@-EF(4?3<[:VA*=A3RL<PDR.!7N3<Z>4JV]V?;.!!;^M"O*&
MD)++KD[TF.7YDF5CH(VZJ.B0XB!L2V8TB3,ZB_"8MN-F5N4-J;178%2"T%.G
M=A9,$#W4?$#=TM)*@$Y<-#@^<Z>X^<.95'6L:\#X=5+%.L@R3)*(N1\."Z^Q
M%`I:>A>T$?=(_T#\DTSS;-2";.\;KH!F9.R"5-U%_]5>TLK?D/@\O[8J.S/"
M-`@8WH_JDV@G;:3)IF0%KX1/]FC*ER@:4V!YST%A=089Z%;(AFHV&5DL3C.A
M\;YGW:"/GQXTY!7EV"=&:1:D`!7Y79>@4</H&P9PZ2F'E^)4""`K(&A,G0!+
M`?U*N&)WL`@YQHTD+("F>$B"F!;U=+-$IS\).S:O<CXZ:Z_PA@.,7(GX+)YU
MIF9:?.145XM6&$XHO9%C;_ROM6KD.5#SO&>><-R6;`&RI1?.0'1&9&*H-@]1
M#I,*Z<9,*<502E4PX1Z8T$<)7"2&ZBBVLVF4I:![`0]0`I16KLW``S:[OJE4
M7_0^*5S7>L;>L0Q8^7J]X-@(101HDV.ED!Y1U<4UA14=,\SD'F?2:(`G,H.8
M9)#"EVR19&LSC5C,C/52,X]CLY1>@TO@;,[,HGT]P\T"`Y41?>D[%B#9R9P"
M)KSNL8IB=NQH4ZD=LXYZ650=T?B@YXB)'P0U'$3:=*X8:39+)%_1FN/DI?LX
M-48%MRLY4IC4LF1;Y]X'S(M/1-E"P_$DXO5Z3=[JL84*PW-O"I@ID,D6+W.6
MD_GTU!&%EXN7`I]_I0'>ZHJT=M(I09F9KB4:*W\4Y6J#^EXXV#]L*IP;?#%E
MZ[P!-6"1U2E82FMV1-*A`9:91H8]&31D:[#^0BPN?AH9AWHW_BS/;C]''Z"N
M17HM/]P<;[9&/&&.W*FS".:78V1-5`1R?>,ZT"CX6(%=@*S)K3VNQ%Z?#2\I
M<O!P+<7X78T\AO]]8?3P[FI17&>6RM6GGR-!FY'Q)!E/TM'H%#X<C/&O$_AG
M9YP\E5].CH&@5/-N6P3CXW1\<)J,#D;)^"C9&1W`;?`=VM#G_4X;F$QZNG^*
MKQGM)SMP\U/\ZN3T).'<6$^D3[`<87Q\C$,9C>#?HP,<W-$AC0Y^.X#1=7U=
M_X9+M9].]FDXN%28]8-K->'%PM^.[E^LT>$X&1V.DD.8^3&OU?AH-+A6HU%Z
M,CE)CNA-.T?X'OCJ^&34NU:'I^GX%`<W.L;=/,2QC28\./AM<G#2QY`"/V*Y
MK"KU+#!B=:0.ZI!][)66K[,W>_P;;=,;>CZ9#11V)F^SBA<BON/]?9S.23J>
MC,/EV9R<+'J'Y;7<56(WX4*?3)+Q87IP>-J^SUVVGQ[M'\!^I$>'QT/4AQ1F
MR^<+_^B(1W6!3??W:?R[2@Z2XN0R$J^M<P.&P"X7PI#142RO-G5#VS48E&=Y
M93*2J/DYAIDL_>KWH`BM^<;?;Y89%JXR-TJ=^ZTU`W6QI>)_<<4`.+3?U>A2
M/J>#I92/2@QZY]QOY*"C,L+\AZ(&X^KC'Y/7Z-'`T@MTY'U\S8%%YJM^%+AF
M.0L67@U3II)BGO!*L?,1UQ-)6U0##7_`?L*3"M`59I1OB+'9$/T2*^WA%!RK
M#3<9!T'"H7)C[^7CSXH%'JZ/Y15_8+I[S&X9YP'Z/CBP_P]MQ6A\2M?C_WN6
M?Y2>`C.C"^B3EEN$'8"CF.X?CMP+@<.?'O8PWE]P;N/T^/C$_M_U`K,3>)3N
M'X]D\/BI;_#\2WCB)#TYD(I^"B*!F3\5.FLV5[`H0F>//41?>&);V8-H&#?H
M_EP7ZX5X666H^M!<AV(*%!]]4[?8^P)B;B7%=*+2;4`7J1=;SO#@!(V>,':V
MF.)M*A59^W4ODL?+>J%KEW+<,"JFF6LM2;K798QQ_6_GYYC/?"';Y)MA"N_/
M+E[]Z>Q9\G_^=V+EOGCD[S_;)N;X>O%YYC/_Q#E6`"%CN:ZJF;^:+*>J_IX=
M9)1LN>=>7C0<)YQIA`F8AP0.8(73R&`LR0-,H=JZ6>\6F.I`GS!<@,SSY:N7
M[XC!LN68DL^3E->8MJQ4@<G%K92DA,XX^J^.=1PJ68O-,`G;,S5'F$LB+4>4
M,V,:C.=3$*W`L@XUMF:L6W-28H*5*]42[.&KO`0;@RXT%QV[88);1P,2(>A(
M<9I%03G$*RH#!II:<=IQ-UEN+_G(%W5^B?D[9P9Q5A\JZI@MD_^P"?+VH:M(
MCOEV<@S>\8=-*4%7$(*QPM#R=5:+F?>:A<*ESU(C#`X?WA/M03+K8Q6<6TE:
MTS7(%3[%SUF/XI/2D^N#-[Z$5[/@Q`3B,U<C)UK!R^=GK`W(>KOCU+;(K[,R
MK#USK89<A-V@6KSNNB`N+A!M19^?O^>4QX+]$5KN-T[+_7/,!8*`.SK&Z@3>
ML-_1AN$/!Z.C!`L]_`'46XY`J;V`>6LVW6M.@(VC?TV>?X]%1FM)U%S+#E7L
MI2`/%^41ZCDFRYC&)D$539OE'"EYDM*Y;`&>5S[ZS&H_7R`96`4Z(0.'R)K@
M3+'@(3$,NF%&=4CD2=V4DM^[9W:=5G\.)"+D)2?QEY+FC!(/'8Y&TXU24%'/
M=E'*;Q-8]EE54Y*<%MH,LK\44XTV<WQJ3=,/;D,S].5`41`@(PHC"`2L!4!?
M(`D&%Z+QR9-M&6OIQU)9Q[J+YG#9&\FU$U+IN$P`5G/-F3S"HO%UP)';^;G(
M'IJH:-X$D!O:A@.8H"S)*M*6KH/<(L]Z9?9U2*?1?<<LJ>NLGBTDPUW2+"0C
M7.)"J)E)\$F/CQ2E-.(GEQ3*TB\:DK!Z-2E^*A%"C"9RAA![&E<KX'+$0)TC
MOD&>MJ"("[MEMV%A25JY)+Z\EKQ'J6&XRF^RQ9P+4=C)H+Y>S@2E?%MZEKM7
MTZ@<5R,MRPZ(6M]Z*ZUU;(-P>&:;KW6-:>5FB88,[@H&W6!?'[KM=0L;T1&6
MV7>5!A)MC$S]=:,/C-ZZ-`4:"*XF@YK2C76Q;(8QA2VS[^%'=5\V/)BX"%+R
M6,A0Z_'T%KS8O1E7I@*S!U/)(0ILW!-[P52H`@6B9-%N@**V*F_#F$WJ=%>*
M:Q=QBCZ?#PQ5RSW<`Z:5+5>BF@8_;F<5)'OL&V#^_RN9YP284A"W/0=>2\Y+
MJU]_5X.LE$Q8S@$]?_^.K>X>.8V%O/H((K_J4S'EDK)F#7J\R`&[9HUN[>;;
M[D"DNE(2HIMB+7&DUOL^_R`]O8Z?,MWUZABQL`=^"B;)G?G?X;13\9+4KTRY
M\H&^4LE&=0LT"OAFGE.6.&8@Y&WJN.)"M743ML4I?*UY*1N(B-N12:/%)'SH
M\SF<#WTR,697CA+8&0>R,<RU\K:DSROAW#S8<(UREV0\,2UB*FS?2-N6#C,O
MB5G8V6+]T$23$YPMV53FU\!?1&V]14$G#C#96+_)/#`-W^$N;S`J66)I--<&
M<8+L!?^I(J@9D)+L92?D`O@;93>I#UGCJZCFFP6H`S5H<VH]@V)3F"K%`1^2
MF4)6\9*YTA]-L:DWSJ%/M-,J5C,RL!1"%;THDJ7TT>(!:&A<]0D&DQU,,(%>
M8-V(1_)385ASX5O$VV-A*H^EXQ!8/$5'^MX!&UCDSIFH<^DQCIC/*<>L2;T*
M.0^@J@TE)=[C7>MF5G9EA$^HA'N*NC^MLJA]8F4(FNXIY,J'[)/HCZKT;#4$
MBSIGTY^^ZY+T.=F0GK7&9V&R`FM,E#/#)OE,2VC@D@&(@7:DV&39K,!BGIR"
M\E?Y^@Y%_&`B/SS^2BOMA]XC4>EEGF%VB8])YV7&YC8\IK82PT5VY\)@+9L<
MJ9#*>()BX@?<O@/S.^N&$V,,[(E!RWH"Z`]!D>*$#?BV:%BYV=R?*])-+XF#
M&25M/%;8PCULH&"T':P#RBJ`-P$78!;2CR6UAP&H#5<KN!`K':;L(1.*_%U4
M<3N4E5!]05:"V?&4UX1^=`FO,U?I"Y2WUI-*9R=<N1!-41)8'S+)O>1MY6[6
MY/9'/,'>S^LT>]2D#O8,`?$].Y6LULK;0N1L:D)E5SNH\R!`HX0JX+@@Q4(M
M>A!C3R<=(5OMJI;/AA<"SR]1H]:QD]/K,U?S0UW!3G!I3$'E1YU)V,'ZFV2G
M>$I6T":C=<Y1K169D95^(EQ=C16K18&YUPNXO&9;I)J*Y>+-`5]_4%)J%=T*
M][*&M%CD-7%6BM*K.^UJLT5BUSP&JJ-E!HF39#5NI[A]2GL"/$89.*\+V')P
M&68M$)_;2[I05,QY(ARHYV[GSMS.T8_O;?-T"X@DM!29M0`-IHDZ`]]0NI7[
MFS,[!\B%-.-6%EMF1!C8+&XOU1*;;=R$PBK5'F(CT<KCI-B1BLR\:N`CXG7G
M`<&KT-$IW(W!8^VU1^](?)E[99BO[_$X.J'CM&YQ%_NWL^04"<MK:RMG_@^S
MM$0+BPON0\U8;$3V3\&6UTK,A0+X;!:-%M'IIG$%.GJU@UI(@D5T8%0X0R*>
M5[D,2U7'W:(,>"RE&\%2HKK%NH<KA&]K+DJJ897;!<6T+4V'BF5=R+E>A!GG
M)/D08<KB+>3-R[TC<8BOQD4?P8\TS4KVYN/QU940M5X+G<K9`T_]2XP8^8-,
M5"6.)%98E'W!X$,.-688Y`LI/V9-FR>4FM8OY>^$0(#;C;G.HG5A]*(_;`V3
M9!DN]0+S0HG!M`RLDQ8Y*&JFN,&,_9&X*IS'0Y_JYD."`,_MSS_]C4#2=K,%
M3HITY)]_^KMRV2DH\*!-2'V<)K]F4I^;K0<9,-5JB'01E!0LW<C(L!F<2GS`
MZ&23^X!]R"(`U`'DIM+.?/OL#8E;L$C-#1(PI+;!_9S)Q4*0W<"[EJ09BEB\
M3`PF1\J"T'N2_87Q6-%!\^'BA65%L""\(H@^)?;>FYZ]N+RP1(D$_PJU7>@'
MZ3SB3K,9XV?=:7)$,>\0S!W)&HR+U0N).DE85T\PYY\Z@K+<4RYKG)(!$MG"
M`MPB1P3FCJ1$XY]+VH:X9EO45PU007Q9E_QZJ*YH6@+5J,\B9EYA89E"KT5O
M]4+2)?3(]!X23J2GU^4:AQ1QY6:`@94R6VQ_5'+T:I5W//M[0B$(1?(Y@O#=
M9G;-[(G5O1;YHX\%JRTC3SRQ(KK&YIJB'"(65M4F'Y2;28(W196SDC7=?LE/
M!&#AS)8SA$R8&8=B,HU<)6<F4!7R"N.4]BT=D&N$CR!H?_C)<O+F<^#Y[(VM
MZL7LCL(T!`238HF6`%F\:NHL7Z3)'S(819K\$7A[1L_XD!5W^`VM!JE>/I:3
M*_*21`\Q\BLQ12:_:)3J_F4'.+I.JDU#N;H-^YE4ZPL`&QF0"N)A8\T3;=5F
M!7HDZWYI\#6U-$8A)3,@A(X$-&+=&9<FEN>:UNT)BME<C*$C3"Q.8V#FY"+E
M"F&!%0T,57,.RM.LR+B6\<6FKE8Y_/&QU)COBX^<GT!)"31_Q:SIJ`;J'[45
M49\@&IV327I\L"^):1]?I\SAT(_VY)@P)NZRB..SAZ)](E]\[!D)9VR($\YT
M24Y?X)1P"I:=Q4`JXU%Z?'RLJ]\>,HXF8DTALFZH12UMU>GYH@<VF!<Q2P21
MK#,"7I''#$#!?AJ!-&PEK601FW16-8DV'4<:S!"79H#5"H@[<^=MA<Z01^EX
M/-$AU]Z,ZI*P[DA;H2<-6=U*(:(I2AU3?RF>XA[2#5B)>\F;SFGK,;Z"=:(#
M)E)BK^<-)K,HD8K&@/FSYC)&,;LCIFXXW(7#V+JE_9:Z;PL)QD^.[[X+15DM
MC5=SB@QJK6.^J.$L0S*#,V9*R%ZV/<PH'%,K?$-TUV:^%5)IPK;6SKD2>1N\
M?VO6ZAH1/*@M^RNBC5C`<#R!L;HV*QS3D]&8>$(+2BM,(DK<<6&"UK([\@D[
MZIEY#S/!S1:EZ>7S,ZD.7^7`([%@7TNK*%9"NR#7OG@CU^*0.32B%RH[`.;E
M-,:MIB->J!V*/U(.SC,XC,`80\8B,>F,^''TC8'$#+R5KVJEDIEE0TH'NS=8
MK5?>$[P`)!X;S2<\N_R(^L'^[N@X=6?O#;O<,7FGQR_WWJ<^.@+$84MJ(B+"
M5?/=537%LM6^<-UG,J?;5-GBPX^K_`+%T$KUQ,[7D&5A*,B-)_06PHR/_N'/
MSXI*03'/9K>H><WN<5LQ'OYZ2_?WX@0]-*D5R.7OS\[>/S_[^O>_OS2#!9_W
M-I,C]4I"D21-SM"1=\VRY%5)\%ZH#3U7T$\DO[>OSEX]U^>E8:';"GJ41=M7
M.!0V3K,E]EJ9I?<[=`T@+4H39<F&Z;><5Q/A(*(?E>16T7ROTOLNPYP9#$7?
ME7G=W!0K=G>J/*R=W2"F=C=_D;RF%IG5\CQ\&#L%"2P03#R2+^0UF6%N57&U
MP9!G*J5$*JP1L7[W@U1&]#%C#DQ1T#^L69QN*QNA@KZF'>IS#K.7KL\]G,HZ
MHA-BA7;$+!66@%:HN17X0`:_0OH([\Z]8T>W5)QEH04"F"6`(*J,,,,WUSF(
M7X)IH)I=A`O0+;["0T,&3N<HM;(T8>$;(R44C0/[A?EE>#+AC2G=17@"-Z#-
M3U&3KA"G`A]^4S64`<DCF>=H="Y23GIIF2D(78O'>$JU:#XE9"_YLS*2.,JM
M4C484:J?^K1,ND(#U+[Z=H5FL,?.;Z+[7+URN[B*0F<KA@V0UA(ME[5P0IN<
M1$AD&(0,@'F\?,YGREX;#TZ!B[0AR2T[2!M"*_>&F&D!],B?:A_)Z0/C(%;`
M[U*ZP88#J@2LJ7U7^(E(6C><H`Q=HH`5NKAA=\6/_41G/U*4E;[41LA"<D'+
ML:&KAG@'/B]%;$GF&BSK(Z2K&Q@[B)`IPQ#`+W32.=BOXI2AV!A#N.6]UDP,
M]HS`?N()W5#E#17KM`P_J8-LD.]E/`#,5\1$5<5&Q5?>Y(M5XGSHR356N^RN
MJ]W@?_9Y5[P66A2@/-BS0=+O@BS0=46O%R9J6:XL#V+&XY/,K(:K4<7O$QQ$
MJ!L&2+RX)K2?&_#^2-UP2%P(EA7E9UBF"N8T('^WRK?*Y$J,@>/'(096<$^B
M+;0H,,T*O=Z"]J$:!<U3#<8(2!JE[P;1J>,=-/0M25=L<CTM@8[[P`Y%4V$7
M,&)/LU.I[!5:)(IBUQNL_G6!N4.@"V?BM:5ZE)97.PIC9=1[4J`L9H(5>84F
M&SK_&<(X]A-[M(OVO%(-K@I&D@067*`'WJ&N.D/I]4(C`*:)QP(K1J>222/N
M2WN<1@_)'2@X-)LF[VYV^P1A:.K*!G3N9-SEY_EDS`@#S_1EWH'=!CX(#Y)#
M1?P\<D-3<I!$>];9]VJX^?"]0A%SDDV8H-6#L!U0E9KVM&DPW\UI<T!T80X]
M')[AE05[.K8H&4"J,9X5U1YI&P^?'JT/DJ`&8[4;3\G(]>O7?;K(BB7''P<8
M0[2^/K=F37E\F@ZD6019:.2AY>X*I$9R8N`EE!]S%PL^R];3TG5]4+XHKDGF
M&\^Q@!^OA>@H5,;/X2V#>Q.V'P,`:?WFG#(8`H5Z+<Q'NBP9DO&60C#_!\R>
MU"]$`GE#'5_FY)JD7WS'3B0O"9G=IOYB-6N#,$R]S`ND3\E2;*7`\5LA/K,(
M^,"7?1H].3A2VT%=[9TK(%1%_XQ.C;:QTQ?"JFGR9:X@!T^CP2&6BH'ASO(E
M33Q#J#I)CO)S[PD9Z]A4WJPV5PM7IR5`_5&^8A,?0:M[4R)VBA$.M,P7;7$B
MT8YH[)&V8IK"OYU0VZP89S_.ZA5PL<V2&[OX)$QSYZ)!B$\(D+-9W*BI6#=.
M%[JTO,2&59+^4[#>KB13G:Q%M>X]P^3RR:H09R2!)WVHQ%]*E3Q"=T/O8`83
M_+&>$+P,"BXU8X\2;S*XQ*J.?U,0K:M<TP!!_<X+8L@F/CDT*2JC=H60U55"
M-#_A\TC?9E/@58F@JI3"$/\LA3ET41$N"@:-LQQ"J>:;D!CBHE4___2W5V^X
MD.TE98U?2%+-<(E1O)1#9J&70!97`OGX"EV#N1,&Z$^L<1(B[U@O7/E.2U'(
M2A_@JG?A;,RIDPDA'QD<DWF?XL.`WP%]6.D_B[Q(D+1/`F?MHOLKY-9ZT4@Q
MBY($"R6Q&ON15"I2ZN!`JV,Y6N':%)5-2,U0*:M>@?=LTD<3,>0U/JBXDD97
M>+5#$<A(/[$;&%6?7.D!:E]ND@@RW86XA-D<K6GSWU@!E,%WD\+:2P:(]W]+
M?6QPWI'?M40@0V+JE*^B1D?$4-GT1`?9KICH:+B%!Y(6#5->5K0/$97$A6!Y
M%]Q`$R$E.XSCBOC&AV22TH5<(/F!;I1NE6_Q7OD<*B?#IVX/2@(C.#H]#;61
MZ7AR)'^U&E(FH_%1<IA@J.X(00X.1SV)@)])X=2)?_,X2("#]/!DG(S3T\DQ
MC"(]/CF!84_&DV&PAHE@,<C_#?A@AT+83Y/QZ1']=P*/PO_Z$!T.^=XQHL<<
MTD?IJ?RELX9!CX[&R036>)),8.$/)KC@HP"X(-<]24;[Z2E!IN#%"+=P,$F/
M#A&+YH2>,>BS[BOE)$[Y`+>]P]@3UWI<9+H7OW:@@#T@V_?YFKMO;D60_`5]
M2I2!=E;6E=1UH]E3MWZ(4.$9Z^:ED$=%O6!4GD!BEG-JZ1Y-$QA,1[;@9S=Q
M,I2ZSP2&W_+M.C'1:*F[R311`HUFDYI;RJ?9N%+!!^]3!-W*`-FIJ]^D'?*Z
M/[`.KFG!!XOFVK3J=_4N+?U)7>PO[53*=0H=D:-C%58:2M$D@$`ZJ:C(:"IA
MBS%+>G(^2RG8T1225@$U^7\-_SF)*K+W@'TVO707SS"JZV,#*-0"6O&?WQ.V
M'8.&C3/$3.I&*%1OZBP#/4;K=MH99!K#=_6P!1)-B)Z+J1#7]3HEO`[>R!3C
MZZIUICY/M;T85;G+;5>X>EC7JUV>VXB2O-AZVAQNPG.3]>75NMIR;'/-@,-:
MFG:V`,$(7`_K^'*,LF*P@S6Y-]P)CC[_)0<-XC;#B`,JS*ARH.YY]N+\W1N.
MGKUBRZ5PY:`.(?W5^]=\F5IG[D$4K<NNLF6&&0,.;9QZB*##!F]DK5S=3?,\
MCJDV9`JV)TX`)&C_EL31NG65=IK=_2'[PO68$YA6\N*V\L!-Z+3*LI6?]>&S
MAO*QSV6,>V;5YXK4HKO>6?G)]TT+%0AY=P3XX</6"H`**[3;7J+4"F?;!)Y-
M,S#PP3A'@L-@9`<,)7:?DIFG_":"T>;;/:1!?*>.`&.2W;?.R7$W"ZBF))J%
MQ74I)L1#9%D"6`29@ZA\AQTVZL`#AA5#;GIL#.B:MT;1])NU/?.V(KFKW+7I
MG@F0AQHK%E"(Z83O"10UB()+B3I%5$T8^F52,@D8IYPU!5QO"DOD%D:M2@<<
M8'8Q]U_F!HOGOO\R(GI0SZ[=*%LC$I77W*^KBAO8)AF'N:5T11M/\"64;LL7
MI#T`S.T%?UPNA?=_1F6>BK`:(:#VC;EH7`@XI($_6X!%NWLYO:DH<+DRMREE
M]6"[S;X7W#?YR$^)KZ"UY&@^EA-&Z>H2C;5.:[IM/6VS&1&BG1^A"ICD8]<9
MIA3N(DBR0#X[3L9^X;;`M<PP'#T7-HN0`\:?\Y'S'=9=XJ\,,^IQ3,>>66Y9
MQ3/0L<:3X/Q*$#?NP5B8X,O(I"T09K:+C2"V@["*T+Z9E9)VM_N6K?I0$Y42
M[#!7\6!$W^%'3%F2*!V5VTA:KCS_418P/WZ2GH!-1(\',^GDH._QS%W4Y1*Z
MHLO6?:ZOB>IJ;,9PYD0'/NG>AP;&ZZP#8Y"^R9'("7':22%,7XWJ,X'UN$18
M#^/^P:!C#IH9CJL'P#>JOW4I@KT#=W7-UF@PQ@CG+)B]I-M_7H@K-*WCP?G9
M=D;$%#/:)XH@7Y@"VSR*\E(AB/%IYT&/(C'8>=J)*68)SJY]MOT`%IF1`:CK
MOL5?S^+>F]X_^-Z^OCL4U\?+M&A-4JM:9-I*,(@0K\DW@A2TI?I2*2CR&(XS
M5+,T%#PT.O/S<=R*@6]Y;'T2^EO.BH*+,&<_J[_'1`3M:^*S$'Y9>8C;2K71
MBG(]\-HO8TM<C\C#S+C.&C/OCT\G?.*I!)R_FHQC=K6'/1OO6X2XXC)SIM$V
M%KNL&E$;\1B[^WY8[L66TW!FQI:[_<4985O0NENHY(LM]P[3O]*@AN/0'@F0
M[IL>MD2K/SJAJ88PSBD:$M)>Q19[E!X='OAL?(*`C$/E<]G*'OZ>?T+]EK.Z
M,G%ATHGX.CHZ-H!*6G1[O56A27TWK!65>X4V6`.`/?=0J=.68*412R&"F%_?
M<UX?CRU2&JL)0T:FC=/(/=2FJU5&,#Y20S'"<XFJ,WU%)P-;#9$V'?0^<SO<
MY:B-X;Y*UYYR0Z,A$XR5/NJ=&^E7;H/5P'Q>+#;XF.X+0W\Y"JJ!QC<EUWCK
M2BFP,Q>+4#0\$KD7-A+,N4D/#NLW7Z]_^YNOF^*WO\'_UK\E)CU.=@<MBO8-
MSQDW0]K71;;'>S&3SMG+=NG,$$/Z^>N'_-,:%'-XV7\;&`NYQ0?MFP&*Z$%M
MOJM8>94AY,O5HMKF>:RVNB;T],X074PNX"?VL41?13G2+_2A?/.%PM+9O2\N
M+R[8ST+Q?@F!8JYMMF1FK?:6HG-R7USKP,DE!QT/&\<8'3P)W[H5Q6#0T##E
M"AE\>GP\27;@_X>'5*^C/[8<WZTE(>5E/-Z_YPZ<]=-[2HT&F1NYHX!?/SF"
M,>W#V([2R<G)(\>&88A??FP'UM`U:SK]M@_2D\DI:2L4+T&$&GMVU]!S(\**
M'&EQ]R7&.-N?7?_K4*=(G$.V-G-S$'XWH9[/&!5LOD'A='PR]FM4Y^@!FS&W
MXWU[<I@>34AVPM]'\/=!>C0^EK_!K'HR3@_W3^3O$R&BTWWYXO0>`7K3L]ZC
M]/1DK%A`#UOI?[29&ZJ^<.<2:LA&P/1D0$@#4H+;0Z#1WI=VB^7V^KF6%^OB
M[?DBZI(\%F6=E%./JE.ECD-T&8(ZF040M^ZA]$4P\2]I_ZCJW,B:<TC+H-^P
M<R7_@3*K*E,^\G7L=NEP2:V9T[H+>@&L'N:)",ME+6+4/R@=$+HY=35<<0<U
M5QP?_HJ-.6I;P33!N:9RPKE!Q1P]JM2A@@NJLW*#^4/8M;Z=H$C0M)C4@R/Y
M0K>=6=]R(0WU</]!0[5>&C32L\TU(L'A0&,%K-LV`0U-C%2G^Q-V?XS2,?#S
MSYR[MKG1'3=I7ZZ4+RYV,#`''UCTP'[#VL,Q[)W0CI^FK#EY2&1EG!K8J=\D
M+X"][YMD9_1T>+3XKG<7F\O=40N+,'7\1QA"X"*]5<,JHM)D9_R4*A)[T+<?
M\%0D33APG:=21>($"\<+P8!D0^."E)WV^.F02`$A#Y8:O*::DU=]#\)U74P%
M($N^G&W+;(E?8IT5G:I=C8^2Z^'9^;\<3T!/P:ZWE(\!M%HM@'1S"F-\X9*1
M1-QP5OT`:8S[2:-+RT(L1.[[^W93=$R&;V.9"F=13R#FW`Q('TLV<C(HY.5+
M],*J:K&!)\9_%G8NAP:AXF20]Z&Z8HJTR8(6UVWS1442)H>>MO5A\/$^3D:'
MK9-!B^\XQ"&,]I4EH933S78"PA>CHEW4FL60F.HTO(!CN[`J!,%LNI6CKJXL
MIX'OFJ;NF_H1K(;9C$*2"KCFFJS2?*M%JP%;GS!5*TNR/+;#$RJ:2(T[XW5X
M)SK.G]5^55]MM]W+.)V`*GV:'NUC?L_1WGCD6Y(/*Z,[HT/LX(6&'*5KW7?/
M%-]-S61&=L-]1+@S2B<C;"K&_Q^-]DY/>V]0BIAQ<ZU1.MK'IF<'>Y.CWNO#
M0,8GP$9/X-K3/9BXN;*[7HC3T3&LSO$IM<S9@]&\I'R)X<$/;M7#'#_F/VZY
MI]`B"?&O5H4I1ZC859X]("06]%27`EU6KG<$MQ6C_J-\"#NN$!<5<\,,+@L?
ME0JK\ZA%8&?\R9Y\A9].>_2'GO:)`P'$*!C1B4$HGU$GBZYG')73V[)UR-;4
M$,2'*-&RMS7;]_DV6G7*_FI9=C`XGLW05+YH-05Z2\W!13'/.Z%.W5S=/!NH
MN&JQ1LK96'UC4P,FG$UJ#P-?ZOIVB>]?^72R$(J99<Q34%8"6$2@.]AE;%'G
MV4R5WZ<$A=0:&%ZF(/QZF0Z6+FQ+K-:2@JZ2K35#6EQTO.NN",5=U)/<Q&49
MP0D>QY:]S4<F,ZY@3CJ$#8)2P!%+>UODBQDI/?J5R%WN'LSM#R0!1):ZUM56
MAY,!ZDA;8+I>@Q(8-&GRG*B<\Q4'6`4&@W;GJ#C'D;M"N@@O,;5.!JP;AT%.
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M=5$2@<'8W/<"Q\3^">'*3?%IEUAQ>`V1/T-FO:T<2N5$UT"J;\+"88R-T/K"
M#'5\/<^?6350&7P8]%"[A*<(?(!E&XE.\:ZPS+'.R<LE*K%+8Z+H3AX?6C4G
M;I6,;(H!C%E6B](?!YS(&#D8Z0P?)+)B<MF+PP,^)40>.D1H;;]P6"@I*C+V
M_O-/?UM4%;K3I]^C5T_X('GQ._"3#U&Q]GHC'Y-D]_$`QN>:/MM^9/PDAW.<
MN`C.9Z,Q$U*>OWQ4CZNF(`1,CT6SE[S3@(@8):U`3U:6U8:P<JRMMP/2>21^
MSB.&BI"X[PC!PUP##29XH]I[F4^Q*+3F](*+&I^8S[`1%#WHO97LH-Q`^ZNH
MSNLMHK^'FEP5HP+CG,_:U0?/SO_EX&"RS]A#JVK-!<,NNY"1DP24A^)_Q##>
MOSW#TM";"FST*"EP7BS`<*XW#6?=@?BUG0C#4F`$K(#*7(\.#F%/P"([X*1A
M1F'305)OEG8GK5`M^V0\3D_`8HR!O*()B^SE]B=9&6MYHB$'R9\F5_@2B[3:
M\D1V@&]=\F1RE(Z.3N_S$#KQ]F1TE$[V]UW-EVPE<Y@P,AVW45D1:H/W?BF`
M)0-,]9!28?/P.7:]]`YKUKNKQ:;9)72>W7GN;I<(4=&T';I1RU)%8HM;EFHD
MVE*IS/_6:4L8C=CY;/H`P<F:C<D?S+!L"4I.3=-3.L,YH=PBS"%"VC18[KW!
M%2$5%ELZ6:LH2FQK&DO1H=IV/;[N5$;UU.&,M,RF2(,/?K?4XCZ+PG@#%[QO
M.4,M0'GZ)&TI>^=-=\HNJ6(,.;F)(,)M8--%1ADWN**",9V+QS"N".VTJ'.`
MT)VSEA`TU)8C6$@`5S4GM-66O4W<9^^SK:$O7'LDBL?'8("&WB567H3>RD4I
MEZ]_S9"+Q:S(L*2',$0E1X@+,<G6IMR^.;""\L>,O*,283&\%=2@L*A'VJ41
M*)64T\`_E`E_"R2-V@D,]GI176$'(4Y<V@MH2@YP-FVAS5*QB_HL9S`T)/]=
M($/2(2+QU,*-B4N]RAC&UD@RK);)MP]Y#<]4'%`*(\;X3GATHZ*C5GU5;ATM
ML+*TG3Y$,[8I-=7B`?/"!H%?-"UT!6#YK1R^>&H4F^U.K=6`CV-:WCG?"K^%
M9M%9\C:_DX:GW%20QK/SU=OG9U\]C8"%9#(OGY]]"<AES\CGFP6(9D*'H"0?
MY-T]@)13UZQQJ'/K\[-?-U%@"+^%*3![$3!K>EN`9C7(UP!]5W$'1-^A2(;,
M]JCJ+O!D:4P;G^T@CH5?27]1C^@B6):69O.QLTZ2JA8OEH/RG!/TF$/J$(=\
M6(\8-M->I>C&6J75P&91=MK.5R_>X'9SM+1G#SP=8'*^`D,)GD1Q+9#%M"*O
M^H7B/<1!"`CPL[8/2[XCGU:#`3!.8%X2O3*O6572+0FCY^3K"/EIYH#*&"&!
MT82HMA]S-0DUNR+\ACS52CH^DMSE5,)ZO@^=R4A7]S!X>GL9$DVQ5_W[DI/T
M,*1IIOR'0LOV(N7^9P*9E:/P2*S83DO[8&?'6,].;UP7%--UK9+6,>`%^0"#
M1T7&O2QFNT#@7%`;87XO<UX\@@W<+!.7;5K-0_>2R.[`].>[74Q27DN!:PRW
MP>ASVM>%#LEU/\!A0.6@G`V53F957DIB0K>RU+JQ/&Q%.NL`:XJ30)@/O`E6
M(B#E>;M67"N9F>;D6`SY^K`<?]B`OC-*=AGB?[(O_NTO'A?]<8=4,3`P._\1
MD*0;=>J&K6XD'+9T:W'!6E5V9R"F*+VJG2CO.\2B;DHZ7R,P-&HH4I/JA?)V
ML-[0BL5@Y9:4NE]W>N9$;9'4*]8.P'4/`BM_JP+50JKM(G]3O=V]VN[*1R[P
M2D/HF-*9\7&*,TX/,-:Z`%UJP8T1&@X+%R772NH#Y<##S6"P;KF?KQ9+#@^5
MVC9\I;4BL&/+KY[&QS]T&5?VSN<_"TVS\#4?X0>+&%1W>6]E,+/1)2T*/%J`
M#GKX;B9]>8PJC=^WPF7:2H#'["N)XGDV-YG$<`IJYW3?KEC7@/8F\#Z!@K:N
M=GE_$[]RZA:-MJ5]%O:2%PR8Q&43*)LB:ZW=`D):TL*(ZAQWG4=1N4>P049.
MFR[9IJZ!M*(:+-P]/6+6YTB$%MM3Z=F%T5&RNWM&TFP07X?@C@HLB+GE8HA;
MDO&>ILA-CS+EWJG/Z0L25M;$V?4-`>V%@@U3W-H<\RPHD`L:R4QL;$<HOT8@
MO;64*KL.3%8RE'$/S(RG\FLSMMFZI-B98B$(:CXF"R-8*&*(TA]2S9)(KK<1
M<Y^^[H;@>&.H>YY'K,=E^,@@I"O68N$?U72=9C+]M&=]HZXGJGO9H.9"RGJ(
MHU1D?!"=Y0@:@55Q5@\SSD'WCVR?7.3:Z#F0EK%@A0M\!K-BAW+2MI(-GYAX
M&[KSU8LJ?75P74Q]@4$3#O6&D2*!AM=;,P=:<[;)4KHE4X!;?)<IQ4H^PU9(
MXF!KQ7&1F.T0J:-9O<+0IF)%1[H_?*4=Z`Q<IB"ZXH"L@!2"2N).-+\##Y,Q
M-K6UB`=UGDA.XQPM%==(#ST:BE+T7[/EZEL8U9Z#H-`?V8LS!'R$5[K?^.(W
M("H*3@#D<&2I+M'?PYS(?O.N(G<YW__E(!OL7;T/64,A..A20]J(,DR>DADG
M51?[+6M-RCM()D@G/==?4%U-7:Q8,QL#9+>*]=Q9S")VV71?K#4UWH#"\D00
MYEHX1.QA75(WJ`Q;ZBKZM(1*N-8\)R@=6+J+MQ=`63=@V[?!-H%6*J25,I<Q
MR%^#UAJM2+#4N$44P9/BJLPTYVZUCKHI(*<K\UWL7:[,(U;4M5UDIWE)#W;D
M56AJ:/):ST`\4UDFS/;4U`8YDC9N"9.$H0990:Y#N!YUM:R_Q\JZ)>[4,M),
M7('OIJ5TW1@="7$UZ<O\JJ;\<8J/[1\Q,_0'RQ2_'FV)U@@?'Z_-@`=).PJU
M^4:4?DM"'^BT<-U8V$@@U4\B^=95F@5_+0IHIR=E>]&#;SWJ2,FF%)8B<*B=
MJ9Z,L998X?>C#L?)EXR*T`)-L53:&%R$:U7V>U/=.P,-V0^XOE$2@58U9-?7
MZ`-=NVKG)X?IZ6@DKN9BUGKF$RZ8`>EYTX8KDNAG5/B`/EA-D2*<JHZ])$>/
MK`QTYQ0*>!VT;^H9U-X6Z;^N1P/6N%AWER`X`KK4*]D,M$4"$2HS(UR?X=5C
MY9+U\^65D\UX+\^3[J78\5LPZ<CKA25(7-T1Z1C2+5>9-6F0/<">84IWJ,@)
M2?U2'`S+32^PQ6\.8GPG9``_';1J`ELX<U6$[[6*T+?7:C&#"%U.V1J)NJ]!
MP-&:D?F/R92P7N/'KY<]+%HK40(Q"%5KQ[J<)UIX\VE."4MMA<[Q9B7F\)JP
M^$%.]K:[T#`A7&DQ][F8#]2CJZ@)8#RGLBSBBO^>)\@OM-^47^88M9G#%Q\I
MK5<Z2GW=3U9?53?;&?'Q<S#A40W9A@2,#WFV9&%S#NPJNT9CYE595K=:.2S7
MB;:7LI,;^Y/V*&GAJE8#GC\5&!LMLA8(VI\977LM6NB?/OZ9:GB18!K,PRT:
M"9"@#>[36BPNST*JWU(0E2R&O2T<K.4:YA[PV4)D-;Z#.A;W/9_2C%H3S;"[
M#,%$WZ&F&$*>.%V87QL4/;P4;F8Q;2>@:-2HY5GJ2053<4J%Z;9+[J0C:D%-
M5%F)'+=B'QTJMM<@7LA^:^JRA(LII&568=`3I:!0CE`[L-YH@89KUL1*R5+V
MYY'0=_U96`?)KCEMWE18I_1C;QU\WS6?SZ<ZB/!KHWO?W6)N47X74IY.^T36
MU%JT9\F3R3Z%*0*(C2L](1<LOR!`KT0=1MD*ZM%-G0-?#3_G_UFY6![3DEUE
MBF$;AHT^!^-%'*QHIY^=?SA#<B*<"AP0@3U:+0UY`>(>0:DT=QUH+5I2+:A(
M4\I+'*='IZ,P)+]&4N;HON'<%;SO()WLG]JY-5:A$1U<?@D2:=ZR]#D0+)D6
MR$[JLE>UU0WU50@/:&X00S;#!E.1&<"U4G(>!E]GV4A<R"DM=QQ(2,AJ0LD>
M'B3[3LE/>"SU36Y9[D4#"GFX)?<CZA@I7%P7434/*UH?KR\X4'+/^.+U=`"Q
MF.5P3?UMGS+TOM&:&E:&/G0_[;/#6`D:+60\5_>?B.!:5RKW+VX=JRQ",_KZ
MXZ5@%U'*?''M0%H$F<BE;J)RJ#I8:&I#E3B\0\#=AM!42.:M-FO>M=4BFW9L
MHP&SS]'!GNV`S2I2)M'WIPNDAUK!9P86G.ZGFXO28SG%B**BLW@L31J?O4W;
MI7)$AVDN$YN0"1HK"OQ,WH):ACTH,7U-`,4NI.=+EP5[M"S/@E=U<8N2C]93
MHYQ%::*.,'.P7D3*))5E%][Z@X<`^UYABI$U3D$B%CRNR[Q$A_)E/J7NKZ.#
MO?U?R8!1BQSOC_>MO;:'\`K)@1%JVAUW^FL$MM?/3"@4=3-L+4UY2\,G6-]I
M%PO0B288<>L:_WS\GK;X659^'_(?SR0SAQ@-O.E#C;"_.:+\V\)H&@<R+`F)
M1;.2"67L"N(:`3C*J>'8-;)\5^+L=ASBRZ5AQ)^Z.GQ[[@Z-DWP6*2ONK2O#
M"X>1D3J[>H7A7%LA4'I&![^BBKNL+#?+U!8%_R3=J:!^CA0'K$HG&T8,,VWH
M`&TQR^Z3OF10^CW$B?M7TV,+J_<F9'-Z_N&[$KC4C?;.[_FU8Q!H%QE!5I=M
M_0G['"$Q<EAX`MJ`G`C8WDV\TB'4,B-!B8A>7`Y[$5YY6QNW"$#."O(Z:M_2
M8ZL!MYFQJX!B?3]L.+[+DR!=P0^-`K^<@-V[7*U`6]3D3B:><YL[RHH53$C6
MPZ6HL9$.;/*3:B#L,V6+E!+.B3AF0+-D85:EI-<@0513,"ZI,B+C,I:N%I2H
MWA&/_UU$K6J%^A5`6;`I5=/"%[`NM8@8K%-_]-+LMJ(N8J'0>Y;/,Y`@H!M1
MLA9LH69PQ$1C.)XS"P/:"QR^Y@+SP,C]@5VBI`Q1>Z=(G@3O_A"8)FEIL6#+
M.\-U+*2+Z:CU>SW$H>5`S2:/Z]][KDWI8E1:L)K$LAX<\AIQ7"7ZSG+1N&-2
M;E-RE"2KK2RPN`,?X97I-28-^.HZ$4CX0'4C]9Z%5Y(D00O8;3@N_=<I8Q=_
MTXY8(>S0=5B'\$J(K#-),)S.0_D:<ZKNLZZDV4N#7(FCT@0XOC%`3.[R+OQ(
M6L[W;F`;U8`B1I:=&1-`;5M-6@'Y]*BQTE9[.;5"E@SL?<4+ISB30ZO6TKIA
MYIS0(HBQ+<3#&HS:7L*Z!T4*MY,J$@:>N2A^P.:4E@NDIWE(!*=1.ZL2T[!`
M2Z^C_ECM]8U6,*1(1+N.<6[U#+J"9SKVO;**XBTFK_KD5$0/\2ZE_>RCCQQ%
M0GC(,,YZB.$WF19Z:A]"UQ)X`V<PK(2Z",>=?(USA*J0?E9VB"VNAB(HDR2:
MD'Z,1G29*<A\=/BE6HD;&6:U*[W6GGV8D406UEH"GK&%.9\7U)%2RMY*U-?)
MF-1W=FYY<:L)&L]E,;UL4/:5:M*LUKUP+KP2WVRCP\&_1!W&\SK+EV7`W&__
M'JI$EM3]SQK*27M-61@!%J"$@7I#Y0D."+D)UM)VE?=HFER=@U*=%4H./(F7
MO$U^KC@DD[!(O@PED2THKPBCS52V*Y%_?52I4/PX'`Q(4@60"&`*2Y=B6HJ$
M\24>;BR<`->C#<;/IZP:,M);;.$?A;?\[XJM_/&S=DD7N"_RB(026[;PV6&$
MZ2CD'R#ZD$#P:'^?OD0+)OA'>M(EVCT)1>&CNIYEL:&DNX!T1G(&`0J-$-!Z
M3C77:7;O[,SX<<'KLRBK')N/[3N8/I4#<\KSQ$21T8FN.RQU?HLL<TL9K:W5
M1G9[1[W[="5@]M0JA>*#5G0\4%MWO^'X?PM`-B[5E^-C#R!='QSM)RVDZX-T
M_V3\A6T$8LP9>?)G8+6_#+J[C6[S/"C7#WG.EZ-2_U\*.*VI[:$4X(L`I3\'
M)?V9H^:KXP0HQ>;KI6//W-$]D)M.L,P^466#\C7G45%@DT[+ZB^`UDZCEP5S
MN8.K_3DF+!"S3T[3X\/]_EC;H>).BTGZZ^0%&83MB_NNX?8"C\$R.`S88O(L
MK.*7IP6<@;[3,B\6''`;';+[MKG)%U34(]W;*NX0+5RK1#4![)G=B0N^O#B7
MA+%[[T6L[J7O9\%E>5QF0IR$T-S:CD;.Z21[FZ.JP>,4!_J!>L1;*5_,<M@I
MKL+B(+_BGSK\$PG`IJHJ2U/IDCKL<5Q-2%@5/=?(&K4J"N^R3>-D5Q9CWW(O
M8Y^TPRD&DZ&]&!_^V^[%'8E:S%B!%_H.(V&$AH7ZGWU;/K3TNB<C/@B!^2C3
M^<RJ=CC!I;,>SX*2<0'JP!2-H!W]]+1]9]_5?SV[:FA9.CS@N>LS+GH%3N:O
M="L6:`QR#S]W2YNXB/J+-]BG;[IG(1'3;?[^E!,LK@I@0=.;DGM+3BTJGJTE
MX1J+)F!P2RI0QPV2!%_4Q[`M1;.DRJ1J`=2$I=7UYEJ<35<X:,*.R\L?02:@
M?GJ+Q16F:2G@1TX]H^:&"Q)OZ[R:$CZ`F$$!2@3S,JF]AT)06-\];_EORB5(
M8H5>*2G\3AWAY'R@U40GD!+Z0$DPGZ>40U'_XA:IW7%3/<DCYQD]!QOECCL3
M):/3DR-QE#4("SL3=%=R5U#[3;EG4]]@%LY;4JG/LQHVO6S7,8+-=2U-IV^X
M;J!8$3@#K@!L(&Y=FDQQ^_&XP[6K&PSA<*8Y>B(L\4D*V%<;3"\@S!])]*%J
MA-N\]EO<WMNX=7T3V:R4V0#*Y?=E=5>B+6`F_.[UABP8`EMAFMH+Y'KCFRZB
M>JI84.;1,/<+LP[GG&D()!O_$27NF:I8M)7BQ98;4`T)/17,GB6O$37;QI%@
M(1">5W)^H]^MP*ICHPYK)&CY9QQ#M=J7)Z,1J!63(ZI4MMH&O!7?71+RB@V?
M;&@$H>\&E.WE3*\2+`RMO[/9K.;VE.CAEFM(E5M@0^+%ML4Z)0(H9<`:L.E)
MPL?WX(EM@QZX,F&M4(P305ZYQ*MHXGZ_HARIJWQ;L05QC,O/BB@G3+8!JJGX
MA`JYR%TTK<D7R4UN0N'K?,,.FC`[.`G+2+@AE6YJEJ(FI[XE<.IJL[9VER$$
MJ^Z+>,4:P6]IK5Y?"E+7\VQY'TA#H>;Z6P*RKC-RRX?:;@UEZ5F3R`35PURM
M(^^8>!'8T=94((_IJ0=/I73#/[8S>+_#6NC=Q+YD1D^F2[G=)#$3/9[PIL.G
MG%V<(ZB)[$7)037!7QML#:V;]:U64.X</678>&8BCHS:<=\UN3YPG=T!J;"@
MC]'6*.^GU:9!M&4"4?ER)2A[E!*4!BTHE#<$[8UU$U0'^_43W0L,U)"FZ=*G
M=`KTAA=J+9\C[D)#L<RJ947<UU/XRU;T'["@_]CU;!L#/6:U+V[C$$^019\1
M=5S):YV&&;HHDW[13DHY4+.JY`[3[J1TL??4FT5A*-$P'Z!I/LM$0[MP40J%
M]PH.LA#[:$(O.>UO3_3$FG$'F%TU)<X>WFUG#Z?)'R[>1X[JUZ_/*64V2K'`
MK*)VN%U`27K<-9]-4W7C"YE552L#"^&C<FDIF/8FT*:2:!SGQZU"H*2=_X4Y
ME107,&W<X;9S"A,''GR'3%#DN"!YUM4F/K]'X3DK@07L<^`Z5ZL$0191LQ&N
M,0GJ_<>R,+<IX\-97SHR0#CX@[7=RPBUA_H$.,QE3%NK-U-+\"##>;2_^\\L
M1BK.KQ,RRWQ&*H&:697$O*K6)45/S"'D>^5I3B_M=.\ZP69C4+YW"8&E+:@0
M&Y,YG-M/@>,HJKW,RNQ:LAXQ(6@%)BI2"!`F:#H*\"H-N!'F%)DS[@2!/W`5
MO'I;8TWVOHTFWDKOZ0URIK$@;ZR?5,YEX7XVKN:[Q+7%T:"B3=L5KE.XMMZ5
M:FXT`H_@UG(TO]N4+5=J[[WJH*:@"7N4N^T!E&YXK]=<[ZX$TNOFI]O.*`,M
M>9\+.S4Z^Z-T`BZ6CH'K4FHG2-W"@E+8&)OF-G<K[>XQ,.H-A9@TETWCB0WF
MTTAF8W=VEDX-VK:O)P72!UG+*&(/Y,F]:['D_E18!W;?DG3J#G)-(IH^6KRT
M[VV2<]&[6TNR9.DQO#3*QNK<I32Q28*\0,.'Y%KW$?>NJ%0+CSZ\L(Z'S6/F
M-?B0N!&6,5"M]FSX-.;N!O:&$18(_G2#U6AT<JP$`8S\*:/9B9!-R7KA165?
M@:A9*=5?;+7:(0CE.K)G$;8&;0QFOZZ2;HFI.T7(!'!A*0L&QKXZ5>,$$A04
MN"V.U.*]9D]WYNWTS,;W3)B%M"+*R]LE")4HJ0BQJX'@>]2@X;UU+4%^$0IH
M/\_]S7,>BON(.&G(6(ETD:*)XAGHYEQ+Y7+F>D-CWBUIWH$&'`FP$YBJ-!H?
M/&%5Q?Q:"9C:P%-PQV9JHZ7)DV/*$]=D*34'.XGVGP-E\)`.I@L,I;_V=7#&
MW7DR2@_VQP]:H;ZI@JP7_"*9:E]0<4'^!BX\4V7B:E,L9KN88BN^@3*_\P5=
M9NK.LZDX%#N$^,I.VR-H*OFT7'S3K+)I_D]?K:36YBOWJ*;E/+S57-R;XOI&
M9ZF`KJWSWM;X"OI:+P%%`L=FEE,C&RC+C`AGFI`(1&:XBUB83^'Q#Y01]IT8
M:#WYQ)U74;<%1'"C2!H==FK9)5E*-'E+.2JT0Q4Z@F)$-24!LKS,MQ;;48C4
M%K0@I:"@SMB24DE%(PY!\J?17;1@?6L<)+"KOVC2B'?3HRW_RJ/8(L9CD<>5
MC:CK,X.-ZS+DQ?FG%84>>\$<R8TE^]@Z-)JUR@O)^BI*".Y4C:(@&/>)Y523
MT.+<_+9'KF\NV\A#$`LBS,S?4)4I;J$G3K@2+/V0*1\X5&DYJ5<5;;M;UE6V
M$H\V(B>OQ0VUOH:!$&@^&IEN,*YNJZ?(ITN<0B*-8`R8KP*)8%=WWRVA6SVQ
M0#6<C0KC;3';$%HO"==M$*V,B<9>6'DA5B1*"Q#4S.8PGBJZL_2=&D8G(I[!
M?JF6H=^0W\Q>CH';2SJ5;!`F<4F`<IEGAHKMVH4AYE#&0>&H;0IG<'.[9PX7
M="N+V&2S1885G2\V7,`++XT8#')X&$L+%Q<TH-EF(4?3<[:VUL)P[14.82;'
MPM)'`P<0M_KZ!E/W,`'?LEIR7T+`4C?0!H-L<8-2VY(93:*3JV]8=9K?=`5V
M?(ZQ7(Y'9,'JTT/-!]1WI,&5L()`\X2Y^<.95!6S:S/Z=5);)DA)[N7:#K*Z
M]'/&1_7Q-O%L]0_$/\DT]$:-]O:^92Z='J$D=SGF^[&TEU^3JY+RLOFU5=F9
M49SA-8WRMO"N--F4K+26U+97'DVY4HR+3TIYKMV(G0T,6ANRH9JM=!:+!"&&
MJ]SWK!L,SW#;WP&'MH*]DT'`&+==@D;=I6\8E!9`D4&LJ0[:,E5B<N=A1@JD
M_&)8!.JJ)!$=]'Z$?$P/3-FH19LGUL["E/AP@)$K$9_5$@5I"2QP\?$\A=*E
MFU+@?ZU5(V>->D1ZYLFY_L7"P^PPZ45G1":&70J'*(=)A;1NII10M&;IRQCR
M71H64G]R8-.?'6B569W.+,2+M4,LMD=:ATQJ;M(FFJAW`^*Z4FL'P<5:KQ>N
M[0UM,HK_%@\T_"/'#+/0*L<DF,3F(M..208I?,E65K8V<X_%S%@O-8]$;+[3
M:ZC10U^Y4<]PL\!`941?^@XL@MCE)EIG?4V98G;L:-,Z"TGU?8=%U1&-#SKK
M>OOL-:'1'ON#.CT!AS@U!G0M"SZT6+S_`=Q_PF@XGD2\7J\IT#"V*&]X[DT!
M,P4RV;9:@IH;57U_W&B7?=9U'M(?JRO2VDFGI`YD$DB7/XIRM4%]+QSL'S;4
MY%%RA##$!&K``G.3L4"0?+]T:*;8H=@[*\B@L6S<G%E<_#0R._5N_%F>W7Z.
M/L#:@!"<&CW<?)VV1EJK*7AYPH[`\LZITL%Z+C7:7XB/E0`CN+7'E=CK\PZ<
M64_(<^3I9U)88)W3?D<PATY._HZX7>?KU\SZ7A@!O<1)_(DV^IVK-1W0[1EF
M20R4)\EXDHY&I_#A8(Q_G<`_.]C:E'\Y.3;<Q:XU,3Y.QP>GR>A@E(R/DIW1
M`=P&WZ%E?][OQ(*%2$_W3_$UH_UDYP!;K\)7)Z<GH"NNK;R==_!)<CQ*Q\?'
M.)31"'O&8FO4G:-#&AW\=@"CZ_H3_X,N\WXZV:>IX#+OTBI/>)GQEZ/[EWET
M.$Y&AZ/D$-;LF%=Y?#0:7.71*#V9G"1'\)Z=(WP+?'%\,NI=X\/3='R*`QL=
M(Q5@;]Z=T82'!K]-#DX>TFQ4U?A98/[J+Q_46_M8>G_J])[K:?@FXZ9/9%M+
M^V<3:42TQ_O[.)V3=#P9A\L9G,7NL#0H;4I/RWPR2<:'Z<'A:?L^=]E^>K1_
M`+N1'AT>#U$M4J8M7X_C/"]NI1?/H_SM>IN`7WD`BR;I_#Z-?U>A1PH(^='$
M,>^\LB&=P.KJM2D3[?I@*@B+6A/OC^E^ECJ?9&L&7:<D^213RX3AHG\8Y1!0
M++F"+U\KR)>R??\F7!=M,#]C,%31]017P;!Q&`.YNA/-10-B!N;#Z:X4]0_Q
M4#$B'T[L[;(GZ0KKZGQM[+UBYEE!?:<_EE?\@4GT4:WSF$'!03@XL/\/K?!H
M?`I7X[]NG9-1>@J,;E?^ST/PBPX'-=T_'+FW@-PX/>QAY[_8=,;I\?&)_7^`
MM&#`^\<C&CC^OV_@_$MXWB0]`3GV1MK28[8LIT4SOI@T_?$5<`\=]I<=PL^T
MTV`<+QIJW&Z-?+&BSO%I-N6/?4$@!U>;1>92!2A)>['E5"'M0]?)8\@64ZJO
M$EG)NKA[D3Q>ULO`X#$LJBF0+?FZU^5U%\(0+HDA='Z.^<47<D)#&-'6!/_G
M?_?%!DIN0O$+A`;H25_,.DS@\F/$XYO/_`P0,)/XUG55S?S59#=6]??L'J0L
M83;U^&=,RV=TT'8+6]S1-#*7K7R(NK#N%IA;0Y\P#(/1I9>O7KZCR!+;S53,
MSJI[3,O2CK41\FQW7.4M=F$%'"K9RLWPD;%G!BS5HIJ%Y&9.Z2)4!PJ+%MR2
MCTU-Z1,JM>A`4&6%S=P4UP&['+KZ]BOOU-)P3`@C4_QK463:@X:8SJK=[D>S
M//>2CWQ1YY=8?'!*&Z>CHIF"Z5F((6\B^Z&K:!6"3&=#7<&`C)@TJ;W9#+V_
MEL5'>_W\C+;:-PZ+`/:#-7^=E6'DS&/ZH!:ZHU;B=C&%:")],8*>,Q)+W4=H
MJ]\X;?7/\1E2471TG+S4H_<[.GJ[R<'HB,![/>GRY4>@EG8YS3HKN2'U&;KO
M0(W")Z[SW=>87_(8Q?*"6U709%YK2P)_\+#WA7:TP)FL9=LK=IL4C+6/1!S:
MM\B$<^OR1RG8G"<G3XJZ`[(:QJ>1J%%.!GO@'"'=YN'0HC,TG-6L"4X="V(R
M(,LG2FUFN`)JN2(IXIW@KEJ++_05#UB_SCW]>2)4A2\%!"HNT7?:A8@.(/-`
M"3,&BJZTJGR0EZ6=IKCF`36?A7`Y;KQ&!$\P'EB1@FY-XO(NVM3IW>D$M"7!
M[[*>P(J/9@#:&[E%K"5B<K$*HU.A]!5^BZ\KEBUG,XOH)D(T,FGBAK9I=2QD
MJE@'(41!`H=J8LE82CJI(&8L7,\YK)[BN@0)<:%:)W$T/<U2&M6(RU\2>4N_
M:$C\ZJ"E4+`$.S$PROEE[#0-O6]<3*%!%DMX%N)AWH:%)='C4D"Y&6RHI+G*
M"2.<RJ'8A:%N:\Y'IJQO>I:[5Y/P6MTMPQE3HUYOI;6.[16.-&WSM:XQK=PL
MT>@'X0[!)>RVQ`B$;F$C`G^9?5=I3-3&R-1?-_K`Z*U+T[X-AHZ2WG6Q;(9M
MP++O$9M8/#R,_2^'V7@,)_N04=?CM):.2;WY>E'CWKF10Q2CN2>,A-EO!=54
M<@[V!BC*.A.%,8=^"IV5HM`\3=%G@Q;SD+F*L,K9<B5Z;7!)=U9!<@^_27[^
MZ7]A,^3&X-[/%T49]T=_5X/HECQJSB`^?_^NX>K%KMJPJBDJ1(\@\JL^%5,N
M;&S6FYDF]-LUA-[=?-L="#MA"DG+;XIUWMMZXO,/LA['KN-N/=C&(M8]@)^"
M/7-GH00X[51")U544ZZ_H:]4)E+U#(T">P/F5*N`R11YFSJNN%QRW81M<=I;
M:U[*!B+B=F3BVG80BYACTS]Y,C%F5Q35Z@:^Q(C=RANB/D6&72ZPX1JP#VT]
M.9&Z;Z1MLX69EX1?[&SY!C`>M[XCF\K\&OB+9+3>HJ`3AUCHT6Z?>6`:B<1=
MWF"`U=IC:7KU18S@V0Q(20X8X)RDMS9K(`)>XUIZYF5=26]<#.+!8$T)X]@5
MR4R%SH^6S!6@:;90O7&Q":*=5LFDD8%E>*KH19$L!;@6VE`4WHY@,-G!!!/H
M18%Q^*G4K(KY%O'V6)BZQN6.Q5.@I^\=L(%%[IR+.I<>2X?YG'+,>B-PDI*^
M\7C$CBAF;B&ZKHSP^:YP3U'W9[W"5R[O-<1_>W(,*=SW(?OT&$4^W"5*J&I.
M6PU)%P&MJWWD7)T(IW72L];XK`#61#E$;*3/M!H,+N$,`@G,.VVM%3D/8"H%
MUJ7EE*2@R+Z#M23P>.9\N/(#[Y$H_3+/&L(?"S'ZO&0`9WQ,;=6RB^S.A05;
M5KH!,@7MQ@^X?0=FTH(2W5.WY;,)>&_^U6XAL#48K@C>_8YT^YZD!7\1&P#=
M_!E.DH%O"^GLO'E$?DXGO8<C7@T5I"^H5S3E037HZ:1,#G@3L"OF=4T+-(6K
M8_<P<+>1GELAK$VG/GO(A"*O'A6H#V6"],&B?BX3Y`L0DEKK297F$R[0B:8H
MZ<@/F23BC+N;M?#B$4^P]_,ZS1XUJ8.]GF`6YY&_9]?6(XM(^HF\YYD=PY#<
M:$THMFQ'O`1C47%>!]Q_#@[?XE#*4&*?,;$"VU'J#D_=R*^$^.'Y)9H7.G9R
MYWWF:GZHJWT+[J8IV#^H0`I;6W]#O0C0)-QDM)<YZO@B0+,RPO4GP`,L(L<F
M`@@6`?R)#;-J*F:<MXU\_4U)*7/?2B]O5A<7B[QFX&B"6!1'X=5FFQ.N'.>G
M4&F[M+>$2;).NU/</J4]`5ZI@HC7!0Q;N`RS48A?[_E8INP<<[?W?N>>NYT[
M<SM'/[ZWS=,M()*PML&YCS0&Z'1&*PU_<\;N`+F0F=#*3LR,"(.XP.VE\GYS
M%#2A1E%5J=ABMDI3J3^F>DVO)_F,@[KS@.!BZ2A8[L;@BX][*08@KY>YMPSX
M>EY"DL=!XS;AZ4P0;9[HWLX:@&@*O+:V<N8,,K-35-(8`R.47\86=?\4;'D-
M]4';R-#9%(!4$=O4G+G6GNQ!1VYU>V@!7H;Q6A$-C[M%&?!8C[#'.I3#IFAK
M8)U^7$V[QE^ZNW<`CWE=*&S@NCOF)%VCSH;D'<V]/W:(K\9E0L&I-LU*CE/@
M\=65$!M'"_THU?\AIYZZ"ON#+)VKR*O&BI>R+QA\R(W'+(Y\(8@`;';PA%(S
M@021PM!",8==M$>,R_3'^V&2K"<H9F6AQ&":#$(7B*P5=5E\@L;^2%P5SOVC
M3W7S(4&`Y_;GG_Y&&+6[V0(G108#-H85+LM8P[F4FL9])7FM!A@PU>"(=!'@
M(BS)H4;WPU.)#YC!MS;<\DP$@'K#W%3:&8V?O2$IFOZ4VB`!0\HBW,\9>BP$
MV2>^:\FWH3C)R\1@?Z7:32>XU?V%\5C16_7AX@7'J$B$X;U7J$8:L??>].S%
MY45HD8)_A6I`=`IU'G&G6:KQLPSH7."\_:+=D:S!B!_VL@/=M=,EA/.*'4%9
M3C%7"$_)D(H<`X*E)$<$YHZD1..?2[Z+^*E;U%<-4$%\69?\>JBN:%H"U:C/
M(M->86&90J]%U_U"4D[TR/0>$@7\AM?E&F$5<>5F@/&I,EML?U1R]&J5]\+[
M>T*!#^5$<#CEN\WLFMD3JWLM\A>(RS@L0:R(KK&YIBB'&+*_-OF@W$P2]U-N
M6F\]0GHD/Q$`=>+LIDWG,3BT!``=C*^BT,6]GZ@Y.2Z3S_HA7^_E:SL]E`,Y
M1[Q)=E5;'TW&:DJYQR:5Z+QJZBQ?I`P@G29_!%[/S8:Y/5O*JT.JF`]TY0J.
M)I%>C'%+_)?)<:`#/?J4J@VCDG/7F-!,Q_!O,@&[Q[HVAD)=@4[)>F#:TXZ&
M-SOJ2E`830D6RSH:DQ8.Y)JV[PF+V5T,;R7,+$[48";E<@$4708K5AA%ZAR4
MJ%G!/?&2%QML!PE_?"PU+O_B(V=@4-H%S5WAI`8:XV'9C:R&QZR>3-+C@WW)
M3P3*($:'OL4GQX3:<A<#3K/#I7TP7WSL&0BGI(ACTE1*SL_@C'\*()[%$$?C
M47I\?*P+WQXQCB;B4.1^C/'$6DJK4_=%'53(.@$+[`R!5^0Q(U`<+NV0W4K+
MR2)VZ2QX$G$ZCF"-A-NUOQ0]PTR&SHA'Z7@\,9@;LVX,B#S6X$DE5G]8B.>*
M%L=D7HJ?O(=&*1^?*ZV3-]T.3UUK*Y@C.C(B&O;YWF!>CE*CJ`BY:QU%X:\=
ML6W#"2X<SAV#L@HH@05$XR?'=]^%ZKJ6BJOI409WV+%7U%*6(9F%&7,>Y"&]
MC=_M/%H%8P,<OYEOA2::`/Q6.V]*Y%[P3C,[6'*7Q^F/#*X!E'[??)[;,ST9
MC:U'G8.RZ^G@U0J0M);<D4[83<^M>U@&;K1H2"^?GPEXP"H'1HAX#H;X@BXK
MV@&Y]L4;N1:'S$$AO5`/?8N%.E5QJQF=Q'*S^Q[$5[22W,PR(:6!W1.LEBO/
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M8*[M?I#JD3[>R@$RRF`(:Q8G'LM&J(2F#IJ]SEWVLO6Y=U-91W0BK-`.F%D;
MK6D>W`)\((-?('V$=^;>L:-;*4X9T<H(3'E`7&)&,^*;ZQRD*<%G4"TUPCCH
M%E]EVFJK<Y1:2`$YMC)64D))-[!?F"R')Q/>F#)H.N(\W(`&/D4-N$+\$'SX
M3=50=BF/9)ZCT;A(.8.G958@&C0>XRG5"/K\EKWDS\I(XI`]#1TTX&#TJ&+I
M4U[I"HVV^ZKH%9JQU'>T[R"Y,O)V[1E%UU:,YB`[%SN<A0]&7;!#R)_P&C"_
MF$_Y3)EKXR%#<(DV)(IE_V@[:-W>$"LM@!KY4^WC,'T0*<0(^%U*-2!*0XO+
M&GN:AI^(H'6["1O4Y3P\U?H>-^RN\+&?Z.37/EJ@ZRN,';O!FW,W=DOHJB$*
MA4^Q$>N/>09+^@CR#31JS.V=,C@$_$+GG/,65)@R)B&#<K=\SYI4PGX-;H]&
MSE<)GK7,-:E.;9#K93P`3+W$;%T%&[;VX<X##M8]B%ILB1*\QU$+'EH++8Y0
M#NR9("EL01+HNJ+/"G/.+&&8!S'C\6F+M:B):'#OH+(7L"'C2MU^7J`-_KAG
MH^5@!(.(4DWLA&!Z!G)WJPVL3*K$R$1^')*6$IR+:-@L"NF)J1@LJD_0/-7,
MBY#94?9N$.X]WD'#>9/,RR;7TQ+HN`_U4_04=N`BF#N[A,I>D46"*':<P>I?
M%Y@&A0V8Q><J?5HCGW04A`)BN*YJ`1B9N:;BY+IG3/#8R^LQ2-KS2C4T*LA5
M$A9P81IXASK:#/;:BXP`S2>.!JRHG88>LS@">YS&_LB9)^A`Z&?K;';[!&%@
MZ<H&=.XDW.7G^63,"`//],7W@=T&/@@/DD-%_#QR(E.>D\1JUMAUERTQ'^!7
M;&].]0D3M#H5M@*J4C.X-DUV[447$EV80P^'9[QR`7./342&]6J,9T4U6)VV
M0TUN#Y*0!#<_,)Z2D>/6K_MTD15+CAX.,(9H?7V&SYI2$C4I27,`LBE0!>.Q
M*@B!`N>1G!AX"670W,6"SQ(/%5!`'Y0O"J[G,)YCX3I>"]%0"%R!@U,&[R=L
M/X9ETK+5.>4?!`KU.IB/4UE>)Z-@A5#\#Y@(JE^(!&JWH79R39(GOF./D)>$
MS&Y3?[$:M4$8IE[F!=*GE"VV4>#XK1#P7`1\X,N^(H"\%:%26%=[YPH(56%P
MHU,CJHB]$%9-\TASA9YX&@T.,U8,%7J6+VGBU"M3TJ?\W'L"OCHVE3>KS=7"
MU8])YXLH];*)CZ#5XRD1.\4(!UKFB[8XD5A%-/9(6S%-X=].J&U6W+@B3E`6
MR+<-=]%L?#ZI>6'1',0G!.SE"+:9`;R"+G1I*98-JR3]IT`:FZJMJ+:]9YA<
M1EH5XEGD-D91JW6ANZ%W,(,)6:R>$+P,"CXR8X_MAFA5'?^FT&97N28C@OJ=
M%\2037QR8%%41O59R^HJ(9K3[WFD;[,I\*I$=&%*0(A_EAHCNJ@(%P5SQED.
MH83T34CK<+&FGW_ZVZLW7"+XDA+@+R0E9KA:*E[*(:/02R"+!(%\?(6^OMP)
M`W00UC@)D7>L%VH-CS]_TB%8'N"JF'-LRXVM@0B/RD"RS/<4'P;\#NC#H`Q8
MY$6"I'T2.`$9G5\AP]>+1HHT<*]:2J4U]B.)4*34P8%6+W&TPK4I*IN06*%2
M5GT"[]F@CR9B>'A\4*EKJM(57NW`$S+23^P&;E-!?O'0NT)NDO@OW85HD=D<
M;6GSWE@ME^'8D\+:2P;80..6&D/AO".O:XGPDL34*=M$C8Z(H;+IB>ZQ73'0
MI7FZ/)"T:)CRLJ)]B*@DKFG+NY@.FL88M0W%-SZJJ^<W\#*\\0U?_Q;OE<^A
M)C5\BCP\*?ET$)#AZ/14*T_3\>2(/K]OX0:/QD?)88+1M2,$>3@<]:3P?2;Y
M4B?]S>-@$0[2PY-1,DY/)\<PBO3XY`2&/!E/AA$J)H1$0?\:[,,.!9J?)N/3
M(_KO!!Z#_T4@%H<3N&6,8#K87)+!(!Z=8VI[>YB.CL;)!)9TDDQ@E0\FN+ZC
M@#(AUSU)1OOI*2'(X,6(,7$P28\.$9KGA)[1`UC=[ZZ6DM1?("/W_A=$C(#X
M\`-"`@Y74=SV<4'O7NR&'RC;#PTD^OS8W3>W`D[^@CX5S8!:,4>@TSQJ3T,&
M(:"%)[B;LT+^&O6Q40D&"7'.MZ5[0D?[@51EBY-VDRI#@?],NEU8+EXG?!HM
M=3?1)DJNT4Q3<WKY%!Q74_G@?8K@>AGH/76%KK1#WK(`QL3%/_A@T8N;5J&S
MWJ4U4JD+%::=DL).12C*"RQ72T/-G@0G2.,5!1P-,>P(:`E1SB,JE4V:4M(J
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M$WMGY2??-RU44>3=$;2:#XDKZ"VLT&Y[B5*K,&X3>#;-9CE"QR#!8:"S`P$3
M.V?)B%1^$T&G\^T>^R&^4T>`\<[N6^?D%IP%)%L2S<+BNA03HBVR+`&8@XQ-
M5.W##AMUX`'#BB4W/38U=,U;HVCZC>:>>5LAX%5.KEV%$V$`%C6%+%P1TPG?
M$RAJ$/F8<GJ*J&(RM+>EW!,P?3F5"KC>%);(+8S:K`YAP:SN3C-C[*HG\!HX
M#GB$9*N\6YE%8F9Y<H'^HD>4BU+S\MUGG<<31DOCWMV7&WG-W?RTG(_:#>.(
M.&(O533:-84OH<Q?OB#MP?AN[^_CTD*\,S<JOU40WPADMV_,1>.BV2$C_=D"
MS//=R^E-13'8E?F`*><(F_'VO>"^R4=.5WP%K24G)F#U9)0Y+X%EZ\.XQSWG
M96>F?ML8J:.=ZJ'ZGJ2&UQFF->XB#K>@BCO&R4[NMGRWG#4</1><BTP%.9/S
M"8?S3&GGK;(E&:9?;N8RS.'+*IZ!CC6>!.=X@G1S#\8:"5_1UE-!+=6?8J&(
MY2*,ZJ4U#V25Z$'%U8]YH%VM4XH-^X?:\Y1:B/F8TB"-/AZG&M*DRB+).I;G
M/\I=P(^?I"=@4]+CP<P\.>A[/#-+]4_!!B$X1*#0SS7]4=63K3).,NF@>-W[
MT"!'G+%C_-ZW1A.Q)QY.J?GI*_E])G`NEPCG8L(LV*<L$#*#$_8]'.Q4W;KD
MR-Z!NU)T:W,:P]QSPM">`A=;N,#$:FAUR8/SL^V,B"EFM$\408Y#!31Z%.6E
M0A#CT\Z#'D5BW;)XVI@IIDG.KGTN_$-:LPW=^ZH?F\4H"@P9WV.T9Y_N+8H8
M?&]??RO*I\#+M-1/$MI:%-]*[(CPW\DWA<2XI:I<*</R&*(S5$`U!#\T.O.O
M<KR0(9EY;'VZR[><BP87875#5G^/"2#:Y<=G?_RRHAMX`U>M*^;[P&N_C,-Q
M%2</,^,*>*Q3.#YECI=1<3Y_-1G'G&\/F\;>MPAQG6KFC,9MK"&PTKA!!3!&
MLK\?I'ZQY?2GF7%XP6EQ21.,-R_8]2V,_L66NP/J7VDP4'!HCVP7X+NNMK0`
M?W1"BQGAP5,TL:39D"WV*#TZG/C:!8($C5,4YK*5/:(B_X2:/^?29>(^IA/Q
M=71T;`"L>O1#X_JN<RLJD@OMY@8PG^ZA4J?8P4HCRD74<&%]SWE]/#Q-::PF
M#!GY/TXC]]"KH<*[S5)?:*DZ!MK(X'@,X@SB59+Z;7<3A"4=,^SB159$T'?-
MNW.7HQ:*1"(-L<H-38TL759VJ:-XI%<Z:E$[_GFQV.!CNB\,[2@I,@J:[I3B
M&ZTKI<;1/%ER/."1R`JQEVG._:]D6.ZQ,D*R33>E4F1;V=4\TC"E-MH,R*AH
MKZ+`\'*UJ+8@MEN-U3$U@)$\,#-C=X;+H%TM/.(RJ1&R1@&4()K]%RBE)E?4
M^\X=N?%W^M16(,W`K]:<8!.O2"KYA)B9Q^%I*X+]16;W.('QCYI<^VA]9.[V
M(J0&//Q8MN^EA>,FX;9P`RV&M>FNECBX3MM1G:M%KRN"&+PGC8,%&P,JK2U)
MB9QEH.\&MMC?N_M,LRJX"?.4%B_.I:@:]_H>&"9RD(2)OV&F_1X;L#W$2^*$
M[;EE9CF$$M+NXACOHHCR'T0:#.:)^3:$%GK8BJ0)4)@^H-SHH6WEVPQEHK&Z
M)Z&F:]3X-'_\=/]7)$6!"6I>4:>[PDPSXN/G`$7-*BPL*-=2O]$3R?`<O-/@
MH95=@*NH*AJ6+FF6HB4O#$VO<7FI0B-ESDB0B`K*!T]=*5HI;!1A"_O[Z@[S
M9WJ`Y;3-S[W#(!>+I@ZP<\7A;:O?]_*U;PJ&8_=%`.W4_TZB/KTD%!7P:YQB
MY`H-/U-3W47"9I+5K&R?Q"W>>DJ9\;#_UG>Q03-B*;`32:>U@)+63K&7[U'(
M+UL6MT7-14_/SO_EX&"RWQLZU%@&ZC4"F\2R$FWAW=5BT^Q2J<LN)N&TRKNL
MO(K>8L51;36_Y_#"`@[<[-LQY,-'H*<Y"NKBZU#!XB<>TCBC;I.=963RZ\8;
M"*+$,:HXZZ?E-O_"_`6%=]`B%\Z(5\(C=`&%"7-K9SO=6A'>)\(N\+@I,N"P
MVK1*]K3V>GT=!V+N._E13S6.M3^^%2"U`W_)@*"#%I!8%4-8.B&:$4'S(%F<
MG7\X^S:Y\5RH][#I$YJ\BP5T7>7.SX:B)6-1HIXBBRI*QP-MZIKV`;%R&;+`
MA'/77DG0-D14W;,(;X^&OI!J$E0\[-+01-;HF9^K'!"UJ!HW#XN?V>Z,(!7<
M7*/*FM[5[/(XPMZ])[$BBH@'=GY=5YN5U,2;D2_P[(1V2@%RG9'AMJ.*OBFU
M1[,\6_3!`/)!X20F7G>*A^G79<D9K!BREGOFMB>*"BW5!YK#!<WA32?3X+E/
M>HO5IWY.B1Y.;`G&4B-&328#B[V>G=3@:^Q\G0MFE[4B49T@3H'P8GHXI"]C
M(CLSTW'Y'5L''/T[V.V;BMVS0U5EC:]>POCO(MN:R\ZCD%"UM+N_8H*PC"':
M6TH6;`8U$F,0#D4$`>0VW-`\JNQSRW&_PON>.BZ?<X]Q_N/A=H2[C5E?,'\U
M%S_N1QEW3==6C"S`S4#"LB_%:HXMB6E;5Z<NR>LHS=KW4'V(2S^DIW)SO)[^
M[Z1D#W1\U\V."E/W]$6<?XT/E)1.U]J];#8UYQ(PP7$ISX:0@'@D`Q%F:2/M
MVXIA`5?.O7.Y8L<Z5U?S3D][[S"><=Z(!?1QT]H]M;4@![CG/%]S@?FB@)V>
M$2QKW,0[#SVM!==8J!I3<N=L0L9-Q(>J?[(XN:[3^MNU2_=-TK,(J\2ZI&L+
MP#TQR\BV\>9%9'Q@'=6F(9S:J^I6D*2]K=7FN!W+I:>YWLS+]E99;NK<MVNM
M^"XK-I0QD,LGC7JU=YUL=Z06BK_^HJ[*"CN82$S^<1T$R_7PLU"E.0/YO'`P
M42_/+I^ICPH!)MY6W(QQ=W^2)I?`QS"PH&ZY"]9&[?@^QTZ6KS0(HY%1$#E;
MAZ_=?@/^LKM_FOS\T_\;0WF>Q\J]&>.=]<)`#/9P\Z:[GS0N%%+_S@?:T*=]
M#P"3GG[L-'OI8A]?AE:=?Z6;'IU>>W^W6.TOPQU*^=_0E?3_[_CZ;[E44=?6
MGW_Z'_].?5OQ3;]$Y]9!ZB7HS<L6]=)Q?1.D@VMX^Z6$_9^I;^NE]+AE*)W[
MF['^@HS@%VF`R:3[\(Z>>#W^_S+_H:@W3?+QCZW6GG3!?XSFGCRWQ[3WY,$_
MKL'G?=3@VCZ>2][)O_[`=%O'R42[S>/PA_[V<7Q+7P.YF)H]BOHO1,J_7"62
M3$)JD?"O_UC52./'5B,1_<G_/UN1U'<$#_E>*4W"C_]QBY-(':/:JZ%\TR$]
MS)/H<"[L&?LXME],J&><E?E.XE5_UMBT&I-=MC5.)S#14Q`H..VCO?$(L_B'
M$SXIP1-^V1D=HBJ#^T54?-\]4WPW,<61W7#9D[8:GIU.1JA=\?]'HSTX.WTW
MA$@U:1FC=+2/VM_!'IRNONO#0$"'VX'_GB:G>S!QL[6[(NMT=`RK<WQ*K']O
M=#_S]#NK+D7:DE2&(QN3DBHB&<HNOOBOY[0O-"+_NI@3*MU?2&,XW#ND_^SG
M/U5H6)/G#1CJKQ(X!;\*OSXO"+5KEORER!>S9']O'W[E?]&!LOL2V:'EA;Y'
MC7$$3_\5_'N4_.K+C9CG.=C3BX868),MGL(]'R^?)SM/GFK&08&.NVK3P.'O
MV#-O,(L,;3E<CNX@;N''(_IQTO[Q#YMRS[:\_[&G]./HX2F`;XB0NGZHD-YR
MMJCS;+:%^7,-T=GU-?9NA,4*VFK[=M!UX4R7L%62AJ26I+TP^>^8O@<G'=VO
M#&?6T.@(FMA<68,#?(Z.:&*Z*0<+@$;#=_==_3O*B+KOZC]<O(^2%U^_/A\<
M1R_"H]Q+^#*&"MFZ$HRGSJ*WC)3G8J0,O]NX&?D*+5[R(C@-33_JW"R##'KU
M0X@!?2KBH_S7C*I+O)^*Y68Y^,PWZHZZL/SXWX/,2/Z9<%.VDF%`DPC65?LA
M$[9+NA8:N[Q^D7>,3OI?TO/P2^Q+!CRD7I(VRU91YWGC!PX:-^;"O'OA@=T1
MLE4W.ME/9MFV.U!T/-ZS$Z^K\IJ;J85WV"@0!)5N[U#0Y6M_\KO\![X4[SI_
M`7^?=S&JWQC@[)D"S@Z-\P)U^'PF"K9BK%.SE?>"M?1+##)REUUF+>-$$L["
MB4_^K$'`<,T'A8A^U9">1;&E8;8G&>KRXM1",YV=_++I&.3OI:!%VPSQY$>8
MYGW[0=[16G!N_[_FKFZGK1P(OTHNNBI(69I0`O2FTJ$D55>E1`E4JO:J+4<H
MTC8@0M1%ZNOT1?ID]<SX9X['X_-#(GJ%1([_QO9X_,TW8S]J<_1BHLMSX.[[
MXSMLA7<L<[6JA-H.1ZYLIXF=S6.UCE!@\4)T-!?IY^&-4\X6/R_N?O4>[F&Z
M9I6>HZE/AA)__<K8-@-AM[C3CZ\^9>_/HG?,:-G6O7#G'M)S%VV:M[Y9V4!<
MA\</A7:*XBJB6!T9Z,-\6O:T$/9K`,W.,6^8V+YQN)#HE%$GCOO',;CQ_S:V
MPU[%O]VN`YZ>(NO2JWFJ^<@PO*I;X_F*SPTXNR\>;DMO3G(S\EG6@KR<<Q"U
M<.`I@HD<&E<670!O83:TM]6=../?">*]#&\7@CTENBB^>H_O&@HNM$>*=5LR
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M!_Y9K3D)AZF":@H&W=+Q[_QH8+9F+%9P4%PD#-:@'^N[8W[Y"`;I:/"7,23-
M>@64T\PX!-=/,#7S1QJLKC&47K.W6,&.S`"Z^`?;P0QY]DDK_8XQ2MXQ-MX1
MND/$S2A@1XO)$`:F"^>RNSOCU?APX]9>83-F5$8*MC)"E@\0RJ)B>(T;%.TE
MFAM7`]?8C1K(!+,2J%U7%,0W6:R`X@DK;,LRT#N%R_OB^\T3=P"\H$_;A<G-
M^HEG89*`M3NI5*?#+@&"FX>WHMY4GMZ8NZ=!>:;"L_`$&`=NUM?KU3V>0^JN
M/1JEE-`''['*:B[HS2JQ#]MHK(S"@CLLS45.:>XG^_MGR-O[4M'QIDE\.$CJ
M_3]@"%LXBKQ[\RVE5#)6E\.T"+?XH1@P&7'HVYT=7BV$MS_J:#,<I,_01_3'
MJ*._?5CT*<:Y0*3%%B=H@JD)JK9"KT#L`Z>L=VJ,NK1C8X/CKG.%;'(ECHDB
M0`]&>3Z$\_+024_X:4@;#:XC8;YM?/;K7'/#0;K)AB;Z=K>SD&18/ARG_='3
M+RV1Z*8N;'C;HPJGG=4T]B$\..(U_;259CV!%:!3DE]&/[(\[G-()8L^,"^T
M-Q2HCZ+L:_Z7H7::LKIY1;:G_=Y)>;U8PC:)RQYWK7&,4=1;$+/;54+<X&?P
M2RXWSX^R;1HUKWDZ2$3O*'[@E(!IM^&\X#*[1C]?67=8RKW*$+&"/`P3*[,B
MA!L&#*H!X%(!1.J0$&LMAMVRLW`)*00$YVZRYRQ0/_.Y4&)CEXMGBCD+H2AE
MIV*Y.':S2JT9=T[O4D,>7::&++&N>[&6<LBS]5KVHUIP`SWI+,AJP98]R;`,
M,]VH*=6R#WY#B[7/>8AP(%4,&KL)W]H%84X>IX=6-L[6&:\A^4^D++R&$'9`
MDK*HV%^]X?%^DEZ38#:*P^IEZK`Z/DK]5Z%"QI\E[W8*15*<QGLC67:X=YBX
MG\.DP?L-$K>WB5NT-PU"G%F&6QDWAVS(X6&:#<EUM^!13LHO>[W]@S15\NSS
M@P>I!YEJ!Z]$AR#!!Y4<'"5[:TL>RC;O?)MB*)XZF;+WJZ(.I!A?2'&IITN%
M,._.%=A7-?/%NSVWW(SJ954@1I'7KC=U/S%6Y`0Y,H^I59-6($"YHL(=4ISH
MP_:E?8T2ETK?S6;ELOR.@VM0R0D9[A%_5SA#`R'%?QN$**REL-"X!)UAI/IS
MYM,9IB:I[P]F_J>E--/]=PE.6)K`6"R7<.5F/,(V7Z;O.>XA$Z,WP8RS4P%+
M[**:GT6=FL,TAS-GH.-^I-CH,YYWWC3CNJPV-^4OKK0N[0C'*35&F5S9HT=G
M9DX\@TP<"DG]Z;CORG&1<F\V<6=FG9A-OOEG^JFW\^NG/+\R+'-C'%52&C,2
M1%LF/]+==X!^M0LL0<?,]_4$&CRCW:\:D?,E>2"N_(*EW6(=Z1O50+PP.9-T
M,2U\5@=&/I^QO*'3!'6M@T3E60+"0%OPJ\\!-2^7"S`U@7EF6L<*Y)1#X+T7
M3;]J5/4IC<55QH<P/$@9:35#2FZ7+J$*14VH0A\B'>,*^>PJQ$XG`XH!$M+N
MN,;--S;#VJ=2'R\/^C`K$_W//B`E9>IN:LM5].1.Q3S9I4KZEG6(U&D/3\@)
ML^M=["OJ"8`UE(37]/+7SX;#:1/=$D%DG^_N,/.$W9T+#/`I*7N@3N!$Y3YR
MZ`PDZ"WO5L\Q'.3^(1M-A?0@LRS_2_';O:KP\4A(#*8D&^8PDM)T('I]B1>K
MU?WKWU!+`0(4`Q0````(`#&%9D?6X#P>EP$``+H1```3``````````````"`
M`0````!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!`A0#%`````@`,85F1TAU!>[%
M````*P(```L``````````````(`!R`$``%]R96QS+RYR96QS4$L!`A0#%```
M``@`,85F1WL7M"54`0``6!```!H``````````````(`!M@(``'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L!`A0#%`````@`,85F1R^GUZ^0`@``:P@`
M`!```````````````(`!0@0``&1O8U!R;W!S+V%P<"YX;6Q02P$"%`,4````
M"``QA69'PBY5/SX!``!I`P``$0``````````````@`$`!P``9&]C4')O<',O
M8V]R92YX;6Q02P$"%`,4````"``QA69'F5R<(Q`&``"<)P``$P``````````
M````@`%M"```>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`#&%9D<<
M!$QC7@(``-(*```-``````````````"``:X.``!X;"]S='EL97,N>&UL4$L!
M`A0#%`````@`,85F1TQ/?Q%``P``L@D```\``````````````(`!-Q$``'AL
M+W=O<FMB;V]K+GAM;%!+`0(4`Q0````(`#&%9D<JD<=S:@(``.((```8````
M``````````"``:04``!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"%`,4
M````"``QA69'I"-BS$H$``!W%@``&```````````````@`%$%P``>&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L!`A0#%`````@`,85F1R`VDHT;`@``2@<`
M`!@``````````````(`!Q!L``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+
M`0(4`Q0````(`#&%9D<G-'&V700``,H4```8``````````````"``14>``!X
M;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"%`,4````"``QA69'+M8PNA,$
M```[$P``&```````````````@`&H(@``>&PO=V]R:W-H965T<R]S:&5E=#4N
M>&UL4$L!`A0#%`````@`,85F1]W3;7"@`0``L0,``!@``````````````(`!
M\28``'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(4`Q0````(`#&%9D><
MO;P-H0$``+$#```8``````````````"``<<H``!X;"]W;W)K<VAE971S+W-H
M965T-RYX;6Q02P$"%`,4````"``QA69':!]<TJ,!``"Q`P``&```````````
M````@`&>*@``>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!`A0#%`````@`
M,85F1_[H"W^B`0``L0,``!@``````````````(`!=RP``'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+`0(4`Q0````(`#&%9D=B_.X2H@$``+$#```9````
M``````````"``4\N``!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`A0#
M%`````@`,85F1_',P$>R`@``*PP``!D``````````````(`!*#```'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"%`,4````"``QA69'RF'59]<!``!%
M!0``&0``````````````@`$1,P``>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+`0(4`Q0````(`#&%9D>VT]C0K`$``!8$```9``````````````"``1\U
M``!X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!`A0#%`````@`,85F1[M8
M(A1R!```4Q@``!D``````````````(`!`C<``'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6Q02P$"%`,4````"``QA69';']`/#D#``"H#@``&0``````````
M````@`&K.P``>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+`0(4`Q0````(
M`#&%9D=P1?YLW0$``!D%```9``````````````"``1L_``!X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L!`A0#%`````@`,85F1R!P^1G.`@``:PT``!D`
M`````````````(`!+T$``'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M%`,4````"``QA69'8][H][P!``"&!```&0``````````````@`$T1```>&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(4`Q0````(`#&%9D?4S1B7&`,`
M`!\-```9``````````````"``2=&``!X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L!`A0#%`````@`,85F1XU`@"-8!```HA8``!D``````````````(`!
M=DD``'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"%`,4````"``QA69'
M?:+[J9("``"2"0``&0``````````````@`$%3@``>&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+`0(4`Q0````(`#&%9D>=6IG!Z0$``)L%```9````````
M``````"``<Y0``!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`A0#%```
M``@`,85F1^(I9@JU`P``6!(``!D``````````````(`![E(``'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"%`,4````"``QA69'J'Z"VDL#``"5#P``
M&0``````````````@`':5@``>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M`0(4`Q0````(`#&%9D=BIY;4G0$``-4#```9``````````````"``5Q:``!X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!`A0#%`````@`,85F1R`0ET.Y
M?```[](!`!0``````````````(`!,%P``'AL+W-H87)E9%-T<FEN9W,N>&UL
64$L%!@`````B`"(`(`D``!O9````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546960993840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 03, 2015</div></th>
<th class="th"><div>Nov. 06, 2013</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RemainingAggregateOfferingPrice', window );">Remaining Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RemainingAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RemainingAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546955657424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 4 &#x2014; Royalty Monetization</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Overview</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Non-Recourse Notes Payable</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On September&nbsp;1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the Consolidated Balance Sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows.</div>      <!-- Field: Page; Sequence: 18; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Foreign Currency Hedge</div></div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments resulted in a loss of $460 and a gain of $4,082 for the three months ended September&nbsp;30, 2015 and 2014, respectively and a loss of $793 and a gain of $732 for the nine months ended September&nbsp;30, 2015 and 2014, respectively. During the nine months ended September&nbsp;30, 2015, the Company realized a currency exchange gain of $1,654 associated with the exercise of a U.S. Dollar/Japanese yen currency option. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of September 30, 2015 and December&nbsp;31, 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of September 30, 2015, the maximum amount of hedge collateral the Company may be required to post is $9,750.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140547207205408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 3 &#x2014; Collaborative and Other Research and Development Contracts</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">U.S.&nbsp;Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;).</div> In January 2007, BARDA/HHS awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&nbsp;24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014 according to its terms.</div>      <!-- Field: Page; Sequence: 15; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 31, 2015, the Company announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options within this contract.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;).</div> In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of September 30, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. As of September 30, 2015, a total of $29,875 has been awarded under exercised options within this contract. BCX4430 is the lead compound in the Company&#x2019;s BSAV research program.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Seqirus UK Limited (&#x201c;SUL&#x201d;).</div> On June 16, 2015, the Company and Seqirus UK Limited (&quot;SUL&quot;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &quot;SUL Agreement&quot;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &quot;Territory&quot;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.</div>  <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. The Company will exercise sole decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and is responsible for all associated costs.</div>  <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div>      <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">In December 2013, the Company submitted a New Drug Application (&quot;NDA&quot;) for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&quot;EMA&quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.</div>    <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement (the &quot;Royalty Term&quot;). The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</div>        <!-- Field: Page; Sequence: 16; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The term of the SUL Agreement shall continue on a country-by-country basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement, subject to applicable cure periods, or if the other party suffers an insolvency event. The Company may also terminate the SUL Agreement if SUL or any of its affiliates seek to challenge the validity of the Company's patents. Termination does not affect a party's rights which have accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations exercised by the Company, the SUL Agreement provides for the termination of any sublicenses granted by SUL to third parties, and in the case of termination by the Company for cause, the ceasing of SUL's activities with respect to RAPIVAB, the discontinued use of all Company intellectual property and the termination of licenses and rights previously granted to SUL. If requested by the Company, SUL shall also promptly sell to the Company all licensed product it then holds in stock, otherwise, SUL may continue to sell such licensed product for designated periods.</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;).</div> In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan and to provide rights for Shionogi to perform a Phase&nbsp;3 clinical trial in Hong Kong. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Green Cross Corporation (&#x201c;Green Cross&#x201d;).</div> In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;).</div> In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained worldwide rights to forodesine. &nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively).</div> In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by the Licensors.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company&#x2019;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June&nbsp;19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&#x2019;s common stock, or in a combination of cash and shares.</div>      <!-- Field: Page; Sequence: 17; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#x201c;VUW&#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0"><div style="display: inline; font-style: italic;">The University of Alabama at Birmingham (&#x201c;UAB&#x201d;).</div> The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 808<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546952757568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember', window );">Collaboration Receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 7,495,000<span></span>
</td>
<td class="nump">$ 3,849,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,641,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember', window );">Deferred Collaborative Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 2,102,000<span></span>
</td>
<td class="nump">1,481,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember', window );">Deferred Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">5,605,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">46,627,000<span></span>
</td>
<td class="nump">54,540,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">1,622,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">$ 23,700,000<span></span>
</td>
<td class="nump">18,232,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">683,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,970,000<span></span>
</td>
<td class="nump">6,172,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred collaboration expense</a></td>
<td class="nump">88,000<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">84,502,000<span></span>
</td>
<td class="nump">89,343,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">47,787,000<span></span>
</td>
<td class="nump">41,116,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
<td class="nump">1,146,000<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseAssets', window );">Deferred collaboration expense</a></td>
<td class="nump">282,000<span></span>
</td>
<td class="nump">177,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,239,000<span></span>
</td>
<td class="nump">6,031,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">138,956,000<span></span>
</td>
<td class="nump">136,874,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,782,000<span></span>
</td>
<td class="nump">2,849,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">23,027,000<span></span>
</td>
<td class="nump">11,329,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">5,517,000<span></span>
</td>
<td class="nump">6,029,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-recourse notes payable</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">64,444,000<span></span>
</td>
<td class="nump">57,293,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">10,122,000<span></span>
</td>
<td class="nump">3,552,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">345,000<span></span>
</td>
<td class="nump">394,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,337 in 2015 and 71,955 in 2014</a></td>
<td class="nump">733,000<span></span>
</td>
<td class="nump">720,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">556,095,000<span></span>
</td>
<td class="nump">542,943,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(130,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(492,782,000)<span></span>
</td>
<td class="num">(467,898,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">64,045,000<span></span>
</td>
<td class="nump">75,635,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 138,956,000<span></span>
</td>
<td class="nump">$ 136,874,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546970567920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 1 &#x2014; Significant Accounting Policies</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $119,736, to continue its planned operations into 2017. The Company&#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond 2017 it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&nbsp;&nbsp;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;). Royalty Sub was formed in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the financial statements for the year ended December&nbsp;31, 2014 and the notes thereto included in the Company&#x2019;s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&nbsp;31, 2014 has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div>      <!-- Field: Page; Sequence: 6; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of September 30, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $70 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,402 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September 30, 2015, the Company believes that the costs of its investments are recoverable in all material respects.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair value of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30, 2015</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br /> Cost</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br /> Interest</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">23,119</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">42</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">28</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">(2</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">23,187</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Corporate debt securities</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">27,249</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">141</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">26</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(14</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">27,402</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,909</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">28</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">10</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(49</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,898</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,277</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">211</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(65</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" margin-top: 0; margin-bottom: 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br /> Cost</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br /> Interest</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">20,307</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">22</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">(23</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">20,306</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Corporate debt securities</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">27,152</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">151</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">5</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(47</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">27,261</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,838</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(63</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,781</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,297</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(133</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>      <!-- Field: Page; Sequence: 7; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at September&nbsp;30, 2015 and December&nbsp;31, 2014.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 65%; font-size: 10pt; text-align: left">Maturing in one year or less</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 14%; font-size: 10pt; text-align: right">23,700</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 14%; font-size: 10pt; text-align: right">18,232</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">27,183</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">25,459</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,604</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">15,657</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Collaborations</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, and product sales to Green Cross Corporation (&#x201c;Green Cross&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;). These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September 30, 2015 and December&nbsp;31, 2014, the Company had the following receivables.</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td>      <td style="padding-bottom: 1pt">&nbsp;</td>      <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30, 2015</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><div style="display: inline; font-size: 10pt">Billed</div></td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><div style="display: inline; font-size: 10pt">Unbilled</div></td>      <td style="padding-bottom: 1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td colspan="3" style="border-bottom: black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">Total</div></td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">5,444</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">5,444</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">129</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">129</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><div style=" margin: 0">Seqirus UK Limited</div> </td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,051</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,444</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,495</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" margin-top: 0; margin-bottom: 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Billed</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Unbilled</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Total</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">2,778</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">2,778</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi &amp; Co. Ltd.</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,071</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,778</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,849</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">&reg;</div>. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">At December 31, 2014, the Company&#x2019;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories. In connection with the June 2015 SUL collaboration, the Company sold all of its available RAPIVAB finished goods inventory to SUL in accordance with terms stipulated in the licensing agreement.</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the Food and Drug Administration (&#x201c;FDA&#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB commercial inventories.</div>      <!-- Field: Page; Sequence: 8; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s inventory consisted of the following at September&nbsp;30, 2015 and December&nbsp;31, 2014:</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 65%; font-size: 10pt; text-align: left">Work in process</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 14%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 14%; font-size: 10pt; text-align: right">267</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished Goods</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">416</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">683</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>      <table border="0" cellpadding="0" cellspacing="5" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">       <tr>     <td style="vertical-align: middle; width: 2%">&nbsp;</td>     <td style="vertical-align: top; text-align: left; width: 3%">&#x2022;</td>     <td style="vertical-align: middle; width: 95%">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</td>    </tr>    <tr>     <td style="vertical-align: middle">&nbsp;</td>     <td style="vertical-align: top; text-align: left">&#x2022;</td>     <td style="vertical-align: middle">fees paid to investigative sites in connection with clinical trials;</td>    </tr>    <tr>     <td style="vertical-align: middle">&nbsp;</td>     <td style="vertical-align: top; text-align: left">&#x2022;</td>     <td style="vertical-align: middle">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</td>    </tr>    <tr>     <td style="vertical-align: middle">&nbsp;</td>     <td style="vertical-align: top; text-align: left">&#x2022;</td>     <td style="vertical-align: middle">professional fees.</td>    </tr>     </table>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September 30, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Loss</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the nine months ended September 30, 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during the nine months ended September 30, 2014.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div>      <!-- Field: Page; Sequence: 9; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">In June 2015, the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&#x201c;Health Canada&#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 20pt"><div style="display: inline; font-style: italic;">Product Sales</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 20pt">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales, and the Company&#x2019;s commercial sales will be minimal.</div>        <!-- Field: Page; Sequence: 10; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) Fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.</div>      <!-- Field: Page; Sequence: 11; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three and nine months ended September&nbsp;30, 2015 and 2014:</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Three Months</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Nine Months</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">5,699</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">6,236</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Royalty revenue</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">126</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">5</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,776</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,951</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; text-indent: -20pt; padding-left: 20pt">Collaborative and other research and development revenues:</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt">U.S. Department of Health and Human Services</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4,582</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,937</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">12,788</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">5,323</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Green Cross Corporation</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">132</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">132</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Shionogi (Japan)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">296</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">296</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">888</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">888</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><div style=" margin: 0">Seqirus UK Limited</div> </td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">152</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">21,835</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total collaborative and other research and development revenues</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">5,162</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">3,233</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">35,643</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6,211</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,987</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,238</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">43,655</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,162</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended September&nbsp;30, 2015 and 2014 was $1,241 and $1,217, respectively, and for the nine months ended September 30, 2015 and 2014 was $3,862 and $3,684, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended September&nbsp;30, 2015 and 2014, and $329 for each of the nine months ended September&nbsp;30, 2015 and 2014.</div>      <!-- Field: Page; Sequence: 12; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>    <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 and 2014 resulted in a loss of $793 and a gain of $732, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized a currency exchange gain of $1,654 during the first nine months of 2015 associated with the exercise of a U.S. Dollar/Japanese yen currency option.</div>    <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of September 30, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended September&nbsp;30, 2015 and 2014 does not include 3,821 and 4,240, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the nine months ended September&nbsp;30, 2015 and 2014 does not include 3,673 and 3,986, respectively, of such potential common shares, as their impact would be anti-dilutive.</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div>  <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div>      <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">The Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 27pt"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 27pt">&nbsp;</div>  <div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development.</div>  <div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Credit Risk</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div>      <!-- Field: Page; Sequence: 13; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In April 2015, the FASB issued ASU No.2015-03, <div style="display: inline; font-style: italic;">Simplifying the Presentation of Debt Issuance Costs</div>. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect this ASU will have a material impact on its consolidated financial statements.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued ASU 2014-09 &#x2013; <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers</div>, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546967032608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life in Years</a></td>
<td class="text">5 years 182 days<span></span>
</td>
<td class="text">5 years 182 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iv)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546964272832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>JPY (&#165;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(460,000)<span></span>
</td>
<td class="nump">$ 4,082,000<span></span>
</td>
<td class="num">(793,000)<span></span>
</td>
<td class="nump">$ 732,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign Currency Transaction Gain (Loss), Realized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAmountOfCollateralRequiredToPost', window );">Maximum Amount of Collateral Required to Post</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet', window );">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</a></td>
<td class="nump">22,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="nump">4,309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Interestreserve', window );">Interest Reserve</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member] | Japan, Yen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments for (Proceeds from) Hedge, Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RequiredForeignCurrencyHedgePerDollar', window );">Required Foreign Currency Hedge Per Dollar | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1', window );">Percentage of Carrying Amount in Excess of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (352,000)<span></span>
</td>
<td class="nump">$ 4,082,000<span></span>
</td>
<td class="nump">$ 861,000<span></span>
</td>
<td class="nump">$ 732,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Interestreserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_Interestreserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAmountOfCollateralRequiredToPost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum amount of collateral required to post.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAmountOfCollateralRequiredToPost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of carrying amount in excess of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RequiredForeignCurrencyHedgePerDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RequiredForeignCurrencyHedgePerDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents revenue recognition royalty and milestone revenue recognized, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4H<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624258-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4A<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 27<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3581-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=bcrx_JapanYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=bcrx_JapanYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546967033904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 2 &#x2014; Stock-Based Compensation</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of September 30, 2015, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;) and the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), both which were amended and restated in March 2014 and approved by the Company&#x2019;s stockholders in May 2014. Stock-based compensation expense of $7,773 ($7,553 of expense related to the Incentive Plan and $220 of expense related to the ESPP) was recognized during the first nine months of 2015, while $6,550 ($6,388 of expense related to the Incentive Plan and $162 of expense related to the ESPP) was recognized during the first nine months of 2014.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There was approximately $14,839 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of September 30, 2015. That cost is expected to be recognized as follows: $1,782 during the remainder of 2015, $5,632 in 2016, $4,627 in 2017, $2,508 in 2018 and $290 in 2019. In addition, the Company has approximately $11,982 of unrecognized compensation cost related to outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock Incentive Plan</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Since March&nbsp;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of September 30, 2015, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of September 30, 2015, 25% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.</div>      <!-- Field: Page; Sequence: 14; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Awards<br /> Available</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Options<br /> Outstanding</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 55%; font-size: 10pt">Balance December 31, 2014</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">2,362</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">9,605</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">6.21</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(155</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards cancelled</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(1,319</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,319</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">11.99</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(1,102</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4.36</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">28</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(28</td>      <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">9.05</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance September 30, 2015</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">917</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,794</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td>      <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">7.19</td>      <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during the first nine months of 2015 and 2014, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the first nine months of 2015 and 2014 was $8.15 and $8.19, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the first nine months of 2015 and 2014. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Weighted Average Assumptions for Stock Option Awards Granted to</div></div>  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Employees and Directors under the Incentive Plan</div></div>  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 70%; font-size: 10pt; text-align: left">Expected Life in Years</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">5.5</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">5.5</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Expected Volatility</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">83</td>      <td style="font-size: 10pt; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">87</td>      <td style="font-size: 10pt; text-align: left">%</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">0.0</td>      <td style="font-size: 10pt; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">0.0</td>      <td style="font-size: 10pt; text-align: left">%</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1.5</td>      <td style="font-size: 10pt; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1.6</td>      <td style="font-size: 10pt; text-align: left">%</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Employee Stock Purchase Plan</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 497 shares remain available for purchase at September 30, 2015. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 41 shares during the first nine months of 2015 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546960826208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">73,337,000<span></span>
</td>
<td class="nump">71,955,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">73,337,000<span></span>
</td>
<td class="nump">71,955,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546964485008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member] | US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member] | Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member] | Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member] | CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,051<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member] | US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 5,444<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member] | Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member] | Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member] | CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 5,444<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">5,444<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 7,495<span></span>
</td>
<td class="nump">$ 3,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3,4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546955570368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">bcrx<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,336,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140547139007344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished Goods</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">416,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net inventories</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 683,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546952910128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">$ 5,699,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,236,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">1,776,000<span></span>
</td>
<td class="nump">$ 1,951,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development</a></td>
<td class="nump">5,162,000<span></span>
</td>
<td class="nump">3,233,000<span></span>
</td>
<td class="nump">35,643,000<span></span>
</td>
<td class="nump">6,211,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
<td class="nump">10,987,000<span></span>
</td>
<td class="nump">$ 3,238,000<span></span>
</td>
<td class="nump">43,655,000<span></span>
</td>
<td class="nump">$ 8,162,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
<td class="nump">1,346,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,361,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">20,067,000<span></span>
</td>
<td class="nump">$ 13,036,000<span></span>
</td>
<td class="nump">53,711,000<span></span>
</td>
<td class="nump">$ 33,286,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,731,000<span></span>
</td>
<td class="nump">$ 1,812,000<span></span>
</td>
<td class="nump">10,326,000<span></span>
</td>
<td class="nump">5,413,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">507,000<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">24,149,000<span></span>
</td>
<td class="nump">$ 14,848,000<span></span>
</td>
<td class="nump">65,905,000<span></span>
</td>
<td class="nump">38,777,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,162,000)<span></span>
</td>
<td class="num">(11,610,000)<span></span>
</td>
<td class="num">(22,250,000)<span></span>
</td>
<td class="num">(30,615,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">134,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">367,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,241,000)<span></span>
</td>
<td class="num">(1,217,000)<span></span>
</td>
<td class="num">(3,862,000)<span></span>
</td>
<td class="num">(3,684,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">(Loss) gain on foreign currency derivative</a></td>
<td class="num">(352,000)<span></span>
</td>
<td class="nump">4,082,000<span></span>
</td>
<td class="nump">861,000<span></span>
</td>
<td class="nump">732,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,621,000)<span></span>
</td>
<td class="num">$ (8,731,000)<span></span>
</td>
<td class="num">$ (24,884,000)<span></span>
</td>
<td class="num">$ (33,517,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">73,262<span></span>
</td>
<td class="nump">71,801<span></span>
</td>
<td class="nump">72,752<span></span>
</td>
<td class="nump">65,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available for sale investments</a></td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="num">$ (2,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (14,530,000)<span></span>
</td>
<td class="num">$ (8,732,000)<span></span>
</td>
<td class="num">$ (24,755,000)<span></span>
</td>
<td class="num">$ (33,519,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and other research and development during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4A<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546952879696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Securities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">23,119</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">42</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">28</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(2</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">23,187</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">27,249</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">141</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">26</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(14</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">27,402</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,909</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">10</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(49</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,898</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,277</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">211</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(65</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,307</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">22</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(23</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,306</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">27,152</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">151</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(47</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">27,261</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,838</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(63</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,781</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,297</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(133</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock', window );">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">23,700</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">18,232</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">27,183</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">25,459</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,604</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">15,657</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><div style="display: inline; font-size: 10pt">Billed</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><div style="display: inline; font-size: 10pt">Unbilled</div></td> <td style="padding-bottom: 1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="border-bottom: black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">Total</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">5,444</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">5,444</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">129</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">129</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><div style=" margin: 0">Seqirus UK Limited</div> </td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,051</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,444</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,495</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi &amp; Co. Ltd.</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,778</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,849</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; font-size: 10pt; text-align: left">Work in process</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">267</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished Goods</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">416</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">683</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock', window );">Schedule of Revenues from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Three Months</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Nine Months</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,699</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">6,236</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">126</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,776</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,951</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: -20pt; padding-left: 20pt">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,582</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,937</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">12,788</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,323</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Shionogi (Japan)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">888</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">888</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><div style=" margin: 0">Seqirus UK Limited</div> </td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">152</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">21,835</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">5,162</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">3,233</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">35,643</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6,211</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,987</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,238</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">43,655</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,162</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available for sale securities debt maturities fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of revenues from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 320<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 320<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 2<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a,b,c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546966825024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $119,736, to continue its planned operations into 2017. The Company&#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond 2017 it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&nbsp;&nbsp;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;). Royalty Sub was formed in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">These financial statements should be read in conjunction with the financial statements for the year ended December&nbsp;31, 2014 and the notes thereto included in the Company&#x2019;s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&nbsp;31, 2014 has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Restricted cash as of September 30, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $70 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,402 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September 30, 2015, the Company believes that the costs of its investments are recoverable in all material respects.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair value of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Amortized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Cost</div></div></td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Accrued</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Interest</div></div></td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gross</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Unrealized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gains</div></div></td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gross</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Unrealized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Losses</div></div></td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Estimated</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Fair&nbsp;Value</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; text-align: left">Obligations of U.S. Government and its agencies</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">23,119</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">42</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">28</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(2</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">23,187</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Corporate debt securities</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">27,249</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">141</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">26</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">(14</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">27,402</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Certificates of deposit</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">20,909</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">28</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">10</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">(49</td> <td style="border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">20,898</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">71,277</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">211</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">64</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">(65</td> <td style="border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="19">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Amortized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Cost</div></div></td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Accrued</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Interest</div></div></td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gross</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Unrealized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gains</div></div></td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gross</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Unrealized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Losses</div></div></td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Estimated</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Fair&nbsp;Value</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; text-align: left">Obligations of U.S. Government and its agencies</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">20,307</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">22</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(23</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">20,306</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Corporate debt securities</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">27,152</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">151</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">5</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">(47</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">27,261</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Certificates of deposit</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">11,838</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">6</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">(63</td> <td style="border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">11,781</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">59,297</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">179</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">(133</td> <td style="border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at September&nbsp;30, 2015 and December&nbsp;31, 2014.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Maturing in one year or less</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">23,700</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">18,232</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Maturing after one year through two years</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">27,183</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">25,459</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">20,604</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">15,657</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Collaborations</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi&nbsp;&amp; Co. Ltd., product sales to Green Cross Corporation and CSL Limited. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September 30, 2015 and December&nbsp;31, 2014, the Company had the following receivables.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">September 30, 2015</div></td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Total</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">5,444</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">5,444</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Green Cross Corporation</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">129</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">-</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">129</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">CSL Limited</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">1,922</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">1,922</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">2,051</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">5,444</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">7,495</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">2,778</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">2,778</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Shionogi &amp; Co. Ltd.</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">1,071</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">1,071</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">1,071</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">2,778</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">3,849</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">&reg;</div>. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">At September 30, 2015 and December 31, 2014, the Company&#x2019;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">During 2014, in connection with the Food and Drug Administration (&#x201c;FDA&#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB commercial inventories.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company&#x2019;s inventory consisted of the following at September&nbsp;30, 2015 and December&nbsp;31, 2014:</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Work in process</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">267</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished Goods</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">416</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Net inventories</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">683</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"> <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td> </tr> </table><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"> <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">fees paid to investigative sites in connection with clinical trials;</div></td> </tr> </table><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"> <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</div></td> </tr> </table><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"> <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">professional fees.</div></td> </tr> </table><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September 30, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Loss</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Accumulated other comprehensive loss is comprised of unrealized gains and losses on investments available-for-sale and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the nine months ended September 30, 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during the nine months ended September 30, 2014.&nbsp;</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In June 2015, the Company entered into a License Agreement (the &#x201c;Agreement&#x201d;) granting CSL Limited (&#x201c;CSL&#x201d;) and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from CSL of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the current quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter when the inventory transfer was completed. Approximately $1,223 of this revenue will be recognized over the expected period of involvement in these regulatory support activities.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Under the terms of the Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the European Union and (iii) by Health Canada for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt"><div style="display: inline; font-style: italic;">Product Sales</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the CSL worldwide license of RAPIVAB, CSL will be primarily responsible for sales of RAPIVAB other than U.S. Government stockpiling sales and the Company&#x2019;s commercial sales will be minimal.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) Fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company recorded the following revenues for the three and nine months ended September&nbsp;30, 2015 and 2014:</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Product sales, net</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">5,699</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">6,236</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Royalty revenue</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">126</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">5</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">1,776</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">1,951</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Collaborative and other research and development revenues:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Department of Health and Human Services</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">4,581</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">2,937</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">12,788</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">5,323</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Green Cross Corporation</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">132</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">-</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">132</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">-</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shionogi (Japan)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">296</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">296</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">888</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">888</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">CSL Limited</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">153</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">21,835</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">5,162</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">3,233</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">35,643</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">6,211</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">10,987</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">3,238</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">43,655</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">8,162</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&nbsp;</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Interest expense for the three months ended September&nbsp;30, 2015 and 2014 was $1,214 and $1,217, respectively, and for the nine months ended September 30, 2015 and 2014 was $3,862 and $3,684, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended September&nbsp;30, 2015 and 2014, and $329 for each of the nine months ended September&nbsp;30, 2015 and 2014.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock', window );">Currency Hedge Agreement [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 and 2014 resulted in a loss of $792 and a gain of $732, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized a currency exchange gain of $1,653 during the first nine months of 2015 associated with the exercise of a U.S. Dollar/Japanese yen currency option.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of September 30, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended September&nbsp;30, 2015 and 2014 does not include 0,000 and 0,000, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the nine months ended September&nbsp;30, 2015 and 2014 does not include 0,000 and 0,000, respectively, of such potential common shares, as their impact would be anti-dilutive.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the CSL transaction as CSL will be responsible for commercial sales on a worldwide basis with the exception of Israel, Japan, Korea and Taiwan.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB (i.e., peramivir) and BCX4430 development expenses, which was earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of the NIAID/HHS and BARDA/HHS BCX4430 programs/collaboration could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company&#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Credit Risk</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In April 2015, the FASB issued ASU No. 2015-03, <div style="display: inline; font-style: italic;">Simplifying the Presentation of Debt Issuance Costs</div>. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect this ASU will have a material impact on its consolidated financial statements.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In May 2014, the FASB issued ASU 2014-09 &#x2013; <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers</div>, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018, however early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents currency hedge agreement policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CurrencyHedgeAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 825<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 825<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 825<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.3A-02)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph k<br><br><br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02, 03<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 954<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 17<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 206<br><br><br><br> -Paragraph b<br><br><br><br> -Subparagraph i, ii<br><br><br><br> -Chapter 2<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 323<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2,12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 325<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section M<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e4975-111524<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3-5<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section B<br><br><br><br> -Paragraph Question 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b),(f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546951166512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">50 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2015</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Feb. 24, 2011</div></th>
<th class="th"><div>May. 31, 2010</div></th>
<th class="th"><div>Sep. 30, 2009</div></th>
<th class="th"><div>Jan. 31, 2007</div></th>
<th class="th"><div>Jun. 30, 2006</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Feb. 24, 2011</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ContractTerm', window );">Contract Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementAdditionalContractValue', window );">Collaborative Agreement Additional Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,191,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementAdjustedContractValue', window );">Collaborative Agreement Adjusted Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable From Awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementPeriodOfcontract', window );">Collaborative Agreement Period of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,314,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,169,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement', window );">Advance Notice Period for Termination of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement', window );">Stock Issued During Period, Value, for Modification of License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PaymentsForModificationOfLicenseAgreement', window );">Payments for Modification of License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 33,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyTerm', window );">Royalty Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents advance notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementAdditionalContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement additional contract value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementAdditionalContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementAdjustedContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement adjusted contract value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementAdjustedContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementPeriodOfcontract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement period of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementPeriodOfcontract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between the contract date and its expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PaymentsForModificationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments for modifications of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PaymentsForModificationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents renewable period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between the date of the Agreement and its expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents stock issued during period value for modification of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 912<br><br><br><br> -SubTopic 310<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51666815&amp;loc=d3e55295-109406<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546960817040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">U.S. Department of Health and Human Services</a></td>
<td class="nump">$ 4,582<span></span>
</td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="nump">$ 12,788<span></span>
</td>
<td class="nump">$ 5,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">U.S. Department of Health and Human Services</a></td>
<td class="nump">132<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">U.S. Department of Health and Human Services</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember', window );">CSL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">U.S. Department of Health and Human Services</a></td>
<td class="nump">152<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,835<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">5,699<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,236<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">$ 1,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">U.S. Department of Health and Human Services</a></td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">35,643<span></span>
</td>
<td class="nump">6,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 10,987<span></span>
</td>
<td class="nump">$ 3,238<span></span>
</td>
<td class="nump">$ 43,655<span></span>
</td>
<td class="nump">$ 8,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative and other research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546964572656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 23,119<span></span>
</td>
<td class="nump">$ 20,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">28<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">23,187<span></span>
</td>
<td class="nump">20,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">27,249<span></span>
</td>
<td class="nump">27,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">27,402<span></span>
</td>
<td class="nump">27,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">20,909<span></span>
</td>
<td class="nump">11,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">20,898<span></span>
</td>
<td class="nump">11,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">71,277<span></span>
</td>
<td class="nump">59,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 71,487<span></span>
</td>
<td class="nump">$ 59,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (aa)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546969997888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Compensation, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Awards<br /> Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Options<br /> Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt">Balance December 31, 2014</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">2,362</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">9,605</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">6.21</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(155</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,319</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,319</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">11.99</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,102</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4.36</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(28</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">9.05</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance September 30, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">917</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,794</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">7.19</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: left">Expected Life in Years</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">5.5</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">5.5</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected Volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">83</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">87</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.0</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.0</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.5</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.6</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546950484624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details Textual) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 03, 2015</div></th>
<th class="th"><div>Nov. 06, 2013</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Mar. 09, 2011</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,654,000<span></span>
</td>
<td class="nump">$ 732,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities', window );">Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityForPortfolioInvestments', window );">Average Maturity for Portfolio Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongtermInvestmentMaturityMinimum', window );">Long-term Investment Maturity, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember', window );">CSL [Member] | Agreement [Member] | RAPIVABMember | Contingent upon EU Marketing Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember', window );">CSL [Member] | Agreement [Member] | RAPIVABMember | Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember', window );">CSL [Member] | Agreement [Member] | RAPIVABMember | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember', window );">CSL [Member] | Agreement [Member] | RAPIVABMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVABMember | Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnSaleOfInvestments', window );">Loss on Sale of Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Investments and Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,736,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,736,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SecuritiesOffered', window );">Securities Offered</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,987,000<span></span>
</td>
<td class="nump">3,238,000<span></span>
</td>
<td class="nump">43,655,000<span></span>
</td>
<td class="nump">8,162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,241,000<span></span>
</td>
<td class="nump">$ 1,217,000<span></span>
</td>
<td class="nump">$ 3,862,000<span></span>
</td>
<td class="nump">$ 3,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
<td class="nump">4,240<span></span>
</td>
<td class="nump">3,673<span></span>
</td>
<td class="nump">3,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityForPortfolioInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity for portfolio investments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityForPortfolioInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongtermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongtermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityperiodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityperiodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SecuritiesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents securities offered for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SecuritiesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4H<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624258-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -Subparagraph (a),(c),(d),(e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4A<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4A<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -Subparagraph (a),(c),(d),(e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.1,2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546955155056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Scheduled Maturity for the Company's Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 23,700<span></span>
</td>
<td class="nump">$ 18,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Maturing after one year through two years</a></td>
<td class="nump">27,183<span></span>
</td>
<td class="nump">25,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears', window );">Maturing after two years</a></td>
<td class="nump">20,604<span></span>
</td>
<td class="nump">15,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total investments</a></td>
<td class="nump">$ 71,487<span></span>
</td>
<td class="nump">$ 59,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities debt maturities after one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents debt maturities after two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (aa)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 320<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546952667168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock Incentive Plan Activities (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available (in shares)</a></td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">9,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock unit awards granted (in shares)</a></td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock unit awards cancelled (in shares)</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Stock option awards granted (in shares)</a></td>
<td class="num">(1,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option awards granted (in shares)</a></td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option awards granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option awards exercised (in shares)</a></td>
<td class="num">(1,102)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock option awards exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Stock option awards cancelled (in shares)</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock option awards cancelled (in shares)</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Stock option awards cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balance September 30, 2015 (in shares)</a></td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance September 30, 2015 (in shares)</a></td>
<td class="nump">9,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Balance September 30, 2015 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)(iii)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001171843-15-006102-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-15-006102-xbrl.zip
M4$L#!!0````(`*B!9D=A.'$YN/L``(Y*"0`1`!P`8F-R>"TR,#$U,#DS,"YX
M;6Q55`D``^P7/5;L%SU6=7@+``$$)0X```0Y`0``[#UK<]LXDM^OZOX#SK>S
ME51)MJB'9=F3;#GV)O%>'C[;LS?S:0HB(0D3DF``T+;FUU]W@R_)HBP_%#L3
M;>UF91)H]!M`H]GX^1_74<@NA392Q:^VO.W6%A.QKP(9CU]M_7+>/#P_.CG9
M^L?KG_^KV7PG8J&Y%0$;3MG%)(T#H8]5)-BO;\X^L"9K[>U[[=./[)>+(]9N
M>;VFYS5;N\WFZY^OASJ4^_@O@_%B\VIK8FVRO[-S=76UC8^WE1[OM%NMSHZ,
MC>6Q+[9<R_VAKZ]GF@^E\O74V&U?13LX3&O0:>6M?97&5D^+#@3;"'][K"YW
MLI?8J=-L><V.5W1+M0:RZ_IE;[%C=[9C(.3B/O!B07-Q[4\6M\<W"SK(^%(8
MN[B+>[>`&FE4M^WUES'9M<@[A#+^LJ0UOAYR4X@DYM(WBW&B5XB2-XM2K.(X
MC1:/$5B]8Z>)V(%&36@EM/3S?D;ZBP>"%PN&,3;1->WAS8(.UFEQ`%H\@]S9
M\;NW$N@>&U2SO'5JFF/.DZ+EB)LAD9"]('6<'2"UNI:S@QUXFS?$%\&<,F7M
M=G?<RVI3>0<3NKXAWZL.M?8&@\$.O2V:FD7M`*JW\^O'#^?^1$2\>0.^D7?I
M]?H__X.QGW'4?4.OSL2($1;[$RU&K[;0Y)NY96]?FV`K>XU:\FK+R"@)Q=:.
M@X.-]P]]7Z<B^.=U(F(CS*D*I3^]$-?V3:C\+\Q7L84_SA!X\'LNI):7_1PT
MT8'(X-66W_;V6CVOM_7Z[Z$]".0E,W8:PIB!-$G(I_M,QH").&`C`-D<\4B&
M\-#*2!@6BRNF5<3C[*V1?XI]YK42N_7WL3W80-Q`W$#<0-Q`W$#<0%PS1&KC
M7K,+ZO\)^I]A_X9[T&#GL-`<';"(Z[&,]QDV;;E_M]L]&:^.Z)60XPF,-E1A
M<+!Z-WH)SRR'U8KKEZUC6+Z003@[`"B'6??[$2@_8+A$:@(N8WCT1VJL'$VS
MAQ+6R`BTM5WPA4?)03PTR1I1R4=M]S,97TP$.U)1PN,I&]->-`RGL%VUL'T%
MUEI%"SW-?9ORD/&Q%B*"MX9=23MA=B)UT$RXME/8\,:!@DY7$\42K2YE()@6
M1G#M3QB/`Q:(2Q&J!+LW`+DX'2%4#1N"!KU7=B(T,T)?2E_@X`!>,*5AW\SU
M%/!(M8&_1VR8&I"X,=OL''?*\`0:PJL<4\.X%LRDPS^$;QF0`#H/NSH5BR9N
MN0(`?:FD#P/3N,6(V`MV)K`0QOVX@AT\O&?`-J`,'B3`5A70<,#G;59EG18^
M(&I8*/D0]CA6`CC:!<VAADR$(2)I,RY.1`S:"KP!AD=(%0ZIAJ`QW$H5LPDW
M;"BP44Q;YJ`!8XVY#H`BDY&.^"`QV5^..D)0&A2%CTWQ:0B;6^A^*<45M0>#
MJ#(->)&D("UNB.V@`0U"-HVE#]A`#Q(Z3Q(P+CX,2_*!-09VHR)$;DM4,5#T
MDK%VPBU0<BD<*=!ZI'2$/$;BD<`)#T>$`,A)1FXPI"5$G4'",EB5OM@:FW!C
ME"\IA.(K8PM&@:40]XNNQ&M;$1KR-E:6387->4R<`[RTT\8K":R`)G(D!4F^
M$*&Q3@$B_H?2$M2_BJ/3?FUR@#.C1L#P"=@8Z#<'/#DT0TP+9A44SFI8Q+_`
MRXP]PCADG&<3F6<#5N!CP<'@ACS$C2$S$P'4!=`%!T1FC\"<8F!8""X%'CL]
M=':A'']&A3KX4OMIY/:89A8?9PV@!^@O0(E&4D?&"<0'`7"?6((#ECAG/D,L
MX!2.YDCD`3I*AY8<P1R%Z@L.8!L\.$?C=$1F0(.;7``%"--`[*_?BZ[BNRT9
M2C;NP1T&'I()-GT5ACPQ,*GEOPZ`CX&=[+-^JY5<'VPQ7X1AP@,77VRYOTW"
M_>QOQ(01*KK\&>0H9;!Z/RVBPP8+>H!?M"CW?%ZS*BE0:O^T\ER]"A=*G/[[
MNMUJMV].V'?&T'L<0@?KH'0DT/ZY#-"-'@$`')V=Y9/H9SWFL?R3)@;#7A1\
M\?R#H[//IOP[.'B)UNZC2_9I&B'+2V"6RH&2]U37$I1*C<%5VS20(C/ZO(W5
MX"7,4I[O5'1JAU1]8VT;:_L.K<T%_FG5!<L4(ZU;@<Z;T,8V-K;QP]E&OD6H
M;-K<XO:&>>#:#M9T0>J>P3H--FU,\RN&:S4RF08+=#K&W9E;5KJM(3[*.IH*
M1^#=QL(V%O97M##0]A%L;,!,8#9!<]M^:DW_7L)4N%<U;F>9;_FT"&DOB,YJ
M=H;.0PPS&^?*%A3[^@+F?!=0$"/8>^>0*>B3:I/RV%;]8+:1C=+02MB/EE$N
M/(Z5-G7K<P2'RW(7_8"^Z-RR?6[,QV(1II4X0;F:'QSD$1*W`R\W\!@S,F7\
MJQ*=FPN`Q6*LK*2-0X-=8C1MI%54.O:JDW<88DC+`('HY=-87&+8AD\1.!N%
MZLILLU/W9Q[G,C6AN$`@)Y$XG#DP0&A2#`BZ6`'\QNW]*`V9B#4X/1H!P"2`
MK*,D"_-D@;EL6IGE71G@`[Q.8A<2P!!2'F=`^VK,1&%*?<@":**([V'<[VHB
M`<E"1ZYD&((,%D2?B@"5TYQ2<8!O%(AQ4`&M418<H0#2;,0N`TO381E',BP+
M8,V/`0+$O1J)$-_GM,Q22#B[8$H>EM$4P_5]BJF.P^DV.R3U.1>)%=$0Z.ZT
M&I1F1/0=@V6XIQX][;H!?*[U%+&_Y&$J%@>B$G!OUR6#I0;IPS^N1P#_`XUS
MS\T$2&JB)@/=UH:DP#=]X>9W[>^?=U;(UZ@F=@27J&F?P"/XXI34\ZW2%Q1_
M)A?Q>728>Y)5TCQ^OY@F`OIHS>,Q]3J\EJ9Y^,^CSQ\/X^#D[,-'4J,B':3?
M[WA[6Z]/=UO'.>YW0*E*21R#1G^`/D#Q6R$^<M"Y-)I!6MX+TT#XH+VA>;5U
M\NGM#.+]+7!X,H/M4KZ:J0FV7O=:^)^<H,68+<,='-JZ<=^MP]WK+</=85;%
M_9++$!<A(*1S'HISX:>:#CTR)3S!\R-P2_74G-!^&\E`NHB47\[?H>^-B;:Q
M@"E.F&,QM"7TFQ0V.R6!NX/VH([`;KM"WZK8KYWB(Z43A=F?=R.STZV58]=[
MEG3BXGJ$ATC"?!X=BT09:6^ELE:8[;VG)K(>ZVZM;-K>T\FFV_3:S8ZW'JOK
MU@OJZ:QN"<7WM+I>O=7UGJ5D[V5UO5IA[CXUC?5([]:+IC]8%]JH/1^YS2&,
MH.OG6%Q,M$K'DXLK]1L>[;Z%5>^_:=%[=U?2;]7:5=_;ZZQ"U]UP_"9DWRK,
MOE=+=J_;6TF<:R>[Z'N!C>^3%-V$A>2:$J)=%/*60"&C:`\@0JD^6SD*]8'(
M^4AD)=)8%T,;*FM55&E91-L6HKY"E&ZNWZ)<,981W72C0\-5X`.9P!S@1V?K
M+F-5XV:.DT4L-Q]^&')0#&\;T&`&]F0!(8/Z\&.0V5T6RKQ-=V`8`#L&NXT#
M5$JE]YD>#U^T6]U&N[/7:/=Z+Q?I5Z:JN[V?;IC)+#6A&#FV.=N.QQBW4;%@
M4W`1&'_!-*MZ015QYAIK7$&EZT'48/JWVV%U;P.F4;I.0IT&&/0CHG<'FMO?
M+]L\T+U.^YNP[:'V\G\3:<4*3O@VP^`XC9:V8=ULRNR5H@=+K.31O/V]%6Y5
M8^@W8&'U!`@]8Y;T&K#H6A]"WV(VN!7'^MET3OOOKNSWG*AGEV.UD^QC.N4'
MCE51F59CMW5CVG\:HC;2\'J-W5[_*8GZ5A/87\_Y/BE23X_!4[+EF<Y+[>UV
M+T^)4):'6=XB'<0_P`M6P-[#.;TAG^%@L$"EPU`\PJK\P8.4"M/W&MV]U7W@
M`^AYE#GI+RZ-WJ#1Z>X]K33J\ZGF3]4?%A&\1VPQ7W)2V#(/5MXG?-RNC:.V
M8'UV]SCJ0L361^#M@>)._8$,+'G60:#0?"PBUV$*T$Z5MB-8):GR^,6LE#)Q
MAH?X=$J390;<2)'P]KRMUZ?>;]Y>F26QTOCU"+O$BL^C]V"*_YN"L=CI1ZZ_
M"-+_DBF/1$!K@#D>WMYOB[%?$9D*-4<8BA[BR9V\%$4ZR"'X3DM9E$=9SMG-
M@P<D`M#&_WK%3R0B2]P[C(/C\N/42HI%#O)"G;H4+>#Y9_PPT+R95DY0CP5^
M`HL=@![!0XL0WZ<1C\^S5*[;<C/:_;TZ9095&%3.%^_$A4?C'M;X:6<J0#_;
MW6?%O=I3RYY+RUD7]S"[3@2W:%Z_-)]GR+N]^O,VF*9[[=N9MX`)M[)N99:Y
MGQWO.;&L7W_>W&KO[MYJK7=C5>XIBPS=E?SSHW#K$W=F<9(E-F,"6A@*/9YB
MRED\HF\_4G,L83!3,J[DU*`#<T#OMZ7<F*>OEB%Q0`@N)FTA5_KS9Z\U:XF]
M5JW[[7F[M2:P%*''(J-;DM&]E8Q:/]AI=SI/2L:BD_`Z,KS:S(=.;[?[M'1T
M2SIN%8=7ZUIW9[+!UD[&&2;PIS5+NSDC^?T(2SH*354]/O'H(7ZSRHY^RZO=
MD71[>_<SLIRPQV;+3:-;(UMJ]S'@/OO/BBT+)IKUL:5^DH75\MZSXLM-I[!&
MOO1JIRIP\L^*+:LZEW>P$HB/M#(FS\V$5<>M?*C/9N]\G\YD*1LJA-=]@L"N
MS7XLPU=;5J>SM3R_J?'?3YJU"[!G*,V5;'U5:=8MV=8OS95L\WP":*NQ!+A'
MZH,-;A-DNSYK=;#[W`2YDEG>F0/U&^IGQH%5+?K.'*A=Z.U]IQ/WG3E0NZ9[
M;AQ8U0\<G2_XP&R.Z"5?2#P['[Z2Z5>(KI!9MP![)O/O*I*J73NUO;U.[[G)
M:B4372RKIULKK1A[`AP?/_;T[>QF"5F/'XOZ=O-@/5F=-<2FOIWI+*'K\6-5
M"\F*\0,"G7W4[4[\SJ3Y\J#K!3S\5FISO<`&X@;B!N(&X@;B!N+W!_'1ZO0]
MU44#YW(<T_?VL65'J;$JR@M;TQJ)X3)G<_M`;5DW+4),/DLT+$\U:)&KAZ:%
M8"816.[,3AG(PFHY3*F.F%5EN7JJXY\F"72S<U79SPY/3_Y]^(9JIQF1@4PF
M7$?<%RFE<]>-@*6R<*?I:LF/M>#T$="$QVS0^HDJ7X5A/D!>OY(9CC7*`3NJ
MNHZ8S<))M`@4%C:*+:"+$+(R8`LKOZG48J%,3!#.2M5A@EQ6_6MF2%<=+E3N
M7@#\4`\&BY2NE&6KHQ/^R_Q,9?&BA3#`DG&TQ,=*]8"6;_,J;-`$861UJ&<X
M_%Y=P9)?+ZA#!GR&'F(Y&@"-LU!&DJY#Y$8:*A,JOJ;"%>`CL.<?&.P?8L-=
MC5'`'1_E%=JT,(F*C<1/X)'9)<*97&B0*Z7#X`IOJ'##%,5+Q;4ODIRN$Z.Y
M"!OL7SQ!_?X?8"4G>5YP><7C&T7*UF@H3VV=LSKI;'3*C`+[(_72;JN7W_1`
MMUA07<"0*L7YW$RH;B"@"DR,F'1U][20T1"O]<C+_N6V]$)NB^T&%L:#&>52
MZI?$]S='OW9ABUV]2:2H.=?(:O9=P>"P%XU!A5QA0KRKH9F$J6F.Y+4(FB-1
M+4](DG]S>'9\N//^_3F-\NGD\.08_VJ0-F&.$YK!_(4?Y*U`46HZH[X6Y-7;
M?)44Q-1=!H$5*W-65`D'>Q\#1\#4#\LJ?HV;;'1F5BF/F6"-2BJGR$QEFDJ4
MSI6]U@'YU0U_Y:*6NKM=<EW(_%%9M[&!MEI8VK]2<%!9N<%NA8F%R.=8XP36
MH)J(95VX'/.2[<2N`MH\XW8JU*AXJ:M;R(Q1BL6/X5U,'\=1T='S\AH-P`:[
M:3$!QB.[/J`WIDJ@:`%O7>5,K%"999S.NDH>&D57R8"$_D2YJ2EYR=RZBHJ/
ML<BGF<QF#H\N#@_8I.I_%YI?#@&T(P>>Y'4\QPK@!1+&1QW%V95/LPME7%F<
M1E[U,LX*/<O8EPD'#[FL="G>0(HTD1W$RE)AZ2E.8D4-T?+FFJP$4%Y=$RNL
M8A%)U."R:3%PJ>H.;CX)X/TS&L4Y2JD6YW":"^X&T<`C*OY*C%G(UAF[GR6-
MRE97U13GI$N71(\56,MRH8!!.;7AEV*)PUWJ@,U<GT2%0E$7"M**>Y6`-2!4
M*NZ"PG&P\RJ:6?((BEZ:3*\KEKZ":KN+BZ:N%JR[!(G\T!(B_S(S(/U;#G7/
M#0`M\)TF79!D3TFR'ZM77;G"JOFJ!WW03$CTA]L2+$5EV3X!.&=P^A/Y*F2V
M.#W.HJ2H-];ZT`DF8TF:#+(8R5B:"59ZSM;2,S>3S2QOR\\$<-*U-W%*$UI=
M9GA5K=N6=Z)=@6>8*+S"S"E#4%6&HO0OXE\,?"Q`_XH;T2J$XFPXTU\YYY'3
MXOP`#_`R\MJ5?#&]$#N<G\1;P^#_R=YA6^!_2>CFYBH[5MW);GX7'Q.N>OHQ
M>V#BTO2Q0/+S_$RB.$/JMEM;KT^[9;9_B7J5HNSF]_<B&%<^`GC8^<_N[N;\
M9P-Q`W$#<0-Q`W$#\3N$^*"]V].=^N3+&4;K&58L:'[H@YX543E9?(.8-'CE
M#FSIAE,8T@5LSM-A'B4ZG?"SCX?L$X9\YBYUH?A1X.ZMYJQ.-.Q%(&#;YRYI
M03"L^Q)W:!-JY@MM.;S0M)NOW"[L+@"<X#JZV(L55Z!02!//"3!D,Q6QNY((
MMY_9N<4OV^?;+,#HH\XB2G78!1B'PWN)OV)9A-&4]H(.M^P@B6Y'QM,H;'^`
MX+6`1@*OU=9?FE8U(]I:S-REBP&I(K88Y`0L#`7=*;RY#91$:4;LDO'SZYAC
MX+R[!-DP=U5.S?4S%!AVMQ`Y?'EQN/6W_J#M3M;8&&5%CSKM^8#]Q^7<*"[=
MSN)SU0U[HMT%X9$*\%9K/-9(,93^-566@@7Y'>4.=G;+$T)%R?$,!3RI"K+;
M@I#^[%JA2@1>QDF:H:.&N/NG^%X1A<6S@#C_JU$&\A&U#W0M4#N79.6"G8D4
M&O>`4XRXY[H.))(.OCL\/%T2@P:U"DE!\$0PTU!Q[=2^9+;7V.UU6.!B)#2Z
MU,;.R!::.5'.69`[9L/0@[O-G3NTCLDT=F9LJ$!`T9G<&L.-S\AW+@U^29,?
M$GQ-I78WGB6*BN:'>`6:I@#70J^ZQ#0KMW^#>DU@3BS5)O<3-=[J[E=(Q86C
M+5'&0SLDHSBTHPNKBC&>0PCG>_F=!U]6B;)4HC+'8B2@1W!4/1_+[I(Z-$;8
MU4I0M2J?O_?K[Y)H5S_WOGWH!^*YH)+4#)Z[M2G=F!C]^'@>N37$2?P9#SO1
ME[ONAW'P0;ICF!7+,-67'AC4?H+E>2O2M!J::Z;Y+N46!K4?736[O;71;'PM
M$Q?0S;ST0V*9_4%_T-O$,C<0-Q`W$#<0-Q`W$+]#B-]I++.:Z/0CAR]O;,'?
M2'6DI[#-/IW))0$H)[&_S5[@=K4,H?D'-Z)JP<%+VKNSH516^)-8A6H\I40K
MW-93\"@0&!@"F!CMB"@!L)):B2%!C/>8"+-'(Q4*/\5(D4['6?!I2(O-+P+C
MH'].(PI/7:KPLMS$)]Q.U%C$`G.>8=,>9'7[9E-;1\JG4%>6U%<$&BG/E^)F
M63<$>S.BE<:1L"P2`67;Q$($>)VZS++Z2,HN*(')93Y/RL4_OL><56UA@%F<
M,$`@8S^_N9$HPJP83*;!W]Y@;Y?Z(]")X,'7E&N+B4!`*?"EZ)/J"8\:[)/2
M@,$1U[!4C_GL6)B%.-;%W>!`K2\3-!SB&0@01==@/BH$R`(32Y,)/""2`5K(
M_(F(,"MG2BBAD%/\<(!BB10P4P25;AJOB'A>MK.)2Z:\<F?B$G2$,>Q+K*XH
M"1Z&2RDGJ#E.)<8<L[P]%,TV*Q1XXAB)T8&`PJD9W_,<V#)7-,MD4VXCA#?:
M&XE!>?SG1P['O<F#9:2_%&:Q.9=`MN!IX_ECB6N,20/?'?M-.@)3H02T4'X%
M84D+VE.8!-E*D;5+.ETI+DW!5V_0Z'=V&RY5$X/!J4O5Q+$Q9E>1&1V%@`/J
M+TEC+;!PUNK2?"OIH#P(-.H:.`],M75M*-<V!(9AF'LX'TQ'\DWJDXH"RH1<
MGI.&'[,$9%XX#OJKF>Q2>*;%&`\4%!@0IJ;9XKC%9:=1])J*Q-_@0%5;TR%^
M.&,EINL!AE/ESA3Z*`?"'BD!"/OLA??R_]E[U^>VC>11]/NM.O\#CJ^WCE-%
MR@3?M'^;*EJV$V7]T)'LW;N?4B`P))&``(.'9.:OO]T]#PQ`@&]*I(34;D*1
MP$Q/3T]/OSLE)0'V.,'7(BQ$S;@9W@Z1ZPDCNNJ92S'&(C1.+),BS6OXAI?0
M3WHTG4H]>&N\:FK3!DE<]WC/;5XKGU*(I#,JB\/(H#2B/#YKF`^%KC-*EN&<
M.9.)0]&`/(E(''00<8"T`N!M`$Y+`R>TT#QOJ8A'Y-0H*B@FA`;HF!P4#AO%
M&$9I^>@Q(=@XYZ`T`1Z=B<.W]=6.:%G:^$O+T:G`FF/T)%VX(LN#EH)76<@?
M32,8%0.#*3OZBAB,3[E'8K_\3(Y4:3J#W-"W^,MK>/Q5-S.J8KP:\>5S17"Q
M_#;1CE4P'@-^T"V$,>=\C3\HW!T([Z79:=0:C0;N?*2JH>M$A0&<&#&*T9DU
M3##A5BWYA</[_5*:#MPC^"[]DN;,*4JL84QJ"&0CCC[:T`3W)X8T'G.7&@S$
MO+%Q6V_AWN`%Q[,H(NDAE+OC(CUXNL-'JRZ/,WR0#B5`$=R4$86N^NBO@[=;
MW']PH7%W]6E5".XN2'X$'#\NBK\`XT*'3(K2+J&[E9.WD#\JS@IX))E!N^;6
MB`[HI%:!Q9B`9.'),CQR66H7((R,:9L@C0%PDX#.97J*3L&?<BZ?E7%[K3U:
MLUY_F,V]8,&8".F]12(F^0;?A*N(]N%+0/('<X9`PDZD_W091/$'DFZ8\RUX
MQVY4?,''(+QA,PNEI_#K^"-(NY:'_30V*FM%$ZE8Y%L\4E]I26B'OT&.Z^*,
M],-RJ2O-F-YK-LJ;A/1T)]3#8^)!M@$G^DAG\V'17E[YNCEH/`36Y<(?#LL@
MYSPX<9<[6#N-_H.A&5;^8&C^1NG[#XWGLBIR/[>[S=Y#X9F6_G"(O@\>',WE
ME:V[K0?AU6+A.I+%<S>J],)'$-KXF,39B[)M9.;+AJV4'K-51VF/D_(`@E:[
MT=!W8R\,::B^$MF_,J0"7^#R]D>I7.+.1?NF"K4J]WHU8C5B-6(U8C5B->(9
MCGBF[G4IX!A"PA$1TL*FJ(0<@Z2<R@&O.]T4ZD1-(Y5-PLNY%:>3I)`NYY6@
M0_FE66O"1_R./O:R^2,UE;:Q?=H*#=^J];L\304^=OOMHN$I38B7B\ND/A7D
M.A6E+5UP8DD31HJR+58..K7NF#%BF&W!/3P\^0,]@.1:1U,XGY+[<Z3'T^+!
MUJKRCY8Q],[R:+K;*8-'9.$]7MT*!QTQJGTQP^)3?_,<!C>_O^0;IPW&P@=%
M@/,*&I1-HJSG:ACR"LU8/`V<"V/(9U(%HQQYY)332@"GKW8)(DXQ9H,H@NS9
M`JH=2;`F**,Y6!IQ!:VM&+`REV]O+M]1YRS06M%_&!896D$5;:7=7^'CX/<A
M3^.+B)`_!1;92M2$J2(-^OTG-K&\#SZH]`NTYZ=]#Y3B_]OUC4B2O$U&GSY=
M<LW^=S(0D.^'1P[0L^+!SX'/Y(%8;9-IM4H[1;0RC75S:-`0]"GP)WB(TQ;5
MHN/VXK/K8^?H;?M-\[>6&V8WJ&%V4Y8?63NO!N/G39I21X?OD-T#B%L2X"V!
M*`!_+MZ\G0+#^Y99^X&0W!@,BD!>,?%QP2QKGMYH9&AA6SAIU.%D$J)KDWU%
M'S(<S&M,^BQ,@X)3W<KDI73U,]0M[U0GNE,W%)PK9MX=PE8=64]W!83EW=>:
MG;T@G"'+0LXE<_UN1.;BM^":YRT6)Y4]"(]\ST8QVDO#A"RN^"07,6A2]5`(
M,Z%XD3Z*-9MXTYG"-+LU/+5;VB=IT.L4X'H-#G6LRW`>45A1C%!XJKKIJ>JN
M;ZKS^S6/S_D:"JL[OT]X+3#Q"*+[ZU@S7-,S&V+%+&^993:S)%B\R)W18';U
MCV5H^,2+-ZZSF[?*G1A'74:>1Y;LQ8?+KY_1'W!3T"(JMY#RMK3M?=>QQ;U_
M@'649T*V5ZYC24KXDN!47\?JR<@:VE.7883UQJZR]W"$^1J2"6C:R)W%\<EZ
MTH2K!Q4I<G!)=G0-NI6BRRNJ)P>L";\5#_R;4?@H_8Z?O\\#_U;%-%ZJ<KQP
M"V(9[K%K:WZ9=&EK'429\_IC%'IN?9Z$#`1#@=`5Z"I`*CD(1WDO'JYKZTS8
M+*!FOU\":#,'Z`H0-(`%>:!OZW/@4-0[1^<G'KV9%O)8`KM1;W0$V/2Q91Z`
MOLN[[NF1%AM#K:^4A4A>U@0@O+3"$&L)\\OHRO_P`PGJZ_BCY8;_QJ(39OE5
MOM$UJUWB*Z[L<CRT2^FQ<=&12-AJ0668H)A`HA5^,-^QB>O[W(JPG@EDSJ_R
M9.-HUR)H,#W+*TY?URQ=;;]PN:50;[K,#[[ST&ML[KE&#G+)`F\MSPH7($()
MD+2WM[EH#[761NE:S:*UKH<^NVQ2>U:PIJ/%)7R7XF&&9Z$6V>S\-UU8%CX=
M=I*^$8DVX]5(;YGO!B&%NS*'VP)/Q>BR":<K-[64-TS,:HF;H"2#P<#&G(V#
M!ZZ4W%VWUS=4@%\.MI;V^^7:9[>57?CV*SDX(I"8!"):IQW!4UK6I-,X.:R>
M3UQ4:2Q@<]#O=0Z#4QXPC-+)H2P\O=*`7#/+7-9,G0'29_?(,4_N>FFA]4_=
M+N5P9A;#32HP!W,G?L:N`^_QZF2EI84>T)*4D_X[15KZ'_,%[:M"P`9KR^""
MTC9$6"0>'W'7P58I92[[T-]P[;""?3]SYT>I:M5L=@>F?FAVQ-@RUL/MQE@F
M28GG[14J?>V-?BG#:.49QBYP'W'AYT1@I3:V@R-Y&;8=(FBC?J/=:S]`_&S^
MF5R8R#[1.SQR0BO7T'ZKJLSJZ"GS'!O&+K`6!LWL-M2.T4=?[]!PS^Y/8UU+
M83Y%HW\5*:'I+`.*>3"SJ9^R71'6+'W9HI3.](TTQD/O&A@'&%^!>YT6_,VU
MB,*P"I4>G3:,2NM3WDYAI&#BIL4PBQ*PU5,BN=M)NWA)^*D3GDKY%O4Y9?LI
MC$6AHJ@(4,UPQR(96C23S/4WK,G>A+D$9$KY=JC!U5R(IE1*H-FLP46F84O"
MEFFQ.*:VE]HW/%P&!VC76HU!^KYLW`58`Q;K1E-9.`1W)KLQ::R.B)P0Q8US
M59]KAG5GN9YL>S5EWMS@E3/4`!%Z<\>6YRW5"1BFC?9*I\.2#!3_Q#/^1:?*
M3&*MC/,"TFNF`PF2N#@&Y1_W7`TCJG*L`IC2G5U93SO;;972J=.BU13Y91%1
M%)]9CM#,SMYCX6I1+4(=!@1&Q&?!K%E*@#,[$7%H\12+#=2,5ZZ6C8^YU.E)
M4I4.9$7OU2>;:%\=5RMT*<!L]7G'H5ZY.@CJ,.L0Y+B'E2D5_OK[K2@,CB<:
M)?2T\+$H^YTJ1<8K"[L0AH0#AY)]1UAR`_2G>[YYF3I$9<7I,X6)YDG,MWB.
M%B4CMR$EY80UHKE0NZ36*3OQS2V7ZH$HW$EN)DL\E^P%O4\OPPM:Z?1H11F3
M;&M'`E1-B\%[6)B;-\#BE&J)XN*B$U^46=))'>K#"0%?`K]^(YLQ<MOI-6_&
M^#3$`KU=@"X6S+G)E%/X3%0><(5)B!<@X55VJ`_Q6(H15'5>VD&TOI,6.8UD
M5181ELJ-L(:PPAIF^Z+Q#X%C)V$`8+.Q7"E,#VG-G$I.Z)F(5^H`B<&\O,:.
MOE;!5WSCBG"78"^`#5CR$CCJ]0PL-:J/[R.;B>_QJM2GQN_IA+ZS_#\-:6XS
MAB(0639^_18F4<RPYV>*1:IM)&Y3$4B<6;!8*[72Y%1*3+JFPI,C@>N1*`:B
M\?[=I;C,%92_G8*EM<LQN6SF8R$PRV'Y)],)RRNI+VWX"`LFI$U18Z"I?Z2;
M.*<=]Q/`A\0._DGECI!N81J+=]4NB!XV(R)?BCI>,-630@F,,RJF@L$%L<=O
M8GF7T>^T,EEJI`"_/*R=WE,-5=/.OOJ%,`:N'=SS[N;S;#M8'1<7QG%YRG%'
MUR@A>V<%("1/1,$JT7%WOOGYX%TCTA&BP,.R-MBD,4>D^"3>B$$2&ZH9+PIU
MV&F69`G8G0B/:EK\1J/[FFB,+M,48,W:/A7W"/>(O`6+%-6BY&I(4-=AA#]5
M'9BBS=>)<V8!/".46?B=+C!`U(:'[T^FBE51^1W1&Y,0;*F?I/A/I1-A2)16
MDDB2N@-GDGI-`]J3.142PEI1MFU1(1W<)UDJ,*N"&%*&SL!_?A3[M9AKR"8.
M^MZA;*7U)19-HU&;TN])36N2CUIW@8NI)KS(F\C,L$`BR[4W7Z9[E3CCX#Z&
M"=,.BI;0XEE1Y(Y=?@O*Q!5/*S>_-GN%VEMD!46V!*[&W)=[$V$W#<:%BJ5U
M(-F1Q8"T4>:)PD?%C8[P8=0/;`^K\`G(M1X:/#)<G-LE=!'<V4.8/X.\_*9L
MS!+S'N]8U!*'T'5P^&FFK5G)##B@R'`J/L57>,KAPB$$9E5-7!T>9M%^AGX;
M,9^-71JKK'TW/[VD;A'$]U2UCDB")+QXT_M%%`]=&FO$M/:Y%B4:,>?">)^H
MQD[9_N86KP17M('"-J&HAQKU!LA(7<Z/-`((U5:3*,<K?KHSK#0F>_@&!;7]
M1AQQLDU2&=9RFBZLW$-#N$S1RJ60A2QV"PEK11<AW$Y>,JQX3%YRDI<2(\%-
MG.8RX2A;]\\/8(F@$(>X8-4*)X_?#`:Q@F/!KMM4TA%P"0/!W8@%(Y'KT+$O
MO&[QR_3*+;IJ,_20W:5:,?LH(D=QMS%17(-,7\C8K&SW*$X+P8I>7I(&B(,1
M56@U,M&`J(JVY6XI_`>_^=_UNO'199[S!E3%">B6MX!PV".\3_IO#8J5>V.T
MC'I=OI>[@>;P5GT$!_O/^HC:E+TQ+._>6D3RWJG'P?R-T4TOHOHHB.-@!A,T
MA7L`1U6W$)\A>^-I4+Y&,!4XA[D.OV7XG.K0AO(%U;'$LLG<T$S'"'882_UQ
MN47GCY1?B'<1R,MTFE5'+[$C2$&B4J#+Q>:L!6P\=L,9+[>7K;TGYUQZY0.O
MH`I?OQ?TIE^?DL-SG8IZE$<$".J\H9(#G42"@W\)70Y9FL-FOHHF7?H=Q^0W
M"<!,Y9CCQ9SJ0H]Y9S..F(A+7B@$RF*:3J:BJ#30+.;L#&6I);V.M^)#&9-K
M;;PC.V]RML128J(N=*+19WIQQA^E+G1XK6-=5LYI-":F:1(C(=,4<1J>C<O!
MP<YV7A(IH8J7JA1V."$UZ%6H-5BH9&N1DI(=_[2V[W"&-1%;D;O`RHUJQU[Z
MGN,_:GO.!VW%^7VM82:["'0796S\RBLB+-3<.\)`^R'[-AU9.AMCP'N#OD3+
M36KQ+ZC4+/313)<_5#FQ!.W,36:X9F6ZX>(<7/===3;1UECCW!RSQU>M3MEZ
M<$B2;T'X,31)^:59&W0TOYTT[:=RU[C&B_<N-$6Q+W<"D,_N4%9!4&MY_*.<
M<T^U^"5N`!\>5@VGSI6JI#C>L:02$N$I4BRUI9W?8?NV:H].M27L?AUA2WJ[
MMKN-?&_7=JW1;^Y;\R-;?D-,H764;15TE-VD_,?&4Z+:J!2IK0;<M45K^Y#=
M5[--,H[;B%16.DD;DF[8:%3#G=YQ=%VOT=5&^4Q5;#R&.OO3!;0")*#AE"DY
M>B8R2R0?UPSF(NQ6&<@V`:X,);7,9*D5;JGQZKI+!Q<#6_UR4.MU&J4%1F20
MVHH8L^50-$R_/V1&KI:"V\7D_\9_LV#A?!H4MS8@(_'8U[$6$8CAVIFVD-$W
M_'Z76I-ULW^L.#DJ!`'"D>?-T?KB3RBJ$/^.YI8M_Z9R3@`(25TO)`@CZIM1
M)Q*81S"R_/3V+9"W$T_?&+U&8_Z#2[5TK\6A?/D.6_.`]B9+17$U77O2D4\N
MW7_+P7B9HE,<RK>&6%!J`-"6_3IV"F8J?2-[5V??A44#J@`[6*=Z3Y`%1N7\
M(\\".C$O``Z#;DR"9OF(YJ%Z'8=G@O%-9EHUZGKU*D?RI07'RG:U]3";NLMB
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M&R:1\?U?AK!39$S&6V!M)P5W=W%R9Y+9<RZ-J&J#9O,TUE1MQF:LK]J39W5`
M'D_P6M[MYD6SH^NJ(DZ=S+E[$)$V[`Y[^XYPSL<PG"`!8`X@C.\]24I"S5JC
M8S[$<@YRHI_X9JS1F*K->,C-Z-7:@R7C_,-NALY>7Y.S1QG>BKMM5'ZE3:R?
MNQ#_-A;WDW(X27^X(=W@^]SA3W(G'LAWH3E\GO9",PZ7I[W4U"E2.4+.Q"I=
M.4+V0%ZSUNOU*ZR=+-9.21^7#%NEEQ'8^'_C,K@P/L4B!:"R[938=AJ]S17S
MRM!6&3^?V9X\^@$Y4;=490?=Q=JS'355IK<C&Z57"DS59CSD9K1J_?8*Y_YI
MV$%%A/].L?PEN0!40O>@B0#-QN,F`CRJA?:$#'Z]!S(.47;:YP`SNY[!<K]@
M'EOQ:@]L8CXA4GH@.V-1GLC37.8*]^=36N9SW<T'M(VW^QL;U$1+4UZAL(;%
ML<_.'-G8)BZ[.U@AT#TG(^X66*O\!GL@KPL'MEMA[=1)[I'S*&0-F9#K7AM?
MD:<<%K^"ZH\&S>GB8QNQY^ECPZSU>A5]Y`*:5T6C/C9_.Y#%/E,"J-[,&!7Q
MB3=&4^Z29GH2A?YD/5;>,X^^<M*N>9)W1F^>`#4\*E"/#T&%E@HMYX&6QPP[
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M2'R7O^Q&01N^K2>1\^)GL]/@_TB@\_-N!U.K;IKU1E?[6`[3H!2F+4":6B%[
MA_U,L;\F\R-"ZS`,L4LK&O7>+?`1ZGAZS;N`#N^MT/G,FW9^2;!ZZ]<Q#1-=
ML_##;.X%"\:&O)FGOCY7*SKQ^[5G^:I+IGSI-H8]O!:-JO$)V32S&`/-;NFN
M-#O:\H^ZQ.UQR1_19_KHAE'\;Q9A>V28P`V<X3AFX2_P8OP>FW)O4,;C=QKI
MVV)>@-*OU!F7(S.+^2L?DZ;=.PW;OW]S8SQS5SZ<1M=)+(^>_!+X<LSW;LCL
M.`BCI9ZFS78#>YK^=SO,;X^00R"=(R6B,:,K7TR#OT3#.\OU>-&2]8C7J;/>
MT@]HNZ.1YX]1Z+GUB(@(3FC+'&Q-H;NM(8^KT?8G@8_XW;]CV(\89D&BL29;
MT"5N&I'1,)DD48S<35!;EFQA['$0SK!].C]OFQ*M(!;Z'3]_GP?^;6+;+(K&
MB8?+]1@N%L[Q'+9K[-KO4\?%9]>#5P*?1<L,Y^K+1YW`6]VE/9TG(7OQ<P,N
M27T[#XCFT]I!6;(;'6QGNH?]DCTT3V8#V=+8XJA_#,(Q<V,`]S@\JV.6\JQF
M/\>QCKH,'6=XAUU%4<(<WIF>O_!ORTL8#/0Y<)`6+$X:GUQ`>L14]_%E=#3J
MC8Y`!WULF;\C[7X=:^!S7O7A\NOGH>]<W7Q:1U.M9JM,%.D,3%-#W#YKT7#R
M#4"-+&I9?QE$<;2\3)-$6C/]./A]:-LHLD1?@IA%GP(8`5;WT?7AJ`(D6E&R
M=XM/;&)Y'^"$QHNO8[VUN3KFOUW?B)3XVV3TZ=.E.,1?T44,1#%S*8TIHF<+
M6JZO%NU:K4X9/MNMAG9UYO'`4>0P]\T0IG<0A(^>-=FJ(WK[Q<]C@(C]S^NE
M<=+A>;?[^*,;V9;W7V:%'WQG4UE-S@03U>MF$RB03U4V9CKK^\!.9NH13CL?
MX;N"_5^QP-:+G_]OBT]9.F#9G`C6]C,V@7W`MT5SJ@&79^3@[(!8T^3S\6^S
MLV8&79X3Z7NKJ1JH;]7_;W82'"4=FY^C2_@^M#R0J]F/?['%5K7Y0+Z`?_K]
M9F_0Y3,5CKDT)9Q#N$.1Y_"K^&L21['EH\6C2#>#A;3,8BY7'Y1>#'!:6]U^
MS\P`MF+F)2@YV=^P>1"B`'`;6_%V]-5]\?-_6929OW#,_,P?06@(+X$.)D&X
MU89T7OS\R0I!?@*6RF`,&,(Q:#0=B,SP^;EOV,2-8I3<42C:BN1>_/SNZNOE
MS7]OOQG7OPYO/@\O/WS_=G4Y_'1K7'VYU"'(3I('X=^!!XS="CF@6V&\]^+G
M+X$^4VZL_%3_89[W+S^X]V^9%<$UX-`=&&XS97]IDTL&3>>&VP$)[G8Q&P7>
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M3T$4`>J_CK]9/[;'Z,`L@[F^M-_;0'+@9:Q#_:!9OHQ6XX`+<1P7622H0);K
M7/F7UMSE(=!;XKU?2BN=3K>1OSJ*9]T1M+6X;)2"UFX.VJT=0/.\P$:$%QNP
M/_S`C[MX+S03VDZFQ#*S0MLLW1Y][1LMZUBH*(/=+-^_7J^7V[U'7<'.VV.6
M<ZU>IW.Z2]S1?VF6<[=FL_%HJVVGJVVO(\E2N:+;Z9S2"O8@R5(5J-OJ]T]V
MB3N39*DD9G:;^Z]VAM:8OX5Y6\F\)19L.&N]C7CC8(6<0,9W'>P5(.P)[&:,
M'(`M52Z7I,DC`=M.,;ONB)>K@@^%V2WX4;OTL.Z!6>`4CNLER"_22)H//VPO
M<9C#(Y)F\R060WVP0A\&PD`1.A@%@3`;$'?&*6=VVZ6VUU:_F9/G#P'N@V!@
M-1'F,%`>2M%NMAMGBH$M'+-F=]EIK6B@FQ?_S@8#J\]V#@/E'HC6H-\].@:B
MB.78TV:VC5)N;[;Z@TX.;IIDLXG7FBW*.3>Z:]H;3KRS4:=3NO!^N]-H%DQ?
M;"I9#<4Z+'1*L=`?M/)*[PHH9%S"QR"\M3R-J#9"C$[)W4&O%":XPOHY<U?I
MQ+L#6("S'("EWO<.(*U_=`"EEG5%=@#I4.6F@=M?@CL6^A2E,6%P:[/H/1O%
MZ7#+$FYV<:URK:ME/@#V5RQ.%C5D6ZZHW$T#Q[SYJ"O"#":*:,'HX_=L'D1N
MO&X][?(=:O0'QR<_::D_"OEU5BRNU>@^YN)V)+_."O)K=LU'7=$NY-==H4SV
M^H=>CV:W_@4KFW[W0V9Y[M_PI^7Z[]@X"-DJ%\"1F&2IL;&YZ?G;<&&/B:==
M^6WI]=C<]/R>`W)V8MVE=).W%IP+:E:LM90,NNTS6^M!;CSM1BBC@M7N]`==
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MKDBR;@Z.2I!(39^M6/SU'S>>NOY7GU'RJN6&E+^]`V=9E?C0:VQJ,=T$N.,N
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MU`RDAWV*W9X7CEL/@V(EPN#\H]!X3<"@//,<%L]3+#-+O\+WV;-8/EEW,HM/
M33V9K]$OM4W)YB>/$#2$;57$^EPQ\B&"*]2*<\M'"3D%DV3EQ^BY(.[:5N<?
M&Y22W:IKT=<1O,C+PAK!V/A^<7MAI#80ZE;DQI%A"6-(.2$($,UE"#>^:LJ'
MV+[\KQRKL6XPK259JV::@P."M]^:SP5M[16ED2N4%5/:BD+K%<H*4?;JD%2V
MHO'S^6,*V=BJM@H')+#':\!!+RFSM>&`CFY$2N7>6%PYW?XIS5ZMV5YQ&3W#
MEC)F>T5OK6>(CV;5Z3QS0YCM?:%9<2^<#1J`<;0;*R[+Q^;Y._4X+],@=6<>
MJB\.=^=ML?IGUZ.PV:@-&BLNEJICY(/NQN8MEZJ=..I.F(W36%"U$Z]6R;V'
M6M'F5_TSW`&X(_J#1^5,#Z59/CTQN.I'6J&E0DN%EG-%RZ/HE\LNM+7]?5T5
M6EJU^"TEF)Y9:_:J%K\GLAM-<X4!M=J*A]R*[@I;9;43#[D3K[H/TF=Y'WWS
MB>\`7!+MQ^X#O[Z_,GZNHG&?1S2N;-=IM$P*QEUBUE4P;A6,6P7C5L&X53!N
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MWDLKF@Y]!__SX:_$O8-W0&H8QI=6&"Y@HS<O5)XI/US>8;C=[3:SY90W`N$@
M4*\KFES><J+3[K0;CP1U:UVM]&9Y>U'3S+66?$ADKZEEWRRE$1/@[AR)2*Y9
MZ`;.E6^'S(K8>\;_NUE]ZM*5E%9"K_<&9FN#A11#=<CUM-/UK-^9TKX)`_CG
MR.L)/-=>*&ZU1>%P`'+0&_2/53R\&K$:L1JQ&K$:L1JQ&O&((](S_&?C&[W_
M!=Z_P?=K_(N:<0ORQ?BM,;/"B0M:%#[:X/\&W<OU-P<TD[2Q^6OT(WP7@QIG
M\_=0CJ$T!?J@232ZIK;J\P%0D-4M_TBBV!TO<FD8C0N%H*S*>110Y*S-GK10
M3YEQ&<SFEK\P)LQGH>5Y"Y3R(A<TZ<BP$7LLQ9X1!\:(&?`4_VG*/`?V`MZ8
MS5AHNQ9\/V7VGZ`#&)9M!PF\4S/LXBBLFC$+?+9`2/]DL7K>"$+=9H[#4_2N
MZT=QF/#O[MUX"N_)7E(X:#P-&<,1XRD-X;$H,JP8OF=$^/C,/`GM*8B^%P8N
MW!;:BG%'.A/\;DNJ65JW-9^'P0]*!8J,L>6&XB4'_@\XP4FB:1#&]9B%,\-'
MR!B'BH'\[\9L%EUL2GK59]V(LI%BLHDN<P,4%;IVS)Q50VZEXO0;[7ZK4G&J
M$:L1JQ&K$:L1JQ'/<,0S57%2>8:4G`=4;+2%EZLS#XN,<NWI^`K>DE:E[0S7
M*$A!6>ZL:(1L[#$;U(N79J=!2H14QMP(?@39-(0Q0+^86:X?P_]1&;+PW[Q&
M!^AB5H@:C*9A:0H6OAFQ\(XA!%2B)T8-#Y8;&A9\(9,C;9@%G@9]R#%`S9F$
MUJQFO.PU<+8P6%A>O`!H[I@/RL[<<AUCM#!NIV[@!Q-70SQ^PO_#(BYJQJ?8
MN3!>I6'S]MO,*_2=\_8G@#4"_1A++!!<:FF!3PBYGEHWGX?&EP`5KU<.&P,9
MD,J)WQCMGTA=>VEBJX&-$%B$"8_%\"<I@!P35A0%H,PB3*1IXL`>>7+8#V8G
M6!>!YATEKN?4@R3&=[$@`C*>=VXX@SV96C.`(((-LJ>@,=JN1ZIJI04>4`O<
M3*7+*8>X^R,D?/>.#</0\B<,C0KOW<CV@@CT]AW<71%H@KV'T`27XQ<R'&D?
MUDL'JF7HB2Y&!EE$\E_A+(3&C21L_.H]L`8OF%-ED$L8.[3L<CN;8>RRHD+N
MOL%02_QY9WP5W#E8%26%[#V;6R&9K)`9_,J`:W+T_)K`YN+]<>?:R,-TEOAN
M>/-^^/K77V\S/#'#(XPKW_C-\A,K7,"ET>C5#/628=T#RT8&IS$^"[AAHUGK
M=LT:0)Z$]07L%%$R[@MQ/'S<<NXLWX9W'6WWT$0&?''FWKFA>C(.F:76Y?IC
M+V'^W]:%\3ZAJP=@&M2TUVQ`&@;@9@:.INXXYIQX'-A)A-S=18C@4@G@3X=Y
M0&"P0D38TJ33()H3XO^&(>9`BWBV+XQO<+LE<[C#T,@'_)Y&K@$"TIL6@4O7
M/@L<?DDB_[Z'FT#A+P#&'C,QMWMQ=Z$M2-R('+0`P!9._7'B8_`57H8O>[V:
M.3`OC*^^\9&-0MRLE#*:;;KN83\R^^3#RFD'XJD5:YLZM1P%&-Y%QLM.I]9H
M-(K74:,;TQ>K0)C0&#N'*PT7R2V0>(E&>+9S>YU;:.&&2W1G-X%N18T6ON$2
MBO$\"H,$.`T?F0*BU7.T2F,,W$];/JSB9;/5KO4[34(YH/_.Q>5)?,?ZML,V
MP,4*WP*H<,J^O!]RH8?]"9?O)(%[/D"J0NOMG;CO<ZMVN9Q!)8[@J*F*>QCK
M`V?-#2[#!8@C43*:N3'2L)A&S%LPHK`'?X2')#GC"T1P!`@78/29VMPBG6)!
MX8C]F),,`YC\+?&9E!W;9"X/)4)0]D#+<U:\,.@?_.9_U^O&1Y=YSAOCVIH`
M3[L%V8@!]0&C[+PU*%[G#1!(O2[?RS'%.;Q5'P%A_%D?,5@S/&UY]]8BD@RU
M'@?S-T8WY;!I$EQ37&4XJCH4?(8L*]>@?(U@*G`.P^?A<'ZF2TL44^RL/)#X
M$^S^#`1"Y&:E-]XPB:=!Z(*(C(="IZ8-;X24]0_>&E_'<'"DY\`81I$;Q18,
M<(M!.S'>`4APUR$.S1R??!PP(D`W#WPXXY)Q*+JUEED_?N&"++_$^]]=_G_M
M=JN!,K)ES$$<@.=@Z2D_P!'@>D3VA[ZA)&*D"]Q\&2*?F`83YD?(D&PO(<J$
M,P*'-X3G(NVF_(;,NH#4^7L,)Q_)J"GZ`4!["8>Q!52O'7X)K1,F$]AM/P$A
M.Z8[J88KN&>>A_]]V6P"+^F0YN2`<`\\*7<Y!7->Z(RVW8:=&9&<']JN6!\B
M;:*JG]6`I<$D=/+@AQ1/RHTDD4S`(S]K=6MF=W`!^UFL".*EQ7DC+;5;:P&[
M!YX-D#!?[2GP/W@GA4S"K>C.C=2T%T<1E$Y2#/MBB3V]\J/8C1.N`@\]CX43
M+E!<^6/0LET4--Y+ZLV(85^NAE?OUXMANER!EX-Z3:%=5Q@E7Y'';M5ARQXQ
MX%*C))P8='3D@;M(IP-Q"QB+I+3E]4<IOZD!HAW&;08N42F_=)'.N%0A;BL!
M+;^'."W*"Y?378:\RDT:=I!X#IZ@9,Y)OPVS-($IC+G76)UI0;S`QK*'35LE
M'CE`SAAU#Y)BYQ3(R&&<!)8G'+\:8#KWL0"A#OF+:S0-RD>NQXRK+^_Q(O:$
MA!))NX.21JF\(?X]2R(;9(A0;5:AB%2X735B57'B+%;M]`=0OZSLBU+.A!4Y
M"6(ZW3HNQIG&E.X/)6B#"FQYFS*7YJ#6[W7V9"YJ26XD;2-<[,3\.BE1"8K2
MKS=@^[?#?Z=F$2%:GR&S^J:Q>!&.H*EE@(24-R#IV4$4U^=>$M7'[@_FU,=,
M>UV(SVZ4E4<`MWBQQ!X7[4,0%_$@A,R=`;E%3!$1/U<1A4K821AR\9++AZCC
MI2PIA9BDZBB]]A#(D'F64-(*^%4JW^+R)`'@FNB(_D`)G0'9!Z0QC5VDDA*,
MW+L`\<SZDXD#[=IH<0-9A@=WX&1(&%*XT6062]=J4L$A(H'!D3;#0LJ#J0!9
M,T1(306%X,TB9ODK@2L%I#@RGY(VBID;R#K@QX"L'BA@!&$D^8\JAXJ'B;)4
M(G&,T!QK45B,@-#V4%BB\!D4TUVT=XK8D`P99+[@3(L_CL79ER01#&]!2J'P
M%J0$%-#A6,$GW'*T2Y*0]J#GZ['%`=!LB)U^_Y?QR065#<@B:X7^_FG%+?]5
MJ%D@@Q6J"(Y1.OY?21"KT>F/GY#U>N(A6XP1A!/+)R5:WJO`/ZW[2%+U=Y\>
M_Q?<8$[`K0X6:I^1Z[@H_\-CE[>?Y-PU$O#7CSQ,(B`JS[5J!I4_)AX!U&C!
M0#9#S6$(!X[SE%?X8F9)Z8_:X@Q@W7@H)P8^H4H"CU$QIC"I^R#TG'O0W>7A
M@/D$4ZEI`CN_\=((,EB!<3.\OOKW\)WQ2M?3_R`ASO]IC64*+C$;+D'U5#JY
MO%*C!/4X&.R.1X_!2;V*0HMY->,W:XY.GW^!AFL17-\L]QXN6\+)',\BV0`F
M#"^N^=2E,SUAQ!XP;(X$,*D:I,CZQD)0$0-A%>+XNU"K="/AU%$22%9*L&P4
M:D$W1<,..7D<;;F$>;B<D?/[L;<`BJ,=Y?Z4!,//?)VR;F/<';%4>IM6FP&'
M&U;"B)=Z#GP850<OG3P%5$Q"FTYO9>P=@G>17OPQ"/@3[U%S&SK`WURD3N+M
M><-(\6:OQ@B,H<Q69I]$1\[C`P_/Q?TT`)8-5RD)0-%B-H^#&3QOTUQ^8,P"
M9+Q3P$Y\#R1K+03+EVP`-7$795>XQ@1UT3%-O48,:"&8N3:1':#`1C*'=QT&
M7P)+"^P_Y\)N%5*@)<XL\4\&,86M7S3%\WZ*\BL>-[QR%''3)"`2))G+(3-+
M$F-$IQIU5XO\EM&KA[H+KG%Q:`81HDF&)=44XDBN&+$L+R':`X[Y?R*-B]9P
M",(G<()HSL2SQ`I2.IJ3TY/(,IZ2&9,'>B:@/!`C1H&=5"\R5,KMO0/1"ZXH
M!';B!2/+$Q&N0$4(N)!^%/NKY7@?CB7E<$H*0S&M#N(2Z309:Q-*T@!\7"2R
MY9FJ$IU2;"ESE6)/W*O):%P,`D:Q0XJ84CPD45/7LR++8Y&TU<X"G"=[7FC%
M:DE1X&VPK@EJJ;LL2Y*ZN$ZS2R.O\/+2M)-+J]M+8*)#H5'Q&FGI(,,O&ZYU
ML46S75-D`^>[J0:L"S!?W@_U.U[G2ZE=^P+N$BEAD-E98CMW,)<<\EG4CQ,/
MA`5B4+@+<U22^%&AKZ31'K?;38/!@;7Z7!)(%1N`Z?]$Z1O2,O)^R,7W!*:5
MLQ$5$47"E>-'8W3\W_O`@Z?NG'L1X.($B=NG:'8%LDO*@;R,A)\!EGMAZ,PI
M-0:F4D>$ADAUM_K&I>5;CJ4TFP_?E_!D>5&PA"S-G<%=#\I.P5!;4,HZ#2:,
MS?FIDC"8,[C6/J-1&U4?V"SFVPN=`#Y\SA!``LN1#"RS*SIE`,S!".]$YLB;
MT)WX7)4D'%T5ZZ,KR(5$;?@9=38BW#\"ERXUQGC$"Q%%S#C[!-)ACO`!,=3D
M##^APP!?A6R.!@<_)B=VQ*]7TI/0BK8@0PW>FA&.!1S?A1/"N0SY5X2FIMEC
MG%0]59KH"H94R&-IB87FZ"4/SA&YSV%NY^UY@;!ED"\MF<.&P,[.K864[EZV
M6K5>N\'/[LQ2STN;HMDDRV76HC\#T0A$'I_)D:*\00/$?ALV#?@`$".([G=,
M3JB=+35,YHHKH/]7[D]2JD5/'X\DFL/!LC`D!=YUE(?VE9L^"\>+/XO`)UZL
M/2@IY<-W6CB\Q5_+'N85+_,GLG>O9"?*E)3JAID-TDU,(#JC@LA#OU#%03L#
M:C_8.@?]<A0U-F)`!S[B1,`]<YTZ'$@_$M::"0Y+K'?&./)0TI\E,\K5B:8@
MC1.Q^"SF,D3&;P.:<W!?!Q$E)!"TV05]3;!9D;`U\4-=(OS*K)^(V\+SLK!Q
MB_(?^JL];U%(I]&&&%G"`^`4%S$.^!H`$VJM&;^SPT,I+!4^8_P7S=TJW`W0
M\5L"(J=IU*47F`>^[0X7_7&/5%$"F.)7-6'](H5(@[JF@8WA5@Y`C&#7.',%
MH>,/(9I*<Y@#%RUY'RP'L^'X(45ZMMW03F;HZ43?9VB0V`V0P"[82IO&S;4\
M>1<9`7D!L3#"@N1JN/]EK*)B)5H7(V+1-#Q?@2-")9</`I>_T>M>PX?1O@*7
M8+BHCQ9U\1'-C6BN)>+F9A810(A<`;^@`=15X($XBQ(PL),(C0ZH37,KA!Q0
M''AX&512KK`J-;`<U)REYD:L'[9NEC$TZ`Q!7#5`-?*"XAS!DG8#/O%W^(&T
M>)24@GODGB/Y@&*PG+'."$WHZ4K(G%/`B6&DURC#*#I5-X!@B\I9AG.CR+`L
M)J^/9.B>?B3#(?T/E&I82!?15/K:T,^_FHJ%A+=,M)RN022/@SH_#X9.8#P4
M>9$EXSSON#`^N,0\2-2BNSQC_\[!C=IWS-T>(<-3PJ$(M"&XB9N"!):/N6!5
M]ZAF8JHF.L8\[9T"L41C4\(G2'U0R5Y#SHF(7!H%D$3)>,Q"8;H#I?:.)&EB
M7=D3AZNF.WCETL?T!5WN"QE.K!E3*:0)>2EN+8.[E<8`0<1UA-=".T;`"^=6
M+*+DQ*2XJTZ``:=!C`/CHBV^E/^CW!?<($+&,8OWAH0+UN5*#^Q(4#-&2<S_
M(.^$CSY.DK'442_2T#00M+M$O0+`ZZP:S2[HK(>=$T"@S9!KZMI0T7*0AEA^
MK0"_(HPL2NV).E!C0<J2Q47<N,U'QH&(T[D8'V_175X3RA<7_]$MBSN@#9GG
M:WC+H2^&PV8S.'H\:HU?79HU.F_8$6R:O^BX41J^D_!I$2]*W`.@/<PI0!UH
MCNH>DJJ*JLRN62T6?Q<4H"%?HD`I<6,*J0?>7H!Q1!)G.T3J:`F:HS&:M-]L
MC`$!K(S4\"3I52[1E6]PL1#O1Q3AM!/-Y\##I!B;U*Z)!RV-2-%*:7:!.,Y[
MZE?G%1MSJ"R-I5`8&>4J0I+UW<WZEWPE]C`E8%CJ5!*MRQDU_U"!2R@3L<E]
M%X6N@:Q-5MICR"TR9G74/)`SXN'C811:%&N)(FNEMX4"59D[4CL/=U!9PEXS
M0X52]L]<AKU,)DN?/#VI3*R=K#E?[3@0`=;]`L.-1!.%X(@`]>7=I[#KN<:<
MA('$1E$_A2+S@@@2E'XY$2PCN+O<#20,G:J$[Q^P22$TZ6EHY:)H<']^#8`V
M_@7_NDC'F%J11HY(3%;B@TBQO&%9<Y#A`P:(@P\OOPVUW5<C+\45"UXIUH>F
M!7@+]0LR[)YAJ,RNO.N7$-USEZ3ERT9^J;%:<"OMH34I%*@V`[5V5S.K'&O2
M8=B<.PE_ZGIVH@\OG5=%_@G-/%C3C%6U$F^(#`:2@&1]E]+T!OP!^"&&CB@6
MPQB/$>LT^$OJR(HKG4M0*CPZX]^!RS\D4P.WR)"U/_%(>U>:+!H8EO@A`:D;
MVXJ?%.>"GO9U4P\B*6?N07,PB+X?DQ"%!W3G%N!Z;F69'/G[9FXRXW&'N`1$
MI`PYAD.?397(>Z5T7JO,A9DE",%$VYKG<YH_8S#I'&AD9O$6\[X,6_T5!#YR
M9Q2&ZVCO;2Z1K#GD2B*I*9.13*3E_G3<SA)A15]'461OJ7\2'@Y0&O49QNQ<
MH^F,&5\2VV,!F2.O,<%F"J?:0VTB@X/K+]?9G%G7G[HCO"MK>HQ'X&-G@\FB
ME/,L+8D,KN*.KF66IN2;HB">="D7QI&I[21I>>B!Z!,;'[`B%4.[>P`J%S=,
M2\\:?OXOBZ;NG85Q-^A><F,9C>Y@,):K)944R>'##Y=?/^O;3B_K3US=9"+9
MI,X(DWF+\@NPD3T;2FNR,%5<U-+B8G-*9O0E4"'GY`097\K-IYKQ"O.IY;RU
M-/!)0,GCRV",[/'E]PO&#4MUS88178<7V.(7ABMRM4?RZL<;)B4^[MKU%"GJ
MUQP*;`4TG.HB2R%I8K28:GP!LW<P)LD=)3)0LZ9L,WBGU(K`IHMQQCE(Z$J9
M744[<ULQG56)UV6@R<HTYS$G&?%X6"0%<VL*5DOSN;(A+!)CM#UR=X<0HGE%
M-;2QT':&!IO-O6#!F.(.:J.R0!&S("$[B5A6"`ZYJH62"ANCDR.#3[Y6S,Z)
MN`-8^.JR](=K3J?`.UEZ"PH4%F1VY%Q8TO5?<<L597-+)%B3"<:1Q&(?J$@`
MY3M8W@PO]I>8FM!(6<R<4"D=:C^)$`6ZT'.QT/EMK!EHS<&P%G?BQII"E7&L
M""M3*A=)X/5]4@85H=EPL4HK/X>11X"3O^"N$SX'`:/F]A0B'BU;&MS<T*ES
MPR7^&P,>>%(&YGQLL3N6[Z-I21,9(QE'A:E3?`,$OCN$[9<=SG-$E#DOL4!$
M8TTPC`XK_Y&Y2O-BJ9!KM2BMT%Z&4-U(NZ'1.#1*S5S+BJP>,`T_34`L@WWH
M:D2`T7XR.1I-I2[W2`F2(NLNXEQ:ES$&,2%=E8=>B_E2$,_O5KS"-$D4H\S<
M55&@S&>4<Q$BQXE!?_%@C!@'VXGOZI<;WF/ZT=72%4NOEC)53F88U;*[KIT9
MRZ9@9`O`0;"%,(BJU]3RQI*NLM[MU0=:/\I1,E);D1?SG-Q*!9H2*AO#Z[B4
M'*@4U-1A0`H0//_*_2DE/_)N++-I?>_U\`UY.?'E<7L)JEG+HK9#AW<YE9X2
M=QO=95%<^D_31PNL6H0^G#"+MI*8,JF"YN^:B`O=*9D'0,(N:C+2(45.=](Q
M0:$457L8>5SXU1H*AV[.7QTM[4>:UK+;+2+F1Q^?/47.[)PG/Y(%:;D4*-0N
M]/%IA09H'Y>9EAM%"5NF='ZO1M+1AF)-(%P.G`+(%B3E!Y79^[)3&YBF"/=U
MG=R8+P<4E(0UGRZ,H0I-0JDX:S')9B910*R0^7#D@L@)P4\HW@`#T6AD<D(I
MFX,?^/4E@A*WYBBMV^3&R[C0TD663J*X4HFXF"O$35IBC9PTI6BLB6N3\E-&
MFM=)%=GE[YXA17[%ZE-W%&VKL:9>496/,3=!J;N3O+H2N5K`9KH9]^A<S8L1
M>UXH7X![7(>!#4-$QBL+ZZU08-%/I1;_E#D/!>2BS`#W]@[+C2)TRTACIKQE
M2&5\#>KB>>XVZL[:3@]HIYO;[[1"0V:7A4L9DP1#8&="PJ(M<O5@#*[4Y=W#
MVB4O&4@Z34HVJ<"5"F'RM&O9Z/"D*ATQ%@HO9GG=N5@N[:%S"0\S^C#FE_Y#
MLEF=,G3Z/PRO+;U*#L"`-PFTZIU^H-7ASKZHO<430MOBT%OA*)@N')+D+J=L
MACK*(BT2\XU9,RYN7L+];TTPW.7*]X,[O@GJ.97%26'N(8C8!=;!]"F9L2"*
M&O[;Q7QD-V-AA/W]#Z.<BCCO*_OW]_]DS<C(%B)4Q=U(I%&@"U8O[Z9*2G#!
MM3BZ1&AP%&TMZA'%7(T0H\0,"TKJJ=P\OSG[!J;`%XY_C]%&N:5;F,6'-BC,
MW7!R^;&PT+P_*9T47N:BN^)S;B0#H?@J)3_FM1YA=+5O&C]'>WM(1SD0LGTB
M`[LDJ!?&AS03E>?P\O10?@Q5)%&J5G+G@>0[^3QWGA!.PU@RJ($K*K.S2O'>
MR_:.&Y0E]Z%GC2Q4`6.]]&:&\K\/WZUP'NG6SC2+5IF^M/L;PR]XL1"9(NBS
M!+U[ONO(TAV\^MHL:S\OLR#H[!\H`<<7L0I(U"(N72LC*AQ.:;07YJ(FH2\R
MA&19#2W`(V.INZ`9<&4JMDM?N[@%4XL,Q:9@Q-D=MYZXTH)MH>DW[^%5\Z?A
M+'`3XHP`'*7O>'JH2[Y0SK(M/&MY+#>QKE&,,Y94U]_97KH,H*BT)_"HUI_>
M\12OHS985GC`K&*-M"C<4M9X:79XP4:B$EZWQDI$?K(PNOOLWE(I=`"X]H(T
MP@4\2I-BGO187A$6ROW5A=4EE`+`0]O3GBJ9,F7",$K9HGR+<X4OM(!^I#H:
M3(^.!"PK/BNBE:GX31*I</]8AMJZN1II>#$`.5(U-,$QQZXC\N[@:&*5#R7E
M24.MX+/9.251PB4B\LLT5PJ^C2OCCR)9896-A`*O]'Q!^`(?6S(3T6XCQ>FY
M^7X@0SU1U(OO,28A'SU%)\8O8`\8>WL_S;VA@CCISHV9/?7)"UP390Z43TA%
MJ6)LK`@_RH9%R)P[?4Z,6]4C7:(TBB&;7H41:+R<3ZZ.35&LVIC,E6'V&%LS
MWO\'C[=(O"FMEJQ5!MZ\GF]!(6`J`SWT@)TYB^L`(UN'TNKST7+#U0UW?W\/
MI'5'$U^IYD0W;O3G\(<;U2]IT^W%K\R9,*4P?R:S04G3VT&OVRYK]MG(+7D3
MR`^V8-&K]Q@++FV7^Z@+ECL\%$VIJ/[XIP`$NZ'O?.3IP?[DALB4Z@2]6WS"
M))\/F&:W^#J^Q+=82!?(M\6<$8)^N[X1&12WR>C3ITN.&D#J*$[124_RJN<T
MJ7KHL)CO`:)/$O.2U)XRYDL[%!\"\V@!N$4#P+45?@VIVHM##UZS\';*JY&M
M;R!^]>6C!G*KWR@&N0[B:OW'*/3<.K<FP!HN&J:^C+7P'&`!!;W$\PLHH?:C
M+H!^C42%V+^INL16K=L!;)U4LF!B+$\CUP:]?.H]8%S=J!U@;#T,C%?<E;,]
M#MNE\/5:K59O-7A\UAU!6XNZ3CEHYJ#3.0!H7Y,8Y7"'%TW8%G7=?5"G3;T/
MD&N1V-L'B9L`N5I(*`&LV\L`EN'S@+PRJ%;S]-679CDD_5)(FJ7'LQB2><A`
M!8GH.@3-@'UA\=?Q-^M'8;.,7KY91DF3^WYW4`9@W6QW6DLPED&Q![CM%-SV
M.G![)=<A@-OOM9H/`&U1)Y)2:$LEO7JSW5L^(,=!KKDQ<DO%HWJKU3$'!P.7
MMX?)M1+=K@&HV82_J@:@U8C5B-6(U8C5B-6(YS>B<9X-0(>VG5":.9-MV3(R
MCO$)DV)+[.?YSP?`AG#Z`GP3^`H+/+GCQ98%8P\+RE)C3AUCW+]D9S#FH1?$
MY7Z]T!4E!1,_9**2[(27_46O:H`%ZWD;,TRL$?[6.\OUT"B));_J%$`LJHXZ
MW!O!:WEA-/K<XJTWL7:A+TL7H-8UI2+%68\7-K+$Z(2A\)"$S/:PQB(%BY'7
MTMID9;S(/Y9AY'"H7IMIOH5+@G%:2!\+V[@\&IL,7ZI@RS*IJ8YP^*:/0?3<
M<6CP>+BBQA0YQ/(^/SS>([-$T6%SDT5>&%\"[649&[S%"&I^CB=GJT6U+\H)
MN_J\4:?/#?6TO';G8[PKCQ!'Z_PEI1GAIRT5N@%HRY5"5XU8C5B-6(U8C5B-
M>'XCGJE"QV46`X662F_3]39LZTY*D.CK+HHO:HH7%H901?M=%:<A*UKJ=>!4
MWD<V1</6)4C*SD394>3*47?H.%4*BO2C=Y9'2>.W4\;B7+"HP^9!1*5-?V`)
M<IZ"00&P,^L/"N/481=!XFF-:+UQSX6<**)\$1Q0Q)_R^#G>"RE*0@)&=4\.
M1,%A"4D6OA'SL!XZQ=YA8*M*"T#=+'$=WBA-Q#Y+M,NL/WU-/*3_CM)A'!ZE
MK3I!BW!,T*<HXH^G(X/B1Q&CD35FHD"*Y\)..Z3P?@MXS7`LL<7W84XA?3+C
MQG*H<#_O+RZZMPB=-N1=CK*YR'PRWMXVC,>P=P''5TI**OL3RTU/F(280LVS
M91C,OE0&`2T>0]WS:YQ6-Q71QV0%"--P)3(%)!&9`D;!G2@(2F2P7,@UF]VC
MCT):?Z8Z"C\%B)CR!D*9Q&4>FXH1J1'&MCJB-`,1?FG@9?5YM?):JH:NT5>O
M5<*FN8G"^OO2`.\6[YAO3['T&$6FW6)0_`T6K$C8-:?%3W"(15!;P>LJ6.X2
MK@#0NL.E9\2[8K2OH>A@32^)*K7+D6^F%JIA]I;#F>9PG#'F:K`"BQIREM`H
M&#`\N8\CMS?H#;J5WE^-6(U8C5B-6(U8C7B&(YZIWO^.^G!@:2K5J"SP*PN`
M;@'XQO.@4VT[U9BCU"\IRR*2-BSR1W(:E6I4S//'Z_G\\9KQV_6-:G1RFXR,
M3Y\NL]G$VH^YFI;Z:]C^5B3R%A28LHR7K4:V_.!8YK;P!'+>TR^;H*O230.L
MT1;:T_1M7I/$O`"L,@/35XQV3<'S.?!9+&K1<B704O5*'!;9H3M/"XU@%F$*
MP(4Q]#RN5=O26)+^RBTQ(VF02+OJ,FQ[327XEC3)YT.P)24ZUE%QBL5YB'$"
MG(+R_1,%??-$9R!\=XYF@0GSJ4O60M0)8JI)2<:(E$N/)S/!<)BK,LRM/9@^
M.\MTQ$33"?7]$@4=N+E-T$,<8*^6&2"R_G_I"2>@`G+R:&*ZK#B1^53=<1#$
M/B9>49L15W0`4,`1//((%&(.B!]-7(5(#=G8HY8WV*%$:S\FZU)2A178;&N2
M]CE7>Q;,79^.#IQA%D68>$Q-!XA;&V/+#;'&%VX2]2<3I2%%D9ZL$6HC8B`3
M'4W(L]EYBYRY*(`FFL^0O6WL!?<JTY@"%]">HZU/Z[?C([81+$Q'I@U,GWN^
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M=!5<V<S^*^$4O('[@^=OIQZ%Y61*`+<%D)Y,!8(56>WM1JD_Q6RGN-H<&WDL
M\HIKA&M>ZB#>/@VV4YI^V,\>@:+I=@%H739LIS3!L-?=$:`;^(7[^KX$OKTK
MIOJE@+7:G4+(BN;=!\*UB<2EG+8U:.\-(3DK9>'D8A[737E<E_M!T\/VQ9H)
M#^;M)W6^LF.G]8'4R10_?00A%'VF7\=75`,J"!??@G<,CGDP\3%(_3]3YH.T
MF_XJROQ=19="*=W8/_H[3OYUK$%#SVQ8/\0LO7)_;O7:C9)=R.+VQ'9`=C2[
M3:BKM]R2(*26]J[E(Z/__EFVU1IB',8=(.8:31&!GVX2\#1@R8NO=RS$B\'F
MS,T-'-I6;-*;XO<!-JKT/,-/K?TW:AU+W@3Y*8_3ZFB)YU<NK]LK3]1NFHWF
MJN6MX:6K%Y<6HSKJXDHY'<ANYM$6M\/."3*F@(]UBRH72(MOOD?:KVV65"K+
M=KJ-LDMSXT7M=9N7LFFS`>=_%6@;7I5[W>2E4EFKT]D1N'D(<Y%!`#[#C0@?
M@'$/9\BE56_*?0I9K%#^>SF0U\-R".BWJFM16H3E$-#+(F5P:=Y;(:A%O.,'
M"OEF.9N1]<NXCH*]:?_+_`>OCI;7:@8E6HV91=*J)9>AYQ?+];_ZZ=^;;.GJ
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M_C0/A">GJ6S:@H.'LLF-*X(L4B\=Q?\O=\O)M7/2LOCY&`N>&2[(@F,I@QS&
M;9B4`-^KP0UHO(+_=CHM_$;^F"VWG,<?@O<2A,H5;R`>?J*XE%#IRWIZ^]@-
MHSB3Y`YC\3T'5'G,>-D%F!H`6[?6ZO>WA,WL-H\`6_L,^]$(9ST6@LCDD[PT
MV[5^:T#A$4%,O24U9&0(QN:>385"[$J#*2P8RD3'0?:Y0;DH4F0=NG;Z"-X9
M\@'9#B#?+K.$":#;UXHY%&Y$>VH+2$9,WT&*@?(P1N$-]E_M]9OZIO+N=`[O
M8LH)[66GUFTU#=[*K5O#'JW=9D_\W8._F[5.HR_^[@NJYVW7\/BM:V6:P[=9
M&_2;LL;'9I@.M$J5HE4#^K[%J=:1'VG9-GY0?.#=#+UC.(^7:9ZLS9!I]4SM
MC6W2PAS%$6DO#22#Z,(8\@0WZG0*"Z3FO_ZD5@R&;->5PG):Q^J4@C6+;J]-
M/.=[+_/8/$F=%&(&T6Z,!`-7,"50-I>N&8X+5,4[K8IF#1A+0C.D?3*RZ-2[
MI61_J15#!>Q4<C"9OL=^8,L":DJ`G2K87QC](2Z;&=F1Q2^K$N[X9*)WHR.Z
M=M),<)F[&/*2B\(T90_`(C!5SY5`:[Z=!NSA$36:G7_P#M<4.L09`D;;\)_Q
ML(^QZ_,X2$)ZA+?6ECVJ8.Y6/N71P6,=\Z86<FMEK:%-=U=U+A$/$JB=QD:@
MHGB80CI,)MB`%@&EZ628D-Y;*]NYTZPUX$+`9\U:$Z2/-4RW)L/NJ!U]$=S4
MV21*;`Q[`GAE2*&(?U5-=_26WZK'+3+64L&X!WLGJ$E?IL`Y174*S'"X"1!`
M(&;>IIW%J>.*FN^-\<K\J1Q:G.OK=7);-PT;V!:VB#&H>9B>ZBEX?WIAB)BI
MB&&O*;V3.-^$5\V?C(_OAT+:M2A>4WA%-A@521..X-*HU*&W]9-H=",78!G7
M)+7GX:=#@FU795,MGA]<,WB723OXT\609IL3K?S26?B@)-H\7)).5=UR,($X
M0H^W@UT.>RV0J@'4*;.\>`JT&GCHOJ)VZ#NBC,2A!/E;*6DTBTECF98%L1"Y
M-QKJI<PQ*7]-M!M.?'D"?:=4]%!1>)H`DG;6G7/'FHJ>GX?LS@V2R%/GL@P(
MH>:4\SZ4596.J&Z'?)A^CB^2T(^=>NX0[3X3T8<8FU[$R>BPR;YIQ/EETZT.
M@F!J8?>"-^$%*'==NSN".S>2>*#0X>QRRFXPV:E--IC$8&Q/]B_.]Y*739,T
MQ;&N-$T]V)ZZ\8C&3$S2IL_O,,O@]B41J!J'@6>DC5[EG+E[-BM);-+YL?T$
M.C\N2S_"L)6V9BK=5^P5F.HTQ[;A2$3`7S$UZ0(J\N:HW_@3L@+BW]'<LN7?
M%&O]SQ<(,EH,!20CZE18IVH!\PC`D9_>@KCDQ-,W1J_1F/]X^R*E`SEK*,>`
M<T<=R&0X-]^P%UG*B1WY^-+:!=3I1DM#718#L;/QB,MR_1Z3`$8`CX"ZUHMM
M)M0#W#G2WQH"VQ*&D6<!>S(O`!:#`F:Y>8WX"$X^"HW7!,Y0%H]\5HCXRL6V
M#":TE@S/"A?_H6&8DR,+JD.2^>Z#N*`R7UZC.I-?"O\[S/R][E`#M`#=)`R`
M"R+3",(W1C@9O6HVVK5FJP]2>.>GTH,O&$JG\X]BP[RLDJ,D&ID6L&:GQ;AF
MR;`;LY'R<;(;Y['QCB,WUPU-_35I[&:MU6T^.L!/"J6#6K?1>72`'QRE+P^/
MR>Y%TWPX1!Z*4?UGZL9L<[$D#V5Z7>!?VM;=;&`^W^ZRVE/\V8]0-Z2!5V9G
MW6':#+"?GAYN=(_OHP)8(>MQ19XC,14;Y23/>XIL9=V]4IV7BKF<)K).74Q9
M87M]>OO^RJRUS$$EGY0PV8,AYRGS#M.\&!P;2V<DD13Q#^D.>8(<I+IFMV.W
M9F.=N>K9LMOV1:M[)GSD8,*'9E+?BJ/LJ-H<P(NTS@Y_<(O@GA-JMN+^J2VM
MVAV--S[8]FS).@^P*X6G_<`;L?T<FLG_8JW%_RA+>&RQ[LD+'"<"WBG!4J'J
M?%#U2.):GM<U+YJ=G/-].41QWTM%FV37R_<=W8A\(,,)DI''CGW?;S^E=NN8
MO=-;7[5/!0$!O<&ZX)*GLE/%8QPJAF"GT=.-Z%VL-4?N!__FG%A^0]%V]"7]
M?2KI3AN-_C$(C559)J4AK)MD?%+D>)J2@16.#8S&YVF+&"8]L^*T#UHF-<9(
M(BHNS(]1_=:>!EB96D")23?X\RQPF)>FKF$'*I$UAV5P5<`R#WL=,2^XYS':
M]R)&3O7GXG,2!!J8<UA[A"GJ,JX\AYVMD$"+?MF_$%_AIT%!GHD^OYBU:(,P
MA)C7\1"Y0#+Y]T[LEPQ#GU/AJDCA,XI#"Q=?QP0U]9H5QZ$[HH9QQHS%T\`1
MP%",,BV2<`@(!B*"2:G$L/$G6V2PGD3+Z9\`'%]-V5)VPB8'3^6,>NZ8\B!Y
M#H$@*+FY<O,4H*)>-Q81UQ(QBV"3.8W*>HUY7%2X6.)WF?CV')URRUQG'K@R
MF8<9LCX/$>@K%[,(L)ZT3)+Z"4/Z\X#A8UB:><%B]9@$EA[,9S;D4'H78!,^
M#P/90R:JE/-=G[JPF)#2;+2'@A4UE.=P^[FV1U7_'9X<.PM$KD*VAR`EV(I.
M<GZ00@.LS@56YA@+C-:G+!GYE4C4\!F2/J]X;[ET*`3.0XEVF4^/:"#<(WX`
M__2\*DL=X%H9D?LXB9.0E?`,['!7'V.F5:9=()(A%::?S3UL.T\`RQW$DOHR
M0ALQ]C<+`Y#0*1UCHEKL\>P8V450).30V8!MRF8AIEG3N(.G=P'E(I@/5C!#
M1CG+R&9CJ+$AW$IN,>:!X08/E#=^4?E#^E).:5D?5$HGY36JO*:R>_CXZSAP
M;DE65G[$9)(]!>VS3A'815<_]P4O:6\/;GA5A+UQH+,L/FI\(O'&-_Z+:89K
M=NY)!N1W+IYA./Z30>@CV3!7GZE_*]'UZ5FG^ZV#@/6/)XB9=?;6'3'SV&Z\
M==3^7NI/_T5UY.GM:^.B49'\`Z/FE-@Z5LJL?T1E7#:F,+""Z]/;37/MQ?UL
M"=V\.$SLW%I"W]OR?YP:7:=4X&Q58<TRH\5)(''K0F=3*C<9L1`+K5BBZ&(P
M-LQ:N]?A[@,R7^LV3U'C<"ZPHOM9L(9E#9_G-83:@YX<0]3E2>V':.:20Z#Y
MMZC$X@>@;1<?3HN%S:R%827Q-$`[OI',J9:-*BWD`@.W/-F<4HZ>`5X8J;W@
MGE<OZJ=UB48,,$6F2H!-^YZ)6H=4+$T8^B/W1YVL^^DT9$C%EAP7QI?`F`4A
MXTTG6Q('"'L&<2/LQ;N@8CZJ')"`KV!\A]J6BH)&ZGD<5#W"ESBU[KB[A+PQ
MHM0;=V.(T1$C6,YFINSR6'>UV<&%$^"X50(RN`4!`5:H=3O,U2=KFW*%&WE!
MLN1RD2D/K'PZ2!YBT#)"RQ=031'E1M2V2GD,]'J27A!@`5K[STPU26%CITJX
M#D-S--4,VMR/5]I"4:L]O5]-Z6R!Z@]6B)0:7;-0ON/:0]]Y[WJ)Z!^Y5(!Z
M13.Y3/GY;K^LP'A]SL(Z+T?/-^?%SW7@6UJ![35P[;F(U9WG\HLH:390O`BS
M^5"+6-WN(;^(DA:'Q8MHM1]P)U9T?<@MHEO2!J1X$9U#[42N)>?F1=D!ZKXY
MZ/8?H"Q[-6(U8C5B-6(U8C5B->)1FI[PGXUO]/X7>/\&WZ_Q+VJ@>(;N^+3L
M#U]`7\/^-`9(,@:),IM8'0ZT]JQ=Z8\DBMWQ(F=:`"%MI:GBL*#H!@V%'P_Q
MD\8XJO`Y51QV*>3)3\B\H%DSA'E#"W33%%@>>WAA2!%X>4+V5^+>H79,!6Y'
M*)H"?2Z!AJHL!M3)8$81C@9#8A<,T+1'S+:2U$ZA#2L@'`/%@P"=1MIEFRSP
MHO+ZDG+M*(2>GJK/A7%NRJ3`1U?J-/:M$3UB_-BM.X@/]TX$EMF69V/G4E',
MVA'(8D(4SZ&!XEEY?6]N$^`]9Y3M)Z4F:01*(U"=@%%D+)P>VTL<9C1JC4:#
M?J=/V7!4LD)%B3TUY@&5?K>\+(XH"H^;C%Q`AAT;]T'B.8BN@RQ3MWR<P2HW
M93#59]VDLT;CS*FGXGR)5KNIJ4<W!GT)1.5R'O7W#0VR^N]H)?H2Q/]E\8W>
MKJ6DMR$-HEJ+DC5;5)L%'3HMO44_K.ZQUFR4-_)M]UN#3)>UHZWTQ!!ZG1:`
MI\E7-VKM-<WRAKKFH-]\#!R*WGRR3>6WM-8Z]@M$(>2&@2B01TI9'\"A39;7
MB/IC?@HL(K2/K@\H@G,"0#"XVD8>B]XM/K&)Y7T`)A0OT!Z:=M!6Z/WM^N8F
M6%A>O+A-1I\^73YX4TY]\UK=\@.0;[JX.5*SFR%__>KG1BA:#>+XO>J0.(Q$
M'T7M@4V,P$]YQ\J[AM;;W6R3^`-C_H&W==DL_J2WM;3==;N18Z+GO:W/B[^6
MN6O@M.:[N)[WMA9T5W[*VUKBP%INW7S>N[K:OYIM@]XNQ4F]U7E*2%GMK\TB
MI5/B)'P&;'T%4LPRI/2[YA/"R6IW<@XGI8+XPW(4WIX+&/50-%@+:<0/(H)E
M+P[1+)5QFKU6;N-7P[$GT-N<X&:W5$/JF\T'!'J;$]8L"74!H!NM9O=A4;WQ
M&6B6"DN=MMG:`VB5QGL9\`3K5/@HM(JTZBWS=Q0]OHZ'88CMUY1T@=8*.<JR
MD)`)$>DU^Z6ZFMEJF5GU>A60QUO.4/14MKSW:5],84U;O[S2H]%L]CN=4UC>
M[?7-N^'-^^'F6U9Z<EI=LSO8<4U7OAW,V#?KQU[1.XV.V:VB=ZH1JQ&K$:L1
MJQ&K$<]PQ#.-WN$2C`$B#(NJN!T];@<C*3S7&O&:2[Q4%P;24.4M=T4))HO;
M1S$T!^,K7([A&#%\87P782TP$!^RACV?&34MAT>P(A,3#<7EY"XFTF13/53Q
M+<<=P\N8'8/=P>-[K,DTYJ98R\-J4EBX3-;.@N'Q1=X<NV0>^!OGFC$+<S]D
M4@E/++)XE`X,$ZKL'L^ZCT09KI`MA?+X!@/X,)!CRD3I.0W@_!LAUI6*JO".
MW<([RG21)8TEA+UE[QG_[Y4OS?G7UF))%=O:0#$HUXR;G9QA="TH>T.^C9%B
M4&K$:G4;!P;\O3CQ-]A3/MD7Y:76%7,]X#E(]@9\*XR7.Q;Z_<:A`9<VU"%G
M?'NAO%\:&K/D_5L/ROZ@;X/T<M-5WAZ]/^2R/H`X%1@(NQ^EE]JEZAUS'?#+
MP!P"_*WHO=0$->CTC@`]'`PL'LGV)?9R5W>WOX[8-2CV`K@(SQJ(99S$^!&]
M\5WOGR_B,&$O7J\#X1H$)LMU)&\11N>A[WP%T24\!.<8E/H-ZV@Z7H/-3>`[
MSAJWHO-2-V!S\``+U`(0]B3\<G9C#@:=-4O1P-@+XJV8>[E[R&RN.ZI;`2R#
M<2^M:+H7E@>-4KG+;/?6,?4L(/N"O06J!XT5Q+$7T+'E4QD)3NP?79B#?8(K
MU^%B_=:>A7;E6:A&K$:L1JQ&K$:L1CS#$<_4LW!MQ10^AU;B3ZZ-@GSE85CR
M,,CJ5!%C?T;&G'!FS,,@9C;/W_0I'9?*=?GP:0$2*07T,`<?LUD4"4L\_.4D
M=AQ=&$/,W^4CR:I3-M9K4@9W/^(&]PF/MN)6_TR\E7PLXI9[UZ>N"HY!%=AL
MC(^1CA&9TTDO."YV<:">*8EOLS"V7+\RY^]HSE^C"2PI#F0@DKJR\.OM%_E=
MJLB;K79.R2F:?3<(MPGB;*_(\SP:@-O8$-JEEN)6-V_S.R@*-[89M$L-PIV\
M#7YS`'<,*]9S,<Q6N3&CV<[KV)EIMX1I-<%E82KWM<"G`\*TFL8R,)6?TE:_
MFS>@[(FG%525A:GT7+:`XK:'29B]+T5SIK*,YQ)XNKU>J=FUTRG9M^R4NX'5
MKIO->LLL!ZMTZ[J-)5OI)F!Q"_H"[XIHRIQ?@L")OK#XZ_B&ETV-5J`NM6V5
M.N;6F--WF+T`0SI[PJTI3;0QNSD,K9V_!."\9Z<$+[UV&4?:#"^%TZPCD78I
MQUEVOJ3SE$"P;Y1RJ[(E5B-6(U8C5B-6(U8CGN&(9VI+5!),94#4#8C#HDX$
MO)\EL\6W9DUK#%T8K^Q*Y*(\&+D1-8H>&S?#ZZM_#]]A.#&)T\8$Y6GM:>KM
M&H1_8IBO,$5>&&JGT`88Q61\S'<Q0&-D+5.Y7M7ZHT+\L-":^!0DL?%*KXC_
M\>KC5[T8_D\JC#J0W0.R9?^5(9.;0/-E^+G15%3*<[40)-%KP@KM*:W42?,H
MTS%%&#@OEIA:23'ZV^-F43RD0,I4\I%Y+L/6%10NS1O>&@QP'LQ<&W[UV9@_
MF(NB#E4UK)IH52'LMAXA&5;D4AMOK"498A#'G+H9AVR"10!II^:PSCO+NS"^
M\X>6?LF0!^_8:UMS.H)_8R_J4<3^2KB.NPT6EVR_1SP,CW("W_,2G/R$`37`
M;OK"<D\MA1$['^'<\$,9)A-#SVN&I[+$_7Z8I6VY/=IYS.[4B$TL/]TJA$68
M^J,HL%W:)`5(=IOD^:;V&B'E"SRGG?NV)3N,,SW:]1XP)14R)0O6?A:\^,WQ
ME[GAQ80?M9;"`H85+8,WAR[;7'A=M^(4D(V:#M.33L'R1"LI_KL<:5D8V;*A
MKABNK)?NUJUSW_'6N2L[!9_G$MKY.64SKTWV=O,NC5GD2%+K_Z.DS=A_LE)*
M.9I5)];UF,R_43+UR[6OYJ%.NZS5=Y]V*]!/8K'-;N\8R]V7_K2.B5F0\G"4
M'TAICS;((%V^R)T.=)9EEYS./8ADFX$WHMRC0?J$T-<VNP\&ZS$9]#HL;8K%
MG=%?C-ZC3/ETUO*(++-YT>QH;1,T?63S<Z^-L?,)Y6,83I"`6+S]9;?MF+LS
MSDT`W85YGC42N]FF[$='HWY@M%:UF]HJJ\_9N+=B9W6)2QM%>\P;(\%^AU"'
M_5SZV\R^)M0!8"EU]3>78L76SK\,<!2C[7+?$`"S"@&H1JQ&K$:L1JQ&K$8\
MPQ'/.`2`BS!5%E%I%I%+2"*_]!00;]@A<]S8^"NQ*%?'37&(CV"ALM#!AE#<
M1^C&D?:(,2=14?J<W0@$5RPXSMV^Z,2<H6^8'(M!%+EI/A"V%.1.^&#T!^_^
M)CUHI1ZWS)PX&<S!?*Q!1N]%UIC%"Y'G1"*NI;N;R4DW3GR']Y"[9YZ'_YU9
MKH\I2.BQ\]R_$M=!"*-D/'9M5W1"G#$,R\5Z`&,O@'.$#0U#JC0<90,)@$RQ
M:!DBB?U`>9N_19@K0G9:ALWU@6SBA(HOUW1_JTU#N]3YSL<`"UEWV+`F#-[E
M$0:DL"*H'F"<AU)8,RPW1:O':AU\8O8#]@$0AD$8A7LK-U1W(`.FR?4'PW-$
MXHP\CH*^=]@H-B)F)R$O$$>Q"S-+.4<1AN\7MQ?&+QKP!6M9:(/4L-4@6XAI
MZ/%9$@/::`MU*H4G02.RW;E(4H,US0,L/H==!T7>VRB@;=?0.K>PPR$EM6'J
M%$6&!&$\`4#J:*["GI0:,(!,H(\`<UJR6[Z.2@6M($T@_E0/2J2&NB0##9<:
M&FE/+/CQASM+9C`V,`C7013,K!@?6O`3@]TG%\P*^5+5A):O&H5BA;\QP!-D
MWO0#7#*>'7C4[(O>CA?&+>8+B;.8V=5"'H+[/(6)Y$Z%;O0G8HB*%UJ^+/QG
MP++]">,>-G9G`2,`A+HB8T$4"R2:H<ZA/!3!]<6V*E+&[S4D`T;'7F(#7<38
MUS+#<C#L!6#)DG)D3YF3>.*,ZKR.L"W0HXC8#A`$1YP/%7.3L@*?,22L>)H`
MPN\"UY&5$/$'7J_086R&FZ'31N@&=%H1"+4E#BUB2(<2AO%RIU`UTA0Q0DA1
M0$I$(8!%)&IYNOE)U5!+F#`L^#=5G,3NJ[GUP^&4`4-KPL`DPC!1%,$AQW^,
MKV+X498?(GSX3"A;[M$>P`7A`G?%@"2\!EA4#%%U5=L>,"=`%9YFSY.L/+,)
M2'9PF)!WU,=!6(\LCV$%487Q"=QMH@PGQW7@+VUC&CW&XY-F<$2G<+/BI8QO
MU8S$]_`V`S).TJ&I+;`;<38/]X^*1B,^R?E*S&;(C<,%A3YQ,<&VQ`DO&FL*
M2.(#!<"AZ0;/7[(428=^!@_YZYW+[I>/,U95+0(#+6LH1!+O&EMN:-Q97L+P
M4,%QQK@HZGO,,89YS5AOU,`"@C`HC,G9&+UMNZ&=S+#3,MWY/H(4,\XX8FJQ
M&X8+"@12[`MY,ETWR.GX64YSI3V67:<XYY%@>HK[Y[#&,-1.M&`N6B<P&R`\
MEW`5)5Z<<H`,AQ`+NS!N2BF'D\K8XTS0]=,1\"&.;5')5M6^]<GC2#%FMQCI
MR7<'4'&9H3)J#BX+R^I1GZJT+/8(1JYAN'A@B'^0=">*[O(`MK0O)<]!#QU>
M`M>"BRR./9J=^"S?9!Z*FKD!@M"%,YK>L73VQ#L`M;J_1VP18+U<O?<S)QFD
M<'J9X8M`,G1R^"7;E(_2!N"R1I9'`E@T11F3ID$4J)-/Z?0VS^0K`-=*KP\!
MT:YS>"#@U!'O<`45A0SG8PH5;4IJIY#"(A859FB<E`K/2R\MT?[Y.?/[-&8P
MYA7>HF2&9U:H3AJ;VDQ%BHS1PH@7<\%0X%MW1D=PPY'&[@\ZX.(H9_<R2S:?
M,.39:,H#KTTP=6'#X;0L\#&'C>D\PV-<$Q@.KPDX.$KXN"4:OX<LK5L=C$B'
M(PT#)%J;LQEDA/2'Z\\3E/Y3_O97$L14\L)%AHQ%)T`6]*RP9HR2F/<@)]YA
M8RRSJW7O(CV75%`NQ!*GSXY&5;KEV_BS&#L_CAQ`E;O&:?G@<KTICOB"@Q'J
MG[@[G"L[#*MD"#D1@Q^-B+=,C@1W`2V10JY3W",F'B`:MXH8/6:XI3DX0KSE
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MIKG":%&A<>-R'2LL#A46-\7BJ^Z*\H$[@[J%U'W6V`.FV%YEL7Z\JC$'B/0L
M`N2A9TAQ^A3C1M<2O1X(>C@Y:1L0Y4CG$=JZ5+_\H=%417!4`:W/:*NK@-;G
ML]E5U&`5T%J1YO,DS2J@M0IHK0):'SDZKE%K-8X2'7>R*WY6`:W/JFW#J^:*
M6LM/)Z`5C^R*Z+XJH/6`,7QFYW`Q?(^V#K/S!`):5W@4SF4)K]HK;MK3CV=M
M=@]'1E4\ZR/%$IJU?JN*Q]P+AP_7#^=)HJ_JQ[07^EYUMVTH4D6S"L[7ZV\;
M(U-%LU:1AM5:JK6<]%JJ:-83"=SJ#&K-017->@!,FKUM4W8J-&YG,ZF0N'$P
MJ]DZ1@N_YQ+-"DRQU=[6XG`NT:Q;%-M-:^WR0MNR0X"35E;&VJ^;E<37"B>G
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M\5WQ1A2TX=MZ$CDO?C;-0:_5;30:17#)";,`?7(MZK+K,OS]-@:(IZ"_LS#Z
M\%>"UJPMP>OV!N7@M?J#3A:\==/O"VR[;C;K+;,<V'XYL-U^KWT88"]Y0[;M
M<=DK!:_;AG_*H!/S;0_/.G3U!F7P='K-06L[>`)_\HV%LR_8=O?:6I#U<'L,
M=<L@0F@:68@*9MP%IK58*CT!N\$415_]6\MC7\=Z0S\=+$>@RH3_K<?:H%?.
M0C*@%4Z<A>X+BY&I7(?!G>LPY]WB>\2<*_\C[U3M3X;8RXP3`<#K^@E\]U5U
MZMQV$?66AN=!LU%*C2WX44?S?F`>=\GM=,GMM4LVRWF_V6EW'WK1G"Z.O,]F
MZ:+K9J=A]C99](:`'G?1V^RTV2R_F<Q&_Z'7+!X_[D8W2@^TV3,W.M`;@GG<
M)6^SS8URVFZVNUWSF(N^HHZ=U$MWGVT#,6G%&OK]=GX-Z;Q;@;0%6ON]3BE(
MK59GF67L"!*@IK<IECJM<B[6[C:7=GIW+/4VQ5*G?./ZO=86$-UC&_H$26X"
MQ.G#1YNW;N;*4$XEVHS:!)A]T&F:+WY&K6MMOO+8FKD>?!F36]EG]T:(;F7Q
M:^3^S;C?^874XZH1JQ&K$:L1JQ&K$:L1CSCBKA%I_-\7S8[K9^W;?R2@V8P7
MFT._7,MDH]?H1_@NAGEM_MX-PW@F(Q5YC*S,LZD1^7`!>UF<[-:%_5BQ@U>^
M,9R'KD<QC34*C/PXO'UGN%&4,,<8WGXWO@07!I?\6C5CUUVY=6=S#U9/D9HP
MR77((H"$5!],#WZ/U0FN8%(+]LG`LGZ9C;HPODW="&:U?,<*'<."K70B@_UP
M28,V)HGKT)MQ8(3LK\0-&4TSSTU#11!<.8V-TV#$&#XZLCSZ,IHR%AM69%CP
MM)/8].H8SA(]95MA2(NP9DA>."9^'3(/"P7Q\3UA6EW`T%',+`>?PM'&+`SA
M(7L*.\,NC"L$Q6#C,4/%D%%DJN7[B>7!>',LQ0CS@'[H!K#4$8/-]--@$%4O
M$[<-M^?"^&"%WL*PG&!.,,/8\/+,C0$PQ)\*>36<`#E$$`/^YC`WK`">Q:V^
M=SW/F%H`BX4!LS`U^DWA)7@(1^1V30H.H.6.N:T*'H*=B?GY.F+DZXD?I,_6
M@F)_BX^1T/B,-."X]7;GXW3#[IB?,$Z7:$T(88LBV+]X:EP">D`1##,'J&;<
M3UU["@>"C!-(W1$0D\=JL*,S."93YD=(A*$8.61V,`'E$REI%CC,X^0)]&%G
MI[/E=)S&["#$8^<"6<R!+NA\".IR,2;;PC).!N`.ST<T#1+/D7/]G<Y^#^#`
M@@V8R(_@V$0(^,R-`)>3`(\#P!*Q\,ZU,=`[2('`TPSCB]-)TX5L[#$$E\XO
MD"^LG]M<\$V.%OQ)P,3/!(TZ$E]B_#B,RW[`R?4G3(20!Q%;!D8P*EPN:/2*
M&0&^'8>0"3B!7;:]($H`4=8H2&*:W<=8+]@-#GD-KW$Z[+YCX-45QI;K`W2`
M3XDC_,E&%^78"^YA@M#%'>4D(?&1;E8-5F![";KD8><!VUB;`5#T1^),1+R[
M3ZP)%DA8S/Y@11&#CVJG'#&/X*!V0IP-<!:,$%)$R3CQQLA/+`4$L#S?^"WQ
M%OG;!OD(E=6#AU7P)-"<M9#<.>62R'D46<D+09(W,3`_N*>M4Z_\9@%3#1<&
MC\WOUXQI<`](#`U6SC$-9)0H2\G@.P`B"-T)0IJ#II:;H'<A.*T+F`0D<RIV
M)<71;@.O49=9`KR$3P`H0]X?AT$T%Q/,&%":8XBD!3B)L'',*7PHR^1A,39W
M[,$2V9WE)62$I&$$2R_@^SMS^>KS)G$(V]KBLI8\94D^E-&S5>IHK)LMLYNU
MZ1?,O@-XVQA`6Z7^];IIDO']X.!M8UAOE;K;Z\UFLW,,\+8QLK=+W37P6M?L
M;`D>\(UP2+?`E\"W=PV9Z)8Z5#K-UB`+4M&,.P&U+B*@6^K,ZS9R=O9-@;K4
MA2J.T[1X[*^@Y`*JL6JP\.*KLFQ#?HN_I[CO:Y+]O[#XZ_B;]6._H]XM=;D,
M"E9X!/`?"TG;,)QN:;A*_6DC:1NVMR+`K5EP@I\0EK;AOMWRNZOY"$BZMA8D
M97P,0A`[;,:<Z",(\+\R9\(*`A$VH9#?T69SY4=QF.#0PQ]N5+^>6C>?AQ0M
M]9G,$_!0Z-Y9,2U+/GKC1G_2XSSRS%X0&,-)R$@4XF^6!5BV.N6A%X/<I;OE
MJHM1]BT8VJ3$#>\LU\,(,!@.XZ[2;2#KU7ZQ%:6'JMUOM5N%J]H0L`.O:JOP
MB?+XS4Z_TSSBJF"[R79WQ_AEO>?NE`8'F(U>=_4R\I#L#?A6&U`:0M`V]P([
M%,9,"K.]ML*OX2WJA@[5'`=&=#NUPLWB1:^^?-1/=Z_D=-=!0*W_&(6>6X]P
M[.C%SXV+1L/4EK`13(=91X%$F5]'"<D\Q#KH@6B8Q-,@)*O*MD'LK4S,4!;:
M3CY&=O7<^\&Y6G('.#L/!^<5M^5NC\M^*8QKH.,S[@[96NP-C@W9UR0F,Q<:
MGK9'7'=7\+1I]X1Q+0I[1X:1#OWV>G:_5-TK!8MFV@&4==IUOU2IVA*4N>4Z
M'W[,04AF0]_1-/&=$SC:I1:<]J"WQ#W6S7\`@-?ALE-JT^F:O>:^`+L@)I,.
M<<-LSXHB7K_9#?RA@SXW%!#>L\@.76XNWR9.L#?`S*,J3K`:L1JQ&K$:L1JQ
M&O'\1CQ`G.`CA01FQ)DJ!C`3NG3)HTOR$7`4B!)A)!S%Y^7:,_-P@1%C/@:%
M"/3R$!"0"\=!.).Q#E0M40_$JV('=HH=V%8^STOWJ?U;QEE^'5\&LUG@D\ZU
M9Q)HJ:'1-'N=G&*R!I*]`=\JD;-4438;W>Z2"6EGT#^Y-NIA'QF+,$+9O<L9
M;"3&NRG&N^ADN<13R,*Y%<:++]:,<;_)[2?A7A%FVJ_A+0]`HY]OAM=7_QZ^
M$X]\6\P!R&$88FB7\M1LZ&V!W2O-EF]1`882]!2L]Q21<RLCFFX!`@O.%A\B
MH``=^/K[//`_))^M\$]&OJ(Y!E!:WF%06^H=Z2W;+H^.6;.K?RS#["=WYL;,
M65Y9SOQ=[GAX8+)!FA%DPS\"V11OVR^P:_XE]B.63?.`B:Y=:'GV>SX":.=E
MHO-KZ#N?105C@+S4,[:GFZO4'-;JY*NM[`C@D5:Y%<<OM:%1^,*15XFWQ%>Z
MGZ,//UAH4TSS?E=O>8V5?BY#?2TD>P.^U4:4^[R[N3I)^P)^#9+MOF4N2KEU
MJ[,&6)I]-PBWPF?Y\357D'4YA'-0#!;X4PQTCT64YL@LO[`=+.V=%56QVDOH
M*YUX'Q#7VM9+-[C9Z.T((6?NR",BK`ZQQD_QNX@-CBB`YE,`>P*CJX(PVF#O
M%N]<#Y3>"<HO2807&MUA^"US1':(#,'98M1/;&)Y'R@1`N7:5`90,WR_?<_P
M&USNU_&OS/+B*0SW:P+:IQ"S(GEIIJ196@?*^!&]\5WOGR_B,&$O7C\N]K[[
MHY/"7]E!+Z]@U<F7'2M$X4-A^8&P47IN3PL;CW5B-Y1K<T@MO4OR09XGB-.'
M.,<KL9KBL5\F;#X2XSL2N?3+"Y^=/KD<_PBN4IQSB%P1W-ILGCHF'^+@+>-2
MPUY9G.;)GK8M**/<PGH&E%%TQE:LM=0HVVQTS%-?:_$I6+':4@7^^`+,"JA*
MA<Q>>]`Y$E1"1SL'GKZ;(M0O$U8/P:$.AKUS483ZI5)JL]?KGPZ-/@PV!N6&
MS9/"QF.=V-LI2++!Q,5*Z\&G>.V-.R@7:AN]8]U"9W6&RS"JX;!,GGTD?G<$
M*EF5&W3R5+*=7#8HET'/8*W;RF6#<BGTZ/QT!50KW#WM?73MO<K`@EA>E8&M
M1JQ&K$:L1JQ&K$8\QQ'/-[Q;RC"R(*+G62/ANGB$8._M.K0?:](EM-@9M!B8
MV([U_$(':[QA<4<1\>TD3,9NRV)RLKXIE5=U9Z,DC*CY$D9U6Z$]I1J!#LC5
M7D"!$*(PH"J;^OWB]L)(+1P84<YM'/0B63D,:>:H`<4NX#><-;<"J9MI^,1/
M^'\`]<(`=>VBAJ4B,>S3B"R/5X<DEY9!/BU#<VK1W)>WGPQA@:?Z>1'+3(M(
M$L7S^/(=%F.)0)\9[MC@J,':CU@<$*MC!O<BA)X*6V(5P@A[][G1%$L*Q@:S
M`%EI=5<LL'=A#&-8_#P6`?8-7L^5H)-A]^F"9?Q]+;,_4\OA!00#!`%'UA9Q
MQ(JL6V8PX$?>.9&H)]L\D<AS'L'AEI_>;@&=[!#?:,Q_O'UAV,SS1`=*"O/!
MOZ.Y98N_4T#6]"<MZCVZS+XR.1Y8?IJ%Y5V=C]:#&-`&2_3_^0)C4@OZI$K`
M5G?]W8>#+U/Q$L/=L4_L(^U#P13[;4WKQ9;0;[!9W(9SYHN0QIECG8G6(QT)
MZCU\J%.P:[=DP1R[O7^4M*'=YGXNWR$QC?F/C<^7>F/[9K[BU?X_RGKVUG>?
M=BO03V*QG5J[W:X6?(`%'[R)?1'?47"4B*;+"]L4YP=N#V\V!P><ZY$6L8(3
MG,L2#KD/#W'CY$$J%SDT!>S`=W]6O2BYV_=@B-L,K.UD;=!L/@*T3PB%*\YS
MA;Y3H\`'NT^764SSHMD1VT1BN&X4V7RGM5%VWA,^AN$$"<R]O32T[9CI7C=K
MC8YY!&!W.3)GC<@U\F:%R$T1V:NU!YT'1:3.@5Z3Y3']L[**[FL5W90*#VZ%
MTJR<AS-#+=6YV><Z.PDT51;'G2V.9[&,U,!8&14KH^)!%]NL]7K]:L'G9%0L
MYU#2=VXLN\R?B=;;Z&VK"56&@\KN<JX4>$P18!V>-L7C@8WD1YFR6LLIKJ6R
M*CZF#6<73E89P[87."M$;HK(5JW?7N$A?0I6Q5,N(?T9AIMZV*W[+J">[!@W
M&R4CT4M;1!-O8Q#8,>1XJ0<V=6%77=QAL)D`50[*)"BP*!=8N8Q='EE8X##P
MC1#`P$[C[CSA$(F6Y-2VVUO(MD&\P;DV.VW$__NCV3`';[$/N&?C^Q1ZC;-1
MWW1M1C&/0-P?^#5`:R6.&QNC18J_7P*XY7P$^HAQO:=`:Z>652"J"1M8ZK.J
M(+\ZU2`;@K]CI@%_&<Z**-F\;B<%=[]HM=@LD^_2;_X#Q+@@<O'TO>%3N'?P
MQI*\"&>>QDI1&;))!I./E22P*<%5G_6:^>7IS4MIT)F"^E@8=6C;R8RS_+(>
MO2*EFA?E?\>`M-D.C8,S7;)*"\3\G$WL/ARX#XJ)U15WL^71RPLKM/)I[L?#
M!A<VAK[S/A4U1$^U_1JR-\L+AS<:W5YNA2O`V`OB;;JC-\MKT[4:N8+-QX-X
MFU;ES5(2ZK2`P!X.QQNW#6^NJ)O?[!\'QYPS;E?OP1QTS:K>0S5B-6(U8C5B
M-6(UXAF.>+:6&<T"J(DSAI!G*N-,QCA3:I)<4[P!K1KV%&;@-@TFQ-M[4*)@
MBVS4GIP+XZ9L$/$\6CEM+W$8&CX,8>_$9Y7Q<WEFS0:$IB']@6"L6XNRZT%[
MR1ADV0"?DA8H&UNLHP4ENC"&SAT97N;6`@>+R!8U"0(G0L-,)"W/\=2*C7L7
MP!TQ(R$K<`@PH;E7V*_&29R$*TS1EAV[=[Q5$6+1$;W-Z3G;FA,Q_XW8NTWP
M;=EI49C))C[^B(T7,SC'=4O,<*#YV!YHM"$'4G]$+0>?FK,06S)NM6$U!,R?
M&`'JSW``V0P(#P:*`M]G'M^JFG@8S521Y5DA+=E'HY;/QBX^`&2;C`$A2<@M
MY?26#2<<#6\U`'>":GH0+FKT8AS\<-%'.UFD*U#0HR'\\N8KC1K#$0`%BEZ*
MDOG<<_%@X%]H()\RRR%3F^CXB=I-Y$9D3P/JN,-6;PF\[,P`D"@.R2!(;P.L
MKL?W3J)2>!8^HY5^%0%FETJ;+=9)?\RQ4:;X.XH!:?G-X79^-W3J5)*2EGH!
M4T6"5.5+2_B@82S;#A,Y2&I016S0%P*=^+:+U!/-00>EGIW"H2&]&!RG#)`U
M4RX)BSI,,J>&%LV0_97`V84_N),DF0=^.58"OSX)>$F2.Q<XF<"@AZ2'?Z2$
M"IB#+5MHU/J`;/)1>//0<<@HC<O.5W2)#(]WB3,LV5`P`K843SF-&$@C1/,1
M,9'(&'HC%L(MZ/JP4["G6`:)31CB^#-S7!OMT?#YORR:NG>6\=U'QA&Y0&BO
MTAVSWPX_7'[]G'[AO/VI9ESY#FP_'CC%/VH4.IA]]>KF4^Y%.M+HNDHG`Q"&
MGC6R9A;:NM^Y:"B?3*U9=JCOPW>YH>ZG+IG%B?:,,<OZ"*-D5(`N.#0SR_5C
MYA/CQY>R'D+%]+3WU?5@1>JB,Q+?8Q'>#6PA&+7FGN3U1/G%D?;%E6P?F:2`
MWH;S0OA0\R[=#]H-H(ZNG$S,))^A(D;\.)>L2E]\T;*>_`%[+U&;*7Z5(BAD
MHC,Q$D`]3P%PWUFNDW-19;F;95L.F[DV'4<?2)QS0W(/S>FZH)L'9`<^,[G'
MY/5C![,9-K"#8R5?%U<8W;G9-R4H01(6S(KWPRQPE!&<BVSBQEL^&=*-I4A/
M8>2>G%)^H%.R.@7(?H(DUI='W$?15@X*K018L5=\&0&T?CP5(X:@"[CHD@*9
MCGQB?'5%!X._DQZA[+$8@:P$#XJ#"EP4MX^*"N-;<<@L'I=@89?7.7"[F,%M
M!)>@#;C2,,1Y,*`SB@+;U0&X*"?RZO-F#KNUANHERS;<2S;LP:45X6OX'VS(
M=V=Y1)&E?3[6O5G\K>@/["'=A9;W,0@OX6"X:WK]-LJK-IOM1KY[RVJXMEO_
M,+ZTPA"C5/YM>0D[#CK0C4Y'GD5?Q^\9N=K7(:3<NY?KF[OE"D\//3>\G&'J
MBUZ'FE(?4.\$,5/:3[-5WD*NN]2PZ#$7LJXQ:+NTK\:!234&:8TY'ZS0AR<B
MS84-4@R([SNT72T_9?7VH-GKY[=A'03[0[P.V>7$7V]W>_U!ON[^MA#3-7V3
MRL][5;TW!]U&Y06M1JQ&K$:L1JQ&K$8\PQ'/U@O*31Z:+%/Y/4O\GJE%*$JM
MM?F:^,+_PTUOY:Z],+3\"1/F05ZI7CJ]LE'OY+0+&7?U<1<B?J8D%G*P@,S*
M'7)\(]UH_=-\4/2D"B]*6O#=#EURB9'M;,8`$Z_<GU+$H^,NL3#ZU6!W+J#*
M)F>`Y>LKXA;#Z"V\JK\K?(S<*1'8PA:HNTQ34Z'TD](8^B#<!>5YHIA]ZK4-
MT2DE['FC9(&^1M@<]P>?0H;26Y2CA9AXY=YIP^(&,CNV1NBT6P@D1@$^OT`#
M77)<*_<I'("=&%$!1[E<.@L4.FV4QEL,M;-`/][(XU!Q'WFJB<M(^SOZG]+V
M%JF7`9^-M;^Y'ZB$`Y'G:SE60)K`5:P`$SHQLB4;?5<NV=OG'IPHY9?3W8U^
M8(R34'H>8M=/D*\(9RRYD((18%SFL(5+`\C1^=!E+U+>'#V!)SN2G$SY)BZ,
MC]RWA^8R\KSA\QR%Y%=/W7MDQ\]YXT1LAC[[6A\;<$'I[G:$0RW-X2&/.@QD
M"1ZI$@/+EZ#0*VX$Y<KE[-Z-"!&IZQ"1"8^.W5AWN\/_D`H2C[N1IGC6(NFL
M3^&58PBX<Y0!PZ*C'X^TMWA(=]]WVC:;A6BA61DVL>R=RKK"!25$2P='#S]P
M4R0#^]'&!VDP3E/)[(`'R\B-R3J(=#%!]:`1X@*/>Z*`(B0WERX8N0O"!R\#
M>7SN;WS$>^DTO*\?,=]-OR3HP&*2L'?'1&R7$"U@;V9!B%\"?@,?"-RC=VH\
M&T[L5TU%L0".7Z.4A.(TGJ0D(G\<BXG/E63CP1Z*8";CKP1NC[$KSUF$6<FX
MD6A[),%(.0:11&!()8B0_]'5$H3EJ-IZ2&Q#EJB'-$0Q``V7%JX.X6-Z@(.4
M@&RXS((9"SEA9CW`''LEPA'^$`OI$*.>1-0>(F_%XK+<3&9&DJ!&S)^$,WB#
MQM$6Q\%+F=#:%PP-A7AFB95G)=BI"X_"C;?@$5J`H(B$6`-.H!.$=1&P9,-M
M\@?G:!E1=FRY(7^M1O)K)I1*?S`+:R;JY-OUATS4B1`X<;01+#8][ZN'>??A
M]CHS#D<7?@TX'B-CB,B/OS3H/?=,YW?@7F:*NN,E,KNGRQ^CZ$)@+5'@+8>`
M^4CA&O7!IKO`^JY\.'-13%$I4>8-]'4CC.)@`5J0W`C^L<AA10<_3WW7*30H
MH93L8\LD6D"9Q#)U"6<Y`%)703+!D#6X"ZBDO#I6A0<)HQRXJ#/!6YLN$B$_
M:"O`R%'?\A9_2Y+5-288'RD+!=#,.S)0B8.-2(35_9$X$\[4N$J7.R(S"V,4
M4!I)Y27.P.@9M=8:"@;$^()0W9Z2!_J<#=8HU]CGVFRQ*/;DKQ^@[]\2('=T
MW61%"BJO24$E6&/!^"1P.%0"W"M\.A,5)W_*\H<)4`)1J];&(,L+X(=EEH+2
MBC4>@VQ`HMY]$'K./=`1WU;4"'[(L-JK*+285S-^L^:(AG_!)6G1&-\L]QZ_
M(0(A]4`/MF5""I'Q-7"(9!X]/Y'I6N%N1>[(8XAD:%*\F'.)*=5*TE!?"TZ.
M7P=.!K(Y46XR!SV'ZR8`A`OT'R.?R6HT,FI:*HGB6`$KDN)A"I,X4R[I$O!E
MYFSQ6T$2OD09\7R0+>#%``2*E'.G(<84*!R$=&J#$0FFER#8.Z[%FP%^2,)@
MSN"/[SX>O<P^?OB>W4:@P#\9;3V%"\'%LRQ,<@4&QI/X$0C!];YLM6J]=D-T
MK`3J(>Z/08(O>[5&HT%\7;LQ`>016^)6'[X7`$)KD0'L2O%!MNJ)T"<X2X!]
M?/P'73UP<;QLFK5>KR>W(@\Q0I-AVQ3#F]F"O&JE*:4RPEAT/0?A*XQ1QLF!
MP#&R#01S$`U$\#GC15ST_>=7HP+(X8'9I+=1"*V`(]69T]=C.-C1&'_3%=LE
MB,U:L]GB$+N:#BYP7Q3+R:_65,_D0*-`S`F?`*$"$TM4FZ85/'G6_7F)AQ28
M/%*;@$2\BD2'JQ5#_>1A2V/=%7.*4)9Z16(BTUB62Z'`*"R1@`G;`1*_9*<%
M(V??OK>X4+&LZQE"K@,FRN9TL>>-!M*Z*4!29IXLJT6FN2A@L2F[`8D1;3-8
M/R5VH_%"D#R1U'+X<,9LK(JT$.L1?$.%-CYQDOM>;)=2=U)6@D!93:`<J`[1
M_=)L$M\&DK%46+^^/YFDIBBQT2@W3KP\16D'/R56_?8M8/A(QT+H__A^R&5T
M8#!PL6$\$N5:\8!<<4V*9S]\%L\BR&AG2A^4+#MW)6KZT$(6[Z(KU%HU$'\B
M%Z.N5'22@[D)E&NCDN.GED(242)9.VMX^QUEND;=[-6,7:W=*8?Y#.H[9\1K
M?&HU88M-[^2IK-93!/Z,\2.OCIBZPDD50:U9XS3\\A31Z&B22,]XBH?TNYD"
M6K=4?`F*(`$!DX6*<V7N09D,).9]!C:I&[WNF\8VD7Q%1F*0Q/5@7)\'-IPS
M/5=`2_E8FSJI\]*<&'0)%(`U?6FTVQC^(X+GQT:F3HWQ"=L"@L[*K4NDVI%-
M&$UAXFA)Z"Z,E'^5A-K+["X5O_[.#6:8&`0,1*1&.BN</0D07(BV3'Q?K`28
M@EI#M'%IOU>Z)/UN>/-^^/K77V^7M22<X8LE&.F5'\5NG'`SR1#]B!,NY%WY
M8[0&H=+RW@7@H^P,]MLO5\.K]TLSU-)=R1L:,O4&BU)6TUU^<HDT]._F5L$7
M!<QUXUIYYXJFW8(.>!9GKJR=T#ZP0*5(9A67`N5"HJ^?#%]N]*?4L.ZMT*$1
M@GO,F)FZ<^Z`ESI+J-F]A#E9IL^!YHAI"S`P^?$C:?EUI%$3!N->1E1+T41)
MHC.Y0AQ,E'5'"8@F@)4$M$E7F<1NF>?5OTW#()E,"^5,?E]18N^%*J68+0\H
M#J!4QD(ZF45Q"]SM5Q2Y4!-X1-/['.U@3DW(#VA%5:9S_1K'0U[;W&6S&G;T
M-:'Q6]G%5;4_``WP1S<UIFQ:W$0(FH6/Z="49H]5JN46CWC&^E4!F\W*H6@G
MCA0IH=1?LE_WTX#N'YBQ1F_AP_/I(G)M-'\$XS$W+4Z#B!+4.21CAD93KX;F
MXSAO4S*FG,7;B(4@G%B`!.[DU?*@_B-O&Z%$:ZH/6CU2TY<T)J0GH\:?$,HT
M["$<09=*MT9S%**0/1>>J""],7,U4V$=<*O/74\:#:*\*[PT04U$]0AH,&]\
M9GE/AN^734H<'`Z+$#E4(CTQ"Z")A!050;!$?T0HE'!LN7#\^*=0#ZZ:I-MA
M`4.R9?P4Q[`Z)J!H*)T'6)O#M)_H!$OZ1I*2?D%4FW]*LQL5V,LBF?J)6%VH
MQVM(.A)23F3-4O=ZU@\AB0)H//7<HS.*VSHYD^1Z$!PD+FCB#%.`':0I%+U0
M@@M=8FPRRYZ+F.0G,O[T@<OGO?]HXX53+1P90+?(D!)*CZ9"HP]J(-+O/+Y@
MW$4KMOA2X1W8;3Q`<)W8G$BFS)L;6K2#,<$.V/4XJ*?>>HX,E;),F=<<[6GV
M9WJ_D.*<7K)R!]$==F%\$""0?PR!<#A\HM(%K!>H2#J$4L\1*MWD-^$SC'BN
M"5]5,9OEE(#\2=1O!C#=4#,K4M4#Q7/<D#AQ/187)[P@+VRTF:/>!MR&\K53
M.$1&;>K;%-4O0B(\;AQ(%11:IS26PC4SLVR64-%;%&<QJ?^842&G'*&EDZW0
MH;D+A!O+HCSC0[N.C0R$W&BTT9;0B;C3?)*X_#?*_UX6@4BPR3HB@>0F\*J/
MUA1+^+FI['<:!_`0N#F7;:(@,V``$T#ZWTJ.BVPX?FC:Q?B1<8*G/!M8$,'J
M*#_5CY>VM2:C:;E\+&-3M#`LF$/Z;2,I1NL2F-S12-IW@"!XS9?4EZV&D[%]
MO(B%JT)7E@YXGFL^&SHX5#3KC1!)$-^7J7Q=1:;>KI?:LF)9*L&%+(T72H6_
M5"J#@62M]HP4G0EFT2AY&,F(NMCZ4]K1?8S4HBX-HIQ$R*]T_8CPDZ9L=VB8
MIN)!<):LB:Y"(-=.5U4@@:*)/@PFH36+\@9^U\<+/U(RE:&7KI];"^[YEE:W
MB*F!1!P5BJU!*HD@XWGRZH)VT@S;LUQ1I*I$6LH0%)DAW/&8H8N82GN-6'R/
M.04RK\*R@6U&HNQ-R$N#X;X*;T;9)+#K<!%D]0YI#:5QB#3%0`Q.+BF62A!3
M,:-\JX5&#)>,#"%TU,8_^>W%RYB?`*G#R\X&8TI925FN;M+0@R5GB1>[<\`O
M82].<PW@;^S2PK\0^HWN]<+)-*U)Y-O\P7WINI[%1>R:_K#TR*2J5DW7J%)6
MYEGWD3#UPO4[#UDL@M8U65R2#K(;\A36%(%*8GHU`C8#R@2P*R_+_(2BJR8$
MK/D@SL2\B@Q_Y*<,<.B9`9%B+G3(&2W<BE$ZX(/I:U]9'E$`*96-.56\DI7Z
M#+A5_2@MV"44E0PGE4J,*P^KIG\CQ#[SLCX^.K`8`Y=91$8I5FKB036:#!3)
MG.H_4M!55JY#H]YLSG>8AQD+)5\$LJ"9%4?P&?IJ+8PJT912#/V+T^OA`DY2
M''NI+Z?L.,2+.4(K;;#2GZ+?>[R)2N"*Z`6+PB@#$3\2,UYB,J'><\5S<$:Z
MIOJ2+I6F'FMUW8EP1%GMCR>E:;_Y3(4EH;H3DK65N73!*H&:1ZX*$X6,_Q%H
MEA2YOGC2TY+,#B7BOL^8P[BE[LK'WN&8+E%)NEG\<,F/ZW^NPI)F5M8LFU>*
MUWU.$W^TZ-!,T<//PZSK\B-5&;P6:53RJE@NXEAR*LL,^+IPJD(V072^PB`.
MI@E2&/D1XOJ$*,P-37-0(Z?D'$UY.N>3<@"M`1GP6[C08]2'R>L)D^$:E`\Y
MRV#Q.^`Y'+6<,T<L*X3EN2LO5HK>;,RDX0X776JF`$"?A#)9\HVO1&31D<$$
M+@D9W91!=:BTFB1-'9$">,5C=O+DWG!?5<54=,)W`B;C_5!8P).GKC1$E];L
MRR)55[T0T/5,\7^"^LGD3R^)W`9ZRQC!G3Q&]YCRS*(1C%*MX0RQ><P5+*N8
M;53DOB6Y#QWJ"8=!I16I9\+U_(DE-!+*UY->DHP2P+UR&")3%SY:]&DIC'(+
M.!R164!\7MY"ST%KUH-"R`>9-5&G52E$7C7/>D"$ZGH!%E<`20^//9803%?3
M:M0HS87>P#)K;XZ_O@VI$S_R=KQD,!,PB(Z\5']C'L$IE)_>;@'=O>O$TS=&
MK]&8_WC[PK!!TQ9=C:FJ'/X=@>(A_DX!6=,P7'MRXY;IR]5=EAJ'FYMT5P8T
M`,C^/U_T7JP86F<=-B4S8?O+@A[',*=!L8:"$)&HJ%GOBE;E9[&4+W@JBE>R
M36_XD]CJUA'P@\S@_)?0/O\E/,5=V.:$P20PZ"0$1=Q!=A^$;XQP,GK5;+1K
MS5:_UNQT?GI1@!S!VSO=?Y2T9L\$XM4P]*X<TV(P\Q_KD9E_8_LN]N+5?N[5
MM%E]I]8=K&A6OV[JK<`_B077G]-BNT#6W>>TX*/L[KXLYC]34$^*^$HA'#?9
M:B_+"]H4SSMO:3%JS>8*2MIZKD=:Q(H;\%R6@*G13V`GS-J@8QYLMH>0`@I!
M6BY4MZ9HH]2NWYS,3AQERFHMU5J.NY:'O94I=V/#I,*3P7J[UND?CL<^VC*:
MM4&K=_[+,)NU7K]__NOHU%K-ULD<XYUO[E]"=%Q=8K*'<1F$<]&/[630;+::
MYT\K*_2Q<UE"M0^/>.W>3N%(!A/7>$4UQWXZ&80V!T]`!WL2B^@_A3OUD(MX
MC!NUW%N@%2,L7^%.KH:L][;$;["'97.;@;7KHK-"-CH:K$\(@2NNJ@I]Z]'7
M-&O]U@HS9X7#4R+!!Y.FRAGTMR"F<-H=[9C/@B`Z-;.[0@NHSM1Z%+9`GJAN
MQOU0V*EUVQ4.]\)AM]8T5YA$3XR]KQ+%3U23J;P6U5K.<"V/*(@U+YJ=C"RV
MO6BE#;$SZ^1C&$Z04'N[;4-SMAU3TY@;M4%_A7]G9VAWN=K.&I,H8ZVP(U6(
MW!21[5:MV]E6B:XP6638W$%SV@^1.B=_37D>Z9\;-*2M/L=O_^=U$M4GEC5_
M(ZJ0:T7(KT$0MA??8$_>>8']Y\__Z_\QC/_)/<X+4\`C-VS\SQ?.[QAZ7F]T
MZPU3?6PU?K_$?&@64IF%+]:,#7^X4?WR]M-GRB?Z7<14?PU%6`7]+-*TQ"/?
M%G/V=:RU_J1G5&XT?^J%X3`;ZV-&E(CC.O]\83?-7L\T!R^HUQ,!Z49!&[ZM
M)Y'SXF?\N==H-);P$&VQW%ZZW`$L5P>CWM+@:+2:97"8#;@8]X*CG<+17@M'
MJPR.%EPK^Z+#W!@=[3(PVBU@RONBP]P8'9TR./K`TC8!@P?R?N!5T?>AD6Z_
M64JK.81DYMP.GB):22'`OPHA,'Y$;WS7`TDW3-B+UUOC8$/"``C,<AST#HF%
M#4D$("H]N;W^M@#)?@][D4FC].R8S6X11&+6[2#:G*D`1*6GJ)!P=X)G&R)J
M=$LQU.L=%$4;4U&C5PK2H&-N#!+57!&__()I^U]8O"<UE1WYGSO=P2`#6-'D
MNX"WF@<URCC`2AZT,6(V)Z+2<]]MMKK'0LP206D`E5W=&R-F;V(QMY!B<A-O
M"=4V[,?<7*;9#ZAMR,?<0L+9&U4;LR%S<WEG-5#VE#F)!X*YJEQTR6MM?4-E
M3&D.F^&0X*N#J/XS*BAKRVB,K9GKP9<Q)>O[[-X(,5E?%MEP_V8\F_^%5'EX
M(8`UV?H&:9\`"*6JOL@IKP5U`_+E`#8V+199$`M!WS0W/'U/X."(.;YKYM+U
M^)*DWQ'WMUQLG;G\1);YF-G-W<X_EHY)B?'E/T'X)Z\'&6`QPO*]T7(N=Z7B
M\B%V3A\UV^L&R[D:J!Y:^Y!`;K'RYODBK]E=8=8_(,Z.YKQ9"U@Y:_GH^FX$
M-Z%!,MT6[.N`SO8E/G-(\MQSKFV/V$,NK=J3MKDB,OSX*WJ(:^]`8M7N1'4X
M\MS=2WXTH!X?@L=$RRE=2)K[$'5$63K;715?L)8!'L$GN;>`LO<D>UY)>ZSJ
M()?2$]^3;G_;T,<#;T6Q8[G8;[JI$:3,='([M4+V#JLH8[%&YD>4FSJT8_?.
MC1>[&U*:9F5(.8Q8]V3,#D-JX8J3CT+C-4$RO+-<CPC\Z2__*^^YD%G_UR3&
MMK>.K+S[M#'P'QJ&I^=I),!":\(RWWWX@>U'H^R7U]@GY!'-5IT"LQ4]_L[R
MJ-KU>V93'(C1,JDN[8HZCH]AKMIFT`)34*GII=9:%7=U5#"?`/H&M6YCA<WY
MR:!O`WO?%ECK7C17Y%8\,8,?_J5MSPW#XN/4`8KZ.I,OS;!X?_1):/DK$Z#/
M1GM^9:Z*B]T,G((J#F>'A\TTQ.=J7CDZ8A[!0'@H7F"C5.)Y3X(;K.#V%>E7
MB#DOGG`$H>"63G_`>PT^05F@UC)7%`]_/M+`01#QI(Z\:5ZLJBO_V&?]N/=_
MT;%GPGCR%`Y^==&5<T2SL<+L\GPX8OMB5>.!QS[^!P[XV8H1;"__/\/XD^;F
M:<Q5)-!1=^+50VS%YAQOOQTH/+N'0_KVPVL6YXM5!N>C`%Y%69U).%&%E@HM
MIR@<K8A`DMY7U1_4D&U!]V#UCQ;A]""S:7>!N6<YG.<0=?;0>U+K#5:$#ISW
MKA2_?@`G\DX#ITCO7:PRJ^T']:$#_;8)V5L?]G=M+:B@">J,I$6*.*5_6U["
M!XZB9,:_VR,<L/FXX8"/&O_W_$+]JD3*AXA(ZS4VCG#!@B#D)O[DCAEF5/Z7
M6>&)Y5,>*<*J<_$<XJO.''F/9V?-'H]_!QY<>A[<HT]`!UR5Q[`9,/]X"EA8
MH>+LB(63<`IF"?<]"'\.\QWCOR[SGH+KKW'1J*CW.&AX9&9[XT9_UC^&C!E7
M*&NQ*#9NK'CS%)#3W2QSU6WY?&C6O-C;([N29G=1E7=7<W,J=*'RO5^9IEYI
MS<5>K]?*%D0JG'XW$+>IV=0OK=#&ZT@=!$2MONJ[1?'6T;_^#2P#=,-K%KJ!
M8VZ"^]_I/:SB2H5;/\SF7K!@3",$60O6LWQ5(O;*1VW0O6/XK7A`S$V_X^=F
M!\#`QSY8]A25JN_PAO<Q\;P%_LP<61M6U?MLFIT7/U^W_[L.8[MAXZ3PK!^T
MH>^DT<KTPZXH[S2V1WD/4-X\;91_^"L!M>/*!QPE^&7T%?LB?9M:OL#@QR`<
M,VQO=^7SF?<K?]O6Z^C]&(6>6X\0L`@+Z:T_T$=9T4.A\A<,C8T.@\?6H!R/
M^1I[#[2@`Z'QH^6&>#\R[6Z4"H?4-U!RVQ9_&?1US27TS9.0O?CY$'C;=`6/
MCK#5=W$68<OG]DDB+#7%[$UCG>4C*E!VT6\=&6O999P`WK8AM48YWGI/!6^H
MCJ(V*I71_3E:JQ1K\/*1T%:TBD='VC:DUEZ!M.[Y(>VS]<.=);,O"8JB0A&-
MX':6JL=&TG1&-,XH+==):$]ASE1,+A50F@6HE0+*)LKE`19[()QFQQ\F\30(
MW;]95GYS#X_`3K]<PFOW#B3BE2WN.+B3=5=``B?1\>@H+!>2VX/>43"87^)C
M(;)=-YMU;"E1JD!T2W'3;.4+8C\QY*S5KCKES&M@GA7A?)7R#:5GX02R'HXH
M@2.KWE"AFXU0=?7E8P97)2TGZG,6UK.XPWBG`V!NNS4=%I'">)#@EOD.B(UN
M2",<2*WOE)M'FOW#T-VF"WE@O&U,EAO@-$^A)5T2"B@4TQ0>$,</1[>'M#VU
MRZ\.LV4.#DJF1S$Q%8[]2QA$!3VU6O5&7R"&/K;,G+D9WAX'X0S#P3DKW]7"
M_'T>^+>)C27GQXF'2_(8P@E7!"BG[MBUWZ<-ZC^['KP2^'*Z<B'(7&$I;+0.
M=-&78_01MBRC`)(8=&9;UERV@*@M:V[D^#K9+<MQ//KQ/2C`2E'>7D4MV*CR
MRZ#9*6FR5'`9]"\.8CC9#0\GM@G+1I6]-J&DFU+Q)AQ09GS43=#J;G+A?Q>U
MK5>NF70;![(*E,'[X.A8+R]WRM'1&[3/%!W;J6@%-),3@%O]C8\;UC@\"LH.
M*.I&FRF&[$%TBY(0E0+48LV(+5![T%4>&,,KV>@AT=LN:1Y9@%XJR7-`_&Z^
MQDV0RP<%+3!S44:\W?06.4U-LV\.ND?+:ZI&K$:L1JQ&K$:L1JQ&/.*(]`S_
MV?A&[W^!]V_P_1K_HF;<@N0Q?FO,K'#B^F\,?+3!_WW1[+C^YH!F$D\W?XU^
MA.]B"X24MVG%KSI)-X8NWN@A\:L^'P`#V=C]/Y(H=L<+\:7K.PP';5PH_&03
M#(X"BIRUV1-[/?0\@\32^H@P->?2)8SB^K:7H#K$ZZ1&1C`VHH(J:J`S&>&*
M,LLU`T:')^Q@XE,P@NL;\931GEC^(JU@.'@;P9<^90];.-1M#/\A:'!N?#YD
M4]A&D$B-3VA.Y2`'-)X;&F,+_G6'QI#HPO@&4Z1?E`'O1@;:26<T7Q+A:A$V
M*AI1O[6G@0<8%J_,887XP"QPF%<TP2HLX$PZN!RIAD-A05Y`,\])"X&!\'<[
MF,W@41KHPN#$S`>PLTD+48QC:_BUL,0E/L%P+@N&""T\5'4\+P@$/!Z`;D#3
MA.ROQ(U<@")BX1W./^=N%P$&07]A7,%`CN/BE#7CGAE3"_8@2%5F?$O:J068
M.KHC(-O0N)^Z]M3P@^P*)*S91208LFZDQ&&_U69(OW;>`BBP'-O&GD[.Q::'
MN_J<R0?:7@\L4"1'ZXTOHU79`C=(I)%(70#%]4SR5DHMQV9YQ%XS;ZP_-.Y.
M<WL>.=VE?*>6O<1RIY[51J%#@=`Z3"8@K*`?6>#\U)V2N0UMEN9,7/3.9$=7
MA7Y_8^%LHW2SC/D74[PZ_S7[S?<'P,!:\!X/#45!U1H:^N>(AK5Q9#=L9KD^
MD"-(T"#OV7%B>1N3R>%NT1M<"/WZ&:"9);/E5,.V21MP`.3OCI3GNRL\$+U@
M5YJP*V;CI+8%M&:\`D!/&MIV@!J!/R'ITV71#D76HGZC_2#NB.5B/QE5?!]C
MR)<`-#53TXO:;PT-3T:**$-BJDS\-XQ=P"ZT46P[U"-;AKYIUH<-]*2]5[<K
MSI8L-D4[\LX-+L-%%!O7<!AGELT2*E(2U4!GMR^,5ZC$ZVKTDMG%>?L3ZMZ6
M,7*!N.RI'WC!9$$Z.CQGQ%,K!D$K`B*#,5&=GP&(W.SC<.$,SD<`'XP(9#'/
MF`4>LQ./&4Z83"+^_HA.ZI]L83#_[P6>*->_"[R[U!HTM^)I,&$@W+ED[8'-
M9,!8A"%'``THLI,(+3+\I3AD5HQ\AZPO:&:2K^&PW-P0::<C\6<L-F;,00S!
MH6;4#<0%Y.%JR$QGW+OQ%*@%NP/,K1'FU[EBM6BH"&.8(`O3O86SV4$X#T(R
M(\'4[YF'AA,J)&<.^EUZ'P>=,LOY*['"F(5D$@*\J'>2<&K-:L:7(`0(+JT0
MSJ]O9>=R@=5-<):(U@^KM=TY$COA##80MZYFV$@0L!<!/#N?PA>T9!C-,^PI
MF\&"PP6!A)N<`"S<ID76KX!&)?N0ML7YO9UGB0V@"8-D,N5;&08HT!M_^L&]
MC]8H3,JV,;2X/DE<!U:+E"%HZL)0!#SEB"1##B`FB@3>?3:Q\$*#'8FFQM@+
M[B-C#-P8B)&)(&7892QQC/^BR^?B&"?MR.=8&@>)]GB'<KE"M*^AZ:6F&TZ)
M'FUXV.6HBY+Q&!D^O.:Y?P&BW1AV7I$ST3F.1%@D>O3O0(-1]M67ICFH]5K=
M&M(`7JJNGS!Z%>?V$;@4WT"(`=:0[F7H,VO+55#PDU;CAXR.U`+GL!PG1#J!
M@Q\Q^<R]"V3F`7:8MS!&0.(,R'/FXO2C!2T_XOHB@DS`A8$#U(7-/!RR&W.B
M05[CI+JCL%)/$L_"#O`&NZ-E"^8S3I`ZR<I)52V7,*!36C)"HV?LPGE`"!<!
MC(R8P'T@Z'$E,,(;XY7Y4THSD5)SX;4(3A%PAR!$D@V18QG?+VXOC%_PW/D$
M\#CAAM5TF7"89QF[/!XT&(8>MX4H%;TU7C6U:8,$[;XV65BI`%%$BP-&!B)8
M#H<1`K2,SYH!NG.4(`.%5SE7U>GP/D@\1*[-U"&=*54=P&EIX(06\$]E2D9^
M9,WQ:E8,A%$A!P3$82/``C`M'ZWN!!L_]5C9P8B"!!1N'+ZMKW9$R]+&7UJ.
M3@76''Z^H\N2+XLO!:^AD#\*9`(D0*Q2,A^8LJ.OB,'X0)4@(?/]`JSZM+6S
M@/P><"&%]E1GIK1A<D/?XB^OX?%7W<RHBFEJQ)>]#$*&B^4W@7:L@O$8\(/V
M]L@"3DUK_$$>#B"\EV:G46LT&N0/02*DZTTG*MWO`#L?,A@ME.;\&BQA'D2P
M8X`]'LU4$X;^N4AV3"D1D&J%Y#KB1Q\-,H)S$T,".&WBZ]&4>6/CMM["O<'+
MB3L&(NG^D;OC(CUX``LQ-5SVK5H"S?#A!X``V@FB"&ZYR*7-,#[3!K1XT?L+
MC8VK3T-%,-XBRV1W0_(CX/AQ4?P%&!>JE"E*NX3N5DY60OZH."O@D>Y[[9I;
M<^USKY`XEN@OLO!D&1XC\3.]`&'D*)F#0`97J#\)Z%RFI^BDA(-34HS>64+Z
MOD:VY<<;^\M/6T7Z1NY4S;$L;A6X'J+4Q<R/)^,GG:O1D?2"2OJ58OS]-`!.
M40?Y%D\M2`0@Y\!QK1F_7=\8-\'"\H!-W"8CX].G2^.5KGYI/V94L(O,:ZA3
MH(6=:P8`NX_G.!#:B66\;!&'2=&F[DG0B4!0M/C3.N@V-ZYS&9,X8OKV@,ZJ
M>0&'G1ED8FC7%#R?X3J+W;\M[OM%EF>!<!+2+0PRO!VZW#U.J`+RT0"X,#"\
M`)664*F3Z:_\F(]X>Y*(NY1'C/D&:"(@\>%.G=91W9C8"L7A]1288@"NA+D5
M\MU'6@P=:N'"=S\U\<Q#(%I0``%[7&9!V1)^QTXO2K/^[KLJF"+*$B.7.8?#
MZZPU8$QR*6R:.],`!9"`G^*TN&TXLNMS(87V$ECN1Z!80%7]_W)A)S#\(%;'
M"M5'<9I<G[Q'/`X#GAP'00R/$D,'\2_DLKX"CN"1Y%N(.2#<!"Z"0J3"Y0HZ
M:TSS6P[&X/#OR2X!.,9[&;;1M[A1,[MGP=SUB>SA_('PCC<RK'/.N2-%?Z"\
M@)N$RK&%*"-,1:29922)C8B![GV:$,9(/,Z`TINKEI5$N3P($N(]_LL/,NOC
M8C*LTH=?`-L(%JJ5M('I<^=YPJ)B.@`QAP3X$<K=EN2=?R2^QCQ)WRMZ%ZD,
M?UR`O&Z`,(\UHV'7LU)-RR16V59G@-,MXIIQ<0:)?76,$[T_]/T$YK]A0DA1
MA^=?%[SJKSO3Q"))#1;M<ZS(T?70)H3F+)*44F+1WI'K0LV3%L=%,L%W43)D
M,5IIX.45ZT4+`[$F4(]=M-N1D$EW)<BT,:\QL]D-NQH[,PQH0F42K=GE2#HI
MLCTE&>Z&V9X%<OF8B`+VY/SEMTMAK<B1[(R+:%G2-32*E;=IJ%!"AAFD5+R`
M\".2(6J%DJ=;IV<]/"7BNI2V0_J`13?O0/V%73A_(M/5U%280J;F.FBLIUN7
MI2M&ZAEQL89^`@5;7#BS&3H^N:W=_I/N6Z%.U,CPQH\F-]D+5;\&;,]G"P3K
M3R1MI7Z$&2NMZW.KF)O6.>67&H@>4DDG&0MKQ\.(\92&\-!<"M(.N4S<&=T3
MTI3`+P/;"L,%0JIB6965>&G=FJTCT@-@':[1DXEV"ORZCH9;P[>X#8LD/XSR
MA,L@+W3@/_C-_Z[7C8_8G>&-<0WBV%M01_Y*&)SX-T;WK4%A%F^,EE&OR]=R
M.S^'E^HCN/G_K(\8G'!XVO+NK44D][L>!W,8*R6`M'M24[AR<51%9WR&+*5I
M0+Y&*!4X9W60T]`[.LKG?WRU!7'2I9.PW/-2Z@,1F4(S&K*KZ1]`R!BC0-<.
MBO<^5XBP%<,(1"@RXJ5'63O)9'IB(5P]5L2;I\7(2H3>K+R$A@VSN&B6#AUI
M"JX9+WL-G"T4FK<T/\\MES2BVRE<3L'$S5DP\?^PB(N:\2EV+K(:7N85I>!Q
MUQL7U*2NATL3)H/KJ77S>4B&`%`8'38F]XOK"]/`3\077IJU=J.Y$0*+,`&Z
M'/H=D=-P3,`%'0#7C'7;HT>>$?8#%!>E+(X2UW/J01)+YP7&9KQST4<TF5JS
MU.`^MFSAO:WN\S(V<)5>+N?/`K*.<EP8W9A30)8DLK]`G4`+?NY2S9M87/I:
M/@):.4:\*Q-Y),Z/H'*,<P-0N>L[`#%3>`F`/-&:S2_88/2'L,1G+8I9W6=I
M3IP,YF!^A)<H7:W6F,7<$$DB:WAG2>L;?QO/=.*3NQ6$`X96CT@=13*Q*[=L
MUF`^0Z%:V1;D21;V%1VW0%IHK^-.97+%TEN$N2)DI[H@RBUNG`A;ABXIT=#D
M)<&535(W*-RP/D8QX38IWRS:![DXPY4`R0K$Q.P'[(-TZ!;MK=S0'/.B1IFD
MQ2,BN5T(Y3'ZG@2OU)W#[4<S2XB($<&0]^$6K661\0EEQ3YX?)9@-!QMH4ZE
M\&3BPU[-X3<>N"$O$FZ`(,X8T+9K:)U;<Q'&`=P5)N!.R7A"<I)E_XG&:PT8
M0"8Z2M"8$:WPZR]3J:`5"D5`^YAT4R$UU"49:+C4T"@,VC,>ETC&C#O7010(
MF7:12K1HO)#Y9F)"N)@M'E1HH(U@#/`$F3?]@/MAR1!F]H54?&'<!C-U%C.[
M6LA#<)])GQ0[%;K1GX@A()H9LWQI332$;\PE"RZ6R<0#IZY7'KA#-&,ED>`8
MW(2+VZI(F=M(%9(!HV,/?<'P.DR:83EXY0(L65*.1'N?*,?(EI4%`ML.$`1'
MG`\F&Z:EK$"$9L33!!!^%[B.3),3D0ZP'0YC,RXEI;01N@&=5@1";8E#BQC2
MH81A\NY6)\!HRP"E+,\%\4<&MUBI=56>;GY2-=02)@P0SBB93CE!M?7#X92:
MW0K;K(XP:7!+Y1?,3LOR0X0/GP'%P^,)>+@'6MB9<&H60G12HLG6UZRRJT32
MOI^G.-P[62^V#J)?'?WE%\9W7V%K0OYU/-4"3X&_M`79[%$[DPF*;]6,Q.=:
MK@^?U-#X$S)VJ<5S:@6M73..@WZ`G#3D=GQ^Q=N6.)U%8TTQ.(D&*@O,X!F4
M&!CGD1#OLOOEHXAB<!$8F-3"(_H`'$V]A@,!1Y'2/7D*)V+L'I#`,%1/Q#.A
MHX18$+UMNZ&=S#!:B>YK;B=F_-#'NM:?LA[DIW15()?BYY"0CSQVY.4B'\49
MC03#4IP[AS7RZTB?2<$Z@5',N"F;FZS3TYLYW6)A%\9-*>5P4B']CE.*&@$?
MXMC&4,T92TW0V^0;TTT:9H+2TISA2&0L&=@#)%;V5[@@XFD@E1K=^XEX#1WN
MD+7@$HICC\=R49@2;3)*,#GN'83NA"(Y-39NB7<TNXZ,3,O8@CC)((7/N%G&
MBI5]B%^03?FH,N]GC:XT#:)`LZA:*EZQ`%PK9?T"HEWG\$`X(9L27!]Q@6:?
MO4@TVI34'D1Q5,BBP@R-E[KSSI17@TP$G(.H%)>'$8PS/&]"9<FFL&]T*6(@
MYF(NF$&:/K_A2&/W!QU.<0RS^Y#=\D\4U]-489KI!%,7-@LH?8&/:18*Y30F
MX.`8W,GVA7Q\E8(?C$AW(LD>)$D[%B&QX@_7GR<H=:>\Z:\DP$52CCZOA0`R
MF&>%-6.4Q-S33><>N'XM8Z`E_9)4/RX\$I?.CD9&&/DV_BS&SH\C!Y"^:YJ6
M#R[7J]5`H"=X1*3TUR&]8*"BD,\H8$3D_4>",R384P9H(\4]8N(Q:%^:8^$O
MKC;8H,V*MO?_?-%X07]'<\N6?PMH1&=Z$MGF$8`D/[TU5%_XQOS'6VGO30W0
MZWJ]:F_0XSMT'EW_<I&1QQ#+3NW5&T\"BP<<^?]\@<65MYA1KUR"SE@6OC4$
M9B40(ZR289@7`(Q!MRBON[+$F?.@\;_#S-]/&O6MA\'\$)5[E(QP_E%HO":(
M+N'>>UYHL.TPR2%!-C!Z5HB@"MD9-*1J5^;K7U"0KE!3A)I/I%D\*]Q\D!)=
M!A&8Z9["2L[80_#UHO;IX63TJMEHUYJM?JW9Z?Q4ROO%==[J_&,I+W>Y;79.
M**GSI^2VX!/:#?)U!"\*N;'$L(MJA+1.KZ$/`:>Y#.9VUU7Y."5=PE]N.&!C
MW8AI[_)FJV::@T,#>@`4G!\JV\T*C8>@R'Z%Q@.@\=7!J?&G9X0]9(O]WL,1
MXJ'NVO],W9AMJER50'FIG)$Y)^EV8M.>JMM^)WG3;>[5FNUUM]]Q03L'-)EM
ML\+1.E+J5BA:=R69[8/`M>XB.D/4`"-J-];=V*=RR6RLT"T!7*8U7Q;'46^+
MC]V5\JRMN52A/KC$N>>$&@$U:H/&NIOLP9=7[=`6>DVU.X^X.V;CU)96[8XF
M.:P5T@^UMBUEBV>]*W#G]`>/S]4>17=^\L+ZB8!W2K!4J*I05:'J.:/J\37H
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M\$%2'PX1(MO=*$261OE,_(2:G!F!SUNTR98R:_;OY*.XVEM5_P1N<&A`MT5!
M\RF@T@0:;3U@K.NA#MDA`N+4:;+&U!Q7'JAX"E--ID9\'_`FB$_/HH8!<OUU
M.D)E>&QV:NW.L>O/GH/14=[DN2.SXPEYUE[59J/6;6R9?5]%(SSD#IF=6K>S
MI7&X\GN?"4L_$?!."99'1]4YW("5V^TI5="H=NBIV:C7&CLSEDW^;X#8]3<Q
M<NXZ:O9MQXWFGK5X`ZP#6S$76;0V?XU^A.^`%;DV?^^&V<R]XUUGJ?_H)=I0
M1X'HFJVOK.SSL?"XIS&Z>'EV9GFJL3`U>4:#.^^S'1E.0MWK]7[%(?.HB2Y\
M'3)W-DK"B(S7V#8;&]V2H=W!GJS!G++*>3MCU4*9DL[?L[D5T@V`R0V_,LN+
M^8N_)C/+-VY%I]>:$08+^`UGS:W@=@J0!Q.W1J_-P\!);)`?+7P`0/LE9,PW
M+K$>@B&S][#']:O4?V"_U1Y*OW;>_D1#WK*_W#")C.__,CZY,Q>7G'GY]ONG
MS$NRKZT.*>*5\<:^'&.J'[?A8@MS:B0.:V5HB;30,R*Z2P>)YV!'<[@F820W
MFF*;X=A@%N`W9',LB`*:)/:?+NDQO<;=D6U!/;4<WK98.6>T15P<E!R?G6]D
M8^-[J=:X^D(Y1`4E\SGTVSWV1NSEY=GHVEJI`>DWT@EXB799T3O7\WAYEG6K
MJ5!^()1_]T?;(OVD$+J#*6DCE.^\(E)P5RWFP15V<<]U-G>5;B.AK2&6DW>=
M%G@BJX(L#X303JW=7F?-KS!Y@IA\%/-Z"90EBM[3,RF;S:J;YP%9=(6LXQ/4
M@\LZ>[CG\U:-K`%MV1B4L5KL:R-_3A[BVF!M@<#*A5\5?JCVZ2P.THF(@ALX
MG363]KY4]FQ<FLU:8VV=N\KG_)@^YPT4OVJ#'C-LH]8>G$+"9YY/;QL3\!A]
M3\[<I;?GD=G&EW%ZOKY'[99RSAOT0,XBS=?V7):<\74]ET6G_JC*!_4$#/V5
M#^K`"&W6>KUU,9L5)D\0DR=K>)!W@0Q0Y#47\/_&97!A?(J=B\K*M865J]%[
M_#J:U095YN(SWZ?3.$@/+GE6EN-'JD&W/;E5ALF'->VO%]>J#7K$#6K5^NU3
MJ..XK^6X>/X]TT/V'/TSO#7U%IB(&J`%@1)UHF0T<V.1J+-MIM*.:5&4-*3R
M<%P`Q(L"`WYV8X\/-A.@RD&9!`76Z,+-)/.K1E8$+P2^$5++F"AVYPF'R/5I
M-7![LM!;8':/#6.&EAUG9L\65H-;V,;W9:M0;`N:F5',(Q#W!WX-T%J)X\;&
M:)'B+VTO^A@EULI'/^GLPVN1SG9K29GCD9(/#[-)2^O+INOMF'W(7P;:O!E>
M7_U[^&X=]@67O&BUV"S#%OMHY:#V2D#M;_@4[AV\L22/PAFCL5*<A6R20=EC
M90%69ZOD;%WY=[#((%P\YC':<T=H[&%L+#G5:JLK8]*ZD=M';H2DEYX58^SZ
MG)XF0>#H3^,U=1^$?^*U`<<4KC:XI!02\8H"8HPY(>+D0*U8`&Q,ET(M)6V'
M7S@\K]0-(UQ<37P*DCB;2_OQZN/7;`;NC,73P*GAB0`T_,FR=Y7!?LR9'\'9
MXI>?QA5P/L%>,-^7+DH.O(M',2J_D-68XL*<L]`-\/JTDS"D]<2N!Y<=O!J[
M,SB[,6)C!!P!!L$$6L#(.(D3/.V`\V#FVO"KS\;\01S>%D"..,.;^$``L,C[
MJ0N#3N#9$(X_(1E6Y%H`5#+'*QV9R9QN?>`W>"W33LUAG<!6+HSO_*&E7[)9
MOO>NY\&]/J?3\3==VQ$5H8VWQ"+2`U*5S_BO]RZ(1/C&;PFP-,H^OOW^*9MC
MG@4E@F.-G$Y*%M:=Y7HD+JVE3P`.!X<]LFR\,HA5<@B`\(H$'V`%L*]4>6L2
M,E8@BCPZP]QH]/>\?!@_]V[Q#GP$;/'4[S"9&$-GAFB,BW+?/[X?YG+>!=%H
M7"*[:2,V`8%7$1`7))%NK"@*;)=0K@#)$H_<53N8S5@(SWH9>LKO!L?8BI+)
M_>=4,GD;]I[-XM^K(O*;1Q`I),J]<P\1>LZA)55%Y,<P=&]?$?D_62GOW%W5
M6U3N/:4HBB=1"KG975>9[#EY_C]*V?47E%TK'V7E2SZ-)1QLG]KFX[=N?FQ/
M\E[4LR?I/:T2IA6JSO_JT[RR7UBL*_?[LM5GX^_=_?*K_/(/N4_=M<T?SM(K
M?Q2?37EYK_-T)EU;,6\UYCO&)S(K/P7WK.Y8B1C[,X+#C>M$RT`L+,SP/[37
MNV@6\<E)(5PGS)$&!!;II5BC"V,(+XB1I&M!&(S11<*]+=R3RSS`^Z0F72`T
MCJ49K^]8ZIVYGS(_=<J00\?&&`-KY'K8+RX8<Q\-O>"XZ(^)T*.2^#;<CY;K
M5[[2,O(>VG:8`%(_"%P_+=)._6MDW$,;.M">C(5)D.RD?RB2C@PW=.H8_[,P
M0*!Q@A#)+T`2OW.=\MB>&D#B)V,<-22ZQM^#>,I`5)/Q0L(Y!5>%ZUMDQL?@
M'J3>41+!+J';]3:8,6'5AY\DI$M!-S/78U$<^*S.@X!X5!,Y`&!>-2.^90,N
M/$;.`C@R\#L<$SB@&'@AW)TXG3MC67<KC\Z(#,_EIPQ=J<J]JX&&2$0?CRM:
M,O*S&J=>86011C"":XZ[I*86>E"U`UU#/Z85.MB633HT`!Y<C/A+Q&PA@'"J
M!>^A;[T[BL.Z<QEY/X`W^3K2D#<EL%M61&@'"J@1L(D/0C-%4M"F6_,Y'`CR
M/LCE`VHB=+9YB&T7*<X=+U+$DN=W:@&3HJ7`T^,@G/%H+/1NCMC4\L8$`.R3
M.^.3D6L2:88X%A]+>Q>?QD<TYQJ%72G.)_MBRE<)U]FJSI'A![&Q`(%<X)@P
MYZ!3G:CQW@54P"/NV.7N([6%D?"WSZP_@E!R50DCI_XPD@-F9I7Q:NB@!3@M
M>`PA5<A2*\Q2V,SZ$WX4Z.%A/9;@1HKS6_0U1;^,+$_$R#!8'4;`X(2([#$<
M)Y\\C!2GP.E0!<>1?TR1@^V&=C*#YV"H7"@>/PVH37GD8AN[Z%RF#;%A`RQ[
M(7W7*<S*^;F,*9R-+]%R_DADQU)W;/@,R1<8P`5P70L/)U^D&-19Q@(0@)<X
M[$'=<TK&I6/!Y5OECROUSW64^T4Y4HI<<DN@EOKHN+J;U7Z=,NUWYCJ.EWK\
MFO_80*(N'RT.YD5ZL!B\]8^L"M=L;CE\#MA!AP\X9GAB+)>DI$NXO/$=XT9>
M.U_#B>6[?XLHS8Q[__+F:ZZF?4'$P!SXNAR4^$WPPT4+P0286YPXKI#HU#-Q
M".<JRB\MIXKLL$F'WYF#;,?R%O#&-71Y`;>/W)A?Y'F\5@B3")/7KR80\8NC
M,'HE&S0"`I$16O?8"9H1'FN&@U$M&+=$+)N+7?B5U#DTG,!OSPKM@((QW"2`
M.Z`[W(-\EFF1[5"W%SRZ)K2U0(^W>L3O8'DY:B%LN4,HA;&,B*%=UI$(V16B
M%QN#E")')O$8Q/,$(_(TJA97_BSQ8G>NQ_J[/LP2)Z*Y"@R'[)C+B?`NA3YS
MB<#'D*$"2$O#.KDLR6655-3AH6]*4]#TF)RJX+,)B'LB(N\.]0[1#D8<4_W(
M<@@I.!D6B&<V\4%>!0'76E#`Y-@+[D%LNN9_2HT@*E%:'(:8Q,4A'T!5BM1T
M2S1^3VP4A,:)!]I9"+*!3'.8`[#*YH)/"A5&,(DL[E)5B`<IDO"$PK:4R/!@
M9*/:4GH0JH8*_"0-B8=F*AJA&,I1D9RN1'E..2GA`-Y(9.6C`EAC(4:2J)W5
M;<2PQ-Q2B3LRA*B?GP,VT&5::QVYEH*X3RYV2@$V)&V7XB=A=@^$SR&1SYH^
M,KFX8QL$?,HGP=AV5BRR8U#ACQ3!;@B[#__B;Z3Q_?!5-(4EU9&28=UQ[!4%
M:E:V&BVNW<:#]LWZ\53L--*XL!#!WV2TB](XWD)^B$2,@=E`A:AFNAPK,6+E
MPO@N3!0PD(PG=]B8D?H,CZ!NS01GT2T;R#.U.':E/#KN&%[&"%3DP_$]ZM0I
M#TX3,H@EP/#\?L)C43(/6CEAKAFSHH0BS"-I&&"^Q6/%81B1:(4O6_?B%I$6
M5"V@'/D,P`>,6UD"=(#S;X3`2\*H2AQ990Q-9B*2_"O9[I``0S;%8'*0_C\%
MT1,X>/HJN872SJS2P[KZ;L2_=2-N)DK\D%$.@6-,+%>(./@D(^%%1?/7X4C6
M,4U+[_A)#\.(L!$VO,-M^!;P_+F%E$XSP07.;W^XR^T_I["70*OZP3?87PEP
M"KBW1*H8:K)PS+@EBRY$:Y.595+/K(C[-P!2S6(K6(H2RGP*8*%A;U,+$\"Z
M3!X7AHC9QS=]S/<BZQA(E209+-^V:/W,(!:&?6FVC'O&X4R7B"DT_,)=N\@+
MXTN@O6S+I,[-1U#S<SPY6RVJ?7%<"GX2S.8&!6N0AFYX5I#J8''6O"7O0:!T
M)[+0XUJ7.U'>,>W8E:9I@=!I^1-^[&1_2'F;9O-*Z1Y4!RH(Q6>R89*.9X4^
MVJ$E\BGM:LW3?%"1NI3-MK!#EPP5XDX'Q+QR?THQC$Z$Q*(SQ=`J+&1\R]=7
M!%>T&\716WA5?]=A'KP7<IM^8`L/@&Y63]T/(9Y#^)G&T`?ARJ[GB60/)4(!
M7[=5GNTH62#/0SOZ#SZ%E(0LBEM`3+QR[[1A<0-!JI"R&T=B%.#S"Y1\4++9
M/L-G\`0R?/9G,`6<XG+IO'#AY$8_+^^U\S+4S@O]>"./S'ER%7E:B7OPW#ZI
MU\MFL<)``=_@L['V-ZZ_E+.0Y5)*!#PWD\<7\`F56(V<``Z\YGR,E&-5V0.R
M7CACG(3B<D5EA6P2&65?N425LJ\/D+IMEZP$VHMIPJUN#]*R'HV/3+=S\><+
MTB,U)4,SJ(G<5GUVKBD)C8KC5F%..9B5*TO85735:B%L8(3_C)>N>`D*O=+B
M*RF`LW$W(D0(]08W#9")EE$WU@P])&\*JQ::D*9X/I1'/H57CB'@SE$&#!NA
M.@6H]!:GI49M-#I7CD5,C$1TH8XM#UE*'UD#DR"H:.G\B1VE'&8WW2N6%>5]
M%J>U'"B4A^E11&52A&H,+:0)&6M@6S[/GL;[1VZFL#4*98&<6MM?6^>PJQ^Q
MA(3.\>DDB^@(;A20L@1@>P9W)CZ!\5U`^=SF5A/V2KX#-64[!:R]1K$(95X\
M8DG$I&4#T]N+"US`KG`M*C;^2N`6&[OR`"J%+P%Y5V@BPI0C8CN4Y$'&7E=S
MX\M1M?60G(:\4O>"HI_(J5L>KHY,CKI+5(H\=@):YHR%G-0HG19.!I^48Z]$
M&L(?8B$.!K9<.R%OQ>*R;$X6&Y$Q<$(:DW$.VN(X>"EW6ON"H:$P8UQ*1=:I
M"X_"54C$0`B*2&H5T4YU9'"H,L(U\P=G=1G9-37EUDA@S01,Z0]F8<TXJK]=
M?\CEH9.$B:.-4!%7)WCU,.\^W%YGQN'HPJ\!QV,\ZA%Y%)<&O9^*2A;9T>]E
M\15WO$1F]R058+F%T!/%#$3)(\FHT`IBZ-0'F^YRG\0,HWAL,@UF_!!DFXOD
MP0*T(+D1_&-1%D9$*>4H-"BAE.QCRR1:0)ENE!-]%(6J0@RZSL%O?YH6`[<\
MWAA-':O"@X0!25P&FC!9WD((%MH*,'C4M[S%WY)D=15)C\'2WP%(_TK<4.`U
MX<%T?R3.A#,UKL/EC@CZMT8L%Y1&#(R>46NMH<1`C"\(U7TH>:#/V2`5*[%\
MKKX6RV@/>J$<HN@,T*LJZI'SFY&ES.%!E):,AC:&2E)[A4_K1Q3+=JB?LV=^
M`KM+%(C/D'T0;^GQ&.YF'ED5A)YS3R&7N`DHV/_`*"A\Y2H*+>;5C-\L@*MF
M_`NN-(O&^&:Y]_@-;2=)^7I<)A-2@"Q(@1511)D*?GXRX,I0+A[,AGZW(`$Z
M6\RYU)(J&#PZBZ1IH'6_#KP'Q&RBM60.*@M7,VJIHS*GG(BSH,P:XB``\Y`B
M6A8N<1)<4@W@R\R)X+Q<DJM$'7'J;,$?SF^U"C)1,D=O!N(N&)&`>`ERNN,B
MK</S'Y(PF#/XX[N_5%CDP_=<)1\JWT,8$15&EH4ZZ7=7.)(N9K1_MEJU7KO!
M]3U8?(TS;73+ONS5&HT&L6/MHN/ND#R3^?"]`!)>[4CX=)4BPPO]$,?BH;##
MU(L)_/YETZSU>CVY'WF0$9H,MTUKT,@]R*M*FI(IE)`(*P@Y*#*%,4HF.0@X
M1K8!@&+AT1&.UGBMG(\H^&1E.+]FX*4;7<)12W5@K2`/G-UHC*YR75%=`MFL
M-9LM"7*HZ_#+1"UW)*]-DGHF?5AIO+*0;OEY\$7@00$Q6RC!D.OM+.O_?%YB
M&07&BE2;ES@FZN=^_RE6JI+G2LAV\%H:-('"SBN2XYC&H;#F%X^Y(@D04`PB
MN>2@!2-GW[X78<C+ZI4L(08\D\UE0$=&W9?V1@&2,M!D.2ORR$4!1TTY"XAT
M:%7!FH&Q&XT7@KJCE!+#U/">->3JWB'%(<1;9W>=?R^V$&5.7_::YP%`A$:@
M)$3A2[-)7!<#O!V',&9Y.LXS1<2TN)X<E6@'-"5`_0(M8-=(FT+2_OA^R`5C
M8`1P+\4@M%.!4EL$-Q'1B&<_?!;/(L@\EDD^*!DN7`^:XK&0A5ZOI9D)?Z3B
M6N^`W<'5D]:"I8O1RMZ!F9^RU^$*./CCN4)W2JTFV97;,[D&*?E]:O8C(262
M)5N'M]]1;FO4S5XM3SL;FYM3IO.9!V5@-:_5SJJ:,*RF%_)4%JTL`G_&.!=0
MIT[=WZ0^H*:K,1]^<\[1ADL,4#OV*1[2[V8*:-VZ\"4H@D2X.0699FY!?M>@
MP9?F+7!HG,,%<J.7$-:X(Y*DJ.P;)'$]&-?G@0U'KS"L<G4]XR66F9-KMG*?
M8^0+M_*0BD5&6QD?C-$N`KHTSJ>LEG$V7!.?>^<&,T;I'<;0N4,MS5GA04F`
MB"@+!M\7*P')5ZTAVKA*]"N=&;P;WKP?OO[UU]ME`PC.\,42O/5*1).2X#9$
M!]Z$BVU7_IA"J$$5>>\"\!'+90%\N1I>O5^:H9;N2E[ASY2N%C1!^EBVV#3N
MLDQ$.BTCZ;)CJJF*2.S(`C<JQKPG:$>\\U=[X7ER5JZ2LA#SL08Y3R&4#)BR
MH=#Y34*\&_TI59E["],#,6C_WF=A-'7GW",ME8-0LPL)<^MRV5-R;*OP9T<:
M_6`P[IY#90%->"2YDO'?P?Q@=Y1@.''-2$!M<Y7)Z)9Y7OW;-`R2R;10S.-W
M`Z6[7*B*V]F*U.)@2*TGI!-3Y,CG_K(B5WY-X!%-TW.T$SDU<5>CE5&9EO4K
M$P]?;7,GQ6K8T;N232B3!:8QG\*-Z%:$C_SED(%@[V-BY!2(B&'E$+G%(V1T
M9,%<8G^YXJZ8`Z9("87NDOW"5%KDIC!CC=["A^?31>3::&@(QF-N>IL&$=4<
MY9",&1H5O1K/[\M9<8PI9[TV8B'0TZ.T**3_R%L@&THN)>'4V"2U=KTB*CTA
MH\!#P&GH4G7^:(X""[+-HA-5$U$M=)7EZN+S(+>YZTG]7)B"5MQG:KDBT$7`
M@PGS,\LKB+98&V]A-IY`P,5&5PNQ<3AK0I*(9`%5'FX(BBVI)(+>B7R)SCZ3
MN.#"Z>6?0CU8:9)N)@#LVS(>B6^/.F6@7BCM!CBCP[2?B`'(XX$4J:<L_"3+
MRFM@+TM:ZB?BE!D;BSR-TKQDI6D..3._I"@X(IE4&6&8Y#R6JRQP#KG\B#-,
M`780DE"B0L$L=(DO\K0#*3F2&\;XTX=+(N]UESDAW$\`1(_\+*$Z]U0:/V^R
M.0=Y6[]Y.=Z0&*S8XAC#S'NLI6%$<*G9G-:FS)L;6K"",0E!$(9354^]Y'H&
M,=\\V19!7K'Z+4>:=GK52T)`IQ6F'*MR'AP(A\,G<HR!$0$Q2K=-ZM]!+9V\
M&WP&,A!+.BAF]IR@D$N*1"2>\Y%:$2FU127Y8#H(7M^QN+XQ+4F(#<@<45/#
MG)8H`X<P)J8>2+3[>2[F&Z*KFZP)J?I"ZY3&4;CL9I;-$DJN0V$7)@O/,:A#
M)SFA\4:R4D#$)#]*.45!&75+:#O<+3U)7/X;59A?%J)(-,JZ^H!<)B[FB8T`
M!N%)IMXPJ:?]1"."MT8QQ6;!P9L`POY64EQD`]FC716C*\8)GJZLVSUR`7T8
MB>W'2UM2D\&E7#J6D1M:]!+,(;V:D12B=?E+[D8D+2FPF3S%._7TJN%D2!QY
M3I'S"*?FTL'*<ZM3W<.C!%W>"&F`4CE3R?@\`RAOUPLY62DF%7A"ED:OI+)2
M*L3`0+(93T9BS816:)0SC&3$5FS]*0W,>DX!MO^@4T2Y72E)JAX:W(*%`0X\
MGS*)4&+45%G@<.FJ"@0VM%V'P22T9E'>\NWZ,25A2!$DTYMH;BVX5U<K@R,'
M$E$]*.4%Z8V+!_T,KQ2-W@W;L]P9C]LLN><S)*+GH,64VBS3YF2@OF4#X^&-
MESAQB-(!PG!?-@FE&]UG!6^5MXSC$+&)@9CG3D@Q4R*$BC+DFR<T2F#3,D3-
M45MYAAN&%Q2GTM3=RMM+C2FK(65ENI*OA]>IA';"1YR&FO^%&?#R"R&RZRX;
MG$Q3!$1*QA_<8:NK#ES<J^D/2W]`JCW4="4A93>4!<F-DG`ES4,6B_AG32[4
M"U*1JZNF2$Z2QRO03*<@V`)+\;(,2NAN:D+`FLR;Y[Y$>.2G#'#H%X!K=B[4
MHADMW(KQQN2#Z6M?%6HK@92"[SP9>5H;(;BM?,TZ((3F#+=3C9KD\=-42H38
M9U[6PT1'$*.F,HO(Z'E*93FH=)V!(ID[1);9$@V4(1M%R6S.=UA+I%<Q%&AX
MQ!%4):6,@H3!8G'*PB^,6Y5;'G'=J/@XQ(NY*/Y$5DEI^=?O)M[)+G"%.]VB
MP+M`!"E0U4-!@&5S<-:8!D$44H0NJ:7N5G4EB0`V(<")O"7M-Y^IB!B1\>O4
M#.;2):B$3![K*+1NLNIC.`E'LZ1(Y?)^1F+?^XQUAAN.KGSL#8+A[N<I_677
M)(H2TLI<M3+-L*D9Q](F<)_3G`TMWD]W/%U]SG67PLR3"^-:9,"4%UPL.05E
M)F1=8%,A>B!.7J''GVFB"(8)A+@^(1YR(X.L!ZCS4,Z7Y`!:EU/@;UAU8TJ5
MYGS8"=?AQ?*$=S'+T/`[..,<M9P31BPKQN2Y&:^>@7[.M!2"+DE2L)=/8@V5
M&E!WB4B`(H4;F+(,;\F@.E22?I(&]TNA]!F=:>DLN>&>CO,\Q#JA.0&3`59X
M&2*E*Y:-2]0ZBEJD;JD7`KI^*.!*4!M9:>DE$>U-;QDCN'/&Z!!1OCA5MQ-H
M%A.^'6[L*3RFSXJ\A@[5Z,((O/,G+>9/+"'A4L:0M`!GA$KNN,#@@+KP@J'9
M7V&!6PB!)&<!\3')9;?."#;-Y^*ARGOLR<.3M2"F.?0B6Y0'?^->K"C)4-(#
M\&RZ_67KZU?M_;+=[GH/T^WN&U':9R*P9[7P+WBPBM?-_]ZN+\M9TUK52O+A
M6DD^]057.[P+^SA$L]!V?^-VC)D8LQI&E:W9M9/O%]K8O+UEI]8=#`X-YP$P
M<'Z8W*+)5870C;I1P6%?UXRQPN3IDN:A6/^>'?UXE$.VI,IVU_*>8NJ#]&DT
MF^N.RG'A.@<<;2V-/3L,8?9W14?KL33HF$>&[,'EYK4`YPQC]28]);43?.)-
MFO6S7,IO3>E+:?5[\_3(Y43`.R58*E15J'J"J#H1B3?/J<T"3MV2>T<96QOF
M^#X]TFC7.OUF=8#68*E9&[1Z%9;6JF"U7K]?H6FMQ;'57-=F_%08\2&EYQ))
M^9<08TTN,1?.N`S"><!3C9[>OINMBM$>T%!7(:LBJ),BJ),1?DL8[>T4V&HP
M<8U75$[SIZ>WV<U!9;NK<+0_COJ5%'L".#IE&5:+12GEMSBX'F>9+=UTR_YR
MPR0ROO_+^,1#;VF],G1R6]SN'B0C1EP7X')P__*>$VIB4&>=&/3@:ZNV9R<)
MK-JG1]RGIEGKM]9YB*L=JD[2B6H[F2MYO?U?R5G?@I@R_7;TUU;TNT6HI=FM
MKNH3WJ`6R,CK+-/5!CWF!G5JW7:U0R>\0]U:TUP7&G4^E_.NJO.3MWZ<"'BG
M!$N%J@I53Q!5)ZOG-"^:G8P*<RB-1!MXU_OS'5UI?"##"1)J+[[93JS+_MA[
M)LUPV*@-^NO">@ZWLL/)4\]FAU`A6>=FJ#;H$3>HW:IU.UL:#:L=>L@=ZF]O
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ME9K=B98'HI:J*.V*Q8FGS')4TV^M2PG"0+W:>0=BR\&>+U&L^20`5BSFYFIM
MVPCH"^-S$*TFP.Q2:;/%.D4I7Z;^CF)`6GYS>-GFM$0L+O4"IHH$J<J7EO!!
MP_#RA\NMU&7G5]D013;C2QN8BEJW:9\WZO6=5I$-TT8D-6QQ*JNEUD1]2-4B
MM1`K@5^?!*+HELON)0:I^"[O2B\)E2HM>@N-6H_!#X_+;8>JR*RWR-;7G*KV
MLJR@<">V"<9=)RJF&I/P^-`;@?)K?'!]P#UVN,1^5KP`)Q5EQXI*\/F_+)JZ
M=Q8VE<(2M5B),%--=/CA\NOG]`MJ87?%RPAC$R3)$6K&IQ@81+80Z<VGW(NR
M>+(V&;75LT;6S,*6M.]<;,(UF5JS[%#?]:KV-!2OGBN;)U`)3HWU1U2[.8\N
MK&B/E>693ZQ\3'51,T7W)!O3WD\;_D;JZC(2WV.1Z/_"6:_6I%&4AZ.K@#JQ
M4;5&R<B1[0GH;0L[V8O&RC3O$L<O:L,L)ROJ"<(/:,FJ],47+>L,C\Q[B2S-
M01SX>O=,T3<4M[2>W],:+U0O9(5"#F39EL-FKDT'#/OK<8Y%[0_FQ-*S'5BH
MHK2\(K1N8?+UFN:\SKXI0<$V>\NSCJD=@T.M2V0;!NIRA]QQF=;3IE4"/PHC
MO.`TUB!-:5/1-3*4((GUY?&:M9):<E!$:RIH%R"`E]O%5@6,NJ%PN!Q>RCV0
MQ755-Z4LJ?-WTD.1)?01R#/L3AX]X(N1WG<E#IG%4PBII_$\='E[=+BH;,"5
MAB%9#MF*HL!V=0">;CW5PZE%M]A2K_Z.;G?<&4!JFC%TUMK0$,3Z"+0:5L\V
M+]8EV4EHB?+VU%K0"'A-?XMWZ>0L'>].:LO`'TF`=XL':GE!WETA'&W7T%?O
M#.*"&F+!O[#!M;P#TR_*@'<CK95E$LE*UV2.J-_:TX#Z+LY50Q%J)!XXLNE!
M=H)56,@TQ,`I"*F\*ZGM!9'J%B'E060SU!8'!@+%B`B0#V!K!$BR^'+?7:DH
M4:5R%.?Q(-21QA$(>%R[>'G'E+P\+,$@Z*E-IVP7`'(*XWP6N"KV<24:$3(J
MWL,"3!W=G-=S"<$/LBN0L&87@0S.,W1Y29M!EYM(CJ2F"B=WVY\2![O"FH)`
MG]*0(PP\XB;]Z*($A?M(VM7YLS6U7$E=V<+&6]<S-NZ!REZ:M6;;I._PH]FK
MR1:$P)$\H;#+B5;4339*AF_5^MTF'[Y5Z_;;1<-SZ4&V`(!#$R6\GQX_KM=3
MZ^;ST/@2X#.O0%*B3HK`<?$;H_V35)^YK8EW_97R@)(15@Z:2EB:Y48)0,)6
M0E,*@5#T_\!>Q;'JQISA\^\LCZ:[G3*6BGFIU8U+2-8,Y:B_N4;BYO=7,31L
MSU,(>,K=V7C,D9H.@^T,1`?G"V/(9U+M=93`.5;'A`.GKW8)(DXQ9H,H@GHS
M"*AV),&:H(SF8&G$W6IT[U`SO?D$:J:?$E>^I,-A+XQ?F0-K4-U/'I,!;\J"
MA1\&[6#N>)'CRXT+F";?.OZ*6GOZS.:M/I?8S6AAR)J!M\FHZ!!G+4A4)Y=.
M'[4#+4-F$1_DS7'Q,9N%V)9/MI_/L<-<6V$EZN$?E-**G&K!?-%8Y4[US*42
M+PXJ\*%0Z,J@4_TS>+>X!9UN#EN1IO>6=X['<U6C/EG8S5?TR\JT\CV2T`TW
M2#)+Q&)7S+_;/0@<-/%B#J]E>"CD`Q0O>X,6OV*,">X5?=5J9N_'"^/S:FPX
M#.\&(@3J+I(:&1=9V9[KV@GJS7\E0=JD#8'B8PMU'$?%G;,$"+P+MZ/D`"[P
MZNU977^>"'""$4K<U*A`W<;4EE+^54LM/0C:)S(0-],.UTKUF+HL1(,EWN:&
MI'58(F\,/QQ>Y^1W_0P!68D;7-S4-AK7.-FGR#9KW4[;<+@AGV9W0[CJ,JTU
MQV(K"P0*]@,-)A&='(N#]9Z.QNO,&5(`<*5AZ7XZ`E]ZA":_:,'QHB#ML08<
M8XY:')G[8FP=B7M<Q"E7'#=-MP22`;W524E!GOT2#@0"#VU?R;E\SVSQK5D3
M@HBOF&<*,HH[N`S5!I.T1S5'I9B5B`!?8"/)F('-S&[1$G,.EW_)UJ@5$>>>
M8R^X*:D%4=XUQA&(?`<$=Y3?_(2(C(S/W/*!;T89(X/&@*13X+WK)3C,\H1X
MO(`_XA6+#0NMR+6QSGS^26K"ZWG*#2@X+@R)URP<G1&SK212!AEM6`$AF8L3
M7S*YO.6#_)Z9):&&8,>JD2+*/YE34]RX<3;W@@4H#GQTV6J.>G@"-M$G"?=$
MW4%\P&7$A0[;\FRZJX4B(Y#%K!!8]R2/AGWT8R7%R/`&4&:;7%=N@];<R.NR
MR@H?Q+R9;Q9'-;S*N%5/])'D-O[1@9:YF\94M,INCXLFK=J@WSW6*@]Z2)\6
M__S.Q8H/TCU__K8KI&C@0B"8*HH6A@<*E%#B.1<2T":*3F<2$I3$)Z6+*"/L
M`;^986/T\HZX7*PE^PB_P$4L#H`3A'$J2Q0!!'*$;%"+0CQZRI"8LVUI@TB;
M_K2D@IR@V"R3%!_8]:1I#Y>JXSCNVU>RK]V@WGH@HM\4`Z7"PR'$AVR[.L_-
M](\5`FYI*W>4I>7-J"*A%D)X_B,(17B&WILUDI=>KK%T6;-XKI.+R+<)JN5T
M;<,M/&C\@S0<D"9D`^U,8U2$CAP^HCNK-@Z<=R>8X:$BHZSGK0RLTF4B<FN3
M&BE;2&=ZL=+]*/7H`.-CT-L=2B-&5(I)*R*5D!.<.,H^FUA"TQ7WE?14<8>X
M9C-5&/XUN,=&T5FMDZ()>4]PMAH,\F#)1I'<=Q4EH#FC23*6QI;;[Y]RP1(`
M/7RI!R:`#&#-W#LWS#V9!C'($$?1=M)%S1SW1G/X\VTDF.Z#T'/NL8LI0953
ML4L4N"5`:U+V%+#Q"5ZY%^RB)G'(/PPOOPWY>JX_W`P_7WW\]/TG!?+,<E@N
MT"T7"ZI'*BSM!"W:<Y'%</&<XDG$&X#C"?,96<@Y>-P/`5N"T3Y3BDV"Q43C
MA4Z,A^3MQ[MT5T<$<[ZS,*(`>(IP\?*@#1$(1<VA27#G79()'V,ON$>G*[-F
MJ(=P+ZL[&R5AQ&30KN0/B,IWE_]?N]UJ%`>?H@RKE`/T.M3G7A+5Q^X/YM2Q
MHW0:I4A4]FYX\W[X^M=?;VGH+U?#J_?X5]Y45L!D8>=+7N8A8&(%Y:QJ.7`9
M3X\+_RU:+;"I"5`]20W8DQ30QTU>.4QQ:EP.?D+VI%O6LBVLRT)W=JRX(=0,
M&--C-,LK2XNI^0V4/VDS:6M(3(]U%C5\PWZB"&6R2%HZY"G:"5UJ-(FX=,-7
M,>7"]8LX[>V"+!"*2Z3KCT#7>3ZGLQ)AU1(F9]BJ;/^?-*P*M7#!2<>*MR'[
MDN4BWQI3_=8H/&!R-"`..9&*Z)J@FJ:,JB@36)PW2B>="MODTBR<<Q!FYQA_
MO2IRUP_\.JZ/CH%/3D48&+G=A7'-YY:;J+R!DM^"0$PR+Q)P^JB:.*5T/JYD
MRZ@UAKBUXX2TU-%"!=OG%PTX@CUS.&(*47QA?$Q")/A:^1J=,)FLBMW/Q%JG
M-S,FGL[Y(E*C.FR[`W<XD`P(1?XB7:/X@9LM$I]LX+A+?&RA$<LXZ!J/>N/$
MKIWX#>A=ZT,NSBXC?K1BD:>O:N,4^^7XD*>+R.0;[=8U[=;GI6C]]WI?[DML
MWN['X<JXMST7M-<-O]+NOUEO;'D/8J0`D*2X]M,T!AFTROT]>84!7H*KT25Z
M\BE8P(VFV-X<J4U*Y=F<B%02(%/0/8-3;Z7WII!<EU)W4+S4R'<G46LG=#T)
MB]$E[E),BO/Y&XOH9DYMTI'();MCNN<SM=9@YD28B$P+\DXJTR3P4]"L_F!9
MALIYIW;T20H&U$G="X#DDI)H++]A@(\:WV'S($)B9S]LS#^@&YY$*U+8<["[
M<<(-5<(.]=UWE1`#`XN),"V`W)A,=+KG9BP$'09)0IXM$`9WKH"8C+02DI(`
M;)<+_(!8N*_XR9XD+N:;^4P<685VFBFW)CU"P.&Y(BKP'3<-I`-@"G31DG9!
MF0WH@(VL,0/^C,]X+NPT$"]*\(&!N5HSH4&CA!Q$*!@X"4UA.3@%,+&I.^;&
MPDRP4RZ40DZ&4G4F;U`G)=H54'BDRT9`3!<[Q9__(!$'",GL*[=P:&!:R86P
M5I&=1+=0"/>(+I<+S3-CV8##;2<1.E?@N3M66[+HE,H`2_:1C/XM(@-TZ93;
M4#&>S,=EUS1//D5>H$[G!]QJBM&XG)O@D=@AH*KU!`*J"J^34V+X-PS9%^F9
M(IKF.@0](X$M(,(^I/5T.SP<.0;6&(*"X9$/BY^8C\/;=]+?.+S];GP)+O#'
M>J-5RT^ZA8$:)&M8J_3,7G/]7%T6[]DH-JYDC-=2?#%R6S3JH3W3`F'4@BUQ
MHC0/"'DLO1FKD`FALV6G<7`:%4HFXS/IT9&X?B*\?KAA$_A^8J?)363&M,)P
M(0)-DU23D^DZ-+[G2I6"4A`MAT>TJ`!1GA\."@_%Y*=QIB0T^CYWCI"E@H?,
MD\=YQ&#C?)IYC+9D%7"!NX;;<V%\L$*TM3@B$\$EER9H7G$^74@Y*+F/F:M.
MN-.D4%+LKJ62A:7^A"/&/"587=F%#I[3==>L.`.?013@82M%)P!_J3<&6J9!
MZ^W.1^%&MW1<9@USRG>C+U/F?`I9A-NT4/>HD<*:6F**\B)YK)J,7\C9`:7E
M7IFN0I:W-@C*<*77SR=K`]!V-"5=6YERU.R\UD&,86Y^-$9M"`"?4<Q#0=F`
M(`6"POE\>;)HNI"-/6;'D7`AZ%F#\*:Z;R5,G)XC$3)!7WK<':FBU;AO'QV,
M2\`()H/+U6.O(F7)LCP2,3PN0H%XD'`IV$<1AZ?^)R@+Q.Y,:L=X?5#H*!=`
M)(YX30-AI4+QPJ6X<RYZI.X4L5F9@@&:-?./Q)G,E#RO1:%F?Q!!]5J<IQ!Q
M1'0ZSX#$!,P1B9)4J\$;(R^P%!!DTOLM\1;YBP)Y@`P.1-?1@EEHRH2C(#EK
MRN'(KR7)2C)S2=[$?/S@GK9.O?(;J,)H7>=A97W-Z,?*V1T9DF`7F&"6"`4(
M@1,$-0=.+3=#[T*P212Q`<N<C%T]-]-G]^E-E`;D`,Z0<<=A(&WH(E=`%IG@
M^:.44[G\4)9#HRF+IT3`$AD&<%JQO#J5/6N):>_$HO7/__,ZB>H3RYJ_T1S*
MJ41T#:/:@)=OP%3?>8']Y\__Z_\QC/]1[V#,T15QS?=DN;BFNXO"U:(/(C*)
M'KH6WM=KN'()7F33-VP,7/1W+FJ8\#_Q<5!O-7[')[_`K3^$&[]>.M9GNA)?
M`/G9H&1XT3]?U%LO#-?YYPN[:?9ZS>[@!:7;T50_1J'GUGF,S8N?VV:CT=#6
MO]M:MD`(_?B51U1\4%%A&^"B='F-=OGR3+/1W'R!A;`5K`TC2(%Q?P`^"?Q-
MA]TM`;B1PMOM#3H:O&X4M.';>A(Y+W[NMAOMSC*\F?FVAZ==-YOUEED.3[<,
MGEZGV]H7'DPJ>*^N#W6&-MMR!#+J-]J]SHN?-Q(\QM;,]>!+Y((1L2S@^9:_
M5"^K2&=:8[O:1SNCS(J.)DBUWQHZJG2UW.!X.Y3)[0$$R:\H2**+L%73KDG)
MU.%&I5ORI=EIU("84-7P4":8B&(ZE,DKF#0R\X_HY[BMM[30@`^74A5:]2Y&
MH\[T6Y0B:F%^*99@D9_[I;"O""W+$;.%A4D7._1$XQJJ54*7$5\(JUB`;G`1
MM)B+0-6$F7O0H2PIG.!Y@^^X@H4W-EZR='/',J&"7+`^>4&E:*=E:5A<!J-W
M,)+2\O*1D.>@@GS%I*.[7&AIEZBH549%S<YQJ>B>$D5LSZ(R&EHZI`*5P'L.
M!)41SJ:4L\F/<,C0*(H+DH+@&JQN(GMM>G5D;YSO$?LZ5A&NFU\K</?US0&(
M1L>_6*H1JQ&K$:L1JQ&K$:L1CZ*V\9^-;_3^%WC_!M^O\2]JQBUH^>/3<KSM
MDIMSH)5OG`R\0@,X+"BZGO"<\WRJSZL_I]I"5NS/J@3_$?FS0QZ+\86R9[^.
M13HLM_5]U=)$BG2&WF;6QVZ_:Y9:'WNM9C=K?MP2L@,OJYTNJ[UV6<WR99G]
MAGE"R]K<5@S+:I4OJ]GKG-ANF1OO5KMT6=U.H]/;?UEPF?WY9AP$,<9@?X(_
MC!_T51@@^Y_&\?S-Z]?W]_<7./M%$$Y>`RY;K_'GU_C@"_%\O)C#\Q08YS#G
MQ6L^.H'\ADH"XJ(R1FA\0#TR8Q;:`GX63[SY?OO^?UYG?Z(!7Z<C%L[`<32'
MYTLFX'_A`WN,+_=@Q0S\D9WFT+!4G[.POF).8)^NP\1WF9%@]]&U'(3JQVUQ
M36^\7C6B-MU[YE-^S,H)UV$F/^/RH/)7;=T;H_./^6(-T?UV_=]M-DR<;)H$
M3W:C6\?_F>ICJ_'[-S@67\=#-.A-2)(@C]\O(6/^91A$T640SD58GO#V94'D
MD0!YC+LH5:'S-30B>PKC9DYJQ.R+27#W^O+J7R]^!@[1Z/>;O4%7+B-].3]L
MQ,C-GM]`!\#X,4=?:<QA!+%GAC$:@?_/%Y+Y%"[TQ<\C._SQ9L5R.5!+,RR1
M0Q8T^6T&.V(1/,)H:6FQ%<;O0:3X.=TG-;;Z+?<2L++,*ZU&.K&CO2"_U::6
M7PD:64DV/74A\(\M\W=9CGT(\Z0Q[QIV9:#-M^":)Y!\#$**-HW>+7`KB,S@
M8*.D39&L7\>_,LN+<<1?$Y#>;T64R'E3W4'P)*AT<VP]"M$**MF&:`4U'9EH
M3?AOL]YL5T1;$>W^1"NIZ2A$.T!YFW/:@8C$J8BV(MH<T0HJV8;3"FHZ!M&:
MC7JC(S@M?03QH%BJI!8O@,>KFT_G36NK9,FE13X&B<@]V8:OB;T["HD0SZPN
MXXJOK21:024G<AGCV*V4:.'CX'<1FQM1W>-/@>5'@#Y5I_\FS6I[M_C$)I;W
M@1#Q=7Q)585"RL!7M/O;]8VHK'R;C#Y]NN0H_AU3<ZY41B@]R:LMTZ3G3<R'
MQ)^@Z6(LKJ/?;8!>WA`Q]=*V/-:I:6U_:I"<G]*I(8YW&<QF+L^+I6?%@Y\#
MG\G6`=7Y>?#S4[0U8O+2#:I.4L.$@?OB)-%'D*N'V/A''87KM/D.=YZ(LY!)
MWKBB,@'NG9:P\?N_&:5QTN_X^?L\\&\3&]/BQXEWJ2HJ?1W?\OZ;MB9Z?':!
MOF+8L7._BW1<OOA9?EV"U$,>"'U_Q$$HV*5#SJAMN)AP[VU_E!,JCL0V)U0<
MG6.=T$%Z0@]HKOEB\?S'*U%=`[5-SV/A9(&:I4^AX4$2O7=ALNC<#^(A-9R=
M$/=8I+RE$4?2V)%(&>^RKO;Q$<AI;Y02X-NA-//*05%:$$=Q=BAM;V\?;Q^1
M2I=1>C(J.3P4PDQXAZ>/8CDK>ERV^:`N'ZK)QWGS[;-41@ZGS&\W:SEMB/E7
M4<BC7%"G?_1U0E+ZSN7MF3L7BE8E:>3V,7T*9TH03S"6:06)G%@HT[D2C2QZ
M##?:9?`I=IXLO10OM"*5S4GEZ;L@5Y#/B7L43Y^D5FH-'X.0N1/_@RBF)>T@
M0N%`21$$[?<,:U01G^>VH\!WQ%?LS/G6:K%9/K422X>4XHL1G@)2@/F*Z@NI
M?JOR4F=*O`56_C4KK8AE/;$4.$J>$('LX`9Z=D1!-<4J3^@A#7F5)_3L/*$[
MG5`Z.L<ZH?D,WW/T=?1.B^GE4%KY.BI?1^7K.!(W/?&C7_DZ*H*H?!TG[^LX
M1Z*I?!T5J6Q(*I6OXZ1]':=$4@7%D<Y.(^QLKV1W'A2EE498:8251G@,;GH&
M1Q^MMC@#SZU/)DD48T2S.)"5@?S`!G*):IGGGT/X(0],99`_/X/\N3$,V=`0
MQ<"*93P(RUA&><4T*J9Q!DQ#\81,``MO6+8I5[C!V"SZ];/UPYTELR=POI=/
M6RF"SON\J<U+5YK9Q>KP/-CAP?;RU>$Y]\.C[V)U>(Y[>+YA5^*OXRN?BC(G
MEB?#I.68[]V0V7$0/@61\]F<JL)=E54`2O>V.FO'/6MYW:_9`?T#'_M@V=/_
M,BO\#F]X'Q//6^#/YYZ@\+R.7+'6M>$65R=O@Y.G-X(>^LX-X"]T;6R.@3\\
MJ;/"/?(;K+<BG`,1SO;<N]-X3MS[8!1YCEQ\PZVN#N,&A_&[?T<HV]6"_I3.
MTQI<G-Y1>J84?!D0JO[_]LZVMVT;B..?*,#<="ZV=['K#0&2V;"3#7M5,#(3
M"Y4ECY*]I9]^I!XLQ99D*98C'OD'BC:5946\^QUY).^.20REVIP?O8ZX[ZS6
M3"0Q'`OF\7#.=]S?\ID(EELGNG-]GB)=\O6].8RW812L50G0@WLR<TB>-A5I
M$%52NO5F=OOGS8BV09P2:CYCJ)5NET92HZC\;4YHK%.C+5%^5ARVB`#,ML)L
MD18`($X!@;0`#/ZMH4%:`%!IB`K2`O1-"]`?*<27(U3;=,)1Y.N=R*'(%UGJ
M4>1+FR)?Q&`Q:$T<B])G0&%8S#"B:,^EP(3@5X2#OH\"'*S4FC0K#U:R!>5'
MZKNCG9YLC'W"6N1P('O/![*3160QFX]NYE]OWJZX&`E*>5.!2_SL:_FG\"/)
M8C[JQ5N*M/B5KD4ZS"UP>#J8X]M7_LR%X,LT3*@`\=XGF/.7K<>B0+PNMIM-
M(*+T7CEPCIG/EB[S94\X>;QGXCN/HT`W&Q'LF!?.Y,TJR(<[P8OO_I"_A47L
MR7N=[KB8_+?A3A+#)UNJ<FYV@;<K+/LW".&JZE[,V*SI(F"EW9KY*12R&*I^
M@.BRK5U%B'4V3.BQY35L/SP,+S@\7*(O2T@5P5I%1\:4R<\ER@_!B.=<_K7B
M_L.*YY_*1X7RZ;=A6@&"HY/2O9/J5M/H?=#[U/8^#7J"123?3XELX7"?R?=*
M'B%_MQPDY655:V:R/1HVT8^888*EZL\:V0P"]`AF]0BP:>(V#2-J;T2#8?''
M*B.Z<]<N^3BT>A-XT\3^\!@,6^.1?Z5K/+Y<T:_OW;9D^H5760]$BOK>J._=
M;LJ-H'%33!^IG0`"J9W:IW92A`:IG4"E(2I([=0ZM5,3I%S%T2".EOA%FSD+
M52`MGWET92JN?!LFOY^3N5=;^@DYZN/@UW&P7KMQEQ0FJ]3)C?>!SR/WAP'^
M'TG^RU23+6A7*<A02R@HI09F:G0NN?OK0<O.@HN8<J^OU..')-9X"R))7_M2
M(OET=3T@*!+UVA<1R6=".P$%D1R<@]JQ2$A2\OFBE,3/;NPRC5[SG_.JDH'G
ML:=T":C@%-`<7=KZ/F4BV8>GU`FFAV%)>Y0>!%OR[`GYYS:3M(^9J!.-Y2S)
M^<?(]3QY346+;<,]3^KJ/NS5D@ZI2A@Y2F52`4'-">IVA<&L+8!^*>UY<:/?
M30Z8UJ%IF;]E8K6YZ;<I1,T$'_TG>$@EQE`N%U#4AB)X2?J2"C\)Y@5/R2:3
M@Z^D22P,XO=)1!$@?M]0T[76D81S=FFTX$3!,6F/()P&C+^Z$WJR1%1V2R'D
M8<?3^ZF#V+!VTFD1`(^TV$1\QJIE6!PWW5@<K!NJ,&@<8W`;'S?^IA<8<Z&D
M[S`Y=D^?I=L7A"YQW1^WLG!V<W5S+=)YFAW,E4.WX,Y6N)%+O?.OU7I=@^W1
M^^/B]V#'A1][[R^R[Y,RL`6!IFTWC`9*]<@+(CDH+=Z]2*2!H*)_OQ7]#]5]
M20NH5O=RZ29']Q0.69ENU"7BG6&MYD^VVBH(1BSDYIO[<2O-4S+%]+J?+YA>
MU[90'G+)2.>2:8\2<LG(Y)+IQ!)RR2CFDI$EJ-L(A+$A%:"M3FLY5"+,J2]S
M,K"DI]66I4'14A@9HN:LLCFMX_M(F""2-#5/TB1,$:8?.C**"0A,"E,00ZT+
MDQ`M#0W3$,/M#A,1N'IPGS3%R6XW!Z[#AT"&J@W]XHNJ#;HD`)$S77CG\'C?
M@>"_3"SW#,VX>`Z$;+O#%RLFR`-3;%P^-ZMHI14:7D2!\SV-+9>@S[GLC5U'
M.N+Q!T:I.RG5TJ"]ABH^&U`3QXYMF/\W]^'0U0!4E%CFD+V1&QPQ,TVED3F8
M>518/S@2.*#L8[A#V1BB96,TPP-E8_HM&_,Q.%CFC\%9*<,`96/T*AO3E\Y1
M-J;?0B$]Z1UE8[0L&_,1-,P\YO_!U@D'D_7&"UXYCQ>R9EOAK%C(U1VTU5]L
M8SK&GVBIH<K.ERK'+%2;$NJ?R3];Z1%Y\J7#\JNFN@/OEX;-;L,Y#*G)=L0%
M\WX+Q%A.LVPF**\O4281P',(3[J"9TI)B;/1J9"'H>!4U/::C*?W4DJW\SO:
M--26\CILI'$J'OQT=3V@5]0I?NTS1))=47_+__X/4$L#!!0````(`*B!9D<G
M9I#!\0@``&%Q```5`!P`8F-R>"TR,#$U,#DS,%]C86PN>&UL550)``/L%SU6
M[!<]5G5X"P`!!"4.```$.0$``.U=W7/B.!)_OZK['SCVV0$F-WN;J<EL,61F
MEJK,D,K'[=[3EK";H!HC<9(@8?_Z:]DF81,DRP8LL74O0S`MN7^M5JN_['G_
M\^,L;2U!2,K9>;MWTFVW@,4\H>S^O'UW$_5O!L-A^^</[_\115^`@2`*DM9X
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M322G`$I&\4((33,'07D2+1A9)!3I$&UV\ZF`R7E['(O':#V]YN^'_<RN5G,X
M;TLZFZ?0[FQ@CDD:+]),QI?XO2#7N)J%GS,(CPI0WXM56?.8\KA$2/K*[Q<P
M`;Q),N!I2L9<9*`^/<Z!2>A+B5RL;X8_0YK/4V%4SF*J-9*+0H@F%C?WSX3(
M<::,"QG=$S+/Y->!5,GUE0Q,U.T5.OE#<?GW?APO9GIU(!FI*8@!G\T%3)$U
MNH0A&I`97'(IOX$:36[)XPMX.\[B`6Z"*H'2)^D5H<F0#<B<*I*:8-FI/;"_
M3<>V_^B+N4&^"ZT\OJ#QP.J24.0LA<]<W)`4;@"-!RXUR`L8J^=OWSB+[7AJ
M3]0\:-R4,\YN%(^__YND"S!`,I$US_#:;EZCV`;X257I>K@,\0ED"6P!%5`8
MZ)N'<$G)F*:9+O=9DFG'E*?H-\I/_UU0M3(@<1WF%9#=9)D)FV<Z.UQS&UJJ
M1%;:YEF_$H52EQH@"Z4/MCGZDVIUA:ZF0A76:CO7KBCZ,D;^RX<T#^0:%*$,
MDD]$,(P)Y8;+AN:&QM0$QWU@\Z"<[5`]R[,1N?1%W.("AY^W,;)^`'H_5468
MG<]#1/PJI/ESC%A0=.1B-LOFC#`ZF:W'3P2?&7TY7C.2P%LZ0>IY@51]P[CB
M>>,5SZY.H2O*4[\HS:Z\*X!_>@7@<$"Z`FG")%A,&*]OK4.R$&X([?%)2!;"
M#4^INQ.2.7"#M%,Z*"3CX0C7)4T4DBEQCLJXNP<5DB&I@Z\LS`O)L-3!YYX9
M"<G>[(;4FCUYAOF^\Q+E)7X_6-7FZ;*,^"2*B9Q&DY0_R)T+-NX3-U^KJ<K;
MP<HT@REA]R"';#37-5#TD7(7$-5K0]FJEG&JS>HAX3WC0M$_,I9'D\^4$18C
MDP,NS>4$AR$>DMBH.2A4_:$MP!+#*]2IJZSDAYZ%`"+A`O)/4X*[QA0^<L;H
M,L4T$S_^G4)F?5FRN2S&]+'[T.:!O13QD*&[R!=Z"<A*1\T&5,[C0H#TX@QR
MAF08%P8D@7M%H0=OK4*Z#PP!U)`I$"!5H4+FI&Z5H6$`0P7"V[\^RRJ-"0$*
M!LASC*O66V.=[F3)1@+'&6.5R4(`?PTQX.Y!!7/'N&5,&%"D$C1&5T\?O170
M;!O6/"#<X)J!*\&7%!W3CZL[">@O/#E&_1A-7!X_<H8>X`*O%=X@.L(&N/N9
M-!AA:`LBU9Z%47'28(3Q'`KL41@5)_4BC.<,GQG;:QH/M5VRRB+26]Z/,1`0
M8"_<F,J]]68)`"[J5K*(2STZYW%>JO,Q0"(_"SX;2KG0[:"CR4:%P%RB=QOG
M%Y+6'G1-OA*E%6@UFIA5RP%HC=D\P]<K,9IG!NW3(XB8RN<TD0VH;5P`D'2=
MVVG!7A%[Z+"8$@$?T1%+=!$'?65;XL%.'&:GQ9[.65X[JJ]1.(F.0!H'29F&
M5(39O^)4S]N%5*II8B.5Y5Q"JATW(0]K!M15&&^/4A@N9XVK!'X\+M-:(X/G
M*HE_':4N6.))5^`__554H'J"TU5$9W\5$1GSH\ZNV'$ZINX576=!')E36K=(
M5:-YJW%Q5$V3\MH9GF.(6/8IC2H)O1H1RC')IEIYY@C"DUWT9!^YM9#:0O=4
MC#*(R"'/&E(/Z6&%84KM'4&"8Y\2L"=I0]H;M9K&^-Y]F."VR8'D4JL`'M+F
M.9!<:M7"F^QT9EQ!U(OTJW6210I)-"N.Q&C"180A:(2CYX2M9$0S+'E/<*(?
M6TJ?^"YO?-[/?1KI@]XGJSNU1=O]V,)WT9WV$P5BQ.!V*OCB?GK[P/\#1,C/
MA(IMSVT?9.XJE:X=X>9_X9;2K*T9V@6C=<*07G9B*..%6!=VE?VO5$TI0P73
M0C=I['XG#;.NZ;"(?/]Z'9)K<@`)5+->(?DC;L(XQ,;PX'W0H@RRJNU7&&=H
MTF,H8<+-%]A7-V_!"CKF5*(C\X7S)'^`]QHDB*6E/=EYI(\FY8(Y6^/_:Q*/
MC/[*Q7==Y,%`6E:3?_G(,`^RK0O`=P`8TAGE#,YU]X3R5.OF$_]HR'1Q-DJY
MW/M#KN[W\?[,:U56=XKU-CJNED_57ZTRJ"`Z,7$!2TAY]I:=;:%.C>%>7FCX
M\K42)>\I=1CA`X9$%K*-?<-34X.K@<H/N[I)K^@L,)T[)K+F&?Y"*-.-(2.&
MWBP:=):_WR%>/==\ATPJL<BVZC>N+D`BE=["??D+)/<8\FP0&/`>Z"X>Q)6]
M'#S5?8?)3)\Z*K<"Q4*:X+N-\N$YY2V#:R.6[WJCLV0C]L>\7?8&JO\_^V-A
M]:GP4LJPA=+3"T"WG&)W3`!)Z1^0_(*'`S+[;(Z>8_>^H!)_NLB2.'DIHN2\
M//3M?+P&<YL/8]]?3F,\0.$KDJI5">];B;PQ:W\?PG8B#P^]D!1DP<4ZX#*P
M;"/UR[@;SX[L>GSMH8%9OFND$E(:P`+27=%"2C<[`+)M]J`Z/TR!#*_I_8:D
M>"[@;$=(2#KG@L4:18?4KNBT,.Y^24@;RN90&PQ>;5O72`NR(R![1B2T%G,[
M%FO(&9*!<T9B"_E#LG*E@$KCU9#,7"F:@Z;50K**+JGI_3[RUHQ_40E5,_D&
MAQI9\8/^1_^/?GCE?U!+`P04````"`"H@69'.OS9'DT\``#*DP0`%0`<`&)C
M<G@M,C`Q-3`Y,S!?9&5F+GAM;%54"0`#[!<]5NP7/59U>`L``00E#@``!#D!
M``#M?5N3VSB2[ON)./_!Q_NLMMV7W>F)Z=E0W=PU6W;5496[MY\F6"0D<4T1
M&EYDJW_]`B0EL20"2)`@D)3YTJZN`L#\$D`BD3?\[3^_KJ)7&Y*D(8U_>?WN
MN[>O7Y'8IT$8+WYY_>EQ,GV\O+U]_9]__]O_FTS>DY@D7D:"5\_;5T_+/`Y(
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M=]0>D\J_]1Q2/]FFV7<^7;WADNSMSS^\?5,0S`1!1MBW,C:;?E[\X,7!A/T;
M9ELF*.8T615RX2609S_Y.MF-5%"L/9`0"4,<QB%O>L?^MVK-B>T-4TD*^9H1
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MB9?2F`2W:9H?E/<38A7M^R;Z*?'X_GW<KIYIU$!DX]_;$C7WTN="M\W3R<+S
MUH5^]H9$6;K[3:$[UDBL?OW/1Y_$'CMF/L7IFOCA/"3!U8M;1D4RN/V`(32K
M_E:A[!1IIHB36_;C\5Y4-W1(](ZQTZ^ADNZFM@Y)?_*>HV/9+&\D(_9PH9HF
M_BN:!"3YY?5;UK.X=/[5CVA*@E]>9TF^'ZZZSW:ZI<\3NE*23;4F@WW5(C;A
M)5R`K)%NVGJG`\&^,P[VA;0RC=7LA%:_I''&;N_744':+Z]3LN`_:/.@9B44
MP#Z5;TT+N&%G6I[,)GNB#B28(@@$]3TZ4-)+&1#5#XA02;0W()H?$:&!F9N`
MP'Y"!$QY^0-B^G=TF"!7;R"X_T`'3GK/!*+Z"SI4H`LI$-W/Z-#!C5C0D]F4
M4FD"H]CL"46#2=$`&)BAL#"I&B#S/A08)FT#Z&*!0L.D>D@\<0<X?WMSA(8-
M]]FD*Y;=9U(:A0&/39D\>Q&/U9BD2T*R=.*7)^UD7;!]DL=>'H2\W=KCOU^2
M+&23L@>F=M<:_)@-EZYQ<O7=ONT-/+53Z<%+[I-B00:_>5%.V#8J#BJ!U4>C
MIWV[U<EA.\VS)4W"/QE7E7!$/1#`*#0B,(27K1&0+W;VZ72Q#^2!C4783@[:
M;!2]SJ[!`;<+K!,.,-)-H^Z``X1ZZP![#=C_=`801A?:Z$*3T3RZT'K&-KK0
M>L`ZNM"&X$+KHI`.S+'61DT=F)>ME=HW,-^;KI(^,`]<:U/*P+QRVC:6@3GF
MM`PP`W//Z1MF+)JE8YJ1R;M)&BYBIHWX'L^K\7V:Q]SC.UG3*/1#HF%YUAO/
MAG&Y#44P^_$I'_AO_CE=)*3X](<72Z:ZK\B:Z%RM!!^_?+P3?_;DCR8^2*.(
ML3KQHAN:7+(#)I3@5C8V0E`QLXRYG]8TOLX_>,EGPG\S7:\3NO$B&7E:74T0
M6W@W_.VO)%@0P,*!M#=`UC\>9C.Z]:)L^Y@_W]U=B@F2MS1`RFSZ</O;]$),
M06,#$Q\FBSSBW1FR-0^!F9$-B7/"5ZX7>T'HQ=,XN/YTLDC2!QXO0^,9\2F3
M.>QHGGD9N_IL[S<DN?[*[GU,-2D]K/?SVWA#HXUBUAV38H29)<'LV'ST(E)\
MC'V'(7JB%^1`WN]+$C\MR>&OB1>G3'&]3=GIR0Z)C,BXU,\W3,`OMPBC@80;
M?@N6H)`WM9,(TVB9%?T9$4FF;,-0TN[(PHM*`AK,J9(6]HVHTX0M\T6QNU,F
M+#[2V#O\IM@"GL]%1=JX-#N.\HW`=>^:N"1,WG,M-V/7B_D56=-4H(]I]'#A
M]H[](IR[.+S"]/,%4WJ6*W:\27U&T&YG`PC!@CNA<+NG4>)A@G9#`8A'9.IA
M.>Z!``8G26^MG?88.`P,NR6/V?5W[279EJ?>2%>5N*D#PO,THRN2G'!7?K;`
M>MF'<U49PZLK0^V85^QU>$=LH*2;1J?KV0%S+Q:NV`U\PS;'AG`+5,)T2@`P
M=9?!`\$T,[=QFB5%B#P78%(1H>[B`$B8<B](GI`G\C6[8!_Y/'U."WZ+<*A[
MV(=Q0Q,2+N+KK_Z2;^3=DI&>0J`^]J%P$VX8+ZX(]TP4)Z-D4<D;8R!>NLE5
MS0<+P+V$^N!]#5?Y2KH#&MLX(#6,U:0VM;%/ZD<:!]5<DT!*L*2EB[!G&N1^
M=I\\DF03^C)-5M;4&>'<R%;1DTKWH[+]@"&XERDS?DY*UL[)WQV1*-V8#2V0
MDXE@XLDZ3YB:E!Y\R\=V".F:UNY_QA`QS"93UT/NXKWTTB63,_R?ZW_E['H2
M<8]&\V]E^[[S@$-A@GS+&ACRFV>$^^W!@P32RC!4'<9W82R7UJ`^`TZN.@,(
M"!;6(=1PNH\T?*@"#??&%!$NK<YC\MN8_-8J^:T?8KGI]GY>L[)+^"QM>P9Y
M>W`[L.7T/74\.\BY0+5#4E&F*8*FJ7%:H?X*NSEN!E:P,FX-S8(5AB12C?!D
M5,M2QGL*#7BTFVIH4&::NF"B6:!&KXSU7")HU!ZJQ6UPFCLO&MDM%%U6LJGE
M`X\P1Y>M;)0%P#PDN_G,)N5HLX$>GUALL-'78$C\ECCEV@G;C^=D6%)',3MB
M5ZW=)'F#&T<==8EO#VG[7*@\'13EUI).#&W!C4Y[T%#Y`X,+%V!-0;=RVR83
M44@6-<I5+)\EVIHUG1:SH1H7!A>S.C8%W5I6!Z10=;XRRC4KG8S328/&L]@M
M4'+6]=@`!4J4_C[:I00"RG7KN/Z<H>HS1AT2>KDKZ%:Q5I8*M5(5`.7*UYAH
M\/+`X^#H;Z$@*+*!D)4P5^"NO4:R!1"KH7=H#`I22#(&.N&I3,&H`53&M*,4
M>XIID4Z@"?&&+P0!G)F.;K5"DM'K0'42C5$N7LA4R6;6U!F-)PI!PAE)J0C\
M*UE4DZ1^(X%'F0YE,3=/F72:(:5.+.M+TF+@FJ$;>(&8NT'CQ]A=:<"/$>J6
MQ(^DLRT2/T3CCJXA0#9_7.!'W9<O"#]RDR&W^-'B"7;#SRMSMR#\6/NSTIJ]
M(3R/;\GT^BP`N,X.NJLMA/+ZW+7(;#M@MO,2PO>3E+_/\,S4JF#"6J_91BZD
MRXXLX`L(RG%*>!9>/@!2TNW%@WR1IQG[_0^2)P\$;722U`2?OR)^,20OT"PF
M0-S*``G7;![IEI#R!9I*,7^(O%A,#["+`>)NBU.2J4]R@B3-#!#!U-8=XJLP
M(3X;J#FY'-C:`$D%Y^_7A>[,=*:#:E7\04R<3C\#9'Z*-^P+A0MQ3I,5?QR[
M?#]&3"&PBP'B?F/?^?XG]AV^=JX]?_D'\9)/;!E%-WD4;7\KR!`3VJ*[(:)_
M>MN):,WNAHCF,3F/N>^3-)WG4168P);A_?RQ-+SY5TPOC.BZ\"^'$>M"8]E"
M,3:H_5SCZ1<O":[862?),6YLXY!4:44#0:N!D.N^[$)!T/'=J8GH9A^HFVJ<
M]_/+FDXV(SPM*;BD:986`ON"JVT/WK8P_JA*1Q@:=2Q.VA+&"XVNU`^DQ624
M[<=JDC)2AU--$J:Y`5L[()_=!Q35ZIN:N"-47G>QL=$@B'5_QHZ5(;_1RI!C
MA3%4%<;V6EQ=SZL["B^V)YI>H?L>%.`X`$F@/C\U,D[S4PA6WEC^;2S_)BS_
M%F9EADT0;L(@]R)9^3=96P2D_QYFR^+BS*V\RW#]1)N"]U2@8*-\(W#=2R]N
M[N29.^)EV=#"&9E2WC>V&0"I.HM@()4>)49%=#[[7M4YVL;]A#*"O7E*J0OM
MSFY8B\DJ#D*;$+I=H5C/2L\XRC7<R/^&^<&S^+K/E%90!3IP5H2S?O0"D$_V
M:@'VS2<M2[Q=[AB4ST)5%YUX;M9U:=<8$I12NVE63B?-@,PV5+42T78%^E/1
MB7WU\FX5;81.;*MQ&@Q%LKL+3-\FFV.6T`EF4<@2!07]HI2_S>QOFI]!Z<VJ
MF5)%1P,!X:OH"K`SH]M6;<W(5#-Z&N4&E$^8;&;;6)^!+,!7\/5<2GQW+B(]
MEOCN<78Z%V#'5UP67_W.0=2S'"N/&,9X/E4Y=%7F@2"R[?[!SY:^5#/\R'6L
M<OC1Z'F&S)Z-8SF!L9Q`,S[-<@)&LYT.S+!39^"'B<^?H'JF25'79N+%P81F
M2W9O2$A*&#7+XE?!P=HY\:O:-_M9!Y8B,/$I:]4*S!';K:#!]>7]!W9`W\Z.
M7LAY4=%`U,A`LN_T\6%V,9U=39L+*+\@0][4!#%!4$RQ%]6L[Y4'64(7N)<!
M$OD>5[-*W,H`"9>/=W?A*I1FCHO:&/C\^X20^#*A:7I)DS4M:R*)*0$T-U'T
MP2M7`*_S%69YQ@N>11%)%EN^;^(YX87+\I2)<L*F1E8/HLM`)FHP'#_8\J+:
M0O-K+MT^^'A%>"&_8M/,?R5>E/&Z7K_F*R_>E3244*3=VT&Z=KNR=L<)W5V*
MXYT]7/<1UY?UX[Q&?8.R)X#<8@07,,55.T_PJ)X8'%/OM6%H5T,]SK5L5TWU
M+"&Z%QJS2M=G$JZF.];V_KX.**U"]&YH<L^O">EIP<@3-A@<>U"L.2T0:8XU
MHN*3(VMJ8[O?6&,6-ZHL[C&7=LRE%69H;B7EP8_S,&5MSR#!KH<S&YWUV^SA
M2SL:`E!&0)A=!F;6E^ITM^M%&A\4[_2@N,H^C')7R"?*T9OB%@.;NSXBK^FF
M`#+`7E9%9P9`_$?HIKV?X]*`F\'N^C#ZSI[*+HE.WNM;[2C($8=2SAM_&&H@
MV8-=Y1O8TPE$;BC%Q89DEP<HH#O)>KH"-7MG[:[S,7Y]C%_7PHH?XS?X4&%?
M5RW\R'&;7LQ*OS%">8Q0;L:G&:'<.G+%=C3RCY.$;KTHVTY6-"99^&>;)\_D
M@UB+((:0T2DV^#)/$A+[S94Q)2U,A)AJ?KJ+BU-!`G\-^W"@2R)>`>T-D/6/
MA]FLG/;'_/GN[E),D+RE"5*\M1?_022QM\TM#'SZ8>G-/DP_LFT@B0T5-C)`
M0,79#[6=)R9$V;@?@D3QAN#V;7W!*?&_6]#-FX"$7(3]R'_@)/]8\_ZR7_VS
M*3.NHE'T9T0DF0JK@))V1Q9>5!+0X"&7M'`0`ER^>IH6>^^.>D7]O9LP]F(_
MC!<SXI-PP[4\IC+7:.;938?KDB*ZK8]/.(BFK0X-611M0Q,'T;/D.3N\82XA
M5]S0-='*N%%5\\$"<!\`!GG8_@2,NLO@@6":F</*X0_,2[>XNLL8W]\21NVP
M*HUP]0-+NLXT>IX9+/>[J+#37=+5*LQ*4ZAX]\B:NB=<.A7RQH,DWOW2&2/5
MQTCU,5+=<*3Z0,*]^[O$HO,HZ&@G5,."B3("H)=YI09THL$&::O,"NC6N]*8
M0&%6:I3K6S(;PCDS%(Z'+YP4?AU&N$@!-A:J[>!"NF8!T]0XK5"SS>`"[90^
M`S0+5N@.&JRJ(.,]A3J;[`;R&I29:B,(FJ4'-'Y0/5\OJK4(FA7)[)UEV7FQ
MWPW-TI3%X%!`"`;*1=C(]V,=Q,"*&^NUC_'N\/!@S>,:+Y!O*G`?+DKP@T%@
M4\+/)).7O"&@[6*&P8^OFSYJ]N0<<R7&7`G!+H3E2FA&W=K.C/AIDO+'1)<T
M8NQ+)^1?.3L(=B0!$R.D8UC+BP!0`4N+&..2QC"%,4QA#%/H+TRA+V(/XN^Z
MD'[\S@"O0ZW=_PPB,4;;"_[K@".3Q7@E&*\$_:9/MQ2X%J\(:;B(^:/T'OO9
M*PU18;R8K&D4^B%)]S_`+PRZ(]JX/K2CJ=O[2[[/UF!P_96_ZD72!_Z%K31Q
M$];#1`(TC9D<S<HR4O?S#U[RF13&-`"1NGU[R]>&T*K3T0"A5R3UDW!=<H:_
MY^;%6P"9&MT,$'G+3;\DS:IE5A0MF1/&J(/)N7AW#D!XQZ&<9:\RNAZJ#:^X
ML*L[.,@L]5)>:H;_PX^4C1=QRZA\NEKUQ0)MQI98$OK\040)^5J(]89TP`@F
M!1*RY*HS=WBPHXV4)`&G6;.["X"U8X0?'Y=,:H3%02+$I.SA!$;*6!H41$'G
M1MW%/I!K+XF9E$L?2%(\.`K#`NQE'TZYYI^\KS`<JN8N`&1>O`C9A6^:IB1+
M;[@F3.[8=@ZDX@[<SP6D#=N_-`'*,%5S-P#23*U[@MO;A_"1?*FI-`F-V8]^
M6>-/YWQI.XQ]P$>$*-0]16L'Y"<A39AT#6DP(W[DI6EQBRW,'\'_Y.7JJMT?
M1+A:#F,?<"W:!;84U1U<@&@J"%G=DJ3B6Z.G"UA,(N>$<9PN2KL,=(J`_0;L
M.#P#"`A\G_NG[OD%ABWYTLA4B*3B\0)^`6"JS$/DQ?);7X>11I?OZ/)%Y/+]
ME)+[^76:A2M&CXC!S8U&Y^WHO!V=MZ/SUK#S%G1)0N>X55%]6KM#:?1'AQ%`
M.&WK<T*W6&%@]:VN0*`6'T?3`MKMJ@\$;_'E)+U9UG=O`1%;?#')`.(V[BT@
M(PRE\QIG!-#8:C>%U#A*J+4+"/,_D,*$V?Z!(/^"%J26JP:(]F=D:+4CFZ"*
M!C:U2L^7"$6)5Y]J$V$`18U5N=*T9$/A8E6GM+T14,!8M:G.9F,H`[!I4>;"
M^:`<P*9AM0T8A>+%JFIIA?!`P6)5N61V<B@VE`I6NZALJ*D#JZH%#@F$`L6J
M;76+M[&835*D:;]3IEMDQ0UV1R4P!UUW6&MIZ>T(ZY9<LO'"B`]Z0Y-'+R*/
MQ,\3!HFDO";(!R^K_N_&"Y/?O"@GA?M!GGUB9D@#&0J/_I($><1$=<W<<<.V
M3^TQ2AJG:DB=!C(,I+@X=$:A-XJ#!`OA(E(%"6GT''",S1E`0!`FM-\0>SMA
MJ;AGTLW4MOL8$#0&!"$*"`*M<?V5/`8$C0%!8T#0&!#4`I),V*"+D1$02SMH
MHNBF38S1_$T/7;B,`KR!.R&Z(!GUFFZG\Z*+C=&8VS8W9=N&LN_+>H;/W.$T
M\6L>IW8&,NAPU@QC>@39+-TX7NAQ7NB;';!3/PLWO'JUWO6^S6`XP#]XVZ+N
M\Q<O"8H24J4+.N6G<0DB3?/56FU`[/<CHV5DM(R,EI'1,C):1D;+R&@9.7_+
MB`G5"MU,MH-M2GG"%YL1D,P+HW3"14+N[7>TL2`-P?B(HC6D%'8+VVA^6_5%
M&(;L^=5.T0C3#4F\!5F5]KWM#4T>:)+-&6IZ2)XYUDM;]#1/:IG.=C__-5PL
M_S^;$?:K,L*-;ZR#]1)`NN9()HJ7/MZ))_ODCT:*NT816_")%[%Y*@/B)`2H
M&INI-LOW%ULBG]8TOLY+AK/?3-?KA&Z\2$:>5M?>:LU**`0_G=R)+/DCN'6"
M(,_E=B+ECL8+MF)6AYU?>0RV'YB<7N6K)JK`G0P0^`&RUU.IU&@YA$'BU]67
M'Y=,TCZ]X)R,8$`W$T2&#'U&8U)I01^\KZ*)5S0U0,QL^G#[V_1"O",:&YCX
M,%GD$>_.=MIZS?A=.1VX)/5B+P@]GC-R_>E$:*7\].01RV4:T9\DF'E\16WO
MV6'%DR]XXNYNZ;$)I-%&(84<DV*$F27!3#7G+LF:G^J)7I`#>;\O2?RT)(>_
M)EZ<SDERF_*+2$0R(N-2/]\P!S\Y))950IQ-VWX+O<P^8X1*0+8<R024\G,'
M[ZID0N1-343@[F7T_9S-8#/+A(W:FC#9R?#=@F[>!"3D=Y$?^0^<N!]K1DO1
MN[(58?)G9U&09,IO!"5-\$AOC3K1,[[VPZ!77*S^667CO,R>$]BE(5T<`&',
M#,(HYTF/AVUR_=6/<G8'+KWKJW6>560?)Y,Q4/F)PM++V`Y8D[!C85$FX3#9
M^I'&WN$WQ9'A^87YIU'^=1SE&X'KWC5]2=BN+`KH\-/ABJQI*KA/:_1P4:=^
M=\^?1@GQ@NT#DRLDF"[8C77!_K`/]1*!TNV/X$6!"W8O7ZZ8QBL-BX!V.QM`
M"/;4"87;/8T2USBT&PI`3]N7[[&KL1SW0`"#';7\%]Z"O(/B:.B"``CGK=ZF
M.>TQ<!@8MGW."TRLO23;\K?JI=M#W-0!X3F[-*_X._1'W)7K`;!>]N'LBGI4
M1H!I$!1F`M%<J)J[!U#3(.52%]X1&RCIKM?I>G;`W,NU*Y*$&X_?8KF[BI=P
M``!3=QD\$$PS\Y[1<Q\?_E\)1]3!)8C;.,V2G"]_?HQ(Y9RZBTL@=S1-M69#
MU,$^B!N:D'`17W_UEUP6[5:]5!,`];$/A;NLPWAQ17@\3!FS)%Y2\L88B)?*
M*57SP0)P+V2/JL8)Z!>T<D'N/F"IJHLLI%C4T#[1I?P[."V;8[6`K>V37SG]
MI4*RL8T#4LMP%#FI36WLD_J1QD$E#D@@)5C2TC[9#PGU"0F*U,R[T.?2X(:0
MM'0"GSAH-7LY@1/D?G:?/))DPPB3G*&RILX(Y\*MHB>5GD#*]@.&X/X4G7'-
M4+)V3O[NB$2IG&EH@9Q,!!-_]$@'%W!3W\]7/*"+!/?9DIL03XIM5]G[96C6
M!9FS*\:3]U4$N(]ON&#5.D_8'2H]!-H>&XJEVU^[_QE#Q+#PY6^4"!'"NN$#
M-,TNO239LEN<S-/><A1\<`7D2XZXS@,.A0GRT\G`D-\\(S"(M[("C1#<RS\[
M2.UG_$HK,BK%^"Z,Y9H3J,^`2Z&<`03W*W^LT3'6Z!#7Z&!?O)_7/+D2/DO;
MGD'%#KB;#EVM`)`#6_ZJ2M.A@;)`"6B:&J<5ZA.W6Q/!P`I6)EN@6;#"/!JJ
MD2^+:EG*>$^A63IVJW8:E)FF+HEH%JC1:U_];1QH&@*JQ6UPFCLO&ME-$ET5
M&U/+!YZ7B:[PKU$6``MCV"T%;%*.-ON3\(G%!I=2#88D:@"G7#MA^_&<#$OJ
M*&9''"AAM[2TP8VC3DW`MX>T_5Y[*=A<GPCEUI).#&W!C4Y[T-`#KP87+L":
M@F[EMLV.WK]T,#AC@WR6:&O6=%K,AM[J-;B8U:%4Z-:R.GZ*J@L6H5RSTLDX
MG31H^!40JZ&'E<^Z$C.@GJW2)4:[U.1#N6X=5YXV]$BV48>$7GXDNE6LE0E)
MK90%0[GR-28:O#SP.#CZ6R@(JNPA9"7,%;AKKY$-!\3Z,SI!"LF60R<\E3ER
M]0?I51DE*,6>8EJD$VA"O.$+00#7H4&W6B$56^I`=:IQH%R\D*F2S:RI,QI/
M%(*$,Y+"4/A7LJ@"6?U&`@_$',IB;IXRZ31#"IM9UI>DSP!IAF[@!6+N!HT?
M8W>E`3]&J%L2/Y+.MDC\$(T[NH8`V?QQ@1]U7[X@_,A-AMSB1XLGV`T_K\S=
M@O!C[<]*:_:&\#R^(MGK*Y(MBV\#T=H+T(2A!54O`F(S%'=I#%N/A1B`'#$4
M4&>,(_!G+X``#05>&0.H*B,&A&4H!*<S+,B#.4!(A@(WS$`R\6P2$+<AO[]!
MH=2AXH1=%YTUS.WT!HOA.NH5W>D-0\O.`#.(3;SU"@6.16MJ]_HC%"46_:G-
M&Z)0C-@T(JU*AU"0V+2BYO(G4#18E"'1E;OYB00H.E1Z$>C]5B@R;)J/M"@Q
M%!0VU09:-1UJ'L"BU)SBD]?HA^+#HL+L;\3FGT6$L@*+4B.TW@I?EX(B1*70
M'.FK-S3A<:)S&H448/CZVYLCG.Q#G\N_%'_@A,[(_!7_]]/L=@_JRY<OWSV'
MU$^V:?:=3U=O=J_FOBF@I3NZ)S'-R.3["9/^_N=GCS%KPEIS05E,QR1@BG08
MI1-N]&7:]8Y,T7.\7<<MX:<AC[3><:"!`57K%]/8,^*2,O8[$K,-^EI:1$GP
M3/$T7^1IQG[_@_BQ9%$;G1I.@L]?,=V2#\D?W143(&YE@(1K-J]T2TCEC"]$
MV06?@LO:#'RDQ;8@P?2+EP1I_4_<8+B+I'X9ML^VU8SP[<HD`+<PIKX7_4&\
M1HCNJ$#-0D[HS>D[+9:_BI]%-+>\JHZ_BIY%3^S;#I;1B\_B9](7ZH!%AX^:
M9!`_2A^J,*2'R(O%QPNPBP'B;@NMDDD6.4&29@:(8!.U0WP5)FQ2:-)<#A?8
MV@1).1_P?KZ_\Z?>U%^&Y/15#FAS@T0][I6R^IKF4W-</E*WFP$B#_>2^SG[
MSHK&Q7>++9I>D$48\SM:$YUZ/?LF]3H.VM#YLIMA(A^]R..IF#N14/OZD3%*
M1"]\!`.D-XOE6A3.Q98W*99D95,K1'5%R7[=%HQE*';;_N6]O@[5SA?ML:9L
M4J?T)DS2[#<F9-@J*[TZTWE&DO>L8W;%+F\=N-+^8Z88<B*<U#-7GNV?JI/^
ML-2%?.CA&R;@\QUXORY,Y=,X./ADRZTI/`QU^AD@L\:#.4U67ESI7I+C&MC%
M`'%\H7[_4S4]UYZ_Y+K<)Z:V1#=Y%&U_*\@0$]JBNR&B?WK;B6C-[H:(YA4O
M'G/?)VDZSZ,J[;\PPSZ6:2W^%5-_(KHN7"5[O4@.Q<B@]BMY3Z/B:VS7-4I:
M^7.0>IT=@./2CTM[27GRQC8.296^%R!H-1!RW3]J4!!T'';=1'1S^K1-4MO8
M"9YHYD7'QH*/-/N#9*?1;D>P>_^>0Q8>-`WINRC*]O8AC&^N]O+B)$@'!+9V
M0'[DQ<<I@\<T-S1Q1ZC\.<_&1H,@UOV!-CXX^HT^.#H^EH7JL:RV9JKB/R_,
M5.]$Z'OXQ(`8I3)SFN8:]'L#8N%++-,\6])$<B'H[3O#9=G&"R.>=G!#2T-R
MSYP3?6Y`#*SLNP7YZ6U<RI_W"4V%K_+U]Z6AL^UW$BZ6_.Y=!ASN71DGB<.]
MLA1,!4)VI](SLK#YQ`'H'M#GIT;&:7X*B?ZG=L^19O]<I9S-^,9*A7Y`*]\:
M$.LJZ73]E8$(4WY.'HFF,E*S2$,OJ\GD7L33Z:0:MAM*'+!]?-YW?-Y73"SU
M/]^F:<YNV'FROS=684*B"#_Q3'0:S3[\IS`KRY8$X28,V%Z5O6XL:XN`]-_#
M;#DC42'*TF6X?J+7#;4I5:!@HWPC<-VK&]4A+EF6#2V<D2GE?6.;`9"JLP@&
M\I"YQ/'=M;:8'B9(7EZ?]R_:)O[+,HM@!9J;IY2ZN([9K=IF\I$RH2L5W:Y0
MK&=E*@3*-=S(_X;YP;/XNL^45A8-.G!6A+-^^#"^2HH]\TDK@,4N=PS*9Z&J
MBTX\-^NZM&L0-TJIW30KIY-F0&9;K`5A:;L"PQ#1B7WU\FX5[H].;*MQ&LP%
ML+L+3-\FF^/JT0EF45C]OL2+M&@'2OG;S/ZF^1F4WJR:*55U$R`@0]4$3;[[
MKK8SH]M6;<W(N\F$ILNCW(#R"9/-;!OK,Y`%A@I(&ES7@@!E=&NY*4:Y!D.2
MV(!R=4*?BAK(L:":'7&&#!"*H5JE9_T\_2">:Q\?UC.,\7P>G=-5F0>"R+;[
M!S];^E+-\"/7L<KA1Z/G&3)[-CZ/KV7U6S^Y16D)=)9"0/5@[0IG^,SBH/FT
M5%[`KGW'S!)P7:[6KNT`.\\:JVC:O24.@D6GM5B!3$+U,(;MHKY`'F%Y8L-)
M;6@@C["]V&$A+P>JRV%[[*._W'4H1["IM[VGN4(9@U(95M8BAJ+#H@5;J.$)
M90DJU==2>5<H;["HN&@R$J&,PZ+X]B->-5/>H4S#H@AW9AJLX`>4+5AT7]-L
MD5?S@'('B];;N3P[U%B'19=M7><?"A2+BMKNH0`H2BSZ9N?=K5<@"LH>?`JK
MI2<)H`S"HKX:36X_@+?S'.`/$Y]&[#"B2?'BYL2+@PG-EB29,*()HV99_"HX
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M*8P#3`4M[;V%[[Y4*MBI73N4=K0T/IAG9D0#T-ZS28LON5_BDB9K6C[^+99,
M@.8&B-K[%:K;BN0`4S3M@QCQ`:9H:H"8CUXI96_C-`NS/&/7_FD4D62QY2IC
M/&>+*J1Y>A6R]9/*GD+J-)`!(!6'^&+_0`.>:EDI1-7Q+]6KM#N;(+B2:G+"
M1(U,$)!0GQ`F'CJ*GB[C&(`Q(S'YP@4>B*'JUB9(HELORK:B0Z7ASP8^*C!(
M%(=[JTUA9$`#P#Y-+R1/]1W_T<0''Z_(VDNRXB8X_Y6PR>+K^-=\Y<55+(SL
M\4#MWO:KGM4#_1EM'YG@/OSFB?V4>K[XWMQQE&\$KOMJ@9?<VDH2OABWBF>#
M9$WM$_Z>;D@2UP^,@UHK``#I8A](_6@\F"'2DC3A`PS`7O;AS,BZLF77[I`O
M%XZTD*)V_S.&Z%X\-*MH-2FWO_S2JI`4._7ON=4[O=@>)Y>=L,'@V(-B#2=>
ML4(,CCVRYF1L]QMK?*(+U1-=8\'[L>"]L(XX^^+]O"9A9!7?96W/H`QT#V=V
MUV1;/5Y`ZH48/7QIQRN_9?8`*\08709FUI?J=+>;ZVRRNI=:IJ#;0VW-/KO=
MHO*&H]P5\HFBAJU$=M>SA3G7C;*!1@4.AP&0\"=TT][/<6G`56AW?1@4^&I#
M*SIYKV^UVTVT/.P(I9R7S@\U9N<#8K<7%=Y5OH'C.(#([85[=Y;L\OA:="=9
M3U>@9C^LW74^5ED<JRQJ8<6/T?AYA!]R7U<M_,AQFU[,2K^QCEZ/"7SBL&5T
MZ@@(C6;T.CKMNC5(4!H$.I6Z`UQE^@00++:*'O#X)"!`+)4W#(4``U%C*9UA
M/.<"B!]+C8S6V3I`G%BJ7;0*R8-J#*@J7(#R7J#(4"E#PG![*!I4RA`H)0B*
M#)4&!,K6A2)#I>R`DJ*AR+!H-AT3TJ%P4>DY!E-BH/A1:3PM\^2@6%%I-XH$
M,2@F+)J,5O;;`9R=NC0_3I+RD)ZLV,F6A7\6RZICQ1F]0:W5DFE#5J<J,9=Y
MDI#8/WJKY$66>V,+$^GUFI_N$BVL(.%7$BP.\DE2*@/0W@!9M]PTSY\N9Y?$
MY%`(NTZ)H(F!C__C858IQ8_Y\]W=I9@;\I8F2/'67OP'D50(:&YA(@^_U,+*
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M%]L:S?P@/X1,*#)<^_B$BQ(!.\UE&B7$"[9<;2'!=,$4WT53I?.3N@&:_1U`
MK(Y#6?6#AB;V";TBSQD/B4YR12*:N*%KHG=7EAF;^L(<T?!JA10,9`#7()4U
M`%3-!PO`?3+O%2ET\G"SSR!2)I5#N@P>"*:98=<0[@)G=\HE#R_C6_GX0JK7
MR268PS:8A>EGJ5!6=[$/Y.A*6%.TW[-5<T?3=$:\J.$VTWX`!^6"*DKNXR-J
MF^:$*VQ7)&6M^.DR3?DMF2ELM08"3O3T%?OLJJFC9:AM72652B"-GF<&R[U\
M+:)Q^8L<858&/(M%D:RI>\*E4R%O/$CBW2^=FM>V'L=4V`=OB]?EN"F8"?5-
MF(4GIM".HPRX=LT90'"_^,;R.V=1?F<@-6SZL\I9SO93AWOH*&-4PYV+,JVQ
MEWFE!E1`N]E!!G>*RHB(;KTKK6H4YDI&N;XELR&<,T,U!O#5R(";4A`N4H"Q
MD6J'&B%=LX!I:IQ6J/W2;AZ?@16L=(*B6;!"__9@5049[RG4>VXWE=*@S%3;
M?-`L/:"MA^H%J:!:BZ!9D<R>@25J*$W$9.DKH9<=S=*414-30#PJRD78R/=C
M'<3`BC.4J3,6\?DFBOAH'M=X@9B;-/P8-40)?C`(;$KXF63RDC<$M%W,,/CQ
M==-'S9Z<8P&H?DM6M`S-M6LU-):JVSJUR:Z-R50:;_<L$[N6#J.XN^8*V;U!
MFX$N3Y&Q>T,S@TB:W@H$A*LX@G:Z(!`EEK((74/V@7"Q5$QH$Z0,U16PE'XR
M$MP%!8U%0VJ;-`O%B44WLA*Y#&4*%@6J:V`[%"\JQ:E5O8(#4CM%8'Z:I+R\
MTI)&C(/IA%.6;3O6@-$:TUH)F!94=:H`LYO^W=7O?CXG1?6J)/0;2X^`.AA)
MO.>KFQ\M8-*`708<LWL&$,:PXS'L6$;SN84=CXY&_+9O1_ZYT?[M4N$%Z`A#
M-'AK*4$6]7BVFE,:A0&_.DZ>O8C7AIVD2T*R=.(7-ZULLBY*3T[RV,L#_C0<
M7*/O,KH-W;X[?=WJ/![*L=.XYKZ6U#H$]3"@YU\1MCH3_JY#[8.\?#ZO&9NF
MI+DL%+Q7/R1N=KX$,0?AO0R2^)#0(/>S1T\ZN>K6>.LR76P//QNJPR0;TATC
M'KPM)ZBT0AW7QX,U=D?\@:$?20:#(.OB!`@[PX.[T'L.H\*PK40A;^\$0K[*
MN34OV`5MK!.RY/HPM^JRXXIP6R;C]OW\R?LJ!M9F%`=P]^\A/7AA<!M?>NLP
M.]C*CF')6SL@O^FL:_ZC*^*FS^F+9UL:B3QNY(I8Q79M:N.`U(T71L7K0#3A
MIW#A#RZD!W>D'OY/`:;=*'CA?J2Q;P3QZ4`.B@QZ*7_GB?]S_:^<G7!1$5Z7
M[:*1I#44=?JZ*!&Y6M&X>/E"7@FRN9F+XET[G3Q520A94W>$SQ@5E^S?,%/N
M$4@7ET"*BU#MG5&%,@_OB`V4HG(?O.O9`7/O"SJB$B82FAL[)UY#(@C:VX>P
MBQ`#77;EC5T0S_C(/K8]K5\O:^*@_MWA5LJTB<=:@,%U$5\@(![:#1\@Q4U%
MM[M3@/(]@<G@<$?C!7_?K;"W59M41+:DJ:-2?N654"E$I6T=%/!+*J&NU,(E
M+9V0O?;"8&>QCX,:6^4+7J.G"UAT39)L^Q!Y<<9HX^*D>-I7?$)`NM@'\M(@
M+E7T9$T'1[A[C73&\QY"_G9T%\-!RU%<P,T8VTEP[27<:9W6S,U,70W]4+1O
MX!T''"QW!A#<[Z@QWN\LXOWZ(A9X&<)T_=&^\&"\XCPE7D!.G;^-40M:?<X@
M:-1<Y(+EV%)U")M47:0MHH]01L\:F4#:1E=%%Y*IFO`6>]LN1J/E2_6<&.AV
MKY:[@K:,A$.YHS6F#CSA@]K'G:9>%6EH-])Z3.\8TSNTL.+':$/AP,^%_H2T
MV2T])OCTF\$O"T5$IU,)B*W7Z]*WX:*;.#7*3C9K=*E::KR=PC:!>.V5U@#@
M!0?Z`\'9JZ.A!B<.]`""L5=23`U&V\<*Q&BOR)@:HSJ^$PC*7J$QP!;K/$7V
M"HJ9$Y"B.`P@9'M%Q2`[#QH-`#W@,>@QK5(VH0`QJ3"`X"`H+%2:2OOIP9(;
MWRWT#]V=01M&@QXF"Z-%=WWH"!B2FXEN17?!#(F51G>'Z`(8$IR/[E[1!;`Z
MA!;=S:,37#.[U]X5Q.!B[JA+V+NAF,&LRE=#)[>@=M:!*AMZ\ZB,,T>G6^CA
MDV>SHE,B-%4E2%D$A/M/4QUL7]$"G0JAAUTW:AJ="J$'5Q6TB4YI:*T3`1+T
M#F#M%GO;_SJ=T/G$]]+E9![1+VGG.F_P@:V7>-,EK5-U-YEE[;)XCB"]C>_7
MA/\A7E3FGKA^']X1`RVQIC>JBUI`_Y.GY?M43Y0_]Q+[8>%N.HCW)\K=BP\)
MW82,[Q?;3VQ?U_'L'S105;WI\5,.&+>BR>XIW?OY/G[DQ;LRQPP`=!FKKO0.
M[:&H'LD674*\E%R1\E\MA/(A7-0W8'J9'Q8KB_T<D>)8CH/ZBA,`U.GJHG#`
M2Q;?QD<V60$J<#\,D(YL&&!(@GXX(.T>19%6:X-WQ`#JR%(LJV4![XH#6!F2
M<:K?:/7!`&6O*U3W<85.HC\`!I!5U,EN_S=&GX`!ZPR&`7PMR0F,L:$/#BCU
M.#X--$W=[`/B06D-ZOI>L07?#-H/A!DT?[LYC'/VNTJFL&MO9P;(!D7#C(;'
M[MJM`,!`F$%W7P&:@Z)A1L.5O3LS-`=UPHR#+4.,[;2-8U*G&3M/GO.L2&*A
M,[+F5[]X<<UXJTR8;S^0@Z)#U0.=3W3J%T_VR>,F!8A;CH(`;I5;J+J5@?LY
M*1NU?U?U-DUS_CH(?XIQ[V@408+V<PN)KQ[^#+>7\06TO9^+EQ8`:(O1',/G
M,W&_+J3X]5>2^&%Z,/_+@,KZ(8#$8Y1!$W;2>,#EC,X``H**3$LO(1?LUA=P
MWSN[F,M,N?+&8SFIL9R4(H=UT)6`QOH"3H/',-<7&+/+-2?35"!GU\LAN@#/
M#H!$;$$?%0DJ(]![;`>ZI=`KY!?1WKH.>G3"PA:K(`HPN@UFBSGPZ"-T4<NV
M6*0;CH".43!AW=;IC4X$MP`B98/038Q.HII&+HSF0"<N32/7#W]`M^O;L:27
MT&5T21^FEXLTC!!=#HAY,2$/8T.7)6*:`=*02W1)IMW0F_3"HY,+8/M%I[`4
M=!I3!T#UQ%4]!S$Z[<D,%_0"\]`I4CTM!9U@"'2:E"&>F/#!HY.89GAC,LX-
MG;K5Z5`!1[L.Y5"!`!+L&D"(SE`.E0Y<`(2U#.54Z<J%AJ"8H1P>FM!-AH(/
MY0S19%'[G$QT)T:?#`%6@>Z]Q$%,,S)Y-TG])0GRB`235:4,3>8TF61+,F&]
MUUZ\32=AH0:4U0`"7H`CVJ]H=<4#,]^Q40#!)*6=ZB'(E?5*:>6+;YZ1Y#XF
M3\N$YHOETQ?Z!_&2],8+DZ;T\%[&UHFGZ@BW_(GM/D[:CJ`N&*4#.JA=H!M5
MC#%P&,K[W\-L&<9L@7&FBU:LV4$''/)Z!A`01.V.@:]CX.L8^#H&OHZ!K]]H
MX*M)/0*=C4?.@AZ5?W0F'X.<`%P1T)ESNNX%UR:)</<446MC@W`$BV8$!0TP
M`X&I$B<5*3<,8[HDP7M*@[(^[(RD)-E(:K:`>[JHW'+Z9)6(?L>EG2HJ?J?)
M9Q[;1GV2ZO%?W7/`5\,S@##>;L?;[7B['6^WX^UVO-VZTNBUE86!76%;*Z4#
MNZ"JE5?;=[+O)RD/]V!W&B8I>#SI9!UY\<3;N\%;WM2TQ[5V?VM)62>W;W.>
M9.TU]XOMH4D5X3G]XB5!%8STGC7,4K;QBY"+XB_I_I;?Y">U\D$##N*"B&<U
MG<\".F]H,B=AEB=$FSM6OCK@>\\90$!P=6N[#\M74F[CE!U413!*D1WWM/3B
MEVN0!R^5*U#$'/L4G!.;7PI"ZSQN_OR`&/PQY[K2_;SX:UJW3!?03#,4^+D!
M,?!E.#('\SL)%TNV[:8;DG@+L@M4?DA"7VBLL/OUX;&W=J+SI\V_KL,JOK>O
MG:_[W3-DJ8-U;(2FX4U%OX?8N1Q5%8[[/&,WQC@(XT5YFO3$+^%W!LTR!YM:
M\^L(V9O"CE_2J^CLA8@!,ONE''/!:7T*1I_DZ)-LY9/LBUCJ?^8II22X*F*L
MRI5<7LIT:HZW'VATQ(Z.V-$1.SIB#3ON[!BF!NJ][?E&-%!?KY/KS4`CE]T8
MTM$EJ;MFEL*S`^27O:)S@*P`BPYQ('OL5:6S(Z<,[+"_#(TE?=WD@?SZ&1N_
M.E[7H$JAO4I+EM9)!]L:E&=8-&DG`3A0)IV;1JWI7H2RZ=Q4;(-N02@+ST;S
M[A(A8#_8]4M%V\0KB9MX[+1:E1"*6D!E;"@M?C/Q"IDR6?!3G/7)Z(2LUA'=
M$I).V(UL$H0)\3.:I),\9M-:%!(Z"BMM&SWKFE"+X;@XH-K,VAQC-,\B1G.?
M-#\]+%A>RI_7([X*>7VY.)BQQ6[:[ZW[W3-AZ6\T8L-$8;:US=3F+P^<K;,P
M_7R3$+)[8L`64V7?=<32-C<1V7IY(LGJG8R7O7YP#`88@P'&!.71+S[ZQ4>_
MN%7S@853[5OSC+?52K\U7WF[*]&WYB5OIXY;M-(Q`9W2*`P\;MK9_SJ=T'E1
MH#LA2W[V;`J+#EV1"9L.;N?Q\H![J^%&-C/?L6$C,TEIIQ3VVH.%F_UKC;PH
M`UL>O!;^%=F0B*[KYVD]Y;I%=_MZ]66=H^53MT7MB2?OJT#)!O1P`2-E)!2E
M,QYI)(JM%;1R0V[E=^&O8(KN8*)F[@D^?BE"07CS(T,V`5Q[21S&"_Z"Q^Z@
M"'V^"<,HSX3!V,!>]N&\9\<J?Y+Z/KZA"0D7\66>)"3VMX?'I&O!3A]I=D52
MUHJ+U&GZ*PD6#%6M@0!^3U]QP"X2D\2+^(OVP8K7V<E*J5RM3Q%\6"\7)1A+
MQ65WJ)126(!"WM@=\7+>"UK9)_?%"_`"8AO;V"=U_VJJDF!)2P=D\U79H%5\
MBA/B1>&?)/B5'=:,V(,X.I3WG29AROY4C[U2Z"]]?\X^`YMU2OG^`O5Q`:5X
M\UBE7XB:.2"8;KTHVRJ8W=C(&;%'#TLW$]OX^K15B[\7D;2B8E<33V3WES1U
M2SB,9K?DCI$9F"(S1K_B.?@5^R'V*,QPEV!7W4;+F/-:[I0`3<M11C?JZ$8=
MW:BC&]6P9T>NREO>CFI00G*ICCJ*;JX@L&07`W1.:AF@;MX9='YFW279=C5B
MBS"`.1G021`EV4<0A0XK=$)$!YF&_0G=\M3!J>5#0"=:M&948N1"%W6BNPG%
M7E@@-'N5%'2@*?T`0'3VZA[HH(-XOH``[54N:`.PRYZS5X!`2VSVZ7D&<L9>
MJ0$=SDA\C5"%`*>NHQ5K`86*4_GI9(&#0L>I#]GQOD)YA%.3`D?860Q3K=Z!
MG7MA,MGP>%H>CLD3C7E(IA=OT^*)V#0K0S6?MQ-.8>LG;[M]QN*[N"8([12C
M*G[X>.K[;"T'.QWAR!G0KK-]EX?Z8><C[P;T)6@<(!B?\U4><;WE?<*DW4$,
M<OEW0>9,^Q&'LA@;=Q@LX<=!'RQI'!<52U8TR3BE_!31!][4VT$(,6%4S$/V
M0:;<S*_(FJ9A]N'%D7D<1:SNX2(2.EESJS&Y(L_9@<ER()`^+B(Q=R?4$_NV
MQ&<O;NB:Z$O&U`5-PC^+?"#I),`[GA4H!"$M8X#1&&`T!A@-(<#HT^-[NB%)
M7*1/+DCLLU-*XYS3[7X&(46JHQ&=^U'C&*1=9Q9E,)5DQH3S"C]8T3EEV\VW
MAL:*SCW;$C'TLF%WAL?HQS'Z40LK?HRF!+#9I3O&>?8;K=7*/H7N;`$4^FYI
M5$<7^]-Y6MN8H-$%"O7'!8G5&5U,45<NN'9;IOEJY25;[J-+B$_"#:<R;>V>
MA`UGT0VI0U"WDCB/=W?ABM?9:30$2-OHF#,$GW^?$!)?\GVTNZ"(#*30Y@:(
M>ERR4>DBG,;L!+O+))R1MS1`RJ='=G'QDD)MNI__RB1-QB-L?\U77OQ(DDWH
M"RPX+7L[<)+Y/LW+D"^2WE$OYD$5-V'LQ7X8+V:'Q7^QO0@C]OD%EUUYJO!P
MF!H6-4/NR,*+KN,LS+;W\TO>BR1\OK?FF`/^A'U&\7DCP2Y90FK'E#6U3WB-
MIYR++_DJ=4-H]#PS6.[]+/5M49<84F2P3F<!!M4,?219&6`L+C@B:3M@?^09
M0'"_D$:7ZNA2%;M4XV>XXB%O?`;N4K-Z-CKG*O#\ICJJ)DJ?C+%YI-WTA<$Z
MX_J[4Z';%#JW$-K1%#'TS0*?:VK@/H3.E:0O/R$G)CJ8;78$V):)SF?6!BW$
M4HK.8]8&J-Q8;G<NQUB3,=9$"RM^C/;UU+/B25_JB%E),(;N]%VB36G\=.S2
M+W4_,_[\YK%<.?-EU'3UY$M=^,9]TQH%UW;*?"-I[8<9`Q#&``0#^9^'P^RC
MMY+YS65-7;B[UCG;(EY*I@NV+#F/CPE4N/,T^Y\Q1/<^)X&(%/W9`8'C6P.6
M"=])2$:0XOD,8*\!.X7/`()[&3/ZM<_"KST0U[!:6T+GV=)7B<[2OR6=.6I,
MO4)G/6D__<-UYK3'/$B73GNX`A/*8`,61H\.?LO^M^#1,7[8C+X('*<I$)*I
MMU6PY`Q#3"'HCD7]N5*:&=`I]U#J6SPHTVR=P[<CX1R0VQW5WL'J]_P_STQD
ML]_\+U!+`P04````"`"H@69')K^00^-2``"ZD`0`%0`<`&)C<G@M,C`Q-3`Y
M,S!?;&%B+GAM;%54"0`#[!<]5NP7/59U>`L``00E#@``!#D!``#E?6MSY+B1
MX/>+N/^`&]_Y9B*DZ>YYK#T>>S>J]1AK5]W22>KQ.B8N'!2)*G&'191)EKIK
M?OWAP5=5$220>%%]'^S62"#R@40BD<C'G__MTSI#S[@H4Y+_Y8LW7[_^`N$\
M)DF:K_[RQ8?[T\7]V=75%__VKW_^'Z>G/^$<%U&%$_2X0P]/VSS!Q3E98_2?
M;^^NT2EZ_<<_O?GF]AWZ\'"&OGG]YOO3-V].7__+Z>F__CE+\U__Q/[O,2HQ
MHB#SDO_G7[YXJJK-GUZ]^OCQX]>?'HOL:U*L7GWS^O6WKYK17]3#V5^3JOV@
M/_C[5^*/[="CJ3]^R\>^^>&''U[QO[9#RW1H()WTS:O_?'=]'S_A=72:YF45
MY3'#I4S_5/)?7I,XJCC3)DE`TA'LOTZ;8:?L5Z=OOCG]]LW7G\KDBW_][_\-
M(<&Z@F3X#B\1^_?#W944Y@^OV(A7.5ZQ9;J.'G%&<>93/!5X.?Q=5A1[GS$\
M?F!XO/D7AL?OAF:K=AO\ER_*=+W)\!>OC#&]Q45*DHO<,LK#TSK!_;Z*BLH%
M]L<36\;_@5119A?SXREMXTP5%K:,\]&4EG%^CRW+Q^&$]O`%(%H=(ZF(7<9&
M7=.?ZH%LPA&ERN'5*KPW,?Y487H>U5JSG9O$>T0\QL6G4W8TO?[AV]<<3?:;
M?RQ6!<9KG%?O\/H1%\W,'#/QD6R(`)ZQLX`4-5E[A$U/=9KUV:1$_3%?"UR2
M;1&+TY)"8Z<WSD\_W'_QKRTX](L`^'___*K#R0_&"8FW['M^8BIC?H<W]*_T
MLQ)%Z#J-<4[/THZ<+ZLGC+YH__N+K]"JB/**6BZH2%=/]*N*H`0_XXQL3M`Z
MRK?+**ZV!491GJ"8K->XB-,H2W_#Z&YQ>_7SXNWO?_?F#]_]^/4X@Q9%(U11
M$4]07X]X%1-J/FRJ?<XM"[*>$"^BL@*"D134H0"J2?]YO3B+G!Z555KMKO(E
M*=9[:]67!I7QD'TQ-J_K3=+`1A0X$M!1#[Q_@5!B,M'FG*JH]*WL950^<@*V
MY>DJBC:OF`B]PEE5-K_A0G7Z^DUMN?ZN_O4_SK9E1>\'Q1DC-J\*CM!=6OXZ
MJ&<UO](4,<7970M:`Q[MP4<,`47];%G:=+E.@*ST*WD7U,P@.XSO*Q+_>K-A
MB(W*W.1XH+1)YW4M9PU@Q"$C`3JLA$WSF&@SSO#H>T\J_$`NTYS>[JDE0.]:
M%3]ESW$5I5GY0*W*;90-'8)Z7T*.0S4(KN6(88$>"&KQ0"TBJ,8$U:CX/R0U
M%X$8<#:0^L+%,[5[[Y^B`K^-2IR<D?6&FL%<T[XG^3,NZ45P\3$JDI)?NOM_
M/R-E14G].Z[N<$Q6.;5SDRGUYPJ>J?JTC9?K;>.<`)T[W`RY64F\+4HGFD`?
M<?Q/F><T07T,3U!+`Q)$G.S]'3$2Z)@*[7"%5%GJ^E!TMO.&#E6W`N!75RZ>
MJ=*.'C-\28K[**/$Q=LBK5)<GN/'JOLO2A?]L6">@N'M`9\(J-WT`?I26_J8
M0?21#_J?<?%(=%7-%=\!S"0H@R@%`TDD]MAK:%N7C5EUVOLII?IBF<81_3F*
M8[+E[KK3#<G2F&+2_C!D<=N8#V*'F\!UO5];C'H(=?@T6#3_^C?0K:P9L;X0
M#B0[IW>*TS>3^%1L/RJ+-VA26S*N!=R;H#.LWHQ*NT!H'K(.6\`Q@3=8%5=2
M_PW]!8EY"$-R&O<L18BTJTYF5<JG@'J5[F\Z7/JHS$ZLE5=J4ISUV._W=L$,
MI_(./^-\BV\+DFSCZCK-\:@S6>D;X)UA=&[7<LJ!HQKZ":KA(X9`6->R&L<)
MB(WNC(5EE!:GSU&VQ:=D>5H]82[\4;XK3]/N!G+ZN#ME.)PFPCVI:3R8`;%L
M3,"0\6M<,!PYBF1)$6SPZZ'WN&,SUKC-2"$;K[6"W6%C`1U:W_$33K89/476
M4<5NM[O3)2GD:,)VE"$4V_8Y#!O/!GN#9(,C17%X<\UQ6YDNN(H];V,5#3?6
MNQKRAL>=WBSOG^@B/>!BW;G#AG:*QF<0T5>8WK4LJ^*A'5?GA#;`TTJ#!Q(A
MQX@L$4<%,5S0W`B$!1.V-&Y:&DM.8\5H[/96@.`_G1U$H)QU>.INU^NHV#&#
MH,`Q3I_%I0UXN"I-9OL,'07J^:@4N)!E#Y-9'HIJ"Z5R]FEPWYT4,PV04VG:
M`057^KUE63V"XU<\6_!SE$GY&BB(X01C#27OFN2K:D\]-QK\79JGZ^UZ2-R4
M/X+(V.3D7LRJ22RT;0X'=`%,*H;%:;5O/J$&D1,T(^*,<S,RBM.A%86::PQ:
M"[P"F%7JNX?`N`OQ1)<X_GI%GE\E.&5.Z._8#TQ=?-?S/=-?_6-!H2<,@\LL
M6AWH!NG?-=7`T3S.4Y$:8(A!\RH1<IZ1249X3IHXC*9_NWN+\_B)VDB_+CZE
MAW:)[F?0M(F)Z9WG31RG2[3PT2\,@T!I$ZIL)U!>>KJX\:<0*[>VX9E<7MGV
M(0:[KPDTYF@8JZR/[DUMC.F.0PVHK<XV4/J,3S=T:4ZCF/[,8]E`\JL]JXO@
M@VGH`:(06IP82AU&\Q-Q_254C4K079?@QL(#14#/3CC\PIZ)T,P<P#I@H&=F
M&!SQ>=PF&&:>7_GZF=Z#TGQU3M91>I@,/CH&*$-[<[F6FAH8^D6`"R,GP]PC
M2BQQ=\Q^Q*R"`DY.HV=<1"M\&I7T\.=IF"5_F12ZD?#?G$8\4^24EU^@WU3D
M%->9)N5IE">G25K@F,I!><IK1O%GS0.U"CNW0Z-IV1`(18Y?RZ*ALB:R1R,E
MD5,H"!3TU>15I"6.TM:2QBFCA.T9*G,T3X)+JH*],P_Q\WO`W18DQC@I+^DJ
M\ESS6XJ8S'8:'PP\\H8G]58?@*\IVM!A3ZQ4'5L75$:^0XT5.4STV&9X/M[A
MU39CB[F[WVXVI*CJ@-%+4IS1ZU"21CFKN/+A753\BMD9O=AL"O(<9>4M'<SL
MN#9!\BYBH<R[&[JQ+CYMZ+YHRKO=+*_R9Y(]3Y2?"HP*Y)P+A++KC=.1A6JZ
MFH!H1%4D:DCC-:8N/J"6.M22=X)J`GNYQZ@F$3$:44-D+QZG1R>\CM>+61+C
M-ZD$+W%14`X6S=I0-8&V&_H/9>`FVG%&1AD7:3JL(HA5$RNZQ2WKQ66+ROYT
MN+#K=F&C;F$W]<+2Z1[9;.WR%O7R$K:\;#K<+'$7CI1V?`OP6A9:PY`YR6AH
M)T[S&C!Z[U;]S)H[9W_ZL"\^(:_LRHP?]>^,<3.(DV?$:3@PPLS!X\,IV+IW
MPCD!A_AV[-JQ_N;'"AR50Q6.!OTKTZ.AY:N&9_51LJJ4U*P*X!108"_1Y)GG
M`BN-E31<+X8=K3FOTSZTW_4^AA9240+BK7B*$C:@@BF.Z`3$M[6H2,LP(25"
M7550T1,[8L9CSRXKNA#OHS4>-0Z'!T%=5'N3N=Y'#!IBX,):>1(.$C6V.#O!
M%X\EM2+CP50L]:_LGNC-[$%/=FKGU6CXE1==SD\?]L/L]*MDKO*XP%3YG6/Q
M[U5^7KM4ZONX1.\H?P=419/S^SKE)Q&!'/`.J`,50#L_<)\%4<#JHD3`'`SL
MZ&$A'GH^GN,O;+EWNIF#1>O,RJDSP.DQ?XZ,?6%LPQ%?SM`00[O0AS>G9Q6&
M\^<,\F[`(K3NT6F<X.RQ,\HP=V"+;+4'\A9W+N^_/>'\X0EW?RVBO*3Z[ZID
MEY@,5\.5BYS"@#T>VL7%_:M@[YF)85R_V0FLZO>@WG,?PYN_`W5C&M3158D:
MY$V>^D(ST-$;'F-:63,X/6!P[\'M8\/@WIB&P6G)NO]PXH(\M#G:9L3+TOL]
MS^J\N]%R:X-C@"?:WERNE48-+&SIM&'N$266&!YJ9_?7\M/HZ(^08Z2=Q+E)
M>W\-U]4&6!HK68;X=;I.F2?WR]__[H_??//Z1_H[_M.;'[_BT0XI:\"V7*99
M&E6X#*`RCV6!C+/.LY**/DTKJ:$Q4"75G\NYDA+``BNI0>X1)99XOH#A@K=>
MR^OV"N6H5$R,AE[+AF=U?D/KP(I'H3*LT$PQEVARS*\@W5'6CEWCC_X.%)9V
M'N=7)`8HY.7]F&-DD@T!UGQ480R,,%EW3Y=CL?(AO7M#?#M<_?![GNN>Q\,G
MYT51,/28F?=VUPVY%4&LO$L/_[\ZFNB.][ZE&HWY)Z.5[*'&*2R@3#K!R=>#
MD!/D(8](,^$B(*A$&DK20QX][O9"3FH"1*>O$_$/:D+_!!4G2)6AKLJ3.]UK
MQ.O2NRQZU/0QODS+.,K^CJ/BDO[FT`)2&`DHA"29T;7V:!M/"[B(`48<LO?R
M2%,\)1J,"G!N'H5J'8O]VS&Q%ZD!;\:.2\L@3$Y)2ZAX/1PMX0P^$X/Q;`Y'
MH4`^W/%G>^\<GGI.%C=<+O)566Z9.^)F26E:DYRGN,J\2*K?6<A0'IS?1]\9
M]MX7<Y`B9?D$Y7BB(+F''.5Q=DO2E15XZ%?PWN/J*J?,Q=>DE/F;!L<`!6IO
M+N=!H[A"&84#.38,$:U8[UP]O:^&K2/)'EYCHL0/P[?`KAWIS7*)BZ-.Y>.#
M(&^#1Y-YJ7=\!%7[M=`"WA![I(6*`B)N_-Q9=F00@01/\&8!)0'>->7R3-1X
MYN\R+LPCM>OXP%CC"WEO3M]7\KH(PQPNY4.<';R62]D5N+K.C:@F=/$)%W%:
M'FEY[>]LU=PYG-]Y^9T:$&]#PROPB*I*,ZFZ(V7W6`&><1[Z4%5"ZB_RY#RJ
M#M\])L<9J*B]^;RIIUHO4;"(P0VFFH:Y2919%#JQZ2JG]A`NJ]MHQSK/4!M7
MHI5T/K66WG0,(ER&TS$N=I*<;-`(RG-J`+.*0`SR3/*<1L1J--5IBH^>ZP8\
M1VG&\+@D!?/@=+;L.7ZLNO\ZVQ8%/NHM:#@+M)*`'C376[%K1!+&,(`RGUCB
MJ*%382'J6#:]:)KB3W]-5T__9QMEK*\+KR+%T.LP&?(\F,T$<4_`('KQ8<!0
MT_87^.(`I/J%0`T--,YDZ*$:/]0AB%X`(V#>E887Z^,&FT^,%_^L>;'N>-%Y
M80(X70RW,K&X*"[O1+4^[5[IY=>BJ:&`FY%L2N=Y&`+N7C1%L`O2)%^)#K.\
M>VZ2;5R5BSRYQ\5S&M/S>K3>S-1XN*=F>%[GT>PU8)X!TX`.7)%FDL=$FW$O
M)%#G_9;%YK(VQRPZ?[&MGDC!<AAM1^M,P?$=LB/#9_9Q.S+$O0;OV.->F`@>
M@;]HQ\[S:53Y.+=`GLEM92.:1VVU[11BJ#/->?$/LHNR:D?U[+LTH[=UDN-Z
M4)=J/72E-)O)H*B")D0O5TH8:M"J",XY`%`7306)NPXW5"/'39`6/70P<LY\
M@+[7"P)[Z*&BQXIURXIB?R3%,5Q!!^A&)A;7),@=X::H#<RQHD,C0\UN!GM3
M!KH4!"Q(-,;7X]O`"+-\5T(K^=6D+J<J;U8X/`Q<\VQ_.E]6]"%<B!%LCCL@
M&O&!?8+(!K,Z9_F*=ZV8)L!9A3:),!!5+AG:?A\6;^7U2H[^"+'0VDE<2R8%
M!*]78H`ES""@`/T?Z\<+2L;I#ZM!)76!58=;TJB^*@&K:5)/BFBHQ*\>@TS?
M.2_.;MY1(%=W(P65I(-`KY.'D[E><`Z0FUT4)%QU6<`;^$K6QS_`HY=T\8D:
M9SR'CC!_#JNH.G*E&!P##?OHS^5<E'E>GJAX&^[F,,P^HL03T[IO)*/3$693
M/N/%JL#<K;=($G[KC;(SDG,=^7.4'=49AT\`JA^G`\B+HTP+(_U*=&[I!;C%
M]C!"+4JHPPDU2*%9T@P[+O;)CEJRHX[LN"'[F2&&DFW!;FBLY*D(P`A1IP^T
M+XGY0K@,I+C(J[3:U6_T=YBW>,Q7K%O#8"J,RG!`0,78M,Z-;0X;-;$5+70D
MP'N/JU!B,='EFWL9^IED6ZH(BMUEFE%-*!4>R3BPU!S,YTE<6JA(@`TD)C)F
M$F4.F7J-[L_Q)BIX%._-\J\XRJHG:F?_=;N.\L:%/.)6TOX:Y'=2AN+<,76/
M.E1X/"5'AM^<.#H]MSO8?^606J"#*^<%>'D+(%;XO,^`IXX!3YP!98UB@`,>
M((W$D.GNU3+?\V>4\RM2[*1*>7`46"7OS>9)(7.8J`$:2!T/LY$H\L90%;]3
M"=8M1Q,!@%-`E+(F*"_73TV<M%6S<YH!5U`_0?[.*3>NG?!2`ORA6Y386`D?
M:<[,*3=P3@W]V2"IF4WC+9>9`0N6P+S',#+%!4?.S__:EA4+>02Z/D<^M^GX
M'``3U.TY@(\U!Z`56JVZ/`5&KAR>5N@U/F5BJ>>SIG[?[SDC+^?8%ISR<4[R
MWE#K](MU\(>=\I(4=Y3E=$9V#3O'SS@C&X9,@\2@^6LR#T0/0>!Y44@0Q+1W
MJA_J`2JJ04RT9(LX:KR05H,<=U?TT$-S9X*QWMK(6%+T69+T6-(HLA`VLM$^
M)M96)D!4`4NLG(HJ.!QC$E70S.4GJH!!"QY5<,2^PZB"89[,+!6Q'*T:S`,C
M\J1I^#J:&^L2E*N$1`!*SMV8_]PR-X,0]*")N$X75"<5SGB5/"O@-7M^_8U3
M<;.\3/,HC]-\Q6,D9?I8X1.H>AZ9VKFV[L%FCK0$/U8HK>M"4\N@U#.4W)`$
M*8QR0%>+`CJ;ILG5F:0B0@3"Q$#FR^AA(QEE:L+X4?%](R:D@I<Q<<B0F8%:
ME9;8DLG(Y`?6RZ<Y-P[**EU'S#]T&:6%OF?,!07@A*MTMF7?!G>"(LOL%G.C
MP&ZIGEZ2+"6],GE#3BN]+RT4:Y-`"%&<38**:0TR:Q3:*+[&O"PM-FB.5%JJ
MK,8(W;2$]K3$+*)_-;>9I)":$L_]I]K=+'\B)"GO22:K.20999!8UYO->=TT
M"H[9ZYLFP;VD0(,EUPVQD2CRQK2^BZBY<(=CG#ZS0TT>FCDQ%%2A97A*UZO?
MU!GIX,*#*ZV18.R1;TJ&%"TJ(8J#3`@)T6&;J6PO;J]^'LMA'QP`DN/^1,ZE
MMP],7U[-4`5+:2VD-?A&\8:0T,%%)]/LL1$(0\V_**-'_EF!D[222^;D8'"0
MR]"D[D_;!C`WZ01HN,JU2`=4G,NJ2&,>G1&5XJ63_X#_N:7:+!/JF/T':[A4
M$<0\)A7]'XKJ@(^.&1'*<%6)JG<QIR54B,>HN!$]WOLU6,_3,LY(N2U$B\'V
MY>`.,UP3[LD\>C<H'_"GZFTF;S-I:5:@06P(W7DD8XL>$]R]>H\UAL(#?C)4
M[[%$OS!$$<<TC,?3UN(21ROF=P.]Q]49U5^W!7E.$YR\W7V@&++^&L^B6>PB
MKM)G[N*:*+L"GPBX3?0!^NEAP;P340L[5'=+Z%H0>PQVG\_T-YQE_Y&3C_D]
MCDJ24^S*<GMD5BF/!^<X2>;UE.W$H)_^RL"C!CX2"`3*?)IB,]'FW4L)F#EH
M#%=>Y2*UXF\X73W1DZ#V`#9_OZ6FY&'L>U@DO`?90)!UO:_N>VT*F_A&W/3Z
M0U]28SYAMG!1,@\T*AE=7[VPZ!PC&;$2MV.^\+Y+P.)-E#;5S19Y<E,]X6)1
MEKB:Z.NE\26X0.PD!/?U8CD*;=U,?C,F#`T4U]4T(HY/H.*QZDM`#/CZPLZI
MG^C(*N@AI8]!J!-*'=,0Q].*8?>9'4X`V;!Y,D$7?&8Z8(+*2U(L<5IM61\)
M7KLS+?@,3K6"#YQ<Z0F7N(?0'#&+P\VR%Z8[O$B0C58M]L7"KWZYQJLH$S=U
M%F3/_)M;UGN7%;C9C8;G:GP)W*L*$%SO*(X"JATQO-`I]XEW:(2-[M59`V+`
M6,]1P'',\"G?DPJ7UR3*V9YJH]>[P`)ZPO<HV:=BJN2N`Q#02&.+J'C=#@<[
MX21\(6`7BTI\K%28_=5AS)X"QGN7*WQB*/]#4SL/N.G6+*C$CK)U0`*G>>57
MHAZ**,''R`U&P6A]`Y2IT;E="Q4'CAKH^J&(CF1-C=\$Q$3/=V)67)*7-&+X
MR"ZI@X.@M\:]R=Q?XVIHZ!<.+U!J\#`#B1I77I:7Y&9;E564)_08#^`/T80>
MR/.AB*7KS>&9'*]=?EUS6B34T&U;5-=:3&_00$TB3X,(XIA\3JXEW<UHT8D$
M6G>_BK8S`]A%9M0_-#84J,*&IO1W10CKZAEE)]'AT3R=.6]W^YA;<-Z,3>G8
M63,$VJ.DOA1/S.@*`3POTVSW*_QO4_;R4K<Z'NZ-H#(4**Q#4[H60@&SZ>RM
MVMK`D1B.\I3H,,ISFFY4LJIS[)^++N]D49U%1;&C`C]44Q?T+32E5P6&\]0C
M67X.J">Q&XK`!K>4.!15Z!&OTCQG<>@LSYF#F!W-%WEBD6*<)ZJTNDKFUMI6
MQ(C+?I7-A_Q1_90:'PQ4)\.3.N_/4T.=R5DUP5FBQZY0M\*2':5M6S+%^^'8
M1\8WQ:')/3XKH1I\W6%N+G?(498/WB:G^6B817V.E[@HF.^D+2Q.\B8TEX?D
M'@B2YE>0O.KIV;U40II&0SO3V@5ES[AX)+HUD!I$^N7R2=[$F<^"+N/Z'<DH
MC0&RPC5V#0$R=IY>IO+M;D^/V0L3&IW6?6C0('@?E_WN;'M1`4#CRP4+^E%8
M`]]V65/-PL2C`)P%;+EI07-ORNT5!('<LYU3!*@\V".KO7CS'WIXG31]D@/9
MJC"I(Y88_[("&$:36?@?68%?5E!V;*<'PB)00(,FMB\EL$&3K!`!#LXY#]"(
M_6(V>T5O>F2AQ]U0T1O1R.$$U=2=($$?2O.ZT>8).@J@X$-$?7#5,L\S#9B`
M;GJ+@1-&\N3=)!MH*E3?H^0&V/0W<'-+/K<'XVJPH50H@T.!RP3$.L^787X=
MGZCG-#P(>E'=F\QY;X5PA08D7"-JK)C#*[+0D5=Y7&"J3<^Q^%?K,7E\"JMO
MRL.@?)EB.CC9>X&U13.@:<.7#;2O4`.?63'24I@S>HJ=$,K)%UD5KOO=OQ07
MLL9MD/V$/I\8#=R5DEG=5]IC8%$O$:*!',:Q.,5<HLFQE^5<J*./F9<S0':$
M)O1`S@1%+%^*$T&1G!#.`V><!@8NO8TRWNKNGNH0'HF!OGU]@MA6_)S2(G1W
MH<7;/6C!?1_5%:8B,G&/EXP"'\U[L_G2+`=@(1H`COD/`O,<KUC=9;U]VD"%
MA!98XSG`,=GBK<1Q9P;0L.@21=X$,'@>IS7.H[;&N<,L[HGWT!1MP+=1]H"+
M]9LQXR<,)B:&D%^,O1I%?DD#&TAS7X'`+RP]&@<>5UHZ48]0Q"@-9WL%4@*'
M=EA(N?)[")Q3<_Z9DOB,KW)Z!^<1?'=I^>M(N)?*)T"U.C:U\XX>+6S4`0\9
MIZ7$9P)AGF$,<B^X\;FM!SS\SC,4C`SX'!*5K`'&2_^G!I5>3>@"]++GFU98
M8*\NS;-H:0H136*Z!GX5OJ2?21NKV?4S8<=4FF_I[V[H@HA"G9(CP<ZDP$/#
M#+@OL]H,2XB%[)LO@)<TBJ)X+=O42#++=MD@.-,&0KI2/=U,"+0DLU`;`VV0
MS-6&YJ1VU88B\,!J0Q%+BVK#&5],U,:76W;]3?.O]A1(^O(ZD!DJ$-#BA+IH
M-M??R=I(*I\87S2/I_9XT6R`ATUX5>+SX$5SBGDOY`7__9:]2-XL^5_+Q7.4
M9LQ_<TD*'A9K^\E>$9SO-_H)M&;_*#^!O]=7>.N\!-=(68@&%RT*_+F=/[&7
M$V_L+X,EMB,1/@O6A'EW$&2P$C2"D)[0L4[?"KMP;F$=JIK:1AR'EA#XMMU$
M5GM=2V61).G8M6YJ.-AF&Y[6U\$D@P]1%?9H`6SUMIA$#?T$*=+BS/Z<D!>B
MR[A9^$;J>Y==WXCFI'9](XK``_M&%+&TZ!MQQA=;+M7.3T(:5&?J&]&5[VG?
M"&AQ7LC%]5WT*5UOU_NFPRTN+M:;C.RP]6!S57B^KZY3>,W^[CI%@-?KB'UN
MAKF/U'0<WTLH+4B-LW.[D"AO0!LW$CTY>"$J4[45I6W5J0LW4(;.)'ZS5Z6J
MA(3(RK')79,H_^D6N$INL+EI1^T]YK.W[4O6EKV>*^(T<*0=I7#"=W,2^+P4
M[7>$>.`.35#N@9\]:A10#X=@[GW;[`CRY#%372_7&&Y:3@VMG&==SL[N)Y(E
M]$[%*C-4.YDRE@Z$:M.C";VIPR/(H`UL`7^`1^Z!?8+*'O#?_^Z/W[SYPX^\
M1L@4*:[VG5PXB#K'3!,)>.7,>#<8!30R`I0.L#>3\XC_&EJ8P)XQUA$%?H1]
M7>S4\D3=:?4/+;TX'@-P'RNV_U2WY_T*74A:@_\C+WA33)V3,$Z$*ZI_ZD0@
M?84O'HADX-A%#:8K2V%XI<B;13_@3]5;.O^O$HD;'@24K?W)?%EV^U`A5ITI
MWH"W"5[E'G'`81Y/)0M/U+AB:+75%R3F\7I'DG29QOPZ=;.\3F/>YV)58"Q+
M_M3^&&+K*0/QTI=&&1OMM$^'=`)V18,-#_;KX\->WFJ,T"R)-6Y=L^F3ONYA
M5S+:LYKVJ,$P0&:K_KXC9GQ_(0[NMMSUHBRW:^'N84GSEY2HIE;/7519CZ30
MA>O;`:Z*G_/BUQ3F*0.*V@I/#.S+\E5J+[8-WR5L!?UNV]NB-L.YHTD$&%Q1
M=+'L^7WZ`^!&D4_L6L);R,)%>%*[XU'*H0=WT"MPG.BS,<RE_HR455FWZYFX
MQ`\--;RT]Z?T=DD']`MT?%,?Y.S`S5S.+L\%XJG:+?`3Y1NOK,/J%M\2:M+M
MQ/]/W=%U/X<6AE<$X[[430\/)!`Y00()]$O]+\,&<73".(VTUX28,MJOR%Y$
M!:LSQF+UN`I6DU3%KX`".C&[:[ELP//83X[`[*12E?\$R-3PIMUB6SV1(OU-
MR[P[_LBBB==-'LK,BUH,9FGJ#7!_PMR3L=2XZ%Q=:@`7Z\&7XH&_P\K&=?-X
M<0_V`0(*OYE@"W#RM14K`J`+<].)Z$OFAZO2-4:/N/J(<<[KS,4-,0GK,,<*
MTJ55R8SD.G8S2`6Z`3$FD^Q[P=XV5@F;=1_]F61TFBRM=K[\;>.0Y^!Q&\;0
MN:U40T4=V)?O;YM8;%<>-Y45#&F8W4;%3<'[\"0<]<:25#+0ICZV8JC)@'@V
MV-`F*M`S0V!.#4LTUT-JNJDQV="$XY"$-_"<%WL51S,'"'I,MC(AQ$@T`NS%
MJC3"4-NN\\P/2#HIW\,"121P;-L.<S1/'#U;>V:-\5.V4';UXT-=DUFD'=3:
M[_")>RXOW':4`;&_;"^DJ\N8]>*D>8LR0-\]6B81\V:`7Z=+WEKT[YC:&B^K
M*X?ZZMIHOJ&Y9(:&S!W915FUD[FB!OX,,3)ZTW@Q&7KPM$\Y(UP!QWD-#^:%
M,D+6NA.*^Y[8'YYZ9L8\G%%#@DRFF.CWN&.5CW.ZIW;OL;SG[_$0X)'2G\KU
MGFQAP5KPF2`*+#N5UD!#E90:7&BBPA3#\V"1/+/\VO>DHH:@V.K41F1;(\UK
M$W'T'@OY'G*BZ,#Q<N3H(*2MYMU2"SBT:H20P*B^?O+[5`\I=A3,E6;CRV54
M<R`7'-AT'*CV.1#R(@G:C<1X`?R>FW7>DRRU\O#/P/.RF<97-E$##W)DPG&%
MV*]*B#HZ)X\6ETQQ(7SH2*\$@T;LR,!7%H-'>K.'BAXAD/(F'L-'AA9@(GY$
MRE7?"G*H<UO=MEG$64EUI_*78+4Z"<%Y7D:_C5\/B:;_]NRBZW16A1BPVGMP
M\IKD6GI2Y1-X$+)T:@^!QQ3VC-6C$M\)A)E^18[WM1R(@OZ0%SC*6-S?7TG&
MD/PI2O-K4I8W^3V.MP6OO+PHTI+^J?^D0B_C-\N'Z)-$7%V#`XJZ*[1<;Y,.
M/[2BF*$O,XK;5XB5@=QKUE%&&:X;J?'LSR!;QOG:$]\+ZG>K]IN(W-,%[1`^
MQX_5NZBJ_^MO:?64YC<Y9N],[5.*9$/:F12X[<R`N]Y<`CX]:^C&(CE&.PH<
MT<V4X3+,!K*T5L3-`IA&A-]?7Z?KM,+).SQ0DW1T#"@R_&`NYQ;-_36J`:)?
M!$C]@&MCG(U]?GTR/CZE],J0EBA"5+=NHGQ'M\<JROEYM,T37/!GL"SZR`LG
M++9E55#E&X4(Q)9)#E%B;>B:D*Q$S7E:QO1XWQ:3A82TO[=605("Q_7>ZB/R
MOY%`A?GE,>J00;^$OK/J+\MH[48E7GLN<Y56&;Y97M%;S7.:;*.,G1MW.!/%
M4Y[2S0.YR"N*^VCE->`LT$)9>M#<>V(ZR*@B2,`.6Y4-NB#$$I<_@W28<T8V
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MQ[YE=EDSFY\R2#`[[C,S;WG=G$[]O\:,U7B?U47':OXDMJ1(!'#I>U2'))!\
MS/N82I\/75F>H<[PF*+8?0['%"5C;LH3Q-GY'U.?"Z=?P#%%Z?K\CJF^.O1T
M3!W)A_=0[OIJ?1:5+)*7_<,NA,]1QJZ"P[\=<=J93P@/_`8"]NB^8-!Y6#C_
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M(3J/^I8ZY@1:_-;:(H8X9G,+CC)9R$E+3&-U7H(+9S`OR.:47MTXGK*.Y-Z;
MD!'E5E;+V(-CDND3Y,GM@<(.\.:V!W9^CVX<O<_@U8W3,;/'("!O9__N]AGQ
M>OXO;Q4C[+-[>MO7BG[>W@9$9+8'UB4I[C`S,1)<W"POTS*.,D:#W_-K"HMY
M'6<R;%_XZ28C:T8*V![G79Y]1T>?ULE':40MD2RY0Y")/MNEF/71R.KR%/W5
M6(K58$?F9W583JI@]V>GFD@%[T0]43Q+X0M[_:9]E;!20`'R%FV5(D`%]3WX
MB)7EFDMO[+&R6<I<FZW5R:WDCR2`DZ0#.B^;LD;NA9N0-14S,E/`?)V_<^3S
MX/.LK3_A&/E(/BM+[U`/>G**'`J'G7Y0[TB.J_0WCH"LFH3R>(..48/S.@\`
MKCLR]8%K5-!R3@VPCEU-U;J'1+A&3.,"0[3YYOL--\;I,ZL=65(3\6Q;%,?M
M<)3&@E]=!^;TUYEB`#BL3845*D`]*UK(@9Z`QV2":+'(<QW>)$G9-HRRVRA-
MKO*S:)/2^Z%$]B=&0ROG#L_J6OX[L&A#X9ZFU,X1D,,4Q)W@+=%DF%\YNDZC
M1]9#GE6<SI/C`H^+1U8O-98I5=W/@9*F"L:UZ/7PX`$M?4Q^_[L_?O/F#S_6
ME3^#B*+V:A!3%GM6>F6)*UD&W?X?H2J-3^+K!!?0($<V%$^`$_&!?8(B!51=
M*=C]A27C7#"\=XEPW8GFBM)!D!O6T61>G&1'4+7O4A;P!EB,7=?;H)@;ES#?
MM'2$[$LH%V2BQBM3+P?.\4=F52MMN^G1(`^'=%8_+;*EX/6]&Q8I`5WF:O#(
MQB:U28SQ;BU:TN:Q;Q5V`M'D8^CN`A,7#6=7BW"7B:'+`^88_&DFK0'&[@OS
MO"'<X3BCIFJZ3&.^V2\IA8N8[OYMQG*O91V9:H>.V")O\9(46!X!X00&W`%I
M#Q>/CDM[2`,=GB&Y!G.4[F&,V-9%/9P11QKM1WP(M$]0C7A]+I^@1XX[FN2>
M.Z^K@PU$O*ROY[;%(JFT?""+F.K8`M\6)-G&+(MNU!>B_!VT=?'4_+Y4R20B
M$/5@DSJ3VA\<>LD]QKQWU7);Y&G%V@@QWR,S%3;3IK6C/:PN803,6,A>*W'\
M]8H\OTIPRK;9=^P'MKN^Z^TN^JM_7-,%R2YXMY>!JEPC(S1WS,!,SIW4#%S;
ML\=_?:PQYA$%COB.@"TVI*";DS4;[%H/CN;Y*GT#CH(=F=M]Q^,:.&+040>^
MZ188)E-7C=\$Q$1##]:[-,-E17)<Z[9WT:=TO5T/N:\FAD)\5Y(IO3BN)+"U
M'3W6:`"8U2WLMJI,<"J,?57KEJ:FGLM:X!+`3S4E\D2'>X%-[_$VM:J&N-HL
MMLSR<6C!C/1QM*R8[-8H-S'@;^GOGZ(2<^L]=.=SJ"B.V>\Z7/:\?0NRP46U
M8\5FJD7.J_WQV])[+-VK"I]`-^;(U*YWX>7PK?$$Y3C0U5&%SP3"/)<71G%;
MN<.KE'FY*?!H?5@%96H8X.HX-)WS%I7BYM@!10RJ]ROD*">)*GL\/S^(..D[
M_(SS[:%XC`^"/@#L3>8K(K\0X$"^=T.$(<YS':Q=^;R'%YVH,<:]8CNC^K2(
MLJL\P9_^`Q^6_)L<!U9M!_-YTFTU5,3!(@HWD':3<9,HL\B]9`RV29?]&2P'
M?AJ;7P1L9"YE&9GB@Z&+ZGTD8LY9J6MJ"%;X9KG(,ERL=KPJXQ+']._;\CPM
M,;NK#'H^S2>"N+=``%W+4(,4:K'B@4X"K[K<9X,9:E!3])^&XX&QVPG$E@`N
M*3,A)O96Q7/HO/2F/M6D7.-+:-#]-`3G.44-"J=+4IR6%(F]QX\''OL7NDZO
MSDH0`_9Z#@6D*)6UU2MWSDA&08/^]F?SUC=E'RRHO8DIYN`,D/KV%,9Y*5M^
MHL@9VZ]\::[\RK<_U,HKGY@RS"N?@&W^/@:EP<XK7V@J7+SR"5SF\,IW(/+2
M5[XA[OD]?'@HH(@]>D^I'"T@,#H6>!`-SNEZ8XM0T8`9?>.<)%KL\>`:(^LU
MR7F\.R\:4]YLJ[*B-YHT7\G]9`H?P9UF(Y/[\J!Q%$0"](FH!%6B'AK!>I)I
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M3\!($%6'J*.L)FX9I%?/E-`3'?:Y=$Q0/<'NI/>[]2/)#K:O].\`=\/>/,XO
M?`(8$M"\.PV&>48F&>&[<$94\:/BG@I?5*1DQ!4P.A9<+F-@3N>5,FI8(:_W
MX\PD6ASR+#(U'A_RDEK9Z3+%R6!,E_)XJ.C(YO4E/B>H!SJL(3G-8Z+-.-^5
M5L:[G4J$2_4S<#V4\>G]E3@9QP-6M<0V;:!")`T22-K6=Y;=?(<VEAY'_>ZO
M][@254FN25DN*HKGX[9BGI$'0LUG4K#>\G4&_7CE+/A$P#VH#]#Y@^<&%Q$#
MB]C=^IG'/@414H.U(/88[#T3+\8X*9E'C\7HT&WV+JI8!-KN9BF/39-(L^%L
M\/P]"%3GA@T+>>(J>"VP26>2:FJX2,0RYT-4J1YO1C$XQJAFM:?F$R(6L([$
M"%\5>J1EPPA;;+M1Y=&`$T.MN%$]1@-*8)O['SU&`PZY44.38>A&;6+_&F_J
MS+RHDG!`)>[Y5=WG:1EGI-P6N`V-G["N%;X`JO61F7W=8D=0@%Q@K5($V/GO
M247MHXJ@RS2/\CBE.Z5UUH4YQ%2DAP`8Z'G7X,>*)4(57(>Q'/Q1_^+4<.A^
MD4SK>K/P2FD=X!->+2&L=W&2PT27;2$%:N2%0S[0BA#Y>-LX$)^03QPCW)0*
MC/78Q?LG:@*15<J\<>2Z2N3IR.,C(:;U\(S.;_$U5.%+)5\C"AF>+VR+!IA)
MVM+R^VB]^;&A)H`1.B$<1(-;?G5?KP_7N`M!/A"H^XXG].M,R#KXH;NGC;@5
MIKCD^6UWL(MQ+\;L[:X;4J==\;#*FPT/,ON)54TJKW)1\USV(.P$"/05V2HR
M7GI\(,)!-T&]*X8!3H)ER#A>5N)GK5[R/ONI(*4T:,<=I%GL.(Z1MX1[^ZB#
MDO;GP$&`PX0C=?K(L$)]S/=RLAYWJ#^N2;'F^)^@FH(3)&A`5.<U74@4V/DB
M--_^'G.F_@:6W?.[5O)?V_I5D3TT,SZG&=Y[C'X@+(+BMB#/:8*3M[L/E+"K
MO'U^7[2O[Q->59>@H*]L#E!RGEG1X<S<GD6#-2O]BC**,?LM^SEF$3R;&G&V
MH[_<LKV<YE\A,A`[$:8_F5.A(#Y7VM!%<D8R.AWK;\`:I^2BG]%PCE1=#V4P
MI]-@&HAS!0#.RYLF`"]MIXP7V@$'_(>O[[]&YW@3%5S>6>S(7W&452*N[Z_;
M=92C>UP\I_%<B39.0(G[6'*R"2^/(4N[#.#+,MFHQ-9B^+4UJ*HM6.6\<RS^
M[2G7LVB35E$V84'H3P"T"]0!.6_>\\3L2FYB]PYM'@7#A;CG7PMS@`/6A)@S
MVK?@TLU#!6AW2[(TWDT55YP:#A;*X6E=BV`+]P0)R.B7^M_0M1,G&4UTN>?Y
M68#DJP=<K'D,`[TKLJA'V</`R%#HT\#`E,[K[)+\E-U8MM2J03D/W=@(R&%>
M!\:X2G189?I`&C_A9)OAFV5S4+/8V-[Y3O*2URN5Z1[#64`/J]K0W.>$"8R8
MR=O@)$IO[&.E7?LU$/4P.YA"W691@9(VL(CQH^SQIMCC3;R'<XAG7;C8$DNK
MX3O-;E,WD5JL"HQ%W9-M3N]Z[-*VFPRVTOX>G'BG",>Y%=R#.H-0+'W^$V.F
M^@[6HG?I..4;A_Z<8>[DSI/%FF4B_;:GD`Z$1N=3<$#7-`CW(5X=#OPF%O6`
M!XKTTF`\,>&F7UD\W!TCH8-C0X&R-C1E`'47+H!PE*=$AU'!8JZH,/.8C2>2
M);@H63)P==@-2?<S\WBLP>E]/:)/X0%Y$;=/&[BN?<\MQI5SV4/F][_[XS=O
M_O`C[YHX1:C[J+1Q(1N.45/@KM^]=DD*G*YR$3L7[WH5SWZBA@Q[7+O#49;^
MAF71:/H3`/>?.B!?.U$=(\B>=$DOX&VJ1@<U^/3+`"*&$?J2X?35"5(CVM'^
M!(@C,>>YY\B/.-ZNMQEK@,S?C5@X2X&?<%ZFS[A[%7^/JYOE0_1)%M0!FP4:
MKZ$'S7DH1H=._<`8]Q'BT1AAHBJ`JT(LL=KW9;5(G_D;*,/H)N_^6WI%G?H`
M?#&53>PMNU.*`2BYTR(]@-.B`W>"&`*('A*J!#F[9$^*#M'GGV_W8T7/(9Q<
M1$6>YJNRM]7/\3*-4]G[N_J'8(?C%`"?*CT1(`.Y&)593>#\"Z6GF1VDI:=E
M'QCKZ<.)_>OI0PS,]+0Y/89ZFAOQ<]+34M$9U-/C_#.M,2,M;40W:K%EX::4
M^[@\U+^PCT%U:%2!>-###!QJX.F7<7%'B7E][`8WW@N"-R8MN\:D44UZ6B,8
MHMJ+MJP1,[;[/HB6F-[-D_JM>#PE=WPP^``:FM3]FY6`V@0`!-+,H_PD>DSR
M7:B;Q+]>E265XW,JUOE*9/&(OF(7ZTU&=ACS0;?U&^\M70!Y*6^CV<#%OD%0
MO67WP=`#9?#YX@0D2X_G&`ODD,"NS;$3")Z@!D71L`\U2"(%AKC*P3.4:&)Y
M<3QKAUZSXB;!XCVN)H+:%;^"[O;QV=V_9.LE8K2A:6&"V5770M*A>I+!@=I*
MW"S;XFBWI$QY?,>$4&I\:MIT8@2$^TH.-0XL*K(K(->@@7YI$`G<GD)E%8:Z
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MG"&"2([1CB*`*H$/JCX2_@O]DA+A..#X(>?0$.@X=\2TEV$D*.\#76M!;VDM
MYMHVG<F-TVVU)S+-N%4&Z#?IMD7+1]ZM0QY8NRX4C;9@NK,XY,^L<F_U97@H
M_1:X*,%<HZSHUV5&/DZ5KU/YQ-P5>C2U5Q<H;_K(P<_(]2GG]K#+<X*%X1KE
M=5UQ2K%-I#=,Q:\L-+X;F-W7W7$"#<A%T3IE@)?;!@>AX'L=J4JD1IJC':4J
M4Y(^?9/L-+3*;I^BNW<+7F!%WAU".@AB31U-YEKP!4`D.A9!6T%8P-KXVE,3
MPNOW!+!9Y%)`U)CD.=%*'A(G,NS9>\I1S"?P:VABE1H4YR\2#3#$H(5)G=+D
M-S%DHJ':_/?;NSNRB[)J=[]]O+X^D^O.\9$0!3H\HVL9H5!1#191N(@"AC?6
ML46"L4H=H"J`9IV0$:+!M=GHV"X%AA=;_Y`7=?(M2\EZBY>DP"/IK;;FM:^7
MU>"[WHT<-NJ`\SR]0+U^["V6FE*'K,#\MP7+@'&Q+0;G];@M]N![WQ8,^LO9
M%<-K9;@K1A;`=_I'O]EADY!R1U'F7J3D%M-%I6?Y2IZ7J#L!.$U$%9"_O$55
MC&!YC.[H!>4U'G2!;3!"#*43T6@X0:HT.TNHT99&:>=/=9;[3ED?*FK?Z[IS
M1G+NZWT@%&&J8]94,?&Z%>4#172BFJ;%N<&)[Q9P<*T#[OI!^STT^YVC3E"#
M*6M#4^/*7\<%MB>(X1NZ?*?-!2=.5_'%;+.W.T;"2&U&JW/[WV8=#B]IFX4K
M&VEWN>UL,MD:&OK@]MNP-$5]19C<S3*NT1GRR>E]"?'1J4$(T)-)AHIA1R)[
M%`+LQ?ULMQ:7.G&3/[#/C4K;K99:FC<MS0URP9LL3>ZOX;Y*:LP.EVKZ$R$)
M2SF4Q:V,#+605-I,Z?SQM"#)EAYW+,B2'F\YUMI#=C&'105HH>\AP?5(&"19
MK<-\"E4ZBA[F+,[^XE/,.V.QB^H;J9M&Y2/C$E)#D_LO(S6$A5DI*3MT&9:3
MJI%`#1;<\Q*XHM2H-`U6E9IFI=_M=$4/_'R5/F9XP5O)7:9Y6N%K%M0CVF-)
M=I3R=\!--3F_^UYG#0)(8'""!`ZG'(D9=D!371`"YK*]VQ')>^'!\D@%M2\,
M;T,#,WLLAD'RO5AY</R";8*,KP,3$>[<15'@=/VX+4J>"R"M!!*3L@H17:8H
M?0-WA<D5\/SXFU=IDF9;=@!U[W/T#,JV"4Y$=/YZLQ5K?;-L:H;2:P[/[5NL
M64,/V0.PS;FAC\`V</!EJ%E!%F+/!>(2P.SK8]HO1-#@VF04M=@RYT*#+_.Q
MB,)8)TB%6:X>VZWN"^)T&?UJH[_A=/54X63QC(MHA=]OF7J\69XSFG"=37RS
MK4IJFB04<XG>`<X"U#":T%SKD@8=%`E\ZN1R1#H4@N><0Q>(6.*Z]WL4?RZO
M6\*.%Q(='PR_,0U,ZN&:).(@0C;OG>`GT6.2:?H*O^JS&H1QG89VC_.4%%Q7
MXX2G(@S==72^`R6Y*,SOY?5'!1']9!@GU('<NQP1U&+";!.!"ZJ107,BT?B>
MMZD)WO0)+@7!94UPL/P@G3U%P'PVU!A-=>.]QZ;:Y2[WC:A_!=$6T[-[*U&]
M_Y9:XP!WE+B@S(*S1%"5-$1O\X0WD=I[4NTB&T)L)@V!(T!>^[;9X@)')3['
MXM^K_"JGJ-%-DAX=T5K?@"VXD;E]N2=&D8"X'6Q195*=JX$8IL>GFLP0$,LL
M'3WUHS1_[)T^<N2C38Z:XUF]'3'-FSR';7ZTV*`$=J0<]G6@_XH.5A6AAEHO
M\"#@^3$B/8?GQA0C/;O11=^27OO=\6O^Y'BHNULVKZ]6/'61XF`=+2>X2K19
MY5>.#EVR;Z,RC5D0J_!K2:1)\2N@3$W,[EJR.#CQ\"<`LK@HWC65A0^R$MEK
M4KLSN6,S809E(?[(?QO&QZFZ)@3(:._ZC;T-E$H^S/'!<,TV,*D'M<:A!O5A
M3O"3Z#')T"RLKVAW.":KG#<+J+/\J:"^2^EA7)$<[P_Z#2?'D:=V)H,8E6"@
M7ER@8.RT35*/?``X2QMG3@^]MO8%11"U&**#D;^Q"*R9\\.:4ZCH<:>HN<..
MRG7+G8.1G#OT``U@Y)MO=F)WI?P>H10\*SI([RW/:8*3M[L/)6MT6/=>R5>+
MN$J?17;\>(U)^$3`HU<?H&M-V8)&40L[R-%LL!;$'H/]"O)^XDOG>#YOZ]G*
M"B(;S``470U(?KN<]7!!'3+HE]"QPI"E(1;X'=J]?T</C2*-Z36+[41E#__P
M9]:<_/O3A_/S[^-AQ]4/ILW$VW\F\D/2G(44U^!1/$F3-^^_1)Y&'P#&&&G_
M^9GD%\+%)UA97N4W&\S^0(\IGBA`;;">3TWQ>1HXJZ7G:TWH7NZ!YFC:>/YV
MQQF37=P^9>SE#:@UR`M-MZT;8#+*@WG$`$!W]4B,@-'"."GAT&3K2QL(:7QF
MKWC#WO0!*S?LX6&IH($A;19K-K3U569$GK-B#4U)@V`=B'0VTGB5AA$6&^J(
M=]&G=+U=BU2*FR4'3P4NRN[P/[<IU64/Y/:XCC?D4XBN4`3A15\HXJ*]J9S1
M"-`;-2YULI&H[=*@@QI\>'&F65%JK$+6-=U12W?<T5WTZ-Y0_`)H$MVM1DPX
M'L`[QW%:9/2"F.P80CA9K*CN8Z:VK-<A^'L3SYP*'%]>#V6$(.X/A]1"S1FQ
M&6MTD,#G!+48]5HYAW-$:LGAH1M2G]U^=^IMM./QVI>DZ/?0^2M.5I@%=9;5
MGNM?LE^!LP!WK28T;UVB]-`"=8UR33DDH:C&B1=,^'*OI]17B&/&JA'7N"%5
M^AUM:*B@$DMKX+M(ZN$3M:B:,O4TIOP=N+CIQ/SN"Y<>Q77,KF".^B(0,&?#
MY"`O\H17.;W*8[*6F8#C@PUSD/<G]9:#S()B"(.+4@XX:#*RA+$#R<ACW/)]
MKV!QMKR5^_CU87@8^):P/YW[1WH13<P`GJ#_^?KKUV_0)JJ;;O^IJ:40;:LG
M4O"6';__W1^_>?/-CX@"/'G]^O6/S9"T+%DX/!>[7N6%9O@?OCWY]ML_L'=(
MQFX^[`]O3G[X_OOZ5]\%LKDEBT=45\3W(=M64E(]7:<^`!^KLHG=GZ<MY!F>
MHY/L)OH\]'UR,KN2F9T3I>OE`\$GYN&$[D_+!F+PRO`CW"3J+/)<;[EI+WV6
M165YL^1*<D1B)L=#*R_+YG5^>C)XO*@%@QA2?*99.]06?)Q?H?0.>](>#4J3
M#336.\V$_@+/#B'#0LW,\0<X8WI@N3TWC;YSU7DD$(.J<YA+P6X7HG;7%;>?
MIR\90Z/-[QK]6?U>.?:O#Z$+M4TQ>OA>(.>>Y_,X7>7I,HVCO*H3X^@5C)N6
M*2ZGK@IZ'T-/:B4@KB6PAP7JT$`-'N&#TC77@I@Q.$AF;0^MB?2?Z0_,,FP'
M)O:49;LO=`WP,"*GP.7CO-M)U@4^5!>MWTKU8#W^PM;AVLT<Y(#MN?!F=\@.
M,'WLH)5QTK.P40NR-B0O_KE-GZ.,F99J;CFM;Z$"J`+#N2A2Z.WE`/7PF)WK
M3F])B!&?YR"H^TDT,@*TY%=O2JMBK08ZH+1W"**7OB<TEWERJT#6+IA=<1L5
M-X7H`<U?@YK2-=/VQ=27YG:&#()?>Z-]/9Q3<2*==1@V/=28&R3F9NH")1MF
M%E'C[;+4P`L9&3-Z&1IGB%^1^"E*\VM2EC?Y)2EPNLI%2:1XU[5=Z_K:E^])
M=8Y+.HJ)]:)D<67T2M<;()$H1U"``FD9&]?R_"7#]2NTHE@CJC:7`F<4UTBC
MI,4:\A@0G!F`EP2&,ZK90CE2(XX:S%&'.NJAQDK'HPY[%)6HQK\_*HC6<+4_
MB*=U#E^<HHV,D#X"*GQCL2Q%.W?(FA0M$K8*4D"H,LEC5R;!8_V)8ZF9*#XA
M89K?/5/OX&93IR0_)VNJ$B3;96HX<*?(IG6]21H]WP.,?A&@P]R4)_E+=)EF
M7+623<FR`YH4H)OEDIX,^>J6WK4'T_85/X%5H!R=VE.=R5$<`-43+=,$JAE9
MX]!+8VNP0#,ARSBWMGIBQ1P;0J.64-(0NF&(B9S;/4=$T50,J7^1X`TI4];Z
MH'[^.!%_01N*Q!/5[FW&/_W+1]YAI`YMV>9ID#8CJEN20!;/<S5(DB>M!3K8
M5D%A)+2>X_&,KE6.RMU$L;F"JTJ.(VPF&KP+&9U\1I%:L:=`KEQ&I4K]0RO1
MRT,`_$4SEV&M(0U>2V.;IQGH.;8J?L+)-J,*M6V@4U<;?V"7@<GH*LW/H?%5
MBF"<1UC5>+!3N<7DI/;H4,7'L0G^OJ6]*,24TY:*[2C;]$H?F!36"6?/CV(`
M+BT3SI9O2^?8LN0MDV3%CF_KY/S_9,6K;<+#DCNSL^!OFY68S(D=&0DMPW$\
MHVLE<WLH>"PYMI\=^^-(=NSW(C<V)^/IL6'J4HRL#M%@N6EQR?J]@A>S:`O5
MR1ONJ8P'E9,<F==YY$3SPL6!]^HL@MONV:7&BLZ7$ED1],1_%>.B8D^`15K^
M2K=369(XY=?FCVGUA&)1^)0EBK/I1&P)/2?8?_Q[M(ER"@OM<"[Z^[%'0CHQ
M^^.'K^^_K@-00A1O5)%7HKUL?G7^AY*>/Q=EE:ZCXU;MXX.`FGY_,M<;D$)C
MHM3"FUT(GH2W1(UA_GTS_"+T-U+\>I7SBD5E^1Y7-\L[ND>+YY'77.4O#;PS
M$Q!<RQJ#S)381L`.YIE1930QX%X@P;M,\[2D9\I/A"1Z@C?]I:G@R2%X:![$
M(2,..JS<*?!Y2.Y4F>?Y30-_["5"%22G/\:B)[TX/M2R0:#30%]#-,$Y?RK!
M'_>R,/<PFMV!#%XL8FL%0@>:C!3X&!]L+<C$1VF/P1"3</4])C@[&EX2NK)'
MYRIONOSBI*YLN?@8%<+!<+-AJ);,SR"0+LOM6OQ.\X'%)A#C9Q@;R/A\K!$Y
M#8\,851CC#C*)W6-FQKK$]3BC7J(S^]EQZHT#+[_V%_B\-OSC*Q9TQF!M*@O
MNP-O0_7)+&ZW::"AME4?LY.F2/%NSCM'8P$G=HCNJOC="2*>_CYJ7G7K8`J)
MJ$^,!LJR9%9?8><2\)"`<VN4`!Y3&6R62L*@-S$(2J0XVE53LD(TV18Z0>.V
MP)LH39I^976+LJ9XKVA,)G6YF$QF+:5#!6BX7`\5[.PD@5CF@TEV2(U*T]*O
M[-6PCA0H]I8SHB6OH\DD^LP/O?&[[#+-32[[T-J&/@00;O,>8F)GHQK09Z>!
M\)+UQVE?7\%IJ]ZVJ53B1K?D.)N-LW)$UZR#E$W^ZGN+BW/^5CT4_*#U(2Q#
M1P&`ISP=!4P`:2U.Z`/E[-3=X([2G$5\!,4&S8M(6!3(`PO]H->]*-^AM-QK
M@L<BTWG`1W2L1D1$""L7(B(WT#:GFH7'<[2=.4NT(L^XX/E`[`^W3]'=NP7+
M!\=ALG1T-B>!+Y;?P[]&[.*3",!I6HB.9EDH?0,\\D?G=OZ&6LMI`[WKA!LT
MB4>-WP3$1,.SKNGH4HB'VJ%333($<GX=3.7EI#J`J:VNC7$&%>VN^P/=A4+:
M.*8P;4BH44#TY^@Q$R$.4<D"=*LF/K`@NRBK=FA-<ES5N40!3@B9H!,5IIK:
MG((%[WH<D`?93@X&V9:R29U7CJI7OP\9'EIKD0P[.=$#LHVH-L]+JM##R/FT
M^!`]9GHNGH5SWD(U3Q;)FD4<5:*->NV7D=@\BE]!BUN-S^[\$0MG=.#J!*T$
M'MPG%^UA$J;"DB+3"9"3ILD-A,?VT+WZ84/RB^V[J/@5\V:=FTU!GJ-L),]!
M[U-0RH,:"/=U(QLTT);B@2X^H!83U*!BD`KABDJ8]K[*Z5UW+;1T]$BV%5?B
M<<>#C>CPBCX^I?$3NS(W3%FW3(EJS$.D,VB*)3%9!<\!$$T[I.LTQU?TQ\G^
M54<#H8$+1Q,ZU^<-1/0+@XDXT,`MJXZY.=2K2L(B0T7]4X%Q?E:0LCPCQ884
M$_:QPG"(0AZ9UK5`<-"(PT8]X'"U:Y468T-90EX`!:HB.D27AX;2_]#=%LY(
M>?2:-SH&(N>'<WEQTQP"U99H<ZP!CIH>4!0*;?-K:H^(F.%PE-PY$P>-5,B)
M$C,-MR$+C1MUKT^,@FS%X]E<;T8&4==M[@AQ^(O68[_`!/,R+NYO[UZ]7=R=
M+]C+5KG=4'5=H;=G__G==]^^1DFQ75'[/=\NZ?`M*^,00+A'!(<H,M50P'F:
M]M_QB&$U/`(BV/LSN19J#NT$47APB3;%V(HWL<VDIX@$D%')^A,%%AG*)MO`
M?/].:^")H1!IE4SI6FQ;L!84LC42X%IY0RKZ71IE^]4A>KJYP2V`:$])#='A
MHZFP)TG*N!MEY_@99V3#^%UGJ8S(O?)7H"TP.;OSW=!B@'HH-*E.!CO#`67P
M31)U5"8]*DE-9?4452B.<O2($?Z$BSAER2J/.[Z3?N+Q-FQ\B`VD+GX$R'GC
M6(>8Z9]G?$NY+M]'(\-@,0]'T[DO,5J#1`PF?&=80=W8[MFG)DA<@%P@B"JK
M/+^1MIJ@.::ZC@BR!U*%3Z"OHR-3^PH`'\,!U,''*DV0=CPM`IUUJ$J2J^=>
M%1$B$!X::OX//$,+)[>XX,][E!+1I%9^"BA^`CD1)J9V7DVK!H]Z\$7JJX$1
M99TFXV-CVY"YZ9$IZCP&.$-4Q8E`^&FX.R[6FXSL,!8=%.OZK.,VDN(GD-TQ
M,;7KW=&`KPLI-`@86E+6B8)MCY:X@UJ\FXRYQ[Z\N+^]_2K`YE"5)@+AIN'F
M.,=E7*3\3G*SK#,EQ@M&Z7X&V20*T[O>*#T4F">G22+1K@#EBSKXE3S9IS2N
M*=UPC`)L%QW9(E"6&FZ;?F&519YTW:/Y'^0'B\YWD(VC,K_[Z)Y>B1X>JMFA
M41\[X(/&#7W&QI@X;TB/Y*(CF?\QP#[2DC4"9K#?FS^]295T7R=\J=0J&ZI\
M`KSYCTWM(7"U@SV["H5*3"<03AIJ[I^I1+,@T/MMS,K'+K<9.RXR+(Z.^PV.
MTV4:]QRV[]*,?D+RL=NTM4DA.M\8N&M)90@BAB'J4$0=CKPT58WEWM-'AR?\
MP`C`'./3A%V-6:`U#[TN.Y;%>RPK&Y;UWU'6+?8!#AQ[NX"X63WCNU+,)Z5_
M^4ZN"^2C8#>AP]G<7WP$1,1`PC>>#<2-=U+$BB"B1+3X07N4!;G82"6#*'+-
M].5]N]J6%?W]MR/O[)(QH%?U@[F<OZ%S>&Q]OS5X,#=&VK+<]J@*\?`MDP>B
MQ"\+YMHWW]_B@KT_7D3QT]]Q5'S(JS2[W&;9[F?N11XWS#0_AYI@BF"\&%O?
M?/^_$$,#,3P01P1Q3)!`Q<R><D:I%<N)$X\9\3O,*[<PXI><>/'F$,@RTA5#
M8LIQ"SOO^]=&.T_S<^C.4P3C9>=]_]KESG-&J9V=QXB?X<[3%4-BRG&_+C%>
MII'>B]:I*-(ZTAIA;"C0!38TI>N=QF&B'M"031%&>4IT&.79DXJ+BMV>6<.N
MF^6Y:&@Z6E=+X0NH'U4^LW,W:@^TN"1RX&$K:JEPF@#8%U8QB6[PBJII?[`E
MY20F#:">!.!Y**@#SHZHJ"%VF=<D8:>I2":^68I"#'=I^:M"T('NM\"J)$HP
M/+SN='@PO20P00P5*T$([@@UMB7C0]I%[1'>F35<6(*V]!$C3ELJ?-A5\V[J
M>U^F>93':;[B*<0*V\YP*I-"BIH@W2<>U$7_:KSX2W^#&6I1$ZGR5G:I-T;8
M*XB(>[Q)&MXL6][P#/R`U0^A4GQ8)=%H14RCCUBH[.-1*YNB8-54V2J^W75#
M^OV@ZL".2U(L<5IM*1U7.;W?IB3A?RX7SU&:#211>(8*BGQRCIV?N"D11"1>
M`$J6"A?C+*,[Z,LTK\.[O]*/FIHA;V`*AZ.)1`NKN$<+BCIB6+I@V1NWJ3O(
MB4>5)DAKV='$^R%SJAJV1PU=(<*V_&TS$D@^3.\0@WWJ52X0.A^";@\J`)Q?
M'?9+^;=HV+DVN*'0_,ZP7[J_K=(?\+Z@)6P$SE^_3IVZ9NYX-=KA04`GSOYD
MGLHU!_'42-A&U'AA&AO2Z&JJS5GCMWM,]U1:I;@\QX_5NZBJ_TO\E*\62VH(
M/WPD[%%DL&:;E0E!42<F@%W+5P,410PJJCX2_EJF7UG-,Y7&&CJA6*%UB]8A
M_2$B6ZP(*+&_'J8[.8Z+;=O(3<7%H_8%:"^.SNP\'DQ`;_PU=GPRMDDRCQ:K
MJ6Q;%@:S>13EB``XZ=?*N:5WF$+<9.YPG$5E*=[7V+4H^:^M:(?:2SJ3V$'0
M:8"6DBXXY[;4`1*SRU(!KP^QQ72_8OWAOJM)L5C1>T9].G5GU6@`@.[G0#%6
M!>.\DL1]K^04:C!!#!74X1(V4D![28@IGPV-D_<D;_+;S],"QU0R1A*KID=#
MC!+YK*Y%BD(^Q4V5@A8V/"C0)B7&=DC>)RYIB:OK(-9YY0&L$@4A(IK\M/&`
M\W;:X?I6XG#]B0ZLM-]N7`,$/]NX0LQ+97>G%,">>F;`3Y-NST,/82N&EXUG
ML!GPQEK5`6N/89R[<WP'<ZZRB'_9,#6@MNPXNEEVJ:[1(GY*\3-.!BVHZ>$@
M$TH^K1>M.P)?WXBR20N@U*&`SX/\NHSW>5!CI:I[WM+7I:>CJ,8IA#VHL"6(
M+C?]A/0<O<`+3=,KI\="#:.520"/-@R'X3K*N/@S]2PB[2J0QR'7`.J-(WTJ
MS(\^VFBQ;Z:P<?6P&G?$\3X1_Y2HP?\$O6@66M&IFQ8!IE?[-4!KTXU74B\P
M"^!O:X7.-YI)7^=HQBX!U].O>[:))+VCQTN^Q>\I;WDX2"7QQTZ.!SI@I?/Z
MJF8M10!2RMHB-0#MUX:'QR2C\)K.AH5`)HC/>%ILB#;W/.<NUE%2(ZFN0T.@
MV8F]J;P%[P7,:!UD'5'AAZ$1W&GAF^5]E$7%[H$T]6]96AK)117"Z%.ZWJZ'
M3%S8#!`#5@^2%_-4#R5MR\DUQ0#E>KMG!0FD6`>\MJRUP$M4'3U!<Z7<V"+<
MMP;+E@]M!>Q8\$'4*5T+/`-8@\#M22RL@]\#ZN*?V[3:,8N4Y.SY?RSS>70L
M\,@:G--Y;7D.%+50PZ8]C[.5:/'*K_"TW<8/,!NK[*'T#5"81N?V+51!:WVH
M<7FH<?PTZ_S*V!6_^$[GS2B/!\J6=%[WN;P-X-E%I4WSFF@ST-*C$S]?C[PM
MK#?%8`J`QF<FCU`CTWM]C!K!`_R,8Y4VH\<ICLF0'W=&!)K',+7D"EMYX'5]
M$Z9-G\Y>.GR]4N:Q]V+^764,5A'CK,!)RFMCR+PZTU_`2_G+9O9;ZX5!/$$"
M>OT?,SN?5!:!`#@;6/BZV^4;5>D;^,26^/6F]N5U'\,!XGBW2Q/@[!K:6*I/
MA[[VSI`(C6T>*0\M^E[/HJ+8L12U-=GFU55^\8E5W[]97D9I\3/K;7ZX00QF
M,/6]3D/R[GN=1LG(`^F"8F/?:X,4$EBQ4$*!%_LCPPQQU&9'N(/'^+AA1=2R
M`K>L6#)6/#-D`[M?-7;HD/M5=RT\I^_M7X47CR5OORLYUB=&0Y/QAF?U=9A+
MP$/.<6N4`+3,(HZ9@+'MQ-%(\<1-TU6FX(2,$$UV>:[$2C54Q)AXE=.K++XF
MI;1"M'PDM`;K\8R^]L``:(C\6Z&@(E64Z<D^`X28&"(B,"!3;A97%61'A()H
M\,FWBSLN<%3B<RS^O<IK95+>1KN!1"GM[\`N[XGY/51%X.!8,@B#QTLU'A81
M".3Y5F4]`?/3YCVI>W,6W<LO\H2*_^3E:/PSXQO1\/3^KT'#>)A=`6S19G[A
MZ466(('+"9H3A9:#2O8B2$0&'L(<M=`7F8G=-'A[46&R2T7Q%J_2/(?HBJ,O
MK:N+%D)XC=&B8G=+&5#H1F_,CTX/VN.QP6YN"N1XBRGI$`FW0Z40Y)5X9]'(
M(I!_8IQ(<#RU:^W2!MY/YPTXC[,?8>Q@J/T4M_R4GSC*F:D#*]M792[V=$\T
M)3.$,W#H2/,#T6$!"B!F<ZI``23!59D%;QP%IBP:92S6M*!>](PX]"@]J"'H
M!'TF'+93R>)4L9+%Z5`EBSJF73RM,.,#M96(Q#/,?"M8F"H]S1(65J3B\`#J
M,_>:_D1_V?R*_A\#27_S_P!02P,$%`````@`J(%F1Y7X'W.V.P``A;`$`!4`
M'`!B8W)X+3(P,34P.3,P7W!R92YX;6Q55`D``^P7/5;L%SU6=7@+``$$)0X`
M``0Y`0``[7U;D]LXDN[[B3C_P<?[S/:E[=WIB>G94-WLFI5==:1R]_;3!(J$
M)*XI0L.+7.I?OP!)22R)`!(D2)`HODQ[2@"9^3&12.0-?_O/IW7P:HNCV"?A
MKZ_?_?3V]2L<NL3SP^6OK[_-G<G\\O;V]7_^_6__SW$^X1!'*,'>J\?=JX=5
M&GHXNB)K_.J_+V;35\ZKMW_YZ[OW]U]>?7NX?/7^[;N/SKMWSMM_=YR__RWP
MP^]_9?_SB&+\BKXRC+/_^^OK59)L_OKFS8\?/WYZ>HR"GTBT?//^[=N?W^Q'
MORZ&LU^]Y#"A//CCF_S'P]"S1__X.1O[[I=??GF3_7H8&OM5`^E#W[WY[R_3
MN;O":^3X89R@T&6TQ/Y?X^R/4^*B)`--RL(K[@CV_YS],(?]R7GWWOGYW4]/
ML??Z[__W_[QZE4,7D0#/\.(5^^^WV>VS=S[ZQ(UV<?*32]9O&.QO?_GY[1LV
M\@VE.L%K'":.1]PT^P<*/8?^UT]VE*L%B=89$Y2Q[#VK""]^??WH1D_._DF,
ME']3?E"RV^!?7\?^>A/@UV]*G&PB'--IV>`I_4,QGI';&E<Y,?@IP51B"USW
M]`3$E?#._O+/J^)-D]"[SMYS>_Z:`#WB('\":'Q.5L#DB$0%2#RRRE(?8_>G
M)=F^\;#/D/G`_L%(_N"\?5?(SK_1/_US0@GP&!$W`5J>$,G]O6VB+M,H8J_T
M8Q<%?V`478?>%?V>%?3)AK9-ZOX;Y@3<X\@GW@W]6UQ!JW1LM\0RM&"DGHWL
MBM`<(_[7%X[KBL@'^AX!;>6?VR8I5R.7]*T1"FZI(GOZ+[RKH$TXKB,BR7I-
MPGE"W._S%:(*_RY-V`;*C`H^Q8!)'9&?ZYT9WI`HH6^?T_VF<B5!AG=#\HT?
MX.B2+I`EB?A"43FJ&P)G>.G'5"+#Y"M:5RTIT;!N2/R-!"DU3*(<)O[WYHSK
MALC?<1#\5TA^A'.,8A)B[S:.4QQQB96,;YOHAPBQ]3O?K1])4$%DY>]UB5J@
M^#$SK=/862*TR<S&-SA(XOU?,L.N1&+QYW_.71PBNLU\"^,-=OV%CSUZKD'^
MJ6D''F^`A;U13(UJ?$O_>2K`\H$&B=X#.GGRI717C35(^@-Z#$X5FGB0B-CR
M\6@2N:](1,_8O[ZFIW+ZRP+3G<:;YN_@GBFS,U)&"'UA=B[^JQN0&'N_ODZB
M]$`%BMRS0]?S!Q4CWFP0V]\<=^4'WG[V(B)KE:,.@8%"7SEH0"0\5J'`%V?K
MP*ADE2BK53`N[P:"BUQ(.+K:.@DYYY-`S4/KI$*"A?"$!P;C_=#!$%B08!!^
M'CH(,$\9&(\/0\=#>MP%0_'1#B@@/@HP)O]N!R;"<SP8C/^P`PR0GP`,RE_L
M``7ND@0C\\O0D>&[ON$&V."M44!L`H[&X.U14$`)CL?@35)@+!".R.#M4T&D
M^8C"W]Z<@4`?^%UG%H1+PI@$OL=R6)Q'%+"<#B=>89S$CIN;2,XF^UY.&J+4
M\]FX'(`53GSZ-0^LR3,E-+ZLFVP*[03#,B[T^&-+>_4]BNZB3"B]WU"08KH"
ML^V;XZ15F-F]F_G,!)FDR8I$_I_8D[/#F]$#-C+S$LS"\]$]()\?T%:9TCTC
M]_MMI,Y"49MLFCG@<H%-Z@<SPD4CG]`/)N1+!SAK#!._N##QW>+&#ZE9XE.S
MFL1^9B<_LH"`F\C8`$P=X]]C_+OA"0@B96,HG(?"&`H?0^%C*%SD3&EBBELG
M*PH(B>WZEQ$MKV5>OXP8NNH9ZF5$TFL[R%Y&=%W9X?8R`NQ*3KR7$697]PEV
M&A4)28*==T[L+T-J:+J(U5.Z+DE#EBGB;$C@NSY6"'RH/:^;V$8=FAH5C$Z6
M$<Y>_06O'\\*-$1#5,[RG)=?SJ?\UY[]J..%)`@HU!$*;DAT2=>H+^!;.E@+
M0=F7I>!^VY#P.OV"HN^8_66RV41DBP(1>4I3=1";!=?<W6?L+3%`<"#C-9#U
MC_O9C.Q0D.SFZ>-T>LDG2#Q2`RE?Z?*-'\C!N7+0MS''_Z<X2P.)L\G][6^3
M"SY(E0-TO!@OTX!-I^!O6'[?#&]QF&*VN%"(/!^%K#3CVYD<Q_<L&9"$,^P2
MJA:IO3)#"3U_[^ZV.+I^VF"7FGEY^L+=XC;<DF`K$4S#I&@!,R>8[NYS%.#L
M9?0]E*,'<H&/Y/V^PN'#"A]_C5`84_/D-J:;/-W)$BQ"J9UWZ&`_7\64!NQO
MF2M&P(5X:#?ED)7A%][/;9,TQ4L4Y"^N\.,+1G3OO9]$5):6A2X,O:\D1,>_
M9')&E2-=CW'E]V_X%`/Q>TRU"S/[Z'YPM[C"&^:;%[(&F&$B#2%T,:OZR%2E
M'W^_H%;`:DV5J3`,"9W6!X9V!]H$H3#HM%XPQ!)EU7@YG=$#-AA):C)V/L,$
M&_1\AR-Z?$]VK&!,^!GX0PT0GL8)6>/H#%6QSH+-ZIZ=J\)Q4Q@^I6U#LCC@
M$_O&E'"QJ$PUP5A$#;K$WV)V$F:G)`!#\BDF&;D-Z7$OR\EFRT$H</(I!ACQ
M8^;`3"/\@)^2"_J2[Y*T%\",@;/AO#?'"#W.8G\97C^Y*[9P]S(O5,Z@.=VS
MPEQ(]!Q^A9EG-'>Z\U>'>'`?B!=J*=GP[AGX@I[\=;H6"D[E&`.D^J&<U*HQ
MW9-*SZ%>\8VQ)R18,-)$LBSQ4C>YB^8XVOJNR"X2#35&.',!%/3$PG4H'=\]
M"S.FDP6`G_UNB$2A-%>,,$`FWJ01W>/B8V#B]&PE%`[E^298I":(SSS2ERA>
M42EF_[G^5THMQX"YPJK_*I*NQ@\<"@AB^=7P2`.)T)2,N#C)%9IMZH?BE0J:
M,]8WU&'A&."?'.+[]T5X_W"(X/&C-'DLWAAK'&K5.+1#+/.XW"U*OB0!SL*Q
M]I1GJ"8!C)49)RC`W6&V8`+BF"CGX5B7>W\F,M+P]M`E1,0@4<B#LJ[8@*L]
M=!UKABXY&O$H)Q-#,Q1LT3UZX(/G+MFR4#7B!LS<M:YHB*_BJOV"UFBL,_8(
M*#!AC<H1\L^/=EA7'\9=`/*\&5O6@I!3(JZML*X@CBL/`,^"+0(A9I5`BGRL
MJPCDRH4\8FF+6`@Y)?):$.M*(L>^'X"^'_4KS\`0#:4IL\`;J98-:HOP*/!-
M.BDQLL6\KP5L#RK<[,$?YFROD4,)AF@H#=FY6A&2E&F+)I3P6D)%FMD'7T,]
MQP1R1@>6&-DB)A"&R_BHU,W`Y:;GRK>6W`C*["P6GFJNRR<9>#[7T/=N21A4
M7'L]=.;!QSG%##E;<('OS[!:#&M"<*(X`C=MVQ:ID'G$%.L";(%%%E!HF!%O
M#TSJ^[%:QP-;D)(&)/8#&_7ML$4GJSH?X#7.MJ0_Z,U7TE?=8<MZ53VF0EML
MV+-"5=RSL%G-]'_/`>MS%W5JKL1X:@:.<V;+\@+O,6"+BP/2':(L-#7*HHY0
M==7`]KT3L\:ZC]1.]APZ>H.I&</>MB<,V+A6^IP.&]8":6G6J#9=IG%"__ZS
MH%,M9XR&CH-7V,T>R?KI\0G@C])`PC7]DF2'<=[AO#AKW0<HY-,#G**!N-ML
MTZ=6IY@@P3`M[5?#/<=7?H1=^J#J4E[@Z)?1$383CKM-=I*BENW1`,Y^X..G
M,D\#F=_"+7U#%GQ>D&C-;OW,NY/S*01.T4#<;_0][S_2]S#QOD;NBETO_(U*
M>G"3!L'NMXP,/J$UIFLB^N/;1D0K3M=$-$L[FJ>NB^-XD09%"@@5P[O%/'=?
MNU?4J@[()LM,\`,ZA80B0='V4`,M4G^@*+O76U!'6SG&(*G":GW.*$/D2CK_
M58XQV;+L;G%9LK]FF-7!>)<D3N),\UTP$^T>[;*]1-9G0--3!][!S1(V3#:B
M>V:&YA:#L.^(=/S8`DU$ZG!:H,%L.>!H`^330XRD86_5$'.$BON=50X:FYP-
MM\F9#8V2#O9%V0(I1P8O=F<V2&:5'4VST`/)?YNO&ILPC4V8^M2$R4_R:@O/
MW_I>B@)1$R;1V!Z0_KN?K+(3"?-#K?S-`ZE*[),Q!7M*]^PRSP0KS^!_GXH1
MQL@48EXY9NSB-7;QDOM2;`&AFD52QUUM2W8)H":;>X2R12PJ.230D)DMDB!$
M02F2:0LB8G6A'G^S)>.*BXN2I\@6-.0:E&LBVJ)`JQ@D36.KMN3'2E<+T-UN
MBU:5"4NMF+8MRD0&CL8HN2WK"WBRJ8Z_VZ*!JUDDH,0\6Q2+&`-9;B`8A<$W
MXP-X%&U9%F)6B6(F(AB5P??G>]$-2S4T[.RYIFR]8>O@&Q&.3><J,-'<I:#G
MIGC+U?@]YYYK3('R1&TQIJ1G]_:3%FS9<Z2FF);8L"V'6HX?`!#+M44!\<(1
MD'0Y,`;V-,>=CI6ZZDG8MIAPBI6Z6@L+NB_A_=EQV04CCR3*^FPX*/0<DJQP
MY+`W4WI6V9^\HR.43LA[<1P$!ECEJ^-5'18"ZR.W6:WP]>7=%VK6W,ZF_)HO
M[B`-16J3^?WL8C*[FE3W?GU&AGBH#F(\SV>?&`4EUWP1-Q;0!9ZE@42VSN50
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M-E:_:2HA$S6@/2T4$S:K'8N7QN*EUG9#6\#3"PUI>`"U)9PYWG&J?,>IS']H
MBVC`T%!U\-H2UP6B`W'+VR(P[6AH#4Y?6V1NO*`<?I\((-)B2Y(-3!6!8SVV
M)+T!-;0X?FN+ZFC)>FYXJ7?/%]:87]V'_.J>6SU]N=BJY\4Z4FVL)5!JB^;1
MKJY;C"G88B^,6:ICEFH+6:JULR&ZSTC]X$1DAX)DYZQ)B!/_SSHWRH@?TF$6
M*8201OFAERF5T-"M;A$H&*$CS;!X,+M8]FA/"%(.`>,UD/6/^]DLQWR>/DZG
MEWR"Q"-UD((V*/P#"Y(?JT>\C#3!^Q6:?9EDK^0#Q!VD@8#BXW\IK4P^(=+!
M[1#$RW,#CZ\;DXZQ^].2;-]XV&<J[@/[!R/Y0RD*S;MZO*!1?#-Y>R1Q+DLO
M4<6[3KW[O,[\=K<X$_`I05G[LV+YA<L9=K&_998@M:A+-+-2D^.I39+<U,8K
M#*1*%IN'*$6R8HB!G$+\F!ROMQ60RQ]HFFAINJ!LN`D&Y%<%GS$!O5W8#"/\
M.Y*YC`BN51YV;JTE;)A,$2[I]MP-5M;OPH6B,+-[MC*WT"59K_TDMU/YZT0T
MU#SAPD\@'CRFU8YIM0*ZK4ZK'9;[;LQ-;=I^LK7#C"T8MH(04?"8V1)3E0NC
M[`1GBT@)^"0P-YTM&2P0F8`>QNR1#@#'1#D&8$L4G2\R4D?DT"5$Q&`K.\K@
M@_OR(^K090+$*5&+N=B2G@1(K>:ZN&V1BTH."2!:"@9@[*?;?QM<LG.(`XNV
M+(4QV;6&BA!EN]@"0%M'_-H.?UN`A1YEU$.(]B`D<@6HQ8=MP41FRJH$<<"8
MC-UVQSQF"VP<8!ZS8K9;]UG+'YV8W3BW(@%%/7;POU*Z>>Z)`B8M"Y_18<XR
M@(Y&*<M]2DWM89*()6R8S'49TQ,,$SVF)[1,[%$_7V?JF6E'>'-4Y?EC!L:8
M@=&"]W$H8(P.N/%P-Q[NVBY2K;DK=7K8B_UER&Z&1O3?*'?#^N'2V9#`=WT<
M'_X!/_JI/K&;@V`]JIK==.*Z5`Z]ZR=VAPZ.[]D;=L+R-]@,'96N)&27J.?M
MBNX67U#T'6>.80"1JG-;*\R%T*HR40.A5SAV(W^3(\-N3T+A#D"FPC0-1-ZR
MT`>.DT+,LJ85N<H]A%RR6YX`A#=\E`9F2BN\]EHO<Z3C><:J+BE5]P4M$C^'
M?(*!BD@4LPXJ[#]LM]RB@!U@Q%)8:VY?6)O1E1/Y+KM534"^$L=JCS0`!%5N
M$5Y199'%).F.C7.2@)]9<;H)!DN[(]L5+ZDR]+/]D<N3=(81-F(*J9<1!?TV
M\BG=,W*-HI!JN?@>1]FMA3!>@+.Z9R>7^0?T!.-#-MP$`PD*ESX]9D_B&"<Q
MM1/\!$_I<O:$Z@X\SP1+6[I^20348;+A9AB($[E)#1[?/0M?\8^221.1D/[3
MS3V@*OM+W<=TS_`)(1)S3S)ZH.2;C,C=1SZ)Z/;@$V^&W0#%<79"R/Q9WO^D
M^?(HG>MXG-5\3/<,E[+P8&M)/L$$$U6-&HO3JW#_49AI@BVZI:28(D[H215N
MLH'GC1'O.BP<;LDNWZ.=W^*0==EG9C\U8-AE]>*S7H,GC8'^,=#?HT#_MQC?
M+:[CQ%]3>G@`5P^R+&2OQ=$X!O-Y*(S!_#&8/P;SP<%\X`G+EK4C.P^?-VB1
M1DIL@0;`+ZD;MK1%Q<`P4G>,@_'I>5<1-7R:^4#`F/6\K8:B3*G'.VUI.J$#
MJ#IA4EN:,JCA!_3UV]*L0`T<J(O3EB)(==&1![K`V/S%+FR4PIE@D'ZQ`23E
M7$BX76F%\:T6W8>#8YG572=5"`Z652:X8B`(CI)51K=R#!".DU4V=^-P%1PW
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MP15A2]*F?.'5.XO9DJNI($EUW$'=>X3?YZW$'UEPVW%+T>UZGF#HXSKT`*N1
MU,CSRSTO0&D`.>+4&!H]534]5=5)'Q,W\;?LVATUOU6=A_6#^7NTRRZ2^8$B
M+^O_F:>]Q,QXR)F(XW2]D?O+VWW)Z/(;77ZCRV]T^;7F\@/ONJ.K;W3UC:Z^
MT=4WNOJT>QSJ6]&V+*1Z:.DRK_N8L.;A!/E!["24Y!0%BOZ*VL_O50J;D,9F
MN6S[]//G%WH_RTVK'J(AOVFRQ1%:XG7NM-[=D.B>1,F"<DV.5;R5OA/8S'KM
M%F'$YN7_=XO/_G+U_^DWH7_*4XW9\CHZY0'$`Y^DE9G+^93_P<]^U')_0Q!0
MH8]00+]5GF0L($`V6,^%$FR-43'YMB'A=9I#3O\RV6PBLD6!B#REJ:U=)R&@
M$#!>`UG_N)\5-X+.T\?I]))/D'BD!E*F)%Q2B5D?5W\1"MM]\4-_G:ZKJ)).
MTKKFOD#6>RS4'(J/:(7\3?'N^8IJW(=GZ(E(%DS32Z9/$4A(B`N;Z`MZXGU^
MSE"MY+#[DZJNN;O*=_2'YQMZF3JUF1I(G4WN;W^;7/`7<>4`'2_&RS1@TZER
MV&RH>!2Q-:;\48@\'[$BS.MO9WHV9IL^*US)JX#_Q-X,L26PNZ,[+"M+9/U2
M]FN%RAL)MA+%:9@4+6#F!--3!4L/*$5Q'\@%/I+W^PJ'#RM\_#5"84R/1;<Q
M.WH%.,$BE-IYAS[VHV-=>+'OT,]V6._/B\<IH0(F%9^D57D4+SPF+0@^B7BH
MCGJ*P[9RMZ#?L!JTLT'-.Y[3[>RG)=F^\;#/CE$?V#\8>1]*CF[ZIW]>4Z,L
MV56&(WD_MTW2%"]1D+^X(@PC&&&@M&+-]->?1='D\P)N3L!`-,5DH_L)A=/S
M@Y05[!_E\?K)#5)Z2L[S-=:;-"D(/ZTQIFRE9Z:,UF<;!2>B.GA9W+0;>E])
MB(Y_R?0S<C,W4:6J:?@4`[<"82JB66\^II&N\(;$G(.GP@P3EQOM#\23(,+(
MV]W318:]R9(>[9;TAT.R'X\IZ'R3HGE6BWQ!C["K-;6TA#DFT&E]8&AWH$T0
MEH=.ZP5##Y0(-5Y.9_2`#:J>V1_0$K^#\E&:TJLUP]!56R[G,TRPD;)F,AL4
M);NO:"V6*/Y0`X2G]!BPQM$9JN(]!C:K>W;V#7R*8\W$\[*##^];\(:;7!&G
M-)7L$K&J@D_L&U/"]:XRU01C$3VN,FN:.=59%PX`0_(I)AGY1.FX"X__7\K&
MZ02SJV=/Q6T8)U'*Y(0I)N&ZD4\QR<B4Q+'2]SB=8/)[W)`(^\N0'C!7;-GN
M)5ZXNX#F=,\*BT71L_`59L'N/"F!+U3BP7T@7JBC9,.[9^"D61^'[I-1)B6_
M%,8ONIUS:3X=:)+L7'D<O>+5.0R2T289*()@0@U3.<8`J7F05DQJU9CN2?U*
M0J]0!M@3$BP8V3W9]Q%Q,?:R(K>I[S*=<(-QG$<9SB(`P%EF+T$E7NHF=]$<
M1UM*FF`+$@TU1CA3<04]L7`'DH[OGH49LT8$@)_];HA$X?*L&&&`S)-+9]A"
MF[ANNF:Q:^S=)2OF6SCK)EZ4\>91Z`N\H';B`WKB,:KS'2:7_`QOTHB:PO$Q
M$>K4AR1<2<KS3;`HOAR&RYEXFMFO)J9MDERB*-I1(UL4]U!\2I\9YC`@4*>-
M'S@4$,0*6\,C30"1=Q?@,I7_;%)@V:DE+@@IK(VI'XIW3]"<L:Q]+%86T#T6
M*RL3RQSD=XN2ZU^`LW"L9;7`BBFV8^'O"0IPU[\MF(`X%M_S4;79V5*]R!<9
M:;+CT"5$Q"!1J(*QI26;7'OH.J`,77(TXE&^V0.:QVB+[M$#'SR9WI:%JA$W
M8-VF+;T4`2JNVJ5MC<8Z8Z_$NR!(:(W*$?+/CSS:TBQ3O@#DV9JVK`4AIP<%
M65U9#\:@YY='RN4!X%VP12#$K![:.6LY%O;\;DRY7,B#[;:(A9!3(J^T!N/0
M\XM`Q[9R*FWEZO<=`4/4\TM1(=Y(M01^6X1'@6_220&_+>9]+6![T#_"'OQA
MSO;]>(7$=S!$/;\76:X5(9GTMFA"":_E>WUE6;;P-=1S3"!G=&"-KBUB`F&X
MC(]*M29<;GJN?&O)C:!.W6+AJ>:Z?)*!IST-?>^6A$'%G7B&SCSX.*>82&8+
M+O#]&59`9TT(3A1'X%8<V"(5,H^88DF++;#(`@H-ZQ/L@4E]/U9K&60+4M*`
MQ'Y@H^Y>MNAD5><#O"V%+>D/>O.5]-5IV+)>58^IT,9.]JQ0%?<L;%8S_=]S
MP,9+>FI<TE.[=6)[:JBW6`';6;2G@'J+3*O5U.T9%+W%4Z7W,!@>Y6R[WL(C
M[XD#!D4YY:QWH,`:DX,!4<ZUZB<@>MK;MY>-U#O4-/44:"\?9["(U89(.3C?
M.XATW.K38JBZGWCIN3^MQ4AM/V&K<1-3BT???F*D?",8'"%[C&_%_FYPB.PQ
MP'D-6N!8#-_NYGG<>%W"X=A88H(#[Y^#XV*/D2UI1`N'Q!XK&MZ@&H[.\`WH
M<W1D[=3AWL?AF\L'=UD;UU;!@1R^`<T-L@GN@8'C8XGQ7.]2[B-,7=TY_]ZA
MNZ[[_1%1P!PZFFTQV=L:WC6O_-P<@$[NF*])6[.[Y=-E&B?T[S\++I?GC%%I
MDL9Y_14]C[!'LHL9^03P1VD@X9I^6;+#N,A7RY3I!?L$EZ4O\)5DBP-[DQ\H
M\N+R3RR>L2_^>5Z911?7#+-8-=4@+``2NRCX`Z-*%KNG0NLMJ.V1STB].;\2
MI*.W#@DDDG8L6?NW#@BD!_IN`Z*4O79(,/T@!D#Z0=J!B&VJ]T7^[7V`0OY&
M`YRB@;C;S$:E&D9,D&"8!B+HI]IS?.5']+.0J+I1,W"T%I)4VGT^)T^I4:@&
M4E/&^]WBX"**T80:Y_C\T@W9<*UBOW_/_&!+EI<@DZ/3MK+0:5K)/![*[A;T
M36L29F_.=$I\@9=^R(ZW593"9G9'['7HU:$TG]8:F7,4(-8J8*_%2N\O?)@R
MBN5/T$I\]6Y2ROV\V+$AF6@6SMALAREH.<AO!B[E8Z^K*N\*[^"-)L#)AY1I
MO?&C./F-*APJ:WD0=K)(</2)3DRNJ(9L@(OZR_1#<J:HY%\O-TN^%4;*4>"Y
M2&A\AUX`V$J\VV1QFDGH'3,X\B7*W<=5YFD@LX3"@D1KNCOGAJ/`T@!.T4`<
M$];W'XL/=(W<%3-$OU&+*[A)@V#W6T8&G]`:TS41_?%M(Z(5IVLBFK5$FJ>N
MB^-XD09%>YK,FSW/2VO=*VH.!6231=H.=I*8%2T/[;[?_R3(WD977:6V%=\!
M"9ML\N:13`,RG2^XQJ!RC$%2A?>)<$89(O>T>J:*V.H&(5V26L=?\$`2%)PZ
M#>C9[@^<'-T%'+9;>Y_)E?3,)Y%OV\+[>Z3CNV=AO*^TE>LF0085<+0!\@,4
MGM;,G])<,<0<H>*[/"L'&;B4;+S`4Q.9-EPX5O<@G_W/LX/\.Q[7&E]A]*:\
MNGS(G$&Z<9.];Y`@/N=FDB8K$@GL/.WOL0&T+?(#5DUQ0W*'6\O8G;YND!`6
M7K",@?@VS/70IXC$W!L.];_)'N!^Q_YRQ0Y6>8[9P>U[*+_O!%0I%;T&/!;N
ME]F1/O1`%FF;KS($G-P3CZM=\86=,6.2$7-=_JV^R[C4U6&H6&#73Y0-/V;J
M_F1UY9EE655_WE`I10$K5Q.:B]U28A3X\<;?\<9?/K'$_7X;QRD]**;1X1A4
M9`?P,I'X7Z+6TTRNC@<_R;O0>/[6]^AZ%5UY+!K;`])_]Y/5#`>9.HM7_N:!
M7%>TT)4Q!7M*]^P6>YK@^U2,,$:F$//*,2)2A]4">[PS6T.+-4'XS!80JEDD
M=1(P;.GE"+@!C1N/L$4L*CG<2X4T&=D621"BH)0C;@LB8G6AGE%F2W]3+BY*
M85=;T)!K4*Z9:(L"K6*0-,T6;*]Y9,]6"S!WQ1:M*A.66EF:MB@3&3@:\SYM
M65_`DTUURJ4M&KB:Q4/_`V$MNRV*18R!K)P>C()R+["^+0>`5]&692%FE1P\
M1[`:3S`JRBW2^B8BG(0Y6\1">*V5(-'5%DTIYI^?DPSF7[D/7M\6P'C%>P4F
MFN\$[+DIWO+==SWGGFM,G0UH)`,]-Z:D9_?V\XULV7.DIIB6^+`MAUJ.'P`0
MS[5%`?'"$9#:$S`&RGUI>VNG3,=[L?8ZNU:9<'MJMG=`U>U\TYYFZ1U$9Z[Y
MMFMKV]NW>H=M3SH_MF>BOC3$.6WLVO.6O4B`JYHIMN>/>8D05W7U;,^2?)$(
M-^EZ;\^%"9V4VH!QM>>JA3;+LN'G`WM.4AW4?<)AM>S<!6B("L=F^`>N3AH/
MP@&UY)3564]+.++#/TWUJ*H3#OOPSU@]J9N'0S[\,Y?N[AG<SB-P4(=_S.JZ
M)0D<V^$?L#1T\X;#-?QS4X/&\O!8P/"/0W6[VL,Q&O[9IK%64^WP!0?7IL-1
M9WW[X?`._ZBDN9G$$;JNK@W\V7%)0(T`PFY_W&('A9Y#DA6.'/9F2L\J^Y-W
MK`RA$_*31=SP9L$V7MWAY8/MD=_L?L+KR[LOD]"[G4T%%Q3R!FGH6S^9W\\N
M)K.KR?X$*B!#/%0',<6]W"@HU385ISD!7>!96DC<LF+7KR3Q79RK#6J/LS.[
M'Z*\/FNRC'`F>=7$PN=KO4YC$H94=*?TK6&,;S`6W)+#&=HN.7DN/HB<?*A6
M<BZR(X-L!?!':2#A<CZ=^FM?>+<%;XR.UY?5XT$$CVMKSW=5IT/U!VC]>+PW
M_T_*O,2U":^8W@'9-<GMFLQ<==TM]ILDG-+3F9J)S1_*%&HU2<??]=[&6(3"
M9]C%_C9STU##-(]79(E*N9%!=_'2)K6GIO+&NF9/U,K<)_KIPDL6U;LDT8;D
M5X_SM11@N`:B#G&UX@PDV-`X0[5B=/8._H;&&:KWFD24:]W;,$[\)$TPM2N"
M`$?+'3,DPP45+9^D\95/I2@6W4'4Z$$Z&!G.C9G%YV2K\POQ6(E^8=$5MHO0
M,`1/UGVE8J:,Q:2=#M)+0D1<C*E.:Z@OZSQ'*R,S'.(?3$^#0.6/UDL4V:$@
MV?'VP]+/^B_O._>P9-9)K>71Z(%:6?LVN1!<[7?ZHXX7SJ_P!D5)=JQ=?,;T
M@S%Y_IRN45AD[XDN&U2>;>#.KU(5':7M*]UOCG]YH/^*D<MW`C1\2O?L7C(_
M+([85]E)K@@2#>V>\$]DBZ.PK$&/QBF'`=$4D\UYR[O%T;40Y\1Q;^:0S#+)
MT`QO"E]UZ4SX7'B$C6.5YYM@L6HS+RW[P^F.%'WIZ,YPQYR\\<5.<J6@UF</
M"AI&O$0R-#Y[O.AJ[+,OH'OLLZ],+%MC]/1P7(ZB-O.BL6.7<,"7;:_,NF\%
MYRWLB+:`IQ<:TO"DUEY!>]]$$J"^;!$Q,:M[D9$%)&T1#1@:JHD`[;4YZ"4Z
MD/0-6P2F'0VM(19BB\S)E;7<=66+KA9RNI<=<>H&&(J>=[."J2)P@!@,2\^[
MRP$UM#C/SQ;5T9+U7!UYL65AC8U,^]#(M.=6CVPC:NCK!\/4\Z[84FVL):)H
MB^;1KJY;C"O88B^,[2!5BZ9$B9WMJ?>^8J&<(=R>;3DDB(#)ZNUI]F&!!4B0
M;T\A]PZJ.ADO[5E4O8-'6XXF&+/AM^5HH0X`C-[P^V\TJ$$!HS3\3AHU4]O`
M"%G2/`-80@(W-2VQNP4)Y'`L++&[@74]<%PL,;:!!;QP7"RQJX%UUG!<AF]$
M-ZZ1AX-EB4FMM3`&CIXEQG7MJCLX4I88TM(R-3@BPS>:%2OXCM!TU2CH@Q/E
MAIFSIO9(XO^9O:IA"R"UAW;8W*<.88W:]ERF5'9#=U=92"`8H:/#0?'@S]A;
M'M63H&4(8+P&LFY9])!:O^S;1MO*QA4G0[069?[C?E:<1.;IXW1ZR<=#/%('
M*6B#PC^PH#]"]0@=/0AR`S)O],:Z%P8!72<1"F;X7ZD?L8L:[DE<65\+G*JW
M1\&`2OO+32%1%.W8E7T95K?A]9.+X_AN<>@D_*Z*9+4GZ*VP7Z'9EPG#3%`G
MS!VDI<3?W](O=!\@%^?9[7,<^B2:8S>EHI6]M)(FP#S-)?RYL%-S$/O+\)GN
MI!_PBJV*2O1`$S63NL5ANK]VA>UWA5J;A-[!$?%\T)\4,LQI1E#S86VP%*E1
M(>!'\4EM-%[X4C)(^(M/.E@#0:5\%79W3^6".QW3O*`YQNY/2[)]XV&?V7`?
MV#\8<1]*E6ST3_^\KKCHM:",]W/;)$WQ$@7YBRM*Z@0C##10<%VVD\291IP2
M^A&IH!?;8[@\1H[BBUV)9K;-'[.^)`72;;S"1.N%O5TS"2*,O!TS:K`W65+#
M>%F^#8"#`GB^R58`^]U'U%>B8DCWA%[AQX354D2II&Z5/]`TT?M#S8Q^_,P,
M+=U*`V)&]`"30O2<2FG["-EP$PQDUJ._/53(23L=0*:89(1:ERSL3X\+*Y8C
MR43F]*P!FV16L/:4'>5EYL??A<M?/J5[1DYL_9+M](G*RY3$\0RCH,)$57^`
MR>^UI^4N/*&WZJLP\^`*QW04TV23F!V`J'E0&L#!0O-;G-`@8B7[)T\U+]M`
M0@6D,+-[MK+4:W8CAI_D&?'\!2L::IYPX2<0#S;0J.H8H2JGZ&2>A=OL(CSF
M2*):8TO/N6=NE)I/,:EOQGX]AHD>^_4,LCAN;'JCH:RF/2^'+1BV@A!1",[9
M4JPI%T:9U\,6D1+P26#1J?;*E_HG$]"CL#W2`>"8*&<[V%*>RQ<9:81BZ!(B
M8K"5'67P5</R<_G090+$*5$+N[97I=<W^>"'A6R1BTH."2`QJ[VRP[X)@<Y&
M,CVUP24[ASCCP):E,';1J:$B1'F]M@#0UA&_=I3#%F"A1QGU>+0]"(E<`6K)
M!K9@(C-E52)78$R4JY9Z:\5P0BOM[>*]JU9JG+S6WDKJ'58:<O7;<T;V$RT]
MR=;M^>-ZC5KSE/OVO%?]!$Z6H]Z>MZ:?>$C*ZMKS6_03CCHU0^U91;W#J'D2
M,ABLX9=YUTNF!0,T_-9(FM++X/;E\(WQ^N6"<)2&;X9WE18,QW3XQGKSM',X
M6I88Z36KXH\X==7OXZ,3LSY`*Q)0_&.'49?L&K;[4'IFA]T^:M#5J-G'7@CV
M;I*[!95KUF@I\MW*1A?""2^U@\(,,V\D,P/`.$JFC$GJ8Y+ZF*0^K-CSF*3>
MLP2-H8`QYBB,\2\MICS(E'AI`2]%2ZO3\XU+PI@$OL?.],XC"EAK6"=>84R/
M\VYVADV<3=:!T4E#E'KLBD7X2:?)T[LY\S2GL%FKPV,#?1*6<G\$'0=!,S0<
M*:Z*A??LA>RZ!-:X-8YQ=8\C^2SG7;M$;O=Q/3Z&\%D:2;R/B)>ZR1P)/Z]\
M='_['UWLCO_6U.](]$AS0-RC'2,H]_&=MGR##39'_!'0KSB!L2":8H01NI=[
M4Q\]^D$6\9!R(1YOA(5TG3)OI[?/*Z.[VHHJR<SE3C<LS#S%%.V[Q0-ZXC-6
MYRD&V#W<_'6/?.\VO$0;/SGSG`%'&R"_:K=[_J/SLVGR)H]QEL,J)/-TD"EB
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M,3\W216I<*R!%HS["(_44!6,-$+V!OG>WK4=>B58Q0*O,-,$6V2#HV1W'Z`P
MH;0Q=9+=><S?(R!3NF?DN=]8:.2)AIH@G*ING]U)W>1H6O,I)MA-*-S8NT81
M"Y'&):<FM?A\U^>)'7SBF,#VXA+8[A:'!*A[$F?N9(E%I3)US,PSGYG7%K'`
MLT6_3A/*YX<^GA@>(N3A\Y!C9:Q<:8X]"9ZUE-68X7F"@K[D`ULPTX((J9&A
M9$O&J"X`:^@U6R"$=.=5BS'8LCH5^"8U,]QL$:(&4,DR[MIK/-.W=3960%1@
MHKD"HN="HGL_D[O8;$%.30/5CS.WU]&IM^J(XV"R3A>=\UD^O`@2^6Q!@L-C
MN=F>NE/;%A-'#DXCW[\M>E@.4Z/,3%O4+P`F<!$`&).>W_0@QX2?%@/&H.>W
M&<@Q4`YC@Z'I>8]_.33RY%0P%CWO%`Q0'QH$0KG7W19'CZ3K2F!].PX_,QX,
MF7+WN[[)#3RK!&[8*9N]/9.CFA6V<(`&;_H"<MO@:*@WI2,)"OHB+,]'G$:G
M;3D-P0[-]=)E;3E.*W-?8?V+<M9MD:6&.$&*C&TY73>!"E(&8<OQN@E.D((=
M6X[<37"29^+;<BAOA)(NS32$3O8:EQV_SLR6,[P>L&15K+;L?#"#\Z69F&I2
M(RWDL<6B5(-%7(AOSP)2LJLAS6!LL1:5CQSUV__88CBJ0:9:,]2>X6C`5:0&
ME;S`H46+L>_@J%:6'Z'JNJ7GX<^Q0Q:.B^*5LPC(C[AQ-T_X@PTT\E0EKE$/
M3Y%#_C*[R"B^#>\VF/T0+@N';5AV%>V)"<0]*A6?ZH3_\9S+;EN^_4\:YS>E
M/A!VPU[H^EGFP'%C>B`L+^4^(EN?0G^Q^T87>)FEPX5&LM9F+;[*`'!K$B7^
MG]GG/E3WA,LLE,P#`##%PL9:S@>;F?O8-^;NLR[(=$U%&,7X"N?_5>*Q^A$F
M"R>O,-V$7#];.O3?`<Y,E]`K+RD.BRI33?3V>0[R;7@2R>%P!9[7!Y9.7'5@
MED[FF6P_6$7<_NXU8=]1^42C^_\Y>2=A'U'/*?G4?GVR?3K@N2D'FM.S#W4P
MBPI?B\3\4G]`'Y@LLA?WFJ`RBQ',,.1A/?O(I;I<,)NE.;WCIISQKL!0>9I1
MGEA.=<41Y6#,@T]#]1_49Z8O24@52DK_5B@7>MIO#$#50TT:HQS**Z[XK2<#
M@`?UF>GF,@!\:`]EH,)5T1P.X$,-PW'TXO"Y.Q]CF-1)0C>6QS3)*E[)#&_8
MF3!<7E-TI;UYZC_(0+O`XFKR!S)QLSM[Q2GN'(X5GV)THSZCM>@;(#NO2>>9
MY:ITK_QM'*?L&BQV(_,A(,WC"CK/+$M,AJ@Y_@4E3(QV=PN^@`$8K?$TP^RS
M+W&WR;3Y]1..7#\^1D!$C(KF]8`E5AL"^F!G@\>6D'586*$(7]"3D\=2#>@1
M5^0>%0\>^UFJ]K-D!MP-BV'"^UARIXS]*\WWKQQJGA]`NL:&@SP4QH9*K354
MZGTFZ-CF1LHGT7<(M@6M!CCPT+1\@0G%JOU<(5L$KU6DGE60J*91V"*Q72$,
M.8G94ES0%:;PE+L6:A-^R9$-\9(ENW;<;Z`C@&NDM]@BP["=K&[:10O[DTEY
MK`&#$$11CD,+&X]-T(DRFEI8FS9!5RN!R+*=I1ZF;=5*V%(?IUM2A=G`[97+
M&6G$I5]!RM)8VRNILP)`2=YV>PT9#!0D-L-.;\://?750-=CH^PYRRSL!G"4
M6SXHI[]89FWK@5$YA]DRP[LE853,-[-%'VI"4T=J5'OVMH&]6P^N>I.8;3G0
M--K#P540MD1Q&N#`6>&`+$];`C3ZP0,D5-KBQ6X)O(HLSO9VX_YL'8JPZ:V!
M>@E[LR+`3?H;M.<EVV3OISMDE-@#JJ3K1WLNLQS-Z[`?1YQ6L/S(P[*#-E4A
M2;#SSHG=%?;2`'O.NC@T.`L2.<D*.W3V!H6[V/$SDS?OY^2Q%F[!80N0=ZW2
M\YYNFECII+513ROQ@;@XWC$17"0XN@OQPRHBZ7+U\(/\@5$4WR`_JFJ!T\JS
M55+"&[*;_XNN04;:GJ`F/`H?J(&QHVCI%K(RM^V]Q4#_+=7*,/X$DX6S4`'\
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M'7),:IZ`E9_;X;FX)FV-3LO5/3@F4<2*4QEI%[OCD*(\8?(#15Z1+/J)#DQB
MJG&RG*3LE_C@0ZDZ7K?ZPIJM:D78/,I)?>20>D.B!?:3-,+*`'7RUC;3.)1E
M&>2"J;E"QO.S&@MUEVA^Q^1M&-.=+`NL9ET"'E8H?"Z;+&TPETP>*-U38!/,
MSW5DYQ@_?[W1]N&UF?R:KA]Q=+?(?HW+48&,.]V82EYG\D9!6R`T>&]A4YNG
MJ,AA[/R._>6*JJ_)%D=HB?>U.O>1[W(];]V\?<@`EVRF2<BZW/A%Q4E;.A3Z
MWF$J3RAW!H19"TW#^Q3M6@3"EPP/K+LTH>>.T//#9;ZIM(37V7L&N<T;!VW`
M^TZ)&0.Z$/CV7DME##-><*M[3BM$#!#LYQN`":35*1C3$\;TA%KI"6T12]SO
MK)4%]JZR],Q<DO-#K<IU6>H/`IXUAA5&U>U/'I,UQF2-,5EC.,D:QCI/P(+N
M73F,VQ,U6P&&GM';RQ1Y.<BJG#Y;J$DQV3>R9:R;QNI>5G,^8V'G%CHO]5>H
M#:0!M=>+R2HQ!OCQP4@JMS(?)))M^:/`,/_%`H6@T64!QNV743R;.:;A)XJA
MG.HEFU6'*9EP;(?18KZ;;4L]F0*.\Z#;`O0P=P*.O')K`4/=,0W[>[@-,V7X
M*A_<[,07FET`![9FDUQ+@:V91&BB\.A'09^#<@(=1$W2=<Y&UD8LCQF1["\.
MRC9R9\E6(9V3$`>O-P'981P[5)`<SX^PFY`H=M*0"D;6@^PDW%2WDLDTH9V6
M1O6#V78ZDYCG#EA]8YK,L9RGRR2U0R^MR?$KL\LKV9U.5SYK`AYZ,RHANM/3
M5-]K":2_D8`^)O"37=>@5K]YX+#._/C[383Q_G++KD`5O=<0I'5<%R)Y><#1
M^IT(RU9?.&;LC1E[+[ZA4`]LL3$5CH?"F`HWIL+U+Q6NMR[I#JP%Z^2K'6==
MW4-">TEP+P9>_L&VA8RWEP*N_"S6J8/9I221P/=8!/9HT,4.66374D1X1?EE
M]A:UO,@:._2#,'L,I1Y+'8/[A_6\IQOWKDY:&WEG+TE`UP-A(<TMNRHZ2^%C
MW>&HB+`;ZZ[P%@=DPZBK\IK6F-[]P>JRC.AM!FC6!.\!/7%.68(9)ILO7Y*8
M$I%U\9N3H\(Y([YRE!ERBY@Y19+;&/ITF&F$R[2<WNDH(;WZ]NHN&;A&4>B'
M2W;WZ7[#\%VV$/T@3;AE<\!9W;/SB9Z9IE3WW84W)*)'__`RI?M\Z.ZN<.1O
M,ZU3RC_^2I(K'--13*U.XL_86U*N2@,X[+?T%@-PX1!'**!?;N*M6=//)-?,
MA7SRV(?-,M%LGFG>@P4E68R2T2;(S^VO_;Z8$\BE7C38'/%BT3D99;1Q#]VA
M<]#84N;0^VR,R8VFN-Z;Z0T)R14CC1+.A+/"/OH61A@%_I_8^TR-#DKN4:D>
M;Y.91'Y,?RKG.4LLL;9?USV`U=:Q>)F!YIA@98O#5&HE\889()CL4)#L)&!7
M#C)&;(&>F-B300:"5RC`<4'%OLTX+X0E&&J6<!C-AF_@L2$W9XPLVQ!9;H?8
MDT39?0IX<13-,\%+"<L<;FH^Q9Y`.O14-,:S>2B,\>PQGCW&LR'1*[&!;PL6
M7"Z)BFUKRQJ!H"$ZG-@2/!?AT"Q$UEX$W,!M3*J+1W@=T[!7#DRGPD)+MNA6
M*;<GR'#CF[8(B0H@"MY!6[2N"CQ*X2U;THZ4Y$?@\`3CH5Q1;6`34M4RHJP$
M,##*%=$]!P80CP)CT_/&4RJP0.*W8%S@;:1,-CBI`P\O4`R&!M[ZJ?<BTVK:
M"1A0Y9Y0/==/PA`_W#RTR&!6RNZ"(V21!=TH6@!'S"*CNIN\##BT0_"!J)F?
MX`SD3I/YLS+,=\X"^9&S974'+&6=E4VRM'44[F+'#[=TG\_3V1]W#J.Q9J^7
MIJ_IL%.+'E(;9?*7NV,Q3UIIN;DNE6AO;X*=1$SK36[S%N6F8(+:NNCY8ET&
MQOG?Z(1Q^(0^,4$%+5VG`;-N/T5TPSCN)&P+N<`+:B/S\P2U/7<8D+`=M0U(
M*I_;*TC6)$H8I6PS56>\:K:!*A-,J5CX](74K%Q<X0V)_>0+%MP?")AAHE@F
MVK"X%K["C\D19#$CD#DFLMWW"O^!OEN0V<4?:)KH2PKJDD3^GYE9(_P(\(EC
M>N.8WBB@>TQO5";VV_P3V>(HS)+QECATJ?93T)^JT^U):&S9G!_S(,\\]N*=
MSA8D!'R2INO.EFP$&$8*MITM>0A`8*#6NRWR,F99]R'+NN<I*K"UHWI6L46S
MC#GH:OF2M9P^UNG;2HB:>/BM6TYUA:B.%]D63=T>>`)_<WN9A\,"SWRP-T[7
M:Q3MV+$ZPB[VMXS.LTOBP4%=V.,Z#=ZJD-2LW=I\.O77K(=;I9='.$9#R/53
MA'%XR9;@_JS&<Q5#AVL@:KZB3R5+?Q+2'7J:")`1C]1`RK<Y/9RA*#,W[Q:?
MJ9)*6%;]YW2-PCF.MK[+<<_5G-UN%!TFU<!HN<H2Z314Z+HDS=,C<3PE*&09
M-C=^B$+7#Y>S(ZD7NPL_H*]?,H6<QI(XCZ[']AJ0*5ZBX#I,_&1WM[ADLW#$
M!'BG#QSP*[H'BGTW[.T+TX1>=]'0[@DO8<I0?(ZK,%BF,--$-Z&CW)27E)`C
MV"2CS'S%29[8S>^/5#'6>3_&8,<8[!B#;24&&S["=;]X\,N)KP(-P#&.>GJR
MUVI)VH*;-E2(BI5FG;]7A]0IFN@O4`+A")&&K@!;!+2-Y0W9B%\@?NK""7;K
MV1+\:15-B%/2ED!0JT"*_=ZVR.*8&M.'U)B>"TD;VZ>*I\R6V&M;^JJV/]66
MC:#/V4D4_QAW6]D-;9,)\/,:#_#GQK6>Z'[UL\R%]D7T-(WK"P/ZVL.^"ETE
M]^>E2M+4'U,O,#$F)(P)"9"U6"<;0;2JNZV'/6[^7]%:%$$7#341K-RD=+VC
M&$^6=(4QH$\)E`1A%>>;8+%2"9[^;#+J6N.^%Z-!XF8WOO2%]+T>I"1)KC$"
MSAK#]6.X7D"WU>'Z87FA=!@98[C[!`6Y96,+%D).QT"@`D@O+B`%0N4E!99`
M@'#\*+8LE3$RU(?(4,\C&K*%TO!(;HN"'>,3->(3D&-Z>\JVM["(72[6K1BP
MB$A]('8M(2#G-:[]XCD?[5IK</QD3EE(B+3XA?W/(]T$Z5_^%U!+`P04````
M"`"H@69'9D"<\QH1``#YL@``$0`<`&)C<G@M,C`Q-3`Y,S`N>'-D550)``/L
M%SU6[!<]5G5X"P`!!"4.```$.0$``.T=RW+C-O*^5?L/7%UV]L"1-8XGF:GQ
MI.171BE[[)7L/$XIB(0D;"A``4C9RM=O`^!;I$12]`@NZV29Z$8_T6@`#?+3
MCT]SSUIB+@BCIYW>VZ..A:G#7$*GIYV'D=T?G0\&G1\_?_J7;?^$*>;(QZXU
M7EGWLX"ZF%^P.;9^.QM>6[9U],/'WKN[&^OA_MQZ=]0[L7L]^^B];7_^]"3<
MC\*9X3FR@!X5'\<.?SKMS'Q_\;';?7Q\?#LFS.$KX;]UV+PKD8\^'`,O&MIA
M`?7Y*D9X&G/OK<#.VRE;=L-&B71L'_7LXUZ,%G`.PI3AA:T2\;LLHHM),0XT
M%(#C)V=6#"];"A`(76+A%Z/HM@)I/$+_S*A,H3$^!=BCXZYL'B.!(W"*B".*
M2:@F2:&7I4`9I<&\F(;K\ZZ_6N`N`-D`A3EQ8KSM2%D$09QBSJ"A@"_A+W@)
M/+04(`3"GB*TB'$F2(P50V&#<K`U%,X\+`IQ5$LQDA2O&$FU%"!)`=R<\4,K
MGG1U8QJ4;+`YH<)'U(EM_K3F(X_'"KKWX<.'KFJ-085;!`C=]KJ_W5R/U&#M
M6,CW.1D'/KYB?'Z!)RCP@/6`_A4@CTP(=B%<>'B.J9\!2#7[B$^Q_Q7-L5@@
M!U<8])__^0_+4B&#S!>,^Q9=0]ZL9QUIKIF#?!75TIHN=(4N]GP1]V4G?;T%
M+CK=F@RM>TMSAE1?31C:,@Y+.-J(!6P<?;![[^S>^\IL;(^XFW13B!C_9R?=
M-.-G+3I7X25&4K^:\)`?QQ^ZTLI=BJ=R;JUF&X_S#%83VU2([_7<A-&O;7E*
MP9Q>R5%2>-$_=M)),V;RDU(51B(<^<-.D!O[2#K65S&*0I'_V1&>M,FQM$E3
M-10D)E4TD4(+?^]LD'P65H6-"$?^V#EPK*4=E5PB0E*_FCC%QC2F^1PCGS29
M8K;DE%5TDF#IGTVT4IQ`51PD$8(<'2=YDHA2YBM\]2QZNE@0.F'A(W@HTZJ/
M4?H]Q!-+)5H?$7=DA-Z<CG47G"TP]PED#*D,7G4PXWARVI$K)3O*C?[PT/@M
M)'`1R!J!;`!0,P2@8.\Z82_"E3'[M"-`KQX.I?[FXCC(JRL.H#B!IZQBJ%`N
MGM05"E`()0;+M."XKDR`(F!=T,A2LH-[`+`(K%)@_O+5$L-VF1.H'XBZ-OPE
M_LJ68Y'/%96.)?$>AH/MBPS-8O6>8_XB#A.+Z055E97YYZ.C(\NV+D):Z9]]
MZEJ7BJPU2,A^ZN9HK;$1".S>TL_J=VYDA,@AQ";$K/=5Q\M;N!@S?!J9M)JE
M'48%\XBK<MLQ\E0&(V88^\+6^;]O@_\2YMH!18%+5.;<V/R-R+7E$SUPA%'$
M"OP^3S%CG6EFK)%BQGISKKFQ[A0WUD/$S7\.OE+'>/8"R><S[!-0A?C&KI.G
MWI8GO6O%DZPW=QGV#JZEC1L_%C:;0-,<",\P%62)8:Z`_['M,2':#TCU";?E
M4,>;'"IN$!:;0%.*+9C$)%O6FVO@"QSJ$*8VFQ2)F3WQV./S.T\1I;:\Y;L:
MW@)\6%>2CX-S2)/!0A/;/5N0*243B+HR$W74!A:A4WL!6G0@5=_!)RH2:,L5
M3F1R2X0#<2G@&/[Y"O0ME>DD'%C]F`/K+N3@E;O`.QBOS%%J=%6DAWBZZ]IF
M2\=MF?Q]H<EU2@*4[3-)6DT3$>E7;NMCL(/GH3'C0`*F<KGT9)!U<5L2AF7\
M3#UR\1)[;!%%=I\CQ]\Y$NQ$NRV/^;[08X[5S)%BS@).K%O)G#4,F5./+A+F
MY%2CF7OE/O6=S=D*>?[*GC,*^?O?K02/DE[;\H,?"OU`9A-#3=:Z29%]Y18^
MT8%\QCP7<V'COP+BKW8U<'&G;=GW0Z%]3Z*9(:3Z;^M2D7V]]MV2G+61!E8F
MT9+M>T=YVV_)_ZPWT:_#:F";L7PT]K[!HB"BTY9+])JN#:PW]XJ3U^X9I;E\
M2QZQM?^V/.%=[27#P06J#EH7^XAX,'CQDQ\@[_FC1)Y@6TYRW#Q<7&B6K'O-
MTL%I)HAP>XF\`,O-0%A2J>&-Z$K8NC9';Q2.5ZH2,C+I[K[3D&Y;+I3?F(P]
MZ`KXLGZ1?,E-2>!+!1O@Z]_"&B2,J7IWJ=3(HPZ>).MKW,"#"6*._(#+\_()
MX^6F;<V5FA)NRY=.RGQI%#%FW82,6<#8!J<Z.%-LTV`^1WPE8P/'#B9+-<>W
MZ#.;^V_+-=Z7NH:F+V/,,*%_<(#80'+`4I^!B5JS^7J7;9GY^S(S#R*2!\L6
M#SU03_!LXSK7>5O6_J'2H-;$#W;?NH)L>5E2G5!;_E"\F;EYS7I8AQ093=:N
MR%++);87'J*PJ(3?Q"?M18CJA%KRCG='1=$B=@Y9%J,9L>Z`$5BT1HP<(D=L
MLD=,IC-9N8*6F*,IMI&`.+^0!(5*];5-F7IBHT?$76%/.:(2QV<VGB\\ML)@
M7'6"22#C@SE9UKNX6*\3<N[0FK/MC?.VO#=?B1I[[Z^A9%9?2V;U$\G4*D>[
M]ZUZ8O659-9/6C++9]9E))D^N(TDLY1D:HF4&QF'X;#[.7W;<VVKO+3ELL5;
MR+O5$!PF[$KG_VW[5T4J;7E.\;YR6=7!P2>JE`RT[1+5B+3E$=_5JE-X51[Q
MJ9N_^A@^R5Z15!<DPQ="6&@L5#P][?@\P!WE1/)6V1_]R_/;FSYU!\/K&SP?
M8]Y1USI/.T4-1$9Q>=M,=R("Z)7X@23Y$V?!XK2CWI+QD8#?="Q]JTR_R.2C
MR^:(T`$T2$DZE@;4ES'N%:`;<%W*U*W#_NAN>-8?7O2C"2,G1&GSWD1)6'<<
M(.U>/LG%*1;JI&PEW??,`P>/)=@&M8,@?M1-^V9Q734HD)>:U'5&*G(6J@)I
M@+'<I;RP`T&(.%C?TKEB_![S.:$*^W;2GW*LL!+1:N$T$5(_B21HWXP1>SF;
MK3TVP$#0&?*N0=,P3*XPOD%/9![,8Y9+FYNK765&B*_RO(<7STX[#L?@W$4B
MZ1=!^/4D@HEFDT1QLVD2E;M7,`V$+]]`D?.O]><&.-@2\@O)`XSA$?+P"#OR
M8)%@$8;H`2RP859/AG\-A&<TF8O'._A@J0P7>.R'9ZM2H@F(<DOQ_0RXG<[N
M']GOL*X3\DA?G>AOUTGM_EZZRF)95!'5^KR_<S?[3`QJ:T/_HE-E^,C<=751
MUHFYKJ(V\*+:"9#NCG%_`BD>2]4F)%JH"+V_1*),,IW\W$Z^D.GLO_)U=/[J
M!O$_L2IA3*Q9(FEU;`-3*'D$5;PV*6PQ;X5U/KJ^)G-Y)33+?L%S(YE?X]ID
M=I-M4D93U2DY&;9![3]9RNSWQLN%9*T7^7TF.:B+M(^POI/T_X.L%KNU9"]&
M>6&2UY#XA4L:35716<MF80N@#9B[L[Q25YW41`<U\']JGZ98O&TH>UF?MBUZ
M5&;40`4I5.-4L7EJ@K0:>9!XGJN^"V:E$@`3)B1UILW#?3>=/PZ)^+-DV[4&
MO)$;L#*.PDH(8!X6C%X&6@"Y-EHL.%LB+V^\JN!&F%+)+#=2T_RGGAFX#C@/
M7Y1\H900\YU_:F!.&K+X!;M37+(AO`7&`)\I9+!L[%<$-G+@7\!Z0*I=OE8W
M:Z3"EOV;Y@)/,.C;S:QJPN.NOA`XV0"I!&GJ7L\FYL]G"&*O&-#;A?RFAPR[
M2AQ(&ZX)&A,OLSO22D\O)_$H$'>)PQ0J[^`5(,T+L!';=YRY@>/+#4Y1+%@A
MA`DC6#B<+'2F%%ZO*@FMU4#-#*SAZV%A*%VJE\,.TB^[#<7;#--\T`%/,)9W
MME14^CG"?$D</)HACE6-?+I$_BM3N\G8U:6CZ:9S)GP9:1QHO6=G,+@<-J7D
M;RP/MH=8>I.+^>WDB@@'>7+[/=+,7B@;NWGP?-J0DE]!V'M^O:<HO58]L^`;
M^'>*TBO5\_T,4O!OH^B(U&O5]"/[1GI6A$S3<NG<'RM#EI[>!=R9@2;DW8AL
MGK8=;/_)6F23Y-SHBK.YMI^:2HMV+,^35QV&DN[:RXLQ_4\0$.@Y9P*\FR_"
MU5;6[)M!S%MPQ-=[UCVXN&G_7AN52D6K?>E7>DUT12B8'9)C&7#*BFB;HQM1
M1!.Q+VO&>9+;K3]^,:/JY[MA>+%C%(ROK\^S7EC::MY8^AG!$O9WG!M&:T_W
M/X*N&9V"N\R34J'HS2BYNM(J@`:<4MY4*0X2:Z5%]=$,DG41,CV:,:Z..A(;
MY>7;#&J$3*H`NS^=<O75Q-L)!&2(PW><.#B19C.0:97.:]+-Y7O0Y$Y7=#8Z
ME->FN$R)[YCP\W)N!S=78@+CQ@<:=VBE@T:F_KZ\V;0YJURB;)PL;S9-HM+)
MZRO2A54#JAF$\=7W/,RG*WGOBTX@Q2<L$!<$LGF1WY1NBFS>'`ZKV&CE%M^&
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M9YC>SW#2RF&!!<XX4&4('O9Q?GBWWJ\)XU8)%7*O@I`^.(-(%2^ILT`@XE?L
MY[32J`/3YL.\5G@]H7(JJ8]M6NPK'V):GO0K]7)C90.``4Z_SMW:B?\6&",K
MC$.>DYJ:0J,4-!MCDO25K.PC`^;/Z)L@MY/4G7DY'60N4HCBU[$T13:B?B3-
MO+YZVD3LRIAFR!R?X:L4-0GO10W/FP55X[>PP++/N;S0(T'/5A)$[2N'&[)J
MZ1IN]L2;SVJ?"S*\Z+Q*[U;&PC\WE;WEDW45J4'2,EX1+OQ?8'J7RQE%5+U'
M2+TY^P*6.C5UV(B`"6&RJ7CA2QN5.&)`0PG5]DK\`J>==5B1R`Y'7\JUV]'B
MVB'0]H&F17D(RZJ3#=^,XMKM=]^;Q!5%PFLRA;X`2]P)!H:EV2IXW7-3VI?K
ME::5HQE@L"F!Y<LYN_9SKW$J;=U_4JD.,P9"!-B]4.]UTRI79VV5#R]W[>3E
M7)15DH:>"M8<RLI@(K<>]:%0UNK58/?O`VKW17XC1M\HB;?P"YZ;MAU1:JB'
M_-;\@]';\@^C"[Q`W->G1%\PK.KD(<F78(YH>#LH=SI6"\-`@9-94MW>I>'U
MI[R46\',$TUFG^].PNG_$CDS>1GK@?K$NPH\;_6+$B@K9CT4,T4^.:HM<G44
M,T66[_$9!8XL49D$7KAUK2:YT0([<LY+G7(FU5?KBMBU(_/4DWS7HK5O,FMU
M/4?'QA4I;A"RX,NA6Q53A/.29&[\[>6MFFG>\XO2WY8OV>L+.5745;6C%Z6=
M+1]CWJZ5;1V\6&WDOU];3Q5KV"]'#S6^V+E%)W5Z>G'Z*?@,;<584J&#EZ2-
M_7W#<ZN>]\C:B[#@MCDM^K%)U37Z^&8ZT=\KDPG.',&__P=02P$"'@,4````
M"`"H@69'83AQ.;C[``".2@D`$0`8```````!````I($`````8F-R>"TR,#$U
M,#DS,"YX;6Q55`4``^P7/59U>`L``00E#@``!#D!``!02P$"'@,4````"`"H
M@69')V:0P?$(``!A<0``%0`8```````!````I($#_```8F-R>"TR,#$U,#DS
M,%]C86PN>&UL550%``/L%SU6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
MJ(%F1SK\V1Y-/```RI,$`!4`&````````0```*2!0P4!`&)C<G@M,C`Q-3`Y
M,S!?9&5F+GAM;%54!0`#[!<]5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`*B!9D<FOY!#XU(``+J0!``5`!@```````$```"D@=]!`0!B8W)X+3(P,34P
M.3,P7VQA8BYX;6Q55`4``^P7/59U>`L``00E#@``!#D!``!02P$"'@,4````
M"`"H@69'E?@?<[8[``"%L`0`%0`8```````!````I($1E0$`8F-R>"TR,#$U
M,#DS,%]P<F4N>&UL550%``/L%SU6=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`J(%F1V9`G/,:$0``^;(``!$`&````````0```*2!%M$!`&)C<G@M,C`Q
M-3`Y,S`N>'-D550%``/L%SU6=7@+``$$)0X```0Y`0``4$L%!@`````&``8`
*&@(``'OB`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546955664672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,884,000)<span></span>
</td>
<td class="num">$ (33,517,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">137,000<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,773,000<span></span>
</td>
<td class="nump">6,550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">329,000<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Change in fair value of foreign currency derivative</a></td>
<td class="nump">793,000<span></span>
</td>
<td class="num">(732,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">1,995,000<span></span>
</td>
<td class="num">$ (1,123,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">683,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,331,000<span></span>
</td>
<td class="num">$ (29,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities', window );">Deferred collaboration expense</a></td>
<td class="num">(117,000)<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">12,582,000<span></span>
</td>
<td class="nump">3,602,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="num">(512,000)<span></span>
</td>
<td class="nump">957,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">1,602,000<span></span>
</td>
<td class="num">(880,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">1,712,000<span></span>
</td>
<td class="num">(24,661,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisitions of furniture and equipment</a></td>
<td class="num">(1,076,000)<span></span>
</td>
<td class="num">(41,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="num">(1,472,000)<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(48,343,000)<span></span>
</td>
<td class="num">(15,852,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">35,874,000<span></span>
</td>
<td class="nump">29,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(15,017,000)<span></span>
</td>
<td class="nump">13,108,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock, net</a></td>
<td class="nump">1,175,000<span></span>
</td>
<td class="nump">106,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,861,000<span></span>
</td>
<td class="nump">4,636,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Employee stock purchase plan sales</a></td>
<td class="nump">356,000<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,392,000<span></span>
</td>
<td class="nump">111,546,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">(Decrease) Increase in cash and cash equivalents</a></td>
<td class="num">(7,913,000)<span></span>
</td>
<td class="nump">99,993,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">54,540,000<span></span>
</td>
<td class="nump">21,164,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 46,627,000<span></span>
</td>
<td class="nump">$ 121,157,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToReportingEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (j)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546970494928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 5 &#x2014; Stockholders&#x2019; Equity</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration statement.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>125</ContextCount>
  <ElementCount>227</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 1 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies</Role>
      <ShortName>Note 1 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 2 - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation</Role>
      <ShortName>Note 2 - Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 4 - Royalty Monetization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization</Role>
      <ShortName>Note 4 - Royalty Monetization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 5 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity</Role>
      <ShortName>Note 5 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies</ParentRole>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-tables</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 2 - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-tables</Role>
      <ShortName>Note 2 - Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-tables</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Statement - Note 1 - Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details</Role>
      <ShortName>Note 1 - Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Statement - Note 1 - Scheduled Maturity for the Company's Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details</Role>
      <ShortName>Note 1 - Scheduled Maturity for the Company's Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Statement - Note 1 - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-1-summary-of-receivables-details</Role>
      <ShortName>Note 1 - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Statement - Note 1 - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-1-inventory-details</Role>
      <ShortName>Note 1 - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Statement - Note 1 - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-1-summary-of-revenues-details</Role>
      <ShortName>Note 1 - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 2 - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-details-textual</Role>
      <ShortName>Note 2 - Stock-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-tables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Statement - Note 2 - Stock Incentive Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-2-stock-incentive-plan-activities-details</Role>
      <ShortName>Note 2 - Stock Incentive Plan Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Statement - Note 2 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details</Role>
      <ShortName>Note 2 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization-details-textual</Role>
      <ShortName>Note 4 - Royalty Monetization (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity-details-textual</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''Consolidated Balance Sheets (Current Period Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Consolidated Statements of Cash Flows (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>bcrx-20150930.xml</File>
    <File>bcrx-20150930_cal.xml</File>
    <File>bcrx-20150930_def.xml</File>
    <File>bcrx-20150930_lab.xml</File>
    <File>bcrx-20150930_pre.xml</File>
    <File>bcrx-20150930.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140546951064464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation (Details Textual)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2013 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bcrx_UnvestedPerformanceSharesMember', window );">Unvested Performance Shares [Member] | Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember', window );">Stock Options and Restricted Stock [Member] | Incentive Plan [Member] | Vest 50% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember', window );">Stock Options and Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear', window );">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,782,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member] | Incentive Plan [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfMilestonesaAchieved', window );">Number of Milestones Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member] | Incentive Plan [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member] | Incentive Plan [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,982,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Incentive Plan [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Incentive Plan [Member] | Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Incentive Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,553,000<span></span>
</td>
<td class="nump">$ 6,388,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.15<span></span>
</td>
<td class="nump">$ 8.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesEnding', window );">Percentage of Common Stock Shares, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,773,000<span></span>
</td>
<td class="nump">$ 6,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfStockbasedCompensationPlans', window );">Number of Stock-based Compensation Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfMilestonesaAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfMilestonesaAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfStockbasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of stock based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfStockbasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares ending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award first vesting period after grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of performance awards that remain unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_UnvestedPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_UnvestedPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_August2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_August2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
